0001104659-21-085768.txt : 20210625 0001104659-21-085768.hdr.sgml : 20210625 20210625164256 ACCESSION NUMBER: 0001104659-21-085768 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 171 FILED AS OF DATE: 20210625 DATE AS OF CHANGE: 20210625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiromic Biopharma, Inc. CENTRAL INDEX KEY: 0001792581 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464762913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-257427 FILM NUMBER: 211048510 BUSINESS ADDRESS: STREET 1: 7707 FANNIN ST. STREET 2: SUITE 140 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 832-968-4888 MAIL ADDRESS: STREET 1: 7707 FANNIN ST. STREET 2: SUITE 140 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: Kiromic, Inc. DATE OF NAME CHANGE: 20191029 S-1 1 krbp-20210625xs1.htm FORM S-1

As filed with the Securities and Exchange Commission on June 25, 2021.

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

KIROMIC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)


Delaware	2836	46-4762913
(State or other jurisdiction of	(Primary Standard Industrial	(I.R.S. Employer
incorporation or organization)	Classification Code Number)	Identification No.)

7707 Fannin, Suite 140

Houston, TX 77054

(832) 968-4888

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Maurizio Chiriva Internati, DBSc., Ph.Ds.

Chief Executive Officer

7707 Fannin, Suite 140

Houston, TX 77054

(832) 968-4888

(Names, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Jeffrey J. Fessler, Esq.		William N. Haddad, Esq
Sheppard, Mullin, Richter & Hampton LLP		Venable, LLP
30 Rockefeller Plaza		1270 Avenue of the Americas, 24th Floor
New York, NY 10112		New York, NY, 10020
Tel.: (212) 634-3067		Tel.:(212) 503-9812

Approximate date of commencement of proposed sale to public:

From time to time after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒
			Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE

(1)	Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act.

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

Table of Contents

The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS

SUBJECT TO COMPLETION

DATED JUNE 25, 2021

4,835,590 Shares

Common Stock

Kiromic BioPharma, Inc.

We are offering 4,835,590 shares of our common stock on a firm commitment basis. Our common stock is listed on the Nasdaq Capital Market under the symbol “KRBP” and, on June 24, 2021, the last reported sale price of our common stock on the Nasdaq Capital Market was $10.34 per share.

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 21. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

	Per Share	Total
Public offering price
Underwriting discounts and commissions⁽¹⁾
Proceeds to us, before expenses

(1)	Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the offering price payable to the underwriters. We refer you to “Underwriting” beginning on page 122 for additional information regarding underwriters’ compensation.

We have granted a 45-day option to the representative of the underwriters to purchase up to 725,338 additional shares of common stock solely to cover over-allotments, if any.

The underwriters expect to deliver the shares to purchasers on or about June , 2021.

ThinkEquity

a division of Fordham Financial Management, Inc.

The date of this prospectus is , 2021

Table of Contents

TABLE OF CONTENTS



Prospectus Summary	1

Risk Factors	21

Special Note Regarding Forward-Looking Statements	54

Use of Proceeds	54

Dividend Policy	55

Capitalization	55

Dilution	55

Management’s Discussion and Analysis of Financial Condition and Results of Operations	56

Business	70

Management	106

Executive Compensation	110

Principal Stockholders	115

Transactions with Related Persons	116

Description of Securities	117

Material U.S. Federal Tax Considerations for Non-U.S. Holders of our Common Stock	119

Underwriting	122

Legal Matters	128

Experts	129

Where You Can Find More Information	129

Financial Statements	F-1

You should rely only on the information contained in this prospectus or in any amended prospectus that we may authorize to be delivered or made available to you. We and the underwriters have not authorized anyone to provide you with different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where such offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of its delivery or any sale of shares of our common stock.

Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of the prospectus outside the United States. See “Underwriting.”

Table of Contents

PROSPECTUS SUMMARY

This summary highlights information that we present more fully in the rest of this prospectus. This summary does not contain all of the information you should consider before buying our shares in this offering. This summary contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements. See “Special Note Regarding Forward-Looking Statements.” You should read the entire prospectus carefully, including the “Risk Factors” section and the financial statements and the notes to those statements.

THE COMPANY

Overview

Revolutionizing Next-Gen Allogenic CAR Therapies for Solid Tumors.

We are a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology.

Our proprietary target discovery engine is called “Diamond.”

Kiromic’s Diamond is big data science meeting target identification, dramatically compressing man-years and billions of drug development dollars to develop a live drug.

Without Kiromic’s Diamond, the management of all the data required to solve the Target Identification puzzle is both challenging and inefficient. Normal data required for target identification would require manual analysis of thousands of cancer tissue samples with billions of data points, looking at millions of mutations, and poring over thousands of publications on oncology and targets.

Diamond (Screening, Prioritizing, and Harmonizing)

Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells. Diamond is an artificial intelligence and machine learning approach that can identify novel surface tumor targets. It uses public and proprietary samples and can expand into the tumor target space.

Diamond addresses the main challenges in today’s clinical pipeline: target identification.

Table of Contents

Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR-T cell therapies and vaccine therapies.

Diamond’s cognitive and deep learning capabilities extract information from our extensive digital library consisting of clinical studies, genomic and proteomic datasets. Diamond harmonizes all the raw data and creates datasets, which allows us to screen for cancer targets. Diamond will identify and prioritize lists of genes (biomarkers, wild type, mutant, isoform, neoepitope, etc.) that are highly and specifically expressed in the disease of interest while providing its distribution and methylation status across the entire patient population. It also maps out the exact portion of the gene that will elicit an immune response.

Diamond performs meta-analysis and convolution studies while standardizing and normalizing data across multiple and variable experimental platforms, then allows for the visualization of consistent and accurate results in a user-friendly fashion.

Table of Contents

See our Diagram below which will walk readers through our process of going from antigens and target libraries to finish with target selection by our artificial intelligence engine.

Table of Contents

Prioritizing T and B Cell Targets. Diamond generates a prioritized list of immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR T cell therapies and vaccine therapies.

Identify Highly Expressed Genes. Diamond’s cognitive and deep learning capabilities extract information from our extensive digital library consisting of clinical studies, genomic and proteomic datasets. Diamond harmonizes all the raw data and creates datasets which allows us to screen for cancer targets. Diamond will identify and prioritize lists of genes (biomarkers, wild type, mutant, isoform, neoepitope, etc.) that are highly and specifically expressed in the disease of interest while providing its distribution status across the entire patient population. It also maps out the exact portion of the gene that will elicit an immune response.

Performs Meta Analysis. Diamond performs meta-analysis and convolution studies while standardizing and normalizing data across multiple and variable experimental platforms, then allows for the visualization of consistent and accurate results in a user-friendly fashion.

Predict Isoform Targets. Cancer cells will down regulate or shed targets in order to avoid detection and destruction by T cells (the immune system). These variations are known as isoforms. CancerSplice also shows a box plot by tissue of expression of the isoform in normal cancer genome atlas tissues and a box plot of the matching isoform in genotype-tissue expression program normal data. The sequence of amino acids that are specific for the selected cancer isoforms are then directly fed to Diamond’s artificial neural capsule network for peptide design and prioritization.

CancerSplice (Isoform Target Prediction)

Table of Contents

can preferentially expand to avoid detection and destruction by T cells. These isoforms can make it impossible for T cells to outright bind the targets on cancer cells. No binding to the target means no killing of cancer cells.

To solve the problem of identifying shared, common cancer-specific antigens derived from alternative splicing and cancer-specific isoform formation, we have developed a fully integrated in silico methodology to predict cancer-specific isoforms called CancerSplice.

CancerSplice allows for the prediction and prioritization of iso-antigens which could serve as a novel source of tumor targets, highly specific for neoplastic cells but without the drawback of also being highly patient-specific.

CancerSplice allows the user to select a tissue type from the cancer genome atlas along with thresholds for filtering isoforms (minimum and maximum tumor and normal cell transcript parts per million). Based on the tissue selected, CancerSplice displays a sorted list of isoforms that are elevated in high-expressing tumors versus normal tissues which have low expression. Differential analysis is then performed and used to generate two types of lists: (1) isoforms expressed in tumor but not expressed in normal tissues; and (2) isoforms expressed in normal tissues but yet at a much higher level in tumors. CancerSplice then allows the user to click on an isoform in the list to select a specific isoform to display in a detailed panel, which shows the multi-sequence alignment for the isoform, as well as all the other isoforms of that gene.

Finally, CancerSplice also shows a box plot by tissue of expression of the isoform in normal cancer genome atlas tissues and a box plot of the matching isoform in genotype-tissue expression program normal data. The sequence of amino acids that are specific for the selected cancer isoforms are then directly fed to Diamond’s artificial neural capsule network for peptide design and prioritization. Therefore, we believe that we have developed unique tools to address the issue with tumor-specific iso-antigens through CancerSplice and Diamond.

Target isoforms are protein variants of the same targets that occur during the normal processing of immature gene transcripts to the mature form.

Target isoforms include variations in their primary amino acid sequence that can change both the final folded form of the target plus their ability to be recognized by modified T cells (autologous/allogeneic) and other cells, such as NK or invariant NKT cells (often used in the allogeneic setting).

Table of Contents

If they are the predominate form on the cell surface, these isoforms can make it impossible for T cells to outright bind the targets on cancer cells.

No binding or insufficient binding to the isoform results in no killing of cancer cells.

Our CancerSplice accurately predicts the most appropriate isoforms for T cells to bind and destroy cancer cells.

Immune Therapies Using Our Artificial Intelligence Selected Targets

With our artificial intelligence (Diamond), we seek to use our targets to train immune cells. The trained immune cells generate a therapeutic immune response in patients. These peptide sequences, known as tumor-specific iso-antigens, generate an immunological response and therefore eradicate cancer cells.

We are developing our brand of CAR cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). These are designed to treat cancer by capitalizing on the immune system’s ability to destroy cancer cells. These products are in the pre-IND stage of the FDA clinical trial process. We are currently going through the IND enabling trials process for these product candidates and we expect that first in human dosing in Phase I of clinical trials will commence in the third quarter of 2021.

CAR-T cell therapy, a form of cancer immunotherapy, has recently emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers. In 2017, two autologous anti-CD19 CAR-T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., (now part of Gilead), were approved by the FDA for the treatment of relapsing/remitting B cell precursor acute lymphoblastic leukemia and relapsing/remitting large B cell lymphoma, respectively. Autologous CAR-T cell therapies are manufactured individually for the patient’s use by modifying the patient’s own T cells outside the body, causing the T cells to express CARs. The entire manufacturing process is dependent on the viability of each patient’s T cells and takes approximately three to four weeks. Allogenic T cell therapies involve engineering healthy donor T cells, which we believe will allow for the creation of an inventory of off-the-shelf products that can be delivered to a larger portion of eligible patients throughout the world.

Table of Contents

We have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since we began principal business operations in 2012.

Engineered T Cell Therapy

White blood cells are a component of the immune system and are responsible for defending the body against infectious pathogens and other foreign material. T cells are a type of white blood cell and are involved in both sensing and killing infected or abnormal cells, including cancer cells, as well as coordinating the activation of other cells in an immune response.

T cells can be distinguished from other white blood cells by T cell receptors present on their cell surface. These receptors contribute to tumor surveillance by directing T cells to recognize infected and destroy cancerous cells. When T cells with cancer-specific receptors are absent, present in low numbers, of poor quality or rendered inactive by suppressive mechanisms, cancer may grow and spread. In addition, standard of care treatments, such as chemotherapy regimens, as well as disease specific factors can damage the patient’s immune system, thereby inhibiting the ability of T cells to kill cancer.

Engineered T cell therapy is a type of immunotherapy treatment whereby human T cells are removed from the body and engineered to express CARs which, when infused into a patient, may recognize and destroy cancer cells in a more targeted manner.

CARs are engineered molecules that, when present on the surface of a T cell, enable the T cell to recognize specific proteins or antigens that are present on the surface of other cells.

There are two primary approaches to engineered T cell therapy: autologous and allogenic. Autologous therapies use engineered T cells derived from the individual patient, while allogenic therapies use engineered T cells derived from healthy donor T cells.

The autologous approach, pioneered by Novartis, Kite and others, has been highly successful in engineering patients’ immune systems to fight cancer, in particular CD19 positive cancers, resulting in significant remission rates. Autologous products are manufactured by first collecting a patient’s white blood cells, through a process known as leukapheresis, separating the T cells from the patient’s blood sample and proliferating the isolated T cells. After the cells have multiplied, the CAR construct is virally transduced into the T cells and the engineered T cells are then propagated until a sufficient number of cells are available for infusion into the patient. Finally, the engineered T cells are frozen, and then shipped back to the clinical center for administration to the patient. The process from leukapheresis to delivery to the clinical center takes approximately three to four weeks.

Allogenic engineered T cells are manufactured in a similar manner as autologous, but with two key differences: (1) allogenic T cells are derived from healthy donors, not cancer patients, and (2) allogenic T cells must also be genetically engineered to minimize the risk of graft-versus-host disease, a condition where allogenic T cells can recognize the patient’s normal tissue as foreign and cause damage in the patient.

Our Approach

Our operating motto is Better Target, Better Life™.

Our goal is to defeat cancer by developing immunotherapies that rely on improving target discovery and validation. With better targets, we believe our therapies will be more effective than the current crop of immunotherapies using older targets.

Table of Contents

We are currently in the process of validating different tumor-specific immunotherapy product candidates for refractory CAR-T cell patients. Refractory CAR-T cell patients are those who have received CAR-T cell treatments for their indication, however, they either showed low or no benefit from this treatment. We validate biomarkers for these product candidates using the technologies and processes discussed in the sections below. The development schema below describes the path forward for developing our novel product candidates.

ABBIE Summary

ABBIE is a novel gene-editing system for inserting therapeutic genes safely into the genome of a host cell.

ABBIE technology comprises two main components, (i) a genome template (extracted from the ALEXIS plasmid), containing the therapeutic genes needed to retrain tumor-killing cells, and (ii) the gene-editing machinery required to safely insert this template into the genome of the therapeutic cells.

The ABBIE protein accompanies the CAR-containing genome template as it passes through the cell membrane into the nucleus and guides the template-flanking sequences (the “glue”) safely into the target genome.

Due to this targeting ability, ABBIE can also be used to remove unwanted, inhibitory genes. CAR expression on the Gamma-Delta T cells allows them to detect and destroy the antigen-expressing targeted cells.

The OFF switch permits fast shutdown in the event of an unexpected toxicity. Additional Anti-tumor factors can help neutralize the toxic tumor microenvironment.

ABBIE: Development

We are currently developing ABBIE (A Binding-Based Integrase Enzyme) for delivering our product candidates. ABBIE is a non-viral gene-editing mechanism to insert the target DNA template information into the T cell genome at a predetermined locus. ABBIE allows for insertion of the genome template into the T cells so that they could express the CAR protein and other accessory proteins while possibly eliminating unwanted inhibitory proteins.

Table of Contents

The non-viral vector template is simultaneously physically comingled with the patient’s T/NK cells. The non-viral vector transfers the target’s genomic information into the T/NK cells, where it is integrated into the T/NK cell’s genome. T/NK cells now have been reprogramed with the genomic information for targeting and can successfully identify the targets on the cancer cells. This T/NK cell therapy is infused into the patient. T/NK cells will hunt down cancer cells with the known targets and destroy these cancer cells.

We believe that this gene delivery platform will deliver the DNA template to the T/NK cell genomes at a lower cost and shorter timeframe versus a viral vector. By comparison, a retroviral vector would have a longer development lead time (~12 months) with an increased insertional mutagenesis risk. Insertional mutagenesis means that a random insertion of the DNA could activate uncontrolled cell growth. ABBIE allows for a more consistent expression and will have a shorter development lead time (3-6 months). It avoids unnecessary risks by targeting a single locus and produces more predictable cell-to-cell expressions.

The development of ABBIE involves a multi-step process, which includes preparation of an integration-deficient lentivirus, a sensitive, targeted gene knock-out assay system, optimization of an inducible ABBIE protein expression system, a powerful screen for gene targeting efficiency, and a sensitive screen of additional ABBIE mutants to further improve efficacy. Altogether, the development plan involves construction of dozens of plasmid constructs, which are complete. To date, we have successfully completed the high transduction efficiency lentivirus system for our assays along with the non-integrating lentivirus system. Optimization of the selection schema is over 70% complete and the construction of the inducible expression and knock-out systems are well underway.

Table of Contents

SWITCHES

ACTIVATION Switch. A rapidly deployed activation switch can provide a survival and proliferation signal to the therapeutic cells to enhance their efficacy and persistence in vivo.

ATTENUATION Switch. A rapidly deployed attenuation switch can intercept activation signals transiently to minimize toxicity following successful anti-tumor interactions. Choice of two non-mutually exclusive Attenuation Switch approaches: (a) a protein-based switch that rapidly triggers attenuation of target cells in a dose-dependent fashion. (b) a small molecule-based approach to rapidly and reversibly attenuate cell signaling.

SAFETY Switch. A rapidly deployed, protein-based safety switch can eliminate therapeutic cells in case of acute toxicity. The safety switch is designed to eliminate either: (a) essentially all active therapeutic cells. (b) only the most active cells, preserving a cohort of backup therapeutic cells for long-term control of residual relapsing tumor cells. The Safety Switch will be co-expressed along with the bioactive chimeric activation receptor (CAR), the Activation Switch, and the Attenuation Switch.

Table of Contents

Manufacturing Allogeneic Effector Cells

The three primary steps to creating our engineered effector cells are: (1) collection, (2) gene editing, and (3) purification, formulation, and storage.

Manufacturing

Step 1. Collection

The starting material for our engineered gamma delta T cell products are white blood cells. For our allogenic products, the cells are collected from a healthy donor. The collected cells are then sent to the Kiromic central processing facility, where the peripheral blood mononuclear cells, including gamma delta T cells, are isolated from the other sample components.

Step 2. Gene Editing

These cells are stimulated to proliferate, then transduced with a non-replicating retroviral vector.

We are also developing ABBIE, which is a non-viral gene-editing mechanism to insert the target DNA template information into the gamma delta T cell genome. The genomic sequence will direct the expression of proteins on the cell surface that allows the transduced gamma delta T cells to recognize and bind to a target molecule that is present on cancer cells.

Step 3. Purification, Formulation, and Storage

These engineered cells are then propagated in cell culture bags until sufficient cells are available. The engineered gamma delta T cells are then washed and frozen at the cell processing site.

For our allogenic products, the engineered cells are frozen and sent to long-term storage in the vapor phase of liquid nitrogen. This inventory will be securely stored and then shipped to oncology centers as needed.

Table of Contents

As noted previously, the gene editing is currently being done with an industry standard retroviral vector, however, in future versions we expect to utilize our non-viral ABBIE gene editing platform.

Our Product Pipeline and Development

Using our proprietary technologies, we are researching and developing multiple product candidates for the treatment of blood cancers and solid tumors. Our product candidates are allogenic engineered cells to be used for specific patients or as off-the-shelf treatments for any patient with a particular cancer type. Each product candidate targets a selected antigen expressed on tumor cells and bears specific engineered attributes.

Table of Contents

Our product pipeline and clinical program projected timelines (clinical timelines and final patient accrual numbers are predicated upon FDA review and will be modified in accordance to FDA particular requirements) are represented in the diagrams below:

Clinical Program

Not only is cancer the second leading cause of mortality worldwide, but 90% of cancer deaths are due to metastatic disease, with the remainder due primarily to locally advanced disease. Current treatments for locally advanced disease include systemic chemotherapy, radiation, and surgery, but offer only limited benefit for many subjects with locally advanced disease that is not amendable to curative surgical resection.

Table of Contents

The field of immunotherapy is currently expanding with a variety of approaches and Kiromic Biopharma’s suite of gamma delta T cell therapies is uniquely positioned to make an impact in this setting based upon our promising preclinical in vitro and in vivo studies which have revealed strong and specific tumor cytotoxicity with minimal adverse effects.

Clinical Program

The ALEXIS platform of products has been designed to incorporate our Diamond target discovery platform into an off the shelf (allogeneic) gamma delta T cell therapy that will be able to address the challenging patient population of metastatic and progressive locally advanced solid malignancies (including ovarian, malignant pleural mesothelioma, and multiple other indications as well).

Multiple solid malignancies express one or both of these biomarkers, and we anticipate that they will eventually be combined into a single powerful CAR-T cell for solid malignancies, or as a synergistic dual therapy that will achieve an impact in this devastating disease.

ALEXIS-ISO-1

Our allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin (the isoform of Mesothelin).

ALEXIS-PRO-1

Our allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1

Our Risks and Challenges

Our prospects should be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by similar companies. Our ability to realize our business objectives and execute our strategies is subject to risks and uncertainties, including, among others, the following:

We have never been profitable and may never achieve or maintain profitability.

If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.

We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.

Our business is dependent on the successful development, regulatory approval and commercialization of our personalized immunotherapy product candidates, which are in the early stages of development and have not been tested in humans.

Our tumor-specific cancer immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.

We may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our immunotherapy candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.

The genome editing field is relatively new and evolving rapidly, and other existing or future technologies may provide significant advantages over our Diamond, CancerSplice and ABBIE technologies, which could materially harm our business.

Table of Contents

If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.

We plan to enter into significant arrangements with collaborators and expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects.

We expect to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.

We may rely on third parties for the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business.

The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.

We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.

Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.

The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.

Our ability to compete effectively in our markets may decline if we do not adequately protect our patents and proprietary rights, and our patents and proprietary rights do not necessarily address all potential threats to our competitive advantage.

In addition, we face other risks and uncertainties that may materially affect our business prospects, financial condition, and results of operations. You should consider the risks discussed in “Risk Factors” and elsewhere in this prospectus before investing in our common stock.

Our Corporate History

We were first organized as a corporation in the State of Texas on August 6, 2006 under the name “Kiromic, Inc.” Between 2006 and 2012, we had minimal operations. On March 15, 2013, we converted to a limited liability company in the State of Texas under the name “Kiromic, LLC.” On May 27, 2016, we converted to a corporation in the State of Delaware under the name “Kiromic, Inc.” On December 16, 2019, we changed our name to “Kiromic BioPharma, Inc.”

We have one wholly-owned subsidiary, GreenPlanet Pharma, Inc., which was incorporated in the State of Delaware on November 26, 2018. GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This subsidiary has not generated any revenues.

Corporate Information

Our principal executive office is 7707 Fannin, Suite 140, Houston, TX 77054. Our telephone number is (832) 968-4888. Our website is www.kiromic.com. The information contained on our website is not a part of this prospectus, nor is such content incorporated by reference herein, and should not be relied upon in determining whether to make an investment in our common stock.

Table of Contents

Implications of Being an Emerging Growth Company

We qualify as an “emerging growth company” under Jumpstart Our Business Act of 2012, as amended, or the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., Critical Audit Matters);

submit certain executive compensation matters to stockholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and

disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an emerging growth company for up to five years from October 15, 2020, which was the date of the first sale of equity securities pursuant to our first effective registration statement as a publicly traded company, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

Table of Contents

THE OFFERING


Common stock offered by us		4,835,590 shares of common stock, $0.001 par value per share.
Over-allotment option		The underwriters have an option for a period of 45 days to acquire up to an additional 725,338 shares of common stock from us at the public offering price, less the underwriting discount, solely for the purpose of covering over-allotments, if any.
Shares of common stock outstanding before this offering⁽¹⁾		7,387,500 shares of common stock.
Shares outstanding after this offering		12,223,090 shares of common stock (or 12,948,428 shares of common stock if the underwriters exercise their over-allotment option in full)
Use of proceeds		We estimate that we will receive net proceeds of approximately $45,519,000 (or approximately $52,419,000 if the underwriters exercise their over-allotment option in full) from the sale of common stock by us in this offering. We plan to use the net proceeds of this offering primarily for clinical trials for our ALEXIS-ISO-1 and ALEXIS-PRO-1 product candidates, GMP facility expansion, intellectual property protection and reinforcement, IND applications and IND enabling trials and working capital and general corporate purposes. The details of our plans are set forth in the “Use of Proceeds” section
Risk factors		Investing in our common stock involves a high degree of risk and purchasers of our common stock may lose part or all of their investment. See “Risk Factors” for a discussion of factors you should carefully consider before deciding to invest in our common stock.
Nasdaq Capital Market symbol		“KRBP”

(1)	The number of shares outstanding is based on shares outstanding as of June 25, 2021 and excludes the following:

558,435 shares of our common stock issuable upon the exercise of outstanding options with a weighted-average exercise price of $8.90 per share;

1,100,281 shares of our common stock issuable upon the vesting of restricted stock units with a weighted-average grant date fair value of $12.22 per share;

62,500 shares of our common stock underlying underwriter’s warrants issued in October 2020 with an exercise price of $15.00 per share;

up to an additional 193,052 shares of our common stock issuable under our Omnibus 2021 Equity Incentive Plan; and

241,780 shares of our common stock underlying the warrants to be issued to the representative of the underwriters in connection with this offering.

Except as otherwise indicated herein, all information in this prospectus assumes the following:

no exercise of the underwriters’ option to purchase up to an additional 725,338 shares of common stock to cover allotments, if any.

SUMMARY FINANCIAL INFORMATION

The following tables summarize our consolidated financial data. We have derived the summary consolidated statement of operations data for the years ended December 31, 2020 and 2019 from our audited consolidated financial statements included elsewhere in this prospectus. The interim condensed consolidated statements of operations data for the three months ended March 31, 2021 and 2020 and interim condensed consolidated balance sheet data as of March 31, 2021 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Such information should be read in conjunction with our

Table of Contents

financial statements and related notes included elsewhere in the prospectus and the information contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below.

Our financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. Our historical results for any period are not necessarily indicative of our future performance.


	Years Ended December 31,				Three Months Ended March 31,
	2020		2019		2021		2020
Statements of Operations Data
Operating expenses:
Research and development	$	5,052,900	$	1,201,700	$	1,885,600	$	1,028,100
General and administrative		14,144,000		2,503,700		2,071,000		824,600
Total operating expenses		19,196,900		3,705,400		3,956,600		1,852,700
Loss from operations		(19,196,900)		(3,705,400)		(3,956,600)		(1,852,700)
Other income (expense)		(3,300)		(22,500)		102,100		—
Net loss	$	(19,200,200)	$	(3,727,900)	$	(3,854,500)	$	(1,852,700)
Net loss per share – basic and diluted	$	(4.42)	$	(1.39)	$	(0.53)	$	(0.78)


	March 31, 2021
	Actual		As adjusted⁽¹⁾
Balance Sheet Data
Cash and cash equivalents	$	7,335,300	52,854,300
Working capital		6,148,900	51,667,900
Total assets		10,152,700	55,671,700
Total liabilities		1,699,900	1,699,900
Total stockholders’ equity		8,452,800	53,971,800

(1)

Gives effect on an as adjusted basis to the sale and issuance by us of 4,835,590 shares of common stock in this offering at an assumed public offering price of $10.34 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on June 24, 2021, after deducting the estimated underwriting discounts and commissions and our estimated offering expenses.

Table of Contents

RISK FACTORS

The shares being offered by us are highly speculative in nature, involve a high degree of risk and should be purchased only by persons who can afford to lose the entire amount invested. Before purchasing any of our shares, you should carefully consider the following factors relating to our business and prospects. If any of the following risks actually occurs, our business, financial condition or operating results will suffer, the trading price of our stock could decline, and you may lose all or part of your investment.

Risks Related to Our Business and Industry

We have never been profitable and may never achieve or maintain profitability.

We have not commercialized any products and have yet to generate any revenue from product sales. The amount of our future net losses will depend, in part, on our expenses and our ability to generate revenues. Our current and future product candidates will require substantial additional development time and resources before we may realize revenue from product sales, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

continue our current research and development programs, including conducting laboratory, preclinical and greenhouse studies for product candidates;

initiate clinical or field trials for product candidates;

seek to identify, assess, acquire or develop additional research programs or product candidates;

maintain, expand and protect our intellectual property portfolio;

seek marketing approvals for any product candidates that may successfully complete development;

establish a sales, marketing and distribution infrastructure to commercialize any products that may obtain marketing approval;

further develop and refine the manufacturing process for our product candidates;

change or add additional manufacturers or suppliers of biological materials or product candidates;

validate a commercial-scale manufacturing facility compliant with current good manufacturing practices, or cGMP;

further develop our genome editing technology;

acquire or in-license other technologies;

seek to attract and retain new and existing personnel; and

expand our facilities.

No clinical studies have begun on any of our new therapeutic product candidates, and it will be several years, if ever, before we obtain regulatory approval for a therapeutic product candidate, at which time any revenues for such product candidate will depend upon many factors, including, market conditions, costs and effectiveness of manufacturing, sales, marketing and distribution operations related to such product candidate, and the terms of any collaboration or other strategic arrangement we may have with respect to such product candidate and levels of reimbursement from third-party payors.

If we are unable to develop and commercialize one or more product candidates either alone or with collaborators, or if revenues from any product candidate that receives marketing approval or is commercialized are insufficient, we may not achieve profitability or sustain profitability, which would have an adverse effect on the value of our common stock will be materially adversely affected.

Table of Contents

The process of identifying product candidates and conducting preclinical and clinical trials is time consuming, expensive, uncertain and takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical or field trials of, and seek marketing approval for, product candidates. In addition, if any therapeutic product candidate that we develop alone or with collaborators obtains marketing approval, we may incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution efforts. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise sufficient capital when needed, we may be forced to delay, reduce or eliminate current or future research programs, product development activities and/or commercialization efforts.

Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis or on favorable terms, we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization efforts. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events could materially adversely affect our financial condition and business prospects.

We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.

We are a genome editing company with a limited operating history. We began principal business operations in 2012 and spent the first three years of our company’s history developing and refining our core technology, and only since then have we focused our efforts on advancing the development of product candidates.

Investment in biopharmaceutical product development is a highly speculative endeavor and entails substantial upfront capital expenditures. There is significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain any required regulatory approvals or become commercially viable. Our platforms and the technologies we are using are new and unproven. We have not yet commenced human clinical trials for any of our product candidates, nor have we demonstrated an ability to initiate or successfully complete any clinical trials, obtain any required marketing approvals, manufacture products, conduct sales, marketing and distribution activities, or arrange for a third party to do any of the foregoing on our behalf.

Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing products. Our limited operating history, particularly in light of the rapidly evolving nature of the biopharmaceutical industries and the genome editing field, may make it difficult to evaluate our technology and business prospects or to predict our future performance.

We may expend our limited resources pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates.

Research programs to identify new product candidates and product development platforms require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs, product candidates or product development platforms that ultimately prove to be unsuccessful. Clinical trials of any of our product candidates is not assured despite the expenditure of significant resources in pursuit of their development, and our spending on current and future research and development programs, product candidates and product development platforms may not yield any commercially viable products.

Additionally, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

Our financial situation creates doubt whether we will continue as a going concern.

We have not generated any revenues to date. For the years ended December 31, 2020 and 2019, we have had a net loss of $19,200,200 and $3,727,900, respectively. For the three months ended March 31, 2021 and 2020, we had a net loss of $3,854,500 and $1,852,700, respectively. There can be no assurances that we will be able to achieve a level of revenues adequate to generate sufficient cash flow from operations or obtain funding from this offering or additional financing through private placements, public offerings and/or bank financing necessary to support our working capital requirements. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern.

Table of Contents

Our business may be adversely affected by the ongoing coronavirus pandemic.

The extent to which the novel coronavirus (“COVID-19”) impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain COVID-19 or treat its impact, among others.

Should COVID-19 persist, our business operations could be delayed or interrupted. For instance, our research and development may be affected by the pandemic. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If COVID-19 persists or spreads, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our research activities, including clinical trials.

Infections and deaths related to the pandemic may disrupt the United States’ healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.

In the event of a new shelter-in-place order or other mandated local travel restrictions, our employees conducting research and development or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.

The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the persistence COVID-19 could materially and adversely affect our business and the value of our common stock.

The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely.

We identified material weaknesses in our internal control over financial reporting at December 31, 2020, and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.

As a public company we are required to comply with the SEC’s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which requires management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. Though we will be required to disclose changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal control over financial reporting pursuant to Section 404 until the year following our first annual report required to be filed with the SEC. However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not effective.

Notwithstanding the foregoing, in connection with the audit of our financial statements for the year ended December 31, 2020, we and our auditors identified certain control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

Table of Contents

The material weaknesses resulted from (i) our lack of a formalized internal control framework, (ii) our lack of segregation of duties in the financial reporting process, and (iii) our lack of qualified technical accounting personnel. These remain material weakness as of the date of this prospectus. In order to remediate these material weaknesses, we have hired and plan to continue to hire additional accounting, finance, system engineers, and data analysts. We have implemented, and plan to continue to implement, new controls, new processes and technologies to implement formalized internal controls framework and procedures. We cannot assure you that the measures that we have taken to remediate, and that will be taken to remediate, these material weaknesses will be sufficient to prevent future material weaknesses from occurring. We also cannot assure you that we have identified all of our existing material weaknesses.

In light of the control deficiencies and the resulting material weaknesses that were identified, we believe that it is possible that, had we and our registered public accounting firm performed an assessment or audit, respectively, of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.

When evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404. If we are unable to remediate our existing material weaknesses or identify additional material weaknesses and are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting once we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources.

Risks Related to our Product Candidates

We have no products approved for sale. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of ALEXIS-ISO-1, ALEXIS-PRO-1, as well as other product candidates derived from our tumor-specific immunotherapy approach, which may never occur.

In the future, we may also become dependent on other product candidates that we may develop or acquire; however, no product candidates based on our tumor-specific immunotherapy approach have been tested in humans and given our early stage of development, it may be many years, if at all, before we have demonstrated the safety and efficacy of a personalized immunotherapy treatment sufficient to warrant approval for commercialization.

We have not previously submitted a biologics license application, or BLA, to the FDA or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.

We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions.

Table of Contents

The clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following:

our ability to raise any additional required capital on acceptable terms, or at all;

timely completion of our preclinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;

whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates;

acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;

our ability to consistently manufacture our product candidates on a timely basis;

our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs;

our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of our product candidates;

the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;

the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;

achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our lead product candidates or any future product candidates or approved products, if any;

the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our cancer immunotherapy approach;

our ability to successfully develop a commercial strategy and thereafter commercialize our current product candidates or any future product candidates in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;

the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved;

the convenience of our treatment or dosing regimen;

acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;

patient demand for our current or future product candidates, if approved;

our ability to establish and enforce intellectual property rights in and to our product candidates; and

our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.

These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidate or any future product candidates to continue our business or achieve profitability.

Table of Contents

We are using our proprietary technologies to develop tumor-specific immunotherapy product candidates to treat cancer. Our foundational science and product development approach are based on our ability to predict the presence of a patient’s tumor-specific iso-antigens, or TSIAs, and develop a TSIA-directed therapy that will elicit a meaningful specific immune-system cell response (T or NK cells). We believe that this approach may offer an improved therapeutic effect by driving an intense, focused attack selectively upon a patient’s tumor. However, this approach to treating cancer is novel and the scientific research that forms the basis of our efforts to predict the presence of TSIA and to develop a CAR that targets TSIA-directed cancer immunotherapy candidates is both preliminary and limited.

Our tumor-specific immunotherapy product candidates have experienced limited testing in humans. We are currently in the process of validating different tumor-specific immunotherapy product candidates. When we validate adequate biomarkers for these product candidates, we will commence preclinical animal studies, and the results of our preclinical animal studies may not translate into humans. For example, our prediction model may fail to accurately predict the presence of TSIAs, resulting in little or no T cell activity, or our therapy may fail to elicit a significant or durable enough T or NK cell response to effectively destroy a tumor.

As such, we cannot assure you that even if we are able to develop cancer immunotherapy candidates capable of recognizing TSIA and eliciting a T cell response, that such therapy would safely and effectively treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.

Furthermore, no regulatory authority has granted approval for a cancer immunotherapy based on a heterologous prime-boost approach. As such, we believe the FDA has limited experience with evaluating our approach, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We may never receive approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications, lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings.

Diamond, CancerSplice and ABBIE are novel technologies, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of any product candidates in humans. Our success depends on our ability to develop and commercialize product candidates using our novel genome editing technology ABBIE. The novel nature of our technology makes it difficult to accurately predict the developmental challenges we may face for product candidates as they proceed through research, preclinical or greenhouse studies and clinical or field trials.

There have been a limited number of clinical trials of products created with genome editing technologies, none of which has utilized our technology, and no therapeutic product candidates created with other genome editing technologies have received marketing approval in the United States or Europe. Because our therapeutic research programs are all in research or preclinical stages, we have not yet been able to assess the safety or efficacy of any product candidates in humans.

Current or future product candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and may cause significant adverse events or toxicities. All of our product candidates are designed to act at the level of DNA, and because animal DNA differs from human DNA, it will be difficult for us to test our therapeutic product candidates in animal models for either safety or efficacy, and any testing that we conduct may not translate to their effects in humans. Moreover, animal models may not exist for some of the targets, diseases or indications that we intend to pursue.

Our product candidates may not be able to properly implement desired genetic edits with sufficient accuracy to be viable therapeutic products, and there may be long-term effects associated with them that we cannot predict at this time. Any problems we experience related to the development of our genome editing technology or any of our or our collaborators’ research programs or product candidates may cause significant delays or unanticipated costs, and we may not be able to satisfactorily solve such problems. These factors may prevent us or our collaborators from completing our preclinical studies or any clinical trials that we or our collaborators may initiate, or profitably commercializing any product candidates on a timely basis, or at all.

Table of Contents

To date, we have focused our efforts on optimizing our proprietary genome editing technology and exploring its potential applications. Other companies have previously undertaken research and development of genome editing technologies using sequence-specific DNA-cutting enzymes, or nucleases, that are designed to perform modifications in the DNA of living cells and organisms, or using zinc finger nucleases, transcription activator- like effector nucleases, or TALENs, and clustered regularly interspaced short palindromic repeats associated protein-9 nuclease, or CRISPR/Cas9, although none has obtained marketing approval for a product candidate developed using such technologies. Other genome editing technologies, or other existing or future technologies, may lead to the development of treatments or products that may be considered better suited for use in human therapeutics, which could reduce or eliminate our commercial opportunity.

We are heavily dependent on the successful development and translation of our technologies, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized. To date, we have invested substantially all of our efforts and financial resources to develop our technologies and advance our current product development programs, including conducting preclinical studies and other early research and development activities, and providing general and administrative support for these operations.

Our future success is dependent on our ability to successfully develop and, where applicable, obtain regulatory approval for, including marketing approval for, and then successfully commercialize, product candidates, either alone or with collaborators. We have not yet developed and commercialized any product candidates, and we may not be able to do so, alone or with collaborators. Our research and development programs may not lead to the successful identification, development or commercialization of any products.

The success of our business depends primarily upon our ability to identify, develop and commercialize products using our proprietary technologies.

All of our current product candidates and product development programs are still in the IND validation process. We may be unsuccessful in advancing those product candidates into clinical development or in identifying any developing additional product candidates.

Our ability to identify and develop product candidates is subject to the numerous risks associated with preclinical and early stage biotechnology development activities, including that:

the use of Diamond and CancerSplice may be ineffective in identifying additional product candidates;

the use of ABBIE may be ineffective in accurately inserting the product candidate into tumor-targeting effector cells;

we may not be able to assemble sufficient resources to acquire or discover additional product candidates;

we may not be able to enter into collaborative arrangements to facilitate development of product candidates;

competitors may develop alternatives that render our product candidates obsolete or less attractive;

our product candidates may be covered by third parties’ patents or other exclusive rights;

the regulatory pathway for a product candidate may be too complex, expensive or otherwise difficult to navigate successfully; or

our product candidates may be shown to not be effective, have harmful side effects or otherwise pose risks not outweighed by such product candidate’s benefits or have other characteristics that may make the products impractical to manufacture, unlikely to receive any required marketing approval, unlikely to generate sufficient market demand or otherwise not achieve profitable commercialization.

Even if we do commence clinical trials of product candidates and continue to identify new product candidates, such product candidates may never be approved. Failure to successfully identify and develop new product candidates and obtain regulatory approvals for our products would have a material adverse effect on our business and financial condition and could cause us to cease operations.

Table of Contents

We sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies or clinical or field trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives.

The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates.

If our collaborators or ourselves fail to achieve announced milestones in the expected timeframes, the commercialization of the product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price of our common stock may decline.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.

We face an inherent risk of product liability and professional indemnity exposure related to the testing in clinical trials of our product candidates. We will face an even greater liability risk if we commercially sell any products that we or our collaborators may develop for human use.

Manufacturing defects, errors in product distribution or storage processes, improper administration or application and known or unknown side effects of product usage may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting from acts by our collaborators, licensees and subcontractors over which we have little or no control. For example, our liability could be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects, improper product administration or the deterioration of a patient’s condition, patient injury or even death.

Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates or products we develop alone or with collaborators caused harm, we could incur substantial liabilities.

Clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities.

Product liability insurance coverage may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage when we begin clinical trials and if our collaborators or ourselves successfully commercialize any products.

Risks Related to Our Organization, Structure and Operations

Our future success depends on our ability to retain our Chief Executive Officer, and other key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on the research and development experience, technical skills, leadership and continued service of certain members of our management and scientific teams, including Maurizio Chiriva Internati, our Chief Executive Officer, Scott Dahlbeck, our Chief Medical Officer, Gianluca Rotino, our Chief Strategy and Innovation Officer, and Tony Tontat, our Chief Financial Officer.

Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. We maintain a $10 million “key man” life insurance policy for Dr. Chiriva Internati, our Chief Executive Officer, but not for any of our other team members. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.

Table of Contents

Recruiting and retaining qualified scientific, clinical, manufacturing and, if we retain commercialization responsibility for any product candidate we develop alone or with collaborators, sales and marketing personnel, will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

The inability to recruit, integrate, motivate and retain additional skilled and qualified personnel, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business.

We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.

We will need to significantly expand our organization, develop, and commercialize product candidates alone or with collaborators. Our ability to compete effectively will depend in part on our ability to effectively manage any future growth. We may have difficulty identifying, hiring and integrating new personnel.

Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can identify and develop product candidates, enter into collaborative arrangements and otherwise operate our business will be limited.

Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel.

Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources from other projects, such as the development of product candidates. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, increase our expenses more than expected, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity.

Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.

Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and clinical trials or regulatory approvals for any of our product candidates could be suspended. We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors, our board committees or as our executive officers.

Table of Contents

Insurance coverage is becoming increasingly expensive, and in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. A successful liability claim or series of claims brought against us could require us to pay substantial amounts and cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.

We are subject to complex tax rules relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.

We are subject to income and non-income taxes in the United States. Income tax accounting often involves complex issues, and judgment is required in determining our provision for income taxes and other tax liabilities. We could become subject to income and non-income taxes in non-US jurisdictions as well. In addition, many operating foreign jurisdictions have detailed transfer pricing rules, which require that all transactions with non-resident related parties be priced using arm’s length pricing principles within the meaning of such rules. The application of withholding tax, goods and services tax, sales taxes and other non-income taxes is not always clear and we may be subject to tax audits relating to such withholding or non-income taxes. We believe that our tax positions are reasonable, and our tax reserves are adequate to cover any potential liability. We are currently not subject to any tax audits.

However, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow.

Our business and operations would suffer in the event of system failures or security breaches.

Despite the implementation of security measures, our computer systems, as well as those of third parties with which we have relationships, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures. If we were to experience a system failure, accident or security breach such an event caused interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs.

For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed.

The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and U.S. federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data. In the ordinary course of our business, we and third parties with which we have relationships collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators’ security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance or other disruptions, and any such breach could compromise our or their networks and the information stored there could be accessed, publicly disclosed, lost or stolen.

Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant costs, including regulatory penalties, fines and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or such third parties’ ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs.

Table of Contents

We or third parties with whom we have relationships may be adversely affected by natural or manmade disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Natural or manmade disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our facilities, that damaged our infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time, and our research and development activities could be setback or delayed.

The disaster recovery and business continuity plan(s) we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or third parties’ ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs.

Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.

Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:

the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, certain other healthcare providers starting in 2022 and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; and

Table of Contents

analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.

Some state laws require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require biotechnology companies to report information on the pricing of certain drug products.

State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation, or the GDPR, which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions, tightens existing European Union data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and if our efforts to comply with GDPR or other applicable European Union laws and regulations are not successful, it could adversely affect our business in the European Union. Moreover, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated, especially following the United Kingdom’s departure from the EU on January 31, 2020 without a deal. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom’s departure from the EU. In addition, on June 28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states.

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

Risks Related to Our Reliance on Third Parties

We expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects.

Working with collaborators poses several significant risks, including the following:

limited availability of resource allocation and other developmental decisions made by our collaborators about the product candidates or technologies that we seek to develop with them may result in the delay or termination of research programs, studies or trials, repetition of or initiation of new studies or trials or provision of insufficient funding or resources for the completion of studies or trials or the successful marketing and distribution of any product candidates that may receive approval;

Table of Contents

collaborators could independently develop, or develop with third parties, product candidates or technologies that compete directly or indirectly with our product candidates or technologies if the collaborators believe that competitive products or technologies are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation; and

disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization activities or that result in costly litigation or arbitration that diverts management attention and resources.

Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements. If our collaborations do not result in the successful development and commercialization of product candidates or technologies, or if one of our collaborators terminates its agreement with us, we may not receive any future funding or milestone or royalty payments under the collaboration.

If we do not receive the funding we expect under these agreements, our development of product candidates or technologies could be delayed, and we may need additional resources to develop such product candidates or technologies. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may need to raise additional capital to pursue further development or commercialization of the applicable product candidates or technologies.

These events could delay development programs and negatively impact the perception of our company in business and financial communities. Failure to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which we operate.

Moreover, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus apply to the activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish in the future are not effective and successful, it may damage our reputation and business prospects, delay or prevent the development and commercialization of product candidates and inhibit or preclude our ability to realize any revenues.

We expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations, or CROs, to conduct preclinical studies and future clinical trials for our product candidates. Nevertheless, we will be responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.

Although we intend to design the trials for our product candidates either alone or with collaborators, third parties may conduct all of the trials. As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Such third parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors.

Table of Contents

We also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For any violations of laws and regulations during the conduct of our preclinical studies and future clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.

If we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results of such completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

If our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization and require significantly greater expenditures.

As a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed.

If we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm our business.

We are dependent on third parties for the supply of various biological materials, such as cells, cytokines and antibodies, and the manufacture of product supplies, such as media, plasmids, mRNA and viral vectors, that are necessary to produce our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all.

Changing suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all. If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially reasonable terms or at acceptable quality levels, if at all.

If we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur additional costs in procuring such materials.

We may rely on third parties for the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business.

We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and expect that we will rely on outside vendors for at least a portion of the manufacturing process of product candidates that we or our collaborators may develop. The facilities used by our contract manufacturers to manufacture product candidates must be approved by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our collaborators engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing providers for compliance with cGMP requirements for manufacture of the product candidates.

We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in products that are safe and effective. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel.

Table of Contents

If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our or our collaborators’ potential products.

If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.

Our research and product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements for the development and potential commercialization of current and future product candidates or the development of ancillary technologies.

We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.

Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense.

Risks Related to Government Regulation

The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.

The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a BLA from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate’s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.

We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogenic T cell therapies for cancer. We may also request regulatory approval of future CAR-based product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee’s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.

We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:

obtaining regulatory authorization to begin a trial, if applicable;

the availability of financial resources to commence and complete the planned trials;

reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

Table of Contents

obtaining approval at each clinical trial site by an independent institutional review board, or IRB;

recruiting suitable patients to participate in a trial;

having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;

clinical trial sites deviating from trial protocol or dropping out of a trial;

addressing any patient safety concerns that arise during the course of a trial;

adding new clinical trial sites; or

manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials.

We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA’s review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.

Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.

We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.

The Biologics Price Competition and Innovation Act was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an approved biologic. Under the Biologics Price Competition and Innovation Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the Biologics Price Competition and Innovation Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.

We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

Table of Contents

The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.

Because we are developing novel CAR T cell immunotherapy product candidates that are novel biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies, formerly known as the Office of Cellular, Tissue and Gene Therapies, within its Center for Biologics Evaluation and Research to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise the Center for Biologics Evaluation and Research on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.

Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies was established within the European Medicines Agency in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products to assess the quality, safety and efficacy of advanced-therapy medicinal products, and to follow scientific developments in the field. Advanced-therapy medicinal products include gene therapy products as well as somatic cell therapy products and tissue engineered products.

These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.

Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.

The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.

If and when our planned Phase 1 clinical trials for ALEXIS ISOFORM and our other initial product candidates are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. If the results from our clinical trials are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.

Table of Contents

The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe an accelerated approval strategy is warranted given the limited alternatives for patients that our initial product candidates target, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.

Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;

the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;

we may be unable to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;

the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

Table of Contents

If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.

We may seek orphan drug designation for at least one of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.

Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek Regenerative Medicine Advanced Therapy, or RMAT, designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA’s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

Table of Contents

We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product’s approved uses (known as “off-label use”), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media.

Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things:

restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;

fines, warning letters or holds on clinical trials;

refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;

product seizure or detention, or refusal to permit the import or export of our product candidates; and

injunctions or the imposition of civil or criminal penalties.

The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. President’s administration may impact our business and industry. Namely, the current U.S. President’s administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA’s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority.

If these executive actions impose restrictions on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

Table of Contents

Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

The gene editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.

Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.

The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. We expect physicians in the large bone marrow transplant centers to be particularly influential and we may not be able to convince them to use our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our product candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:

the clinical indications for which our product candidates are approved;

physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;

the potential and perceived advantages of our product candidates over alternative treatments;

the prevalence and severity of any side effects;

product labeling or product insert requirements of the FDA or other regulatory authorities;

limitations or warnings contained in the labeling approved by the FDA;

the timing of market introduction of our product candidates as well as competitive products;

the cost of treatment in relation to alternative treatments;

the availability of coverage and adequate reimbursement by third-party payors and government authorities;

the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;

relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and

the effectiveness of our sales and marketing efforts.

If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete

Table of Contents

Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.

Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.

Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;

safe, effective and medically necessary;

appropriate for the specific patient;

cost-effective; and

neither experimental nor investigational.

Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time- consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare & Medicaid Services, or the CMS, revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates.

In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

Table of Contents

The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.

Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. In particular, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations, among other things, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our product candidates, under the Medicaid drug rebate program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid drug rebate program, extended the Medicaid drug rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government’s comparative effectiveness research. Additionally, the Affordable Care Act allowed states to implement expanded eligibility criteria for Medicaid programs, imposed a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program and implemented a new Patient-Centered Outcomes Research Institute. We are still unsure of the full impact that the Affordable Care Act will have on our business.

Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the U.S. President has signed two Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual’s failure to maintain Affordable Care Act-mandated health insurance, commonly known as the “individual mandate”, as part of the Tax Cuts and Jobs Act of 2017, or the Tax Act. On January 22, 2018, the U.S. President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including the so-called “Cadillac” tax on certain high cost employer- sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. In July 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.

Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2027, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

Table of Contents

In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President’s administration’s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current U.S. President’s administration released a “Blueprint”, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or the HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. On January 31, 2019, the HHS Office of Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products to consumers. While some of these and other proposed measures may require authorization through additional legislation to become effective, Congress and the current U.S. President’s administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.

Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

the demand for our product candidates, if we obtain regulatory approval;

our ability to set a price that we believe is fair for our products;

our ability to generate revenue and achieve or maintain profitability;

the level of taxes that we are required to pay; and

the availability of capital.

Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.

Risks Related to Intellectual Property

Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our business position.

The patent positions of biopharmaceutical and biotechnology companies and other actors in our fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office (the USPTO) and its foreign counterparts are sometimes uncertain and could change in the future.

Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or designed around. U.S. patents and patent applications may also be subject to interference or derivation proceedings, and U.S. patents may be subject to reexamination, post-grant review and/ or inter parties review proceedings in the USPTO.

Table of Contents

International patents may also be subject to opposition or comparable proceedings in the corresponding international patent office, which could result in either loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes.

Furthermore, even if not challenged, our patents and patent applications may not adequately protect our technology and any product candidates or products that we develop alone or with collaborators or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications that we hold with respect to our product candidates or potential products is threatened, it could dissuade companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, such product candidates or potential products.

In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries or to develop and commercialize our technology and product candidates or products without providing any compensation to us, or may limit the scope of patent protection that we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We rely on our outside counsel and employ an outside firm to pay these fees due to USPTO and non-US patent agencies. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Although an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market which would have a material adverse effect on our business.

If the patent applications we hold or have in-licensed with respect to our current and future research and development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our technology or any products and product candidates that we or our collaborators may develop, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our or our collaborators’ ability to commercialize future product candidates. Any such outcome could have a material adverse effect on our business.

Our ability to compete effectively in our markets may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantages.

We rely on patent protection as well as trademark, trade secret and other intellectual property rights protection and contractual restrictions to protect Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates. Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating to Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates, as well as successfully defending these rights against third-party challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates from unauthorized use by third parties to the extent that valid and enforceable patents or effectively protected trade secrets cover them.

Our ability to obtain and maintain patent protection for Diamond, CancerSplice, ABBIE, and ALEXIS and other product candidates is uncertain due to a number of factors, including the following factors:

we may not have been the first to invent the technology covered by our pending patent applications or issued patents;

we may not be the first to file patent applications covering product candidates, including their compositions or methods of use, as patent applications in the United States and most other countries are confidential for a period of time after filing;

our compositions and methods may not be patentable;

our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;

any or all of our pending patent applications may not result in issued patents;

Table of Contents

others may independently develop identical, similar or alternative technologies, products or compositions, or methods of use thereof;

others may design around our patent claims to produce competitive technologies or products that fall outside of the scope of our patents;

we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection;

we may not seek or obtain patent protection in countries and jurisdictions that may eventually provide us a significant business opportunity;

we may decide not to maintain or pursue patents and patent applications that, at some point in time, may cover our products, potential products, or product candidates;

any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages or may be successfully challenged by third parties;

others may identify prior art or other bases upon which to challenge and ultimately invalidate our patents or otherwise render them unenforceable;

the growing scientific and patent literature relating to engineered endonucleases and modified CAR-T/NK cells, including our own patents and publications, may make it increasingly difficult or impossible to patent new engineered nucleases and modified CAR-T/NK cells in the future;

our representatives or their agents may fail to apply for patents in a timely fashion; and

despite our efforts to enter into agreements with employees, consultants, collaborators, and advisors to confirm ownership and chain of title in patents and patent applications, an inventorship or ownership dispute could arise that may permit one or more third parties to practice our technologies or enforce our patent rights, including possible efforts to enforce patent rights against.

Even if we have or obtain patents covering Diamond, CancerSplice, ABBIE, and ALEXIS or any other product candidates or compositions, others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop any product candidates or to successfully commercialize any approved products alone or with collaborators. In addition, because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that may cover Diamond, CancerSplice, ABBIE, and ALEXIS or any other product candidates or compositions. These patent applications may have priority over patent applications filed by us.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products.

In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited.

Without patent protection for current or future product candidates, we may be open to competition from generic versions of such potential products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to those we or our collaborators may develop.

Table of Contents

In addition, we also try to protect our trade secrets, know-how and other proprietary information through non-disclosure and confidentiality provisions in our agreements with parties who have access to them, such as our employees, consultants and research partners. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets, know-how and/or other proprietary information in the event of unauthorized uses or disclosure or other breaches of the provisions, and we may not be able to prevent such unauthorized uses or disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure and uses is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. In addition, monitoring unauthorized disclosure and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the United States may be less willing to protect trade secrets.

We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

Because we may rely on third parties to manufacture our potential product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our current and potential product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our manufacturers, collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, are used inappropriately to create new inventions or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. Additionally, we may need to outsource and rely on third parties for many aspects of the development, sales and marketing of any products covered under our current and future license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our licensors. If we fail to comply with any of our obligations under these agreements, or we are subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license.

In some cases, patent prosecution of our licensed technology is controlled solely by the licensor. If such licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we license from such licensor, we could lose our rights to such intellectual property or the exclusivity of such rights, and our competitors could market competing products using such intellectual property. In that event, we may be required to expend significant time and resources to develop or license replacement technology.

If we are unable to do so, we or our collaborators may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. In other cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners.

Table of Contents

Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;

the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;

the sublicensing of patent and other rights under our collaborative development relationships;

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

the priority of invention of patented technology.

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, thereby potentially extending the term of marketing exclusivity for such product candidates, our business may be harmed.

In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process.

In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements.

Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Table of Contents

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk.

Our commercial success depends in part upon our ability to develop, manufacture, market and sell product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical, biotechnology is common, including patent infringement lawsuits, and such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings before the USPTO and corresponding international patent offices.

The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors.

Numerous United States, EU and other internationally issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.

For example, we are aware of certain patents held by third parties relating to the modification of CAR-T/NK cells, including the production of CAR-T/NK cells. Although conducting clinical trials and other development activities with respect to our CAR-T/NK product candidates is not considered an act of infringement in the United States, if and when any of our CAR-T/NK product candidates are approved by the FDA, those third parties may seek to enforce their patents by filing a patent infringement lawsuit against us.

As a result of any patent infringement claims, or in order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from a third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights.

These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we or our collaborators could be prevented from commercializing one or more product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly.

We or our collaborators might also be forced to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

Further, if a patent infringement suit is brought against us, our collaborators or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. In addition, defending such claims has in the past and may in the future cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages if we are found to be infringing a third party’s patent rights.

These damages potentially include increased damages and attorneys’ fees if we are found to have infringed such rights willfully. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property

Table of Contents

litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.

We have been and may in the future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our or our collaborators’ ability to further develop or commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable.

Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our technologies, compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those technologies, compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our or our collaborators’ ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we or our collaborators obtain a license.

Competitors may infringe our patents. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and/or being interpreted narrowly and could put our patent applications at risk of not issuing and/or could impact the validity or enforceability positions of our other patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology.

Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We may now and in the future employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Table of Contents

Our governing documents designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of state law actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.

Our Fourth Amended and Restated Certificate of Incorporation dictates that the Delaware Court of Chancery is the sole and exclusive forum for certain state law based actions including certain derivative actions or proceedings brought on behalf of us; an action asserting a breach of fiduciary duty owed by an officer, a director, employee or to our shareholders; any claim arising under Delaware corporate law; and any action asserting a claim governed by the internal affairs doctrine.

This exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or other federal securities laws for which there is exclusive federal or concurrent federal and state jurisdiction.

This choice of forum provision may limit our stockholders’ ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.

Risks Related to this Offering and the Market for Our Common Stock

Our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the public offering price.

The market price of our common stock may fluctuate significantly in response to several factors, most of which we cannot control, including:

quarterly variations in our operating results compared to market expectations;

adverse publicity about us, the industries we participate in or individual scandals;

announcements of new offerings or significant price reductions by us or our competitors;

stock price performance of our competitors;

fluctuations in stock market prices and volumes;

changes in senior management or key personnel;

changes in financial estimates by securities analysts;

the market’s reaction to our reduced disclosure as a result of being an “emerging growth company” under the JOBS Act;

negative earnings or other announcements by us or our competitors;

defaults on indebtedness, incurrence of additional indebtedness, or issuances of additional capital stock;

global economic, legal and regulatory factors unrelated to our performance; and

the other factors listed in this “Risk Factors” section.

The public offering price of our common stock has been determined by us based upon many factors and may not be indicative of prices that will prevail following the closing of this offering. Volatility in the market price of our common stock may prevent investors from being able to sell their shares at or above the public offering price. As a result, you may suffer a loss on your investment.

Table of Contents

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, the market price for our common stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our common stock to decline.

As our public offering price is substantially higher than our net tangible book value per share, you will experience immediate and substantial dilution.

If you purchase shares in this offering, you will pay more for your shares of common stock than the amount paid by our existing stockholders for their shares on a per share basis. As a result, you will experience immediate and substantial dilution in net tangible book value per share in relation to the price that you paid for your shares. We expect the dilution as a result of the offering to be $5.58 per share to new investors purchasing our shares in this offering. In addition, you will experience further dilution to the extent that our shares are issued upon the exercise of any warrants or exercise of stock options under any stock incentive plans. See “Dilution” for a more complete description of how the value of your investment in our shares will be diluted upon completion of this offering.

We have considerable discretion as to the use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree.

We intend to use the net proceeds from this offering primarily for clinical trials for our ALEXIS-ISO-1 and ALEXIS-PRO-1 product candidates, GMP facility expansion, intellectual property protection and reinforcement, IND applications and IND enabling trials and working capital and general corporate purposes. However we have considerable discretion in the application of the proceeds. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may be used for corporate or other purposes with which you do not agree or that do not improve our profitability or increase our share price. The net proceeds from this offering may also be placed in investments that do not produce income or that lose value.

We do not expect to pay dividends in the foreseeable future after this offering, and you must rely on price appreciation of your shares for return on your investment.

We have paid no cash dividends on any class of our stock to date and we do not anticipate paying cash dividends in the near term. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares after price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant.

We may issue additional debt and equity securities, which are senior to our common stock as to distributions and in liquidation, which could materially adversely affect the market price of our common stock.

In the future, we may attempt to increase our capital resources by entering into additional debt or debt-like financing that is secured by all or up to all of our assets, or issuing debt or equity securities, which could include issuances of commercial paper, medium-term notes, senior notes, subordinated notes or shares. In the event of our liquidation, our lenders and holders of our debt securities would receive a distribution of our available assets before distributions to our stockholders. In addition, any additional preferred stock, if issued by our company, may have a preference with respect to distributions and upon liquidation, which could further limit our ability to make distributions to our stockholders. Because our decision to incur debt and issue securities in our future offerings will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings and debt financing.

Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future. Thus, you will bear the risk of our future offerings reducing the value of your common stock and diluting your interest in our company.

Table of Contents

We are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies and our stockholders could receive less information than they might expect to receive from more mature public companies.

We are required to publicly report on an ongoing basis as an “emerging growth company” (as defined in the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth companies, including but not limited to:

not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;

being permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

being exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We would remain an emerging growth company for up to five years from October 15, 2020, which is the date of the first sale of equity securities pursuant to our first effective registration statement as a publicly traded company, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.

Because we are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, our stockholders could receive less information than they might expect to receive from more mature public companies. We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking advantage of these exemptions would result in less active trading or more volatility in the price of our common stock.

Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and/or debt financings and collaborations, licensing agreements or other strategic arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your rights as a common stockholder.

To the extent that we raise additional capital through debt financing, it would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends.

To the extent we raise additional capital through arrangements with collaborators or otherwise, we may be required to relinquish some of our technologies, research programs, product development activities, product candidates and/or future revenue streams, license our technologies and/or product candidates on unfavorable terms or otherwise agree to terms unfavorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited to, the sections entitled “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business.” These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

our goals and strategies;

our future business development, financial condition and results of operations;

expected changes in our revenue, costs or expenditures;

growth of and competition trends in our industry;

our expectations regarding demand for, and market acceptance of, our products;

our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;

our expectation regarding the use of proceeds from this offering;

fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19; and

relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

This prospectus also contains certain data and information, which we obtained from various government and private publications. Although we believe that the publications and reports are reliable, we have not independently verified the data. Statistical data in these publications includes projections that are based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual results may differ from the projections based on these assumptions.

The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Although we will become a public company after this offering and have ongoing disclosure obligations under United States federal securities laws, we do not intend to update or otherwise revise the forward-looking statements in this prospectus, whether as a result of new information, future events or otherwise.

USE OF PROCEEDS

We estimate that the net proceeds from the sale of the 4,835,590 shares of common stock that we are selling in this offering will be approximately $45,519,000, assuming an offering price of $10.34 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on June 24, 2021, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their over-allotment option in full, we estimate that the net proceeds from this offering will be approximately $52,419,000.

Table of Contents

We plan to use the net proceeds of this offering primarily for clinical trials for our ALEXIS-ISO-1 and ALEXIS-PRO-1 product candidates, GMP facility expansion, intellectual property protection and reinforcement, IND applications and IND enabling trials and working capital and the remainder for general corporate purposes.

We may also use a portion of the net proceeds of this offering to acquire or invest in complementary businesses, products, or technologies, or to obtain the right to use such complementary technologies. We have no commitments with respect to any acquisition or investment.

As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. The amounts and timing of our actual expenditures will depend on numerous factors, including the status of our product development efforts, sales and marketing activities, technological advances, amount of cash generated or used by our operations and competition. Accordingly, our management will have broad discretion in the application of the net proceeds and investors will be relying on the judgment of our management regarding the application of the proceeds of this offering.

Pending use of the proceeds from this offering as described above, we intend to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade securities or certificates of deposit.

DIVIDEND POLICY

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the near future. See also “Risk Factors — Risks Related to this Offering and the Market for Our Common Stock — Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on price appreciation of your shares for return on your investment.” We may enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock.

Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant.

CAPITALIZATION

The following table sets forth our total capitalization as of March 31, 2021:

on an actual basis;

on an as adjusted basis giving further effect to the sale and issuance by us of 4,835,590 shares of common stock in this offering, assuming an offering price of $10.34 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on June 24, 2021, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

You should read this table together with our consolidated financial statements, the related notes included elsewhere in this prospectus and the information under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”


	March 31, 2021
	Actual		As adjusted
Cash and cash equivalents	$	7,335,300	$	52,854,300
Stockholders’ equity:
Common Stock		1,200		6,000
Additional paid-in capital		53,933,900		99,448,100
Accumulated deficit		(45,482,300)		(45,482,300)
Total stockholders’ equity		8,452,800		53,971,800
Total capitalization		8,452,800		53,971,800

DILUTION

If you purchase shares of our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share and our net tangible book value per share after this offering. Dilution results from the fact that the

Table of Contents

public offering price per share is substantially in excess of the net tangible book value per share attributable to the existing stockholders for our presently outstanding common stock.

Our net tangible book value was approximately $8,452,800 or $1.15 per share, as of March 31, 2021. Our net tangible book value represents the amount of our total consolidated tangible assets (which is calculated by subtracting net intangible assets, deferred tax assets, and prepaid offering expenses from our total consolidated assets), less the amount of our total consolidated liabilities.

After giving effect to the sale and issuance by us of 4,835,590 shares of common stock in this offering, assuming an offering price of $10.34 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on June 24, 2021 and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2021 would have been $57,971,800 or $4.76 per share. This represents an immediate increase in net tangible book value of $3.61 per share to our existing stockholders, and an immediate dilution in net tangible book value of $5.58 per share to new investors. The following table illustrates this per share dilution:


Assumed public offering price per share			$	10.34
Net tangible book value as of March 31, 2021	$	1.15
Increase in net tangible book value attributable to this offering	$	3.61
As adjusted net tangible book value, after this offering			$	4.76
Dilution to new investors in this offering			$	5.58

If the underwriters’ over-allotment option is exercised in full, our as adjusted net tangible book value per share after this offering would be $65,471,800 and dilution per share to new investors purchasing common stock in this offering would be $5.26 assuming an offering price of $10.34 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on June 24, 2021, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

The as adjusted information discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based on the offering price of our shares and other terms of this offering determined at pricing.

The number of shares outstanding is based on shares outstanding as of June 25, 2021, and except as noted above, excludes the following currently outstanding securities:

558,435 shares of our common stock issuable upon the exercise of outstanding options with a weighted-average exercise price of $8.90 per share;

1,100,281 shares of our common stock issuable upon the vesting of restricted stock units with a weighted-average grant date fair value of $12.22 per share;

62,500 shares of our common stock underlying underwriter’s warrants issued in October 2020 with an exercise price of $15.00 per share;

up to an additional 193,052 shares of our common stock issuable under our Omnibus 2021 Equity Incentive Plan; and

241,780 shares of our common stock underlying the warrants to be issued to the representative of the underwriters in connection with this offering.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion together with our financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that are based on our current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under “Risk Factors” and elsewhere in this prospectus. See “Special Note Regarding Forward-Looking Statements.”

Overview

Kiromic BioPharma, Inc. (together with its subsidiary, “we,” “us,” “our” or the “Company”) is a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. Our proprietary target discovery engine is called “DIAMOND.” We are focused on extending the benefits of immunotherapy by leveraging our proprietary technologies. Our approach seeks to generate a therapeutic immune response in patients by unleashing the

Table of Contents

demonstrated natural power of a patient’s own immune system to recognize tumor-specific peptide sequences presented on cancer cells, known as tumor specific iso-antigens, capable of generating an immunological response and therefore eradicate cancer cells.

We are developing our brand of chimeric antigen receptor (“CAR”) T cell product candidates known as ALEXIS. Our two product candidates are called ALEXIS-ISO-1 and ALEXIS-PRO-1. ALEXIS-ISO-1 is our allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin (the isoform of Mesothelin). ALEXIS-PRO-1 is our allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. These are designed to treat cancer by capitalizing on the immune system’s ability to destroy cancer cells. These products are in the pre-initial new drug (“IND”) stages of the US Food and Drug Administration (the “FDA”) clinical trial process. We are currently going through the IND enabling trials process and we expect that first in human dosing in Phase I of clinical trials will commence in the third quarter of 2021.

CAR T cell therapy, a form of cancer immunotherapy, has recently emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers. In 2017, two autologous anti-CD19 CAR T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., were approved by the FDA for the treatment of relapsing/remitting B-cell precursor acute lymphoblastic leukemia and relapsing/remitting large B cell lymphoma, respectively. Autologous CAR T cell therapies are manufactured individually for the patient’s use by modifying the patient’s own T cells outside the body, causing the T cells to express CARs. The entire manufacturing process is dependent on the viability of each patient’s T cells and takes approximately two to four weeks. Allogenic T cell therapies involve engineering healthy donor T cells, which we believe will allow for the creation of an inventory of off-the-shelf products that can be delivered to a larger portion of eligible patients throughout the world.

Trends and Uncertainties — COVID-19

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our service providers, suppliers, contract research organizations and our clinical trials, all of which are uncertain and cannot be predicted. As of the date of this filing, the extent to which the COVID-19 pandemic may in the future materially impact our financial condition, liquidity or results of operations is uncertain.

New Investigational Drug Application Resubmission Announcement

On December 17, 2020, we filed two investigational new drug (“IND”) applications with the FDA. The first application was for a Phase 1 clinical trial of intravenously administered allogenic CAR-T for epithelial ovarian carcinoma (“EOC”) and malignant pleural mesothelioma (“MPM”). The second application was for a Phase 1 clinical trial of an intrapleural/intraperitoneal administered allogenic CAR-T for EOC and MPM.

Since filing the original applications in December 2020, we have had communications with the FDA, and numerous consults with scientific board and clinical advisors regarding resubmission. On March 9, 2021, we announced that we planned to resubmit the two IND applications. The revised applications will be for first in-human dosing of our Off-the-Shelf, Allogenic Gamma-Delta T cell therapy for metastatic and progressive locally advanced solid malignancies.

In May 2021, we resubmitted the two IND applications. The revised IND applications are for first in-human dosing of our Off-the-Shelf, Allogenic Gamma-Delta T cell therapy for metastatic and progressive locally advanced solid malignancies. On May 17, 2021, we announced that the first IND application was for a Phase I clinical trial of our ALEXIS-PRO-1 product candidate. On May 24, 2021, we announced that the second IND application was for a Phase 1 clinical trial of our ALEXIS-ISO-1 product candidate.

Table of Contents

In Silico Solutions, LLC Membership Interest Purchase Agreement

On June 14, 2021, we entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with In Silico Solutions, LLC (“In Silico”) and Michael Ryan (the “Seller”) pursuant to which we acquired all of the outstanding membership interests of In Silico from the Seller for an aggregate purchase price of $540,000 (the “Purchase Price”). The Purchase Price is payable in full through (i) the delivery to the Seller of a number of shares of our stock that is equal to $400,000 and (i) the delivery to the employees of In Silico of our restricted stock units under the Company’s 2021 Omnibus Equity Incentive Plan that is equal to $140,000.

Pursuant to the Purchase Agreement, as soon as practicable following the closing, the Purchase Price shall be subject to a working capital adjustment. In addition, the Purchase Agreement contains customary representations, warranties, covenants (including restrictive covenants), indemnification and other terms for transactions of this nature. The Purchase Agreement may be terminated by either us or the Seller if the closing does not occur on or before the 45^th day following execution of the Purchase Agreement.

Principal Factors Affecting Our Financial Performance

Our operating results are primarily affected by the following factors:

slow or delayed IND applications;

slow or delayed clinical trial enrollment;

patent reinforcement and prosecution; and

changes in laws or the regulatory environment affecting our company.

Emerging Growth Company

We are an “emerging growth company” under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

submit certain executive compensation matters to stockholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and

We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an emerging growth company for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

Table of Contents

Components of Results of Operations

Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates. These include the following:

salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;

expenses incurred under agreements with third parties, including CROs and other third parties that conduct preclinical research and development activities and clinical trials on our behalf;

costs of developing and scaling our manufacturing process and manufacturing drug products for use in our preclinical studies and future clinical trials, including the costs of contract manufacturing organizations, or CMOs, that will manufacture our clinical trial material for use in our preclinical studies and potential future clinical trials;

costs of outside consultants, including their fees and related travel expenses;

costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;

license payments made for intellectual property used in research and development activities; and

facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we initiate a Phase 1/2a clinical trial for our ALEXIS-PRO-1 and ALEXIS-ISO-1 product candidates and continue to discover and develop additional product candidates.

We cannot determine with certainty the duration and costs of future clinical trials of our ALEXIS-PRO-1 and ALEXIS-ISO-1 product candidates, or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our ALEXIS-PRO-1 and ALEXIS-ISO-1 product candidates and any other our product candidate we may develop will depend on a variety of factors, including:

the scope, rate of progress, expense and results of clinical trials of our ALEXIS-PRO-1 and ALEXIS-ISO-1 product candidates, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;

uncertainties in clinical trial design and patient enrollment rates;

the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability;

significant and changing government regulation and regulatory guidance;

the timing and receipt of any marketing approvals; and

the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another

Table of Contents

regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, operations and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs that are not specifically attributable to research activities.

We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs.

Results of Operations

Comparison of the Three Months Ended March 31, 2021 and 2020

The following table sets forth key components of our results of operations for the three months ended March 31, 2021 and 2020.


	Three Months Ended March 31,				Increase (Decrease)
	2021		2020		$		%
Operating expenses:
Research and development	$	1,885,600	$	1,028,100	$	857,500	83.41	%
General and administrative		2,071,000		824,600		1,246,400	151.15	%
Total operating expenses		3,956,600		1,852,700		2,103,900	113.56	%
Loss from operations		(3,956,600)		(1,852,700)		2,103,900	113.56	%
Other income (expense)
Gain on loan extinguishment		105,800		—		105,800	100.00	%
Interest expense		(3,700)		—		3,700	100.00	%
Total other income		102,100		—		102,100	100.00	%
Net loss	$	(3,854,500)	$	(1,852,700)	$	2,206,000	119.07	%

Table of Contents

Research and development expenses. Our research and development expenses increased by $857,500, or 83.41%, to $1,885,600 for the three months ended March 31, 2021 from $1,028,100 for the three months ended March 31, 2020. The following table summarizes our research and development expenses by product candidate or development program:


	Three Months Ended March 31,				Increase (Decrease)
	2021		2020		$		%
Direct research and development expenses by product candidate:
ALEXIS-PRO-1	$	26,000	$	17,900	$	8,100	45.25	%
ALEXIS-ISO-1		484,700		14,700		470,000	3,197.28	%
Platform development, early-stage research and unallocated expenses:
Employee-related costs		855,900		423,900		432,000	101.91	%
Laboratory supplies and services		120,700		66,600		54,100	81.23	%
Outsourced research and development (net of reimbursements)		150,000		396,000		(246,000)	(62.12)	%
Laboratory equipment and maintenance		32,400		14,400		18,000	125.00	%
Facility-related costs		155,800		78,700		77,100	97.97	%
Intellectual property		60,000		14,700		45,300	308.16	%
Other research and development costs		100		1,200		(1,100)	(91.67)	%
Total research and development expenses	$	1,885,600	$	1,028,100	$	857,500	83.41	%

As illustrated above, the increase in research and development expenses resulted from (i) a $470,000 increase ALEXIS-ISO-1 direct research and development costs which primarily included a $384,300 increase in disposables and consumables, a $24,000 increase in non-capitalizable equipment and maintenance, and a $36,100 increase in supplies, all of which attributed to Gamma Delta T-Cell manufacturing and in-vivo experimentation; (ii) a $432,000 increase in employee related costs, which primarily included a $288,900 increase in wages, benefits and payroll taxes and a $142,700 increase in stock compensation expenses attributable to research and development employees; (iii) a $77,100 increase in facility-related costs, primarily driven by $61,300 increase in allocated depreciation expenses, $8,300 increase in allocated rent expenses with the remaining amount attributed to repairs, maintenance, and utilities; (iv) a $54,100 increase in laboratory supplies in services, which primarily included a $40,300 increase in supplies and a $13,400 increase in spending on disposables and consumables for in-vitro testing and validation of pipeline candidates, with the remaining balance driven by postage spending; (v) a $45,300 increase in intellectual property which consists of increased legal expenses and intellectual property filing primarily attributed to DIAMOND and other technologies currently in development; (vi) a $18,000 increase in laboratory equipment and maintenance, driven entirely by new non-capitalizable equipment purchases not directly attributed to an ALEXIS product candidate.

These increases were offset by a $246,000 decrease in outsourced research and development costs, which primarily included reduced stock compensation expenses of $281,000 attributable to non-employees. The offsetting difference of $35,000 was primarily attributed to increased clinical consulting fees.

These cost increases were primarily incurred to support in-vitro testing and validation of our product candidates.

Augmented our research and development team: As of March 31, 2021 compared to March 31, 2020, our average headcount increased to 16 employees from 5.5 employees allocable to research and development and clinical trials preparation.

ALEXIS-ISO-1 Manufacturing and Experimentation: $470,000 increase in spending during the three months ended March 31, 2021 from manufacturing expanded Gamma Delta T-Cells in the recently completed GMP facilities. In addition, in-vivo experimentation costs in the recently completed vivarium facilities contributed to the increase.

General and administrative expenses. Our general and administrative expenses increased by $1,246,400, or 151.15%, to $2,071,000 for the three months ended March 31, 2021 from $824,600 for the three months ended March 31, 2020.

During the three months ended March 31, 2021, the increase primarily resulted from an increase in stock compensation expenses of $627,500, professional services of $511,500, and wages and salaries of $158,600.

Table of Contents

Employee related expenses were impacted by increases to headcount, employee salary rates, and equity grant modifications. As of March 31, 2021 compared to March 31, 2020, the headcount for employees allocated to general and administrative purposes increased to 6.5 employees from 3.5 employees, respectively. In addition, the Chief Executive Officer’s salary increased to an annual rate of $504,000 from $280,000 as of March 31, 2021 and 2020, respectively.

As of March 31, 2021 compared to March 31, 2020, the increase in stock compensation expense was primarily driven by stock option grant modification allocated to general and administrative expense which increased stock compensation expense by $577,500.

The increase in professional services expenses was driven by an increase of $341,800 from accounting and audit fees and an increase of $169,700 of other consulting and corporate development fees incurred during the three months ended March 31, 2021 compared to the same period in the prior year.

Gain on loan extinguishment. Gain on loan extinguishment was $105,800 and $0 for the three months ended March 31, 2021 and 2020, respectively. During the year ended December 31, 2020, we applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021 the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,800.

Interest expense. Interest expense was $3,700 and $0 for the three months ended March 31, 2021 and 2020, respectively. The increase is entirely driven by cash paid for interest attributed to the financing arrangement for our Director and Officer Insurance policy. The total amount financed was $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of March 31, 2021, the remaining payable balance on the financed amount was $227,800.

Net loss. As a result of the cumulative effect of the factors described above, our net loss increased to $3,854,500 during the three months ended March 31, 2021 compared to $1,852,700 during the three months ended March 31, 2020.

Comparison of the Years Ended December 31, 2020 and 2019

The following table sets forth key components of our results of operations for the years ended December 31, 2020 and 2019.


	Year Ended December 31,				Increase (Decrease)
	2020		2019		$		%
Operating expenses:
Research and development	$	5,052,900	$	1,201,700	$	3,851,200	320.48	%
General and administrative		14,144,000		2,503,700		11,640,300	464.92	%
Total operating expenses		19,196,900		3,705,400		15,491,500	418.08	%
Loss from operations		(19,196,900)		(3,705,400)		15,491,500	418.08	%
Other expense
Interest expense		(3,300)		(22,500)		(19,200)	(85.33)	%
Total other expense		(3,300)		(22,500)		(19,200)	(85.33)	%
Net loss	$	(19,200,200)	$	(3,727,900)	$	15,510,700	416.07	%

Table of Contents

Research and development expenses. Our research and development expenses increased by $3,851,200, or 320.48%, to $5,052,900 for the year ended December 31, 2020 from $1,201,700 for the year ended December 31, 2019. The following table summarizes our research and development expenses by product candidate or development program:


	Year Ended December 31,				Increase (Decrease)
	2020		2019		$		%
Direct research and development expenses by product candidate:
ALEXIS-PRO-1	$	89,900	$	—	$	89,900	100.00	%
ALEXIS-ISO-1		331,600		15,900		315,700	1,985.53	%
Platform development, early-stage research and unallocated expenses:
Employee-related costs		2,821,700		574,300		2,247,400	391.33	%
Laboratory supplies and services		385,500		218,600		166,900	76.35	%
Outsourced research and development		800,400		321,700		478,700	148.80	%
Laboratory equipment and maintenance		57,500		17,100		40,400	236.26	%
Facility-related costs		344,700		40,700		304,000	746.93	%
Intellectual property		217,800		12,100		205,700	1,700.00	%
Other research and development costs		3,800		1,300		2,500	192.31	%
Total research and development expenses	$	5,052,900	$	1,201,700	$	3,851,200	320.48	%

As illustrated above, the increase in research and development expenses resulted from (i) a $2,247,400 increase in employee related costs, which primarily included a $1,020,900 increase in wages, benefits and payroll taxes and a $1,183,800 increase in stock compensation expenses attributable to research and development employees; (ii) a $166,900 increase in laboratory supplies in services, which primarily included a $109,800 increase in spending on disposables and consumables for in-vitro testing and validation of pipeline candidates, with the remaining balance driven by supplies spending; (iii) a $304,000 increase in facility-related costs, primarily driven by a $181,200 increase in allocated rent net of granting agency reimbursements, and a $113,200 increase in allocated depreciation expenses with the remaining amount attributed to repairs, maintenance, and utilities; (iv) a $205,700 increase in intellectual property expenses, which was driven by legal expenses and intellectual property filings for new patents; (v) a $40,400 increase in laboratory equipment and maintenance, driven entirely by new non-capitalizable equipment purchases and maintenance to support in-vitro testing and validation by our research and development scientists; and (vi) a $478,700 increase in outsourced research and development costs driven by a $197,400 increase in research studies and other consulting fees with the remaining balance driven by increased stock based compensation expenses attributed to non-employees.

These cost increases were primarily incurred to support in-vitro testing and validation of our product candidates. This required increases to our headcount, square footage at our Houston Facility, experimentation costs, and intellectual property families to protect our findings. In addition, we incurred costs related to the following:

Augmented our research and development team: As of December 31, 2020 compared to December 31, 2019, our average headcount increased to 9 employees from 2 employees allocable to research and development and clinical trials preparation.

Amended lease agreements: We amended our Houston facility lease agreement to expand the leased property by 4,100 square feet.

In-vitro experimentation costs: $584,000 in disposable and consumable spending during the year ended December 31, 2020 for validation experiments and other services related to our ALEXIS-ISO-1 and ALEXIS-PRO-1 candidates, and ABBIE.

Intellectual property augmentation: Longwood University (“Longwood”), granted us the exclusive right to negotiate a worldwide, exclusive license for certain patent rights. The patent rights pertain to “T-cells expressing a chimeric -PD l-CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer.” As compensation for this right, we agreed to pay Longwood an upfront fee of $15,000. We also agreed to reimburse Longwood for fees and expenses incurred for the preparation, filing, prosecution and maintenance of such patent rights. We also filed two utility patent applications and four provisional patent applications to protect intellectual property associated with our other value drivers.

Table of Contents

The cost increases were also partially due to the difference in grant reimbursements in the years ended December 31, 2020 and 2019. In August 2018, the National Institute of Health (NIH), the primary agency of the United States government responsible for biomedical and public health research, awarded a Phase I/II grant in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and which covers the period September 2018 through August 2019, entitles us to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase I completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000. During the years ended December 31, 2020 and 2019, we recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the statements of operations pursuant to the grant from the NIH.

General and administrative expenses. Our general and administrative expenses increased by $11,640,300, or 464.92%, to $14,144,000 for the year ended December 31, 2020 from $2,503,700 for the year ended December 31, 2019.

During the year ended December 31, 2020, the increase primarily resulted from an increase in stock compensation expenses of $11,257,900, an increase in wages and salaries totaling $606,800, offset by reduced professional services expenses of $411,500.

The increase in stock compensation expense was primarily driven by common stock issuances of 725,536 shares to our Chief Financial Officer and Chief Operating Officer (“CFO and COO”), Chief Strategy and Innovation Officer (“CSIO”), Chief Medical Officer (“CMO”), and another employee in exchange for services rendered totaling $9,432,000. In addition, stock option grant modification allocated to general and administrative expense increased stock compensation expense by $1,791,200.

Wages and salaries were impacted by increases to headcount, and employee salary rates. As of December 31, 2020 compared to December 31, 2019, the headcount for employees allocated to general and administrative purposes increased to 4.5 employees from three employees, respectively. In addition, the Chief Executive Officer’s salary increased to an annual rate of $504,000 from $280,000 as of December 31, 2020 and 2019, respectively. Furthermore, the CSIO and CFO and COO transitioned from consulting agreements to employment agreements after the IPO was completed. The salary rates for each of those executives is $300,000 annually.

Interest expense. Interest expense decreased by $19,200, to $3,300 for the year ended December 31, 2020 from $22,500 for the year ended December 31, 2019. The decrease is driven by the variance in the balance of convertible promissory notes during the year ended December 31, 2019.

Total interest expense accrued on the notes in the year ended December 31, 2019 totaled $22,500. On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock.

Total interest expense accrued in the year ended December 31, 2020 was primarily driven by $3,100 of cash paid for interest on the Note payable. The Note payable is attributed to the Director and Officer’s insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months.

Net loss. As a result of the cumulative effect of the factors described above, our net loss increased to $19,200,200 during the year ended December 31, 2020 compared to $3,727,900 during the year ended December 31, 2019.

Liquidity and Capital Resources

As of March 31, 2021, we had cash and cash equivalents of $7,335,300. As of December 31, 2020 we had cash and cash equivalents of $10,150,500. We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily with proceeds from the sale of our convertible promissory notes, preferred stock, and common stock from the initial public offering.

Table of Contents

Due to our increased expenditures related to our ongoing research and development efforts following the completion of our initial public offering on October 15, 2020, we determined that our current levels of cash will not be sufficient to meet our anticipated cash needs for our operations through June 30, 2022. We have incurred significant operating losses since inception, and we expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with contract manufacturing organizations and building out internal capacity to have product manufactured to support preclinical studies and clinical trials, expanding our intellectual property portfolio and providing general and administrative support for our operations. As a result, substantial doubt exists regarding the going concern assumption on our condensed consolidated financial statements.

We are seeking significant additional capital funding to develop our platform, hire additional scientific professionals, hire other general and administrative employees, and clinical trials. However, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. In consideration of our plans, substantial doubt cannot be alleviated with respect to our continued operations through May 14, 2022. Management’s plans, of which the raising additional capital is not within management’s control and cannot be assured, do not alleviate such substantial doubt through June 30, 2022.

Summary of Cash Flow for the three months ended March 31, 2021 and 2020

The following table sets forth a summary of our cash flows for the periods presented:


	Three Months Ended March 31,
	2021		2020
Net cash used in operating activities	$	(2,635,900)	$	(1,480,300)
Net cash used in investing activities		(44,700)		(406,300)
Net cash (used in) provided by financing activities		(134,600)		3,000,000
Net (decrease) increase in cash and cash equivalents		(2,815,200)		1,113,400
Cash and cash equivalents at beginning of the year		10,150,500		1,929,100
Cash and cash equivalents at end of the period		7,335,300		3,042,500

Cash flows from operating activities

Net cash used in operating activities was $2,635,900 for the three months ended March 31, 2021, as compared to $1,480,300 for three months ended March 31, 2020. In the three ended March 31, 2021, net loss of $3,854,500 and outflows from accrued expenses and other current liabilities in the amount of $65,400 were the cash outflows drivers. These cash outflows were offset by stock compensation expenses from stock compensation expenses from stock options and restricted stock units of $945,200, accounts payable of $273,600, and prepaid expenses and other current assets of $75,400. Net cash used in operating activities increased by a total of $1,155,600 period-over-period. The main driver for the increase is the $2,001,800 increase in net loss offset by non-cash inflows from increased stock compensation expenses in the amount of $489,200 and cash inflows from accounts payable in the amount of $308,800. We primarily used cash to augment our headcount, develop our ALEXIS-ISO-1 product candidate, and pay for other corporate development costs. See “Results of Operations” above for further details.

Cash flows from investing activities

Net cash used in investing activities was $44,700 for the three months ended March 31, 2021, as compared to $406,300 for the three months ended March 31, 2020. Our net cash used in investing activities consisted entirely of purchases of property and equipment. This was primarily driven by reduced cash outflows from equipment and leasehold improvements attributed to our Clean Room and Vivarium current good manufacturing practices facilities located in our Houston office.

Cash flows from financing activities

Cash outflows from financing activities was $134,600 during the three months ended March 31, 2021. Net cash provided from financing activities during the three months ended March 31, 2020 totaled $3,000,000.

During the three months ended March 31, 2021, we paid $134,600 towards our financing arrangement for our Director and Officer Insurance policy. During the three months ended March 31, 2020, the net cash provided by financing activities consisted of proceeds from the Series B Preferred Stock round of financing totaling $3,000,000.

Table of Contents

Summary of Cash Flow for the years ended December 31, 2020 and 2019

The following table sets forth a summary of our cash flows for the periods presented:


	Year Ended December 31,
	2020		2019
Net cash used in operating activities	$	(6,126,600)	$	(2,913,900)
Net cash used in investing activities		(1,457,600)		(302,700)
Net cash provided by financing activities		15,805,600		4,761,400
Net increase in cash and cash equivalents		8,221,400		1,544,800
Cash and cash equivalents at beginning of the year		1,929,100		384,300
Cash and cash equivalents at end of the year		10,150,500		1,929,100

Cash flows from operating activities

Net cash used in operating activities was $6,126,600 for the year ended December 31, 2020, as compared to $2,913,900 for year ended December 31, 2019. In the year ended December 31, 2020, net loss of $19,200,200 and outflows from prepaid expenses and other current assets in the amount of $499,700 were the cash drivers. These cash outflows were offset by non-cash stock compensation expenses from common stock issuances in the amount of $9,432,000, stock compensation expenses from stock options and restricted stock units of $3,813,700, and accrued expenses in the amount of $112,900.

Net cash used in operating activities increased by a total of $3,212,700 year-over-year. The main driver for the increase is the $15,428,100 increase in net loss offset by non-cash inflows from increased stock compensation expenses in the amount of $12,722,800. We primarily used cash to augment our research and development team, expand our leased property, expand our intellectual property portfolio, and pay for corporate development costs related to obtaining additional financing. See “Results of Operations” above for further details.

Cash flows from investing activities

Net cash used in investing activities was $1,457,600 for the year ended December 31, 2020, as compared to $302,700 for the year ended December 31, 2019. Our net cash used in investing activities consisted entirely of purchases of property and equipment.

Net cash used in investing activities increased by a total of $1,154,900 in the year ended December 31, 2020 from December 31, 2019. This was primarily driven by equipment additions and leasehold improvements attributed to our Clean Room and Vivarium current good manufacturing practices facilities located in our Houston office.

Cash flows from financing activities

Net cash provided by financing activities was $15,805,600 during the year ended December 31, 2020 as compared to $4,761,400 for the year ended December 31, 2019. For the year ended December 31, 2020, the net cash provided by financing activities primarily consisted of net proceeds from the initial public offering of $12,332,700 and proceeds from preferred stock issuance in the amount of $3,000,000. In addition, there were proceeds from a note payable of $362,400 net of repayments, and loan payable of $105,600, net of repayments. For the year ended December 31, 2019, the net cash provided by financing activities consisted of proceeds from the sale of convertible promissory notes for $250,000, proceeds from preferred stock issuance in the amount of $4,500,000, and exercise of stock options to purchase common stock for $11,400.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements for any of the periods presented.

Table of Contents

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require management’s difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial statements:

Fair Value Measurements —The carrying value of our cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, we take into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

We account for financial instruments in accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.

Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy leveling during the three months ended March 31, 2021 and 2020.

Stock-Based Compensation — We record stock compensation expense related to our 2017 Equity Incentive Plan in accordance with ASC 718, Compensation — Stock Compensation. We measure and recognize stock compensation expense for all stock-based awards, including stock options and restricted stock units (“RSUs”).

Stock compensation expense for RSUs is estimated based on the number of units that vest multiplied by the fair value of the Company’s common stock on the vesting date. Stock compensation expense for stock options is based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model. The calculation of stock-based compensation expense requires that we make assumptions and judgments about the variables used in the Black- Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.

Table of Contents

We estimate the grant-date fair value of stock options using the Black-Scholes option-valuation model. During the three months ended March 31, 2021, we did not grant any stock options. During the three months ended March 31, 2020, all equity grants under the 2017 Equity Incentive Plan were granted when we were a non-public company. The assumptions used to value such stock options were determined as follows:

Expected Term. The expected term represents the period that our stock options are expected to be outstanding. Equity grants during the three months ended March 31, 2020 had limitations on the sale or transfer of our common stock as a privately held company. Prior to becoming publicly traded, we did not believe our historical exercise pattern was indicative of future exercise patterns. We have consequently used the SAB No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. We do not plan to continue to use the SAB 110 simplified method after we have sufficient trading history as a publicly traded company.

Risk-Free Interest Rate. We base the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.

Volatility. We determine the price volatility based on the historical volatilities of industry peers as we have limited trading history for our common stock price. We intend to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield. The expected dividend assumption is based on our current expectations about our anticipated dividend policy. To date, we have not declared any dividends and, therefore, we used an expected dividend yield of zero.

Common Stock Valuations. During the three months ended March 31, 2020, the fair value of the common stock underlying our stock-based compensation grants was determined by our board of directors, with input from management and third-party valuations. We believe that the board of directors had the relevant experience and expertise to determine the fair value of our common stock. Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our common stock at each grant date. These factors include:

valuations of the common stock performed by third-party specialists;

the prices, rights, preferences, and privileges of our Series A-1 Preferred Stock and Series B Preferred Stock relative to those of our common stock;

lack of marketability of the common stock;

current business conditions and projections;

hiring of key personnel and the experience of management;

our stage of development;

likelihood of achieving a liquidity event, a merger or acquisition of our company given prevailing market conditions, or other liquidation event;

the market performance of comparable publicly traded companies; and

the U.S. and global capital market conditions.

In valuing our common stock, the board of directors determined the equity value of our business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in our industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in our cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

Table of Contents

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method, or OPM, or probability — weighted expected return model, or PWERM.

The option pricing method is based on the Black Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires us to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values we expect those outcomes could yield. Since in February 2018, we have valued our common stock based on a PWERM.

Application of our approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of our common stock.

For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.

Warrants Underlying Shares of IPO Common Stock — We record warrants to purchase shares of common stock underlying our shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.

We estimate the fair value of warrants using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:

Expected Term. The expected term represents the period that our warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period.

Volatility. We determine the price volatility based on the historical volatilities of industry peers as we had one day of trading history as of the initial public offering date. We intend to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Common Stock Valuations. The fair value of our common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.

Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.

Table of Contents

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

BUSINESS

Overview

Revolutionizing Next-Gen Allogenic CAR Therapies for Solid Tumors.

We are a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology.

Our proprietary target discovery engine is called “Diamond.”

Kiromic’s Diamond is big data science meeting target identification, dramatically compressing man-years and billions of drug development dollars to develop a live drug.

Diamond (Screening, Prioritizing, and Harmonizing)

Table of Contents

Diamond addresses the main challenges in today’s clinical pipeline: target identification.

Table of Contents

See our Diagram below which will walk readers through our process of going from antigens and target libraries to finish with target selection by our artificial intelligence engine.

Table of Contents

CancerSplice (Isoform Target Prediction)

Cancer cells will down-regulate or shed targets in order to avoid detection and destruction by T cells (the immune system). One mechanism for this tumor defense is the selection for alternative splice forms of target proteins. These variations are known as isoforms. Target isoforms include variations in their primary amino acid sequence that can change both the final folded form of the target plus their ability to be recognized by pre-existing and modified T cells. Within a heterogeneous cancer cell population, isoforms can preferentially expand to avoid detection and destruction by T cells. These isoforms can make it impossible for T cells to outright bind the targets on cancer cells. No binding to the target means no killing of cancer cells.

Table of Contents

Target isoforms are protein variants of the same targets that occur during the normal processing of immature gene transcripts to the mature form.

If they are the predominate form on the cell surface, these isoforms can make it impossible for T cells to outright bind the targets on cancer cells.

Table of Contents

No binding or insufficient binding to the isoform results in no killing of cancer cells.

Our CancerSplice accurately predicts the most appropriate isoforms for T cells to bind and destroy cancer cells.

Immune Therapies Using Our Artificial Intelligence Selected Targets

Table of Contents

Engineered T Cell Therapy

CARs are engineered molecules that, when present on the surface of a T cell, enable the T cell to recognize specific proteins or antigens that are present on the surface of other cells.

Our Approach

Our operating motto is Better Target, Better Life™.

Table of Contents

ABBIE Summary

ABBIE is a novel gene-editing system for inserting therapeutic genes safely into the genome of a host cell.

The OFF switch permits fast shutdown in the event of an unexpected toxicity. Additional Anti-tumor factors can help neutralize the toxic tumor microenvironment.

ABBIE: Development

Table of Contents

SWITCHES

ACTIVATION Switch. A rapidly deployed activation switch can provide a survival and proliferation signal to the therapeutic cells to enhance their efficacy and persistence in vivo.

Table of Contents

Manufacturing Allogeneic Effector Cells

The three primary steps to creating our engineered effector cells are: (1) collection, (2) gene editing, and (3) purification, formulation, and storage.

Manufacturing

Step 1. Collection

Step 2. Gene Editing

These cells are stimulated to proliferate, then transduced with a non-replicating retroviral vector.

Step 3. Purification, Formulation, and Storage

These engineered cells are then propagated in cell culture bags until sufficient cells are available. The engineered gamma delta T cells are then washed and frozen at the cell processing site.

Table of Contents

As noted previously, the gene editing is currently being done with an industry standard retroviral vector, however, in future versions we expect to utilize our non-viral ABBIE gene editing platform.

Our Product Pipeline and Development

[Update Pipeline]

Table of Contents

Clinical Program

What makes this challenging is that solid tumors develop in complex and dynamic microenvironments that influence their growth, invasion, and metastasis. Therefore, effective novel therapies are needed for subjects with advanced solid tumors. The field of immunotherapy is currently expanding with a variety of approaches and Kiromic Biopharma’s suite of gamma delta T cell therapies is uniquely positioned to make an impact in this setting based upon our promising preclinical in vitro and in vivo studies which have revealed strong and specific tumor cytotoxicity with minimal adverse effects.

Table of Contents

Clinical Program

ALEXIS-ISO-1

Our allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin (the isoform of Mesothelin).

ALEXIS-PRO-1

Our allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1

PD-1: Avoiding Antigen Escape

To further boost the potency of our effector cells, we have developed an off the shelf chimeric gamma delta PD1 T cell switch receptor therapy that interferes with the inhibitory “checkpoint” protein, PD-L1, found on most tumor cells and cells of the tumor microenvironment (TME). By converting what is normally an inhibitory signal into an activating signal, we predict that this will overcome the resistance of the TME and mitigate the issue of antigen loss typically seen with solid malignancies in particular.

Table of Contents

The chPD1 Receptor is activated by engagement with PD-L1+ (or even PD-L2+) tumors.

Typical checkpoint inhibitors block PD-1 and PD-L1, although they have limitations since they do nothing to actually activate/energize the T cell into action, and since typically the subject’s T cells are not working properly, the results are not as optimized as they would otherwise be.

Our chPD-1 (chimeric PD-1) thus takes it one step further by converting PD-1 and PD-L1 from an inhibitory signal to an activation signal. This pivotal transformation allows our chimeric T-cells to then kill solid tumor cells and the cells of the TME.

Although this chimeric PD1 gamma delta T cell can effectively lyse both hematologic and solid tumors expressing PD-L1, the focus of the first related Investigational New Drug (IND) submission will focus on solid malignancies that express PD-L1 as this represents one of the greatest need in oncology at this time. This IND submission is supported by strong in vitro and in vivo tumor cytotoxicity data, and thus far no significant adverse effects have been noted in the animal models tested, which has included the testing of multiple types of solid malignancies.

Development Plan

ALEXIS-ISO-1 will be studied in “A Phase 1, Open-label, Dose Escalation Study of an Allogeneic Gamma Delta CAR-T Cell Therapy (KB-ISM) in Subjects with Isomesothelin positive Metastatic or Progressive Locally Advanced Solid Malignancies.

The primary goal will be to assess safety, tolerability, and efficacy at increasing dose levels in order to estimate the optimal biologic dose (OBD) which will serve as the dose for an additional 20 patient cohort expansion.

Prior to treatment, all patients are expected to undergo selected screening process to assure that they meet all the corresponding inclusion and exclusion criteria, and are expressing the intended target (Iso Mesothelin).

ALEXIS-PRO-1 will be studied in “A Phase 1, First-in-Human, Open-label, Dose Escalation Study of an Allogeneic Gamma Delta PD1 T Cell Switch Receptor Therapy (KB-PD1) in Subjects with PD-L1 positive Metastatic or Progressive Locally Advanced Solid Malignancies”.

We filed Phase 1 IND submissions for both ALEXIS-PRO-1 and ALEXIS-ISO-1 in May 2021 with the first patients projected for enrollment in Q3 2021, and with first results projected in Q4 2021.

Table of Contents

Our Manufacturing Operations

We have invested resources to optimize our manufacturing process, including the development of improved analytical methods. We plan to continue to invest in process science, product characterization and manufacturing to continuously improve our production and supply chain capabilities over time.

Our product candidates are designed and manufactured via a platform comprised of defined unit operations and technologies. The process is gradually developed from small to larger scales, incorporating compliant procedures to create current cGMP conditions. Although we have a platformbased manufacturing model, each product is unique and for each new product candidate, a developmental phase is necessary to individually customize each engineering step and to create a robust procedure that can later be implemented in a cGMP environment to ensure the production of clinical batches. This work is performed in our research and development environment to evaluate and assess variability in each step of the process in order to define the most reliable production conditions.

We will engage third-party CMOs to manufacture the retroviral vector that delivers the applicable CAR gene into the T cells under cGMP. We believe all materials and components utilized in the production of the cell line, retroviral vector and final T cell product are readily available from qualified suppliers.

We believe the use of contract manufacturing and testing for the first clinical product candidates is cost-efficient and has allowed us to rapidly prepare for clinical trials in accordance with our development plans. We expect third-party CMOs will be capable of providing and processing sufficient quantities of product candidates to meet anticipated clinical trial demands.

In addition, we believe we have sufficient space at our headquarters in Houston, Texas, which is being adapted to manufacture clinical grade products.

If any of our product candidates are approved, to meet projected needs for commercial sale quantities, we anticipate that we will need to obtain additional manufacturing capacity through CMOs to be able to supply and process products on a patient-by-patient basis.

We intend to screen multiple manufacturers, including both current and alternate suppliers, to secure sufficient capacity for commercial purposes prior to the filing of a Biological License Application. We believe that commercial requirements can be met, although we cannot be certain that identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs.

Our Intellectual Property

Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, product development technologies, and know-how.

Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and applications related to our technology, inventions, and improvements that are important to the development and implementation of our business.

We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.

With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of using and manufacturing the same.

Table of Contents

Patents

We are actively building an intellectual property portfolio around our product candidates and our discovery programs, based on intellectual property we own as well as licensed intellectual property. We are the owners of, co-owners of, or the licensee of multiple patents and patent applications in the United States and worldwide. Our patent portfolio includes patent applications having claims directed to aspects of our lead product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1, as well as other research-stage candidates. Our patent portfolio and filing strategy is designed to provide multiple layers of protection by pursuing claims directed toward: (1) antigen binding domains directed to the targets of our product candidates; (2) CAR constructs used in our product candidates; (3) methods of treatment for therapeutic indications; (4) manufacturing processes; and (5) and methods for genetically engineering immune cells suitable for autologous and allogenic use.

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional application to which priority is claimed. In the United States, patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier- filed patent. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.

As of June 25, 2021, our patent estate includes three issued U.S. patents and 22 pending patent applications (13 of which are in the U.S.), each of which we own, jointly own, or have an exclusive commercial license (either in its entirety or within our field of use), as is more fully described below. Our patent families related to our product candidates are described below.

Diamond (Screening, Prioritizing, and Harmonizing) and CancerSplice (Isoform Target Prediction), Therapeutic Targets and Vaccine Therapeutics

Our tumor targets patent estate includes nine patent portfolios directed to target identification processes, therapeutics and treatments we co-developed or developed internally (1-9) and one licensed patent portfolio (10) directed to therapeutics and treatments related to a vaccine therapeutic under development.

The application titled “Platform for Identification of Tumor-Associated Cancer/Testis Antigens” is a United States utility patent application that is expected to expire on April 25, 2037, absent any patent term adjustment (PTA) or patent term extension (PTE). The claims in this patent application include composition of matter, use and process for a method of identifying cancer/testes antigens (CTAs) useful as cancer treatment targets, the method comprising: identifying human sperm proteins to which patients diagnosed with solid or hematological malignancies have established a humoral immune response.

The application entitled “Methods for Identifying and Using Diseases-Associated Antigens” is an International Patent Cooperation Treaty (PCT) patent application from which national/regional applications, if filed, are expected to expire on May 29, 2040. The claims in this patent application are directed in part to methods for identifying proteins encoded by genes having tumor-associated hot-spot mutations and/or tumor-associated mRNA splice variants, methods for identifying immunogenic portions of such proteins, and uses thereof.

The application titled, “Anti-Human/Mouse Sperm Protein 17 (SP17) Antibody and Derivatives Thereof” is a United States utility patent application that is expected to expire on March 22, 2037, absent any patent term adjustment or patent term extension. The claims in this patent application include composition of matter, use, and method for a novel monoclonal antibody, designated as GD6, and various derivatives thereof, which target an epitope of human and murine Sperm Protein 17 (SP17) which possesses broad expression on cells derived from numerous solid malignancies.

The family that includes patents and patent applications entitled “Compositions and Methods for Treating Cancers” contains one United States utility patent, and patent applications filed in Europe, Mexico, and China that are expected to expire on March 13, 2037, absent any patent term adjustment or patent term extension. The claims in the patent and patent applications are directed to a particular galectin protein, compositions containing the protein, polynucleotides encoding the protein, and, in certain instances, uses thereof.

Table of Contents

The family titled, “CdS Quantum Dot-Chitosan-Anti-SP17 Nanohybrid as a Potential Cancer Biomarker” contains one utility patent filed in the United States that is expected to expire on February 23, 2038, absent any patent term adjustment or patent term extension. The claims in this patent application include composition of matter of a nanoconjugate consisting of a quantum dot nanoparticle conjugated to an anti-SP17 antibody, wherein the conjugating molecule is chitosan. The claims in this patent application also include methods for detecting cancer cells in biological systems consisting in administering the anti-SP17 nanoconjugate and performing imaging analysis using the quantum-dot fluorescence emission.

The family includes a United States Provisional Application and an international Patent Cooperation Treaty (PCT) application entitled “Peptide Compositions for the Treatment of Pathogenic Infections” from which national/regional applications, if filed, are expected to expire on May 7, 2041.

The family titled, “Hydrogen Peroxide-Containing Oral Care Composition for Mitigation, Prevention, or Treatment of Human Coronavirus-Associated Infections.” It is a United States Provisional Application that is expected to expire on May 14, 2021. No claims were filed with the provisional application. We plan to file a United States utility patent application claiming priority to the provisional application before the provisional application expires.

The family containing one application filed in Europe entitled, “Novel Nanoparticle — Based Vaccine Targeting Cancer/Testis Antigens (CTA) and its’ Use in Solid and Hematological Malignancies,” that is expected to expire on November 19, 2035, absent any extension of the patent right by a supplementary protection certificate (SPC). The claims in this patent application are directed to an oral vaccine composition and use thereof.

The application entitled “Disease-Associated Isoform Identifier” is a United States Provisional Application expected to expire on November 19, 2021. We plan to file at least an international PCT patent application claiming priority to this provisional application on or before November 18, 2021.

10.

The family has been exclusively in-licensed from Mercer University. It is titled, “Nanospheres Encapsulating Bioactive Material and Method for Formulation of Nanospheres” and contains three issued United States Patents and one pending application. One of the issued patents is expected to expire on September 29, 2029 supplemented by 540 days of patent term adjustment, the remaining two issued patents and the pending application are expected to expire on September 29, 2029. The claims in this patent family include composition of matter and methods for a method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or betacyclodextrin, in an aqueous medium in a first vessel.

Chimeric PD1 Receptor

Chimeric PD1 Receptor is the additional targeting element that interferes with the inhibitory “checkpoint” protein, PD1 found on most activated T cells and other effector cells.

The Chimeric PD1 Receptor patent family includes patent applications entitled, “PD1-Specific Chimeric Antigen Receptor as an Immunotherapy” that have been exclusively in-licensed from Longwood University. The patent family contains patent applications filed in the United States and in other jurisdictions and are expected to expire on September 26, 2038, absent any patent term adjustment or patent term extension. The claims in the patent applications are directed to a chimeric antigen receptor (CAR) polypeptide; a vector comprising the CAR polypeptide; and a T lymphocyte genetically modified to express the CAR polypeptide. The claims in the patent application also are directed to a method of treating cancer using T lymphocytes genetically modified to express the CAR polypeptide.

Iso-Mesothelin Binding Molecules, Chimeric PD1 Molecule and Gamma-Delta T-cell Expansion

We have developed binding molecules directed to an iso-mesothelin isoform expressed in tumors at a higher level than in non-tumor tissues, including chimeric antigen receptor (CAR) binding molecules. We also have developed a chimeric PD1 molecule and effector cell expansion processes, e.g., Gamma-Delta T-cell expansion processes and Invariant Natural Killer T (iNKT) cell manufacturing processes, for manufacturing allogeneic effector cells.

The family includes a first United States Provisional Application entitled “Mesothelin Isoform Binding Molecules and Uses Thereof” and two subsequent United States Provisional Applications entitled “Mesothelin Isoform Binding Molecules and Chimeric PD1 Binding Molecules, Cells Containing the Same and Uses Thereof.” The first United States Provisional Application is expected to expire on July 8, 2021. We plan to file at least an international PCT patent application claiming priority to at least the first provisional application on or before July 7, 2021.

Table of Contents

Switch Technology

The Activation Switch can provide a survival and proliferation signal to the therapeutic cells to enhance their efficacy and persistence in vivo. The Attenuation Switch can intercept activation signals transiently to minimize toxicity following successful anti-tumor interactions. The Safety Switch can eliminate therapeutic cells in case of acute toxicity.

The Switch Technology patent family titled “Tri Switch Technology for Multi-Dimensional Control of Cell Therapy” is a United States Provisional Application that is expected to expire on June 15, 2021. No claims were filed on the provisional application. We plan to file a United States utility patent application claiming priority to the provisional application before the provisional application expires.

ABBIE (Genetic Delivery Vehicle)

ABBIE is the delivery vehicle for our lead product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1, as well as our other research-stage candidates.

The ABBIE patent family has been exclusively in-licensed from CGA 369 Intellectual Holdings, Inc. It is entitled, “CAS 9 Retroviral Integrase and CAS 9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism.” The patent family contains patent applications that were filed in Europe, China, Japan, Korea, and the United States and patents granted are expected to expire on March 31, 2036, absent any patent term adjustment or patent term extension. The claims in this patent family are directed to recombinant proteins, compositions that include such proteins and guide RNA, vectors encoding such proteins, and methods of use. Two patent applications in the family are not currently pending and we have made submissions for reinstatement.

License Agreements

Mercer University

On December 1, 2016, we entered into a license agreement with Mercer University, or Mercer, pursuant to which Mercer granted to us an exclusive license for certain inventions and technologies related to nanoparticles useful as vaccines. As compensation for this license, we paid Mercer a license fee and agreed to pay royalties of the net selling price of all licensed products sold once we start selling the products developed with the licensed intellectual property. Finally, we also agreed to make the following milestone payments: (i) upon initiation of an FDA Phase II clinical trial; (ii) upon the first dosing in the FDA Phase III clinical trial, and (iii) upon BLA approval. The potential milestone payments total $325,000 in the aggregate. The royalty range for the license agreement is between 1% and 5%. The term of this license agreement continues until all licensed patents expire. The Mercer patents associated with the license agreement contain three issued United States Patents and one pending application, the last of which is expected to expire on September 29, 2029 (with 540 days of patent term adjustment). We may terminate this agreement at any time upon sixty (60) days written notice. Mercer may terminate this agreement upon the occurrence of a material breach of the agreement that is not cured by us within sixty (60) days of notice of such breach.

CGA 369

On September 14, 2018, we entered into a license agreement with CGA 369 Intellectual Holdings, Inc., or CGA, which was amended on October 16, 2019. Pursuant to this license agreement, CGA granted to us an exclusive license for certain inventions and technologies related to the use of engineered DNA binding proteins exhibiting genome specificity such as Cas9, TALE, and Zing finger proteins attached by a linker with viral integrases or a recombinase in older to deliver DNA sequence of interest (or gene of interest) to a targeted site in a genome of a cell or organism. As compensation for this license, we agreed to pay CGA a license fee, which payment is conditioned upon a sublicense and our receipt of upfront fee in connection with such sublicense of at least $5 million. We also agreed to pay royalties based on a percentage of the net selling price of all licensed products sold once we start selling the products developed with the licensed intellectual property. The net selling price is equal, subject to certain exceptions, to the gross selling price less (i) sales and excise taxes, value added taxes, and duties which fall due and are paid by the purchaser as a direct consequence of such sales and any other governmental charges imposed upon the importation, use or sale of such product, but only to the extent that such taxes and duties are actually included and itemized in the gross amounts invoiced to and specifically paid by the purchaser over and above the usual selling price of such product, customarily included and itemized in the gross amounts invoiced to and specifically paid by the purchaser over and above the usual selling price of all comparable products in the relevant market and are not recovered or recoverable; (ii) trade, quantity and cash discounts that are customary in the pharmaceutical industry and that are actually allowed on such product; (iii) allowances or credits to customers on account of rejection, withdrawal, recall, or return of such product or on account of retroactive price reductions or price protection charges or reprocurement/failure to supply charges affecting such product, to the extent that such allowances, credits or charges are customary in the pharmaceutical industry;

Table of Contents

and (iv) discounts, rebates and chargebacks specifically related to such product on an accrual basis, which shall be trued up and reconciled in the ordinary course of business, including, but not limited to, those granted to government agencies. Finally, we also agreed to make the following milestone payments: (i) upon completion of a positive Phase III clinical trial; (ii) upon FDA approval; (iii) upon our aggregate net sales of licensed products reaching $100 million in a single calendar year; (iv) upon our aggregate net sales of licensed products reaching $250 million in a single calendar year, and (v) upon our aggregate net sales of licensed products reaching $500 million in a single calendar year. The potential milestone payments total to $9.5 million in the aggregate. The royalty range for the CGA 369 license is between 1% and 5%. The CGA 369 patents associated with the license agreement contains five utility applications in Europe, China, Japan, Korea, and the United States, the last of which is expected to expire on March 31, 2036. The term of this license agreement continues until all licensed patents expire. We may terminate this agreement at any time upon sixty (60) days written notice. CGA may terminate this agreement upon the occurrence of a material breach of the agreement that is not cured by us within ninety (90) days of notice of such breach.

Longwood University

Effective March 25, 2020, we entered into a license agreement with Longwood University, or Longwood. Pursuant to this license agreement, Longwood granted to us the exclusive right to negotiate a worldwide, exclusive license for certain patent rights. The patent rights pertain to “T-cells expressing a chimeric-PD l- CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer.” As compensation for this right, we agreed to pay Longwood an upfront fee of $15,000. We also agreed to reimburse Longwood for fees and expenses incurred for the preparation, filing, prosecution and maintenance of such patent rights.

Our Research and Development Collaborations

MDACC Grant

We provided a grant to the University of Texas, MD Anderson Cancer Center (“MDACC”). The arrangement provides for MDACC to test the efficacy of: 1) Isoform targeting (and/or other isoforms for hematological diseases: 2) ALEXIS Isoform Mesothelin Targeting: The anti-mesothelin isoform CAR we plan to test in these pre-clinical studies could be potentially developed for more effective and safer target expression expressing solid malignancies and/or alternative targets for solid tumor. As compensation for this collaboration, we agreed to pay MDACC a fee. The agreement’s commencement date was April 1, 2020 and terminated on March 31, 2021.

On April 8, 2021, we entered into a letter of intent (the “Letter of Intent”) with the MDACC pursuant to which MDACC shall receive a research grant from us titled, “Validation of biomarker isomeso for pancreatic cancer,” which is aimed at discovering new cancer-specific antigen targets (the “Grant”). The total costs to be paid in connection with the Grant shall be $300,000. Pursuant to the Letter of Intent, the Grant shall commence on April 1, 2021 and end on March 31, 2022.

Molipharma Agreement

On April 3, 2020, we entered into a joint venture agreement (“Joint Venture”) with Molipharma, S.R.L. (“Molipharma”) to collaborate in (1) a clinical trial program in oncology development (“Oncology”) and (2) a clinical trial program in COVID-19 Vaccine (“COVID-19 Vaccine”).

With respect to Oncology, we will grant a low single digit royalty to Molipharma for turnover of the marketing of ovarian cancer research in Europe. With respect to COVID-19 Vaccine, economic rights in Europe will transfer to Molipharma, and economic rights in the United States will transfer to us. Molipharma agreed to undertake to financially support the research program for COVID-19 and we agreed to financially support the research program in oncology. The Joint Venture has a duration of five years, extendable for a further five years, unless notice of non-renewal is sent one year before the expiration date. The parties may withdraw from the Joint Venture only for serious and justified reasons or by mutual consent.

Leon Office (H.K.) Agreement

On January 28, 2021, we executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on our behalf. Leon will seek to introduce organizations and individuals that will create business development opportunities for us, to expand our reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. The cost of the agreement is $360,000 annually, payable in four quarterly installments.

Table of Contents

Our Competition

Our products will compete with novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to standard of care treatments.

In 2017, two autologous anti-CD19 CAR T cell therapies, Kymriah, developed by Novartis International AG, and Yescarta, developed by Kite Pharma, Inc., were approved by the FDA for the treatment of relapsing/remitting B-cell precursor acute lymphoblastic leukemia and relapsing/remitting large B cell lymphoma, respectively.

Due to the promising therapeutic effect of T cell therapies in clinical trials, we anticipate increasing competition from existing and new companies developing these therapies, as well as in the development of allogenic T cell therapies.

Potential cell therapy competitors include:

Autologous T cell therapy competition: Adaptimmune Therapeutics PLC, Amgen Inc., Autolus Therapeutics PLC, Bluebird Bio, Gilead (acquired Kite), Novartis International AG, Celgene (acquired Juno), Tmunity Therapeutics, Inc. and Unum Therapeutics Inc.

Allogenic T cell therapy competition: Atara Biotherapeutics, Inc., Celyad S.A., CRISPR Therapeutics AG, Fate Therapeutics Inc., Intellia Therapeutics, Inc., Gilead (acquired Kite), Allogene Therapeutics, Inc., Poseida Therapeutics, Inc., Precision Biosciences, Inc. and Sangamo Therapeutics, Inc.

Competition will also arise from non-cell based immune and other pursued by small-cap biotechnology and large-cap pharmaceutical companies including Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Incyte Corporation, Merck & Co., Inc., and F. Hoffmann-La Roche AG. For instance, we may experience competition from companies, such as Amgen Inc., Regeneron Pharmaceuticals, Inc., Xencor Inc., MacroGenics, Inc., GlaxoSmithKline plc and F. Hoffmann-La Roche AG, that are pursuing bispecific antibodies, which target both the cancer antigen and T cell receptor, thus bringing both cancer cells and T cells in close proximity to maximize the likelihood of an immune response to the cancer cells. Additionally, companies, such as Amgen Inc., GlaxoSmithKline plc and Seattle Genetics, Inc., are pursuing antibody drug conjugates, which utilize the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.

Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, pre-clinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.

Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience.

These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, as well as for technologies complementary to, or necessary for, our programs.

GreenPlanet Pharma

Our wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns.

This business is recently formed and the product was recently developed. This business has not generated any revenues.

Government Regulation

As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to

Table of Contents

demonstrate product safety and efficacy and the submission of a Biologic License Application, or BLA, for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them.

Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.

U.S. Product Development Process

In the United States, the FDA regulates pharmaceutical and biological products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:

completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;

submission to the FDA of an IND, which must become effective before human clinical trials may begin;

approval by an independent IRB or ethics committee at each clinical site before the trial is commenced;

performance of adequate and well-controlled human clinical trials according to the FDA’s GCPs, and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;

submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;

satisfactory completion of an FDA Advisory Committee review, if applicable;

satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product’s identity, strength, quality and purity and, if applicable, the FDA’s current good tissue practices, or GTPs, for the use of human cellular and tissue products;

potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and

FDA review and approval, or licensure, of the BLA.

Table of Contents

Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.

Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor’s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA’s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Certain clinical trials involving human gene transfer research also must be overseen by an Institutional Biosafety Committee, or IBC, a standing committee to provide peer review of the safety of research plans, procedures, personnel training and environmental risks of work involving recombinant DNA molecules. IBCs are typically assigned certain review responsibilities relating to the use of recombinant DNA molecules, including reviewing potential environmental risks, assessing containment levels, and evaluating the adequacy of facilities, personnel training, and compliance with the National Institutes of Health Guidelines. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.

Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.

Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.

Table of Contents

Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor’s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the biological product has been associated with unexpected serious harm to patients.

Human immunotherapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval.

Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.

U.S. Review and Approval Processes

After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.

Under the Prescription Drug User Fee Act, or the PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product’s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product.

Table of Contents

A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.

Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and cellular and tissue based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.

Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.

Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.

If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product’s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.

In addition, under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, the Pediatric Research Equity Act does not apply to any product for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s).

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

Table of Contents

If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.

A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Expedited Development and Review Programs

The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.

Any product, submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

Regenerative Medicine Advanced Therapy, or RMAT, designation was established by FDA in 2017 to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review.

Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.

Table of Contents

Breakthrough therapy designation is also intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a product candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.

Fast Track designation, priority review, RMAT and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.

Post-Approval Requirements

Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product’s approved uses (known as “off-label use”), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physicians deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, it is permissible to share in certain circumstances truthful and not misleading information that is consistent with the product’s approved labeling.

In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval.

The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures.

Also, new government requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval of our products under development.

U.S. Marketing Exclusivity

The Biologics Price Competition and Innovation Act amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The Biologics Price Competition and Innovation Act, however, bars the FDA from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity may be extended by six months, for a total of 12.5 years, if the FDA requests that the innovator company conduct pediatric clinical investigations of the product.

Table of Contents

Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.

Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued “Written Request” for such a trial.

Other U.S. Healthcare Laws and Compliance Requirements

In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the CMS, other divisions of the HHS (e.g., the Office of Inspector General, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments). For example, our business practices, including any future sales, marketing and scientific/educational grant programs may be required to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the patient data privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, transparency requirements, and similar state, local and foreign laws, each as amended.

The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti- Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and other individuals and entities on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.

Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if “one purpose” of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).

The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.

Table of Contents

The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies are being investigated or, in the past, have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies’ marketing of the product for unapproved, and thus non-reimbursable, uses.

HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.

Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members.

In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.

If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

100

Table of Contents

Coverage, Pricing and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time.

Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Healthcare Reform

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:

created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;

increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;

101

Table of Contents

created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient drugs to be covered under Medicare Part D;

extended manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and added new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;

expanded of the list of entities eligible for discounts under the 340B Drug Discount Program;

created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;

expanded healthcare fraud and abuse laws, including the Foreign Corrupt Practices Act, or the FCPA, and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;

created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;

required reporting of certain financial arrangements with physicians and teaching hospitals;

required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to physicians;

established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and

created a licensure framework for follow on biologic products.

On January 22, 2018, the former U.S. President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.

The Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”.

Congress is continuing to consider legislation that would alter other aspects of the Affordable Care Act. The ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is unclear. In July 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act.

102

Table of Contents

We anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President’s administration’s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the U.S. President’s administration released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. On January 31, 2019, the HHS Office of Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products to consumers. While some of these and other proposed measures may require authorization through additional legislation to become effective, Congress and the U.S. President’s administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

The Foreign Corrupt Practices Act

The FCPA prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

103

Table of Contents

Additional Regulation

In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.

Overseas Government Regulation

In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country’s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country’s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.

The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.

For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

European Union General Data Protection Regulation

In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU’s General Data Protection Regulation, or the GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.

The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.

104

Table of Contents

California Consumer Privacy Act

California recently enacted legislation that has been dubbed the first “GDPR-like” law in the United States. Known as the California Consumer Privacy Act, or the CPPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. When it goes into effect on January 1, 2020, the CCPA will require covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Legislators have stated that amendments will be proposed to the CCPA before it goes into effect, but it remains unclear what, if any, modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.

Human Capital

Our Employees. As of June 25, 2021, we had a total of 33 employees. Of the 33 employees, 32 employees were employed in the United States of America with one employee employed in Italy. Our highly qualified and experienced team includes scientists, physicians, laboratory technicians, finance professionals, and administrative professionals. We also utilize a number of consultants for financial reporting, clinical, regulatory, and Securities and Exchange Commission (“SEC”) compliance.

We believe that we maintain a satisfactory working relationship with our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations. None of our employees is represented by a labor union.

Employee Engagement, Talent Development & Benefits. We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, and opportunities for equity ownership.

Diversity, Inclusion, and Culture. Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.

Legal Proceedings

From time to time in the future, we may become involved in litigation or other legal proceedings that arise in the ordinary course of business. A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against us by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. We believe that all of the claims in the complaint are without merit and we intend to defend vigorously against them.

We are not currently party to any other legal proceedings, and we are not aware of any other pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results or financial condition. To the extent that we are subject to a legal proceeding, it could have a material adverse impact on us because of litigation costs and diversion of management resources.

105

Table of Contents

MANAGEMENT

Directors and Executive Officers

The following sets forth information about our directors, director nominees, and executive officers as of the date of this prospectus:


Name	Age	Position
Maurizio Chiriva Internati	53	Chairman, Chief Executive Officer and President
Tony Tontat	54	Chief Financial Officer and Director
Scott Dahlbeck	59	Chief Medical Officer
Gianluca Rotino	49	Chief Strategy and Innovation Officer and Director
Ignacio Nunez	44	Chief Operating and Manufacturing Officer
Pietro Bersani	53	Director
Americo Cicchetti	54	Director
Michael Nagel	59	Director
Jerry Schneider	73	Director

Maurizio Chiriva Internati, DBSc, PhDs. Dr. Chiriva Internati has served as our Chairman and Chief Executive Officer since February 2018 and as our President since October 2019. Between December 2012 and September 2019, he served as Chief Scientific Officer. Between December 2012 and August 2018, he also served as our Director of Clinical Translation Research. Dr. Chiriva Internati has been an Associate Professor at the MD Anderson Cancer Center in Houston, Texas since August 2019. Prior to that, he served as an Associate Professor at Texas Tech University Health Sciences Center from September 2013 to June 2017. His research has led to the identification of novel cancer-testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. This led to the development of the bioinformatic software Diamond CancerSplice, which is a key core platform of our company, leading to the discovery and prioritization of isoform antigens via insilico system.

Dr. Chiriva Internati earned a PhD in Immunology from the University of Nottingham, United Kingdom. He also earned a PhD in Morphological Science from the Università degli Studi di Milano, Italy, and a Doctoral Degree in Biological Sciences from the University of Milan, Italy. Dr. Chiriva-Internati was a Post-Doctoral Fellow in Immunology at the University of Arkansas for Medical Sciences, earned a certificate in Artificial Intelligence from MIT Sloan School of Management and earned a certificate in Financial Technology from Oxford Saïd Business School. Dr. Chiriva Internati was selected to serve on our board of directors due to his industry experience.

Tony Tontat. Mr. Tontat has served as our Chief Financial Officer since October 2019, as our Chief Operating Officer from August 2019 to April 2021 and as a member of our board of directors since January 2020. Prior to joining us, Mr. Tontat worked as a business and financial consultant and Financial Analyst since November 2011 for Exuma Blue Advisors, LLC, where he worked with many private and public companies. He primarily helped these companies raise funds at various stages of life cycle. He worked in financial teams to raise funds for public companies like Sorrento Therapeutics, Inc. and NantKwest. Prior to this, he worked as an investment analyst at healthcare- specialist hedge funds in New York and also worked as investment banker at HSBC Investment Bank in their New York and Paris offices. Mr. Tontat earned his BA in Economics from Harvard University. Mr. Tontat was selected to serve on our board of directors due to his financing experience.

Scott Dahlbeck, MD, PharmD. Dr. Dahlbeck has served as our Chief Medical Officer since October 2019. He previously served as our President from January 2013 to October 2019. Dr. Dahlbeck is an expert in prostate cancer research and treatment and has served as a Radiation Oncologist for several cancer centers, including as an Adjunct Assistant Professor in Internal Medicine, Pathology, and Urology at the Texas Tech University Health Sciences Center. Dr. Dahlbeck has also patented, manufactured, and commercialized IP and has more than a decade of experience in medical and oncology commerce. Dr. Dahlbeck earned an MD from the University of Texas Health Science Center at Houston, completed residencies in family practice and radiation oncology, and earned a PharmD degree from the University of Nebraska Medical Center, College of Pharmacy.

Ignacio Núñez. Mr. Núñez has over 20 years of global experience in corporate functions including manufacturing, research, operational excellence and strategy. He has held senior leadership positions in companies including General Electric, Johnson & Johnson and Novartis. Most recently, he was the Executive Director of Manufacturing at the Gene Therapy Program of the University of Pennsylvania.

106

Table of Contents

Before that, he was the Head of Manufacturing Strategy and Operations Excellence at Novartis, where he was charged with transforming manufacturing operations in support of the ramp up of Kymriah, the first FDA-approved CAR-T cell therapy, which was developed at the University of Pennsylvania.

Mr. Núñez holds an MSC in Chemical Engineering from the University of Granada and is a Lean Six Sigma Master Black Belt.

Gianluca Rotino. Mr. Rotino has served as our Chief Strategy and Innovation Officer and as a member of our board of directors since January 2014. Prior to that, he served in various other senior positions, including Chief Business Officer and Executive VP of Corporate Development. Mr. Rotino is a seasoned business executive with experience in corporate strategy, business development, and capital fund raising. Mr. Rotino held positions as both CEO and Chairman of the Board for several Italian companies. His previous experience includes senior level managerial positions for companies in Italy in different fields, such as high tech, international development and corporate consulting. Mr. Rotino also worked in several law firm in Milan, Italy, where he specialized in mergers, acquisitions, intellectual property, and corporate law. Mr. Rotino earned his Business Development Degree in Pharma from the EBD Academy in London, UK, and a B.S. by EBD Group and Pharmaceutical Training International (PTI). He has also completed course work for drug discovery, development and commercialization provided by The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Development. Mr. Rotino earned his BA in Electronics at the Institute of Technology Feltrinelli in Milan. Mr. Rotino also has also earned a certificate in Essential Epidemiologic Tools for Public Heath Practice from Johns Hopkins University, earned a certificate in the Artificial Intelligence Programme from Said Business School at the University of Oxford, and earned a certificate in Leadership and Innovation from Massachusetts Institute of Technology. Mr. Rotino was selected to serve on our board of directors due to his corporate strategy, business development, and capital fund raising experience.

Pietro Bersani, CPA, JD. Mr. Bersani has served as a member of our board of directors since June 2020. Since April 2020, Mr. Bersani is a Partner with B2B CFO Partners, LLC, which provides strategic management advisory services to owners of privately held companies. During October 2016 and July 2018, he served as the President, and Chief Executive Officer at K.P. Diamond Eagle, Inc., a consulting firm specialized in development of innovative commercial and private aviation business models. He also held the same positions at K.P. Diamond Eagle, Inc. between November 2019 and March 2020. He later served as a Senior Director within Alvarez & Marsal’s Private Equity Performance Improvement Practice, LLP between August 2018 and October 2019. Prior to those professional experiences, Mr. Bersani served as the Chief Financial Officer of Fuel Systems Solutions, Inc. between April 2011 and October 2016.

Mr. Bersani is a Certified Public Accountant and is also a Certified Public Auditor and a Chartered Certified Accountant in Italy where he developed a significant knowledge of US GAAP and IFRS. Mr. Bersani earned a BA and MA in Business Economics from L. Bocconi University, Italy. Mr. Bersani was designated by certain holders of our Series B Preferred Stock. Except for the foregoing, there is no arrangement or understanding between any director or executive officer and any other person pursuant to which he was or is to be selected as a director.

Americo Cicchetti, PhD. Dr. Cicchetti has served as a member of our board of directors since March 2020. Dr. Cicchetti has served as a Professor of Management at Università Cattolica del Sacro Cuore, Faculty of Economics, Rome since 2006. He is also currently the Director of the Graduate School of Health Economics and Management at Università Cattolica del Sacro Cuore.

In addition to his academic experience, Dr. Cicchetti was a member of the Price and Reimbursement Committee of the Italian National Drug Agency from 2009-2015.

He is a member of the European Network of Health Technology Assessment; Member of the Innovation Steering Group of the National HTA Program for Medical Devices (Ministry of Health, Italy); Member of the National Immunization Technical Advisory Group at the Ministry of Health, Italy since 2019; Member of the Health and Research Commission of the Rome Foundation since 2007; and a Member of the Board of Directors of the Health and Research Foundation since 2017.

Furthermore, Dr. Cicchetti is the Chief Executive Officer and Director for Molipharma, whose core business is the research and development of new drugs and diagnostics aimed at predicting, detecting and treating female oncological diseases. He also serves as an independent board member for Foundation Health and Research, and Leonida SICAF, a fixed capital investment company. He obtained his PhD in Management from University of Bologna, and his B.A. from University of Rome. Dr. Cicchetti was selected to serve on the board due to his industry experience.

Michael Nagel. Mr. Nagel has served on our board of directors since October 2020. He has over 30 years of sales and marketing experience in the medical device industry. Since 2012, Mr. Nagel has served as the President and CEO of Vomaris Innovations, Inc, which specializes in wireless microcurrent-generating technologies that are focused on regeneration, healing, and recovery. Previously, Mr. Nagel served as the Chief Commercial Officer of Neomend, a biomaterial company that developed ProGel, a PMA

107

Table of Contents

approved surgical sealant for lung surgery. From 1997 to 2005, Mr. Nagel also served as Co-Founder and Vice President of Worldwide Sales and Marketing at Vascular Solutions (VASC).

In addition to Mr. Nagel’s executive experience, he also serves as a director for Franklin Mountain Medical, LLC an early stage company in the structural heart market. Mr. Nagel holds both a B.A. in Business and a M.B.A. from the University of St. Thomas. Mr. Nagel was selected to serve on the board of directors due to his industry experience.

Jerry Schneider. Mr. Schneider has served on our board of directors since October 2020. He has been an independent business and financial consultant since 2014. From 2004 to 2013, he was the Chief Financial Officer of Vistage International, a private equity-owned CEO peer-advisory membership company with over 20,000 global members. Prior to Vistage, Mr. Schneider spent seven years at Fresenius Medical Care — North America in Boston, a global dialysis service and products company owned by Fresenius Medical Care, a German publicly DAX traded company, where he served as Chief Financial Officer and later as Senior Vice President of Strategic Planning. Between 1994 and 1997, Mr. Schneider was the Executive Vice President and Chief Financial Officer of then NYSE publicly held GranCare, Inc. (GC), a healthcare company in the long-term care, assisted living and institutional pharmacy business. He currently serves on the board of directors and audit committee for Cognex, a provider of vision systems, software, sensors, and industrial barcode readers used in manufacturing automation since 2016. Cognex (CGNX) is publicly traded on the Nasdaq stock exchange. He serves on other for-profit and non-profit boards. Mr. Schneider received his Juris Doctor from Loyola Law School, and a B.S. in Accounting from the University of California at Berkeley. He has experience of being a “financial expert” appointed by the U.C. Regents which oversee the University of California’s budget of over $30M. In addition to his business and financial experience, Mr. Schneider was selected to serve on the board of directors due to his being an audit committee “financial expert” under the SEC regulations.

Family Relationships

Mr. Rotino is Dr. Chiriva Internati’s nephew. There are no other family relationships among any of our officers or directors.

Involvement in Certain Legal Proceedings

To the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item 401(f) of Regulation S-K in the past ten years.

Corporate Governance

Governance Structure

Currently, our Chief Executive Officer is also our Chairman. Our board believes that, at this time, having a combined Chief Executive Officer and Chairman is the appropriate leadership structure for our company. In making this determination, the board considered, among other matters, Dr. Chiriva Internati’s tenure, having served with our company since 2012, and his industry experience. Among the benefits of a combined Chief Executive Officer/Chairman considered by the board is that such structure promotes clearer leadership and direction for our company and allows for a single, focused chain of command to execute our strategic initiatives and business plans.

The Board’s Role in Risk Oversight

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. Management is responsible for the day-to-day management of the risks we face, while the Board, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, the Board is responsible for satisfying itself that the risk management processes designed and implemented by management are adequate and functioning as designed.

The Board believes that establishing the right “tone at the top” and that full and open communication between executive management and the Board are essential for effective risk management and oversight. Our CEO communicates frequently with members of the Board to discuss strategy and challenges facing our company. Senior management usually attends our regular quarterly Board meetings and is available to address any questions or concerns raised by the Board on risk management-related and any other matters. Each quarter, the Board receives presentations from senior management on matters involving our key areas of operations.

Director Independence

Our Board has determined that a majority of the Board consists of members who are currently “independent” as that term is defined under Nasdaq Listing Rule 5605(a)(2). The Board considers Pietro Bersani, Americo Cicchetti, Michael Nagel, and Jerry Schneider to

108

Table of Contents

be “independent.” Dr. Chiriva-Internati, our Chief Executive Officer, Mr. Rotino, our Chief Strategy and Innovation Officer, and Mr. Tontat, our Chief Financial Officer are not considered to be “independent” as defined by Nasdaq Listing Rule 5605(a)(2).

Committees of the Board of Directors

Our Board has established standing Audit, Compensation and Corporate Governance/Nominating Committees to devote attention to specific subjects and to assist it in the discharge of its responsibilities. All committees operate under a written charter adopted by our Board, each of which is available on our Internet website at https://ir.kiromic.com.

Audit Committee

The Audit Committee’s responsibilities include: (i) reviewing the independence, qualifications, services, fees, and performance of the independent registered public accountants, (ii) appointing, replacing and discharging the independent registered public accounting firm, (iii) pre-approving the professional services provided by the independent registered public accounting firm, (iv) reviewing the scope of the annual audit and reports and recommendations submitted by the independent registered public accounting firm, and (v) reviewing our financial reporting and accounting policies, including any significant changes, with management and the independent registered public accounting firm. The Audit Committee also prepares the Audit Committee report that is required pursuant to the rules of the SEC.

The Audit Committee currently consists of Pietro Bersani, chairman, Michael Nagel, and Jerry Schneider. We believe that each of Pietro Bersani, Michael Nagel, and Jerry Schneider is “independent” as that term is defined under applicable SEC and Nasdaq rules. Pietro Bersani is our audit committee financial expert. The board of directors has adopted a written charter setting forth the authority and responsibilities of the Audit Committee. The charter is available on our website at https://ir.kiromic.com.

Compensation Committee

The Compensation Committee has responsibility for assisting the board of directors in, among other things, (i) evaluating and making recommendations regarding the compensation of the executive officers and directors of our company, (ii) assuring that the executive officers are compensated effectively in a manner consistent with our stated compensation strategy, (iii) producing an annual report on executive compensation in accordance with the rules and regulations promulgated by the SEC, (iv) periodically evaluating the terms and administration of our incentive plans and benefit programs and (v) monitoring of compliance with the legal prohibition on loans to our directors and executive officers.

The Compensation Committee currently consists of Jerry Schneider, chairman, Pietro Bersani, and Americo Cicchetti. We believe that all of the members are “independent” under the current listing standards of Nasdaq. The board of directors has adopted a written charter setting forth the authority and responsibilities of the Compensation Committee which is available on our website at https://ir.kiromic.com.

Corporate Governance/Nominating Committee

The Corporate Governance/Nominating Committee has responsibility for assisting the board of directors in, among other things, (i) effecting board organization, membership and function including identifying qualified board nominees, (ii) effecting the organization, membership and function of board committees including composition and recommendation of qualified candidates, (iii) establishment of and subsequent periodic evaluation of successor planning for the chief executive officer and other executive officers, (iv) development and evaluation of criteria for board membership such as overall qualifications, term limits, age limits and independence and (v) oversight of compliance with the Corporate Governance Guidelines. The Corporate Governance/Nominating Committee shall identify and evaluate the qualifications of all candidates for nomination for election as directors. Potential nominees are identified by the board of directors based on the criteria, skills and qualifications that have been recognized by the Corporate Governance/Nominating Committee. While our nomination and corporate governance policy does not prescribe specific diversity standards, the Corporate Governance/Nominating Committee and its independent members seek to identify nominees that have a variety of perspectives, professional experience, education, differences in viewpoints and skills, and personal qualities that will result in a well-rounded board of directors.

The Corporate Governance/Nominating Committee currently consists of Michael Nagel, chairman, Pietro Bersani and Americo Cicchetti. We believe that all of the members are “independent” under the current listing standards of Nasdaq. The board of directors has adopted a written charter setting forth the authority and responsibilities of the Corporate Governance/Nominating Committee which is available on our website at https://ir.kiromic.com.

109

Table of Contents

Code of Business Conduct and Ethics

We have adopted a Code of Business Conduct and Ethics to ensure that our business is conducted in a consistently legal and ethical manner. All of our employees, including our executive officers and directors, are required to comply with our Code of Business Conduct and Ethics.

The full text of the Code of Business Conduct and Ethics is posted on our website at https:// ir.kiromic.com/. Any waiver of the Code of Business Conduct and Ethics for directors or executive officers must be approved by our Audit Committee. We will disclose future amendments to our Code of Business Conduct and Ethics, or waivers from our Code of Business Conduct and Ethics for our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, on our website within four business days following the date of the amendment or waiver. In addition, we will disclose any waiver from our Code of Business Conduct and Ethics for our other executive officers and our directors on our website. A copy of our Code of Business Conduct and Ethics will also be provided free of charge upon request to: Secretary, Kiromic BioPharma, Inc. 7707 Fannin Street, Suite 140, Houston, TX 77054.

EXECUTIVE COMPENSATION

Summary Compensation Table

The following table contains compensation information for our Chief Executive Officer and certain other executives who were the most highly compensated executive officers for the years ended December 31:


Name & Principal Position	Year	Salary		Bonus⁽¹⁾		Stock In Lieu of Cash Bonus⁽²⁾		Equity incentive plan grants⁽³⁾		Other		Total
Maurizio Chiriva Internati,	2020	$	437,900	$	—	$	—	$	6,535,000	$	—	$	6,972,900
Chief Executive Officer	2019	$	280,000	$	—	$	—	$	—	$	—	$	280,000
Tony Tontat,	2020	$	75,000	$	—	$	5,226,000	$	2,654,800	$	90,000	$	8,045,800
Chief Operating Officer and Chief Financial Officer⁽⁴⁾	2019	$	—	$	—	$	—	$	—	$	67,500	$	67,500
Gianluca Rotino,	2020	$	75,000	$	—	$	4,160,000	$	2,665,600	$	579,700	$	7,480,300
Chief Strategy and Innovation Officer	2019	$	—	$	—	$	—	$	—	$	207,800	$	207,800

(1)	There were no discretionary cash bonuses accrued or paid during the years ended December 31, 2020 and 2019 for any executive officers.

(2)	On June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Chief Financial Officer and Chief Operating Officer and Chief Strategy and Innovation Officer, respectively. The shares were issued in exchange for services rendered and no cash considerations.

(3)

Represents the grant date fair value of restricted stock units (“RSUs”) and non-qualified stock options granted to executives. None of the RSUs have vested as of December 31, 2020. Our named executive officers will only realize compensation to the extent the fair market value of our common stock is greater than the exercise price of such stock options. The grant date fair value of option awards granted in 2020 is in accordance with ASC Topic 718, or ASC 718. For information regarding assumptions underlying the valuation of equity awards, see Note 10 contained in the Annual Report on Form 10-K for the year ended December 31, 2020.

(4)	On April 21, 2021, the Company and Mr. Tontat signed an addendum to Mr. Tontat’s employment agreement which removed the title of Chief Operating Officer from Mr. Tontat’s list of principal positions at the Company.

Employment Agreements

On October 15, 2020, we entered into an Executive Agreement (the “Chiriva-Internati Agreement”) with Dr. Maurizio Chiriva-Internati, our Chief Executive Officer. The term of the Chiriva-Internati Agreement commenced on October 15, 2020 and will continue until termination by either the Company or Dr. Chiriva-Internati. Pursuant to the Chiriva-Internati Agreement, Dr. Chiriva-Internati’s current base compensation is $504,000 per year.

110

Table of Contents

On October 15, 2020, we entered into an Executive Agreement (the “Rotino Agreement”) with Mr. Gianluca Rotino, our Chief Strategy and Innovation Officer. The term of the Rotino Agreement commenced on October 1, 2020 and will continue until termination by either the Company or Mr. Rotino. Pursuant to the Rotino Agreement, Mr. Rotino’s current base compensation is $300,000 per year.

On October 15, 2020, we entered into an Executive Agreement (the “Tontat Agreement”) with Mr. Tony Tontat, our Chief Financial Officer and Chief Operating Officer. The term of the Tontat Agreement commenced on October 15, 2020 and will continue until termination by either the Company or Mr. Tontat. Pursuant to the Tontat Agreement, Mr. Tontat’s current base compensation is $300,000 per year. On April 21, 2021, we signed an addendum to the Tontat Agreement which removed the title of Chief Operating Officer from the list of Mr. Tontat’s principal positions.

Collectively, the three agreements above are referenced as “the Executive Employment Agreements”. Unless otherwise referenced, The Executive Employment Agreements are between “the Executive” and the Company.

The Executive may terminate this Agreement and Executive’s employment by the Company. In addition, the Company may also terminate the Executive Agreement. If the termination notice by the Executive is other than for “Good Reason” as defined in the Executive Employment Agreements, the Company shall have no further obligations other than the payment of all compensation and other benefits payable to the Executive through the date of such termination, including any earned but unpaid bonus. Similarly, if the Company terminates the Executive Employment Agreement “for cause”, upon the death, or permanent disability as defined in the Executive Employment Agreements, then the Company shall have no further obligations other than the payment of all compensation and other benefits payable to the Executive through the date of such termination, including any earned but unpaid bonus.

The Company will incur further obligations:

If the Executive terminates the Executive Employment Agreement for “Good Reason” as defined in the Executive Employment Agreement, or

If the Company terminates the Executive Employment Agreement for any reason other than “for cause”, upon the Executive’s death, or disability as defined in the Executive Employment Agreement.

Those obligations are outlined below:

The Company shall pay the Executive an amount equal to twenty-four (24) months of Executive’s then-current Base Salary (less all applicable tax withholdings) payable in installments during the one year period immediately following the termination date in accordance with the then-current generally applicable payroll schedule of the Company commencing on the first regularly scheduled pay date of the Company processed after Executive has executed, delivered to the Company and not revoked the Release (with the first payment to include a catchup for any amounts that would have been paid had the Release been effective on the termination date);

Conditioned on Executive’s proper and timely election to continue the Company’s health insurance benefits under COBRA, or under applicable state law, reimbursement of the additional costs incurred by Executive for continuing such benefits at the same level in which Executive participated prior to the date Executive’s employment terminated for the shorter of (a) twenty-four (24) months from the date of termination or (b) until the Executive obtains reasonably comparable coverage, with such reimbursements to begin at the same time as severance pay set forth the Executive Employment Agreement;

The Earned but Unpaid Bonus (if any), to be paid at the same time such bonus would have been paid if no such termination had occurred;

All stock options, restricted stock unit and other stock-based awards granted to Executive that were scheduled to vest during the 12-month period immediately following Executive’s termination of employment shall become immediately vested and exercisable (if applicable) and with respect to restricted stock units and similar awards, including the RSUs described in the Executive Employment Agreement, shall be settled within 30 days after the termination date; and

Executive shall be entitled to receive his annual bonus for the year of termination as determined by the Board, pro-rated based on the number of days that Executive was employed by the Company during the year in which such termination of employment occurred (to be paid at the same time such bonus would have been paid if no such termination had occurred).

111

Table of Contents

Outstanding Equity Awards as of December 31, 2020


Name & Principal Position	Year	Salary		Bonus⁽¹⁾		Stock In Lieu of Cash Bonus⁽²⁾		Equity incentive plan grants⁽³⁾		Other		Total
Maurizio Chiriva Internati,	2020	$	437,900	$	—	$	—	$	6,535,000	$	—	$	6,972,900
Chief Executive Officer	2019	$	280,000	$	—	$	—	$	—	$	—	$	280,000
Tony Tontat,	2020	$	75,000	$	—	$	5,226,000	$	2,654,800	$	90,000	$	8,045,800
Chief Operating Officer and Chief Financial Officer⁽⁴⁾	2019	$	—	$	—	$	—	$	—	$	67,500	$	67,500
Gianluca Rotino,	2020	$	75,000	$	—	$	4,160,000	$	2,665,600	$	579,700	$	7,480,300
Chief Strategy and Innovation Officer	2019	$	—	$	—	$	—	$	—	$	207,800	$	207,800

(1)	There were no discretionary cash bonuses accrued or paid during the years ended December 31, 2020 and 2019 for any executive officers.

(2)	On June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Chief Financial Officer and Chief Operating Officer and Chief Strategy and Innovation Officer, respectively. The shares were issued in exchange for services rendered and no cash considerations.

(3)

(4)	On April 21, 2021, the Company and Mr. Tontat signed an addendum to Mr. Tontat’s employment agreement which removed the title of Chief Operating Officer from Mr. Tontat’s list of principal positions at the Company.

112

Table of Contents

Director Compensation

During year ended December 31, 2020, our non-employee directors received the following compensation for their services on the Board and its committees:


	Cash Fees		Option Awards⁽¹⁾		Total
Pietro Bersani⁽²⁾	$	20,250	$	42,400	$	62,650
Americo Cicchetti⁽³⁾	$	—	$	42,600	$	42,600
Michael Nagel⁽⁴⁾	$	7,000	$	43,200	$	50,200
Jerry Schneider⁽⁵⁾	$	7,750	$	43,200	$	50,950

(1)	Represents the aggregate grant date fair value of stock options granted to the directors, computed in each case in accordance with ASC 718 — Compensation — Stock Compensation. 5,278 stock options were issued to all non-employee directors on August 20, 2020.

(2)	As of December 31, 2020, Pietro Bersani held 5,278 stock options, of which 3,959 are exercisable.

(3)	As of December 31, 2020, Americo Cicchetti held 5,278 stock options, of which 5,278 are exercisable.

(4)	As of December 31, 2020, Michael Nagel held 5,278 stock options, of which 2,639 are exercisable.

(5)	As of December 31, 2020, Jerry Schneider held 5,278 stock options, of which 2,639 are exercisable.

Securities authorized for issuance under equity compensation plans

The following table provides information relating to our equity compensation plans as of December 31, 2020. As of December 31, 2020, we had our 2017 Equity Incentive Plan, which was approved by our Board of Directors and our shareholders.


	Equity Compensation Plans
	Number of securities to be issued upon exercise of outstanding options, warrants and rights		Weighted average exercise price of outstanding options			Number of securities remaining available for future issuance
Equity compensation plans approved by security holders	1,435,963	⁽¹⁾	$	10.03	⁽²⁾	270,933	⁽³⁾
Equity compensation plans not approved by security holders
Total	1,435,963		$	10.03		270,933

(1)	Includes 946,245 restricted stock units that were outstanding on December 31, 2020 under the Company’s 2017 Equity Incentive Plan. Restricted stock unit awards may be settled only for shares of common stock on a one-for-one basis.

(2)	Only option awards were used in computing the weighted-average exercise price.

(3)

This amount represents shares of common stock available for issuance under the Company’s 2017 Equity Incentive Plan. Awards available for grant under the Company’s 2017 Equity Incentive Plan include stock options, stock appreciation rights, restricted stock, restricted stock units, other stock awards, performance awards, and any combination of the foregoing awards.

2017 Equity Incentive Plan

On January 20, 2017, our board of directors adopted our 2017 Equity Incentive Plan, or the Plan. The following is a summary of certain significant features of the Plan. The information which follows is subject to, and qualified in its entirety by reference to, the Plan document itself, which is filed as an exhibit to the registration statement of which this prospectus forms a part.

Awards that may be granted include incentive stock options as described in section 422(b) of the Internal Revenue Code of 1986, as amended, non-qualified stock options (i.e., options that are not incentive stock options), stock appreciation rights, or SARs, and awards of restricted stock or restricted stock units, or RSUs. These awards offer our employees, consultants and directors the possibility of future value, depending on the long-term price appreciation of our common stock and the award holder’s continuing service with our company or one or more of its subsidiaries.

113

Table of Contents

All of the permissible types of awards under the Plan are described in more detail as follows:

Purposes of Plan: The purpose of the Plan is to offer selected employees, consultants and directors the opportunity to acquire equity in our company.

Administration of the Plan: Administration of the Plan is entrusted to the board of directors, which may delegate its duties and responsibilities to one or more committees. Among other things, the board or committee has the authority to select persons who will receive awards, determine the types of awards and the number of shares to be covered by awards, and to establish the terms, conditions, restrictions and other provisions of awards.

Eligible Recipients: Persons eligible to receive awards under the Plan will be those employees, consultants and directors of our company and its subsidiaries who are selected by the board or committee.

Shares Available Under the Plan: The maximum number of shares of common stock that may be delivered to participants under the Plan is 1,708,615, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award under the Plan for which the award is canceled, forfeited or expires again become available for grants under the Plan. Shares subject to an award that is settled in cash will not again be made available for grants under the Plan.

Stock Options:

General. Subject to the provisions of the Plan, the board or committee has the authority to determine all grants of stock options. That determination will include: (i) the number of shares subject to any option; (ii) the exercise price per share; (iii) the expiration date of the option; (iv) the manner, time and date of permitted exercise; (v) other restrictions, if any, on the option or the shares underlying the option; and (vi) any other terms and conditions as the compensation committee may determine.

Option Price. The exercise price for stock options will be determined at the time of grant. Normally, the exercise price will not be less than the fair market value on the date of grant, as determined in good faith by the board or committee. As a matter of tax law, the exercise price for any incentive stock option awarded may not be less than the fair market value of the shares on the date of grant. However, incentive stock option grants to any person owning more than 10% of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.

Exercise of Options. An option may be exercised only in accordance with the terms and conditions for the option agreement as established by the board or committee at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price. Payments may be made in cash or, at the option of the board or committee, by actual or constructive delivery of shares of common stock to the holder of the option based upon the fair market value of the shares on the date of exercise.

Expiration or Termination. Options, if not previously exercised, will expire on the expiration date established by the board or committee at the time of grant; provided that such term cannot exceed ten years and that such term of an incentive stock option granted to a holder of more than 10% of our voting stock cannot exceed five years. Options will terminate before their expiration date if the holder’s service with us terminates before the expiration date. The option may remain exercisable for specified periods after certain terminations of service, including terminations as a result of death, disability or retirement, with the precise period during which the option may be exercised to be established by the board or committee and reflected in the grant evidencing the award.

SARs. SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The board or committee will determine the number of shares covered by SAR, the exercise price of each SAR and the conditions and limitations applicable to the exercise of each SAR. The term of a SAR may not be longer than ten years.

Restricted Stock and RSUs. Restricted stock is an award of nontransferable shares of our common stock that remain forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. The board or committee may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the board or committee, subject to the conditions and limitations contained in the Plan.

114

Table of Contents

Other Material Provisions: Awards will be evidenced by a written agreement, in such form as may be approved by the board or committee. In the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment will be made by the board or committee to the number of shares covered by outstanding awards or to the exercise price of such awards. The board or committee is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a change of control of our company, including acceleration of vesting.

Except as otherwise determined by the board or committee at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.

The board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend the Plan or any outstanding award or may terminate the Plan as to further grants, provided that no amendment will, without the approval of our stockholders, increase the number of shares available under the Plan or change the persons eligible for awards under the Plan. No amendment that would adversely affect any outstanding award made under the Plan can be made without the consent of the holder of such award.

Except as set forth above, we do not have any ongoing plan or arrangement for the compensation of directors and executive officers.

PRINCIPAL STOCKHOLDERS

The following table sets forth certain information regarding beneficial ownership of shares of our common stock as June 25, 2021 by (i) each person known to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, (iii) each of our named executive officers, and (iv) all of our directors and executive officers as a group. Except as otherwise indicated, the persons named in the table below have sole voting and investment power with respect to all shares beneficially owned, subject to community property laws, where applicable.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting or investment power with respect to the securities. Shares of common stock that may be acquired by an individual or group within 60 days of June 25, 2021, pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Percentage of ownership is based on 7,387,500 shares of common stock outstanding on June 25, 2021. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options or other convertible securities held by that person or entity that are currently exercisable or releasable or that will become exercisable or releasable within 60 days of June 25, 2021. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

115

Table of Contents

Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them, based on information provided to us by such stockholders. Unless otherwise indicated, the address for each director and executive officer listed is: c/o Kiromic BioPharma, Inc., 7707 Fannin Street, Suite 140, Houston, TX 77008.


	Number of Shares Beneficially Owned Prior to Offering	Percentage of Common Stock Beneficially Owned
Beneficial Owner	Number of Shares Beneficially Owned Prior to Offering		Before Offering		After Offering
Directors and Executive Officers
Maurizio Chiriva Internati	1,375,272	18.61		11.25
Tony Tontat⁽¹⁾	453,518	6.10		3.69
Gianluca Rotino⁽²⁾	467,806	6.21		3.78
Scott Dahlbeck⁽³⁾	443,828	5.99		3.63
Ignacio Nunez	—	—		—
Pietro Bersani⁽⁴⁾	5,278	*		*
Americo Cicchetti⁽⁴⁾	5,278	*		*
Michael Nagel⁽⁴⁾	5,278	*		*
Jerry Schneider⁽⁵⁾	10,278	*		*
All executive officers and directors (9 persons)⁽⁶⁾	2,766,536	36.30		22.21
Other 5% Stockholders:
Encap (Global) Asset Management Limited⁽⁷⁾	498,333	6.74		4.08
Jose A. Figueroa⁽⁸⁾	478,912	6.48		3.92

* Less than 1%

(1)

Includes 51,519 options to purchase common stock which are exercisable within 60 days.

(2)

Includes 147,806 options to purchase common stock which are exercisable within 60 days.

(3)

Includes 14,311 options to purchase common stock which are exercisable within 60 days.

(4)

Includes options to purchase common stock which are exercisable within 60 days.

(5)

Includes 5,278 options to purchase common stock which are exercisable within 60 days

(6)

Includes 234,748 options to purchase common stock which are exercisable within 60 days.

(7)

The address of Encap (Global) Asset Management Limited is 12-S Sebright Plaza, 6-23 Shell Street, North Point, Hong Kong.

(8)

The address of Jose A. Figueroa is 4504 South Professional Drive, Apt 10208, Edinburg, TX 78539.

TRANSACTIONS WITH RELATED PERSONS

The following is a description of transactions or series of transactions since January 1, 2019 or any currently proposed transaction, to which we were or are to be a participant and in which the amount involved in the transaction or series of transactions exceeds $120,000, and in which any of our directors, executive officers or persons who we know hold more than five percent of any class of our capital stock, including their immediate family members, had or will have a direct or indirect material interest, other than compensation arrangements with our directors and executive officers.

Prior to completion of the initial public offering on October 15, 2020, we maintained two separate consulting agreements with our Chief Strategy and Innovation Officer (the “CSIO”), and the Chief Financial Officer and Chief Operating Officer (the “CFO and COO”).

Beginning in the year ended December 31, 2014, we entered into our first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from our Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for our business development strategies. The consulting fees paid to the CSIO totaled $0 and $319,300 in the three months ended March 31, 2021 and 2020, respectively. The consulting fees paid to the CSIO totaled $579,700 and $207,800 in the years ended December 31, 2020 and 2019, respectively. In addition, we issued the CSIO 320,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations.

Beginning in the year ended December 31, 2018, we entered into our first consulting agreement with the CFO and COO. Initially, his title was “Consultant”, and we changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $0 and

116

Table of Contents

$30,000 in the three months ended March 31, 2021 and 2020, respectively. The consulting fees paid to the CFO and COO totaled $140,000 and $67,500 in the years ended December 31, 2020 and 2019, respectively. In addition, we issued the CFO and COO 402,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations.

After we completed the initial public offering on October 15, 2020, the CFO and COO and the CSIO became full time employees.

DESCRIPTION OF SECURITIES

General

The following description summarizes important terms of the classes of our capital stock. This summary does not purport to be complete and is qualified in its entirety by the provisions of our current certificate of incorporation, as amended, and our current bylaws, which have been filed as exhibits to the registration statement of which this prospectus is a part.

We are authorized to issue 300,000,000 shares of common stock, par value $0.001 per share, and 60,000,000 shares of preferred stock, $0.0001 par value per share.

As of the date of this prospectus, there are 7,387,500 shares of common stock issued and outstanding.

Common Stock

Voting Rights. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Under our certificate of incorporation and bylaws, any corporate action to be taken by vote of stockholders other than for election of directors shall be authorized by the affirmative vote of the majority of votes cast. Directors are elected by a plurality of votes. Stockholders do not have cumulative voting rights.

Dividend Rights. Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.

Liquidation Rights. In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.

Other Rights. Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock.

Preferred Stock

Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors.

Authority is granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the Delaware General Corporate Law, or DGCL, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL. The powers, preferences and relative, participating, optional and other special rights of each such series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Without limiting the generality of the foregoing, the resolution or resolutions providing for the issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.

Warrants

As of the date of the prospectus, there are 62,500 representative warrants outstanding. In connection with the IPO on October 15, 2020, we granted the Underwriters’ Warrants to purchase an aggregate of 62,500 shares of common stock at an exercise price of

117

Table of Contents

$15.00 per share, which is 125% of the initial public offering price. The Underwriters’ Warrants have a five-year term and are not exercisable prior to April 13, 2021.

Options

As of the date of this prospectus, there are options for the purchase of 558,435 shares of common stock outstanding under our 2017 Equity Incentive Plan with a weighted average exercise price of $8.90 per share.

Restricted Stock Units

As of the date of this prospectus, there are 1,100,281 shares of common stock issuable upon the vesting of restricted stock units with a weighted-average grant date fair value of $12.22 per share.

Transfer Agent and Registrar

VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598 telephone 212-828-8436, is the transfer agent for our common stock.

Anti-Takeover Effects of Provisions of Delaware State Law

Our Fourth Amended and Restated Certificate of Incorporation and our Second Amended and Restated Bylaws, or our certificate of incorporation and our bylaws, include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our board of directors or management team, including the following:

Board of Directors Vacancies. Our bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors will be permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This will make it more difficult to change the composition of our board of directors and will promote continuity of management.

Stockholder Action; Special Meeting of Stockholders. A holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our bylaws further provide that special meetings of our stockholders may be called only by our board of directors, the chairman of our board of directors, our president or chief executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.

Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our bylaws will also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.

No Cumulative Voting. The Delaware General Corporation Law provides that stockholders are not entitled to cumulate votes in the election of directors unless a corporation’s certificate of incorporation provides otherwise. Our certificate of incorporation does not provide for cumulative voting.

Issuance of Undesignated Preferred Stock. Our board of directors will have the authority, without further action by our stockholders, to issue up to 60,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.

118

Table of Contents

MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF THE COMPANY’S COMMON STOCK

The following is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the ownership and disposition of the Company’s common stock but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. No ruling on the U.S. federal, state, or local tax considerations relevant to the Company’s operations or to the purchase, ownership or disposition of its shares, has been requested from the IRS or other tax authority. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of the tax consequences described below.

This summary also does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S. federal gift and estate tax laws, except to the limited extent set forth below. In addition, this discussion does not address tax considerations applicable to an investor’s particular circumstances or to investors that may be subject to special tax rules, including, without limitation:

banks, insurance companies or other financial institutions, regulated investment companies or real estate investment trusts;

persons subject to the alternative minimum tax or Medicare contribution tax on net investment income;

tax-exempt organizations or governmental organizations;

controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax;

brokers or dealers in securities or currencies;

traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;

persons that own, or are deemed to own, more than five percent of the Company’s capital stock (except to the extent specifically set forth below);

US expatriates and certain former citizens or long-term residents of the United States;

partnerships or entities classified as partnerships for U.S. federal income tax purposes or other pass- through entities (and investors therein);

persons who hold the Company’s common stock as a position in a hedging transaction, “straddle,” “conversion transaction” or other risk reduction transaction or integrated investment;

persons who hold or receive the Company’s common stock pursuant to the exercise of any employee stock option or otherwise as compensation;

persons who do not hold the Company’s common stock as a capital asset within the meaning of Section 1221 of the Internal Revenue Code; or

persons deemed to sell the Company’s common stock under the constructive sale provisions of the Internal Revenue Code.

In addition, if a partnership or entity classified as a partnership for U.S. federal income tax purposes holds the Company’s common stock, the tax treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership. Accordingly, partnerships that hold the Company’s common stock, and partners in such partnerships, should consult their tax advisors.

You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of the Company’s common stock arising

119

Table of Contents

under the U.S. federal estate or gift tax rules or under the laws of any state, local, non-U.S., or other taxing jurisdiction or under any applicable tax treaty.

Non-U.S. Holder Defined

For purposes of this discussion, you are a non-U.S. holder (other than a partnership) if you are any holder other than:

an individual citizen or resident of the United States (for U.S. federal income tax purposes);

a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States, any state thereof, or the District of Columbia;

an estate whose income is subject to U.S. federal income tax regardless of its source; or

a trust (x) whose administration is subject to the primary supervision of a U.S. court and which has one or more “U.S. persons” (within the meaning of Section 7701(a)(30) of the Internal Revenue Code) who have the authority to control all substantial decisions of the trust or (y) which has made a valid election to be treated as a U.S. person

Distributions

As described in “Dividend Policy,” the Company has never declared or paid cash dividends on its common stock and does not anticipate paying any dividends on its common stock in the foreseeable future. However, if the Company does make distributions on its common stock, those payments will constitute dividends for U.S. tax purposes to the extent paid from the Company’s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both the Company’s current and its accumulated earnings and profits, they will constitute a return of capital and will first reduce your basis in the Company’s common stock, but not below zero, and then will be treated as gain from the sale of stock as described below under “— Gain on Disposition of common stock.”

Subject to the discussion below on effectively connected income, backup withholding and foreign accounts, any dividend paid to a non-U.S. holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a non-U.S. holder must provide us with an IRS Form W-8BEN, IRS Form W-8BEN-E, or other appropriate version of IRS Form W-8 certifying qualification for the reduced rate. A non-U.S. holder of shares of the Company’s common stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. If the non-U.S. holder holds the stock through a financial institution or other agent acting on the non-U.S. holder’s behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to the Company or its paying agent, either directly or through other intermediaries.

Dividends received by a non-U.S. holder that are effectively connected with such non-U.S. holder’s conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, attributable to a permanent establishment maintained by a non-U.S. holder in the United States) are generally exempt from the withholding tax described above. In order to obtain this exemption, a non-U.S. holder must provide us with an IRS Form W-8ECI or other applicable IRS Form W-8 properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition, if a non-U.S. holder is a corporate non-U.S. holder, dividends received by such non-U.S. holder that are effectively connected with such non-U.S. holder’s conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty. You should consult your tax advisor regarding any applicable tax treaties that may provide for different rules.

Gain on Disposition of Common Stock

Subject to the discussion below regarding backup withholding and foreign accounts, a non-U.S. holder generally will not be required to pay U.S. federal income tax on any gain realized upon the sale or other disposition of the Company’s common stock unless:

the gain is effectively connected with the non-U.S. holder’s conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment maintained by such non-U.S. holder in the United States);

120

Table of Contents

the non-U.S. holder’s are a non-resident alien individual who is present in the United States for a period or periods aggregating 183 days or more during the taxable year in which the sale or disposition occurs and certain other conditions are met; or

the Company’s common stock constitutes a United States real property interest by reason of its status as a “United States real property holding corporation,” or USRPHC, for U.S. federal income tax purposes at any time within the shorter of (i) the five-year period preceding the non-U.S. holder’s disposition of the Company’s common stock, or (ii) the non-U.S. holder’s holding period for its common stock.

The Company believes that it is not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination of whether it is a USRPHC depends on the fair market value of its U.S. real property relative to the fair market value of its other business assets, there can be no assurance that the Company will not become a USRPHC in the future. Even if it becomes a USRPHC, however, as long as the Company’s common stock is regularly traded on an established securities market, such common stock will be treated as U.S. real property interests only if the non-U.S. holder’s actually or constructively hold more than five percent of such regularly traded common stock at any time during the shorter of (i) the five-year period preceding the non-U.S. holder’s disposition of the Company’s common stock, or (ii) the non-U.S. holder’s holding period for the Company’s common stock.

Gains described in the first bullet point above, generally will be subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates, and a corporate non-U.S. holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. An individual non-U.S. holder described in the second bullet above, you will be required to pay a flat 30% tax (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year (provided the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses). You should consult any applicable income tax or other treaties that may provide for different rules.

Backup Withholding and Information Reporting

Generally, the Company must report annually to the IRS, regardless of whether any tax was withheld, the amount of dividends paid to a non-U.S. holder, the non-U.S. holder’s name and address and the amount of tax withheld, if any. A similar report will be sent to the non-U.S. holder. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in the non-U.S. holder’s country of residence.

Payments of dividends or of proceeds on the disposition of stock made to a non-U.S. holder may be subject to information reporting and backup withholding at a current rate of 24% unless such non-U.S. holder establishes an exemption, for example, by properly certifying such non-U.S. holder’s non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E, or another appropriate version of IRS Form W-8.

Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner.

Foreign Account Tax Compliance

The Foreign Account Tax Compliance Act, or FATCA, imposes withholding tax at a rate of 30% on dividends on and gross proceeds from the sale or other disposition of the Company’s common stock paid to “foreign financial institutions” (as specially defined under these rules), unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and gross proceeds from the sale or other disposition of the Company’s common stock paid to a “non-financial foreign entity” (as specially defined for purposes of these rules) unless such entity provides the withholding agent with a certification identifying certain substantial direct and indirect U.S. owners of the entity, certifies that there are none or otherwise establishes an exemption. The withholding provisions under FATCA generally apply to dividends on our common stock, and under current transition rules, are expected to apply with respect to the gross proceeds from the sale or other disposition of the Company’s common stock on or after

121

Table of Contents

January 1, 2019. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their own tax advisors regarding the possible implications of this legislation on their investment in the Company’s common stock.

Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing of the Company’s common stock, including the consequences of any proposed change in applicable laws.

UNDERWRITING

ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”) is acting as representative of the underwriters of this offering. We have entered into an underwriting agreement dated June __, 2021 with the representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase from us, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of common shares listed next to its name in the following table:


Underwriter		Number of Shares
ThinkEquity, a division of Fordham Financial Management, Inc
Total

The underwriters are committed to purchase all shares offered by us other than those covered by the over- allotment option described below, if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters’ obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers’ certificates and legal opinions.

The underwriters are offering the shares subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

The underwriters propose to offer the shares offered by us to the public at the public offering price set forth on the cover of the prospectus. After the shares are released for sale to the public, the underwriters may change the offering price and other selling terms at various times.

Over-Allotment Option

We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the representative to purchase a maximum of additional shares of common stock (15% of the shares sold in this offering) from us to cover over-allotments, if any. If the representative exercises all or part of this option, it will purchase shares covered by the option at the public offering price per share that appears on the cover page of this prospectus, less the underwriting discount. If this option is exercised in full, the total offering price to the public will be $ and the total net proceeds, before expenses, to us will be $ .

Discount

The following table shows the public offering price, underwriting discounts and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.


	Per Share	Total Without Over-Allotment Option	Total With Over-Allotment Option
Public offering price
Underwriting discount (7.0%)
Proceeds, before expense, to us

We have agreed to pay a non-accountable expense allowance to the underwriters equal to 1% of the gross proceeds received in this offering (excluding proceeds received from exercise of the underwriters’ over-allotment option).

122

Table of Contents

In addition, we have agreed to reimburse the representative for fees and expenses of legal counsel to the underwriters in an amount not to exceed $100,000, fees and expenses related to the use of book building, prospectus tracking and compliance software for the offering in the amount of $29,500, up to $5,000 for background checks of our officers and directors, $10,000 for data services and communications expenses, $3,000 for the costs associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones, up to $10,000 for the representative's actual accountable road show expenses and up to $25,000 of the representative's market making and trading, and clearing firm settlement expenses.

We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non-accountable expense allowance, will be approximately $481,000.

Representative’s Warrants

We have agreed to issue to the representative warrants to purchase up to a total of __ shares of our common stock (“the Representative’s Warrants”). The Representative’s Warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per share of the shares of common stock sold in this offering. The Representative’s Warrants are exercisable at any time, from time to time, in whole or in part, during the four and one half year period commencing six months from the effective date of the registration statement related to this offering.

The Representative’s Warrants and the shares of common stock underlying the Representative’s Warrants have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Representative or permitted assignees under such rule may not sell, transfer, assign, pledge, or hypothecate the Representative’s Warrants or the securities underlying the Representative’s Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Representative’s Warrants or the underlying shares of common stock for a period of 180 days from the effective date of the registration statement. Additionally, the Representative’s Warrants may not be sold, transferred, assigned, pledged, or hypothecated for a 180-day period following the effective date of the registration statement, except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners. The Representative’s Warrants will provide for adjustment in the number and price of the Representative’s Warrants and the shares of common stock underlying the Representative’s Warrants in the event of recapitalization, merger, stock split, or other structural transaction, or a future financing undertaken by us.

Discretionary Accounts

The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

Lock-Up Agreements

Pursuant to certain “lock-up” agreements, we, our executive officers and directors and our stockholders, have agreed not to, without the prior written consent of the representative, offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired, for a period of 3 months from the date of this prospectus, in the case of our directors, officers, and certain of our other stockholders.

Right of First Refusal.

Subject to certain limited exceptions, until 12 months after the closing of this public offering, ThinkEquity has a right of first refusal to act as sole investment banker, sole book-runner and/or sole placement agent, at ThinkEquity’s sole discretion, for each and every future public and private equity and debt offering, including all equity-linked offerings, by us or any of our successors or subsidiaries during such 12-month period on terms customary to the representative.

Indemnification

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities.

123

Table of Contents

Electronic Offer, Sale and Distribution of Shares

A prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representative may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters’ websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.

Stabilization

In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.

Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.

Over-allotment transactions involve sales by the underwriters of securities in excess of the number of securities that underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of securities over- allotted by the underwriters is not greater than the number of securities that they may purchase in the over- allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing securities in the open market.

Syndicate covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared with the price at which they may purchase securities through exercise of the over-allotment option. If the underwriters sell more securities than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase in the offering.

Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our securities. These transactions may be effected on the Nasdaq Capital Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.

Passive Market Making

In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq Capital Market or on the OTCQB in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the securities and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.

Other Relationships

Certain of the underwriters and their affiliates may provide in the future, various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have no present arrangements with any of the underwriters for any further services.

124

Table of Contents

Offer restrictions outside the United States

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

Australia

This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus.

China

The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People’s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to “qualified domestic institutional investors.”

European Economic Area and the United Kingdom

The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (“Prospectus Directive”), as implemented in Member States of the European Economic Area (each, a “Relevant Member State”) and the United Kingdom, from the requirement to produce a prospectus for offers of securities.

An offer to the public of securities has not been made, and may not be made, in a Relevant Member State and the United Kingdom except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State and the United Kingdom:

to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;

to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than €43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than €50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);

to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or

in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.

125

Table of Contents

France

This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code monétaire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorité des marchés financiers (“AMF”). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.

This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.

Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifiés) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d’investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.

Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.

Ireland

The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the “Prospectus Regulations”). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.

Israel

The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.

Italy

The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ-$$-Aga e la Borsa, “CONSOB” pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (“Decree No. 58”), other than:

to Italian qualified investors, as defined in Article 100 of Decree no.58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 (“Regulation no. 1197l”) as amended (“Qualified Investors”); and

in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971 as amended.

Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:

made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and

126

Table of Contents

in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.

Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.

Japan

The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the “FIEL”) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.

Portugal

This document is not being distributed in the context of a public offer of financial securities (oferta pública de valores mobiliários) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (Código dos Valores Mobiliários). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comissăo do Mercado de Valores Mobiliários) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are “qualified investors” (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

Sweden

This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are “qualified investors” (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

Switzerland

The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (“SIX”) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).

This document is personal to the recipient only and not for general circulation in Switzerland.

127

Table of Contents

United Arab Emirates

Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company.

No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.

United Kingdom

Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (“FSMA”)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to “qualified investors” (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.

Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (“FPO”), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together “relevant persons”). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Canada

The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering

LEGAL MATTERS

The validity of the shares of our common stock offered hereby will be passed upon for us by Sheppard, Mullin, Richter & Hampton LLP, New York, New York. Venable, LLP, New York, New York has acted as counsel for the underwriters in connection with certain legal matters related to this offering.

128

Table of Contents

EXPERTS

The financial statements as of December 31, 2020 and 2019, and for each of the two years in the period ended December 31, 2020, included in this Prospectus have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein (which report expresses an unqualified opinion on the financial statements and includes an explanatory paragraph referring to conditions which raise substantial doubt about the Company’s ability to continue as a going concern). Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We have filed a registration statement, of which this prospectus is a part, on Form S-1 with the SEC relating to this offering. This prospectus does not contain all of the information in the registration statement and the exhibits included with the registration statement. For further information pertaining to us and the common stock to be sold in this offering, you should refer to the registration statement and its exhibits. References in this prospectus to any of our contracts, agreements or other documents are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contracts, agreements or documents. You may read and copy the registration statement, the related exhibits and other material we file with the SEC at the SEC’s public reference room in Washington, D.C. at 100 F Street, Room 1580, N.E., Washington, D.C. 20549. You can also request copies of those documents, upon payment of a duplicating fee, by writing to the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The SEC also maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file with the SEC. The website address is http://www.sec.gov.

We are subject to the informational requirements of the Exchange Act, and, in accordance with the Exchange Act, we currently file reports, proxy and information statements and other information with the SEC. Such annual, quarterly and special reports, proxy and information statements and other information can be inspected and copied at the locations set forth above. We also anticipate making these documents publicly available, free of charge, on our website as soon as reasonably practicable after filing such documents with the SEC. Information on, or accessible through, our website is not part of this prospectus.

129

Table of Contents

FINANCIAL STATEMENTS

	Page
Audited Consolidated Financial Statements for the Years December 31, 2020 and 2019
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets as of December 31, 2020 and 2019	F-3
Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019	F-4
Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2020 and 2019	F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019	F-6
Notes to Consolidated Financial Statements	F-7 to F-25
For the Three Months Ended March 31, 2021 and 2020 – Unaudited
Condensed Consolidated Balance Sheets as of March 31, 2021, and December 31, 2020 – Unaudited	F-26
Condensed Consolidated Statements of Operations for the Three Months ended March 31, 2021 and 2020 – Unaudited	F-27
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Three Months March 31, 2021 and 2020 – Unaudited	F-28
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020 – Unaudited	F-29
Notes to Condensed Consolidated Financial Statements	F-30 to F-44

F-1

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the stockholders and the Board of Directors of Kiromic BioPharma, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Kiromic BioPharma, Inc. and subsidiary (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred significant losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Deloitte & Touche LLP

Houston, Texas

March 31, 2021

We have served as the Company’s auditor since 2016.

F-2

Table of Contents

KIROMIC BIOPHARMA, INC.

Consolidated Balance Sheets


	December 31,		December 31,
	2020		2019
Assets
Current Assets:
Cash and cash equivalents	$	10,150,500	$	1,929,100
Inventories		—		22,200
Prepaid expenses and other current assets		588,800		89,100
Total current assets		10,739,300		2,040,400
Property and equipment, net		2,066,000		587,900
Other assets		24,400		24,400
Total Assets	$	12,829,700	$	2,652,700

Liabilities and Stockholders’ Equity:
Current Liabilities:
Accounts payable	$	665,200	$	452,400
Accrued expenses and other current liabilities		334,200		221,300
Interest payable		200		—
Loan payable		105,600		—
Note payable		362,400		—
Total current liabilities		1,467,600		673,700

Total Liabilities		1,467,600		673,700

Commitments and contingencies (Note 9)
Stockholders’ Equity:
Series A‑1 Preferred Stock, $0.0001 par value: 24,000,000 shares authorized as of December 31, 2020 and 2019; 0 and 21,822,301 shares issued and outstanding as of December 31, 2020 and 2019, respectively		—		9,134,700
Series B Preferred Stock, $0.0001 par value: 16,500,000 and 14,130,435 shares authorized as of December 31, 2020 and 2019, respectively; 0 and 9,869,659 shares issued and outstanding as of December 31, 2020 and 2019, respectively		—		1,306,900
Preferred Stock, $0.0001 par value: 19,500,000 and 21,869,565 shares authorized as of December 31, 2020 and 2019, respectively; 0 shares issued and outstanding as of December 31, 2020 and 2019		—		—
Common stock, $0.001 par value: 300,000,000 shares authorized as of December 31, 2020 and 2019; 7,332,999 and 2,863,812 shares issued and outstanding as of December 31, 2020 and 2019, respectively		1,200		—
Additional paid-in capital		52,988,700		13,965,000
Accumulated deficit		(41,627,800)		(22,427,600)
Total Stockholders’ Equity		11,362,100		1,979,000

Total Liabilities and Stockholders’ Equity	$	12,829,700	$	2,652,700

See accompanying notes to the consolidated financial statements

F-3

Table of Contents

KIROMIC BIOPHARMA, INC.

Consolidated Statements of Operations


	Years Ended
	December 31,
	2020		2019
Operating expenses:
Research and development	$	5,052,900	$	1,201,700
General and administrative		14,144,000		2,503,700
Total operating expenses		19,196,900		3,705,400
Loss from operations		(19,196,900)		(3,705,400)
Other expense
Interest expense		(3,300)		(22,500)
Total other expense		(3,300)		(22,500)
Net loss	$	(19,200,200)	$	(3,727,900)
Net loss per share, basic and diluted	$	(4.42)	$	(1.39)
Weighted average common shares outstanding, basic and diluted		4,505,867		2,862,809

See accompanying notes to the consolidated financial statements

F-4

Table of Contents

KIROMIC BIOPHARMA, INC.

Consolidated Statements of Stockholders’ Equity


	Series A‑1			Series B
	Preferred Stock			Preferred Stock			Common Stock
										Additional
	Number of			Number of			Number of			Paid-In		Accumulated
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Total
Balance at January 1, 2019	20,886,782	$	8,727,400	—	$	—	2,863,093	$	—	$	10,237,600	$	(18,699,700)	$	265,300
Conversion of convertible promissory notes and accrued interest into Series A‑1 Preferred Stock	935,519		407,300	—		—	—		—		—		—		407,300
Issuance of Series B Preferred Stock	—		—	9,782,609		1,056,300	—		—		—		—		1,056,300
Series B Preferred Stock discount amortization	—		—	—		210,600	—		—		(210,600)		—		—
Warrants underlying Series B Preferred Stock issuance	—		—	—		—	—		—		3,443,700		—		3,443,700
Accretion and settlement of Series B Preferred Stock dividend	—		—	87,050		40,000	—		—		(40,000)		—		—
Exercised stock options	—		—	—		—	1,719		—		11,400		—		11,400
Stock compensation expense	—		—	—		—	—		—		522,900		—		522,900
Net loss	—		—	—		—	—		—		—		(3,727,900)		(3,727,900)
Balance at December 31, 2019	21,822,301		9,134,700	9,869,659	$	1,306,900	2,864,812	$	—	$	13,965,000	$	(22,427,600)	$	1,979,000
Issuance of Series B Preferred Stock	—		—	6,521,738		331,700	—		—		—		—		331,700
Series B Preferred Stock discount amortization	—		—	—		692,700	—		—		(692,700)		—		—
Warrants underlying Series B Preferred Stock issuance	—		—	—		—	—		—		2,668,300		—		2,668,300
Exercise of warrants	—		—	—		—	1,399,921		—		4,900		—		4,900
Common stock issuance net of issuance costs and discount amortization	—		—	—		—	1,250,000		1,200		11,974,200		—		11,975,400
Warrants underlying common stock discount amortization	—		—	—		—	—		—		(19,700)		—		(19,700)
Warrants underlying common stock issuance	—		—	—		—	—		—		377,000		—		377,000
Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion	(21,822,301)		(9,134,700)	—		—	624,594		—		9,134,700		—		—
Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion	—		—	(16,391,397)		(2,331,300)	469,136		—		2,331,300		—		—
Common stock issuance to employees and non-employees	—		—	—		—	725,536		—		9,432,000		—		9,432,000
Stock compensation expense	—		—	—		—	—		—		3,813,700		—		3,813,700
Net loss	—		—	—		—	—		—		—		(19,200,200)		(19,200,200)
Balance at December 31, 2020	—	$	—	—	$	—	7,333,999		1,200		52,988,700		(41,627,800)		11,362,100

See accompanying notes to the consolidated financial statements

F-5

Table of Contents

KIROMIC BIOPHARMA, INC.

Consolidated Statements of Cash Flows


	Years Ended
	December 31,
	2020		2019
Cash flows from operating activities:
Net loss	$	(19,200,200)	$	(3,727,900)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation		200,000		87,500
Stock compensation expense		13,245,700		522,900
Non-cash interest		200		20,500
Inventory obsolescence impairment		22,200		—
Changes in operating assets and liabilities:
Unbilled receivables from granting agency		—		24,300
Inventories		—		(5,900)
Prepaid expenses and other current assets		(499,700)		46,200
Other assets		—		(6,600)
Accounts payable		(7,700)		293,400
Accrued expenses and other current liabilities		112,900		(151,300)
Deferred rent		—		(19,000)
Convertible promissory notes derivative liability		—		2,000
Net cash used for operating activities		(6,126,600)		(2,913,900)
Cash flows from investing activities:
Purchases of property and equipment		(1,457,600)		(302,700)
Net cash used for investing activities		(1,457,600)		(302,700)
Cash flows from financing activities:
Proceeds from sale of convertible promissory notes		—		250,000
Exercise of stock options		—		11,400
Proceeds from issuance of common stock		15,000,000		—
Issuance costs		(2,667,300)		—
Proceeds from warrant exercise		4,900		—
Proceeds from loan payable		115,600		—
Repayments of loan payable		(10,000)		—
Borrowings from note payable		540,500		—
Repayments of note payable		(178,100)		—
Proceeds from Series B Preferred Stock issuance		3,000,000		4,500,000
Net cash provided by financing activities		15,805,600		4,761,400
Net change in cash and cash equivalents		8,221,400		1,544,800
Cash and cash equivalents:
Beginning of year		1,929,100		384,300
End of year	$	10,150,500	$	1,929,100

Supplemental disclosures of non-cash investing and financing activities:
Accruals for property and equipment	$	220,500	$	74,700
Cash paid for interest on note payable	$	3,100	$	—
Conversion of accounts payable into convertible promissory notes	$	—	$	134,800
Conversion of convertible promissory notes and accrued interest into Series A‑1 Preferred Stock	$	—	$	407,300
Accretion and settlement of Series B Preferred Stock dividend	$	—	$	40,000

See accompanying notes to the consolidated financial statements

F-6

Table of Contents

KIROMIC BIOPHARMA, INC.

Notes to Consolidated Financial Statements

1.	ORGANIZATION

Nature of Business

Kiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.

The Company is a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.

The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.

Going Concern — The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flows from operations of $6,126,600 for the year ended December 31, 2020, and an accumulated deficit of $41,627,800 as of December 31, 2020. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Although the Company completed its initial public offering on October 15, 2020 and received net proceeds of $12,332,700, the Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in fiscal year 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the U.S. government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase I completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

F-7

Table of Contents

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.

On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.

Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.

The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.

The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.

Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets.

Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded.

Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.

F-8

Table of Contents

During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets.

Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.

Estimated useful lives of property and equipment are as follows for the major classes of assets:


Asset Description		Estimated Lives
Laboratory Equipment		3 - 8
Leasehold Improvements		1 - 7
Office Furniture, Fixtures, and Equipment		5
Software		3 - 5

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively.

Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.

Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.

The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019.

Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.

F-9

Table of Contents

The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH.

Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.

Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.

Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.

The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.

F-10

Table of Contents

Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:


	December 31,		December 31,
	2020		2019
Convertible promissory notes
Beginning balance	$	—	$	—
Amounts allocated to the embedded derivative liability at inception (at fair value)		—		(21,000)
Conversions from accounts payable into convertible promissory notes		—		134,800
Proceeds from issuances of convertible promissory notes		—		250,000
Conversions into Series A‑1 Stock		—		(363,800)
Ending balance	$	—	$	—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability
Beginning balance	$	—	$	—
Realized and unrealized gains and losses		—		2,000
Fair value of embedded derivative liability at inception		—		21,000
Amounts derecognized upon conversion of the related convertible promissory notes		—		(23,000)
Ending balance	$	—	$	—

Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options.

The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.

The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.

Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.

Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.

The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:

Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.

F-11

Table of Contents

Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.

Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:

●

valuations of the common stock performed by third-party specialists;

●

the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;

●

lack of marketability of the common stock;

●

current business conditions and projections;

●

hiring of key personnel and the experience of management;

●

the Company’s stage of development;

●

likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;

●

the market performance of comparable publicly traded companies; and

●

the US and global capital market conditions.

In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).

The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

F-12

Table of Contents

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.

Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.

For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant.

Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.

The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:

Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period.

Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.

Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.

Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.

Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.

Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.

F-13

Table of Contents

On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019.

3.	NET LOSS PER COMMON SHARE

Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted loss per share:


	Years Ended
	December 31,
	2020		2019
Net loss	$	(19,200,200)	$	(3,727,900)
Less: Accretion and settlement of Series B Preferred Stock dividend		—		(40,000)
Less: Series B Preferred Stock discount amortization		(692,700)		(210,600)
Less: IPO Common Stock discount amortization		(19,700)		—
Net loss attributable to common shareholders, basic and diluted	$	(19,912,600)	$	(3,978,500)
Weighted average common shares outstanding, basic and diluted		4,505,867		2,862,809
Net loss per common share, basic and diluted	$	(4.42)	$	(1.39)

F-14

Table of Contents

For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


	December 31,	December 31,
	2020	2019
Stock options to purchase	1,647	75,405
Restricted Stock Units	95,815	—
Series A‑1 Preferred Stock	—	624,594
Series B Preferred Stock	—	282,478
Warrants underlying Series B Preferred Stock	—	839,784
Total	97,462	1,822,261

4.	PROPERTY AND EQUIPMENT, NET

Property and equipment, net consisted of the following at December 31:


	2020		2019
Equipment	$	780,500	$	488,800
Leasehold improvements		1,229,700		302,700
Office furniture, fixtures, and equipment		16,600		16,600
Software		151,700		141,500
Construction in progress		449,200		—
		2,627,700		949,600
Less: Accumulated depreciation		(561,700)		(361,700)
Total	$	2,066,000	$	587,900

Depreciation expense was $200,000 and $87,500 for the years ended December 31, 2020 and 2019, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the consolidated statements of operations.

5.	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at December 31:


	2020		2019
Accrued consulting and outside services	$	143,200	$	221,300
Accrued compensation		191,000		—
Total	$	334,200	$	221,300

6.	CURRENT LOAN PAYABLE

On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. The SBA Loan was forgiven on February 16, 2021. See Note 14.

The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.

F-15

Table of Contents

As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 during year ended December 31, 2020 in the consolidated balance sheet. During year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020.

The Company accrued $200 of interest expense during the year ended December 31, 2020. The Company accrues interest over the term of the loan and does not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency. If any amount of the loan is ultimately forgiven, income from the extinguishment of debt would be recognized as a gain on loan extinguishment in the consolidated statement of operations.

7.	NOTE PAYABLE

In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of December 31, 2020, the remaining payable balance on the financed amount was approximately $362,400.

8.CONVERTIBLE PROMISSORY NOTES

Starting in June 2016, the Company sold convertible promissory notes to certain investors to help finance its operations. The convertible promissory notes were in amounts ranging from $12,500 to $500,000, earning annual interest between 6% and 17% and all maturing either on June 1, 2019, January 2, 2020, or June 30, 2020 (the “Maturity Date”).

The convertible promissory notes were convertible into shares issued in the Company’s Next Financing Close by dividing the total amount of convertible promissory notes, plus accrued interest (the “Balance”) by the applicable conversion price, as defined in the convertible promissory notes. If the convertible promissory notes have not been converted, the Balance shall be payable in full if the Company consummates a change of control transaction. If there has not been a Next Financing Close or a change in control by the Maturity Date, then at the noteholders’ option, the Company shall either repay the Balance then outstanding or convert into the Company’s common stock at a set conversion price then in effect, as defined in the convertible promissory notes.

The estimated fair value of the conversion discount related embedded derivative was determined using a probability-weighted expected return model. The probability of a Next Financing Close occurring prior to the Maturity Date was determined to be 55% during the year ended December 31, 2019. The net present value of the conversion discount related embedded derivative was measured using a discount rate of 25% as of December 31, 2019. Below is a table that outlines the initial value of issuances and the bifurcated embedded derivative liability during the years ended December 31:


	2020		2019
Convertible promissory notes- issuances	$	—	$	250,000
Conversion of accounts payable into convertible promissory notes		—		134,800
Total issuances and conversions into convertible promissory notes		—		384,800

Embedded derivative liability
Initial fair value upon issuance of convertible promissory notes		—		21,000
Realized and unrealized gains and losses		—		2,000
Converted embedded derivative liability into Series A‑1 Preferred Stock		—		(23,000)
Embedded derivative liability balance at December 31	$	—	$	—

On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. See Note 10 for further details. No additional convertible promissory notes were issued for year ended December 31, 2020 following the conversion on August 15, 2019.

F-16

Table of Contents

9.COMMITMENTS AND CONTINGENCIES

Facility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.

On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.

The total lease payments per month will be $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477 and $23,039 beginning May 1, 2021 and May 1, 2022, respectively. The Company records rent expense on a straight-line basis over the term of the leases.

As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:


	Amount
2021	$	265,200
2022		269,700
2023		274,200
2024		230,400
Total	$	1,039,500

Annual rent expense for the facility lease agreements was $262,900 and $129,100 for the years ended December 31, 2020 and 2019, respectively, and is included as an allocation between research and development and general and administrative expense in the consolidated statements of operations.

License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of December 31, 2020 and 2019, the Company has not incurred any milestone or royalty liabilities related to these license agreements.

Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. The Company regularly assesses all contingencies and believes, as of December 31, 2020, the Company was not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows.

10.STOCKHOLDERS’ EQUITY

On December 16, 2019, the Company amended and restated its certificate of incorporation to, among other things, (i) complete a 1-for-10 reverse split of the Company’s outstanding shares of common stock; (ii) increase the Company’s authorized Preferred Stock to 60,000,000 shares and (iii) change the par value of the Preferred Stock from $0.01 to $0.0001 per share.

On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares of common stock.

Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits during the years ended December 31, 2020 and 2019.

As of December 31, 2020 and 2019, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares and of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock. Additionally, 16,500,000 shares and 14,130,435 shares were designated as Series B Preferred Stock as of December 31, 2020 and 2019, respectively.

Common Stock — As of December 31, 2020 and 2019, the Company has a single class of common stock.

On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share. In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.

F-17

Table of Contents

Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the year ended December 31, 2020:


	2020
Common Stock
Balance at January 1,	$	—
Common stock IPO proceeds, net of issuance costs		12,332,700
Common stock IPO discount		(377,000)
Common stock IPO discount amortization		19,700
Balance at December 31,	$	11,975,400

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There were 0 and 839,952 warrants outstanding as of December 31, 2020 and 2019, respectively.

On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSIO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.

Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.

The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted the Plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.

There were 270,933 shares and 258,813 shares available for issuance as of December 31, 2020 and 2019, respectively.

Series A-1 Preferred Stock — In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation the holders of the shares of Series A-1 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.50, the original issue price.

On matters submitted to a vote of the stockholders of the Company, Series A-1 Preferred Stock and common stock vote together as one class, with the vote of the Series A-1 Preferred Stock on an as-converted basis. Each holder of Series A-1 Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series A-1 Preferred Stock held by such holder are then convertible.

With respect rights on liquidation, winding up and dissolution, shares of the Series A-1 Preferred Stock rank senior to all shares of common stock.

Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.

In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.

F-18

Table of Contents

Series B Preferred Stock — On September 13, 2019, the Company amended and restated its certificate of incorporation to authorize the issuance of up to 14,130,435 shares of Series B Preferred Stock. On September 13, 2019, the Company sold 7,608,696 shares of Series B Preferred Stock for $3,500,000. On November 13, 2019, the Company issued an additional 2,173,913 shares of Series B Preferred Stock for $1,000,000. In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). See below for further details.

Until the filing of the amended and restated certificate of incorporation on December 16, 2019, shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. The amended and restated certificate of incorporation eliminated the clause requiring the dividend accrual. In addition, on December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, the Company issued 87,050 shares of Series B Preferred Stock to the investors. The Company treated this transaction as accretion and settlement of a Series B Preferred Stock dividends in the amount of $40,000. Accordingly, additional paid-in capital was reduced by $40,000.

The Series B Preferred Stock conversion price is initially equal to the Series B Preferred Stock original issuance price of $0.46 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock. The holders of the Series B Preferred Stock held a special redemption right. In the event the Company had not filed an initial registration statement with the United States Securities and Exchange Commission and submitted an application to be listed on the Nasdaq Stock market on or prior to November 15, 2019, subject to Delaware law governing distributions to stockholders and the Company’s ability to redeem its shares, all or part of the shares of Series B Preferred Stock held by any holder of record as of such date of shares of Series B Preferred Stock with an aggregate purchase price of at least $1,000,000 would have been be redeemable at the option of such holders of record commencing any time on or after November 16, 2019 at a price equal to the purchase price paid for such shares plus all unpaid dividends accrued on such shares. Also, in the event that the Company was not ultimately approved for listing on a Nasdaq Stock Market tier lower than the Nasdaq Global Select Market, the special redemption right would remain in effect and may have been exercisable on any date thereafter. If the Company was unable to execute a redemption upon request of a holder, interest would accrue on the shares at rate of 14.6%, or warrants underlying the shares would be exercisable and the fair market value of the shares of common stock received in connection therewith would be treated as payment in exchange for the shares of Series B Preferred Stock submitted for redemption by such holder.

On November 12, 2019 and November 13, 2019, the Series B Preferred Stock investors signed waivers, which provided consent to the Company to eliminate the special redemption right. When the Company amended and restated its certificate of incorporation on December 16, 2019, the special redemption right provision was eliminated.

The elimination of the special redemption right allows for permanent equity classification for the Series B Preferred Stock. Since the Warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series B Preferred Stock and the Warrants. The fair value of the Warrants is offset by a contra account, which is classified as a discount to the Series B Preferred Stock. The discount is amortized using the effective interest method at an effective interest rate of 28% per annum.

On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

In connection with the IPO, all shares of the Company's Series B Preferred Stock were converted into 469,136 shares of common stock, and the value of the Series B Preferred Stock converted into additional-paid-in-capital.

Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock, the Series B Preferred Stock discount amortized, and value of Series B Preferred Stock that was converted into additional-paid-in-capital during the years ended December 31:


	2020		2019
Series B Preferred Stock
Balance at January 1,	$	1,306,900	$	4,500,000
Series B Preferred Stock proceeds		3,000,000		(3,443,700)
Series B Preferred Stock discount		(2,668,300)		210,600
Series B Preferred Stock discount amortization		692,700		40,000
Series B Preferred Stock conversion to common stock		(2,331,300)		—
Balance at December 31,	$	—	$	1,306,900

F-19

Table of Contents

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.

On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.

With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.

Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.

Conversion of Convertible Promissory Notes — On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $405,300. Per the convertible promissory notes, the notes containing a $250,000 principal balance with a 17% coupon rate had a conversion price of $0.43. Additionally, the Company settled an accounts payable with a vendor by issuing a convertible promissory note in the amount of $134,800 with a 6% coupon rate, with a conversion rate of $0.43. Accordingly, 935,519 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.

In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.

Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. Under the original terms of the warrant agreements, the warrants become have exercisable in accordance with the schedule set forth below following completion by the Company of an IPO and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.

●

30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

●

An additional 30% of the warrants beginning nine months after the Listing Date; and

●

The remainder of the warrants beginning twelve months after the Listing Date.

As of December 31, 2019, the Company sold 9,782,609 shares of Series B Preferred Stock, which contained 839,952 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. During the year ended December 31, 2020, the Company sold an additional 6,521,738 shares of Series B Preferred Stock, which contained 559,969 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants were equity classified and the fair value of $5,208,700 is reflected as additional paid-in capital. On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.

On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There are no warrants underlying Series B Preferred Stock outstanding as of December 31, 2020.

F-20

Table of Contents

The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the years ended December 31:


	2020		2019
Risk-free interest rate	1.54% - 1.88	%	1.54% - 1.84	%
Expected volatility	71.95% - 72.71	%	71.95% - 72.20	%
Expected life (years)	10.00		10.00
Expected dividend yield	0	%	0	%

Representative's Warrants — In connection with the IPO, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at December 31, 2020.

These warrants were equity classified and the fair value of $377,000 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the year ended December 31, 2020:


	2020
Risk-free interest rate	0.18	%
Expected volatility	94.08	%
Expected life (years)	2.74
Expected dividend yield	0	%

11.STOCK-BASED COMPENSATION

2017 Stock Incentive Plan — Stock Options

The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:


	2020		2019
Risk-free interest rate	0.15% - 2.92	%	1.60% - 2.92	%
Expected volatility	72.29% - 82.52	%	72.29% - 78.16	%
Expected life (years)	4.93 – 6.07		4.93 – 6.07
Expected dividend yield	0	%	0	%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.

F-21

Table of Contents

The following table summarizes the activity for all stock options outstanding at December 31 under the Plan:


	2020			2019
		Weighted			Weighted
		Average			Average
		Exercise			Exercise
	Shares	Price		Shares	Price
Options outstanding at beginning of year	598,083	$	11.04	520,517	$	8.64
Granted	86,536		17.95	209,505		17.29
Exercised	—		—	(1,719)		6.64
Cancelled and forfeited	(194,901)		15.06	(130,220)		11.56
Balance at December 31	489,718	$	10.03	598,083	$	11.04
Options exercisable at December 31:	441,430	$	9.50	368,527	$	7.72
Weighted average grant date fair value for options granted during the year:		$	17.43		$	10.82

The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2020 and 2019 under the Plan:


	Options Outstanding						Options Exercisable
		Weighted
		Average	Weighted					Weighted
		Remaining	Average		Aggregate			Average		Aggregate
As of	Options	Contractual	Exercise		Intrinsic		Options	Exercise		Intrinsic
December 31,	Outstanding	Life	Price		Value		Exercisable	Price		Value
2020	489,718	6.37	$	10.03	$	554,900	441,430	$	9.50	$	—
2019	598,083	8.07	$	11.04	$	19,163,700	368,527	$	7.72	$	13,031,000

Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the consolidated statements of operations for the years ended December 31, 2020 and 2019 as follows:


	2020		2019
Research and development	$	1,008,000	$	332,000
General and administrative		332,000		190,900
Total	$	1,340,000	$	522,900

On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $65,900 of stock compensation expense allocable to general and administrative for the year December 31, 2020. Included in that amount were $34,800 of incremental compensation costs resulting from the modifications for the year ended December 31, 2020.

As of December 31, 2020, total unrecognized stock compensation expense is $473,900, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.79 years.

2017 Stock Incentive Plan — Restricted Stock Units

In January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.

F-22

Table of Contents

The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.

The following table summarizes the activity for all RSUs outstanding at December 31 under the Plan:


	2020
		Weighted Average
		Grant Date
		Fair Value
	Shares	Per Share
Nonvested RSUs at beginning of year	—	$	—
Granted	1,655,579		12.84
Vested	—		—
Cancelled and forfeited	(709,334)		12.87
Nonvested RSUs at December 31	946,245	$	12.81

During the year ended December 31, 2020, 1,655,579 RSUs were granted and 709,334 RSUs were cancelled. During the year ended December 31, 2020, no RSUs vested. No RSUs were granted or vested in the year ended December 31, 2019.

On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $748,400 and $1,725,300 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020. Included in those amounts were incremental compensation costs of $166,900 and $402,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020.

12.INCOME TAXES

For the years ended December 31, 2020 and 2019, the Company recognized no provision or benefit from income taxes.

The following is a reconciliation of the effective income tax rate to the statutory federal income tax rate for the years ended December 31, 2020 and 2019.


	2020		2019
Federal income tax at statutory rates	21.00	%	21.00	%
Federal income tax rate reduction	—	%	—	%
Change in valuation allowance	(21.00)		(21.00)
Effective income tax rate	—	%	—	%

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. The Company recorded a valuation allowance to fully offset the net deferred tax asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets as of December 31, 2020 and 2019 due to the significant uncertainty about the realization of the deferred tax asset until the Company can operate profitably.

F-23

Table of Contents

The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows as of December 31:


	2020		2019
Deferred tax assets (liabilities):
Net operating loss carryforward	$	3,842,900	$	2,605,400
Stock compensation expense		3,379,000		597,400
Intangible assets		23,600		27,800
Total gross deferred tax assets		7,245,500		3,230,600
Valuation allowance		(7,061,600)		(3,198,100)
Property and equipment		(183,900)		(32,500)
Net deferred tax assets (liabilities)		—		—

As of December 31, 2020 and 2019, the Company has a US net operating loss ("NOL") carryforward of $18,299,500 and $12,406,800, respectively. The NOL carryforwards may be subject to annual limitations due to "change in ownership" provisions of Internal Revenue Code Section 382 ("Section 382") that can be triggered due to future ownership changes. Additionally, the NOL loss carryforwards are subject to examination and adjustments by the Internal Revenue Service until the statute of limitations closes on the year in which the NOL is utilized.

As of December 31, 2020 and 2019, there were no material uncertain tax positions taken by the Company. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months.

As of December 31, 2020, the Company is not currently under audit by any income tax authority.

On March 27, 2020, in response to the COVID-19 pandemic, the president of the United States signed the CARES Act. The Company does not expect there to be any significant benefit to its income tax provision as a result of the CARES Act, and the Company continues to monitor for any potential tax legislation related to the COVID-19 pandemic.

13.RELATED PARTY TRANSACTIONS

During the year ended December 31, 2020, the Company maintained two separate consulting agreements with the Company’s CSIO and the Company’s CFO and COO. Those consulting agreements were terminated after the completion of the IPO in October 2020.

Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO was entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company’s Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company’s business development strategies. The consulting fees paid to the CSIO totaled $579,700 and $207,800 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CSIO 320,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.

Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month plus discretionary bonuses approved by management. The consulting fees paid to the CFO and COO totaled $140,000 and $67,500 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CFO and COO 402,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.

On June 8, 2020, the Company issued the Chief Medical Officer and another employee 3,106 and 430 shares of common stock, respectively. The shares were issued in exchange for services rendered and no cash considerations. See Note 10.

F-24

Table of Contents

14.SUBSEQUENT EVENTS

Strategic Alliance Agreement with Leon Office (H.K.)

On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. The cost of the agreement is $360,000 annually, payable in four quarterly installments.

Loan Payable Forgiveness

During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021 the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,600 and $300, respectively.

Lease Facility Expansion

On March 22, 2020, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.

If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.

The future minimum commitments under the amended lease agreement will be as follows:


	Amount
2021	$	380,600
2022		546,700
2023		551,100
2024		461,200
Total	$	1,939,600

Legal Complaint Filed Against the Company

A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.

F-25

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Balance Sheets

(Unaudited)


	March 31,		December 31,
	2021		2020
Assets
Current Assets:
Cash and cash equivalents	$	7,335,300	$	10,150,500
Prepaid expenses and other current assets		513,500		588,800
Total current assets		7,848,800		10,739,300
Property and equipment, net		2,279,500		2,066,000
Other assets		24,400		24,400
Total Assets	$	10,152,700	$	12,829,700

Liabilities and Stockholders’ Equity:
Current Liabilities:
Accounts payable	$	1,203,200	$	665,200
Accrued expenses and other current liabilities		268,900		334,200
Interest payable		—		200
Loan payable		—		105,600
Note payable		227,800		362,400
Total current liabilities		1,699,900		1,467,600

Total Liabilities		1,699,900		1,467,600

Commitments and contingencies (Note 8)
Stockholders’ Equity:
Common stock, $0.001 par value: 300,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 7,332,999 shares issued and outstanding as of March 31, 2021 and December 31, 2020		1,200		1,200
Additional paid-in capital		53,933,900		52,988,700
Accumulated deficit		(45,482,300)		(41,627,800)
Total Stockholders’ Equity		8,452,800		11,362,100

Total Liabilities and Stockholders’ Equity	$	10,152,700	$	12,829,700

See accompanying notes to the condensed consolidated financial statements

F-26

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended
	March 31,
	2021		2020
Operating expenses:
Research and development	$	1,885,600	$	1,028,100
General and administrative		2,071,000		824,600
Total operating expenses		3,956,600		1,852,700
Loss from operations		(3,956,600)		(1,852,700)
Other income (expense)
Gain on loan extinguishment		105,800		—
Interest expense		(3,700)		—
Total other expense		102,100		—
Net loss	$	(3,854,500)	$	(1,852,700)
Net loss per share, basic and diluted	$	(0.53)	$	(0.78)
Weighted average common shares outstanding, basic and diluted		7,332,999		2,863,812

See accompanying notes to the condensed consolidated financial statements

F-27

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)


	Three Months Ended March 31, 2021
	Common Stock			Additional
	Number of			Paid-In		Accumulated
	Shares	Amount		Capital		Deficit		Total
Balance at January 1, 2021	7,332,999		1,200		52,988,700		(41,627,800)		11,362,100
Common stock discount amortization	—		—		24,700		—		24,700
Warrants underlying common stock issuance	—		—		(24,700)		—		(24,700)
Stock compensation expense	—		—		945,200		—		945,200
Net loss	—		—		—		(3,854,500)		(3,854,500)
Balance at March 31, 2021	7,332,999		1,200		53,933,900		(45,482,300)		8,452,800


	Three Months Ended March 31, 2020
	Series A‑1			Series B
	Preferred Stock			Preferred Stock			Common Stock
										Additional
	Number of			Number of			Number of			Paid-In		Accumulated
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Total
Balance at January 1, 2020	21,822,301	$	9,134,700	9,869,659	$	1,306,900	2,863,812	$	—	$	13,965,000	$	(22,427,600)	$	1,979,000
Issuance of Series B Preferred Stock	—		—	6,521,738		331,700	—		—		—		—		331,700
Series B Preferred Stock discount amortization	—		—	—		368,400	—		—		(368,400)		—		—
Warrants underlying Series B Preferred Stock issuance	—		—	—		—	—		—		2,668,300		—		2,668,300
Stock compensation expense	—		—	—		—	—		—		456,000		—		456,000
Net loss	—		—	—		—	—		—		—		(1,852,700)		(1,852,700)
Balance at March 31, 2020	21,822,301	$	9,134,700	16,391,397	$	2,007,000	2,863,812	$	—	$	16,720,900	$	(24,280,300)	$	3,582,300

See accompanying notes to the condensed consolidated financial statements

F-28

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Three Months Ended
	March 31,
	2021		2020
Cash flows from operating activities:
Net loss	$	(3,854,500)	$	(1,852,700)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation		95,600		33,800
Stock compensation expense		945,200		456,000
Gain on loan extinguishment		(105,800)		—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		75,400		(99,700)
Accounts payable		273,600		(35,200)
Accrued expenses and other current liabilities		(65,400)		17,500
Net cash used for operating activities		(2,635,900)		(1,480,300)
Cash flows from investing activities:
Purchases of property and equipment		(44,700)		(406,300)
Net cash used for investing activities		(44,700)		(406,300)
Cash flows from financing activities:
Repayments of note payable		(134,600)		—
Proceeds from Series B Preferred Stock issuance		—		3,000,000
Net cash (used in) provided by financing activities		(134,600)		3,000,000
Net change in cash and cash equivalents		(2,815,200)		1,113,400
Cash and cash equivalents:
Beginning of year		10,150,500		1,929,100
End of period	$	7,335,300	$	3,042,500

Supplemental disclosures of non-cash investing and financing activities:
Accruals for property and equipment	$	264,400	$	230,700
Cash paid for interest on note payable	$	3,700	$	—
Warrants underlying Series B Preferred Stock issuance	$	—	$	2,668,300

See accompanying notes to the condensed consolidated financial statements

F-29

Table of Contents

KIROMIC BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.	ORGANIZATION

Nature of Business

The Company is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.

Going Concern — These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $2,635,900 for the three months ended March 31, 2021, and an accumulated deficit of $45,482,300 as of March 31, 2021. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. The Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in the third quarter of 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase 1 completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

F-30

Table of Contents

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.

All intercompany balances were eliminated upon consolidation.

Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Estimated useful lives of property and equipment are as follows for the major classes of assets:


Asset Description		Estimated Lives
Laboratory Equipment		3 - 8
Leasehold Improvements		1 - 7
Office Furniture, Fixtures, and Equipment		5
Software		3 - 5

F-31

Table of Contents

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020.

Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.

The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020.

Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH.

Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

F-32

Table of Contents

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020.

Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options.

The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.

The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:

F-33

Table of Contents

Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:

●

valuations of the common stock performed by third-party specialists;

●

the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;

●

lack of marketability of the common stock;

●

current business conditions and projections;

●

hiring of key personnel and the experience of management;

●

the Company’s stage of development;

●

likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;

●

the market performance of comparable publicly traded companies; and

●

the US and global capital market conditions.

F-34

Table of Contents

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.

Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

F-35

Table of Contents

3.NET LOSS PER COMMON SHARE

Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, restricted stock units, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share:


	Three Months Ended
	March 31,
	2021		2020
Net loss	$	(3,854,500)	$	(1,852,700)
Less: Series B Preferred Stock discount amortization		—		(368,400)
Less: IPO Common Stock discount amortization		(24,700)		—
Net loss attributable to common shareholders, basic and diluted	$	(3,879,200)	$	(2,221,100)
Weighted average common shares outstanding, basic and diluted		7,332,999		2,863,812
Net loss per common share, basic and diluted	$	(0.53)	$	(0.78)

For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


	March 31,	March 31,
	2021	2020
Stock options to purchase	677	404,391
Restricted Stock Units	32,000	—
Series A‑1 Preferred Stock	—	624,594
Series B Preferred Stock	—	469,136
Warrants underlying Series B Preferred Stock	—	1,399,807
Total	32,677	2,897,928

4.PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2021 and December 31, 2020:


	March 31,		December 31,
	2021		2020
Equipment	$	1,138,900	$	780,500
Leasehold improvements		1,274,600		1,229,700
Office furniture, fixtures, and equipment		16,600		16,600
Software		151,700		151,700
Construction in progress		355,000		449,200
		2,936,800		2,627,700
Less: Accumulated depreciation		(657,300)		(561,700)
Total	$	2,279,500	$	2,066,000

Depreciation expense was $95,600 and $33,800 for the three months ended March 31, 2021 and, 2020, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the condensed consolidated statements of operations.

F-36

Table of Contents

5.ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at March 31, 2021 and December 31, 2020:


	March 31,		December 31,
	2021		2020
Accrued consulting and outside services	$	173,900	$	143,200
Accrued compensation		95,000		191,000
Total	$	268,900	$	334,200

6.LOAN PAYABLE

On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to apply for forgiveness of the SBA Loan in accordance with the terms of the CARES Act.

As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 as of December 31, 2020 in the condensed consolidated balance sheet. During the year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020. The Company accrued interest over the term of the loan and did not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency.

During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021, the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,800. The forgiveness was classified as a gain on loan extinguishment in the condensed consolidated statement of operations.

7.NOTE PAYABLE

In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of March 31, 2021 and December 31, 2020, the remaining payable balance on the financed amount was $227,800 and $362,400, respectively.

8.COMMITMENTS AND CONTINGENCIES

F-37

Table of Contents

On March 22, 2021, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90-days notice of cancellation.

If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.

The total lease payments per month were $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477, 45,554, and $46,116 beginning May 1, 2021, August 1, 2021, and May 1, 2023, respectively. The Company records rent expense as incurred over the term of the leases.

As of March 31, 2021, the future minimum commitments under the amended lease agreement will be as follows:


	Amount
2021	$	316,600
2022		546,700
2023		551,100
2024		461,200
Total	$	1,875,600

Rent expense for the facility lease agreements was $69,000 and $60,000 during the three months ended March 31, 2021 and 2020, respectively. Rent expense is included as an allocation between research and development and general and administrative expense in the condensed consolidated statements of operations.

License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of March 31, 2021 and December 31, 2020, the Company has not incurred any milestone or royalty liabilities related to these license agreements.

Strategic Alliance Agreement with Leon Office (H.K.) — On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. They will also use commercially reasonable efforts to research the Asian market, with a primary, but not exclusive, focus on determining the most suitable structures for the development of medical partnerships or joint ventures with scientific partners in the Asian market with a mission to test products to be created by the joint venture resulting from such partnership and to develop validation programs for any products produced by such joint venture, including programs for clinical trials and human testing and, ultimately, for product certification. The cost of the agreement is $360,000 annually, payable in four quarterly installments.

Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.

The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows.

9.STOCKHOLDERS’ EQUITY

On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.

F-38

Table of Contents

Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.

As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.

Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.

On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.

Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.

Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.

In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.


	2021
Common Stock
Balance at January 1,	$	11,975,400
Common stock IPO discount amortization		24,700
Balance at March 31,	$	12,000,100

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants underlying shares of Series B Preferred Stock became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700.

On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.

The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted a stock option plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.

F-39

Table of Contents

There were 322,063 shares and 271,949 shares available for issuance as of March 31, 2021 and 2020, respectively.

Series B Preferred Stock — On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.

Accordingly, in connection with the IPO, all shares of the Company’s Series B Preferred Stock were converted into 469,136 shares of common stock on October 15, 2020.

Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized during the three months ended March 31:


	2020
Series B Preferred Stock
Balance at January 1,	$	1,306,900
Series B Preferred Stock proceeds		3,000,000
Series B Preferred Stock discount		(2,668,300)
Series B Preferred Stock discount amortization		368,400
Balance at March 31,	$	2,007,000

Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. The warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.

●

30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");

●

An additional 30% of the warrants beginning nine months after the Listing Date; and

●

The remainder of the warrants beginning twelve months after the Listing Date.

As of March 31, 2020, the Company sold 16,391,397 shares of Series B Preferred Stock, which contained 1,399,921 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants are equity classified and the fair value of $5,533,000 is reflected as additional paid-in capital.

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.

F-40

Table of Contents

On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. As of March 31, 2021, there were no warrants underlying Series B Preferred Stock.

The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the three months ended March 31, 2021 and 2020:


	March 31,
	2020
Risk-free interest rate	1.54% - 1.88	%
Expected volatility	71.95% - 72.71	%
Expected life (years)	10
Expected dividend yield	0	%

Representative's Warrants — In connection with the IPO on October 15, 2020, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at March 31, 2021.

These warrants were equity classified. As of March 31, 2021 and December 31, 2020, the warrant fair values of $332,600 and $357,300, respectively, is reflected as additional paid-in capital. On the issuance date, the Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions on October 15:


	2020
Risk-free interest rate	0.18	%
Expected volatility	94.08	%
Expected life (years)	2.74
Expected dividend yield	0	%

10.STOCK-BASED COMPENSATION

2017 Stock Incentive Plan — Stock Options

There were no options granted during the three months ended March 31, 2021. The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the three months ended March 31:


	2020
Risk-free interest rate	1.59% - 2.92	%
Expected volatility	72.29% - 78.16	%
Expected life (years)	4.93 – 6.07
Expected dividend yield	0	%

F-41

Table of Contents

The following table summarizes the activity for all stock options outstanding at March 31 under the Plan:


	2021			2020
		Weighted			Weighted
		Average			Average
		Exercise			Exercise
	Shares	Price		Shares	Price
Options outstanding at beginning of year	489,718	$	10.03	598,083	$	11.11
Granted	—		—	17,631		12.02
Exercised	—		—	—		—
Cancelled and forfeited	(57,149)		17.88	(30,768)		11.88
Balance at December 31	432,569	$	8.99	584,946	$	11.09
Options exercisable at December 31:	408,306	$	8.75	361,720	$	7.67
Weighted average grant date fair value for options granted during the year:		$	—		$	35.62

The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021 and 2020 under the Plan:


	Options Outstanding						Options Exercisable
		Weighted
		Average	Weighted					Weighted
		Remaining	Average		Aggregate			Average		Aggregate
As of	Options	Contractual	Exercise		Intrinsic		Options	Exercise		Intrinsic
March 31,	Outstanding	Life	Price		Value		Exercisable	Price		Value
2021	432,569	6.72	$	8.99	$	839,700	408,306	$	8.75	$	269,514
2020	584,946	8.02	$	11.09	$	18,712,900	361,720	$	7.67	$	12,808,800

Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 as follows:


	2021		2020
Research and development	$	19,000	$	425,000
General and administrative		102,000		31,000
Total	$	121,000	$	456,000

On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $20,900 of stock compensation expense allocable to general and administrative for the three months ended March 31, 2021. Included in that amount were $9,600 of incremental compensation costs resulting from the modifications for the three months ended March 31, 2021.

As of March 31, 2021, total unrecognized stock compensation expense is $252,700, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.25 years.

2017 Stock Incentive Plan — Restricted Stock Units

F-42

Table of Contents

The following table summarizes the activity for all RSUs outstanding at March 31 under the Plan:


	2021			2020
		Weighted Average			Weighted Average
		Grant Date			Grant Date
		Fair Value			Fair Value
	Shares	Per Share		Shares	Per Share
Nonvested RSUs at beginning of year	946,245	$	12.81	—	$	—
Granted	6,019		9.00	—		—
Vested	—		—	—		—
Cancelled and forfeited	—		—	—		—
Nonvested RSUs at December 31	952,264	$	12.79	—	$	—

On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $267,700 and $556,600 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021. Included in those amounts were incremental compensation costs of $20,400 and $44,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021.

11.INCOME TAXES

The Company’s effective tax rate from continuing operations was 0% for the three months ended March 31, 2021 and 2020. The Company recorded no income tax provision for the three months ended March 31, 2021 and 2020.

The provision for income taxes during the interim reporting periods is calculated by applying an estimate of the annual effective tax rate for the full fiscal year to "ordinary" income or loss for the reporting period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities.

The income tax rates vary from the US federal statutory rate of 21% primarily due to the full valuation allowance on the Company’s deferred tax assets. The Company has recorded the full valuation allowance based on an evaluation of both positive and negative evidence, including latest forecasts and cumulative losses in recent years. The Company has concluded that it was more likely than not that none of its deferred tax assets would be realized.

12.RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2020, the Company maintained two separate consulting agreements with the Company's Chief Strategy and Innovation Officer (the "CSIO"), and the Chief Financial Officer and Chief Operating Officer (the "CFO and COO").

Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company's Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company's business development strategies. The consulting fees paid to the CSIO totaled $0 and $319,300 in the three months ended March 31, 2021 and 2020, respectively.

F-43

Table of Contents

Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $0 and $30,000 in the three months ended March 31, 2021 and 2020, respectively.

After the Company completed the IPO on October 15, 2020, the CFO and COO and the CSIO became full time employees.

13.SUBSEQUENT EVENTS

Research Grant Agreement with University of Texas MD Anderson Cancer Center

On April 8, 2021, the Company entered into a letter of intent (the “Letter of Intent”) with the University of Texas MD Anderson Cancer Center (“MD Anderson”) pursuant to which MD Anderson shall receive a research grant from the Company titled, “Validation of biomarker isomeso for pancreatic cancer,” which is aimed at discovering new cancer-specific antigen targets (the “Grant”). The total costs to the Company to be paid in connection with the Grant shall be $300,000. Pursuant to the Letter of Intent, the Grant shall commence on April 1, 2021 and end on March 31, 2022.

F-44

Table of Contents

4,835,590 Shares of Common Stock

Kiromic BioPharma, Inc.

PRELIMINARY PROSPECTUS

ThinkEquity

a division of Fordham Financial Management, Inc.

, 2021

Table of Contents

PART II

INFORMATION NOT REQUIRED IN THE PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution

The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of common shares being registered. All amounts, other than the SEC registration fee and FINRA filing fee, are estimates.


	Amount
SEC registration fee	$	6,273
FINRA fee		9,125
Accounting fees and expenses		300,000
Legal fees and expenses		125,000
Transfer agent fees and expenses		1,000
Printing and related fees		37,000
Miscellaneous fees		2,602
Total	$	481,000

Item 14. Indemnification of Directors and Officers

Section 145 of the General Corporation Law of the State of Delaware provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement in connection with specified actions, suits and proceedings whether civil, criminal, administrative, or investigative, other than a derivative action by or in the right of the corporation, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification extends only to expenses, including attorneys’ fees, incurred in connection with the defense or settlement of such action and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation’s certificate of incorporation, bylaws, disinterested director vote, stockholder vote, agreement or otherwise.

Our Fourth Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws provide for indemnification of directors and officers to the fullest extent permitted by law, including payment of expenses in advance of resolution of any such matter.

We have entered into separate indemnification agreements with our directors and officers. Each indemnification agreement will provide, among other things, for indemnification to the fullest extent permitted by law and our certificate of incorporation and bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements will provide for the advancement or payment of all expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our certificate of incorporation and bylaws.

We maintain standard policies of insurance under which coverage is provided (a) to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act, and (b) to us with respect to payments which we may make to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Item 15. Recent Sales of Unregistered Securities

During the past three years, we issued the following securities, which were not registered under the Securities Act.

Between June 8, 2018 and August 14, 2018, we entered into agreements to issue preferred stock and received advances of $900,000. The advances received under the agreements were recorded as liabilities until the preferred stock was issued and bore interest at a rate of 6.5%. The agreements were amended on September 10, 2018, when, in exchange for additional preferred stock to be issued, the advances no longer bore interest. On December 20, 2018, 2,032,749 shares of Series A-1 Preferred Stock were issued for $912,800, representing the advances received and accrued interest through September 10, 2018.

II-1

Table of Contents

On December 20, 2018, following the issuance of shares of Series A-1 Preferred Stock described above, the outstanding principal and accrued interest of then outstanding convertible promissory notes was converted into shares of Series A-1 Preferred Stock. At the time of conversion, the outstanding principal and accrued interest attributable to outstanding convertible promissory notes (“the notes”) totaled approximately $7,541,600.

Accordingly, the notes were converted into an aggregate of 18,854,033 shares of Series A-1 Preferred Stock at a conversion price of $0.40 per share.

During 2019, we issued additional convertible promissory notes in the aggregate principal amount of $250,000 to certain investors. The notes accrued interest at a rate of 17% and were to mature on June 1, 2021. These notes were convertible into shares issued in our next financing (as defined in the notes) by dividing the total amount of notes, plus accrued interest, by the applicable conversion price (defined generally as 85% of the lowest per share selling price in the next financing). Prior to the issuance of shares of Series B Preferred Stock (as discussed below), each holder agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. Therefore, on August 15, 2019, these notes were converted into an aggregate of 632,123 shares of Series A-1 Preferred Stock at a conversion price of $0.43 per share.

In addition, during 2019, we settled an outstanding account payable with a vendor in the amount of $134,800 by issuing to that vendor a convertible promissory note for the amount owed. That convertible promissory note accrued interest at a rate of 6% and was to mature on June 30, 2020. This note was convertible into shares issued in our next financing (as defined in the note) by dividing the total amount of the convertible promissory note, plus accrued interest, by the applicable conversion price (defined generally as 90% of the lowest per share selling price in the next financing). Prior to the issuance of shares of Series B Preferred Stock (as discussed below), the holder agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. Therefore, on August 15, 2019, this note was converted into 303,396 shares of Series A-1 Preferred Stock at a conversion price of $0.45 per share.

On September 7, 2019, we entered into a Series B Preferred Stock purchase agreement with certain investors for the sale of shares of our Series B Preferred Stock at a price of $0.46 per share. On September 13, 2019, we sold an aggregate of 7,608,696 shares for total gross proceeds of approximately $3,500,000. On November 13, 2019, we sold an additional 2,173,913 shares for gross proceeds of $1,000,000. The shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. On December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, we issued 87,050 shares of Series B Preferred Stock to the investors.

On January 24, 2020, we issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, we filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.

We also issued each investor a warrant to purchase 0.0859 shares of common stock for each Series B Preferred Share purchased, or warrants for an aggregate of 1,399,921 shares of common stock (the “Pre-Funded Warrants”). The Pre-Funded warrants had an exercise price of $0.003494 per share and expired ten years after the date of issuance. On June 8, 2020 and June 10, 2020, the holders of all the outstanding Pre-Funded Warrants exercised the warrants for cash and received 1,399,921 shares of common stock upon exercise.

On June 19, 2020, we issued an aggregate of 722,000 shares of common stock to out Chief Financial Officer and Chief Strategy and Innovation Officer for prior services rendered.

No underwriters were involved in these issuances. We believe that each of the above issuances was exempt from registration under the Securities Act in reliance on Regulation S under the Securities Act or pursuant to Section 4(2) of the Securities Act regarding transactions not involving a public offering.

II-2

Table of Contents

Item 16. Exhibits.

(a)Exhibits


Exhibit No.		Description
1.1*		Form of Underwriting Agreement
3.1		Fourth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1filed with Form 8-K on October 21, 2021)
3.2		Second Amended and Restated Bylaws of Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 3.5 filed with Amendment No. 1 to Form S-1 on June 26, 2020)
4.1*		Form of Representative’s Warrant
5.1*		Opinion of Sheppard Mullin Richter & Hampton, LLP
10.1†		Employment Agreement between Kiromic BioPharma, Inc. and Tony Tontat (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to Form S-1 filed on June 26, 2020)
10.2#		License Agreement, dated December 1, 2016, between Mercer University and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.10 filed with Form S-1 on May 11, 2020)
10.3#		License Agreement, dated September 14, 2018, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.11 filed with Form S-1 on May 11, 2020)
10.4#		Amendment to License Agreement, dated October 16, 2019, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.12 filed with Form S-1 on May 11, 2020)
10.5#		Amended and Restated License Agreement dated as of November 30, 2020 by and between Longwood University and Kiromic Biopharma, Inc. (incorporated by reference to Exhibit 10.1 filed with Form 8-K on January 29, 2021)
10.6#		Collaboration Agreement, dated February 6, 2020, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.14 filed with Form S-1 on May 11, 2020)
10.7		Lease Agreement, dated October 9, 2015, between Timothy L. Sharma d/b/a Cambridge Properties and Kiromic, Inc. (incorporated by reference to Exhibit 10.15 filed with Form S-1 on May 11, 2020)
10.8		Second Amendment to Lease Agreement, dated May 6, 2016, between Cambridge Properties and Kiromic, Inc. (incorporated by reference to Exhibit 10.16 filed with Form S-1 on May 11, 2020)
10.9		Third Amendment to Lease Agreement, dated November 7, 2018, between Cambridge Properties and Kiromic, Inc. (incorporated by reference to Exhibit 10.17 filed with Form S-1 on May 11, 2020)
10.10		Fourth Amendment to Lease Agreement, dated October 8, 2019, between Cambridge Properties and Kiromic, Inc. (incorporated by reference to Exhibit 10.18 filed with Form S-1 on May 11, 2020)
10.11*		Fifth Amendment to Lease Agreement, dated December 2, 2020, between Cambridge Properties and Kiromic BioPharma, Inc.
10.12*		Sixth Amendment to Lease Agreement, dated March 22, 2021, between Cambridge Properties and Kiromic BioPharma, Inc.
10.13†		Employment Agreement dated January 1, 2020 between Kiromic BioPharma, Inc and Scott Dahlbeck (incorporated by reference to Exhibit 10.19 filed with Amendment No. 1 to Form S-1 on June 26, 2020)
10.14†		Employment Agreement between Kiromic BioPharma, Inc. and Gianluca Rotino (incorporated by reference to Exhibit 10.20 to Amendment No. 1 to Form S-1 dated June 26, 2020)
10.15†		Employment Agreement between Kiromic BioPharma, Inc. and Maurizio Chiriva Internati (incorporated by reference to Exhibit 10.21 to Amendment No. 1 to Form S-1 dated June 26, 2020)
10.16†		Kiromic, Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.25 to Form S-1 on May 11, 2020)
10.17#		Joint venture agreement, dated April 6, 2020, between Molipharma S.R.L. and Kiromic BioPharma, Inc. (incorporated by reference to Exhibit 10.28 filed with Form S-1 on May 11, 2020)
10.18†		Form of Director Services Agreement between Kiromic BioPharma, Inc. and all independent directors (incorporated by reference to Exhibit 10.24 filed with Amendment No. 1 to Form S-1 on June 26, 2020)
10.19		Form of Director Indemnification Agreement between Kiromic BioPharma, Inc. and all independent directors (incorporated by reference to Exhibt 10.25 filed with Amendment No.1 to Form S-1 on June 26, 2020)
10.20		Strategic Alliance Agreement by and between Kiromic BioPharma, Inc. and Leon Office (H.K.) Ltd, effective as of January 28, 2021 (incorporate by reference to Exhibit 10.1 to Form 8-K filed on February 12, 2021)
10.21†		Employment Agreement between Kiromic BioPharma, Inc. and Ignacio Nunez (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 7, 2021)
10.22		Membership Interest Purchase Agreement dated as of June 14, 2021 among Kiromic BioPharma, Inc., In Silico Solution, LLC and Michael Ryan (incorporated by reference to Exhibit 2.1 to Form 8-K filed on June 17, 2021)

II-3

Table of Contents


Exhibit No.		Description
10.23†		Kiromic BioPharma, Inc 2021 Omnibus Equity Incentive Plan (incorporate by reference to Appendix A to Schedule 14A filed on April 30, 2021)
23.1*		Consent of Sheppard Mullin Richter & Hampton, LLP (included in Exhibit 5.1)
23.2*		Consent of Deloitte & Touche LLP, independent registered public accounting firm.
24.1*		Power of Attorney (included in the signature page)
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

*	Filed herewith

†	Executive Compensation Plan or Agreement

#	Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).

(b)

Financial Statement Schedules

All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.

Item 17. Undertakings

(a)

The undersigned registrant hereby undertakes as follows:

(1)

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)

To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii)

To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

(iii)

To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2)

That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)

To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4)

That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration

II-4

Table of Contents

statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5)

That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i)

Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii)

Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii)

The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and

(iv)

Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b)

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned pursuant to the foregoing provisions, or otherwise, the undersigned has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the undersigned of expenses incurred or paid by a director, officer or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the undersigned will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-5

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on June 25, 2021.


	KIROMIC BIOPHARMA, INC.

	By:	/s/ Maurizio Chiriva-Internati
		Maurizio Chiriva Internati Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints each of Maurizio Chiriva Internati and Tony Tontat as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him and his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement and to file a new registration statement under Rule 461, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.


SIGNATURE	TITLE	DATE

/s/ Maurizio Chiriva-Internati
Maurizio Chiriva Internati	Chairman and Chief Executive Officer (principal executive officer)	June 25, 2021

/s/ Tony Tontat
Tony Tontat	Chief Financial Officer and Director (principal financial and accounting officer)	June 25, 2021

/s/ Gianluca Rotino
Gianluca Rotino	Director	June 25, 2021

/s/ Pietro Bersani
Pietro Bersani	Director	June 25, 2021

/s/ Americo Cicchetti
Americo Cicchetti	Director	June 25, 2021

/s/ Michael Nagel
Michael Nagel	Director	June 25, 2021

/s/ Jerry Schneider
Jerry Schneider	Director	June 25, 2021

II-6

EX-1.1 2 krbp-20210625xex1d1.htm EXHIBIT-1.1

Exhibit 1.1

UNDERWRITING AGREEMENT

between

KIROMIC BIOPHARMA, INC.

and

THINKEQUITY

A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC.

as Representative of the Several Underwriters

-1-

KIROMIC BIOPHARMA, INC.

UNDERWRITING AGREEMENT

New York, New York
June ___, 2021

ThinkEquity

A Division of Fordham Financial Management, Inc.

As Representative of the several Underwriters named on Schedule 1 attached hereto
17 State Street, 22^nd Fl

New York, NY 10004

Ladies and Gentlemen:

The undersigned, Kiromic BioPharma, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Kiromic BioPharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

1.	Purchase and Sale of Shares.

1.1Firm Shares.

1.1.1.Nature and Purchase of Firm Shares.

(i)On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell to the several Underwriters, an aggregate of [____________] shares (“Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).

(ii)The Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares set forth opposite their respective names on Schedule 1 attached hereto and made a part hereof at a purchase price of $[_____] per share (93% of the per Firm Share offering price). The Firm Shares are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus (as defined in Section 2.1.1 hereof).

1.1.2.Shares Payment and Delivery.

(i)Delivery and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on the second (2^nd) Business Day following the effective date (the “Effective Date”) of the Registration Statement (as defined in Section 2.1.1 below) (or the third (3^rd) Business Day following the Effective Date if the Registration Statement is declared effective after 4:01 p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices of Venable LLP, 1270 Avenue of the Americas, 24^th Floor, New York, NY 10010 (“Representative Counsel”), or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment for the Firm Shares is called the “Closing Date.”

-1-

(ii)Payment for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares (or through the facilities of the Depository Trust Company (“DTC”)) for the account of the Underwriters. The Firm Shares shall be registered in such name or names and in such authorized denominations as the Representative may request in writing at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of payment by the Representative for all of the Firm Shares. The term “Business Day” means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York, New York.

1.2Over-allotment Option.

1.2.1.Option Shares. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Company hereby grants to the Underwriters an option to purchase up to [______] additional shares of Common Stock, representing fifteen percent (15%) of the Firm Shares sold in the offering, from the Company (the “Over-allotment Option”). Such [_____] additional shares of Common Stock, the net proceeds of which will be deposited with the Company’s account, are hereinafter referred to as “Option Shares.” The purchase price to be paid per Option Share shall be equal to the price per Firm Share set forth in Section 1.1.1 hereof. The Firm Shares and the Option Shares are hereinafter referred to together as the “Public Securities.” The offering and sale of the Public Securities is hereinafter referred to as the “Offering.”

1.2.2.Exercise of Option. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to all (at any time) or any part (from time to time) of the Option Shares within 45 days after the Effective Date. The Underwriters shall not be under any obligation to purchase any Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares to be purchased and the date and time for delivery of and payment for the Option Shares (the “Option Closing Date”), which shall not be later than one (1) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of Representative Counsel or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Shares does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Shares, subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option Shares specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total number of Option Shares then being purchased as set forth in Schedule 1 opposite the name of such Underwriter.

1.2.3.Payment and Delivery. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option Shares shall be registered in such name or names and in such authorized denominations as the Representative may request in writing at least one (1) full Business Day prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment by the Representative for applicable Option Shares.

-2-

1.3Representative’s Warrants.

1.3.1.Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date an option (“Representative’s Warrant”) for the purchase of an aggregate of [_____] shares of Common Stock, representing up to 5% of the Firm Shares, for an aggregate purchase price of $100.00. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six (6) months after the Effective Date and expiring on the five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[_____], which is equal to 125% of the initial public offering price of the Firm Shares. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

1.3.2.Delivery. Delivery of the Representative’s Warrant Agreement shall be made on the Closing Date and shall be issued in the name or names and in such authorized denominations as the Representative may request.

2.Representations and Warranties of the Company. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date and as of the Option Closing Date, if any, as follows:

2.1Filing of Registration Statement.

2.1.1.Pursuant to the Securities Act. The Company has filed with the U.S. Securities and Exchange Commission (the “Commission”) a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-______), including any related prospectus or prospectuses, for the registration of the Public Securities and the Representative’s Securities under the Securities Act of 1933, as amended (the “Securities Act”), which registration statement and amendment or amendments have been prepared by the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of the Commission under the Securities Act (the “Securities Act Regulations”) and will contain all material statements that are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations. Except as the context may otherwise require, such registration statement, as amended, on file with the Commission at the time the registration statement became effective (including the Preliminary Prospectus included in the registration statement, financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act Regulations (the “Rule 430A Information”)), is referred to herein as the “Registration Statement.” If the Company files any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term “Registration Statement” shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the Commission on the date hereof.

-3-

Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a “Preliminary Prospectus.” The Preliminary Prospectus, subject to completion, dated October 6, 2020, that was included in the Registration Statement immediately prior to the Applicable Time is hereinafter called the “Pricing Prospectus.” The final prospectus in the form first furnished to the Underwriters for use in the Offering is hereinafter called the “Prospectus.” Any reference to the “most recent Preliminary Prospectus” shall be deemed to refer to the latest Preliminary Prospectus included in the Registration Statement.

“Applicable Time” means 4:45 p.m., Eastern time, on the date of this Agreement.

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Securities Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the Company, (ii) a “road show that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Public Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g).

“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433 (the “Bona Fide Electronic Road Show”)), as evidenced by its being specified in Schedule 2-B hereto.

“Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.

“Pricing Disclosure Package” means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing Prospectus and the information included on Schedule 2-A hereto, all considered together.

2.1.2.Pursuant to the Exchange Act. The Company has filed with the Commission a Form 8-A (File Number 001-39619) providing for the registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), of the shares of Common Stock. The registration of the shares of Common Stock under the Exchange Act has been declared effective by the Commission on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.

2.2Stock Exchange Listing. The shares of Common Stock have been approved for listing on the NASDAQ Capital Market (the “Exchange”), and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange, nor has the Company received any written notification that the Exchange is contemplating terminating such listing except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

-4-

2.3No Stop Orders, etc. Neither the Commission nor, to the Company’s knowledge, any state regulatory authority has issued any order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company’s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if any) from the Commission for additional information.

2.4Disclosures in Registration Statement.

2.4.1.Compliance with Securities Act and 10b-5 Representation.

(i)Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

(ii)Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

(iii)The Pricing Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information furnished to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided by or on behalf of any Underwriter consists solely of the following disclosure contained in the “Underwriting” section of the Prospectus: the information under the subsections “Discretionary Accounts,” “Electronic Offer, Sale and Distribution of Shares” and “Stabilization” (the “Underwriters’ Information”); and

(iv)Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to the Underwriters’ Information.

-5-

2.4.2.Disclosure of Agreements. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus or (ii) is material to the Company’s business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company’s knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company’s knowledge, any other party is in default thereunder and, to the Company’s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company’s knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each, a “Governmental Entity”), including, without limitation, those relating to environmental laws and regulations.

2.4.3.Prior Securities Transactions. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Preliminary Prospectus.

2.4.4.Regulations. The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects of federal, state, local and all foreign regulation on the Offering and the Company’s business as currently contemplated are correct in all material respects and no other such regulations are required to be disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus which are not so disclosed.

2.5Changes After Dates in Registration Statement.

2.5.1.No Material Adverse Change. Since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change in the financial position or results of operations of the Company, nor any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the Company (a “Material Adverse Change”); (ii) there have been no material transactions entered into by the Company, other than as contemplated pursuant to this Agreement; and (iii) no officer or director of the Company has resigned from any position with the Company.

2.5.2.Recent Securities Transactions, etc. Subsequent to the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred

-6-

any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock.

2.6Independent Accountants. To the knowledge of the Company, Deloitte & Touche LLP (the “Auditor”), whose report is filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.

2.7Financial Statements, etc. The financial statements, including the notes thereto and supporting schedules included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present the financial position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included in the Registration Statement present fairly the information required to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information and the related notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of the Securities Act and the Securities Act Regulations and present fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company’s financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) the Company has not incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been any change in the capital stock of the Company, or, other than in the course of business, any grants under any stock compensation plan, and (d) there has not been any material adverse change in the Company’s long-term or short-term debt.

2.8Authorized Capital; Options, etc. The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date the adjusted authorized, issued and outstanding stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible or exercisable into shares of Common

-7-

Stock of the Company, or any contracts or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.

2.9Valid Issuance of Securities, etc.

2.9.1.Outstanding Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. The authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock were at all relevant times either registered under the Securities Act and the applicable state securities or “blue sky” laws or, based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration requirements.

2.9.2.Securities Sold Pursuant to this Agreement. The Public Securities and Representative’s Securities have been duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Public Securities and Representative’s Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities and Representative’s Securities has been duly and validly taken. The Public Securities and Representative’s Securities conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Representative’s Warrant Agreement has been duly and validly taken; the shares of Common Stock issuable upon exercise of the Representative’s Warrant have been duly authorized and reserved for issuance by all necessary corporate action on the part of the Company and when paid for and issued in accordance with the Representative’s Warrant and the Representative’s Warrant Agreement, such shares of Common Stock will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability by reason of being such holders; and such shares of Common Stock are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.

2.10Registration Rights of Third Parties. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities in a registration statement to be filed by the Company.

2.11Validity and Binding Effect of Agreements. This Agreement and the Representative’s Warrant Agreement have been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

-8-

2.12No Conflicts, etc. The execution, delivery and performance by the Company of this Agreement, the Representative’s Warrant Agreement and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions of the Company’s Certificate of Incorporation (as the same may be amended or restated from time to time, the “Charter”) or the by-laws of the Company; or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof.

2.13No Defaults; Violations. No material default exists in the due performance and observance of any term, covenant or condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not in violation of any term or provision of its Charter or by-laws, or in violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity.

2.14Corporate Power; Licenses; Consents.

2.14.1.Conduct of Business. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

2.14.2.Transactions Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained. No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance, sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this Agreement and the Representative’s Warrant Agreement and as contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (“FINRA”).

2.15D&O Questionnaires. To the Company’s knowledge, all information contained in the questionnaires (the “Questionnaires”) completed by each of the Company’s directors and officers immediately prior to the Offering (the “Insiders”) as supplemented by all information concerning the Company’s directors, officers and principal shareholders as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section 2.24 below), provided to the Underwriters, is true and correct in all material respects and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.

2.16Litigation; Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company’s knowledge, threatened against, or involving the Company or, to the Company’s knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Pricing Disclosure Package and the

-9-

Prospectus or in connection with the Company’s listing application for the listing of the Public Securities on the Exchange.

2.17Good Standing. The Company has been duly organized and is validly existing as a corporation and is in good standing under the laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.

2.18Insurance. The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which the Company believes are adequate, including, but not limited to, directors and officers insurance coverage at least equal to $3,000,000 and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.

2.19Transactions Affecting Disclosure to FINRA.

2.19.1.Finder’s Fees. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder’s, consulting or origination fee by the Company or any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings of the Company or, to the Company’s knowledge, any of its shareholders that may affect the Underwriters’ compensation, as determined by FINRA.

2.19.2.Payments Within Twelve (12) Months. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder’s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the Effective Date, other than the payment to the Underwriters as provided hereunder in connection with the Offering.

2.19.3.Use of Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.

2.19.4.FINRA Affiliation. To the Company’s knowledge, there is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any class of the Company's securities or (iii) beneficial owner of the Company's unregistered equity securities which were acquired during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

2.19.5.Information. All information provided by the Company in its FINRA questionnaire to Representative Counsel specifically for use by Representative Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all material respects.

-10-

2.20Foreign Corrupt Practices Act. None of the Company or, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or any other person acting on behalf of the Company, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Change or (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.

2.21Compliance with OFAC. None of the Company or, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or any other person acting on behalf of the Company, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

2.22Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

2.23Officers’ Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Representative Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.

2.24Lock-Up Agreements. Schedule 3 hereto contains a complete and accurate list of the Company’s officers, directors and each owner of the Company’s outstanding shares of Common Stock (or securities convertible or exercisable into shares of Common Stock) (collectively, the “Lock-Up Parties”). The Company has caused each of the Lock-Up Parties to deliver to the Representative an executed Lock-Up Agreement, in the form attached hereto as Exhibit B (the “Lock-Up Agreement”), prior to the execution of this Agreement.

2.25Subsidiaries. All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have a material adverse effect on the assets, business or operations of the Company taken as a whole. The Company’s ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

2.26Related Party Transactions. There are no business relationships or related party transactions involving the Company or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not been described as required.

-11-

2.27Board of Directors. The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing Prospectus and the Prospectus captioned “Management.” The qualifications of the persons serving as board members and the overall composition of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the “Sarbanes-Oxley Act”) applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the Board of Directors of the Company qualifies as an “audit committee financial expert,” as such term is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of the persons serving on the Board of Directors qualify as “independent,” as defined under the listing rules of the Exchange.

2.28Sarbanes-Oxley Compliance.

2.28.1.Disclosure Controls. The Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure that all material information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company’s Exchange Act filings and other public disclosure documents.

2.28.2.Compliance. The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company’s future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.

2.29Accounting Controls. The Company maintains systems of “internal control over financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, its respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal controls. The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known to the Company’s management and that have adversely affected or are reasonably likely to adversely affect the Company’ ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company’s management, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

2.30No Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to register as an “investment company,” as defined in the Investment Company Act of 1940, as amended.

2.31No Labor Disputes. No labor dispute with the employees of the Company exists or, to the knowledge of the Company, is imminent.

-12-

2.32Intellectual Property Rights. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (“Intellectual Property Rights”) necessary for the conduct of the business of the Company as currently carried on and as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company necessary for the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. The Company has not received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other claims in this Section 2.32, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 2.32, reasonably be expected to result in a Material Adverse Change; (D) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 2.32, reasonably be expected to result in a Material Adverse Change; and (E) to the Company’s knowledge, no employee of the Company is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company, or actions undertaken by the employee while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company’s knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus contain in all material respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons. To the Company’s knowledge, there is no prior art or public or commercial activity that may render any patent included in the Intellectual Property Rights invalid or that would preclude the issuance of any patent on any patent application included in the Intellectual Property which has not been disclosed to the U.S. Patent and Trademark Office or the relevant foreign patent authority, as the case may be. The Company has not, and to the Company’s knowledge, no third party has, committed any act or omitted to undertake any act the effect of such commission or omission would reasonably be expected to result in a legal determination that any item of Intellectual Property Rights thereby was rendered invalid or unenforceable in whole or in part. The manufacture, use and sale of the products or product candidates described in the Registration Statement,

-13-

the Pricing Disclosure Package and the Prospectus as under development by the Company fall within the scope of one or more claims of the patents or patent applications included in the Intellectual Property Rights. Other than information disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property Rights that are owned or purported to be owned by the Company that would confer upon any governmental agency or body, university, college, other educational institution or research center any claim or right in or to any such Intellectual Property Rights.

2.33Taxes. Except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the Company, (i) the Company has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof, and (ii) the Company has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the Company. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company. The term “taxes” means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto. The term “returns” means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.

2.34ERISA Compliance. The Company and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company or its “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company, any member of any group of organizations described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company is a member. No “reportable event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company or any of its ERISA Affiliates. No “employee benefit plan” established or maintained by the Company or any of its ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each “employee benefit plan” established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.

2.35Compliance with Laws. The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the Company, including, without limitation, all statutes, rules, or regulations relating to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company and, without limiting the foregoing, include (i) the

-14-

Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), (ii) the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act and Laws applicable to hazardous or regulated substances and radioactive or biologic materials, (iii) the federal Anti-Kickback Statute, (iv) the False Claims Act, (v) the Civil Monetary Penalties Law, (vi) the Physician Payments Sunshine Act, (vii) the criminal False Claims Law, (viii) the Health Insurance Portability and Accountability Act of 1996 as amended by the Health Information Technology for Economic and Clinical Health Act and (ix) licensing and certification Laws covering any aspect of the business of the Company (“Applicable Laws”), except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws and/or to carry on its business as now conducted (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding nor, to the Company’s knowledge, has there been any material noncompliance with or violation of any Applicable Laws by the Company that could reasonably be expected to require the issuance of any such communication or result in an investigation, corrective action, or enforcement action by any Governmental Entity; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Entity has threatened or is considering such action; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.

2.36Clinical and Preclinical Studies. The studies, tests and clinical trials conducted by or on behalf of the Company were and, if still pending, are being conducted in accordance with experimental protocols, procedures and controls pursuant to all Applicable Laws and Authorizations, except where such failure to comply would not, individually or in the aggregate, result in a Material Adverse Change; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has no knowledge of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and the Company has not received any written notices or correspondence from any Governmental Entity requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.

2.37Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within

-15-

the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.

2.38Real Property. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company; and all of the leases and subleases material to the business of the Company, and under which the Company holds properties described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, are in full force and effect, and the Company has not received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company to the continued possession of the leased or subleased premises under any such lease or sublease.

2.39Contracts Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company’s liquidity or the availability of or requirements for their capital resources required to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have not been described or incorporated by reference as required.

2.40Loans to Directors or Officers. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their respective family members, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

2.41Integration. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities issued in such prior offerings under the Securities Act.

2.42Smaller Reporting Company. As of the time of filing of the Registration Statement, the Company was a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act Regulations.

2.43Industry Data. The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.

2.44Emerging Growth Company. From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly in or through any Person authorized to act on its behalf in any Testing-the Waters Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”). “Testing-the-Waters Communication” means

-16-

any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.

2.45Testing-the-Waters Communications. The Company has not (i) alone engaged in any Testing-the-Waters Communications, other than Testing-the-Waters Communications with the written consent of the Representative and with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company confirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule 2-C hereto. “Written Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act.

2.46Electronic Road Show. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of the Securities Act Regulations such that no filing of any “road show” (as defined in Rule 433(h) of the Securities Act Regulations) is required in connection with the Offering.

2.47Margin Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the shares of Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

3.	Covenants of the Company. The Company covenants and agrees as follows:

3.1Amendments to Registration Statement. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Representative shall reasonably object in writing.

3.2Federal Securities Laws.

3.2.1.Compliance. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of the receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Public Securities and Representative’s Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Public Securities and Representative’s Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether

-17-

the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use reasonable efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

3.2.2.Continued Compliance. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (“Rule 172”), would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of its intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters shall reasonably object.

3.2.3.Exchange Act Registration. For a period of three (3) years after the date of this Agreement, the Company shall use reasonable efforts to maintain the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister the shares of Common Stock under the Exchange Act without the prior written consent of the Representative.

3.2.4.Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Underwriters as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including

-18-

timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

3.2.5.Testing-the-Waters Communications. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

3.3Delivery to the Underwriters of Registration Statements. The Company has delivered or made available or shall deliver or make available to the Representative and counsel for the Representative, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

3.4Delivery to the Underwriters of Prospectuses. The Company has delivered or made available or will deliver or make available to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

3.5Effectiveness and Events Requiring Notice to the Representative. The Company shall use reasonable efforts to cause the Registration Statement to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative immediately and confirm the notice in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v) of the receipt of any comments or request for any additional information from the Commission; and (vi) of the happening of any event during the period described in this Section 3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration

-19-

Statement in order to make the statements therein not misleading, or (b) in the Pricing Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.

3.6Review of Financial Statements. For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s financial statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.

3.7Listing. The Company shall use reasonable efforts to maintain the listing of the shares of Common Stock (including the Public Securities) on the Exchange for at least three years from the date of this Agreement.

3.8Intentionally omitted.

3.9Reports to the Representative.

3.9.1.Periodic Reports, etc. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act; and (v) such additional documents and information with respect to the Company and the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably request; provided the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable to the Representative and Representative Counsel in connection with the Representative’s receipt of such information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Representative pursuant to this Section 3.9.1.

3.9.2.Transfer Agent; Transfer Sheets. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer agent and registrar acceptable to the Representative (the “Transfer Agent”) and shall furnish to the Representative at the Company’s sole cost and expense such transfer sheets of the Company’s securities as the Representative may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. VStock Transfer, LLC, is acceptable to the Representative to act as Transfer Agent for the shares of Common Stock.

3.9.3.Trading Reports. During such time as the Public Securities are listed on the Exchange, the Company shall provide, if available and upon the Representative’s request, to the Representative, at the Company’s expense, such reports published by Exchange relating to price trading of the Public Securities, as the Representative shall reasonably request. Documents made freely available by the Exchange through its website shall be deemed to have been delivered to the Representative pursuant to this Section 3.9.3.

3.10Payment of Expenses

-20-

3.10.1.General Expenses Related to the Offering. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and communication expenses relating to the registration of the shares of Common Stock to be sold in the Offering (including the Over-allotment Shares) with the Commission; (b) all Public Filing System filing fees associated with the review of the Offering by FINRA; (c) all fees and expenses relating to the listing of such Public Securities on the Exchange and such other stock exchanges as the Company and the Representative together determine; (d) all fees, expenses and disbursements relating to background checks of the Company’s officers and directors in an amount not to exceed $5,000 in the aggregate; (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Public Securities under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f) the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers’ Agreement, Underwriters’ Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary; (g) the costs and expenses of the public relations firm referred to in Section 3.8; (i) the costs of preparing, printing and delivering certificates representing the Public Securities; (h) fees and expenses of the transfer agent for the shares of Common Stock; (i) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters; (j) the costs associated with one set of bound volumes of the public offering materials, as well as the costs associated with commemorative mementos and lucite tombstones in an amount not to exceed $3,000 in aggregate, each of which the Company or its designee shall provide within a reasonable time after the Closing Date in such quantities as the Representative may reasonably request; (k) the fees and expenses of the Company’s accountants; (l) the fees and expenses of the Company’s legal counsel and other agents and representatives; (m) fees and expenses of the Representative’s legal counsel not to exceed $100,000; (n) the $29,500 cost associated with the Underwriter’s use of Ipreo’s book-building, prospectus tracking and compliance software for the Offering; (o) $10,000 for data services and communications expenses; (p) up to $10,000 of the Underwriters’ actual accountable “road show” expenses for the Offering; and (q) up to $25,000 of ThinkEquity’s market making and trading, and clearing firm settlement expenses for the Offering. The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters.

3.10.2.Non-accountable Expenses. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10.1, on the Closing Date it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of the Firm Shares (excluding the Option Shares), less the Advance (as such term is defined in Section 8.3 hereof), provided, however, that in the event that the Offering is terminated, the Company agrees to reimburse the Underwriters pursuant to Section 8.3 hereof.

3.11Application of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application thereof described under the caption “Use of Proceeds” in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

3.12Delivery of Earnings Statements to Security Holders. The Company shall make generally available to its security holders as soon as practicable, but not later than the first day of the fifteenth (15^th) full calendar month following the date of this Agreement, an earnings statement (which need not be certified by independent registered public accounting firm unless required by the Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement. If

-21-

such earnings statement is available on Edgar it shall be deemed to have been delivered to the Representative pursuant to this Section 3.12.

3.13Stabilization. Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Public Securities.

3.14Internal Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

3.15Accountants. As of the date of this Agreement, the Company shall retain an independent registered public accounting firm reasonably acceptable to the Representative, and the Company shall continue to retain a nationally recognized independent registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable to the Representative.

3.16FINRA. The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company's securities or (iii) any beneficial owner of the Company's unregistered equity securities which were acquired during the 180 days immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

3.17No Fiduciary Duties. The Company acknowledges and agrees that the Underwriters’ responsibility to the Company is solely contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement.

3.18Company Lock-Up Agreements.

3.18.1.Restriction on Sales of Capital Stock. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of 90 days after the date of this Agreement (the “Lock-Up Period”), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.

-22-

The restrictions contained in this Section 3.18.1 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on the date hereof, which is disclosed in the Registration Statement, Disclosure Package and Prospectus, provided that such options, warrants, and securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, or (iii) the issuance by the Company of stock options or shares of capital stock of the Company under any equity compensation plan of the Company, provided that in each of (ii) and (iii) above, the underlying shares shall be restricted from sale during the entire Lock-Up Period.

3.18.2.Restriction on Continuous Offerings. Notwithstanding the restrictions contained in Section 3.18.1, the Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of 12 months after the date of this Agreement, directly or indirectly in any “at-the-market” or continuous equity transaction, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company.

3.19Release of D&O Lock-up Period. If the Representative, in its sole discretion, agrees to release or waive the restrictions set forth in the Lock-Up Agreements described in Section 2.24 hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit C hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.

3.20Blue Sky Qualifications. The Company shall use reasonable efforts, in cooperation with the Underwriters, if necessary, to qualify the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Public Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.

3.21Reporting Requirements. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities as may be required under Rule 463 under the Securities Act Regulations.

3.22Emerging Growth Company Status. The Company shall promptly notify the Representative if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of the Public Securities within the meaning of the Securities Act and (ii) fifteen (15) days following the completion of the Lock-Up Period.

4.Conditions of Underwriters’ Obligations. The obligations of the Underwriters to purchase and pay for the Public Securities, as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made

-23-

pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:

4.1Regulatory Matters.

4.1.1.Effectiveness of Registration Statement; Rule 430A Information. The Registration Statement has become effective not later than 5:00 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.

4.1.2.FINRA Clearance. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.

4.1.3.Exchange Stock Market Clearance. On the Closing Date, the Company’s shares of Common Stock, including the Firm Shares, shall have been approved for listing on the Exchange, subject only to official notice of issuance. On the first Option Closing Date (if any), the Company’s shares of Common Stock, including the Option Shares, shall have been approved for listing on the Exchange, subject only to official notice of issuance.

4.2Company Counsel Matters.

4.2.1.Closing Date Opinion of Counsel. On the Closing Date, the Representative shall have received the favorable opinion of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, dated the Closing Date and addressed to the Representative, in a form reasonably acceptable to the Representative.

4.2.2.Opinion of Special Intellectual Property Counsel for the Company. On the Closing Date, the Representative shall have received the opinion of Scott Whitaker, Esq. special intellectual property counsel for the Company, dated the Closing Date, in a form reasonably acceptable to the Representative.

4.2.3.Option Closing Date Opinions of Counsel. On the Option Closing Date, if any, the Representative shall have received the favorable opinions of each counsel listed in Sections 4.2.1 and 4.2.2, dated the Option Closing Date, addressed to the Representative and in form and substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made by such counsels in their respective opinions delivered on the Closing Date.

4.2.4.Reliance. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company

-24-

and officers of departments of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements or certificates shall be delivered to Representative Counsel if requested. The opinion of Sheppard, Mullin, Richter & Hampton LLP and any opinion relied upon by Sheppard, Mullin, Richter & Hampton LLP shall include a statement to the effect that it may be relied upon by Representative Counsel in its opinion delivered to the Underwriters.

4.3Comfort Letters.

4.3.1.Cold Comfort Letter. At the time this Agreement is executed you shall have received a cold comfort letter containing statements and information of the type customarily included in accountants’ comfort letters with respect to the financial statements and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.

4.3.2.Bring-down Comfort Letter. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date not more than three (3) business days prior to the Closing Date or the Option Closing Date, as applicable.

4.4Officers’ Certificates.

4.4.1.Officers’ Certificate. The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer, its President and its Chief Financial Officer stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) to their knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference in the Pricing Disclosure Package, any material adverse change in the financial position or results of operations of the Company, or any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except as set forth in the Prospectus.

-25-

4.4.2.Secretary’s Certificate. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors relating to the Offering are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.

4.5No Material Changes. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been no material adverse change or development involving a prospective material adverse change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial condition or income of the Company, except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

4.6Delivery of Agreements.

4.6.1.Lock-Up Agreements. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the Lock-Up Agreements from each of the persons listed in Schedule 3 hereto.

4.6.2.Representative’s Warrant Agreement. On the Closing Date, the Company shall have delivered to the Representative executed copies of the Representative’s Warrant Agreement.

4.7Additional Documents. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall have been furnished with such documents and opinions as they may require for the purpose of enabling Representative Counsel to deliver an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities and the Representative’s Securities as herein contemplated shall be satisfactory in form and substance to the Representative and Representative Counsel.

4.8Intentionally omitted.

5.	Indemnification.

5.1Indemnification of the Underwriters.

-26-

5.1.1.General. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates, counsel, and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the “Underwriter Indemnified Parties,” and each an “Underwriter Indemnified Party”), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a “Claim”), (i) arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement, the Pricing Disclosure Package, any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters Communication (as from time to time each may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including any “road show” or investor presentations made to investors by the Company (whether in person or electronically); or (C) any application or other document or written communication (in this Section 5, collectively called “application”) executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities and Representative’s Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, the Underwriters’ Information or (ii) otherwise arising in connection with or allegedly in connection with the Offering. The Company also agrees that it will reimburse each Underwriter Indemnified Party for all fees and expenses (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) (collectively, the “Expenses”), and further agrees wherever and whenever possible to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending any Claim.

5.1.2.Procedure. If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the approval of such Underwriter Indemnified Party) and payment of actual expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the Company, and shall be advanced by the Company. The Company shall not be liable for any settlement of any action effected without its consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Underwriters, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified Party, from all liabilities, expenses and claims arising out of such action for which indemnification or contribution may be sought and (ii) does not include a statement

-27-

as to or an admission of fault, culpability or a failure to act, by or on behalf of any Underwriter Indemnified Party.

5.2Indemnification of the Company. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, the Underwriters’ Information. In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.

-28-

5.3Contribution.

5.3.1.Contribution Rights. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other, from the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement (before deducting expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total underwriting discounts and commissions received by the Underwriters with respect to the shares of the Common Stock purchased under this Agreement, as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Offering of the Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

5.3.2.Contribution Procedure. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party (“contributing party”), notify the contributing party of the commencement thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution

-29-

under the Securities Act, the Exchange Act or otherwise available. Each Underwriter’s obligations to contribute pursuant to this Section 5.3 are several and not joint.

6.	Default by an Underwriter.

6.1Default Not Exceeding 10% of Firm Shares or Option Shares. If any Underwriter or Underwriters shall default in its or their obligations to purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised hereunder, and if the number of the Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.

6.2Default Exceeding 10% of Firm Shares or Option Shares. In the event that the default addressed in Section 6.1 relates to more than 10% of the Firm Shares or Option Shares, you may in your discretion arrange for yourself or for another party or parties to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one (1) Business Day after such default relating to more than 10% of the Firm Shares or Option Shares, you do not arrange for the purchase of such Firm Shares or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure another party or parties satisfactory to you to purchase said Firm Shares or Option Shares on such terms. In the event that neither you nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this Section 6, this Agreement will automatically be terminated without liability on the part of the Company (except as provided in Sections 3.9 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided, further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.

6.3Postponement of Closing Date. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary. The term “Underwriter” as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been a party to this Agreement with respect to such shares of Common Stock.

7.	Additional Covenants.

7.1Board Composition and Board Designations. The Company shall ensure that: (i) the qualifications of the persons serving as members of the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its Public Securities listed on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member of the Audit Committee of the Board of Directors qualifies as an “audit committee financial expert,” as such term is defined under Regulation S-K and the listing rules of the Exchange.

-30-

7.2Prohibition on Press Releases and Public Announcements. The Company shall not issue press releases or engage in any other publicity, without the Representative’s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1^st) Business Day following the forty-fifth (45^th) day after the Closing Date, other than normal and customary releases issued in the ordinary course of the Company’s business.

7.3Right of First Refusal. Provided that the Firm Shares are sold in accordance with the terms of this Agreement, the Representative shall have an irrevocable right of first refusal (the “Right of First Refusal”), for a period of twelve (12) months after the date the Offering is completed, to act as sole and exclusive investment banker, sole and exclusive book-runner, sole and exclusive financial advisor, sole and exclusive underwriter and/or sole and exclusive placement agent, at the Representative’s sole and exclusive discretion, for each and every future public and private equity and debt offering, including all equity linked financings (each, a “Subject Transaction”), during such twelve (12) month period, of the Company, or any successor to or subsidiary of the Company, on terms and conditions customary to the Representative for such Subject Transactions. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of the Representative.

The Company shall notify the Representative of its intention to pursue a Subject Transaction, including the material terms thereof, by providing written notice thereof by registered mail or overnight courier service addressed to the Representative. If the Representative fails to exercise its Right of First Refusal with respect to any Subject Transaction within ten (10) Business Days after the mailing of such written notice, then the Representative shall have no further claim or right with respect to the Subject Transaction. The Representative may elect, in its sole and absolute discretion, not to exercise its Right of First Refusal with respect to any Subject Transaction; provided that any such election by the Representative shall not adversely affect the Representative’s Right of First Refusal with respect to any other Subject Transaction during the twelve (12) month period agreed to above.

8.	Effective Date of this Agreement and Termination Thereof.

8.1Effective Date. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered counterparts of such signatures to the other party.

8.2Termination. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared by a New York State or federal authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Shares or Option Shares; or (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representative shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material change in general market conditions as in the Representative’s judgment would make it impracticable to proceed with the offering, sale and/or

-31-

delivery of the Public Securities or to enforce contracts made by the Underwriters for the sale of the Public Securities.

8.3Expenses. Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section 6.2 above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable (including the fees and disbursements of Representative Counsel) up to $150,000, inclusive of the $25,000 advance for accountable expenses previously paid by the Company to the Representative (the “Advance”) and upon demand the Company shall pay the full amount thereof to the Representative on behalf of the Underwriters; provided, however, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(f)(2)(C).

8.4Indemnification. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.

8.5Representations, Warranties, Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Public Securities.

9.	Miscellaneous.

9.1Notices. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.


If to the Representative:

ThinkEquity
17 State Street, 22^nd Fl.
New York, NY 10004
Attn: Mr. Eric Lord, Head of Investment Banking
Fax: (212) 349-2550

with a copy (which shall not constitute notice) to:

William N. Haddad, Esq.
Venable LLP
1270 Avenue of the Americas
24^th Floor
New York, NY 10020
Fax: (212) 307-5598

-32-

If to the Company:

Kiromic BioPharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
Attention: Maurizio Chiriva Internati, Chief Executive Officer
Fax No: (866) 419-6193

with a copy (which shall not constitute notice) to:

Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, NY 10112-0015
Attention: Jeffrey Fessler, Esq.
Fax No: (917) 438-6133

9.2Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

9.3Amendment. This Agreement may only be amended by a written instrument executed by each of the parties hereto.

9.4Entire Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that certain engagement letter between the Company and ThinkEquity, a division of Fordham Financial Management, Inc., dated February 7, 2020, shall remain in full force and effect.

9.5Binding Effect. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term “successors and assigns” shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.

9.6Governing Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof to the extent that such principles or rules would require or permit the application of the laws of any jurisdiction other than those of the State of New York. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled

-33-

to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

9.7Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.

9.8Waiver, etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

[Signature Page Follows]

-34-

If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

	Very truly yours,
	KIROMIC BIOPHARMA, INC.

	By:
		Name:
		Title:

Confirmed as of the date first written
above mentioned, on behalf of itself and as
Representative of the several Underwriters
named on Schedule 1 hereto:

THINKEQUITY

A Division of Fordham Financial Management, Inc.


By:
	Name:
	Title:

[Signature Page to Underwriting Agreement]

SCHEDULE 1

Underwriter	Total Number of Firm Shares to be Purchased	Number of Additional Shares to be Purchased if the Over-Allotment Option is Fully Exercised

ThinkEquity, a division of Fordham Financial Management, Inc. .


		-


TOTAL

-1-

SCHEDULE 2-A

Pricing Information

Number of Firm Shares:

Number of Option Shares:

Public Offering Price per Share: $

Underwriting Discount per Share: $

Underwriting Non-accountable expense allowance per Share: $

Proceeds to Company per Share (before expenses): $

SCHEDULE 2-B

Issuer General Use Free Writing Prospectuses

[None.]

SCHEDULE 2-C

Written Testing-the-Waters Communications

[None.]

-1-

SCHEDULE 3

List of Lock-Up Parties

-1-

EXHIBIT A

Form of Representative’s Warrant Agreement

-1-

EXHIBIT B

Lock-Up Agreement

[·], 2021

ThinkEquity

A Division of Fordham Financial Management, Inc.

17 State Street, 22^nd Floor

New York, NY 10004

As Representative of the several Underwriters named on Schedule 1 to the Underwriting Agreement referenced below

Ladies and Gentlemen:

The undersigned understands that ThinkEquity, a Division of Fordham Financial Management, Inc. (the “Representative”), proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Kiromic BioPharma, Inc., a Delaware corporation (the “Company”), providing for the initial public offering (the “Public Offering”) of shares of common stock, par value $0.001 per share, of the Company (the “Common Shares”).

To induce the Representative to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representative, the undersigned will not, during the period commencing on the date hereof and ending 90 days after the date of the Underwriting Agreement relating to the Public Offering (the “Lock-Up Period”), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions after the completion of the Public Offering; provided that no filing under Section 13 or Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other public announcement shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up Securities as a bona fide gift, by will or intestacy or to a family member or trust for the benefit of the undersigned or a family member (for purposes of this lock-up agreement, “family member” means any relationship by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; (d) if the undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up Securities to another corporation, partnership or other business entity that controls, is controlled by or is under common control with the undersigned or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned; (e) if the undersigned is a trust, to a trustee or beneficiary of the trust; provided that in the case of any transfer pursuant to the foregoing clauses (b), (c)

-1-

(d) or (e), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver to the Representative a lock-up agreement substantially in the form of this lock-up agreement and (iii) no filing under Section 13 or Section 16(a) of the Exchange Act or other public announcement shall be required or shall be voluntarily made; (f) the receipt by the undersigned from the Company of Common Shares upon the vesting of restricted stock awards or stock units or upon the exercise of options to purchase the Company’s Common Shares issued under an equity incentive plan of the Company or an employment arrangement described in the Pricing Prospectus (as defined in the Underwriting Agreement) (the “Plan Shares”) or the transfer of Common Shares or any securities convertible into Common Shares to the Company upon a vesting event of the Company’s securities or upon the exercise of options to purchase the Company’s securities, in each case on a “cashless” or “net exercise” basis or to cover tax obligations of the undersigned in connection with such vesting or exercise, but only to the extent such right expires during the Lock-up Period, provided that no filing under Section 13 or Section 16(a) of the Exchange Act or other public announcement shall be required or shall be voluntarily made within 60 days after the date of the Underwriting Agreement, and after such 60th day, if the undersigned is required to file a report under Section 13 or Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned shall include a statement in such schedule or report to the effect that the purpose of such transfer was to cover tax withholding obligations of the undersigned in connection with such vesting or exercise and, provided further, that the Plan Shares shall be subject to the terms of this lock-up agreement; (g) the transfer of Lock-Up Securities pursuant to agreements described in the Pricing Prospectus under which the Company has the option to repurchase such securities or a right of first refusal with respect to the transfer of such securities, provided that if the undersigned is required to file a report under Section 13 or Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned shall include a statement in such schedule or report describing the purpose of the transaction; (h) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities, provided that (i) such plan does not provide for the transfer of Lock-Up Securities during the Lock-Up Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan, such public announcement or filing shall include a statement to the effect that no transfer of Lock-Up Securities may be made under such plan during the Lock-Up Period; (i) the transfer of Lock-Up Securities that occurs by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement, provided that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this lock-up agreement for the balance of the Lock-Up Period, and provided further, that any filing under Section 13 or Section 16(a) of the Exchange Act that is required to be made during the Lock-Up Period as a result of such transfer shall include a statement that such transfer has occurred by operation of law; and (j) the transfer of Lock-Up Securities pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Shares involving a change of control (as defined below) of the Company after the closing of the Public Offering and approved by the Company’s board of directors; provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Lock-Up Securities owned by the undersigned shall remain subject to the restrictions contained in this lock-up agreement. For purposes of clause (j) above, “change of control” shall mean the consummation of any bona fide third party tender offer, merger, amalgamation, consolidation or other similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total voting power of the voting stock of the Company. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s Lock-Up Securities except in compliance with this lock-up agreement.

The undersigned agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement during the period from the date hereof to and including the

-3-

34^th day following the expiration of the Lock-Up Period, the undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such action unless it has received written confirmation from the Company that the Lock-Up Period has expired.

If the undersigned is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any issuer-directed or “friends and family” Securities that the undersigned may purchase in the Public Offering; (ii) the Representative agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Representative will notify the Company of the impending release or waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two (2) business days before the effective date of the release or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2) business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect at the time of such transfer.

The undersigned understands that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns.

The undersigned understands that, if the Underwriting Agreement is not executed bySeptember 30, 2021, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Shares to be sold thereunder, then this lock-up agreement shall be void and of no further force or effect.

-3-

Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representative.


	Very truly yours,




	(Name - Please Print)




	(Signature)



	(Name of Signatory, in the case of entities - Please Print)




	(Title of Signatory, in the case of entities - Please Print)



	Address:

-4-

EXHIBIT C

Form of Press Release

KIROMIC BIOPHARMA, INC.

[Date]

Kiromic BioPharma, Inc. (the “Company”) announced today that ThinkEquity, a division of Fordham Financial Management, Inc., acting as representative for the underwriters in the Company’s recent public offering of _______ shares of the Company’s common stock, is [waiving] [releasing] a lock-up restriction with respect to _________ shares of the Company’s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on _________, 20___, and the shares may be sold on or after such date.

This press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.

-1-

EX-4.1 3 krbp-20210625xex4d1.htm EXHIBIT-4.1

Exhibit 4.1

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE DATE OF THE UNDERWRITING AGREEMENT (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO December , 2021. VOID AFTER 5:00 P.M., EASTERN TIME, June , 2026.

WARRANT TO PURCHASE COMMON STOCK

KIROMIC BIOPHARMA INC.

Warrant Shares: [ ]

Initial Exercise Date: December __, 2021

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, ThinkEquity, a division of Fordham Financial Management, Inc. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2021 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to at 5:00 p.m. (New York time) on the date (such date, the “Termination Date”) that is five (5) years following the effective date of the offering , but not thereafter, to subscribe for and purchase from Kiromic BioPharma, Inc., a Delaware corporation (the “Company”), up to [ ] shares of Common Stock, par value $0.001 per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section 1:

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

“Commission” means the United States Securities and Exchange Commission.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Trading Day” means a day on which the New York Stock Exchange is open for trading.

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if Common Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Section 2. Exercise.

a. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within three (3) Business Days of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b. Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $[ ], subject to adjustment hereunder (the “Exercise Price”).

c. Cashless Exercise. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise;

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).

Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

d. Mechanics of Exercise.

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its transfer agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two (2) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). If the Warrant Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at the expense of the Company, any legal opinions or other documentation required by it to deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation from the Holder, including with respect to affiliate status) and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the transfer agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide a confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant Shares upon a cashless exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to

accrue) for each Trading Day after the second Trading Day following such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii. Rescission Rights. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however, that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder’s right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

viii. Signature. This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to exercise this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Purchase Warrant. No additional legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant. The Company shall honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance with the terms, conditions and time periods set forth herein.

e. Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or

supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

Section 3. Certain Adjustments.

a. Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then in effect.

b. [RESERVED]

c. Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d. Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such

extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.

e. Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable by holders of Common Stock as a result of such Fundamental Transaction for each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

f. Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

g. Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any defect therein shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

a. Transferability. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:

i. by operation of law or by reason of reorganization of the Company;

ii. to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;

iii. if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;

iv. that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or

v. the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period.

Subject to the foregoing restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

b. New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c. Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d. Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

Section 5. Registration Rights.

a. Demand Registration.

i. Grant of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Warrants (“Majority Holders”), agrees to register on Form S-3, on one occasion, all or any portion of the shares of Common Stock underlying the Warrants (collectively, the “Registrable Securities”). On such occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its best efforts to have the registration statement declared effective promptly thereafter, subject to compliance with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 5.b hereof and either: (i) the Holder has elected to participate in the offering covered by such registration

statement or (ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. The demand for registration may be made at any time during a period of four (4) years beginning on the Initial Exercise Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such Demand Notice.

ii. Terms. The Company shall bear all fees and expenses, attendant to the registration of the Registrable Securities pursuant to Section 5.a.i, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. The Company agrees to use its best efforts to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit to general service of process in such State or (ii) the principal shareholders of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section 5.a.i to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell the shares of Common Stock covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding the provisions of this Section 5.a.ii, the Holder shall be entitled to a demand registration under this Section 5.a.ii on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the effective date of the offering in accordance with FINRA Rule 5110(f)(2)(G)(iv).

b. “Piggy-Back” Registration.

i. Grant of Right. The Holder shall have the right, for a period of no more than two (2) years from the Initial Exercise Date in accordance with FINRA Rule 5110(f)(2)(G)(v), to include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.

ii. Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5.a.i hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company during the two (2) year period following the Initial Exercise Date until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back” rights provided for herein by giving written notice within ten (10) days of the receipt of the Company’s notice of its intention to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 5.a.ii;

provided, however, that such registration rights shall terminate on the second anniversary of the Initial Exercise Date.

c. General Terms.

i. Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 5.a of the Underwriting Agreement (as defined below). The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the foregoing provisions.

ii. Exercise of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

iii. Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort” letter dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report on the Company’s financial statements included in such registration statement, in each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’ letter, with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.

iv. Underwriting Agreement. The Holders shall be parties to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except as they may relate to such Holders, their Warrant Shares and their intended methods of distribution.

v. Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

vi. Damages. Should the registration or the effectiveness thereof required by Sections 5.a hereof be delayed by the Company or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.

Section 6. Miscellaneous.

a. No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

b. Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c. Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.

d. Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e. Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the underwriting agreement, dated October 15, 2020, by and between the Company and ThinkEquity, a division of Fordham Financial Management, Inc., as representatives of the underwriters set forth therein (the “Underwriting Agreement”).

f. Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

g. Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h. Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Underwriting Agreement.

i. Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j. Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k. Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l. Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Majority Holders.

m. Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n. Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.


	KIROMIC BIOPHARMA, INC.


	By:
		Name:
		Title:

[Signature Page to Warrant]

EX-5.1 4 krbp-20210625xex5d1.htm EXHIBIT-5.1

Exhibit 5.1

	Sheppard, Mullin, Richter & Hampton LLP
		30 Rockefeller Plaza
		New York, New York 10112-0015
		212.653.8700 main
		212.653.8701 fax
		www.sheppardmullin.com

June 25, 2021

VIA ELECTRONIC MAIL

Kiromic BioPharma, Inc.

7707 Fannin, Suite 140

Houston, TX 77054

Re: Registration Statement on Form S-1

Ladies and Gentlemen:

We are acting as counsel to Kiromic BioPharma, Inc., a Delaware corporation (the “Company”), in connection with its registration statement on Form S-1 (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”), relating to the proposed public offering of shares of common stock of the Company, par value $0.001 per share (the “Shares”), with a proposed maximum aggregate offering price of up to $57,500,000, including Shares issuable upon exercise of an over-allotment option granted by the Company. The Shares will be sold by the Company pursuant to an underwriting agreement to be entered into by and among the Company and ThinkEquity, a division of Fordham Financial Management, Inc., as the representative of the several underwriters to be named therein (the “Agreement”). This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. § 229.601(b)(5), in connection with the Registration Statement.

In connection with this opinion, we have reviewed and relied upon the following:

· the Registration Statement and the related prospectus included therein;

· the form of Agreement;

· the Certificate of Incorporation of the Company in effect on the date hereof;

· the Bylaws of the Company in effect on the date hereof;

· the resolutions of the Board of Directors of the Company authorizing/ratifying the execution and delivery of the Agreement, the issuance and sale of the Shares, the preparation and filing of the Registration Statement, and other actions with regard thereto; and

· such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion.

In our examination, we have assumed the genuineness of all signatures, including endorsements, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic, certified or photocopy, and the authenticity of the originals of such copies. As to any facts relevant to the opinions stated herein that we did not independently establish or verify, we have relied upon statements

-1-

and representations of officers and other representatives of the Company and others and of public officials.

Based upon, subject to and limited by the foregoing, we are of the opinion that following (i) execution and delivery by the Company of the Agreement, (ii) effectiveness of the Registration Statement, (iii) issuance of the Shares pursuant to the terms of the Agreement, and (iv) receipt by the Company of the consideration for the Shares specified in the resolutions, the Shares will be duly authorized for issuance and, when issued, delivered and paid for in accordance with the terms of the Agreement, will be validly issued, fully paid and nonassessable.

We also hereby consent to the reference to our firm under the caption “Legal Matters” in the prospectus which forms part of the Registration Statement.

We express no opinion as to matters governed by any laws other than the Delaware General Corporation Law. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

This opinion letter is rendered to you solely for use in connection with the issuance and sale of the Shares in accordance with the Registration Statement as of the date first written above and is not to be relied on for any other purpose. We disclaim any obligation to advise you of facts, circumstances, events or developments that hereafter may be brought to our attention and that may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Shares.

	Respectfully submitted,

	/s/ Sheppard, Mullin, Richter & Hampton LLP

	SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

-2-

EX-10.11 5 krbp-20210625xex10d11.htm EXHIBIT-10.11

Exhibit 10.11

FIFTH AMENDMENT TO LEASE AGREEMENT

THIS FIFTH AMENDMENT (the “Fifth Amendment”) is made and entered into as of the Effective Date set forth on the signature page (the “Effective Date”) by and between CAMBRIDGE PROPERTIES (herein referred to as “Lessor”) and KIROMIC BIOPHARMA, INC, (herein referred to as “Lessee”) on the following terms and conditions, and thus;

WITNESSETH

WHEREAS, Lessor, as Lessor therein, and Lessee, as Lessee therein, entered into a certain Lease Agreement (the “Lease”) for approximately 9,352 square feet of net rentable area on the first floor in Suite 140 of the building known as the Fannin South Professional Building the (the “Building) located at 7707 Fannin, Houston, Texas 77054;

WHEREAS, Lessor and Lessee agreed to expand the Leased Premise to include Suite 107; and

WHEREAS, Lessor and Lessee agreed to relinquish Suite 107 from the Leased Premise; and

WHEREAS, Lessor and Lessee agreed to extend the Term for two (2) years; and

WHEREAS, Lessor and Lessee agreed to expand the Leased Premise to include Suites 204 and 290, totaling 13,486 net rentable square feet; and

WHEREAS, Lessor and Lessee desire to further amend, modify, and supplement the Lease as hereinafter set forth;

NOW, THEREFORE, for and in consideration of the sum of TEN AND NO/100 DOLLARS ($10.00) and other valuable consideration respectively paid by each party to the other and receipt and sufficiency of which is hereby acknowledged, Lessor and Lessee do hereby supplement and amend the Lease as follows:

Section 2 A. TERM shall be extended through April 30, 2026.

Section 5. BASE RENT shall be as follows:


	Rental Rate	Annual Rent	Monthly Rent
Year 1	$20.00	$269,720.00	$22,476.67
Year 2	$20.00	$269,720.00	$22,476.67
Year 3	$20.50	$276,463.00	$23,038.58
Year 4	$20.50	$276,463.00	$23,038.58
Year 5	$21.00	$283,206.00	$23,600.50

[Type here]

Section 6. ADDITIONAL RENT shall reflect a 2021 Base Year Expense Stop for the Leased Premises.

Section 34. BROKERS Lessor and Lessee acknowledge that neither party has had any dealings with a real estate broker for this transaction and that no commission payment is due.

EXHIBITS: Exhibit “J” is attached hereto and made a part of the Lease Agreement for all purposes.

It is understood and agreed that except as provided herein in this Fifth Amendment, all terms and conditions of the First Amendment, Second Amendment, Third Amendment, Fourth Amendment and the original Lease Agreement, shall apply to this Fifth Amendment during the Term and any renewals thereof.

EXCEPT as expressly hereby amended, the undersigned has caused this Amendment to be duly executed and effective on this 2nd day of December, 2020.

LESSOR		LESSEE

CAMBRIDGE PROPERTIES		KIROMIC BIOPHARMA INC

By:	/s/ Trey Miller	By:	/s/ Maurizio Chiriva-Internati

Name:	Trey Miller	Name:

Title:	Real Estate Manager	Title:	CEO

[Type here]

EXHIBIT J

TERMINATION OPTION

1.If, and only if, after the April 30, 2024, Lessee requests in writing to expand the Premises by leasing additional space in the Building (an “Expansion Request”), and Lessor cannot reasonably accommodate such Expansion Request within ninety (90) days after Lessor’s receipt of the Expansion Request, Lessee shall have the one-time option (the “Termination Option”) to terminate this Lease as to the entire Premises, said termination to be effective (the “Termination Date”) 90 days after the date of the Termination Notice (defined below). The Expansion Request must include the amount of additional rentable square footage Lessee desires to lease in the Building. As used herein, the words “reasonably accommodate” means that Lessor cannot or will not lease to Lessee at least 95% of the rentable square footage requested by Lessee in the Expansion Request. For the avoidance of doubt, Lessee shall not have any Termination Option for an Expansion Request given prior to May 1, 2024.

2.The Termination Option may be exercisable by Lessee and will be effective only if, upon the date of the Termination Notice, and upon the day immediately prior to the Termination Date there is no default by Lessee under this Lease. The Termination Option is personal to the originally Lessee named in this Lease, and without the prior, written consent of Lessor, shall not be assigned or transferred to any person or entity other than the original Lessee, and any transfer in violation hereof shall be null and void.

3.The Termination Option is subject to each of the following requirements (any of which Lessor may waive in writing in its sole and absolute discretion):

a.Lessee must provide written notice (the “Termination Notice”) to Lessor of Lessee’s exercise of the Termination Option no earlier than ninety (90) days. The Termination Notice, once provided to Lessor, shall be irrevocable.

b.Lessee must pay to Lessor the Termination Payment. The “Termination Payment” shall be (i) a cash payment equal to 3 months of Base Rent and Additional Rent, if applicable, plus (ii) forfeiture of Lessee’s security deposit under the Lease. The Termination Payment shall be made at the same time as the Termination Notice. The Termination Payment is not a prepayment of rent under the Lease but is separate consideration for the Termination Option; and Lessee must continue to pay all rent under the Lease following the Termination Notice up to and including the Termination Date.

4.Lessee must comply with all provisions of this Lease with respect to the expiration or termination of this Lease and surrender of the Premises. Any holdover by Lessee in all or any portion of the Premises after the Termination Date shall be a default by Lessee under this Lease and will be subject to the holdover provisions of this Lease.

5.Lessee shall continue to perform all of Lessee’s obligations under the Lease for the period up to and including the Termination Date, including, without

[Type here]

limitation, the obligation to pay all rent and any other costs or charges for the period up to and including the Termination Date. Any provision of this Lease which is intended to survive the expiration or termination of this Lease shall survive the Termination Date.

6.With respect to all dates for exercising any rights and the performance of any obligations in connection with the exercise or implementation of this Termination Option, time shall be of the essence.

7.As of the date Lessee provides Lessor with a Termination Notice, any unexercised rights or options of Lessee to extend or renew the Term or to expand the Premises (whether expansion options, rights of refusal, rights of offer, or other similar rights), and any outstanding Lessee improvement allowance, rental abatement, or other allowance or credits not claimed and properly utilized by Lessee in accordance with this Lease as of such date, shall immediately be deemed terminated and no longer available or of any further force or effect.

8.If at any time after a Termination Notice, up to and including the Termination Date, default occurs, then Lessor may elect, but is not obligated, by written notice given to Lessee to cancel and declare null and void Lessee’s exercise of the Termination Option, and this Lease shall continue in full force and effect for the full Term hereof unaffected by Lessee’s exercise of the Termination Option.

EX-10.12 6 krbp-20210625xex10d12.htm EXHIBIT-10.12

Exhibit 10.12

SIXTH AMENDMENT TO LEASE AGREEMENT

THIS SIXTH AMENDMENT (the “Sixth Amendment”) is made and entered into as of the Effective Date set forth on the signature page (the “Effective Date”) by and between CAMBRIDGE PROPERTIES (herein referred to as “Lessor”) and KIROMIC BIOPHARMA, INC, (herein referred to as “Lessee”) on the following terms and conditions, and thus;

WITNESSETH

WHEREAS, Lessor and Lessee agreed to expand the Leased Premise to include Suite 107; and

WHEREAS, Lessor and Lessee agreed to relinquish Suite 107 from the Leased Premise; and

WHEREAS, Lessor and Lessee agreed to extend the Term for two (2) years; and

WHEREAS, Lessor and Lessee agreed to expand the Leased Premise to include Suites 204 and 290, totaling 13,486 net rentable square feet; and

WHEREAS, Lessor and Lessee agreed to extend the Term for sixty (60) months; and

WHEREAS, Lessor and Lessee desire to further amend, modify, and supplement the Lease as hereinafter set forth;

Section 1. LEASED PREMISES shall be expanded to include Suite 200 (the “Second Expansion Premises”) as follows:

Suite 200	14,393 SF Net Rentable Area
Former Corridor Space	992 SF Net Usable Area

Section 2 A. TERM shall commence August 1, 2021, and continue through April 30, 2026.

Section 5. BASE RENT shall be as follows:

For Suites 140/204/290

	Rental Rate	Annual Rent	Monthly Rent
Year 1	$20.00	$269,720.00	$22,476.67
Year 2	$20.00	$269,720.00	$22,476.67
Year 3	$20.50	$276,463.00	$23,038.58
Year 4	$20.50	$276,463.00	$23,038.58
Year 5	$21.00	$283,206.00	$23,600.50

For Second Expansion Premises


	Rental Rate	Annual Rent	Monthly Rent
Term	$18.00	$276,930.00	$23,077.50

Section 6. ADDITIONAL RENT shall reflect a 2021 Base Year Expense Stop for the Leased Premises.

Section 34. BROKERS Lessor and Lessee acknowledge that neither party has had any dealings with a real estate broker for this transaction and that no commission payment is due.

EXHIBITS: Exhibits “A” and “J” are attached hereto and made a part of the Lease Agreement for all purposes.

It is understood and agreed that except as provided herein in this Sixth Amendment, all terms and conditions of the First Amendment, Second Amendment, Third Amendment, Fourth Amendment, Fifth Amendment and the original Lease Agreement, shall apply to this Sixth Amendment during the Term and any renewals thereof.

EXCEPT as expressly hereby amended, the undersigned has caused this Sixth Amendment to be duly executed and effective on this 22nd day of March, 2021.

LESSOR		LESSEE

CAMBRIDGE PROPERTIES		KIROMIC BIOPHARMA, INC

By:	/s/ Trey Miller	By:	/s/ Maurizio Chiriva-Internati

Name:	Trey Miller	Name:	Maurizio Chiriva-Internati

Title:	Real Estate Manager	Title:	CEO

EXHIBIT A

SECOND EXPANSION PREMISES

FLOOR PLAN

EXHIBIT J

TERMINATION OPTION

3.The Termination Option is subject to each of the following requirements (any of which Lessor may waive in writing in its sole and absolute discretion):

5.Lessee shall continue to perform all of Lessee’s obligations under the Lease for the period up to and including the Termination Date, including, without limitation, the obligation to pay all rent and any other costs or charges for the period up to and including the Termination Date. Any provision of this Lease which is intended to survive the expiration or termination of this Lease shall survive the Termination Date.

EX-23.2 7 krbp-20210625xex23d2.htm EXHIBIT-23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement on Form S-1 of our report dated March 31, 2021 relating to the financial statements of Kiromic BioPharma, Inc. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Deloitte & Touche LLP

Houston, Texas

June 25, 2021

EX-101.SCH 8 krbp-20210625.xsd XBRL TAXONOMY EXTENSION SCHEMA 100200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 140802 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Initial Issuance and Bifurcated Embedded Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 141201 - Disclosure - INCOME TAXES - Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 141202 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 200200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 200400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 240301 - Disclosure - NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 240401 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 240501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 240801 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 100100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100300 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 131003 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables) link:presentationLink link:calculationLink link:definitionLink 140202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 140203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 140204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 140302 - Disclosure - NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 140401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 140601 - Disclosure - CURRENT LOAN PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 140701 - Disclosure - NOTE PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 140801 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 141001 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details) link:presentationLink link:calculationLink link:definitionLink 141002 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 141003 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 141004 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 141005 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 141006 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Warrants Underlying Series B Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 141007 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details) link:presentationLink link:calculationLink link:definitionLink 141008 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 141101 - Disclosure - STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 141102 - Disclosure - STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 141103 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Modifications (Details) link:presentationLink link:calculationLink link:definitionLink 141104 - Disclosure - STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 141203 - Disclosure - INCOME TAXES - Net Operating Loss Carryforward (Details) link:presentationLink link:calculationLink link:definitionLink 141301 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 141401 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 230903 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 240204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 240302 - Disclosure - NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 240601 - Disclosure - LOAN PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 240701 - Disclosure - NOTE PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 240901 - Disclosure - STOCKHOLDERS' EQUITY - Information (Details) link:presentationLink link:calculationLink link:definitionLink 240902 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 240903 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 240904 - Disclosure - STOCKHOLDERS' EQUITY - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 240905 - Disclosure - STOCKHOLDERS' EQUITY - Conversion of Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 240906 - Disclosure - STOCKHOLDERS' EQUITY - Warrants Underlying Series B Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 240907 - Disclosure - STOCKHOLDERS' EQUITY - Estimate the fair value of the warrants (Details) link:presentationLink link:calculationLink link:definitionLink 240908 - Disclosure - STOCKHOLDERS' EQUITY - Representative's Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 241001 - Disclosure - STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 241002 - Disclosure - STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 241003 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Modifications (Details) link:presentationLink link:calculationLink link:definitionLink 241004 - Disclosure - STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 241201 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 241301 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 100090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 110101 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 110201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 110301 - Disclosure - NET LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 110401 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 110501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 110601 - Disclosure - CURRENT LOAN PAYABLE link:presentationLink link:calculationLink link:definitionLink 110701 - Disclosure - NOTE PAYABLE link:presentationLink link:calculationLink link:definitionLink 110801 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 110901 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 111001 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 111101 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 111201 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 111301 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 111401 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 120202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 130203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 130303 - Disclosure - NET LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 130403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 130503 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 130803 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 130903 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 131103 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 131203 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 131403 - Disclosure - SUBSEQUENT EVENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 140101 - Disclosure - ORGANIZATION (Details) link:presentationLink link:calculationLink link:definitionLink 140201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 140301 - Disclosure - NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 140501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 140901 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 210101 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 210301 - Disclosure - NET LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 210401 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 210501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 210601 - Disclosure - LOAN PAYABLE link:presentationLink link:calculationLink link:definitionLink 210701 - Disclosure - NOTE PAYABLE link:presentationLink link:calculationLink link:definitionLink 210801 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 210901 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 211001 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 211101 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 211201 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 211301 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 230303 - Disclosure - NET LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 230403 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 230503 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 230803 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 231003 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 240101 - Disclosure - ORGANIZATION (Details) link:presentationLink link:calculationLink link:definitionLink 240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 241101 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 krbp-20210625_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 krbp-20210625_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 krbp-20210625_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information Document Type Entity Registrant Name Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Central Index Key Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock [Member] Series A-1 Preferred Stock Series B Preferred Stock [Member] Series B Preferred Stock Preferred Stock [Member] Preferred Stock Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Inventory, Net Inventories Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Total Other Assets, Noncurrent Other assets Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity: Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable The amount of accrued expenses and other current liabilities as at the end of the reporting period. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities Total Interest Payable, Current Interest payable Loans Payable, Current Loan payable Short-term Debt Note payable Liabilities, Current Total current liabilities Liabilities Total Liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity: Preferred Stock, Value, Issued Balance at end of period Balance at beginning of period Preferred Stock Common Stock, Value, Issued Ending Balance Beginning Balance Common stock, $0.001 par value: 300,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 7,332,999 shares issued and outstanding as of March 31, 2021 and December 31, 2020 Common stock, $0.001 par value: 300,000,000 shares authorized as of December 31, 2020 and 2019; 7,332,999 and 2,863,812 shares issued and outstanding as of December 31, 2020 and 2019, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at end of period Balance at beginning of period Total Stockholders' Equity Liabilities and Equity Total Liabilities and Stockholders' Equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value ( in dollars per share) Preferred Stock, Shares Authorized Preferred stock, authorized Preferred Stock, Shares Issued Preferred stock, issued Preferred Stock, Shares Outstanding Preferred stock, outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, authorized Common Stock, Shares, Issued Common stock, issued Common Stock, Shares, Outstanding Common stock, outstanding Condensed Consolidated Statements of Operations Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other expense Interest Expense Interest expense Interest expense Nonoperating Income (Expense). Total other expense Net Income (Loss) Attributable to Parent Net loss Net loss Earnings Per Share, Basic and Diluted Net loss per share, basic and diluted Net loss per common share, basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average common shares outstanding, basic and diluted Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-In Capital Retained Earnings [Member] Accumulated Deficit Shares, Outstanding Balance at end of period (in shares) Balance at beginning of period (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock (in shares) Equity impact of the value of new preferred stock issued during the period. Stock Issued During Period, Preferred Stock, New Issues, Value Issuance of Series B Preferred Stock Number of new preferred stock issued during the period. Stock Issued During Period, Preferred Stock, New Issues, Shares Issuance of Series B Preferred Stock Stock Issued During Period, Value, New Issues Common stock issuance net of issuance costs and discount amortization Issuance of stock Stock Issued During Period, Shares, New Issues Common stock issuance net of issuance costs and discount amortization (in shares) Shares issued Amortization of discount on preferred shares issued. Preferred Stock, Amortization of Discount Series B Preferred Stock discount amortization Series B Preferred Stock discount amortization Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants on preferred stock. Adjustments to Additional Paid in Capital, Warrants Issued, Preferred Stock Warrants underlying Series B Preferred Stock issuance Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock. Adjustments to Additional Paid in Capital, Warrant Discount Amortization Warrants underlying common stock discount amortization Less: IPO Common Stock discount amortization Common stock IPO discount amortization Adjustments to Additional Paid in Capital, Warrant Issued Common stock IPO discount Warrants underlying common stock issuance Fair value of warrants reflected as additional paid-in capital Value of accretion and settlement of dividend during the reporting period. Preferred Stock, Accretion and Settlement of Dividends Accretion and settlement of Series B Preferred Stock dividend Less: Accretion and settlement of Series B Preferred Stock dividend Accretion of dividend Accretion and settlement of Series B Preferred Stock dividend Shares issued in settlement of dividend during the period. Preferred Stock, Accretion and Settlement of Dividends, Shares Accretion and settlement of Series B Preferred Stock Dividend (in shares) Value of warrant exercised during period. Warrants Exercised During period, Value Exercise of warrants Number of warrant exercised during period. Warrants Exercised During period, Shares Exercise of warrants (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercised stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Exercised stock options (in shares) Value of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock. Series A1 Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split and Conversions, Value Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion Shares of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock. Series A1 Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split and Conversions, Shares Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares) Value of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock. Series B Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split And Conversions, Value Series B Preferred Stock conversion to common stock Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion Shares of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock. Series B Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split and Conversions, Shares Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares) Value of shares issued to employee and nonemployees. Stock Issued During Period, Value, Employees and Non-Employees Common stock issuance to employees and non-employees Shares issued to employee and nonemployees. Stock Issued During Period, Shares, Employees and Non-employees Common stock issuance to employees and non-employees APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock compensation expense Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Depreciation Depreciation Share-based Payment Arrangement, Noncash Expense Stock compensation expense Other Noncash Expense Non-cash interest Inventory Write-down Inventory obsolescence impairment Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Unbilled Receivables Unbilled receivables from granting agency Increase (Decrease) in Inventories Inventories Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities The amount of increase (decrease) in deferred rent. Increase (Decrease) In Deferred Rent Deferred rent The amount of increase (decrease) in convertible promissory notes derivative liability. Increase (Decrease) In Convertible Promissory Notes Derivative Liability Convertible promissory notes derivative liability Net Cash Provided by (Used in) Operating Activities Net cash used for operating activities Cash flow from operations Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used for investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Notes Payable Proceeds from sale of convertible promissory notes Proceeds from Stock Options Exercised Exercise of stock options Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Payments of Stock Issuance Costs Issuance costs Offering expenses Proceeds from Issuance of Warrants Proceeds from warrant exercise Proceeds from issuance of warrants Cash received from loan payable. Proceeds From Loan Payable Proceeds from loan payable Loan initial proceeds Repayments of Bank Debt Repayments of loan payable Proceeds from Bank Debt Borrowings from note payable Repayments of Notes Payable Repayment of notes payable Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from Series B Preferred Stock issuance Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash and cash equivalents Cash and Cash Equivalents [Abstract] Cash and cash equivalents: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents End of period Beginning of year Supplemental Cash Flow Information [Abstract] Supplemental disclosures of non-cash investing and financing activities: Capital Expenditures Incurred but Not yet Paid Accruals for property and equipment Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest on note payable Notes Issued Conversion of accounts payable into convertible promissory notes Debt Conversion, Converted Instrument, Amount Conversions into Series A1 Stock Conversions into Series A1 Stock Conversion of convertible promissory notes and accrued interest into Series A1 Preferred Stock Conversion of convertible promissory notes and accrued interest into Series A1 Preferred Stock ORGANIZATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] ORGANIZATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NET LOSS PER COMMON SHARE Earnings Per Share [Text Block] NET LOSS PER COMMON SHARE PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT, NET ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES LOAN PAYABLE Long-term Debt [Text Block] LOAN PAYABLE CURRENT LOAN PAYABLE NOTE PAYABLE Short-term Debt [Text Block] NOTE PAYABLE CONVERTIBLE PROMISSORY NOTES The entire disclosure of debt. Convertible Debt [Text Block] CONVERTIBLE PROMISSORY NOTES COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] STOCK-BASED COMPENSATION INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk and Other Uncertainties Disclosure of accounting policy for deposit. Deposit [Policy Text Block] Deposit Inventory, Policy [Policy Text Block] Inventories Deferred Charges, Policy [Policy Text Block] Deferred Initial Public Offering Costs Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Internal Use Software, Policy [Policy Text Block] Internal Use Software Development Costs Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Income Tax, Policy [Policy Text Block] Income Taxes Research and Development Expense, Policy [Policy Text Block] Research and Development Expense Disclosure of accounting policy for proceeds from grants. Proceeds from Grants [Policy Text Block] Proceeds from Grants Disclosure of accounting policy for convertible promissory notes derivative liability. Convertible Promissory Notes Derivative Liability [Policy Text Block] Convertible Promissory Notes Derivative Liability Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Disclosure of accounting policy for nonvested stock options and restricted stock units. Nonvested Stock Options and Restricted Stock Units [Policy Text Block] Nonvested Stock Options and Restricted Stock Units Share-based Payment Arrangement [Policy Text Block] Stock-Based Compensation Segment Reporting, Policy [Policy Text Block] Segment Data New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Tabular disclosure of estimated useful lives of property and equipment. Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block] Schedule of estimated useful lives of property and equipment Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of Level 3 liabilities measured at fair value on a recurring and nonrecurring basis Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of earnings per share, basic and diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of antidilutive securities excluded from computation of earnings per share Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Tabular disclosure of information pertaining to accrued expenses and other liabilities. Accrued Liabilities And Other Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Convertible Debt [Table Text Block] Schedule of initial value of issuances and the bifurcated embedded derivative liability Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum rental payments for operating leases Fair Value Measurement Inputs and Valuation Techniques [Table] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Information pertaining to Common Stock warrants. Common Stock Warrant [Member] Common Stock Warrants - Representative EX-101.PRE 12 krbp-20210625_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 krbp-20210625xs1006.jpg GRAPHIC begin 644 krbp-20210625xs1006.jpg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end GRAPHIC 14 krbp-20210625xs1008.jpg GRAPHIC begin 644 krbp-20210625xs1008.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#TGQ]X^_X0 MK[)_H;7'GDC@@8XKBO\ A?7_ %!W_P"^Q1\>O^85_OM_*O&*ZZ5*,HW9Q5:L MXS:3/9_^%]?]0=_^^Q1_POK_ *@[_P#?8KQBBM/8P[&?MZG<]G_X7U_U!W_[ M[%'_ OK_J#O_P!]BO&**/8P[![>IW/9_P#A?7_4'?\ [[%'_"^O^H.__?8K MQG%%'L8=@]O4[GLW_"^?^H.__?8I?^%\_P#4'?\ [[%>,44>QAV#ZQ/N>S_\ M+Y_Z@[_]]BC_ (7Q_P!0=_\ OL5XQ11[&'8/;U.Y[/\ \+X_Z@[_ /?8H_X7 MS_U!W_[[%>,44>QAV#ZQ4[GL_P#POG_J#O\ ]]BC_A?/_4'?_OL5XQ2XH]C# ML'MZG<]F_P"%\?\ 4'?_ +[%'_"^/^H._P#WV*\9H%'L8=@]O4[GM@^.68M_ M]D/_ -]BH3\>,?\ ,'?_ +[%>2*?W%56ZTO8P[![>IW/9?\ A?/_ %!W_P"^ MQ1_POC_J#O\ ]]BO&:*?L8=@]O4[GLW_ OC_J#O_P!]BC_A?'_4'?\ [[%> M,TN*/8P[![>IW/9?^%\?]0=_^^Q1_P +X_Z@[_\ ?8KQJDH]C#L'MZG<]F_X M7S_U!W_[[%'_ OG_J#O_P!]BO&**/8P[!]8J=SV?_A?/_4'?_OL4#X\9/\ MR!W_ .^Q7C%*.M'L8=@]O4[GLY^.^/\ F#O_ -]BD_X7S_U!W_[[%>.N.!4= M'L8=@]O4[GLW_"^?^H.__?8H_P"%\_\ 4'?_ +[%>,44>QAV#ZQ4[GL__"^? M^H.__?8H_P"%\_\ 4'?_ +[%>,44>QAV#V]3N>S_ /"^?^H._P#WV*/^%\_] M0=_^^Q7C%+1[&'8/;U.Y[-_POG_J#O\ ]]BC_A?/_4'?_OL5XR:2CV,.POK% M3N>S_P#"^?\ J#O_ -]BC_A?/_4'?_OL5XQ11[&'8?UB?<]G_P"%\_\ 4'?_ M +[%'_"^/^H._P#WV*\8I11[&'8/;U.Y[0/COD_\@>3_ +[%.;XZ;1_R"'_[ M[%>-0KDTLQ[4O8P[![>IW/8/^%\?]0=_^^Q1_P +Y_Z@[_\ ?8KQBBG[&'8/ M;U.Y[/\ \+Y_Z@[_ /?8H_X7S_U!W_[[%>,44>QAV#V]3N>S?\+Y_P"H._\ MWV*/^%]?]0=_^^Q7C-)1[&'8/;U.Y[/_ ,+Z_P"H._\ WV*/^%]?]0=_^^Q7 MC%%'L8=@]O4[GL__ OK_J#O_P!]BC_A?7_4'?\ [[%>,44>QAV#V]3N>S_\ M+Z_Z@[_]]BC_ (7S_P!0=_\ OL5XQ2T>QAV#V]3N>S_\+Y_Z@[_]]BC_ (7S M_P!0=_\ OL5XQ11[&'8/;U.Y[-_POG_J#O\ ]]BC_A?7_4'?_OL5XQ11[&'8 M/;U.Y[/_ ,+Z_P"H._\ WV*/^%]?]0=_^^Q7C%%'L8=@]O4[GL__ OK_J#O M_P!]BC_A?7_4'?\ [[%>,44>QAV#V]3N>T?\+Y_Z@[_]]BD_X7S_ -0=_P#O ML5XS11[&'8/;U.Y[-_POK_J#O_WV*/\ A?7_ %!W_P"^Q7C%%'L8=@]O4[GL M_P#POG_J#O\ ]]BE_P"%\_\ 4'?_ +[%>+TIZ4>QAV#V]3N>S?\ "^O^H.__ M 'V*/^%]?]0=_P#OL5XQ11[&'8/;U.Y[/_POK_J#O_WV*/\ A?7_ %!W_P"^ MQ7C%%'L8=@]O4[GL_P#POK_J#O\ ]]BC_A?7_4'?_OL5XQ11[&'8/;U.Y[/_ M ,+Z_P"H._\ WV*/^%]?]0=_^^Q7C%%'L8=@]O4[GL__ OK_J#O_P!]BC_A M?7_4'?\ [[%>,44>QAV#V]3N>S_\+Z_Z@[_]]BC_ (7U_P!0=_\ OL5XQ11[ M&'8/;U.Y[/\ \+Y_Z@[_ /?8H_X7S_U!W_[[%>,TE'L8=@]O4[GL_P#POK_J M#O\ ]]BC_A?7_4'?_OL5XQ11[&'8/;U.Y[/_ ,+Z_P"H._\ WV*7_A?/_4'? M_OL5XO11[&'8/;U.Y[1_POG_ *@[_P#?8H_X7S_U!W_[[%>,9HS1[&'8/;U. MY[-_POG_ *@[_P#?8H_X7U_U!W_[[%>,T4>QAV#V]3N>S?\ "^O^H.__ 'V* M/^%]?]0=_P#OL5XQBBCV,.P>WJ=SV?\ X7U_U!W_ .^Q1_POK_J#O_WV*\8H MH]C#L'MZG<]G_P"%]?\ 4'?_ +[%'_"^O^H._P#WV*\8HH]C#L'MZG<]G_X7 MU_U!W_[[%'_"^O\ J#O_ -]BO&**/8P[![>IW/9_^%]?]0=_^^Q1_P +Z_Z@ M[_\ ?8KQBBCV,.P>WJ=SV?\ X7U_U!W_ .^Q1_POK_J#O_WV*\8HH]C#L'MZ MG<]G_P"%]?\ 4'?_ +[%'_"^O^H._P#WV*\8HH]C#L'MZG<]G_X7U_U!W_[[ M%'_"^O\ J#O_ -]BO&**/8P[![>IW/9_^%]?]0=_^^Q1_P +Z_Z@[_\ ?8KQ MBBCV,.P>WJ=SV?\ X7U_U!W_ .^Q1_POK_J#O_WV*\9I*/8P[![>IW/9_P#A M?7_4'?\ [[%2VWQS^T744/\ 9#C>P7.X=Z\3JUIG_(3MO^NJ_P Z/8P[![>I MW/L2WE\ZVBEQC>@;'ID9HJ.P_P"0=;?].?'K_ )A7^^W\J\8K MV?X]?\PK_?;^5>,5WT?@1YU?^(PHHI<5J8ABBBB@ HHHH **** "BBB@0444 MHH 44$T=!24#"@=:*7% $R-\A%1-2@TC4@&T44H%, %+0!3@I]*0#:3%2;#3 M2I]* &8HIV*3:: &TY!DBC!IXX% "R$' %1&G,:;0 E%%%,0444H% P%+VI1 M2&D E%%%, HHHH *4"DIPH EC;;3)>3FD)Q32O^85_OM_*O&!7L_P > M?^85_OM_(UXR*[Z/P(\^O_$8444HK4Q "EVTY13CBD!&124I-)3 2EHXIVWW MI -Q1BG8%.4 ]: &8H%64A5Q@,,TUX&0\BBXR&C%.*&C% AM)3L4E !2&BEH M 0#-31PDC/?*!5F_0QX0# H'8BWPIP!FD\].RU6I*+ 6O/7TI#*I[5 M6HS18+DYD3TIAD'85%FB@0_.:*0=*6@!AHI2*2F E%+10(*!112&+FD)I**8 M"T4"C% !1129H 6ES2"E ). ,FD JJSG %(Z,A^85IV=F?++2L(Q[]34=Y$( MU89W#L:S]I[UC3D]VYG4M)16AF+2444P$HHHH **** %%%%% !1110 4444 M%21!6;#&HZ=!$T\@5:QK248[EP5V6X[%II JYJ:6 M]DD/EXQFO-J5IS5C=02V)I$B4>9M&:(KP*A++@"EM[5R/WF2#3-1MI#!LB7K M6!6A)%-'>9P 15>;3HBQXJQI%BUO'^\ZFK=Q%M.>U%[/074Y*ZL'\T[1Q5%E M*-M-=-=R* 2.U8?D_:96-=E#$..DMB90NKE9:0CFI7C\M]M1L.:]&,DU='.U M8912TE4(**** "BBB@ HQ2\4H(H ,4A-*>:3% "44H%+@"@ H-.P,<4R@!* M*** "BBC% !11BB@ I:*0T +1B@44 &*6DS29H 7-&:,TE "YI*** "BBB@! M<4E**,4 )1110 4444 %%%% !1110 5:TS_D)VW_ %U7^=5:M:9_R$[;_KJO M\Z /L"P_Y!UM_P!LMCQWX\_\PK_ 'V_E7C% M>S_'@9_LK_?;^1KQK;7?1^!'GU_XC&TX"EVTM:F(HZ4A-(332:0 :3%%%,0M M%&*7% PZ4151TP:L6=STC M?D&I+J'RV]C4CL9Q&*:14S*:C(JB1E*!2XIZ1EB * )K*-FF!'0=ZGU.=9&" M#MWICRBWBV+]X]:HLQ8Y-+?4K;02FTN:2F2%%%)0 4H% &:D5:8"8IP!IRIS MBK @.W.*0%,BF59; ."*C(4T 145*$I3"<9Q0!#13BN*3I3 3%%+FE'- " 4 M&G=*159SA02:0#: I8X )^E6/LZQC=,X7_9'6@W(1=L*!?\ :/6@8J6H7F=P M@].].%TL/_'O& ?[QZU6+,[;F))]32&@+]A_G.TH=F).:FN'9)^3E6&2*J5; MOEPT3=B@I6U!7L12187>G*?RJ*I893$>1E3U7UITT V>;$H]*86*]%%%, M0E&*444 )2T44 %+0** $HHHH$':BBBD ]-N?FZ5?M$C5MT=9;]*NZ>^Q&-< M.+B][G32>AL6DAN+C8W:M8:>S21+)+% H M#$#%0+>1RR;5P14.HZ?+E:150A(K MU6_,(*[>M"!&-+<$RLG6J\=R(I2",4L^5(D"]:KW0W(''!K1&J0/)OE)IC') MJ)&!^M/KU:$KQ.2JK,****W,PH-%)0 4444 %%%+B@ S3@::!2F@ )I*** % M!YH/6E49-*S#/2D RC%.R/2DS3 3%+BDS12 ,4444P"BBB@ HHI* "BBE% " M4444 %%%% !1110 4N:2B@!:2BB@ HHHH **** "BBB@ JUIG_(3MO\ KJO\ MZJU:TS_D)VW_ %U7^= 'V!8?\@ZV_P"N2?R%%%A_R#K;_KDG\A17EL]9;'CW MQW_YA7^^W\C7C@KV+X\?\PK_ 'V_E7C8-=]'X$>?7_B,<:;3NM(16AB,)H-+ MBDI@)3A1BEI %%%%, I,4M% !2B@4[%(!R'!!]*UFQ<60<=1UK'!K2T^4>6Z M'I2942EYNUN14BF*3KP:CNDV2G'0U .M.PB_]D!&5.:>46VCW,/F[4W3BS2C M/W:BOY"]PP[#I4];#Z7*LCEV+&HR:<:3%42-I:7%+BF W%+BEQ3@* $5:O6T M(>JR)N.*V].LV;'%(+V*36^V0<5K6]CYL/2K1TUBX)%;%G:B./&*=B6SC[C3 M&$F,4)I#L/NUV,UJA;)44HA15Z57*0YG&_V6RMTJ9M-.SI73-"A;H*D6W0KT MHY0YSC7TML$[:S;BU:-L8KT,VJ$8P*J?V1%)=!F4$>E14?)%R?0ND^>2CW.! M\B11N*$#UQ2K&Q. ,FO2)--C:,J8QMQZ5R&I6R6[NJ-M /:N3"XOV]U:UCKK MX?V5M3*\M$YE;G^Z*:;DJI6-0H]>](RQDY,GZ4FR+_GI^E=9SD9))R23]:3% M2[(?^>OZ4OEP_P#/7]*!6(A2XJ0)#_SU_2G".'_GM^E RN:O7BYL;60=QBH3 M%!_SV_0U;:.!]-3]_P (V.E)C2,WM3X9FA;(Y!ZCUJ7RK?\ Y^/T-'DVW_/Q M^AIB"2W$B>;!RIZKW%(UC<)'O:,A:T]&MH_M>Y)2PQTQQ71LBLI5@,&N#$XQ MT9J*1UT,*JL>9LX"BM2?3%>YD$4Z#GHW%5I-.GCZ;7_W2*[HR329RN+3L5** MF-K.HYB-1E'7JC#ZBF2-I:2EI@!I*6DH$&:***0 J%W'I6K;QQ^7@5D,67H: MOV$IVG=7FXE2O=G73M;0MP7*VL_'K766%P)H@U<>(%FER36]:O\ 9X0 :Y)( MJ2-J2516#JDUR7_6X.#N-.P[:E:01N"N!Q65>X1<5/-(PD+ \5G7$IDSFK2-$,B"')S3\\U! M&,YQ4J@CK7H4>:/H85+,?24M%=9SA28IU%,!N*7%+24 %%%&* "BI(87GD$< M8RQZ"M&70;R*+S"N0.2!6*,O%*%)Z4I.TXQ@B@.!BD E%&**8!2448I )1BG4E,!*448 MHH #24M)0 4444 %%%% !1110 4444 %%%% !1110 4444 %6M,_Y"=M_P!= M5_G56K6F?\A.V_ZZK_.@#[ L/^0=;?\ 7)/Y"BBP_P"0=;?]#6IB/V MTFVGJ>*>,&D!#BBI62HR,4 ,HIV*3% #:6C%&* %%+FD[4E,!U(6"#BF>93')-#) MC(DW;A4,C;:B,^PXI'?>*+C;$:3;S3HI\FF+$9!2K"4-.Z!%I7I6?G(X-1=J MC+X:BR>C'MJBZ9)&@8]Q7*ZO;K-N*\/Z>M=5;R*V4/\ $*R+VT\TDCK64:,( M7Y%8T=:SUF3Z5+">1QV([T&FCV,K%+B MII(2AYJ/%,!H%**4"EQ2 0U:C7?IDN.H;/\ *JP!8X R?:MG3[$):7!N2%&W M=L[TF[%15V8T44DSA(T+'VJX;:WMD#7#[W_YYJ?YTR2].W9;H(D]1U-,A@:X MD51DY/)H O0W;QVQN,".,<1H.YJ)]=O'C*9 SW%5[V=9)!'&,11\*/ZU6(J) M4H3UDKE*K*.D6.,I<_O &]S3EY'[N1E/IFH:3FM"+E@7%U#_ ,M&_$YI_P#: M5PWW]K?45 LK#@\CT-/"Q2=#L;]* NR07B$_-;QG\*0RVK=86'T-0O"Z=1D> MHIE%@NRSMM6_B9?UH-M"?N3@_48JK2T"N3&V;LR'Z&FFWE'\)_"HQD=Z=O1R%')/M72Z=Y<5L$DV^8!DCTKBQJDH71 MU89)RLS*FMIK652W0]Q6A!*73DT:A?V3%(7?:?4=JC^S+*H-KI%4%; IVVFY)YIR8@ 0\8K#G M1(,MS2F*%..*.8.4Q3$WH:40.3TK7*1=NKM;-8H@<5<=S&K*R'*NU.*:I9GQ4ZXZ4]8P#FM6['&I J #)I6 M"LN!3+B3:E4%NB'P36#;-4T23VQ9LBECB('-6(YU=>:"12YF%A$PM))(*&<8 MJ$_,::8,D4[JBE0YIZG8:E9E9:T3U+2NB& D2+]:M30[93GH>14,> U6[I\P MQR>V#3;U'R^Z4I+97ZBH)8DBB*LNY/2IO.YZU4O92T9 HEL3!NYSFJ6J@&2# MYD[CN*J6VCWUXF^*!BOJ:UM.@:?6HHF.$8_,/6N_2-8E"1J%4=A7/*?+H=L* M:EJ>27%E/:2>7/&R-[BI(K%F423,(H_4]:]$UZUCETV65HU,D8RI(Z5YI-/) M,V9')([=A3C+F0IP466#=1VV5M4Y_P">C=:+&1GGE#L270]:I5HZ-93W=ZOE M1LP ()QP.*IZ(E-MF=C!(K9\G[)IF0?W\H_(4]_#UY8S-/=Q#R$RQP- M/*S,>#P!Z"E>^P[M/P7:0W%_)+(H8QCY0:[_!K.=2SLC:%/F5V>,RQ202&.52KCJ#3* M]!\7Z.D]E]KBC_?(><#J*X%H95ZQL/PJXRYE/2I 89#\PV'U M'2H<$=0129%,@E:W<#5%\TYZMZ?2BX6$W)8#"X:"!XV41C:N1UJ;IE6:5S*<%N3S4T,_E*1WJ1; M5SU%2IILTI^5"1ZXJ*E.,]QQDT56O[A&R)&QZ5-%J\\AVN0Z^A%6QI,49_TB M8?1>:&:SML^1 #C^)N:YZM!;Q-H5'U%"1W8P;, =RO'\ZW=,MX(;0"+CGGG- M<_')/<*9)9"ENO7'&?:JYU"991Y!\N,'A16%; RJ0LGJ:TL2J6U M 5=S ]NMUIY8+F"9'.)(P<=JI+);78Q*/*E[,.AKIPF']C3L]3+ M$UO:SNM"EGBDJ>XM);BNJ'@R;R7XD3R+=?+@7H!U/UIM_J,M\P!^2)?NQKT%4J+=P;6R"MB[/\ MQ3EH/]L_RK'K6O/^0#9CW-#Z!'9E?3[P0Y@F^:WDX8>GO4=]:&UFPIW1MRC> MHJK6I8SIX,;H<@^E27$-T@?\11=!9E2I1RM6AH]X?^68 M'U-3IHMSM^9XE^KBE=!RLRFEO;37+[8D+&M3^P9Y2-LL9/LV:Z/1=);3( M")0/,8YS7-B\3["DYK5F^'P_M9J+T1Q5Q9SVK 31E<]*AKO];MX;C393(!E1 MD&O/ZG!8KZS3YFK-%8K#^PE9/1BXI*7-'6NTY1M%.(IM !1110 4444 %%%& M* "BEQ10 F*,444 )12]J2@ HHHH **** "K6F?\A.V_ZZK_ #JK5K3/^0G; M?]=5_G0!]@6'_(.MO^N2?R%%%A_R#K;_ *Y)_(45Y;/66QX[\>?^85_OM_(U MXQ7L_P >?^85_OM_(UXQ7?1^!'GU_P"(PI1249K4Q%HI**!!FG TVB@!V:,T MG>BD,=124H% "BI%VCK3 *HJK<>E5\YIV#F[% MV34)9.IQ4?GLW4U6%.)HL*[)3,WJ:EM\RN :IYS5[3^91F@#7L?DN%%==E4I&*L*MPX=:@V17EE8&B*X[&K$L VDUEL= MLN*M$RN:329&:8)2*(T+H"*CD4KUK2-@NT2^>0:LK.9;.1.Z_-5.*,O6A:08 MC*15NQI"[,]6W&K/D!HR33!"5F(QT-76(CA)QVHFR8*S.9N&DL[Y)X1\R M'\ZZVWUNSEB!DD"2!IK+25FLKJ=NKG;7-*-SMIRY4 M='XC\3H$-K:#=G[S'H17*?:;:7_70;?=*9=9=(I?48JMBJC%)$RFV]306PAN M"OV:Y4L3]UNU>D:1IL>GZ=%&J@/C+'U->51L8Y5?^ZB:SJD.EV$DC2+ MYA&$4'J:\IFE>XG>60DLY)HI)A6:V-'[-8JF)+O:E@N9;=LQMCU'8U2@DB74;>I9.J22-F2"-S],4OVR-SS8Q@>Q-/5; M>^ \O$,_<'HU7=*\+ZAJCMQY4:G!9J+I;A:3V*7F6#??MV7_ ':D2#3)W"QB M53WSV_6MJ\\ WT,9>*=9<#)&*PS#(F;>WC;<.'8]Z2:>S!IK=%L0Z9"C10WY M20\%B*U?#VDV]SJ:,]Q'.$&1ZU@IIL<)!N'W?[*_XU?TS4/L-\CVR!54_-CT M]Z3VT*COJCTY8%4>WH*PO%-E:M8?:'PK1GJ!UJQ;>(M.NX=ZW*)CJ&.*Y/Q; MXCANXOL5H^Y<_.PK*,7S&TY1Y3);4K6+_50[O=JCDU5I>IP!V'%8]&<5TKD2Z3I\W?:5/YUB5L$F?PP.,^5)_C67';S2G"1. MWT%)%2U9+;WLD *\/&>JM4WV>WO%+6[^7+WC;O\ 2GPZ'>S#)58QZN0*F_L> MWMSNN;^-<=DY-#:&D^IE2120N4D4JP[&FX)Z"NA_M'2$A$4L4EUCHS4Z2ZC$ M8ETRVAV@%]*ELYY);E%#D?*.]8::EJU M[+Y,3N">, 8Q5^.ZCT)O,DF-S>'J >%I2NU8<;)W.VKG_$]O9SI#]HG\IAT] MZBA\96S! \+!B<'FL+Q)+<2Z@&E;,97,>.F*B,7_XT6Q^ ME)H:>C(O[1ME^Y9)^)-20:IB3*VD2XK*'6K4:$)P"2?2G9"39TMOJ[7T3)MC M6=1E3M'S5E7FL7:MM!56'7Y14=K97C2*\,3*1R&/ K3NM)MYA]HN+A%D4?O% M3DFIT3-/>:,,ZK>MUF_("G1-J5X<1>:_TJV;W2;48M[0RN/XI*@EUZ]==D;B M)/1!5>B)TZLM1Z-= ;KV]%NOHSG-2J^D6JD*\MTXZ\\?SKGY)9)6S([,?./9:PQPKV(&3^M9\>LWT=QYYF9F/4'I5:7I4.*'",E9K M0.>2=TSIK'63JSO87H5%E7"L#T-<]=6[VEU)!(,,AQ4:DJP93A@<@UO7R+K& MDI?Q ?:(1MF ZGW_ %J84X4M(*R*E.5363NSGZ :**U,AX&::PQ3E-.89%(" M*DIQ%(:8"4444"%%."T@%/H&-(Q333F-,H ***2@!>U)2BDH **** "BBB@ MJUIG_(3MO^NJ_P ZJU:TS_D)VW_75?YT ?8%A_R#K;_KDG\A118?\@ZV_P"N M2?R%%>6SUEL>._'G_F%?[[?R->,5[/\ 'C_F%?[[?R->,XKOH_ CSZ_\1B44 M45J8A112XH$%%%+B@8E+B@"I$B9S@"D P"IHH&D/ J];Z>,;I#@4Z:5(ALC& M/>EO:LV]#1?$<;JY);R4 M' Z^YJO]GE72 N,!WW?TJWJ<8P"6S@"FA/5$EO"]S,(T[]3Z"IY[UX M'$-I(R1IQN4XW&I;@C3;46RX^T2#,C>@]*S *-PVT-,R/J.FOYLC/- LT5:TZ18KQ _W'^5OQIEY;FVNI(^HSD'VH78'JKD!)I,T8I0*8B2*0KP>E M7+=/]$N=O3&:IX4"MC2;.XGM;DK$Q4KP?6HG.,5>3L73BY.R1@ &GB-CVJ_] MG,1Q*A5AV-!7"[F(C7WZU7,GL3RE-8CO&?6O:-#B1=$M=IR-@Y_"O(OM"1\0 MID_WFK>T'QG-I0\FY7SH/U%9U(N2T-:4E%ZGIVSVKRWQ7(]KK232K8B-)7:%2HNH M[)G&[?6D]A6SJ]G#%.K"0)N[51ABM5E4O/D9Z"M:=15(*2,ITW"7*PCLRRY8 MX]J=]A\L>;(?W0_6MJ*.Q9YN(1$V8\@= >E5S!RHS5G:XD&!A / ME44GV"ZG8E86QZD8I\6H.O"(B?AFH)KRX=B#*V/;BF3H6$TG!_TBYBB'^\": M>T&DP?>GDF8=E&*RV9F.223[FFT68KKL=9I=U;/I-ZMO;#$8W8?G-9#Z_>,, M1".(?["XJSX88/-=V_\ STB/]*PW&V1E]#BDDKLMR=DR:6\N9SF2>1OJU5^] M+2HC2.%12S'H!5&>XVM;3--N)"+DR&W@7DR'C-3PZ?:Z7$+C4CNE(RD Z_C5 M"^U2>].TG9$/NQKP!2O?8JR6YL2:U:*SV\ \O<,&X Y-8MS8S1YE!\V,G[Z\ M_G52IX+N:W/R-E>ZGD&A*VP.5]R"MQ2=6T8IUN+;IZE:6RM+356W[#$Z_>4= M#74Z/HMO9EIU7EAC!K"5>//[/J:PHRY>?H>>M!,B[GC<#U(J.O6I+2"6,H\* M%3VQ7&ZGI^F:5=L9(Y)-W(4#@5K&=R)4K',JC2'"*6/H!71W.E7-QI5DH4(% M7YBYQBJ+ZRR96UMHX1V.,G]:M:M/-+861>5LLF6P<9IN]Q)))B0:5IT+9N+O MS&'.(^E$VLVMH2MG9H2/XGYK*,H1=J_G4#H/<5!1561-V7KRW1D%S!S&WWA_=-4:M6=SY#%'YB;AA2W=KY# MY4[HVY4T>0/N5<5+!P34=20\/0(?,/EJ"K MQJA10]1IV=R[J]A]@O2J\PO\T;>HJA7061&KZ6]BY'VF$;HF/<>E83(48JPP M0<$4D^@Y+JAH.#4BM3,4"F23%0143)BG*V*D&&H K[:7;4YC%,(Q0 P"@F@F MFDT (32444P"BBB@ I*6DH **** "BBB@ JUIG_(3MO^NJ_SJK5K3/\ D)VW M_75?YT ?8%A_R#K;_KDG\A118?\ (.MO^N2?R%%>6SUEL>._'G_F%?[[?RKQ MD&O9?CS_ ,PK_?;^1KQFN^C\"//K_P 1CP :"GI3"U3EH[=>V:BGNVZ*,51=VW^^*KU+"V'%(#J=,(!6ND63$8KD]/FQBNABG!0 FG$R MJVL2ERQI&AWBI(U5N:F( IR.79V,YD\KFEBJ#&:C9CCBJ,SL&ZU"&S4#;A44BBJ\$QVTKR$FK2+2LB,J W2I G'%.2/<,U M,J8K>.@6N,CC)J41'< *E0!:F0 D$=:ILI(OP6RI:A6YSR:PM>F^Q;64X0UT M'VF,0_,=I KB/%&K1S,L,:;U4\DU\WA98OZX^>]M;]CWJ\<-]67):_3N8%]/ M]IEP#RQQ1KLBO=QHHP$C Q^ I+*=)K^!#;KRXS4M_=1-?RYMT(!QFO>ZGEI: M&.AVNK>AS6XT4>GQ_;Y &EE7]TOH3WJ738+>;=<3VRK;Q\D^I]*L75Q%>VZS M&W3Y#M ]!VI-ZCC&RN.+=:I.V&P+=2:JY+1'9VS MWUY%:Q??D8 5Z[:>$]/2WB%U"LTP0 L:\[T,_8=5M[RYC2&-&&<]?RKV:!X[ MB)98F#(PR"*PJR?0Z*$59W///%7@F&*U:\TU"I7[T8KBH='O)",Q[,_WB!7M M>O7$=GHT[NP4E<+]:\@EED<$S3NX]&;-.G)M$U813%BT2))%^U7<<8]!S_*N M_LHX$LXQ!@QA>"*\OGN !A*TX]6NM-M[2)93\W+ ^AXKBS'!3Q48J,K6.C!8 MJ%"3NBYXPF6*\01 !B/F(KE6F+').35Z\NY8[R19@)48Y&[TI!:VE\1]EE$, MA_@D/!/UKLPU+V-*--N]CFKS]K4"#YI9!DR>@]!6<7CTB+RTPUXP M^9O[E3RN^H:.)R=TMN<-ZD?Y-0]7)/=WCW3;%X4-6&G3ZA)MC&$'WG;@"M*2]M-'C,%B!+<'[TY[ M?2G^(YIK"]DTV "&W7H$ZGZUSU:+WM3)^[HMQ\LLD\ADE:M&Q)5(_FP.,"L)48N?M.IT1JR4>3H>CS316\;22NJJ!GD MUP5_XCFDU"1H@K09PJL*SM1U">[NI2TKE"W"YXJB.:TC"VY$ZE]C;_M73[C_ M (^K!0Q_BCXK0O[2QNK6T5;KR?D^0/Z5RX0]36GK&/L]B/\ ID/ZTVM=!*6C MN$N@77)@>.9?56%49;.Y@/[R%Q[XJ.*>: YBE=/]TXJ_'KU\@VNXD7T<9IZD M^ZS,(]>*2MM-5L9N+RQ7)_B3BG&UT>ZX@N'A<]G'%%^XIJ.4;D9JK-& :3-*ZE33:HDFMKF2UN$FC.&4YK3UFW21(]1@_U6SUEL>.?'K_F%?[[?RKQD5[-\>O^85_OM_*O&*[Z/P(\^O\ Q&+1 M116IB+FG!V'0TW%."^]("U:SMO 8Y%6Y5SSG%4HMBG6DRD] ;R\< MM4>(C_%5=B]+Y<+='JKFC)HL!9^S G MAQ2M;!!RXJKN/K2[CZT 68T0G!JY':(QX<5F!B.E.$KCHQI6!,N7.G2Q?,%R MOJ*I;#FKUMJ$D.]#U!J[+;PSQ>;!CW%*[6X[)[&(5---7)(\9&*K,M5<1 M%4T,1=ABF MF1!F@1IVB"- 34C7^UL UFR7F!@&H8G+RC-.Y+C?<[&PNB MT8S5PR-69IH'E@&MD1KLJD832(-Q-12$@\5.5YXICID4G Q39$KDBH9$+-5A M5P:F$8(Z5#@:Q7.@RPCPON2#4CB2PMA9VP+W,PS*RCI M[5#>INEHA=0NT&VTMF_T>+C/]X^M,T^9Y?,@P26'R@>M.73H[>,27\P3OY:G M+&GQ:Q%;7""SA$29P7/WB*730.MV68+0HNZ]D$('\)ZFE>Y@";+6$ _\]&&2 M:S;R;_3'+DMGD$TZ*=*+#OV%EB>0[G8M73^&M2O+.VJD^U#>FHDE>Z,:ZM6M;J2%A@H<#Z4RW MM9+J=88ERQ_2O2HO#5K.UB^P6C J/]9(/XC66%+$ #)/0"IFA96.0WRJYQI.3L9-CH6I^7++]DDV&,XXK&9'1RCJ0X." M#7T&D0"V]OIOE7EK BS2G#.1S6<:MW8UG1LKW,CP[;&*T8RKL< MG/S=2*DUU[=+$^8-S9X% ME9>R3;:-_;.&%:1?0RDDW]$JD8J\G8E0DW9(K0PO/,L48RS&MN=(K*V5&.$7^'O(?\ "I;> M*#0=/,]QAKR7[B?W16%/>3<_3L!T%:VDM]D MTJ]NSU(V+6)707T0M=$L[;HTG[Q_UIOL$>Y@A2Q]34XB$:[G_ 5,/+B7(%5) M93(W/2F2*TF\UH:O_JK/_KD/ZUGV\3SS+&@R36]JFF3/;P,O)C3!%93JPA)* M3-(4Y2BVDVTFMNR.LOC$;,O_30 M U4.N.G_ ![6\4/H0*@?5-0NFVM.W/84FFQII=3T;3P%LDRJ+)_$$Z9JR&.: M\]T[79M*;R\F5#]X&M.3QD"5$<& ?O9K-P=S95(V*^O3 ZK+L(QFLKS 3R*N MZE#B7[1&2T,WS*:HK$S'I5K8RE>XRXB5EW"J++@XK7F@*P9-9D@P:I$-$6*< MI*L&4X(Z&C%*!5"-NZ U;2UNE_X^8>)!ZCUK% J]I=R;2Z!;F-_E<>HJ74K$ M6MUE.89/F0CTJ5H[%/57,W;2[:G$=.$=405]E&TU9\ND\N@" "E*Y%2E*0KQ M2&5RM,(Q4Y%,84P(2*2G$4E #:*4TE !1110 4444 %6],_Y"=M_UU7^=5*M MZ9_R$[;_ *ZK_.@#Z_L/^0=;?]LMCQSX]?\ MPK_?;^5>,5[/\>O^85_OM_*O&*[Z/P(\^O\ Q&&:6DHK4Q%IH MA2@T@'-S3#3^U-- #:*4TE,04444 %**2EH&.S111B@ JQ:W3V[@@_+W%08I M<4@-B95FA$R#KUK,D'-7=/E#(T+=^E5;@>7*1213U5ROTI0Y%/W(W!XH\H'D M&F2-R34T)VG<>U-6(YYZ4UW!.!TH&;UAJ&PC)K:&JH1C-<0KLG0U(+IAW--, MAP3.YBO$D[U:5U;O7"Q:FR$H5!)%2&_ M3H"*$P<2Y&HI9,"JZ7*[&&;U&/RJNLGO5B$B6PEB/5/G'TJE0AON:-I=D3(G7) K MH3K $-R,<* F?PKE+1L3AST49JXC$Z/<.3RTP_D:EHJ+L=%)>1/I]E<$\AL$ M^U9NHVJ"X+P-\K_,OXU!"RR>&I"0A;EC^Z;^^/2N<>&9&*NA#+P016O=WX@,$*]8USD=C7H&A>&K;5] M.BOKZ/$KC.T=QZTG+EU92CSZ(\[\+VJ7.MHLO11N%>CW&GVTD1+0H3CCY:LS M>"]/@?[;:!HI(AG _B]JXV_\67(\R%45) 2IKP\PPN(Q%:,Z+T_(]/"5J5"D MXU%JV\;7LIEO 6#<\5 ([$'!>1C[5H-#8:ADNWV>Y8]?X35>XTN>P?$B9 M7LZ\@U[L=DF>3):MH%-E$N51S]33K?4K2*[B8V:X##+$]*HS-Q57EF '4G I MN/,K,2DT[H]MMIHKFVCEA8,C*,$5POC>]1=1@6*0%U'S8-9-_J5UI]O;6=O. MZ!8PS@'N1S5*UT^XU#=6G;;<]8'BO1Y(?.^UJ!C.T]:\W\8>(UUN]6.#_ (]XONGU MKGVZU&RT1IJ+N.=5R5AIHHHS6AD*!S6C8Z9K06<-JBQPQA0HP.*\O,,R6$:BE=L[\'@7B$Y-V2/-_%5V)+Z.RB_U M-J@0#W[U@UTVOVNFIK$AFN"/[RKUK->XTN$XM[9Y1_TU./Y&N^A4YZ<9);G+ M6IN,VF]BG97XDD)Y9B: MO[0/2(CR,U,HK4TK2C>EIYV\JUCY=SW]A3;L0DV[%CP[;.UPUPP"P)]YST%= M0UQ:B/5:IP .K>YJ.$O/:O!N)(&Y1FN&O@U6FIM MV.REB?9QY$KFGJ;:G;$RPE/LYZ/"/\*PY;NXFSYD\C?5JL6>IW-GPC[D[HW( MK0":9JPX(M;H]OX2:[$N70YW[VQ@T5=O-+N+%\2I\O9AT-5A%D\&JN9V8Q06 M8*HR3TJTZBU38.93U/I5M+>/3X0\I!GII7*M8J*I;H,U M,EL[=1@5,;F-!\B"H7NW;OBC46AOZ2T4MNUA<,#GF,GL:JRG[-*T;+AE.#6/ M'.\<@=2=P.16[.ZZI8B[0?OH^) ._O4M69:=T57E\U"*S7 W$&K2/M>H[F/# M;QT-4B65@E/$="BIU7-40-6.MNR7^T+!K1^98_FC)_E6RU"PJY(E5W6@97(IG>I&%,- #324&B@84444 M%%%% !5O2_\ D)VW_71?YU4JYI?_ "%+;_KHO\Z /KZP_P"0?;?]O^85_OM_*O&*[Z/P(\^O M_$84445J8A1110 X44"E(H :#244@$HI:* $I<444P "G4@I:0"T4E I@/I M*3-(32 GMWV3J?>K%\H8[Q5$'!J?S]RX:@?2Q6)YIR,0>*<8MW*G-/@B)E ( MH$32MB$>IJJ.M7+A< "JA'-)#8$Y%,I^*;3 4:E_M%)/EGB#>]988^M+NSUHL M%S1)MG.4FS?.+^\#_WQG\: Z$<9VPR/^%77'EZ M'%_TT;/Y9%9[G;"H]>36A>';I-C'W )_4T,:%TPE[:\B(RH0-^M=%X/\.I>V M_P!LN23&> OK7-:0V;MXO^>B$?D,UT/ACQ5#I4+6=V#Y:L=K"O/S+ZQ[!_5] M_P ;'9@?8^U7MMB_XB\*PP@7ELP0*1O#=,5Z/XI0Z;I$NRT7.XM_'@9)K+ 0Q+PZ6(W\^W MF;8J=%5KTMOU/9+^6*UMGFD;$2*2QKP74?L=_JMS-'>B)6H2WE^5FG+'; M;CH/3-8E[J$]\^9&VQC[L:]!5S^U[>1W-Y8))(3\S@X.?RIS?V%.F5\^&3\2 M*:TW)EKLS''%7;*3DQGH:F.EV\G^HOXV)_A;C^M1-I]U;.&PC?[C9JKID\K0 MP6EQ<7)BMH7E;T49J6YTG4[*/?<6ZO<^9%Q(P55)8] !FMW3_ K=W*^==,EI M;]2\IQ^E:_B"YTWPOJTMGIM@K7"G/FR\@?08KE]4U>^U-@;NX9QV7/ _"MDV M]C%J,=]3>&IZ%X??%C"U[=#K,_0?3I6[;^+H)]*EO?);,1 =?K7F5;VD?/X? MU1?3:?YUR8G 4<0U*HKM'10Q=6E>,-F7M8BM[E/[2B@$\,G+LGWD^M8B0Z?. M<).\)]9.?Y4FE:M-I!^)(VZ,*T]3T>WN[0ZGI'S0G_60_Q1G_"NN*4% MR]#G;Y_>ZF>VE2'F&:.5?4''\ZB>QN8A\\+8]0*IH2IR"016C#J=Y&H43LRC MLQR*K4C0M:5>"WW6MR"UM+P0W\)]:AU*Q_L^;:OS1MRCCH12_P!J%C^_MXY/ MH,5J6NH:9J4"Z?=QM$2?W;YSM-+5:E:-6N.BMQ^M M59-(O5=5""3<0/W9W52:(<6:<(%IX0FF/$EQ)M'T'_ZZYWM71>)E:SALM/"D M+'&&;ZD"JVDZ2DL9O;]O*LX^>>K^PI)V5RI*[Y4,TK2A<@W5T?+M(^2Q_B]A M2:KJWVS%O;KY5I'PJ#O[FDU35WOL00KY5HGW(Q_6LRFE?5DMI*R'+UJQ#*8; MA&!XS@U67K4C]:9*)[Z'R;IL?=?YA^-5LFKTBFYTQ9>K1':?I5"A#>YI6>L7 M%L/+D_?0G@H_-;,-A8S(+NWQ%.PRD#GC/K6+9VJ)$;RYXC7[B_WC56>[EN)_ M.9B&'W<=A4M7V+3LM26]CNHIV-RC!B>IZ56W&M.#6W*B&^07$/3G[P_&I9-) MM[Q#-IDP;N8F/S"G>VY-K[&-FDITL4D+E)$*,.Q&*95$BYK4T=VBF,A/[L\, MOK5"*WDFY5?E_O'I6E9&&)#%N#O^E2]BH[EZYMH5DP%^1N0:J^4 QC;D=JUB ML;:9',4SL.&J@OV6YG^24HP]>E2BY(HR6;1G(&13HX_:NBCL?W8PZ2GT!IK6 M29^:%E]\52D9RC8R8XZMQQU:-B ,I3DA*GD51C)EC3F4[K:3_5R?H:BEM3!, MT;#I3U3!!Z&M&11>6H?'[V/AO<4MF%^96,@Q4QHZN;*:4JKD%!XZJR)6FZ55 MD2F4F96SUEL>.?'K_F%?[[?RKQBO9_CU_S"O]]OY5XQ7?1^!'GU_P"(PHHHK4Q" MBBB@!PIZ\U&*>N!R:0#C$>HII4CM4JS8[5,DBN<'% RD:*OM;*XRO6H&MG7M M1<+$&**>4(ZBFD4""DI*=3 **#10 F:2EHH *6BBD Y3CFKUJ2>35 "KD3;8 M^*3*0Z8Y%XIK')J,F@!P M:D)YI*2@!:!12B@!R#)I[G HCP#1)R?:D,CS4JL<>(ER1. G.3]!B MK^JG:UNG81@UT'B3PD+:9)++:(W."K,!BLS4M.9IT\R:--J =<]JK#XB%>"J M0V8JM"=*3A+VC"AB"SI_'6G/[UA*G[MV<)J%_%'"+&PRL*\.XZR&F MZ0IBAN[OH$3:I]#_ )-99K2D=K?0(XAQY[Y;_/X5?D0G=W(+.8?:(VEY&X%L MU[#9/#+81%64(5&VO']+M#>780\1+\TC>@J[>ZU.UT/L\K1P1_*J@]0*\W,< M!];Y;2M8[,%B_J][J]S;\20O-J3OIP@? PQZG-(QW* M7<9(2<;@0>A]*6TU[4+9A^^\U1_#(,BNVA3]E3C!:V.>K-5)N3TN9K'YJN:1 M-Y.JV[GH6VG\>*NG4M.NWS=Z>%)ZO%P:T=)T72K_ %!7M;PA4(81RCG\\5HY M::F:CKHS!U:W-IJUQ"1T\E7J%/R@_6NYU"\@NK.2Z@N6E5!RA//Y5Y=.XEN)) ,!F)Q1%N6X22C ML>U>!_&UC?Z]?-P)!R"0?:G, M[O\ >=F^IJ713=RE7:5K&SKSW%]K$U_+\T?9'S(6[=UK1.VYBUS:HS*W_ ^-VEZJG_3+/Y UD365Q FYT(7U MK9\+C?%J:9ZVSG]#0Y*4;ICBFI69SPJYINI7&F7(F@;C^)#T852Z$\T9J]S- M::HZB]T^VUNU.HZ4H68E-T-)SK M,41=P$)+#/I3+/1-4N75H+9P0>"W'\Z[73M!GTU)M3O8E,R1']VI!)IRDD5& M+;N98FDFO;G4M0*BR1B$5E!+XZ 5G7WB&WU)?)FLE2%>$V$C ^E9FIZI-J<^ MZ3Y(UX6,=%%4::CW)E/HC1C@TV=MJW#PGUD'%+)I#YS;SQS+Z@UFFE!(Z$BJ ML3==BRUA=1GF%B/44R52N 00:E@OKJ+&V=L#L>E6VUAI0%N+>.0#CI1J%HEW MPUHUUJ1EP-MLRD,Q]>U7IO \MKF9I@\2?,RCJ:[/0(X!HMN8$"(1G K0=000 M>F*P=1W.F-)65SQ:]NWN9B,;47A4]*JU>U@(FKW(CQMWGI5&NA;',]Q1R< 5 M,HGMR)%WH?45:T:))KY0_..@KJKBTA6W)F0$8X%<=?%JE-0L=%'#>TAS7,*S MOOMZ>3?6WFIT\X#!6I'T>W@5I[9OM8'\ [?6LJ[OI96,:X2)3@*M06]S-:R" M2&0HP]*ZK=48\RV8^XN9GI@)J$8CE[3)_6J] MUH\T"^;$PFA/1DIWZ$M=47-'F>Z@N;)F/SKE?K5!,PY4_>SS3],G%I?Q2=P< M'-2ZG%Y.HR@=&.X4NH/X1(99%;*NP^AK7M=3NH\#?N'HPS6+$:O0GI561FVT M=)#JD$H FM@#ZK5M(+.Y&8YMK>C5S$)(P":TK>UGD^ZA'UXI-)$<[;VN6WT MZ93\@#CU%+:1RQ3\J0.X-/CMWAP7N!'[ YJT+R,@1^87/J:QK3DJ;<=S2E&+ MFN;0JSV0PS)]<50([5MD@ DD8K(EP9&(Z9KGP->=2ZD;8RE"%G$K,*K2+5MZ MKR5Z)QF=*M491Q6E-5":AFB,^056:KO^85_OM_*O&*]G^/7_,*_P!]OY5XQ7?1^!'G5_XC"BBBM3$* M44"B@!0*":*2D M+FFT4P)XYG3H:NQ7 E7!X-9F: ME*9=PYYH!'8XH$1E32BK /7!H:'/2BXRN:2GM&R]130*!"8HQ3L48H ;2T\ M(6/ J9;8]31<=B!5)/2K"J57FE8K$/>H3,6-(8CD$\4B]:;@DU,D9VYHN%B- MS41-/<8-1YH 4'!ISG(J/O4AY0&D!'2@$FE5"QX%6XXA$NY^OI0V-(1%\M,G MK4;MGK2R2;C[5"6I#$)%-%!.:2@0II,9I0,TIP*!V%'%%,SS0#0 _)%)N)HZ MT8Q0 NZFDTA-)F@!#78^&/%XL8X[&Y0LN<(P[5QIJ2W.+N$^CC^=88C#4\1# MDJ*Z-J%:=&?-!G9ZSJ\7B#5%L6/D20RX3)X;GO7,:P)(=4ECD4J5P,'Z5)<( M6\2,3P?,W#\ZFFOXM1EDM[W 8'$I!I>MW6E M.3"05/53TK9U'Q-=ZAIL,H*J(VPR'D'TKF+BVEM93'(/H>QJU9@R6T$Z;=P M'N*U:6YFFUH6E?3M3D5)%^RSMP&7E2:DUW3+J"2*)$\V.- -T?//OZ5FZ;&) M-0BW=%.36GIU[.E[<:D\A\E#G8W(8^E)Z#5FM2O.3IFFK;*P$\_S28Z@=A68 MIXQ6S+J&GZS*\EZAMKACQ(GW?Q]*J7.C7-NHFC(GA/1X^::?<&K[%FR!U+29 M['@RP?O(\^G<5B#.>>M6;&Y:TU"*4$C#8;Z'@U9UNR%GJ+;>8I1YD9]0>:-F M)ZJY0J:TO)+&X6:/J.H]:AI#3).MM]?DUBTETS C=U+(2>_I7)O&8Y&1QAE) M!^M$4K0RI*A(=#D$5KZQ''=0PZG;C"R#;*/1A_\ JI;,IOF1GVUY/9S++$Y! M'4=B/2M"ZLX]4A^VZ>G[W_EK .H/J!616WX3G%MK\+,>O '8FF^Z%'LRC)HF MHPP>=);L$QFJ*@L< $GTKW&^CLH[0W,P'EL/F7L*\QE\0P6EQ(-/L(5&>&89 M/ZU$9N70N<%'J9MOI&H72?NK24C^\5('YUT7A_P]=6EV&N;F"(OP(]X)/X5S MUUXAU*Z)W7!0>B#:/TK<\/H=+TR?Q%?LSG&RV5SG+>OZ&E5BY0<>XZ3C&2?8 MZO4-$TA6,,]T$9QT/ S5+1M%M=.N[H):.\;0/F16W C%]TRV3?_861[M_]:K%OKD&H:G+;WUE$)5=E61!@]:MZ@UMIX? # M$#^+M4UL1*%10L%.DI0NA000]Y)F 'ZBNCMKG1[6V$\,44)Z%Q M@!C[5Q>FP2ZBKZEJL[1:=">%'&\^@K)UK6'U2Z!4>7!'\L<:\ "MJU!5X.F^ MI%.LZ34SO=3UBQ@MGEEV29'" ]:Y&3Q7,HVVEE;0#U\L$USY=FX9R?J:3.*C M!X*.&BU>]Q8C%RK-.UCJ-$N]4UC5$26\D6WC^>3:Q K4;7+A[*\U!'++'-M M )X*\#%9O_($\)9!Q=7Y_$+_ )Q4&G_-X/U >C _J*Z6D]3--K077M.AGB75 M]/'^C2_ZQ1_ W>N?Q6MH&J)9SM;77S6]1:SI;Z7>;0=T$GS1..A%6 MM-&925US(S\4"DS15$#\X%/AA>XDV(/J?2FP0O<2K'&,L:NSR+;H+.W.6)P[ MCN:+C2ZLZ/1/%"Z+;&W<&6!3C=GG/M4VJ>/5FMFBL82K,,;F[5Q]WB/9 ISM M'S?6JPJ.2+=S3VDEH*[,[L['+,AJWJ%F;RVMYHP"0-I: MLC2[9[R18E&,?>/H*Z&^:$V<$4;%4Z @]36;T9JM5J9<.FI&P.35V) MM-@/ >8_D*PY5>.=E?.1ZU/$W2KL8MVV1T2ZG@8A@C3WQDT\7L\G60CV!Q61 M$U6XWIV1A.3+P8MR3FG U75ZD#4B21JK,:!C#3:4TE "4444#"BBB@ J M[I/_ "%+;_KHO\ZI5=TG_D*VW_71?YT MSZ]L?\ D'VW_7)?Y"BBQ_Y!]M_U MR7^0HKRV>NCQSX]?\PK_ 'V_E7C%>S_'K_F%?[[?RKQBN^C\"/.K_P 1A113 M@M:F(E%.V^]&V@!M%.V$TA4T )11BG!2: $YHJRMLQ7.*/LCXSBD!6I:>T3* M>12K"S=J8#0Q'0U*DY'7I4;(5/--Z4@-%)(Y!@X_&GFU1NF/PK,!.:GCN'3H MU*Q5RT+!B>*FCTPGEJ@34I4QT-;-I-]J@+?Q5+;12293:&&W7G&:H3W(Y"BK M\\+ESN'%4I+<9ZBA R@Q+')I!UJPT'N*:(>>HIW%82-,GFK> J4Q451]X4CG M/1J3&BM+C-0&IW4U$5-,0RKL$!DA]*9#;;EWFKJ@I;,.])LI(A+16XPHRU5' MF9SDFF,>3FFDT *6IA-%)0(6E%(!2]* %)QTII-+FCC- Q #3@M/51C-!;G% M*X"'@4PYK7L]--S"7 I(M)EEGV["!FLO;Q3L5R:&9'"S@G%,8;3BNWAT)8[4 M@+\Q%<[?:/-%(QVG%1#$*4K#<=#&/6E1L2H?1@:E:UD4_=-1LI0\UNI)DV-J MX!77(F/&Z$-^8K%<[I7_ -X_SK>OV$D]M/C[MJJ_D*P=PW$^YH14B[;W8,?V M>Y&^,_=/=:6)6M+Y"/G1N 1WS5,:JW\H14M(S\D?WL=S7K^N:5;7&E3[ M8D215RK 8P:\B_LZ!23+?1@YY __ %URY=F$<;!R2M8Z,9@Y8:2C>]S.Q5FU MO;BT;,,I7U&>#5]$T*)?WLL\C^B@XI?[1TR)2L6F[SV9G_\ K5Z-SCM;J2)< MV6J%(KJU:.X9@!-$.I/K7M&B^ =)_L.VCU&/[5(%R';L".E>*IXCN80%M[:U MC Y!,0)_.O4?"WQ1M9=(*:E"PFMDRS*.& %95%*VAM3<;ZG(?$+P4GAR[CGL M0S6LW1<9VUPA!'56'U%>A^.?&EYJL]O/9JHL /D)& M\+P:'>ZHA"2+*O(5NE9XBLJ5)U&MAT:?/444]S%_X1O5,,1;,54X'O4DL:Z) M;X;!OI!_W['^->QX!7@=J\>\7!1XAG 4J>^1UKR\LS2>,J2A*-DCOQV CAH* M47$=2AEG=GA8.,GMC_Z]KWB;5%N[M+.V.+.U&Q% M'0GN?SS4OF_V%H1B7B]NQEB.JI_DUSOUH6KN#T5BSIMXVGZC#2\0VC,YSW.?_KTW3+*35IY=1U.5H].C.XEN-_L M*ZRXT**"QN3<3".WEE,MPV>2O/ _2N'U_7O[29;6U7RM/AXCC'&?GK6-1170E8YFVW=A6GH6GG4]6A@( M_=YW2'T4=:S#75V/_$C\*S7CC%S>_NXO4+W_ )TI.R'!7>IF^([Y;S5G$1_< M0_NXQ[#BKFE<^%-3'^[_ #%Q]*YL=*B)BS7:9^&;T'H*\^CF5*K M6]C'<[*F!G3I^T>QCSNEA";:W8-(?]9(/Y"H;%0@DN9!E4'&>YJJ 2?4FKUX MIA@BM5[#<_UKT#DOU*+.78L>I.32*-QQ04(I8SM?FF068[<2,% Z]Z=>%440 MQ?<7J?4U);2B-\-]UN,^E%]:/;J#C=&WW7'2E?4NVAGT#(((ZCFI%B9SP*O6 MU@&8&1@!3;)2;-*[MQJ.FVM]TV#9(?I69)=1P_)"H^M;UJHFLKG3T^Z4+J?< M5R3@J[*>H.#41+EW)VO92>M-$\LC!0,D\ "H*W=%LQ! ^IS+D)Q$I_B:J=D2 MDVR62;^RK!;9I!)5!9*>):#/E+OF4TR>]5? M-]Z8TM!2B3O)[U5DDJ-Y:KO+06D+))521\TLDF:KN](L;(U0,:O^85_OM_*O&*]G^/7_,*_P!]OY5X MR*[Z/P(\ZO\ Q&*.*,T8I*U,0IR@FD"DU32\ $BMK[.L;Y I9" .*M1,G4*4-D- MN,5,+- ,$"G"8(:E$H;FJY;$N392GTQ6Y J)+ *IXK3:;C!IPVLM+E#VC.5O M8"C\"J6SUKI[FU$C50DTTYZ5+C8UC--&2(\]*40,>@K4;3]B9J@[M&Q%0S1- M,=#92.P'2MRTC2S4*6!)ZU@K<-GJ:L+<,<9-2[LN-D6=09PQPW%9#R-G[QK1 ME?S$YK,E7#&A Q-Q/61057H*TISDGH-*^AP<\4O]FQN8V&( MV7./05SX_6O>QI<5S8%1"I49!&*\U\1Z7;^'[X26UN97DY&1\JFO0IU.;0)T M[:G/VVFLR^;-/("H/"KCA1V%%2G&K%PFKI[A3FZ34X[G6ZK\0Y M+NT,-O;A-W#$US(@L=2)9'%O.?X&Z$^U9X -)L'8U&&PE'#1Y:2LBJV)J5Y< MU1W);BQN+1L2QD#^\.E1$5H66J7%H"AQ-"1@QOR*M&UT_4EW6L@M[@]8G^Z? MI71?N8VOL8E;.DKC3-0D[!,?H:SKNRN+.4I/&5([CD?G6KID4W_"-ZBZQ.P) M49"GWI/8<5J4-.U'[-F"8>9;2<,I[>XINHZ>UG('0[[>3F-QW%41QP1@UJ:9 M?HB-97?S6LO&3_ ?44;:B6NC,RI;>YFM)EFA<5UOB*[TJTTV1]2V&(]F[T.;4BE33B?.EQ)<:C=-*$ M=\_= '059@\/ZM< %+*0 ]R,5WLNO:6ZE;"]M[12,#]V3ZYK2L_"]Y8Z6[V]] )YC\K;P./Q-+ MKJ"/1)HY'&YQA5SUKRBNKN?">M7!W2W,4Q]Y5_QJJ?!NL#I%$?I*O^-&7X58 M2ER.5Q8RM+$3YN6QS]%;4GA368_O6F?HX/\ 6I]*\*WMS?K'=0-'%U8FNRI5 MA3@YR>B.2%*/2M.&QL;.:-7?[7I-FNYPO30D\PT;\U'B MCO3))?,..M:&G:FL)\BZ7S+9^"#U7W%96:,TFAIV-G4]-DLU%S;/YMH_*NO; MV-9JW#C^(U=TC6'T]S%(/-M9.)(SZ58U;1DCB%_IS>;9OSQU3V-*]M&4U=7B M0Z?J36UY%(6X##/TJ]JMA#_:!*\)( X(]ZYY$+&N@E9[S1H/)RTL;;#CK@T/ M1W''56(M/T^*XO?+7YD3YG8] *9K6K?:;@06WR6T7RH!W]ZL:C*-'TU=.B/^ MDR?-.P_E7/4)7U"3LK(O6UVS?NY#N4^M:%HN=&OT'8@_J*Q(03(N*Z2PC1K2 M]3<,F,''XT2%'4YM34\,K1N'1B&'0TSR@/XA0 H[U1%C>)CU2W\V/"W2#YE' M\545?R]1MS=VZ@3+_K$'\Z6PVN8KB6G>=5'S>>: M7S:9%B[YOO3#-[U4\VFF2F%BP\M0-)41DJ-GH&/9ZA9J0M32: %)IE&:* $I M31BB@8E%%% !1110 5>T?_D*VW_71?YU1J]H_P#R%;;_ *Z+_.D-;GUY8_\ M(/MO^N2_R%%+8_\ (/MO^N2_R%%>8SUD>-_'K_F%?[[?RKQBO9_CU_S"O]]O MY5XQ7?1^!'G5_P"(Q0:D! '-1BES6AB+N/:KUA$7D%457)XK>TJW.02*:1,G M97-J"V7R1FIP!$O%(&V*!3&8MTK2UCFYVP\P,>:KS''2FS[E' J!&9N#4W'< M7RVDZ5-&A08-/B^0=*;+(2>*.87,+)TXJ)9&'%31$'[U$B*#D52D5:Z'1J6Y M-.(4'FB.10F*KRR_-P::U%*(^ZV^40*YJ\0AR<5T<8\TX-9^IVX0' K*2U-Z M3T,$'FIT/RU"1\U64'R5FS=(%?G%)*N>:8>&IS-E:0RLPP:3%*QYIM,1,@RM M,=>:DBZ8J3:IZTKCL5DC9V JY-(L,(C3KW-1%_+&%J MGK2&,)RE/C)+C M'K6=17B5'<["V*Q1%H^E:>F8N"2]8MLY6U4&MFPC)B_=GFO+D:LUH+!(Y?,% M/FO8(6VEAFI+1)!"5?K69*R7#Q2\+P:TCH:Q MT/2X-8AM(V)G3RS]X;NU<3XF:\U34X9--D\VS/!;KL]@_2NFC)WT+D[K4S=7\2.&%E9)%]EBX.4!#MZU MEMJ\DGWX+?\ ","I-5TH6P%W:MYMG)RKC^'V-9>178DK'/)N^IJQ:C;'B2Q1 MOHG/P=/*^X?\ ^M6,&J02$4["YC79=+?^&5/IS4+0:3VFG!_W3519 M>]62!F"E9ESQGL2>*]]L-%TRTTZ.WM[.'R"HX MV@[J^:&TC4(XANKZ MXDEO\7'F'+;OZ4P6EE=D&TF\N0]8Y/7VK5)I:LR;3=TCI[7Q)X;*1V(TIFC! M^1YFS@_B.E4-1\57MC.T,&GV=NO\)$(.1ZYKF[JRN+0_OHF4=F[5=M+B+4;< M6-X^''^IE/8^AHY5N',WH2#Q9K,D\0-[(B;QE4)4=:AUN[N9-3E#W$KJ>1EC M5"XMI;.X,4J[74_G6GJUN9WL6A&6FB497*Y78Y^*6Z9ML4DK-Z*2:V++2?$%TP*O- O]Z5RH_6 MK7_"0-:*4TW3XH%[,PW']:R;N_U.^8F:XD.>RG _2GJQ:(Z)8(-+&[4O$4KL M/^6<#D_R-:^E^(X9UP[FMC7[JW MM(8]+L6Q!$/G8?QM656E&K%TY:W-:=64'SQTL=/>^*=/BM':*;;7M] M/=3.SRNP8YP34,DF>!4=98/ 4\(GR:W'B<9/$6YN@J,4;<.M6A> #E>:IUMZ M%I(NW:]NODLH/F=CW/I7:VENO4MS M6W0T?[#U!;P6SV[HW]XCC\ZV[3P?+YJR-(I"?,P]?:M?P/JEQ?1/:7*BX1>[ M#D#ZUTNIV\5BHC@)_>:P0HK2+T,9*S+>E:>=2NQ$#A1R372W/A2U^S$Q%@X'4]ZJ^&K%[;?J5PP MALU'+-_$?:NBU/7K>RL()DCWK,"4![UY&-EB_;)4=OZW/1PL,/[)NIN>;2H8 MY&0]5.*9S74F^\/W[%KNSD@D;JT9R/U-1/H>E7))L-50'LDO!_2O64]-3SW# M^4YP+FM/2M4ETR7^_ W$D1Z$59E\+:FB[HD6=?6,YK,FLKNW)$T$B?44[IBM M*.IMZGI<,]M_:.E'? W+Q#K&:N>&D^PV!(,_C5:,P \\UI?0R:U%MT$2&5A]*N:/*9)[E2?O1FJMVX>)2G" MCM3M&?;J&/5&'Z&ET&MT9Y)R11FB0;97'H:;FJ('@XJU9WDEI.)(SR.H]15/ M-31PS-]V)F/L* 1KWUO'=0?;K,*T@<]=V0PR%GQ5GB-*4V8*2W!I8Y#@XI-D8Y&*R]S!JE65@>:Q9I>Y=+@57:12](Y++ MQ55U9>:$.URVSCL:9YA[FH(7WG%3-$P7-:Q8TFM!#(Q/%+L9AFFQ8W?-5SS$ MVX%:7*Z"6BG>,TNHVWF)P14L*'.145ZS%>*B95-ZG.O8RACA<_2GK"R+AE(J M[#M>2V2ZM"ZJ,XKG;.Q(Y21,&HR.*NSPL'(QTJNR8'2BXK%-Q@T MRK$B5 1S3N*Q+">:D)-) F#D]*>[ 'BE!DXK5TZU4,'?!JBUM(I^[4D,T MJ.%R:RK)M:%0MI/K_*N:N@MT7G9MTC')-7M9OFU&4OTC4;8U]!7/><\;D9XKHIQ M;V')JUB_IFI&R=K:X&^SEX=#V]Z9JNE_89!+"WF6DG*./Y&J8VC&":/M?A71/^/6!]3N M!_%)PF?US6[X;UO4]2F?4;@0V6BVP^<(FT$^GN:Y<8JDZ$HTM&UH=&&Y(U8N M>J.YDBC:W>-D79M(QBO$=4M9$U2Y6&%S&'.W ]Z[6Y^)%M*Q@MX& &<=8G'_ M33-KKR48?A5C^U;S/S3,W^]S5N+7KJ,P M?\\W'%6Q;Z9JAS;2?8YL?,G^ML;5O]V,+2QZEII8&;2PW^[)C^ ME(K3N75TV?4(!9W*8O$'[F4%="F&A:M!=LD:R1ANH)&#[5'J4CZC<3'3M4BMUW$>60$/\ZM^ M$]%U6"ZO?M'[Z*:!@'5MV3@U4GH1&/O',HFCV?RB.2[D'?M4B7NHR'99P+;H M>!M'-4DT_4(+AU:!X]K$?,N*Z3P^/-U&.&28,4&]P.@ IO0E:NQS9/Z?I6*;*S@'5:I:]XHGO]2G9#A-V%^E8+WLK]7)HC%V"4E?0Z M1UMCP'6H&6+<$C&]V. !7/>=;O@"[#%M$W\1]:IZ$K5EF_ MG_X1W21;1$?;[D9D(_@7T_6N+GD,DF2]EEN_,NIFW2R')-8K AC3BK$S M=R(TM+BI;6SGO;I+:W0M(YP *LBQ9TG2IM6O5@B&$'+N>BBM'7]5B94TO3_D MLX.#C^-O6K.J7<6A:;_8]BP^T.,W,HZY],URM2M=2W[JLAU:>D:--J;EF(AM MEY>5^ !5K2]"4PB_U5C!8CD9X9_84S5-9DU)DLK*/R;13M2->-WN:+WT0E&V MK.CTC4+>VNGCTY?+L;9=TTIZR'_.*IWOC<74KR+ PK.U65=,TJ+2(L> M:?FG8>OI^E<^!R !R>E)13U*E-K1%BZO);RX,TQRQZ5O:/H\,=O_ &GJS>7: MKRL9^](:73M)M=*MQJ6M#!ZPVQZO]?:LC5M6N-7NC)*=L8X2,=%%.]]$3;EU MEN6=8UV3590JCRK6/B.(= *N^(90++2XAVA)_6N:')%;WB@>5/9Q_P!V ?KB MG972"[:;9D;A321VJ+=1NJB"U;WMU:,&@N'0CT-;5IXHU:65+=MER&.-KKFN M

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end

GRAPHIC 15 krbp-20210625xs1009.jpg GRAPHIC begin 644 krbp-20210625xs1009.jpg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end GRAPHIC 16 krbp-20210625xs1010.jpg GRAPHIC begin 644 krbp-20210625xs1010.jpg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end GRAPHIC 17 krbp-20210625xs1011.jpg GRAPHIC begin 644 krbp-20210625xs1011.jpg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�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end GRAPHIC 18 krbp-20210625xs1012.jpg GRAPHIC begin 644 krbp-20210625xs1012.jpg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krbp-20210625xs1014.jpg GRAPHIC begin 644 krbp-20210625xs1014.jpg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end GRAPHIC 21 krbp-20210625xs1015.jpg GRAPHIC begin 644 krbp-20210625xs1015.jpg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end GRAPHIC 22 krbp-20210625xs1016.jpg GRAPHIC begin 644 krbp-20210625xs1016.jpg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end GRAPHIC 23 krbp-20210625xs1017.jpg GRAPHIC begin 644 krbp-20210625xs1017.jpg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end GRAPHIC 24 krbp-20210625xs1018.jpg GRAPHIC begin 644 krbp-20210625xs1018.jpg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end GRAPHIC 25 krbp-20210625xs1019.jpg GRAPHIC begin 644 krbp-20210625xs1019.jpg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krbp-20210625xs1020.jpg GRAPHIC begin 644 krbp-20210625xs1020.jpg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
4#QI>^,_AAXJEO8D0VN8UV]QAO\*L?#C4;_ $OX/_:M-@2:X1CA7; Z M_44 >S45X?I'Q<8Z_G M0!ZM17S_ !?&/Q=J&@G4+'1D:*W;]_-VQ[/Z!XU\?\ B">.[BT:./39_+XUT5_%!\.BX_XF 7=LQQ70UXSI_B M.-_C$;*XTJV2X6!6DN>=PX&>]1WGQ3\2:YK5]:>%=+2:"QSYDC_Q8_&@#VJB MO*-#^*\VL^$=3NC:B'5+!A]^MKRPV,5G':1KN#S-R_X M T >IT5Y/X:^*UQKO@[5;YK=$O\ 3U)*C[K<'W]JYA/C#XOOM";4K'14:"U) M%Q-VZ]N?I0![_6%XH\6Z9X0T];W5&D6%F"C8,G-<:WQ;@B^&\7B1[;_2)#Y: MPC^_Q_C7E7Q!\5^*M>\)0R:UI:P64[AX95_3O0!]-V%[#J-C#>0$F*90RYZX MJS6#X2;;X-TYAU%L#^E>5/\ %GQ1=:SJNE:7I*7,]JYPP_A4>O/UH ]SHKRS MP-\5FUG2-4DUF 07.G M(%Z'&?\ "N:E^+WB6YMY]:L[&U72H7QL=_G8>H&: M />**\=U[XO74-EX?O=.MT,6I.JNK=5R>>]:OC/XA7_A[Q'H&GP0QM'J!42% MLY&<=/SH ])>>*-@KR*K'H">M25\R^/=9\2?\+0L]L9$B$&WB#?*_'?FNW\4 M_$[7?"G]CQ75BAN+F(&6,==QS@#F@#V.@G )KRR#QEXP?P=+J4VE16]VTN(T ME; "'/)YK*\)?%O4;OQ7'H.LQ6[-.=J2P$X!Q[F@#T"S\?:)?>(KG0X9)/ME MN"9,J-HQUYS[58T'QGHWB2]N[33K@R36K%9 1W_R*\>\,-Y?QNUU\ [4"_$UQ)OB=JEKJT&@:1;0MJ0CW3O*V%0\\=?:@#UNBO.?AQ\1)_%-U=Z M5J4"1:A:GYBARK#GIS[5Z-0 4444 %%%% !1110 4444 %%%% !1110!1UBZ MN++2+JYM(3-/&FY(Q_$?2O$/$WCG4]=TZYTF_P#!<\MTWR)(4)"GU^[7OM1F M"$OO,2%O4J,T >#:;X URS^#-_9R1M]JF?S5M^X')_.IO#>I:KJ/PEUK0)M( MN(9K:V9$+*?G.>PQ7N_6HU@B7.V)!GKA1S0!Y3\.],U6T^$=W:PQ/;W[;M@8 M%3G%>/\ ]CW\F@WUE=>';RXUKS"S7;J2 OMQ_6OKE55!A5"CT Q3/(BR3Y29 M/4[1S0!X%XM\-ZM>_"30VM[21I;0YDBVG<.O:DU_3=8\?_#RRN(M,F@N=-8! MH7R#(!W''O7T!L39LVKM],<4)&D:[415'H!B@#YFT&PTBYOK"VNO"FK?:E=0 M[LYVJJ:-KW@?XE#Q#IVF27]I-&%V1C) P./;I7O@@A5MRQ1AO4*,U MP7C'P9X@UC5_M^D:[):*5VF''R_6@#SGPC?WNL?%S5+N[M3!-);N?)SDK\IX M-/\ !'A/4[^Q\8V,MM) ]UGR6=2 Q^;U^M>B^ _ALOA6]N=3O;U[W4;C[\C] MJ[U8T0DJBKGK@8H ^?? WBOQ!X"M3X>O?#MU/ME(22-2!C)]C7M7B"P?7_"E MU:)E'N(> >QZXK6:")VW-$C-ZE034E 'SMX(\0>(/ALLV@WGA^YN4,N4DC4X MY/7.#6II-CJ-U\;8M5>PFB@DB#%F4X'"\9KW)X8I&W/$C-ZE032B- VX(H/K MB@#P_1M%U!OC9J\[VLJV\RLHE*G;RI'6L?2GU[X7^(M9A?1Y[VWO2?+DB4GU MQT!]:^B!&@;<$4-ZXYI'BCDQOC5L=-PS0!X!X6\&ZQ%X7\3ZU?6KQ3WT;^3! MCYB"<]*AT[P9J^J?!V2VCMGCN[>Z,RQ.I!88':OH?:"NW QZ8I%14&%4 >@& M* /%_#'C/5M9TF/PE?:!=02-;F W!!"CC /2O/(/#A\-7]Y8Z]X>U"\S(3%) M;L0I&?\ =-?5(@A5]RQ(&]0HS2O#%(O3/K7O04*,* .PI'1)% MVNJL/0C- 'A7A#1]9\4?$2X\6WEC)96JH0B2 AB>,?RJ[\(-+O['QAK\MU:R MQ1R,=K.I /(KVE45%VJH5?0#%(L:(25103UP* /,?CQ_R3]_^NJ_SKS9_$WB M#5/AS;^%(= G9YU"K.JDJ5_+Z5[?X^\(GQGX>;3%N3 2X;?C/0UI>&]"30M# MM+!BLKVZ;?,*C)H \(\7>#-4TSP?X6TZ.VDGFBE5Y@BD[>37<_$[PA?^(/ F MG_V?'NN;,*_E>O3/\J]49$?[R*V/49IV.,4 ?-NMZEXB\<^']-\*PZ#<0/ R M^;+(I"_*,>E;/Q1\+:M9:#X9:SMGN1INWS!&,G()/]:]V6&-&++&BL>I"@&G M,BNNUE# ]B,T >!>/=-U?QYX5TGQ%!IDR26TA$MJ?OD<$]-T34?$ M.FP2>%M4BF#@--*YVH?7[M?1:QHB[5157T P*:L$*-N2)%/J% H \.\'Z/?V MWQ)\6326DJ0R0,L;E2 WRCI4OPETG4++PMXECN;26)Y8W"*ZD%N#7MPC0$D( MH)ZD#K0L:*"%10#UP* / _ EM1R7'-L4(+CYO:L?PAI>I MO\0K2X\-Z=?:=IX;,Z3DA<<\=!7TF(HPI4(H!ZC'6A(HX\^7&B9Z[1B@#G/' M]C<:EX*U&UM4+S/$=JCOQ7DWA>#5O$WPTO\ P?+ILUK<0(QCED!"L>>.1[U[ M_3$BCC)*1HI/4A0* /FVTUCQ%I_@:?P0?#]RUTY\H2[#MQG.>E>Q_"_PY<^% M_!%K87G%P29''H2!Q^E=>88B^\QIO_O;1FGT >&:=I&HI\?);UK.46I7_6[3 MM[=Z?X$TK4+;Q5XQDFM)42:-PC,I ;@=*]N\M-V[8N[UQS0(T4DA%!/7 ZT M> _#O1M2M?AWXB@GLIHY9%;8C(06X-8,VGW>F_ JYBO+>2"0WN0KJ0>KU]." M-%! 10#U %)R>*/$6J_#RT\*0:!.6 MF0(LX4E2N\7>#M4TSX?>&M,6VDGGBF#RA%)VD[?3Z5[EX=T1-#T*RT] MBLKVR;/,*C)Y/^-:K(C_ 'E5OJ,T >2?$KP=J'B'X?:8UA&6NK.)#Y..2 O( MKB]:U'Q#XYT/2?#$.@W$#VSCSI9%('&1Z5](XP,"F+#$C%DC16/4A0* /(OB M/X(N1\/-(2RC,U]I.S:5&2<$?X5F_"SP;?ZAHNMZCJT4D5[>J88S(""!R#U_ M"O<2H888 CT-"JJ#"J%'H!B@#Y3M?#I\.7MW8Z_X>U"[)D/ER6[$*1_WR:^@ M_AY8VMAX0MDL[&:RB)&([LH-. & !Z"@#Y\U"S MU_X<_$V[UZ#3)+^RNMV?+4GACDCC.*F\?VFK_$70+#7K;29X6M'Q);/G>R\\ MCCWKWQXTD&'16'HPS0L:(NU455] ,"@#YQ\,Z?HFH:YI\4OA758YUD5C+(YV MH0C:C%\9-4N39RBV-NRK(5.#TQS7N:P0HVY(HU/J% IWEH&W;%W> MN.: /!OAKX9U*?3O%EE-;20-=2$1F12 >5/?Z5AZ!)XD\#:OKND+H<]T;U6C M1U4XY!&_!^BZM!\,/%]M<6,R7 M,KY5"IRQPW2HVT;Q$GP5M;>RMYXY%G)GB4$,4Y[?E7T2(XP" BX/48ZT"- N MT(H7TQQ0!\K0Z3-=WGAV73_#5S:"":,7$S(O;!#$ (D '0!12^6F[=L7=ZXYH )/\ 5MCT->+?#?2K^U^+ M/B:YN+66."5R4D92 W)KVNFB-%8LJ*">I H ^=P?$'@3XH:G>1:/->)>E_+V M X^8Y'.*G\$Z5K*:=XP:]T^6&:Y0LJ%3R3MX%?0+11NP9D4L.A(Y%'EIS\B\ M]>.M 'A7@C1]1M_A#J]K+9RI.^[;&RD$\>E9&E^"=7UCX+SV*VLD=Y%,^!/B!K-M'8>'+_P[=*\?[HSA2% MYYZ5B7_]L^#_ (RSZL-*GNK>Z;:K1J<88D=<>]>_""$/O$2!O[VT9I7BCD(+ MQHQ'0LN<4 >%6ND:A>?&V:\DLYH[:XMP#(5.!D#O69HKZ[\+M=UJWDT:>\AO M2QBDB4D9/T!KZ)\M VX(N[UQS2/%')C?&K8Z;AF@#Y_\+^#=9M_"OB+6KVU> M.XOXR(X,?-^7XU9\,:/J4/P-U6SDLY5N7+[8RIW'KVKWG:I7;@8],4@C0+M" M*%],<4 >>?!JQNK#P##!P'% 'SE#X,UC4O@Y##%:2+=VMR9?*92"P^7M^%4?$VL>)O%G@>TT?\ X1^X MB^PA5DD*'YMHP,#'M7TVJ*J[54 >@%-$$0! B0 ]1M'- &/X7BDB\'V$I IK00NVYXD9O4J": /GSQOX3NE\(^']0T73)TAM'$ MC6S99UZ>W]*H:S=>(?%WB/PWJ,NAW%M;VLB)DJ223$ (TP.@VCB@#P?XIZ9J^G>-=%\0VMC+=0PH,K&I)!]*/'46H^)/$7A35 M(],G56,;2(5)V<]^*]Y>-)%VNBL/1AFD\J/C]VG'3Y1Q0!Y)\;+#6KG3;%K& M.:6Q1OW\4.GXUY]I&C74GQ T2^L_#T]A9#&>.2>!WKZ>9%==K*&![ M$9IOE1C&(TXZ<=* /#- TC48OB]KET]I*L#QN%*]1CT MZ2=W/2OH,1H&+!%W'OBD\J/!'EI@]?E'- 'S%X2U?5M&\07&M:K MX9O=1U"9_DE8$>6#Z94U=\:>%[R#Q@/$5SI-U=Z=>KO>.$G>A.>#P:^C_L\/ M_/&/_OD4YHT==K(K+Z$9% 'DWPFT_2O[1NKZRT.]T]]NW?<-G=_XZ*];IJ1I M&,(BJ/11BG4 %%%% !1110 4444 %%%% !1110 4444 '2H6NK=6VM/$&]"X MS5;6KB&UT:ZGN)C#$B$M(.JCUKYF\1WT.H7.HW6B3ZK>20MN-R'(1/T_K0!] M2M+&BAF=54]R<"F_:8-P7SH]QZ#<,FOGS5?$FJZA\ [?49;N3[7'=K'YH/) M-9'B#1M>T;PCI7BXZ]/)/(ZC9N/R]<=_:@#WGQ3XXTGPDULE^Y+W#A$53SDU M3\8>)=5T[3K&XT*S2[\^10_SCY5)'O7BOQ1LY=2MO#.M3W+F6_5$9<\*<]17 M0>-M-NO"'@_0K2WU&>0R702.* /=[5WEM(9)5VR,@++Z''-<7XA\2^( M;#QGI^G6.FK-82_ZV4L,CK[U4U7XB2^'Y;6Q_L6]O/\ 1XV,L2D@Y4>Q]:XK MQ1KE[HH ]U,\0)#2H".H+#BD%S 4+B:,H.K;ABO MGK6HM5UOXS7FB6VJS6L$RD-M8].:S?#6B:[JOB?5?"/]OW$=I;AG)R?FQ^/O M0!],K-$R;UD0I_>##%--U;@ F>(9Z?..:\!\%:EJ<7@OQ7IUQ>R2_8@1&Y/( MY%H_#23Q.^N3C[+*5CBW'MWZT ?5#7$*,%::,,>@+#)I7FCCQOD1< M]-S 9KY>U&RU^7P#:^,I]>G>Y60(J;CP!GW]JW/'^O:C<>'_ 3>_:I$EN60 MRE6QNY(YH ^A6FB0@-(BD] 6 S2&>(,5,J @9(+"O#OBMJ-W;>)O"B6]TZ+( MZ[PK=>5ZUF:\FK:O\78]&M=5FM8KB!%XIC3Q(VUI45O0L :\T^"^LZQJ.A7- MMJRW&;:3;$\ZD,5Y]:XSXDOJ]W\6+32=.OY+;[7'LR#P.3DT >_^=%Y?F>8F MS^]N&/SHCFBE&8Y4?']U@:^<_'>I:CX9NM+\'-J-R]JBAYY80=\F<<G^/K:TTA=4;2KK",MW&^ W'/('O0!]$O:-6]&< TXS1 @&5 3T M&X,[G4K93*/(ECW;!S].E;7Q&O;Q?$_AVWT?5)$BGB1$F# M=0<#- 'T(EQ#(Q5)HV8=E8$TLDT40S)(B#U9@*^>=4TW5_AOXTT.ZBUB6[2^ M(,J.QYSUJQJ-UJOQ#^*$^@/J,MI8VP^XC8SQG^M 'OR2QR+N2167U4Y%--S; MA2QGB '!.\5X)X2U35/#/C_5/"4M_+=V0BD,99B2N <5@^$M%UGQG)K\)UN> M"WM)G(0,>3DX[T ?3BNCKN5E9?4'(IBW,#/L6:,M_=#C->$?#K6_$5YX"\1V M5O#:U>ZA#K48=FBG)"R8'N* /HN2>&(XD MEC0_[3 4\.K+N# KZ@\5\KWGBB7Q/XBU235I]3=(79+>*T5B%P<#. ?2NG\, MZWXRO/AOK5I +LW-L<0/*C!]G'3/U- 'OJ7,$C;4GC9O0.":EKYW^%-UIK>( M;=-0O]0AUD [X9\A7/XBOHB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQ!I":]H-YI< MCE$N8S&6'45X[:_!C7]/COM-LM96+3;CKP-S?6O=** /(W^%-^WPN'A7[6GG M"Y\[S.V,UJ^(_AY=ZS\/;#P]'<*LULRDN>AP#_C7H]% 'F'BKX73:]X0TG3H MKL1WNG*-C]B:J7WPUU[5_"NFZ?J&HI+=6EQYA@Q7 ^(_AY=:QX_P!.U^*X1(;88*?G_C7H]% 'F\/PZNX_BA)X MI-ROD,"/+[T[PY\/;O1O'>IZ])<*T5VK*J#J,X_PKT:B@#R_1_AI>:=9>(H' MN48ZGG81_#T_PINF_#&\LOA?<>%VND,\LK.'[>C[B_;O_C3?$7PIDUKP3H^EK=".^TU0$D[$Y/\ C7J5% 'AQ^#>OW=UIM[J M.M>?<6LBG:W("@CI75+\.[L?$NW\3?:5\F.-5*=^ !_2O1Z* /-4^'%S_P + M)G\1O<(;>4$&/O@C%8E[\)M:TK6[F]\+ZE'%%CZ/Y&K7,=Q)4N%6&V&"AZGK_C7HU% 'GOQ! M^&P\674&IV5S]FU*W^X^,AL=,U6\*>$?%UAJ@GU;4[>2!4*A$B7.?7.*]+HH M \7UKX7^+/$-Q]EU+5X9+#S=X;8-X'I_DURGQ/T-;'Q3X;T6UG9/)C2*.7N# MP :^DZRK_P -:/JE]%>WMC'-)++5O$FK&\AM,& M&/U^M7?%?PKO+CQ'_P )!X;U V=\WWU/0]J]4 "J !@#@4M 'F7@_P"%\NCW MM[K&K7IN]6ND92V.%R#_ (U-X#^'=WX4;6C/CT4 >6>%_ MAOJ_AO1M;M[?4%CNKY]T4H'W>0?Z52T;X5:O<>)X-8\1ZA',T PJQ*!O^N,5 M[!10!X[J?PEU;3M=N-2\+ZC'"+ABSQ2H" 3])=2=]RR MI& ,<<5Z'10!Y#X=^%>JCQ;%X@\07T4DT(&U85 !QZXQ7KU%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117&? M$.^U*STA381D$.K>8#W!&!^/2@#LZ*X'X;ZGJU_:S?VA$QW,Q9R?NG/W:[Z@ M HSFJ&MZC'I6C7=[(VT11,P/OCC]:\L^'VKZQ8^*_L^LW$KPZNC7%N).@Z8 M_P"^J /8J*Y_Q#XPTWPX\4-P7EN9?N01#+&N<\1?$5K;PC/J5G8W,,P8(JR+ MT.1_C0!Z'17F=UXI@UWP)#>7-U=ZG!XKL-'U^RN[M]+CD/]/U+4UTZ2VN+2 MY==T:3 ?./;% '6T5YAIOQ*FG\>ZAIDUK.;6/"1*%Y4\L"\\::/9:!'K#S[H)>$5?O,WH!Z MUYUXI\7P:]KOAU(([FUD%V"8Y."R[6YXH ]FHJO=WD&GV,EUYMT=E6)I%P)"3@8H [JBN5U3Q_I.E7WV&82-=&(2I$@R6! M&>*F\.^-=-\2"Y6V$D4]OS)!(,,!ZT =)33(@<(6&X]!7'3?$?3K:[$5S9W4 M,)D$8N'7Y,YQ]:J:G/YGQ/T9HY"8GMG88/!'R\T =]17 ^']=L-*T[7+^74K MB[AM[C]YYF/W?L..E3+\4M$-S C1SK;S,%2Y*_(2: .XHK \0>+],\/00O<. MTLD_^JBC&6?Z50TKXA:5JFJP:8L(;+PW8K>7[%82 MX3([$G']:YZ/XHZ$;W[/.)H P)BDD7Y9/I0!V]%31#,H@&?+^M '5,ZHNYB /4TH((R#D&O/O%WB M*SU[X@#M*1F"#+' M]36/8>)++4-9NM+BW"YME#2 ]L@'^M8/B+Q+9ZKH>OV-HSB>R0K(>F#0!VRL MKJ&4@@]Q2UP?AWQ)9Z#\/]*GO9&>22)0D8Y=S@=*UM%\;:=J]Q+;M'+:7$:[ MS%.,$KZT =-17(V'Q L-3U(6MI:W,L1?8+A1\A-==0 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07-G;WB*EQ$LBJP M8!AG!%3T4 06UE;6>_[/"L>\[FVC&34]%% '!?%)Y[K1K31K23;/?SJGK@ @ MDUR7BGPWKWAB#2M?N-66[CTMT78L9!5._<^@KV&:PMKBYBN)85>6+[C$9VTZ M\L[>_M7MKJ)987&&1AD&@#RNUU2SL?B@^I:L0MO>VBFTGA:;86;VEO M:1K X(9-HP: /,/%5[:7WPET[[)*DOEF!7V'.#MZ&I?%ET_A/4M(\11*PAN+ M46T^T9R2,C^0KT2'PQH]O:/:1V,0@=MY3:,9_P FKEYI=E?VR6]U;QRQ(051 MU! Q0!Y9'=WW@_X>1:DD8_M#5)P\LK+D1[R!D_2LRX/_ !<#PL\FMOJ<[."S M Y1,E>.^*]HN=/M+NS-I/!') 1C8R@BJ%KX7T:R*&"PA1HVW*VT9!^M '#6% MW;V7Q8\0QW$BPO/ !"7XW'"]*YKPU;W45UK%E<^(1IER;A_-CE!&\'N#D9KV M.\\/Z7?7L=Y<6D;W$?W9-HR/QJ/4/#&CZI.)[NQB>7^_M )_&@#RG4],M_#E MYX9GGN/MFD17#M+,!E0[,""?UJYX\U?2M3\4^&!8.DSK< F2/D*,-QD5ZDVB MZ=)IO]GO:Q-:XQY;*"*K6WA;1;14$.GPKL;>IV#(/UH EUZULKS0KBWU%@MM M(FUV)QCWKSKPSJU]X?\ %=EXI7-K#>6[03 MQAXF&"I'!JAIOAS2=)E,MG9Q1R'^(*,_G0!XS:PS/X6UZ1$9H(M3WSH!DLOT M_*MGXC^(M#U7P]I,5@ZRM]JB*!1]P;UZ^E>E7FGKI^EW?]E6$$DTGS&)AA9# M[\5YY-X6U?Q#=VELWA^TTBSBF6::1#EFP00!\H]* +-G!'-\9+>0GGR+L9\E 'A6LZO<:[X$DU+4=<8RS2*5L(L@)\PX*YKL+3)\8>%#S_ M ,@W_P!E2NU7PAH2RR2#38,R'+#8,?E6@NF6:SPS"!!)"FR-LE^-/#>I:LK&Q?3U2*4C*QOM7J>U6;S M5=.U7XR:+)I^&V0D22@<,<^O>NP\4P7R6T%O9:%;:E: ;6CD."OIC@UA^&O" M^HW'BB/6]2L(-.AMH_+MK:'KUSD\#WH E^+JA_#-LK+N4W<0(_X&M9WCZTM_ M(\*+Y*X6YB &.@R*])O+"VU"(174*RH&# ,,\BFW.FVEV(1/ C^20T>X9VD4 M >?^*HE7XC>%#&F&*%<@>QJIX#U*PT/4/$%KJ\BV]Z;EW9I>-ZX'3/7H:],F MTZTGNH;F2!&F@_U;D644D@_B*C)^M 'CL2&3POXOOH(V M2PN+G,(*X#Q58+@J2J'C@GMWKV5M*L6L/L/V6( M6V,>6% 'Y4R\T;3M0M%M;JTBEA08564''TH \Q;PU+)_;&J6?B!-0U![0HPC M/5>?<^IK:^'GB'0;?PE9VGG16UQ'A)89"%;?T/!]Z['3= TS2-_V*U2+>,-@ M=:K2^$M#FO/M;:=#YV=VX*!SZT C?%?7GOYE@CN85:)WX#C:O0UA: M9=17K>.;B'<8WSM)&,BO7-0\.:3JCQO>644KQC"L5&0*?'H>F1+*L=G"BS#: MX5 P]Z /$[Z*X2'P==FY:TM5MPIN-I(C8A<9]*Z_3?#]O?>($U.[\2Q:@\, M)#*A_@/KR:] ET;3YM/%A):1-; 8$94$"JUAX9TC3&Q]JQ[/PMHUA=_:;>PB6;LVT.=7U&W^P:5I$PAO+Z3;Y MI'W%&,G\LU5N?#VI:3X>U66^UNYOE:U<%)6) ..HH Z/PQKH\1:'!J0B\KS< M_(>V"1_2MBO$-#T[Q'%\.5UFTUR2W^SAGCMTR%(WG@\UN77C'5]:TOPY8Z=* M+:]U1-\L_P#= &3C]: /4Z,UYC=7&N>"O$VE)RT5X_?+XML M/"-OXH;Q!(\J*LDEOD[&4G&.OO7IUE/>![.\TA==U634YY(;2>5I(FMG?<\$$9(10"1@C//2@#U6C-)]0MGU*\L+*S;RT%JC$LW0DD?2@#V&BO';;Q?KL_@75'$\RW=I. M(X+B1"I<'')S]:L:W)XG\*/I6K3:Y)@#ME\5!O'#>' M/LYR(/-\W\!Q^M=)7D6L6FH:A\8A#IUW]D9[++RC[P&!TK4\,:AK&G>+M6\. MZGJC7<44'G1W$A.4' Y)^M 'I.:*\0USQ3Z;KU_>/'.JR JQA8%@",] M/UKI=6U'7=6\5Z5IVG:@UG!=V1FEQG(X4\<^] 'I5&:\S\/ZMJ^A^*=7T74] M0?4(;>V-Q%))DL,8&/UIGAVW\1>-;4ZY)KLUE;ROF"W@) "^_- 'I^:*\BUS MQ9A49KS[7]1UG6_&0\.:3>FQAAB$MQ,OWCG(P/RJIXGU#4_ GAT1 MG5)[NYNYEC2:7+&,'KB@#TS-(M!M]3$1 MB$PSL/:MC-LT9KR:T\8ZOX9&O:7JLYO9K! \,YZL&.!G\:Q'\6ZE#ID&J0:OJ,]^65WM M3$_E$'DJ!0![I1FO)M3U?Q%J_C2RTFPU![*&[M!))URAXZ>])KNJ:M9>+8-* MU'5KNQT]8E$5U&&Q(^3]X]/2@#T*\\0P6>O6NDO!,TMPI974?*,8Z_G6QFO/ M-0U:]M_'GAZPBO#+;2V[%V!R)" O/ZUAVVMZC>>,+NTUG6KK3)$GQ;1#*Q.N M/7I0!ZG)JME%J,>GO<(+N1=RQ=R/7]*N9KQS6M$O;CXOV2QZO,C26X='#'Y1 M\W I^K^+;BX\5SZ/)J=Y:V=E&JL]NK%Y']21]* /8**\5/C+7$\%:V5N9S/9 MR@6UU(C*74^N>O6KFK/XIT#2-/\ $3:[).'D036Y)V$,0.!GWH ]>HKS74=: MUGQ1XKCT/2;TZ?;QP+-<2K]X[AD ?K2^)M2U+P)X9*'4YKRZNIA''-+EC'P? M\* /2IZCJ*SR".YBGB?:,]QD<=:]GH **** "BBB@ H MHHH **** "BBB@ HHHH PU\11MK1T[RCN!QNK;8[5)QG K@X_P#D>G_WC_.N M[D.(V(["@#)T;6I-3N+B-[8Q"(X!/>MBN0\/ZG@45R?AC7;JYN)K.\.YXP3N^E4[G7;[4]0EAM)TMX8^C-WH M[BBN5\.ZYQUZ> M^\.7$Y^6XB'45E:9K&MZF(HX02J/F1_44 =W(_EQL_H,USVG^+K:]OQ:F,QD MG )]:W9<_8VW==G->76MI(\%Q?0YWV\F<#TS3 [_ %77H]+NX+=HRQE. ?2M M=&WHK>HS7G>KWZZE-I=R.I(##WXK9UW7[FVF@TZR4>G%(#K**X675-9 MT*ZA-\XEBDZU;\1ZY=6DEG+:/A)1G'K0!U]%<%CWFM7\[W$HV0&,[,],UFWNH:M:!IGU& M$NI_U2__ *J .RU2\:PT^6Y50Q09P:J>']7?6+$W#QA"#C -9DFIMJO@^:=P M!)@AL4[P-_R!V_WO\: "\\8Q6EW+ ;9CY9QFH5\<1,R@6KM9&G:OKFI^9;6S@L.2Y[ M4 >@5@:;K\E]K=S8-$%6+HV>M9N@:]>#5#INH?,Y. WO4.@?\C?J./3_ H M[>@G R:XS5+C58KB9FU"&%5)V)W(_*I-)UF]U;2+N $"[081O6@#H[?4[2[N M'@@F5W3[P!Z5D]QFMW6=>NGU/^S;.18BOWY&H Z^B MN1T76KN+5QIMY*L^_P"[(M==0 4444 %%%% !1110 4444 %%%% !1110!RW MC3PY=ZU;VMSIDRPZC9R>9"S=#TR#^54K>'QAJFFWUEK,%G$LMNR(8I,Y8CZ" MNU+*O4@9]32T <;IOA>]M/AU)H3E/M31LH(/&2V:Q#X U2#P[HCVDT<>L:6, M+D_(XX!!_6O3:* //(O#7B+Q%XAL=1\2?9X+>Q.Z."!MP=N.3P/3]:K>(O#/ MB7Q-?16US:V,-I%.'2Z1OWH4=ON_UKTRB@#SK5?"&L:;XDEUK0([6Y^TH%G@ MNL8R,\@D'UJS?Z'KVN^"]2T^\M;*UO)UVQK"1MZ'J<"N\HH Y'5O#=[>_#S^ MPXRGVKR53)/&00?Z5O:)926&AVEG,1YD401L=,UH44 >?:1X9URPU;5;&=+> M31;]W=GW_.-Q)QC'OZU2M/#_ (TT/3IM#TXVDM@Q813R/AT4G)XP<]3WKTZD M#*V=K XZX- &'X1\.1^%_#\.FK(9&7YI'/\ $QZFN6O/"FMZ+X@N[_P_!9W5 MM>'?+#=8&&]0<'U->C44 $Y+.[M[2VO'D#;83\N ?7 JQXU\,WO MB#2M-MK4H'M[F.5]QQPK G^5=A10!Q\7AF\3XBC7B4^R_91#C/.< ?TJI>^# M;V\\6:OJ'FK';WEF8$*M\P;*G^E=W10!X^/!'BV7PJOATPZ?%;Q,I\]2-TH! M!Y^7CI786GAF]A\3Z5J+%/*M;+R'&>=V%']*["B@#C?^$5NI/'5]JLI3[%,_"6_3-(%I=:6),Q-,^UD'IT->ET4 >>XB5;JWN,;=P'4'!]^U=3X:CU9;>5M7L[2VE+?(MO@C'N<"MVB@#A? M$GAC68O$D?B+PY+%]K*>7-#,<*Z\]^?7TJ'4_#GB#Q5H)75TMK;4+>59;;RV MWKD>O ]J[\,K9PP..N#2T 6(@L1ZXVC%10^#]03 M6O$UV6C\O4HBD/S<@G/6N]HH P/!FC7&@^&+73KHJ9HAAMIR*\S\/#Q%'XS\ M23Z#Y$I$X5XIFVC[HYS@U[76;I^A6.F7EU=6L026Y;=*?4]* .,T[X?W5]:Z MM=:_,IU+4EPPCY6,#D =.],TO2_&.F)!8-IVE3V\)""X. Q0<=-O7'O7I%% M'&?\(O?'X@P:Z?+%LMOY;*#SGCM^%5_%^F>)=:DGT^"QL);"4 ++*WSQ\]0- MO]:[NCI0!Y_!X(OK77O#]RDJR0:=;F*1F;YB<+_A5/Q)X=\4>*)3975EI\=M MYNY;M6_>JOM\O]:]+5E894@CV-+0!Y]KGA;7(/$FE:SHIAF>VA$$BSMC*\\] M#ZU#J'A37;#Q#)K>C0V<[W:*+FWN,8##N#@^IKT>B@#S_5?#VO>(?!EY87=K M9VMY*P*+"?EQ[G J_P")O#%[J_@VWTJW9!/&8R2QX^5@3_*NQHH \ZU+PAKF MGZO:Z[X>EA-Z(%AN(93A7 &.N#[]JL:EX;USQ9X>:/65M[;4()1);>4=RY [ M\#UKO:* .%T:W\6K>01ZAI>E) G#RQD;C^&VNZHHH **** "BBB@ HHHH ** M** "BBB@ HHHH \XO;IM/\637)@D=58\!3S70V'BD:EY3\S#C^5= M$UO"S;FB0D]RHH6"%#E8D!]0HH XKPNC+)JNY&&5.,J1FG>"597O]R,OU7'K M7:+%&F=L:C/7 ZT)%''G9&JYZX&* .&\/1N?%%X"C %6&2IQUK,:SBTW4Y8] M2MIGB)^5HQ_]:O3%AC1BRQJ&/<#FDD@BE_UD:-_O#- ''Z/'I\GVJ73()XYU MC(4R#KP?:L*W:W$%VEW9S2WS$["5)Q^E>G)#%%_JXU7Z#%-^S0;RWDIN/?:* M .%T)7'AW404<''0J?:M+P*K+8S;E93N_B&*ZH0Q*I58T /4 =:5(TC&$15' ML,4 ,N/^/>3_ '37&^#[;SXM1AE1@KDCYABNWZTQ(HX\[$5<]<#% 'EMQ8SV M&LI:LCLB2@J0I(QFMGQ!:W%EK-MJB1,\852<#., 5W+0Q.VYHT+>I7FE9%== MK*&7T(IW \_UC47\27%M!:6\H"D;BRD5)XHMGMSI4 5F,> 2HSZ5W4=O#$-6(Z9&:0')>+U8Z19X1B<+T&>U:L>BV>IZ=:-=1DLB8':M MEHHW #HK = 1FE & ,#VH RSH=K!ID]K F%=3P?6N L[2YN-0BTQD<(LIZJ M<=:]4I@AB#[Q&@;UV\T .-"0K8PHS69KJ.?"^F (Y.T9 4^U=\ M\:2##HK#T(S2&&)E"M&A4= 1TH PIQ<#PABW#"7RAP.O2N,MVM1II!0%V@#'I48MH%)(AC!/7Y10!Q.EJX\%7*E&W9/!4YK4\#JRZ.V MY64[NXQ72"&,*5$:A3U&.*5(TC&$15'H!B@#.\0@G0;L $G9T ]ZQ/",#2Z! M/$592P(&1CM76LH92K $'L:1(TC&$15'H!B@#S"&VM]/O)H=5M9R-QVM&/\ MZU=!I,>G/8WTUC!/&0FW]X.OZ5ULEO#*JD=C3_ :KBQU'BR6Z>1*L2*K,I' Q7. M^&M N-.DN/MB1LK]!UI@96APW&J^)3J)B9(D.&.[NO[4M9IISD(-I//Y5J^#8W^U M72F-DR#@%<5VQMH"^\Q(6]=HS3EBC0DHBJ3W Q0!Y[I5Z^BZ]<+-;R'S&V\* M:-=L#::\]Q<0226LAW905Z UO"[[VB0MZE1FGO&D@PZ*P]",TP.-T%-&GU6- MK2WN5D0;@SCC/Y5VE1QV\,7,<2*?90*DI %%%% !1110 4444 %%%% !1110 M 4444 <-\2=0?3K?29EG,*?:AYA!QD96M'3/'FAZEJ*Z?%<,D[#Y/,0J'^A/ M6L+XMFV&GZ0;L9@%ZA?Z;EK)\=W&BWO]A0:&;=]2^TQF+[.!N"]\X[=* /1] M+\0:?JYNEM)@S6K[)0>-IQFG:7KECK+7 LI/,$#F-R!QD5Y7XDN9OA_XAN;J M&/,6M6X3:. )N!_(5Z!X#T+^P?"MK;R#_2)!YDQ(Y+GK_*@!^K>-M'T?4!93 MRN\_\2Q(7V_7'2L#Q'\2(=&\5:7IX5S;3KNE/EDG'.,?I6-XHBB\+7^I^(M+ MOK2Y=L&XLYP&)QG@$Y([T:YJ%G<>,?!VI7D,-O%/%EA(HP#\W% '51ZJUQXT M@\O5B+>2V\P694@D8//^?2I+KXC^';0'?J7@G3K*X\.>*Y)K:*1FNIP2Z@_P 34 =I=_$3P]:3PQO=EEEQ M^\12RKGU(X%:M[XATVP:S$TX'VMML)'.XUYCHNFV)^"]\YMHF>^G=H;>[XSSM&T=*S]7UC3]4^+?AX65PD_EQ-N9#D#)7%9FDZZV@: M9XPO8X%F9;T *XRHX7DT >BZ7X[T75=0%C%+)',WW!+&4W?3(KG_ /A9L">/ MI]%D206L8V@B)B=_^&:Y#Q%<>9J'AB[?4K26YDN5/EVT:IM!([BNE633[7XT M3B\%O&);5?+WJ!N; Z>] &_INJM#XCUA[G5_.MX4#_9]I_=#"_X_K3Y/B3X< MCDA'VIBDN,2*A*C/J>@KC5*_\)9XWQC'V8?R2C2M+L#\#=YMHBQ@W[RHSGUS M0!Z9JGB'3-'TU;^[N56!P"A')?/3 [UF:=X^T+4KF"VAG=;B=MJ1R(58_@:\ MT:X17\%7FK'=I*0A7:3E _R[O=$O?BEX6;2C [*QWM"!CHW7% 'K MDLT<$32RN$11EF8X %"TW% MLJ7"==F1N_3--\'7_AB30]-BL9+/S3$HV@+OW8&?QS0!O:9K^GZM9S75I.&C MA)63/&TCUKBO%7Q2L],MK*736,JS3A&;82-N1G%,KZRU&_\'W5@R-;27"F/;T RO% '8:AXYT32YY[: MXN&-Q!@/&BEFY&>@J_H_B/3-F[I722W$<-LUPS#RU7<2/2O(-*L+;7?!UI9_V[80Q%%#*+=!(K@>O7.: M]*O;?[+X1F@\SS-EMMW_ -[CK0!E3?$KPY$D;BY>17."T<98+]2.E;%UXDTR MUTE-3,WF6SC*-&"V?RKS/X>7WA:W^'4Z7C6@F"OYPE W$X]ZS]%UZ[T'PE8P M+%&(+Z^9;>6Y4,L49;@\^Q% 'J.E>--(UA)_LTKK+"NYHY$*MCZ'FN4T+XEQ MZ[-K-E(KHR>8MN5C(X"]SVK#M"B_%NP5;^&Z>2V(E\E J]1P0.M7?!\VGP:C MXMM91!'=^;*T:%0&QM[4 2^"?'NGZ5X:VZM=RR3&YD!(4MM&>Y'2N_\ ^$GT MK[38P"Y4M>C,!'1OQKS[P'I5A-\.-4EDM8I'DDGW,R@GJ:Q;:V/_ K#2]9C M_P!;I=U)(&[[0S#&?QH ]?/B#31K@T?[0OVTKO$?MS_A4,OBG2XKF\@,Q+VB MAI0JDXSG_"O(WEF,'_"QD4[A<' _Z9$ #]2:TK359-"\'7WB;R(YKC5+O@RJ M"JH2=I.>V#0!Z!I7C?1]7N)+>"21)E4L$D0J6'MGK6AIGB#3]6L9;NUG#11$ MB0GC:1R]C#H=K#/0UJ0S1W$2RPNKHPR&4Y!H DHHHH **** "BHWGBCD6-Y M%#M]U2>34E !1110 4444 %%%% !1110 444A(4$GH* %HKAKK6-6US5I++2 M7\F*(X9Q2)>:]H.IPQ7KO=P2G&0"<5Q_7(WT3MM<]#^SIVLY+FM>W4[JBJ]Q M=);V3W+G"JF[FO/]+\47_P#;B/(]8M#<0:BP4,1@FE5Q'LYJ"BVWV'0PGM:;J. M2BEIJ>AT5Q&BZSJ=KKYTO49?.)X!SG%=O5T:RJJZTL9XC#RH22;O?5!1116Q MSA1110 4444 %%%% !1110 444V25(D+R.J*.['% #J*X?Q%\1;+3"UO8C[3 M<]BO(!J/P7K^M:A?R+JJ%8IEWPY!'?\ _771]5J*G[1Z(YOK5-U/9Q=V=Y11 M17.=(4444 %%%% !1110 4444 %%%% %6^TVSU)%2\MTF53D!NU4+#PIH>F7 M9N[33XXYS_'DDC\SQ6S10!YW?:/JGC'Q?;G4;,6VD:9)OCW=9VQU^G/Z5Z(! M@8%%% &)<^$-!N[TW<^GH\Y.2Q9N3],XJSJ/A_2M6ABBOK*.9(O]6#D;?IBM M*B@"A'HFG174=REJ@FC3RU?G(7T_6G6VDV%I#-#;VR1QS$M(H_B)ZU=HH HQ MZ/I\.GM81VR+:MUC'0\YIDVA:9<:8NFS6<;V:C"Q'H*T:* ,>R\*Z)I\L4MK MI\4'[DA)!'Y5J44 4!HNG":>46J>9<+ME;^^..OY M"G)I-A'IO]GI;(+3&WRNV*NT4 ZKXJL=5ET=-(L]/&4BZM(WJ>3ZFO4Z* &R1I+&R2*&1A@@C@UC6OA'0K*_% M[;:=''< Y#JQZ_3.*VZ* /.X-&U/Q3XW35=8LQ;66FL5MHVY,A_O?J:[G4-, MLM5M#:WUND\)ZHU6Z* ,O_A'=)_LH:8;*,V8Z1')Q^/6DTSPUH^CR-)8V,<3 ML,%LDG\S6K10!1CT?3XDN$2UC"W!)E&/OY]:AC\.:3''!&EE&$MVW1#GY#[5 MJ44 5(=,L[>]FO(K=4N)AB20=6_SBFPZ38V]S/HH \]\&> K!/#5K'K6 MF(UXAR MM,CT;3HM.;3TM8Q:-G,78Y.35ZB@"A_8NG?V9_9OV2/['C'E8XI9-'T^731I MTEI&UH%VB(CC%7J* ,2T\)Z'ITB36NG1I)$=R-DD@^V37+6NBZGXG\;C5M8L MUMK+3R5MHVY,A_O?K^E>B44 9>J>'=*UID;4+19F3[I+$8_(U;L-/M-,MEMK M*!(8EZ*M6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I'^XWTI:0C M*D>HH \ETIP5UF$: ]](]RP681Y .T=\5=LXM?TF+2-$BN%MY+GS'?(W%!Q@ M#/I7;Z#H@T6.Z02&3SYC+SVR ,?I2WFBB[URSU(RD&V5AM]H(_$NMZY<:;:6DR6[S1GSVV@X(ST_(5LW_ (/N MSJ%Q<:7J3VD=U_KD !S[CBK5CX1@T^]L9X)3MM8RF#_$3GD_G1=!J)O M[/N;MK^/;I]P8<",?O0#@Y_*M"/4=>\12SS6-VEK#;(I"[ =[%"5#$TP^-M6N)&U"&>3*R[5MA""I7/KZ_A763>" B::+* MZ,1M 0Q(^^#G.?SJM_P@ES%*T-MJ9BL'D\PQ;%)'/0'%.Z#4;8ZCK.N>)9(H MKD6UI D;LFP$DE02/UKN1P!GK6/IF@IIVJW5ZLI;SU1=I[;5 _I6S4L$%%%% M(84444 %%%% !45P";>0#KMJ6BD]1IV=SA/ ;K'?:A#(0)2QX/6NIU'5M/L) MXHKM@'D.%R,UC:MX2>6^-]IMP;>8\L!T-16'A&XDOTO-5NC.R'*K7GT_;4H^ MR4>N_2QZ]9X:O/V\IVTVZW'>.-2$.DI;1-\T_I_=KEK^^TZ30K2WMTD%S )I4(3]FT[R32\CG M_!EK:W=U)>SSM+>KPRMVKNZY)?#-U8^(#?V,JK$QRR&NM'2NK!PE"#A)6:_' MS.+,*D:E13C*Z:^[R"BBBNLX HHHH **** "BBB@ K&U/Q3I&DL4NKM!(/X M52,+TU=E74_BK I:/ M3;9I6Z!GX_2L3RO%_C*0,V^&V;ORJXK0\(W7AYKPV?\ 9R_:4./,/(/ZUZ?# ML" (JJO8 8KMJ5(89VA#7NSAITYXE7J3T[(Y#P_\/=.TK;-=?Z3<=SA2BHP5M3 MHJ***YSH"BBB@ HHHH **** "BBLK7M=@T&R%U.I9=X4@$< G&: -6BL;P_X MBMO$$$LUL,(CE021\WN*V: "BN7\3^*KOP_*HAT:YO8MA=Y(L84#UR16/H/Q M'NM?F@-OX?O/LTC[#/\ +M7!P>] 'H%%-5PPX(SZ9I20.I% "T4A8#J0*7(H M **3<"<9&?2L^;6["'5XM+>=1=RJ66/O@8_QH T:*QX->$WB.?2/LLH,4>_S MB/E/3@?G6N6 ZD"@!:**0,#T(- "T4R65(87ED8*B*68GL!6'>>*+5/"UUK= MEBXB@5B /XBM &_161X;UK^WM"MM1:,1&92=F>G)%:Y..M !12 @]"#61KNO M#1&M ;6:?[1+Y?[L?=X/)_*@#8HI-PQDG%&Y<9R,?6@!:*,TFX9QD9H 6BD# M ]"#2YH **,BDW#.,C/I0 M%!('6D!!&00: %HI-PSC(SZ4M !11D4FX9QD9 MH 6BC-(&!Z$&@!:*3('<4%@.I H 6B@D 9-("",@@T +1534;X6&GSW8C:7R MEW;$ZFHM&U0:OI<%Z(7A\T9\N3J* -"BC(I-PSC(SZ4 +1110 4444 %%%% M!1110 4444 %%%% !112,P498@#WH 6BH&O+9?O3H/J:KSZSIUL,RWD2CW85 M2BWLA.274OT5S=SXYT*WX%V)6["/FL6\\:7E\YM[& 6ZMQYDGWL?2M88:K+I M8PGBJ4>MSL+[6+'3A_I$ZJ?[HY/Y5F-XRTK^!I7/M&?\*Q;73X8AYT[?:)6Y M+2<_SJXTMJJ9CMXPWLHK94(+NS%XF;VLB_!XPTR641N9(L]"Z$#^57&\0Z8I MP;E?PK!#P3_++;HP_P!T5(EI9!ABWCS[J*'0AY@L1,V#XETH=;G_ ,=-6[34 M[.]&8+A&/IGG\JR5TZRMW!EMG>WD'(:,[?Y5'LJ;TNT:>U MJ+6R9U]13W,%LNZ:5$'^TP%<98^+9],5[74XWF9/]7+&,[OK52W+:Y>M>ZG) M@=(X >%'O0L+*_O; \5&WN[G6?\ "3:2)"GVH9^G%.'B/2S)L%TN:QVM=*CC M"&VB/_ 149M=-*X%K&!Z[15>QAYD?6)KL=.^I62*&-U#@],.*@EUW385R]TF M/8YKGUTG3#RL?YFGK8:?$V3;H1[C-+V,.[']8EV1L1^)-*D?:MTN?<8J[%J% MG,,IL[5]0E:]U1V9I#E8]W" MCTK.(8O^^15%DM!+@0PC_@(IJ%-]&#JU%U1.OC#2S)L9I%']XHAIDMZ?$NIEVW+ MI\0^13QO/O\ I0L++FUV[C>*CRW6_8Z"3Q;I,;[?.9O<(35>3QIIZ'Y(IY/] MU#_A4,=K9QC @BV_[HJ01VY.(T1?H*OV5)=&9^VJ/JB2+QCI[_?CFC_WD/\ MA3CXPTQ3R9/^^#_A3DM8"/G1#]14$]I:#I$GY"DH4F]F5[6JET)%\8Z67"DR M '^+8<#]*T+?7M-NI?+BND+>A.*SK:ULV7:T,1'H5%17^AZ;-$0D:Q-V9."# M2=.E>VJ&JM2U]#I^M%<,NN:SH:+#<11W4*\+(7P<>_%9UW\5#!NC6P7S.Q$F M0/TI+!U9/W5<'C:45[SL>C3W$5M"TLTBHBC)+'%>1^+_ !A<:_='3-+W?9L[ M6(_C/^%95_KNM>*IMLLICM^X4X7%;>B1Z/HT>YW5I1U8UW4<*J'OSUEV."OB MW7]R&D>YK>$?#*Z=")91F9^2?2NWDN([:'+NJ@#UKAAXIFN9?(TRW>9CP-JY MK1M/#>J:HPEU>X,<77R4/)^IK"O%RES578WP[48\M)7-6P\1VUYJ1ME?GH"> MA_&J^AM]L\4:K=?PH1&OY UH7'AVR>P^SP1"%U'R2*,,#ZYK(A?_ (0K28A< M_OY;B?:SCN?6N=RI\KU<]CI.UHKB8O&^H7;W!L]$DFA@?87!//'TKH]" MUF'7=-6\A5D^8HZ,,%6'4?K18#3HHHI %%%% !7->+_#">(K%8ECC,NX NXZ M+GG'X5TM% ')^#?!\?AF*4,D9DW$1NHYV^A_2NLHHH I:Q_R!+__ *]I/_03 M7"> YXK?X8/+-=_9466;,V<%?F->@WT!NK"YMP<&6)D!],@BN+3P [?#R?PU M+=8>1W<2*.A)/^- '%3^))=)UG2[G2=0U6X@GN/+F^UY\MQ@].![5M7DFN:Y M\4+W18-7GM;&&))2J'W;@?E4\O@+Q!J=OIL&H:A D.GRAHXXHP P QDX^M=+ M8^%9;7QY>^(#,#'<0K&(\=,$_P"- ',:?'JOC37M0A&KW-G8::P@5(6PSL,C M<3_P']:IV?B?5]"T7Q5+>WKWJ:9#HGB>ZO-(\1V^G2 MW #7-O, 1_O8)^M9W@?0H?$&F>)K:>9[BVO)QBX(^\0%Y'XB@#%_X2&_M[*R MU"RO]6N-4+H9XW1C$X)&0!CTSWJUJ6CW&H_%?3'_ +2NX)+BT\WY7P8^%.T< M>_Z5UFE>'O%FEFWLA>64ME"0!(T"[RH_K5GQ+X2U.[\2Z?K^D74<5U;H8W61 M0593C_"@"E9ZE?Q_$'5M/:[D>WM[#&;K2Y)A(T MS2$,!TW#% '$OXNUO4/#NB:5!=>5J-_,8'NNX53M)^O-.\16NN>$=1T-;?7K MJ:WNK@1S+*^23@GCVXK3O_!5E8^%;:WO=46SN[:X:6"[SC:2<@=:Y?6EO-6\ M3^';636H]4NHYPQ6W4!40 \G!Z_XT >M>)[1[[PQ?Q)<20-Y#-OC.#PI.*\L M\,Z1+:_";4[QK^XEC>*91 [95>O(%>RW-N+FRFMF.!+&T9/ID8K@M+\%ZU9Z M!J7A^:\B?3YED$#!1N4MGK0!RFG:9K5E\.K?7H=;GCDMQO2!&PFW=C!%:?B? MQK=S7>C:=Y\]M'X>V!+D'/ QGTKK5$RKX!_X1[SQYFS;YF/]K-4=4\! M3S6^EW5A=+%JEA&(P[+N5QZ$?G0!D^#M>O5\8-IL$FH76E21[EDNU.Y&],D# MUK7^).IWNFIHOV.X>'S;T(^T_>7:>*U_#MEK\,SR:Q):%<858(@/U%,\8^&) M?$HTT1S"/[+>UL4MED98VP(+I8[!OW4BMACG.,G\*[FT\+2VWCFYU\S QS0+$$QTP3_ (T[ M1/"\FE^(=6U)I@RWI!56^;K^5 M-UU/$>@6ND:M!KL\D]_((IHY#E!NP,@>V:Z$?#NX'A?4]*^U+ON[CS@V.@SG M%:WB'PC-K.EZ3:).$-E,LC$C[V"#_2@#F9/[8$^-M&B;5[B\M=1.V:.5L@- MDW\0Z)X3LO%?]OW,MR!')+"6^1E(R1BMZ#X=W,/AO5-,:^\V M6]F$IE8=\@_TK9UWPI+JW@6/0$F"2+&B>9C^Z,4 <]JFM:GXD\0Z5H=C>/91 M26PN+J1#AC[ _C21W6K>$_'%OHO]H37UG?0L81.V61P">OX"M35?!%V[Z;J. ME7@M]4L8A%N*Y60#L:72O!^I2ZZ=>UV]6:_2,I B+A(N#S^M ',^'M2FN?$T MT.OZMJ%GJ:W+".$DK"Z;N ,C!X]ZW_!&KW]_KWB.&ZNI)8[>8+$K'(4;1TJ* M^\':_K^JVS:Q=6OV:UG$J/%$!(V#D#(YI]SX+UK3O$=UJ'A^_CAAO5"SQR*# M@@ 9&?I0!C6GB#5G\/\ BR9KZ4RVMPRP,3]P<<"FVND^(]0\#Q^('\0W*:@D M E15;Y" ,X(]ZLW?A*;PMX&\0B:Z-PUTQD+DUA/"WV&]:UFO&,4^#PV"P)_2M;48=8\$ZWI MERNKW%[9WDGE30SMG!QU'YUE^,] &GZUX2TC3IC T;827_:YY-=/!X2US5M: MM;WQ)?QRPV9)AAB4 ,<=3B@#!T2;7-<\2:S+-J\\>G:;<%A$KR0J1)L MXYQUK9FOKB/X?7MSX9U.ZOY@>#*V9(QSD=N:Z'4+#Q,=*MX[.YM#< 8G5X5V M-^%9FB>#]6T#2+][*\A&IWDOFO\ NQY8Y)P!T[T 9.AZG"WA/4[NSUB^FO4M M\RQ7)^:-^,D @5137M:L_#'AC7C>S/$SB.[4GA@3@$_B:W[#P1J4C:K>:E/ MMY>P>2%@0*H'')QWXK5L_!RIX"7PYI:3-JAU+55U,LS01Q(WE \#IZ>]>C>#_ MR:!X?N+"]F-U-<@I+(>I7L/UK+LO"'B70-UGI%Y:26!ZNH$"*. 6))-&G>);.]N9;<7"&1 M 6;!X K@=8N;SQWXF%A9EA9PG!;L/4T4J-24_?;26X5:\(PO!7;V.6UK5%U; M4C-;6RP1J?D1!4D=Y>PD2-'(/<@U[%H_@S1])A0+;))*.LCC)S6U)96LL?ER M0(R^A%=,LQIQ]V,;HY%EM25Y3EJSQRQ\37"X\X@@=JTO[:@D.Y)-A/4&N@\0 M_#NVOV\_3"MM+W4#AJP$^&^K+&S&>/>.@]?UK2-?#S7->QG+#XF#Y;7-&WU. M.2/*SH"*4:B=V+. MJ.MLL>. ?4FJDWB)UC9!(&)'Y5E#PYKLOS-;GW^85JZ;X'O;J16OBL,.02@Y M+"LW[""NVC6*Q$W9)G._9=7O(IKVUA>2!#DGU^E16M],YW"3:Z]17M%O:PVM MNL$,86-1@ 5POB7P/+->M?:4%!?F2/ID^HJ:6-A.3C-670JM@9PBI0=WU,^U MU S)^\^5A3GO2,_/@5DOIVI6[>7)8S[AW49J6V\/ZW>O^[M&4#G]X<5LU36K M:.=>TV47MT5>IM9FY_;?'"@?C3AX@;:IYG::I+G$ MK$&M:+52G+65MBEI)>NT#-2:?J3VY-O<[HV'8C%>@^'/#RZ3 \LY#W4W+GT]A4?B7PO%K M4(DAQ'=1_=;U]C6/URFYE MZI*-R64V/]KBIUTO5,8^P2?G4N-/NBDZKZ,W#K C'R@&J%]K[X)4D8K._L_4 MVE$:Z?-N/KTJW;^$M9OI"CQI;IW=N:5J4=6T/]]+2*9AO-J_B&Y-O9J\A'!Q MT%3+\-M>9@[>1GJ02:].\.>'8/#]D8HSOE<[GD]36U7//,)1=J2T.BGEL913 MJMW/,+7X]2%1VC'_UJV[#X.>U=MX$:S;PQ#]ER#N)F5NH? SFMZUL+6R1TMH4C5SN8*.IIMII MUI8M*UK D1E;<^T=3ZT-W!(M4444AA1110 4444 %%%% "$@=2!]: 0>A!^E M ^(WD2ZO)W*Y&<#=P/R- ' MH-%U3Z+XTL-:FGMUCFM[J%=[0RJ0Q' MJ,CGI0!-@F?KBM+7_ !GIF@+ LQ>::<9CBA4LS#UXH Z*D) &20/K M7GOB'XBFV\(3ZE9V5S#,&"*)(VX/'M[U6NO%D&M^ H[VYN+S3RAC$DJJ068@ MYQQTH ],HKGM(\2V%UJ/]C)(YNHH%DRXQN7CG]:7_A,-+&JW]@9"'L4WS.1\ MHZ\9]>* -74=,L]5MC;WL"S1'G::I:9X=T31I6DL;2*&0\%LY/ZUCV7Q&TJ[ MOX;9X;B!)VVPS2(0CGV.*YD:-XCU#61+)+-'#.G% ' M>45PGA[X@V]UX4_M/4(IH_(0&9V0@'GMQ[UHVWC[2+C3[N_;S8K:W;:'="/, M/^SQS0!U5%<;I_Q'TJ]U"&TFAN+0S\1//&55_P 2*EU?X@Z5I.HSZ>Z3S740 M!,<2%B1C/8>] '6T5PO_ M30WL%N8([F9_^6D*1L6C^HQQ6S#XPTZZ\.?VW M:B2:#.-B*2P/IC&: .AHKEM%\=:?J^I_VZ7KVIOIR)-;W2 MC(CG0J6'J,@4 =51574-0MM+LI+N[D$<,8RS&N9L?B+IEW>P6\EO:W;Z/\ #I+V^E8J)2!W+'C@4 >ET5RVC>.M/U;4AI[0SVMRPW(DZ%=X M]LBCQ_XDE\,>&+B]MXV:?&(R%) /J: .IHKAM$^(5K+X335+^*>/RPHD9D(W M$G'''O6]JOBBPTC2;?4;DL()RH3 Y^;I0!MT5S&K^.M,T>XCMYEFDGEB\Z.. M-"2P_ >]9B_%31);(SPQ7,DRG#VZQMO3ZC% '=45@:9XPTG5-!?6(Y]EM'GS M-_!0CJ"*QX?B?H[W$:R074-O(VU+AXV"'\<4 =O17,:]XZTCP_>"_#RZ%HZB1,7,OS2$CG/I72T5Y MU7%U*L>61Z='!TZ4N:(4445RG4%%%% !1110 4444 %!('6FR.(XV<]%&:X# M2[*[\9R7>H7.H300+(8X(HCC '@TF1ZUY9J&NZSI6C:OI6][B>U90LX M^]L8D _I53P_-J4_BJPM+D74=ND0D(9NYP=QYZ1_+10>,^]9D7C2=+=7O=.:%O.6-B#E<,<9'-*PSL**Y:?QM90ZA>VI M4G[-$)0PZ,,#_&N?U#Q-="QU6ZLXY1B98#BBS%<])HKAH?&5\+2TM8 M-->XU!H1)(GH,=>OUJEJ/BK4'UO2)K6TG#R1NKVI[L& YHL%ST:BL'PUXC_M MU+B.6W:WN;=]DL9['_)K>I#"C ]*** $(!&" :7I110 4444 %(45OO*#]12 MT4 %%8/B[43I^B/YGT5F7%]Y6B&: AY1"&5,\GBN2\(^+KVXCMK?4(&WW$K*DA[XS_ (46 M&>@45RNH^,H]/.I V[.;)D7 _B+$C^E9Z^.M1:Z6R_L23[9+'YL*=F7CD\^X MHLQ7.ZHKCAX[C;2()X[-VOII#$ML.NX?C[4B^.6AM;T7UBT%[:@,T/\ >!SR M.?8T687.RHK(\/ZK=:O8_:;BS-L&P8P>ZGO6O2&%%%% !1110 4444 %%%% M!1110 4444 %>9?$Z*.?Q#X9CE0.ANER"..HKTVJMUIUI>RQ2W$"R/$=R$_P MF@#ROX@VTEOXTT"=[K[%9"+8L^W*QMSUJS;:9!:ZI<^(8=>75+ZUM6Q%&!R- MIQG!->EWVFV>I6_D7ENDT?HPJKI_AS2=+9S9V:1EQM;DG(].: /$/$6I'6O MDFHWVMA[J63Y+&+@)UX(!_I73:??66D>-[*ZULJD,]@JVTTOW0>.,GIT->A+ MX1T%6D8:;#^\Y;CBK5[H6F:C;1V]W9QRQ1_9CC M#?G[5RD>N:CXA^'GB:VO/+N)+-6C2>)>)1AAGCZ5Z?J6BZ?JZ*M];+,%Y&21 MBGVFDV-C9FTMK:.. ]4 X/UH \QN+^PO_@T8K:6.1HXU255(R#N'!J3QY:"W M\+>')HX/]"M[A'N%1> N5Y->@6_AG1[6&:&&QC2.8YD4=":T)+2WFMC;21(\ M)&-C#(Q0!Y=\0=5TO7M.TFQT>6*XOGN(VA$."4'KQT[59\/0+_PM35!,BM(E MD@)89YPE=Q8^&M'TVX\^TL8HY?[V,X^F>E7$TZTCO9+Q(%%Q(,/)W(H \Z\! M6EM_PDWBT^0G-PP^Z.EUV^G6EI+ M-+! J/,DT:U73[BW:00C9 I&[('3'K7FFIZR_B+PQ MJ][J.LBW=69$T^,8/#8Y&?;TKU^V\*:)9W@N[>PCCF!R&&?Y4'PKHANGN3I\ M)E?[QQP?PH \HT^..YU/P$LR"1?L[<,,_P )KI?$<4B:=$]NZ6L8:W&(CC[@]JFETZTGO8KR2!6N(@0CGJ* .*^+MK=W/A#-MN MV1RAI=HS\OTKGH='L/$$.FB3Q=%+''(DD4(4 @@@XZ\=*]>DC2:-HY$5T88* ML,@UC0>$M#MKH7,.GQI*#D$$\'Z4 <;H,$;?&+6BZ*[+;Q@,PSV-8FE:K-X= MA\;7MG"&>*X!5,<9P.<5Z]'IUI%>R7B0*MQ( 'D'4@5&FCZ>@N MK'BX.91C M[_UH \/UV9+J/P[>2ZY]NNI;M',*?=CR1VSQ71KJ&F:;\:;Z74BD8:V01R.! M@''K7H,'A+0K;'E:=$N&##O@BI[SP]I5_)))W^:-$ M R1Q[^U=/\18FD\"ZFJIN;RNF,]Q6G8>&-'TRX\^SLDBE_O FM26))XFCE4, MC#!4C@T >3ZK=VNI_!>,6$B3- L1E6/DKAP3FJ7C/Q)I6H^!M%MK2Z2:;S(, MJAR5QC.?2O5K+0-+TZ":"ULXXXIL[TQD&J\/A+0K=66/380&.3QWH YFR@BF M^(]B98UM>BI8VR7*W"PJ)E3RPW<+Z4 MV+3K2"[FNHX%6:;_ %CCJU 'A[VTTOA'Q5':QLRIJ1=XT'5 S9KH?%FO:%J' MPSCL+*2&:YEB2.&"/!8/QV[=#7IT&EV5L)A#;(HF):08^\3ZU2M_"NB6MW]J MAT^%9@<@XS@_2@#SD6)'CKPE;W\8>6.S^8.,\X:O70H484 #T%5I-.M);V.\ M>!3<1C"/W JU0 4444 %%%% $<\\=M \TK!8T&68]JBMM0MKRV-Q;RB2(=6% M4/%/_(L:A_UR-9'PZ4?\(Q@C@N>/PIVTN!IMXNT5)-C7>'_NE#DU)+XHTF'9 MONL%QE5VG)'TK UNSM1XZT5!;0[627(V#GI6=KT5Q'\0;5=.L;>=Q;-^[D(5 M<9'M3L*YVUCKVG:C.8;:X#2 9VD8/ZTW6= L- ME=)113G.4YD447"QYC!X'U&2VTY[ ME@)C(4N<'K&3_P#JK2OO#M^\VO&*,%;A$$//7!4_TKO**+L+'G-M;Z[I=W%K M$.G>:9;=89(=PRI X/ZUH6FF:W=:_IFHZC'&#''(&"?P@L"!U]*[:BBX6.8\ M.:3=V&MZO<3J!'<2[HSZC _PKIZ**0PHHHH **** "BBB@ HHHH Y'Q'H,_B M/7;.VN%_XE<(+OS]YNWZBLG4O!L^EZFTFAQ?Z/=0-%.I/?C!_G7HE%.XK'#W MF@7\OAK1+1(QYMM+ND'H.?\ &LZZT/5FEU>R6URD]PD\DT47"QS M47A*U1DO T@N_* P6^7.!7)VNEZ[916DJZ?O?3[ACMW#]XI!Y'_?5>HT47'8 M\U?0M;U"/5+BXMECDNIX9$3(X4/DUT<>E72^,;*^*#R([%HF/^T=O^!KIZ*+ MBL>:CPUJ]D(M1@A62>UNFD\HD?.I!']:6YT36==DOM5GM1;O+&D<4)()P"#3+:&08=(E4CW %6J**0PHHHH **** "BBB@ HHHH **** M "BBB@"M>ZA:Z>B/=2K&KL%4GN3P!5@$, 1T->:?%^PFNK'3'CNWB'VI%VJ> MY9>:NZQ$NC>&K.VOO$,\4A.=R9\R3/8&V M,T,EPI#CIZU6\+:IKLGAJ?Q7J6INT%NKB.W'1CC@GGWH ]BHKR1+'Q3<^%)_ M%!UN1+EXFGCMQG8%/('7TQ5&?QOJ*^'= LY;QXIK\,T]PHRP4,PX_(4 >TU2 MAU:SN8[A[>42BW)60+S@CM^E>7:%K=ZWB;^Q[34+R[L;N(_OI5.Z)L'OGZ5! M\.-'O+>XUZ[_ +3E9;>ZE5HSG$AW-R>?:@#U31M9@UNT-S;I(B!BN)%*GCZU MHUXM)XFUA/AL+Z"YV79O#&' QQN(J[K;>(_"PTO7)-8>X^TSI'/;L/D 8@<< M^] 'KE%>:7EYJWB_QE/I5EJ+V-A9Q*SM']YV89[$>]+X/N]:M_B!J>BZE?M= M0V$,9/?E>OYT =5XH\3Q>&A8F6)I/M*=0T18F62S +.>AR!_C7G2:#>S_&:[C359D80^ M9N!/3KMZ]*=;Z3J.I_%#Q!:VFH-:*L:[Y$^\WRK[T >QT5Y+I7B_5/#]CXBL M-1G^V3:8<12MU8$X&:Q4\5ZA;P6>K6^J7=U>R2*TMJ8SLVGD@<]OI0![I17D M]Q>>(=?\?R:59Z@]I:?9UFDQU7[O _.I/%EU':W(KTW<,7$%L"<$9Y;! MH ]4HKQ^3QCK%S\(O[5CF*ZA#<>5OQC=@D<_E4VK6GB;1?#T7B==>0K>9WSD5R7C2RO=3D$W3:C*C7# 8!/RMCKUH ]9N]=MK/6+;3)$ ME,UP"594)48QU/XUJ5YKJ5Y?:+XWT#37NVFB,3M*[#);&VH-(@U_QU+=ZBVK MRV%FDQC@CAR,@'&3@CT- 'J-%4$W:5HI::5IFMXBS.W5L#->>Z':Z_XZAFUF M369;&U:5DMX8,CY0>IP1[4 >HUG:YJJ:+H]QJ$B%UA&2H[UYMXB\2S#Q/_PC MTNHW%M;6<0,LT*DO(V!WSQUJA%K][>^'_$.E3RS75K!&'@N95(+#/0T =[)X MW@2YT.$V[YU5 Z'/W&VBG8ZY M]I:WW=\@XS0![ 3@$^E8'A[Q1%KU_J5K'"R&RE,3$]SQ_C7%)XHU'6+;PW96 MUP4NI9,79![+D'/XBLKPYH^J:OXA\3QV>I/8P)_2@#UW5=2BTC M3I;V=7:.,9(123^0K%N_&=M;:GI%F()#_:7W"1C;]17#VWB;5S\/_$$=S<"6 M[TV1XEF(^\!D G\J?J,SW/B/P-/*,W_BZ36_$&I13:G=6 M-M:,8X5MU.6([D@CUKL?AOKU_K.DW"7X=GMY2B2NN#(N>#^E ':T444 %%%% M %:_LX]0L)K24D1RKM;% H[+Y;75KN*/=NV#&*[&BG<#*FT*"?4K*_D= MS-:*54^N<=?RI7T.W?7H]7+-YZ1F,#M@D'^E:E%(#&NO#EK#^=;-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROCSP_>>(-$CCL'5; MJ"99HP_0D$'!_*N=U;PUXEU&?1M::.U:_L04DMF),; D<]/:O3** /.]%\)Z MVGB+4M6U$VZF\M#$L<71#D>WM6AX:$O8> Y="U-E.\/N9>@!&,UVE-D198V MC<95@5(]0: /'-3LO$.@^#+_ $Y]6M6TJ.)@DP;,FWLN,>E6=,\&ZA?>$/#^ MI6+1IJ5BI*),N5=26X/!]:ZY?AMX=%Y]H>V9QNW^4QRN?I761QI%&L<:A448 M '84 JP*()-+OI&EWDG>I)) MQT]Z]#HH \N/P^U,^"4TCS(O/%V9LY.,9)KH/&?AF\U[0]/L[9D$D%Q'(V[T M5@3_ "KL:* /.M3\/:IIGB@ZOH-Y;)--"J7%O,V <#&1Q]:S/ 27#-)U^Z6YNT<3*,;T;!(J]HN@Z=H%J;?3K=8D)RQ M'5CZF@#G_B%X8O\ Q-::>FGRI%+;3^=N;VP1_*LBZ\-^*_$UY9VNN/;1:=;2 M+(WE$DRE>G45Z510!Y-\3--M]2UW0+&QE_T_>(G1.OE $\_B!7J5G:QV5G%; M1+MCC4*H]*S++PMI=CK$^JQP[KR;K(W)'T_*MJ@#@=6\.ZY;>/HO$&D>3)%+ M&(ITD)! X&1@5?T7PW>6/C?5M9F9/)O$4*!U!PO^!KKZ* //?^$"GN]8\127 MWJI!)&:9HVE>+-,^SZ?+9Z;/;0D(+@K\Q0<>G7%>BT4 &KR MW\?WVM.R"WGMA$H'4'C_ K ;PEXBTS7M7DT]+6XM]1)/FS9+QY].*].HH \ M8\0>'+WPY$+O3[R53,UYO$B>Y)S6E_8GC'Q#H5GI%W);1ZMV)L[Z/S(2P8K[BK4,*6\"0QC"(H51["@#S_5/!NI:9K$.I^' MUMYL0B&6"X&00,\C@^M:<.BZEK?AW4;#6;6UM7N$*)]G'3(/7BNQHH \DD\) M>-;OPT_AR::U6S3Y5E!.YUSD#I6SXD\(:K=Z%H8T]HOMVF,&PY.UJ]"HH X2 MY\-ZMJGB?1=8NQ"GV:)EG12>IV]/R-9]GX>\6^%+V[AT1K>YT^XE,BK,2#&3 MUZ#ZUZ736D1" SJI/0$XS0!4@AFNM)$-^%$LD964+TY :?H'B_P )R7%E MHS6UUIKR-)$)B08\G..!7I#3PHX1Y8U8] 6 -24 >=ZMX5UN'7D\0Z6MK+=3 M1!+JWF&58\\\+2 MAX]NEQ*DW/4@+T_*J_BK0O$OB03:<]I8BU=QLN>?,0>W%>D44 5--L_L&EV] MFSF3RD"%CWKA]/\ 5Q:_$"YU9Y$.FM^\CB]'/)/YUZ'10!P7AWP//H_C'4= M2DD1[20'[.O="<$_KFKOA/PS=Z+J6MW%PR%;VP('7\J["B@#S-? FI# M0?$ED7C\S49F>(Y/ )/7\ZO3>#K]]2\,7 =-NF(%F]_I7?44 >;3^%-PKL_#\=^FG_P#$QM[>&M&H^-]$TJXFM;FY_TF$ M&HRQR,C K'^)/30_^OU?_ $): MS-(LK:Y^,>L230I(RVT6-XR!\M '<:)XDTSQ!9O=6%PKHG#@\%#[CM67)\0M M 74?L4<[S/O"%HEW*"3C&:\_2*>TUKQS;:6I0^6&5$XP?DSC\,UU_P .6T%O M!6G&$6YE"#S2X!;S.^<\YH V+OQQH=E=-:RW/^D*RKY:C+9;IQ2:GXXT72KE M8)YF:3 +!%W; ?7TKD?#=C:W/Q9UR::%9&1$V[AD#BL7P[9ZQ?:AKT$=_9PN M;@ATN$!;&!C&0>,8H ]4N_$^EVFDQZFUQOMI?N-'\V[Z5'HGBW2=>:1+2.0;6 ]<5Y\\EYX+T72_#L,UO=W-Y.VRXE *1C Z<54TFUDMOBV]M=7\=P MTMDPE:)0H'"^@% 'HM,O)8O[2\#R:F]%NL[Y"*KC*Y.>M !IGCK1=4U!;&*9TG?[BRKMW_3 MUIM]X^T#3Y;B&6Z)F@;:\:#+#\*\UUB*\36_"][>:C;23S7 988$"[5*L>H MKH/!.GVESX]\533P)*XDVC>N>,T =+J/CK3(_"-QKEC,)D13M &<-Z$5B6/C MA/$G@BXN1>&RNT3+R[.$^;M6%H4$:Z1X]MTC4QH[E$QD*?GZ"I5-LWP.E,0B M\P1$-M S_K.] 'J&B2&71+-VG\\M&"9N1\3_$.+P_XMLM+<'R77=,0 MN2.F,?K3K#3-COI6J_8XA;+N78#D_B*R]>@%OX\\-KJ+12R>6RO(Z## M'Y: .Y@\1Z=<:C%8)-_I,D?FJA'.VE'B'3SJUQI@F_TJWC\V1/1>?\#7"74L M-A\9K5YF6**:U*Q$\ \CI^55;2Z@NOBOXC:"0.%T[!(Z9^>@#K)_B3X:@VEK MS*EBC,HR%(]?2I)OB)X<@O(K=KT'S< 2*,ID^]<3X4TNQE^%.MS26T;R.UP2 MS+D\$XJ(:=9CX'-)]G3S I(AVT8MG<9ECY>)^&'X5YUIY,EQ*Y0*HS@CU].E;.H M:C::79O=7DRQ0KU9CBO//A+86GEZQ=^2C3F];#D9(Y/3TI?C ;H6FC>3((X? MM8\QV^Z.F,^V: .GTWQUHFIW#6\,[+*%+A)%VE@.X]:\OM_%EIK.O:KJ6J7] MZGV24K:P0DA>!WP?6NFC\)ZGJ>LZ7?W&KV.VW<.HMU4%UR#C@#BJW@FWMY++ MQ:6@B8K(=*TW18 M=1N+I4M9$5HV8\L".,5Y3I=O;GX'74I@B+AOO;!GJ.]3:B\2W_@;^T_^07]D M3.[[F_"8S0!Z)IGC;2-4CGDA>55@7>Q=,<>U,TWQWHFIZ@ME%,\'?#-S?V=M;2LJ#"HHP<^N.U>7&;AAD11C\R(0XQD_Y%<7X2 M:R/C_7UUH(=0WCR!.,_N\G&,^V*U?B+I,=WX>BU7353SM-D$Z&( 9 R"./K0 M!UEUKMA9ZK;:;++BZN 3&@[C_(K3KR_P5,/&'B^X\3,-UO!$(;?/8\Y_G7J% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% %+4-*L]3\G[7$)/)?>F>Q]?TIL.C6-OJLVI1P*MU,H5Y.Y M&!5^B@#.M]#T^UU"ZOHK=5N+H8E;^]T_PK'?X>^'6U'[:MD$DWARJ'"E@?:[FV G/WG0X+?6NBHH P; MOP=HE[I,.FS6:F"$YC]5/J/RIMCX+T/3[A)[>R19E0IO[D'KG\JZ"B@#FK+P M)H-CJ O8[0-*&W)N.0I]16BOA_34O+R[6W437B%)F_O#GC]:U** ,O\ X1_3 M?[$;2/LZ_8F4J8NV#6%XPMX=/\.0VL'A\:I"AVK;@@;178T4 >3^%/#CZOK= MGJC:-_8L=CG$).3(2,9S7IVHZ=::M8R6=["LT$@PR-T-6J* .8LO /AZQ:-X M[)2\3;D9N2OTK7LM%L=/O+FZMH%2:Y.96'\1K0HH S;30=.LFO##;(OVP[IQ M_?//7\S6;:>!="LK>[MX;0"&Z/[R/MUS7244 0VMM%9VL=M H6*-=JJ.PK-U M[PSI?B.*--1MQ(8SE&[K6Q10!@ZKX.T;6;6W@O;42"W $3_Q*/K3M/\ "6BZ M7*TMI9I&[Q^4S#JR\]?SK@Z=8)=);VZH+IMTN/XC6E10!D1>&M*AT9M M)2U063"ZS&\N>(@<\FNWHH PO"/AN#PMH$&G0D,5&7?^\?6M 6VBB@ HHHH **** "BBB@ HHHH __V0$! end GRAPHIC 27 krbp-20210625xs1021.jpg GRAPHIC begin 644 krbp-20210625xs1021.jpg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end GRAPHIC 28 krbp-20210625xs1022.jpg GRAPHIC begin 644 krbp-20210625xs1022.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH ***CGN(;6!IIY4BB099W. * )**PKGQ?I,! CDDNB>UJGF_RJLOBJXNY MEAHUZQ/>YC:$?J* .FHK >_\1>62-(MTXSN^U X_#%8NA^*==O[2XNSIL<\$ M4A0[),,,>@QS0!W-%8UGXITFZBW/%IM6TN)9K]?L\?RJ@BY ^N: .W.J:>#@WUL#_UV7_& MIX9X;A-\$L.+& MTCCT<);0INOE4E$ .-K>E=M7)>.5W)HN.U^O_H+4 .TK0=.3PXMP8#)*T#$F M5B_8^M6_!8"^'(@ S8 JQI@_XI6,'_ )]V_K4/A ;= 0#^^U $_BCCPS?_ M /7+^HJKX0;=I<@]),?H*L^*3CPQJ'_7+^HJIX.S_9]P#VG/\A0!T=<_X016 M\.A64,IGFR"/^FC5T%8'@TY\/*?^F\W_ *,:@#+UNUG\*L=9TM\6I=?M-H?N MD$@;E].O3VKJK"_M]2M$N;:0/&W<=CZ5E^,/^1 MVI7 _P#'J .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ***CGE$%O+,1D1H6(^@S0!)7G?Q M ^75@WKISK_Y$6KUKXTU&]NTAM]*#K(N],,<[:R?&?\ :5[ ]_)ID\216YC8 MXX&6!SUH ](@_P"/>/\ W1_*I*BMSFVB/^P/Y5+0 R7_ %+_ .Z:XGX?959U M_P!G/ZUVTO\ J7_W37&^!TV32#U@!_\ 'C0!VM8Q_ T 1^*_^17U#_KE_454$#%K>@=K@_\ H(JWXJ_Y%B__ M .N?]157PGPNIKC&V[(_\=6@#HJP/!O_ "+R_P#7>;_T8U;]<_X,.?#JY_Y[ MS?\ HQJ '>,?^1)-*O9/+BNT$G9'(! M/X5JT*2>PVFMPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?#=I]ROK$P_0U8 MIDR[H)%]5(_2@#S[PD-FLV Q_P L9%_("NJ\6KN\*:B/^F7]17.:"GE^(;!? M>Y7\L5T_B9=WAJ_'_3(T 6]+D\W2[9_5!5NLKPW)YOARQ?UB%:M #9/]4_\ MNFN1$#9J#I_TZJ?_'S772?ZMOH:Y#PJV=;G4=K51_X^: .QKFO&R[M*@/\ M=F!_0UTM96OV,NH:>(H0"X;(S0 _0/\ D V?_7.M*JFEVSVFF6]O)C>BX.*M MT 9'BC_D6K[_ *Y_U%4O"G^NUH>E\1_XXM7O$PSX/^!T =K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !116%XI\2P>&M,:X=?,G;Y8HAU9J +^K:O::+ITU]>2!(8 MEW-SSBO*M>^.D$96VT/2YY[ASM#3#"_A@UP^LR:WXPO;K5-!@$M!&R MKMQ[ULWMCIC6%M/8.C@ ;X67YD]U/3% %ZX\;>.?ED%W9QAE#;%&=OJI^7K4 MMMX_\:6K1/.EK>QMW3(4>S< @UDC7[;3WABN-7FCCC<"+ X]SC&>./K5RYNI MFN4U+3M1AF?KM0;6^ISQ0,]&\/\ Q)T/5[5/M5PME> [)+>7@AO;VKL(IHYT M#Q.KJ1D$&O!K&\TC6?%JRZA'M,L3%L#&S )P*U=*UJ3PWJ*36+/)I18>9NZ@ M'NWN* /9Z*I:5JUGK-BEY8SK+"W<'H?>KM @HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TKPG7+RXU_Q==) M>W$D:13M#$B'& #C->[5X1X_AA@\770B&V&=001V_4UA7ERQN=F!LZENX M];5[3F'45D13CRW4 D_[P&:W=-\0ZAI4F"Y1<_ZN4ED;Z-R:XS3=5D-K]& M^E;ZLK#*D$>U>4WFAR(_F64@4?Q1-]UOK4-MJE_I;[)+FXM%]%YC)]AR15*M M.'QHY)8:,M:;/7:*Y'2?%4L@5+GRYT/_ "VA/3ZCK75QRQS+NC<,/8UM3JQJ M+W69HEXGK&:Y72!CQ/:?\ 7Q??S6NSO4\RQG7U0T 97@YMWA'33_TR_J:W*Y_P M0=W@S2S_ -,OZFN@H :_W&^E# M_IG_ %K'\%?\QD^M\W_H*T =57/^#/\ D7E_Z[S?^C&KH*YWP7QH)_Z^)?\ MT-J )?%W_(OO_P!=HO\ T,5B?#@YAUP9Y&JW'_H9K=\5C=H+C_IK%_Z&*Y_X M;G!U]>XU2?\ ]#- '=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110!#>3?9[*>?./+C9_P AFO 9)]7UFSN?&FHS?:K: MWG=+6!6PJX/!([]J]YU4 Z1>!AD&!P1_P$UX/=:(R:MH6@V]U*-.N8UE>(=% M9P,GW_&@#DM1\6:YKT,[B:5VE7F%<[<#CA>QJSI.A^)GA-G+;7#%H\JP4[AC MD5[]X>\ :%X>C_T>U624MN:209)/T[5TRPQ*VY8D!Z9"B@#Y\T#X1ZMKBPWV MK(;<$MN20_-[<&NM3X-*;5T.I/',/N.B\?EFO6:* /!)?@]XBT^ZEO+?4EG$ M:,T8Q\Q..G6L60:Q8Z(;&[1HYY&!D$OR[<]>M?2M>(?&:V6VURRNI5D\FYC, M9\L]QCK^= S'^$^OR:9XL;3%N0UO=2!/*W9"GU_SZU]#U\Q_#_38(O&>FIOS M')-D'^('TKZ<' H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% $=Q(8K:60#)1"P'T%>)^,;9KS1VO3_ *TR MB<^PSDBO9[^6.*RE\Q@H92H^IXKR;Q?BS\.W&X\!/+^I(Q7'B7[T4=N#6K9Y MO;W9AOHWC&68\?6O0=*U*Z@B0SD$MV Z5Y99.SWD?/(Z5Z)ODCM8B_I5Q3BK M'L5XJ=DSM(KQ98P1UJK>7$;J5D7-<]!>N -I-/N-0?8JK&TDSG;&B]6;TJG/ M0X?J_*[D<=I+-=RII,4Q:)?,D\DD ?@.I]JM6?BF_P!-D_?F1S_$J@I(/JG4 MUZ%X4T/^Q-'1) #=2_/,WJU7-0T+3=4C*75HC9ZLORM^8YJ7AD]5HSGEC$VX MR5T<_I'C.6ZP=\=RO4K]R1/^ ]37807T%PJ;) &<9"DX/Y5YOJ7PXNK>9I=* MN%>/J(Y&*E?H1R?QK.@U/5]!;R]:MK@0 _+,R@'Z#%1S5:6ZNA>QI5=:;U/8 M:*\[M/%2DHUKJBX8Y$$N,'\>M=99:_;S1 W'[EO4_=/TK6GB83\CGJ8>I#=& MQ13(YHYD#1N&4]Q3ZW,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHI"RK]Y@/J: .'T@_\ %36O_7Q>_P UKM9_ M^/>7_(-(G4HM_"=PQUH I^!QM\ M&:8/2+^IKH*S=)6QL--@L[>Y1XX5P"6%7A/">DJ?]]"@"3K6%96T5KXJNEB! M&^V5SD]]QK;$B'HZGZ&L/SXX/%]R\KJB"Q0Y)X^\: -ZBL4>+=!)(_M.'(ZC MG_"I4\2Z-)]W4(C^= &K15:'4;.X_P!53?@=N!_ MA0!LUSO@S_D!M_U\2_\ H;5T5<=H6L6&B:%++?7"Q W$FT'JWS'I0!M^)$,F MCNH&?WD9_)Q7,_#?)E\0..8VU.8JW8_.:S=8US6O%D4UII4$MM9@'?)@;CQ_ M%Z#Z5L?"R-H?!_E/@O'F:\EN9&@ M^('A_>2L<:QQQ L&!!P.U>J>+%E;PU>>23O"9X]!R:\CGAA/BOP[=12+))B ME0W]['\J!GNU%8NL^*M%\/H#JE_#;L>B,XW'\*SM/^)'A34KA8(-7@$C' #N M%R?SH$=712!@P!!!!Z$5RVJ?$/P_I-V]K)/+/,GWDMH_,*^QQ0!U5>,_&34+ MB/5-/ACMXYX5X<./NEL8(]Z[C2_B/X?U:[6VB>YA=C@&YA,8)],FL+XHZ7%( M]K?S?)#&"6?L2,8!^M 'G'PUM+]?B)'!.08X)0^ .!D9'\Z^DJ\(^%9MKGQQ M-.MUR(C\K'!9LC Q]*]WH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH *"<#)HJM>3A$$*N%EE^5!2;L!SEYJ2:EJ# M$.%M[9BJ9.-[XY_#!K@/B9*J>'A%G#R3(1] >:Z_51 MI'8Q6;K]Z+I4&C:5!8VZ!5C49QW/<_ MG2IQYG=]#CQ]91_=QW9=*BFE34M(170>.0FHY(4E4K(@92,$$9JP5%8OB?5X M]$T2>Y9L-MVIZY/%,##U7X=Z3?&22UWVBCZ=34W@KQ%KPDN/MLHNK0L-C,>06SW]*[?7-=_L[PY+?I\DQ7$2R#[S^F M*QG1A/='53Q52&FZ\SS[3?'2P-NGCFM7)^=T&,_53S7;:?XR66%7;R[E",@Q MMM8#W!YKD?#%_9>-WEM-:TQ([Z(;FNH%V%OQ XJ6_P#AQ?V<[2Z1<)+&>0C' M8X_X'WK'V52G\#-N?#U=URL](L]=T^^'[J< ]PXV_P ZOI(D@RCJP]CFO"Y[ MK5]"G!O(9-@.#]HC+ GV@F7S ?^!$UV_A_5Y]16:&Y11-"0"Z=&R,_A6M/$0J. MRW.:KAZE+XD;=%%%;F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 5Q7BNU:77[0SO*]O,GEQQQRJFQQDECGVJGJGB/Q#->O"EA<6=FC%6 M=(3(SCU!XVU+#J?A=")+Q[J60=/M@+%3[9Z4 <5(ZV5WE'O% N98E:.1>YQG MD=Z[A?A_IE_"DLFI7KLZ@G]XO&?H*YZ]T_PQ(SM_:DD<+RM*(BF2&)R>_2EE M\1Z4R&STJ2X64@*DS7!C7/K0,V9?A-I#9(M0S_L7K/C]* ,V/P+K4#9M] M4M8?]Q&_QIS^ M5OIU;5-5BNT ^96W*!_=JPRW\9S'>:C&?0V[2?UH>]U^- M"PU654 R=VE$X'_?5 #-2\."UNK&SM-0O#=3,/G++D1KC=V]#6I-X-6Y3;-K M.HN/=E_^)JOX1AO-1N9]:U&X\]R?*@_=[ JCN!VSQ77T"//-3^'NF6T7F?:[ MZ:1CA8S(/F/Y5B'PV;2=HX8-K+U+Y;'XBO0KR[635\9&RSC,F<]6((VU)I$M MN^GAY'CW3,92I(XWHTEOXK\Q0<$! M"#^HKL[]+2VL)KKR(F"+GH*@\-VQ@TI96;,DY\QOK0!RSZ=XLM%:274KV95& M25E0#]:K>&_!W]K1_P!I7\\I20L!&Q!<#=R">F">:[+Q1.(/#MX,D/+&8H\= MV88%7=+A$&EVL>T*1$N1[XYH$"65O9:8UM;1+'$D9554=!BN9^&W_(OW@]-0 MN!_X]772C,3CU4UQ_P -F!T74E[KJER/_'Z .SHHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ7.EW>1G]R_\ Z":\ M$U/3I+2UTK6+5BR%U!+'!!7&1QT [5]!NBR(R,,JP((]17B>LV&ISZCJ>D>? MMT^U$ERJ$?N6 SZ\=*]9OX)+B!5BE$;*ZMGZ=JE:.*>/RY0DG'S \T >3_ W\+:C8 M7$=S=FWD60DR(3\KJPQW([5U]O96UIGR(5CSUQ M7*_$J(7'ANV@9]J27\"N0,_*6YH X'P;X;?2-6T6>XC8WMW.D^Y?NK$%(P?T MKW"O&_"OVJ3Q=IUA#*[1V!?=NZ["V MXNI1% @R23_*N6K65[(Z*5%O(=<@TJPFO[@@[1\B]V/:O +^\FU75)[N7 M[\KEL#MD]*V?%_BJ7Q!?[8\K9Q'$2>ON?>L>TBS\YX(-*$>57>Y[F'H\D>9[ MF];[HK1%Z$BKL*DC+&LV&?S67/05JVEM=:I=V^FV0S/<.%SZ*.6_3--W>B%- MJG%R9WWPS\/M+<2>(+C[O,5LGH.[?CQ7I]5-,L8M,TVWLH1B.% @_ 5;KIBK M*Q\_.;G)R84444R )P,FO%_B3K%[J.MP65K\MM&VU9%&0S'CD5Z7XJUJ/1]' ME?S%6>0;8@3WKSGPW8WDLTMW='?%C +
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Þ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�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end GRAPHIC 29 krbp-20210625xs1023.jpg GRAPHIC begin 644 krbp-20210625xs1023.jpg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�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end GRAPHIC 30 krbp-20210625xs1026.jpg GRAPHIC begin 644 krbp-20210625xs1026.jpg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end GRAPHIC 31 krbp-20210625xs1027.jpg GRAPHIC begin 644 krbp-20210625xs1027.jpg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end GRAPHIC 32 krbp-20210625xs1028.jpg GRAPHIC begin 644 krbp-20210625xs1028.jpg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krbp-20210625xs1029.jpg GRAPHIC begin 644 krbp-20210625xs1029.jpg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krbp-20210625xs1030.jpg GRAPHIC begin 644 krbp-20210625xs1030.jpg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end GRAPHIC 35 krbp-20210625xs1031.jpg GRAPHIC begin 644 krbp-20210625xs1031.jpg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end GRAPHIC 36 krbp-20210625xs1032.jpg GRAPHIC begin 644 krbp-20210625xs1032.jpg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end GRAPHIC 37 krbp-20210625xs1033.jpg GRAPHIC begin 644 krbp-20210625xs1033.jpg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end GRAPHIC 38 krbp-20210625xs1034.jpg GRAPHIC begin 644 krbp-20210625xs1034.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BD)"C).!4G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%5[ZZCL;&>YE;;'&A8GTH X;7OB))I7C&/2H M;9);5-HN92>4+' '\JZCQ-K$FB^'+K4H$61HD+*">#Q7D%O>2:AH>KO/HEY< M76IR>8MTF, C'ZBN@@UB34_@[?17)/VNTC:&56ZC:,#-6T3FX$8_ER-D+C.>E:GB+QI)IWA&SUJQA23[0ZKM,G\) M&8^(HI;06^]K;:?F3'W?RI/%5]%J'PITJ>&$0IYZIL'8KD']119#.C\1>+-: MM/$UAHVDVEO++=0"4&5R #SGH/:I[6]\=-=PK<:=IRP%QYA65B0O?'%V5P9(PC L.XI:6#J M=ODA,GKBN9\-^))]8U36+:>)(TLIS&C ]1@=?SKIF^Z?I7DMB2MOXV*D@B=L M$?1:20V>JFZ@#A#,FX]!NK&UGQ+'I6M:7IVP.U]+L+$_<'//Z5Y^W@FR7X:C M6'EF;4!9BX6;=R/ER!]*CU32K75-4\(37:%Y+O8LQS]X ?\ UJ=D*YZ_)<0P MJ&DD50?4TY75UW*P*^H->(W-Q)JWC/5;>[TF[U.VLV\J&".0*(Q[Y^M6K2_U M?0_#^OI':7%I:E!]G2616:(G.>GX43^(/!.FV7@!]5@FD6]$"S--OYD)P2#^=07VGKK/BSPSI]Q)(()K/\ >!6^ M]C-S"(Q(94"'D,3Q2QSQ3+NCD5QZ@YKRWQ19Z!IVKVNFR-=744, M>5TV#) SCYCQ_6JO@Z3;XKU2UT^"?3;=[-G2*=\[6RHS[46T"YZU]JM_-\OS MDW_W=W-/DECB7=(ZJOJ37@\=O;Z=#LUW2;U+L2!O[3@D##KUXS6SXEOVU/Q- MI]A]GNM5L$M%E6*-PIDR =QSBCE"YZ_'-',NZ-U<>H.:Q_%NLRZ!X%8]2L/&<2V6F7.GZ9,N);>:56 /'( .:ZSXF#=X#OP#@ MDQC/I\XHMJ%]#>TK4TO]-M9W=%FEB5V0-T)%-EGU!=;AB1(38F,EV+'>&SQ@ M>F*\QU;PE::1X"MM01'1P\/^-O#;:>3'')< -&3G)P>:R-=LS;>) M-5N-9TBXU*VED)@N+>0'RACTSQBBR%<]H!!&0&HUL;R>YCC8@F?[Z?[)X'2N7\8:%8W7Q,T82Q;AI!P*26H[GILEQ#" 9)%3/J:>K*Z[E8,/4&O*=#TJ'QIXIUI]8D>6*U?RH(- MV @X_P :V? JR:9XAUO1$G>6SMBCPACG9NW9'Z"BP7.B\3>(5\/6EO+Y8D:: M81!2<8R#S^E5)_$TD7C&UT@)']GFMA,92W(//^%87Q4TBTN[?3+J:/=+]I$. M<_PD$G^59FJ>&K*Y\?:1I'SI9I8@;%/498XII(+L]4BFCF7=&ZN/53FFM@+5Y3L/A'QIK%AI4CQVHTYK@1YR X4D8KGM)MCJFD-=W.@ZE?71VDDRK/(,JA[TE[J=II^W[3+ MM+= 6)_ 468,?A3K/4K34 WV:8.5ZC&"/P M-%F'+)="W1112)*MRY:XA@'1CEOI4-YI,5[,QYVMS MSG/O786MU!>VL=S;2K+#(,HZ]&%9-SXQ\.V=P]O<:O;1RQG:R,W(--7$*BL"KM 6$@X^NZI[OXW*6]MJUM+,YPJ*W)J)O''AA6*G6[0$'!&ZG=A9& W@7Q!+9_8IO%#&UV;"B M0D$KTQG=6CJW@6WOO"MKH5K<&WBMY X=EW9/.?U-=!INM:;JZ,VGWD5RJ_>, M9SBKU*["QQFO^";O5-=L]6L=5%G/;0B)3Y6[UYZCUI(/"_B>.>-Y/%(=%8%E M\@\CT^]7:447"PU5(C"L;M_V<9Q63J7@>6ZLM)2UU'[/=::08YMF0<>V:[*J< MFJ6,6H1V$ES&MW(-R1$_,PIW8K'*7G@6\&JOJFE:N;*\G7%RWEEED/KC(I'\ M,C1O#.KRZG/-JDUQ$QF/(X /W1SCK7<4C*KJ58!E/!!&0:+A8^?]3FBNO#R6 M=MXCGNQ(0L-AL.Y3Z-ST'TKU*S\'N-9T;5WN0K65OY9BVYW9![_C70QZ+ID4 M_G1Z?:K)UW")0?Y5>IN0)'&ZWX)N;SQ'_;FEZH;&[:/RW)3>"/ID5%I7@&6S MU>XU"]U5[Q[FW,,P92,Y(Y'/'2NWHI786//C\/M6^QG35\1-_9A/^H:(E@N< MXW9K0U/P+YKV-QI-^]A>6<0A67&[<@ &",C/2NQHHNPL)M$'B+0+C2S-Y(FVY?&<8(/]*UZ*+CL>>?\ "M[V>""P MO=>EGTJ$@BVV$$@=!G-=#-X75_$-IJ<<^Q+:U-LL6W.1Q@Y_"NBHHNQ6.;\- M>%?^$?T"YTS[5YWG%SOVXQN&.E9Q^'\9\-P:;]M*W-O,9H;E5P4;.>F?:NUH MHNQV.%MO NI-K>GZGJ>N&[DLY R+Y94%<=.O7WI]WX*U1;^\FTK7FM+>[8M) M"T9< G@XY&*[>BB[%8PO"WAF#PQIK6T4C2R.Y>21OXF/6J7B?PGZO+EMTTS<;O3C\37144786,'Q9X=;Q+I<=K'=?9I(Y1*DFW=@ M@'M^-4['PI=1:Y8ZM>ZBMQ/;V_DMB+;OZ\]?>ND-U )FA,J^8J[BN>0/6H[# M4K/4X#/97"3Q [2R'(S1=C,.X\(1W7BZ?6II]T4UK]G:#;VQC.:Q(OA]JMA' M+::7XCDM;!V)$.PDKGK@YXKT&BB[%8S]$TI-%TJ&Q21Y/+&"[G)8^M:%%%(8 M4444 %%%% !1110 4444 %%%% !1110 5A:E),9KL+ MV/3H[JRDG 697VP[>O3I]*6/0M/BL&LEA/D,Q<@L2=Q[YZYJ.'PYI\+E]LKM MC +RLV![9/%6Y)FTZL9.^J..O[Q[^^N=1BM9I&AD @F525" @G^M;4LG]IZK M:WNG3H+P0!O*D7(*L.Q[5T=M86ME8BSAC"P!2NTGL:IOX=TV2*-%C91'G:R2 M$$>V0:?.BG6@^EK'-W$37,5Y ]I##=1SJ\T7F#9-\O3VZU-ITLK^,HV%J+8- M; .@.21DX)KH$\/Z4Q20Y8ER6)^O6I;#1[/3G9X$;S&&"[L6./J:.= M6!UH\K1?JC=WI#&"'[^,LY^Z@]ZDOYGCA"1'$LAV@^GO^%9EL@DFPQS;*<$] MV;U/ZUQU:EGRHBE35N>1 6"G=D \=#5$&S1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XM_Y%/4_^ MN)K:K'\5(\GA;44C1G O^1%T?_KA_4UD>/O#>CIX9U34%L(A M=^6S^;SG.#S6=X7\]&N?#V_N+2"? M]Y"P6-XRK]/3K3U3)Z$?A7PWHT?AVRU!-/B6[$&X2C.'+Q-3TY2[7 M+C]]'@XP/6FGN!D^$OL]QXZN-8\/VDEOH<5N1+U"NV.P-::^/?$5W!-?66FV MCV<;L A<>:0#CIN_I3=,;4?"'BBYT%+>6?2[H%[5MA*QL?X3[[>%H6E3<8VZK[5RVM>*]:36Y M--T;3%?REW//<<(?8>4/,W_>S[UYUKES=-XQOHO$/] MK_V*#H\>MG1X!IAP22?F*DXR.:Y_0+2=8/$RQZ;=V\<(%'E[3N^]Z4VD)%W6?&EU&VFVNBV(N;Z^C\U4<$N M@K@QX_P#$"6:ZK)IMH-.(WE!*/-"=<_>ZXKJ_'6EW&L^#[ZRM5W3.H91Z MX(/]*\HA@T4:&EL^@:JVM8$9AV,$)Z9SMQBDD@;/2-1\92:;=:9=2Q1G1[U1 M^_&M%E8+EF+QWXG; M1X]-J,UL+= (6V%"N-^[&/>K0LKKP+K&DZBUM/=6AL_)N#%&6:,D@ M]!]*=@N;6G>-M2M];;2/$&G+;W+1-+$T1^5P 3ZGT-98Q5@!@CW%!19!<]!UKQ[+:#3K2QLPVHWJ;Q',P58_KR*32/ M&U^-7.F:W:0)*T321/;N&5L DCJ>PKBM8T#4UDT36-;M;F\A\HI=B($R+SQQ MR>@K4\/V>G7'BA)M"T:\$,$3GS[I2HW%2,8(Y[465@N7X_'WB"_BGOM-TVUD MLHG9=CN!*0O7C=_2O0M.NVOM/@N6B:)I$!*-U!KQ2[AT$>-<:7JECX@#MY8 MLHV$;MV/ KUSPH+]?#5F-3+&[V?/NZ^V?PI-#3,76O$VN)K4NGZ-IT;B!,-0B\0'6/L '^ MAI9!]K?7 I?A=;2VOBC5\V-U;02A6B$ZG)7GJ2.M.V@KZG:>-_$TWA72[>\A M@67:PHW7IR>:G^)UO-.17)6-IHE] MKFF+HNBZB7659)I+A618L$>HYI=1G,FOZE%XE&LL58"TCLP_ELN/8$4[!F"58@?EZ8;D^IJ:UNIM/\ B5J(O;:?=?6Z(DB1$H7V+GGH!D&H?"GA MYM3^&]_8W<$D2,.I# C!&/Q%&@'4:SXM>R\2:;I-E&DK7 \R9C_ G'/Y M&L-O'VKZG=W1T.RM6M;9RC-<2 %B.N.14'@#2;S4WN]3U>"2.Y2!;.(NI! 4 M$$_CQ7+66D:=H5UJ%IXCTO4'E\UG@DMD9E<$Y[#WHL@N>M>%/$2^)-(^U>5Y M4L;F.5,YPP__ %UNUR'P[L_LN@2-]@DLEFF,BQ2'YL8')X%=?4OF:7-9['DE@>022(OSIP,=*N:$Z-=6R17UP'FE.Q"QVHH&>!^=2Z:M< MQEA8^SYDSK-3=GG=5.UD4(#[O_\ JJ>.!3:H8Q\R+M8>M56(O+YE(RK2 ?\ M?)J\L4L5T H)0]3GM7FQ]Z3?0F7NQ4>I)9RM+&0Q7T%NRYDESM/IQ5NLV[LIIM8L[E /+BSNY]C3$:5%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %! (P1D45 M3U6[DL=+N;J*(RR1H66,=6- %C[/#_SQC_[Y%.V)MV[1M],<5YA=:QXOTG2X M_$-Y=VIA9E+V!!#*"<8'O73-JM_=:]HIMF9;6Z@:66(KTX!&3^-.PKG5 # M ]*%54&%4 >PH9@JECT S7G,6O^(?&6JW=OH,T=C86K[?M3@DR'T%"0[GHI M1&(+*I(Z$CI2&&)GWF-"P_B*C->>IX@\0^%=>M-.UYH[RSNV"1W: @AB>A_. MM2RUV\F^)=YI+2YLX[7S$7W^7_&BPKG8TQXHY""Z*Q'3(SBN5\>ZW=Z-IMI+ M92['DN41B/0L!_6NKC):-2>I%(8;$R3M7GCI2[5V[=HV^F.*S+[Q'I&FW"P7 M=]%'*W\).34G]N:9]D>Z%Y'Y"-L:3/ /''ZB@"^44KM*@KZ8XI%BC7&U%&.F M!TK/MO$&E7@G,%[$X@.)#G 7\:99>)='U"Y-O:W\,DHXV@XS]/6@#5IGDQ;] M_EIO_O;1FH(=1M+B\FM(IU>>'_6(.JTP:M8D7)%PF+89F_V/K^5 %L(H8L%& MX]3CFJ6L::-3TNYM 0C3(5WXY%5U\4:(UVEL-1A\Y\;5SUS[UK@Y&10!G:+I M::7I%E9L%>2WA6+S,#)P,5H,JNNUE# ]B,UGZCKVEZ25%]>Q0D] 3D_D*D&L M:>VGM?K=QM:J,M(#D >] %M$2-=J*%'H!BD,49?>8T+#^(KS62OBO0VNDMAJ M,)E?[HSU_&MD$$9!R* $90P(8 @]012)&D8PB*H]%&*S]1U[2])8+>WL4+'H MI.3^0JS#J%G<6GVJ*YB:#&=X88% $QAB9P[1H6'\149I]8T/BO0Y[L6T>HPM M*3@+GK^-7=0U:PTN$37MU'"AZ%CUH LO%'(07C5B.A(SBE"*&W!0#ZXKD_$_ MBB)?!MYJ>C7B/)$5PRGIE@.GXU9T3Q;IES86$5QJ$7VV6%&92?XB/6G8#I&5 M6^\H/U%+C(QVH!R,CI69J/B#2M*<)>WL43GHI.3^E(#02*.,DI&BYZ[5 H:* M-V#-&C,.A*@D54;6=.6P^W&[B^SFX]:YW3?$CZEX[GLK:Y M673Q;)(FWID@YIV ZUHHV8,R*6'0DU!( R>E<%X2N[F&[F25_+B M2)FDC<\[@?O?Y]:J7OCJ\N[*XMTTWS"R%0R],^O7TJ/:*UV9NO%1NR:_;4=! M\3K+!<>;%>%FC,CG:I[@^W-9VN)<+="ZOWM%>[C,9,;<#GZ=>*S+=-0=8+Q65JME*>WDWD2S?>0CH?H:RY-6M!9QK M;R><'8_Z,X^X/8^OXTL,Q8>5&6-NRE%AR!M)Z<^M=+3MJ>FX2Y=3?69XD%GJ ML*-&OS)M.,CUSZ_P!:YN+0;[[6T=O++/+& MF1\PXZ<"NQT"VN8(Y5D$ZJZC8DA'!SST[XKEQ$G"#<'J85+17NON#C%;M9VEIN\R;;M3B- ?1>A_&M&N2@K0/(Q$KS"BBBMC$*S;N]E MAUBSMEQY&=2DU7PS9W[P!)I(0=@X&<=O:N>7X7V&Y8GU&\>Q5LBT,AV?3KTKMK:WBM+ M:.W@0)%&H55'8"J;T$CEXM;\17-V;6?0/(MV+*9_M ;:.><8K(^$]W!'I-YI M;?)>6]PQEC/7MS7HE>>PNW^_+;L1O^H!%*Z"QE_$V]MYK; M3]&C(:_N+N)HU'50&ZGTZUSUSH=WJ_Q-N+.WU*:QECLE+21$@G 48XKMM%\! MZ;I-^-0EEFO;T<":=B*)]>61C/-%Y13'&./\*=[!8\Q\8^% M-0T6UL;BZUZZOD-W&/+E8D?>'J:]BW,MGN098)D#U-9OB'P];^(K6&"XD9%B ME60%1W!!_I6NJA5"CH!BDW<$K'E/@+2-,U^#7+S5[>*[N_M+JQF 8H!G &?H M*QH;:!/AGJMM"=T']J*@/J"R4FKRV$.N:@-1LM2TNX9S\EB6*3CL3R,'I74^ M#O"'VOP.]G?));)<7(N$4\L "",_]\U>VI)F>.=*LM)T71[*T@2UM;N6-+J2 M-=I8 CJ?Q-6O&^@Z/HNAZ;J&F6\-M>12IY4D0"L_'MUKO=8\/V&N:3_9U['O MAP,$'!!'0@USME\-K&WO8+B[O[N]2 YBBF<[5/;C/-2F.QG^#F_XN7XFW'DQ MH?U%9MNZO#X_*D$>6XX^CUU>L^ K+5=4.HPW=Q97#+MD:!B-X]\$53N_"-IX M<\*>(/L3RR-V[D4%%QV!_#FBTL_P"Q-%U^WUAXELI&7;:6 M=RK,CEAQ@=.W:N^UCP!8ZGJCZE;W=Q8W,@Q(T#$!_P ,BB'X=:+%HEQIQ$KM M<$-+.S$NS @@YS["JYD*QYGXF@$7ARSEA\,P:9"DD>RX,JF5OPP#]:ZB.V@U MWXB65GJZ++;6^GJ\$DZ;K\6F/Y5Q+#&9;9/N(/ M,'..QINL^'-)L?A?8WMO91)=XAD\\*-^XC)YKJ8?AUIT>EWMI)E*X6-#3F)TFT8\DP(?_ !T5 MY#;V.J:UXMUZ>+2K*_E2RV\(M[:*%3E8T" _08KE=7\ 6 M>I:I)J-O>W-C<3?ZTP,1O^O(H3&T>;7FF7ND^#_$4,YM4C,R,L$$ZN(FRV1@ M=*V/$OAC2M.^'-A>6UI&ETGER>65UAC50& YX%/F%8Y"2TMM;^)<-MJ\220PV2M!%(, MJY.8SS6UU;KM2>)B M&QZ=:CT'P19Z#J$E[%=3S3RIM=I"23[\FE?0=CJ:*S](TO\ LJW>'[3+<;G+ M[I#DC)SBM"I&%%%% !1110 4444 %%%% !39)$BC:21@J*,EB< "G5A>+&(T MF-]7DNH9+A MX%<&1!EE]!7.>*[6QA\*RRQI'&\2!H'0 ,#VP15/3I-5;6IFMDA:4P+YGF-C MO]*W]C&4>9:>IE[5J7*SK8+V"XGEAB<-)%PX]*L5R7A4SG6]8^TA!+N7<$.1 MWKH]0U"WTNRDN[EML48RQK*K%0E8TA/FCS,DNKE;2V>=U8J@R0HR:\T\;7\6 MI20OYDT*KB2,X+ >Y6NCU3Q5I=]X=F>"],$C@!5(&_KZ5Y_+YNHB%KOS L.4 MDXVC9VY'7-U:X1XOLSL&V$_0?A18W*QZ1]F MFB%B+EC^]DXYQZ<5S5Q/8Z:M[I[^<^ )+<;CC.![^]7;B\@CT=4O]]T4.\(3 M\T0/'S5SN]KG+[5]7L2KI$T2N$NC,#N53C<3]!Z&M6V^'E]<:1YDEUY%TPSL M48SZ FN5L]6DDDVPHR*,+$S,1M'O7K?A+59-3TL^7LMO QMUME5N%R#_G'2 MNRD6.*^N'D%NKL_RM(/FQ['%-61PQ6$F3>,,8E#9^M;2QLN;3^F?2NO4;YDR MEX?TY=%MY8KE!-,QQ&0,EE_PJ_# ]Q.57[^,.W91]>YJ>WTV4X\P^4@&,*Q) M(//4]*O2;+&R=HUX120/4UDU.J^>IH$5KQ=]_PO\ Y'1&1!(( MRZAR,A<\D5D7T;MXAT]PC%1NR0.!P:P9M35M3?46FP8I@J)G^ <$?G74R:C& ME[:V^W)G!(;TXS5TJRJ-VZ&=?#NBDWU+U%%%;'.%%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% $;P0R-N>)&/J5!IX P /04M% !1110 4A 8$$ @]0:6B@! HP /0 M4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 5'/!%=0M#,@>-A@J>]244 8D'A>PAN!(V^55.4CNL>%W"%.2WX]J MZ7A*=/WL1+Y')]=J5?=P\/FREH]Y]HU:ZN;.S*6C-E8^"(C_ #J6_N(-1OC- MJ+"S4+M,D8.&8=./>JMEH^LPEKN&">RMHSL8$$%C[_G5RPT'4M?END@.7@.& M$W0Y[\]>E>#6LZK]FM.AG%5&E%J[,I]32,1XN8[_ "^"DBD';^0IB7,:AI3& MT22$;]H^]SVS4\6F?V-J$UIJ-OFYA88*\J">>OXUZ6WA&VDN+*6.%9;;K(LG M)''&/QJ/8ML=.A.HM]C!\%6MIJ>ISRFU3R53;MD'(]_QKT>&"*!-D4:HOHHJ M"VTRRLYGEMK>.)W^\5&,U;KJA#E5CTZ5/DC80HI.2H/U% 55Z*!]!2T5=C6X M5'.N^WD7;NRI&/7BI**'J-.SN2$DNLA).[WJY16-.A&'F=%;$SJ^1DVNB+;&W_TB1UMY&= W8$8Q3KG1(I]1 M-ZLC1RF)HSM]QUK4HJO90M:Q'UBI?FOJ4ETRW73S:%05*X)(Y/O5*#19+>XL M")S(EL""7^\<@_XUM5E7EU-'K=E K8CDW;AZ\&J4(IW1#J2::;\S5HHHJB H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **0L ,D@?6F&>(=94'_ A0!)12 @C(((]12T %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 444A('4@?6@!:*:9$'5U_.@2(>CJ?QH M=12%E R2 /K2&1!U=?SH =11UHH **** "BBDW+C.1CZT +14;7$*G#31CZL M*%GA;[LL9^C"G9AC6VNZ:]EVNFZWK5I MH5@UU=-P/NJ.K'T%>)ZWK=]XKU<,0VTG;'$.BBO3P$:LNON'EYA.E&SM>?0] M+\+^)=(U)1%:6J6\J#D! /UKL(V!&<]:X/PKX?73(%R,R-R[>M=NIV1@"N?% M1@I^X=&%G-P]\EEB2:-HY%!5A@BH;.PMK%"MO&%SU/VMFX M827!(CP.!@9YK#\"Q'^QI;INMQ.[?^/$4[Q"#_;NDD9ZR_\ HLU>)TJ.W30R MI.U)277]6=%YT1<)O7<>V:JV6K6M_+J^0%C>2[5)68M@1EPF:10S')VC!.>]/F'[5]CTOSHQN^=?EZ\]*%E1TWJX*^H->2:ZD!" R-NZ?,2V<&A2!56VE8[^BBBK-@JK,EH;V!I2OV@9\L$\]* MM5D7L,C:]82*I*+NW'TX- &O1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 45'-<16Z;II%1?5C63/XNT"V.)=5M@?3>,U482E\*N3 M*<8_$[&U17-?\)WH)SLNC(!W0 _UIK^.-.*Y@M[R?_KG%D?SJ_85?Y2/;T][ MG3T5P-[\1Y+969=(FP.\H*UC/X[U?5K>5HI(;.+.TA<.WZBMHX*M+6UC&>.H MQTOJ>BZIKEAI$1>YF&[M&O+'\!S7(2:AKNOSF6&Z;3[$_<4 B0_4]ORK#T>" MW:\%Q/))<3'^.5BV/H#TKK?,C"X7-="HQH^;.:6(E6\D4?[#OY#^^UK4'B_N M^<:4^&[0CY[J]<^IF_\ K5;_ +1(!C# &H1(Y;AB333F1[I5&G^(+,[=/UIO M(_A292Y ^N13DL_%#']YKP [[8R/ZUIQ2R!?F(XJ1;@%L9I.3[+[D4DN[^]F M<=/\0XXUV3_OD_XU!+%XILR)H-5^T%>?*D4X;]:Z>*1=HS4P9'XP*S]JUNE] MQK[.ZTD_O,BQ\;VS2);ZG!)9SGC+ E"?][&*ZI65U#*05/((KD=>M;*6SD2X M0%&&,XY'TKFK36]:TRS:PM9X9K< JDDK?.H_+FD\,JBYJ>@UBG3?+4U.L\1^ M*'L9TL-,19[Y^O.5C'O6(J^+M08&?4DMT](%*G^=4M$:UT]GDFI)'ZTIMO%EOAX= M765Q_!(IP?UK5&IL['! %(;XYR7!]J+RZQ7W"TZ2?WE*36/%TD0C2UMH9!PT MA(8'\,U%]L\:L/\ CYL1G_IE_P#95LI>+(/NTK2 \@5-TOLK[BWS/7G?WF,M MEXFD&Z;66!;J(\@#ZDJ$_P!:VX[P!L8)JRES&3W%#FU] ME?<"BG]I_>8,>I^,;4YGBM+A1U"C:3^9K1L_&]FTP@U""6RF/'S@E?\ OK&* MT78,M8NK65O=0O'.BLK#!XJ4J=324;>A3E4IZQE?U.PCD26,21NKHPR&4Y!I M20H)) ZDUYGIFLZMX<0V4,$=Y: YC,DA#*/3H:NZAXCU/6;(V<5F;3S3AY= MQX7VK-X.?-IMW-8XR#C=[]C1O_%=U<74EKHELLQC.UIW/RY] .]418^(=4N/ M,U.^:% ,+';-L'U/)J;2HK32[9((B"5ZD]2?6M>*[0\DULTJ>D%\^IAS.I\< MOD9)\+7#')U*]8>C3<4P^%YP:A5JA;I4[;_ M (G.G0KLG9-K%^Z=E,]!\-2L/^0C>MZ;ILXK2:[C,E6$O8PM6YS6QFH0?7\3 M"&C^(H05BUZ8QC[H8DD?CFF+?>*-%?SIYDO[9>73;A\>Q)KI%OH3WJO=74#( M5/H:35]5M]'L'N[@_*O M11U8]@*\[@N[CP_?SW&DO&\)=0@DU)(H;>W.Y8HWW! MF]3P/2E]3]Z_V?Q*^NKDM]K\"ZLWB'5Y#/+?/:V[\K%"2I [9-2KH=XPVG5M M1V>GVBM..XB90J'IZ5)]H"#%:.36D58RY4]9.YC-X:B+9EDFE/K(^XTZ/PW$ M&S%)+%[QMM-;"SHS:?U6-5W@[>0?6W25IZ^9[*2 ,FN?USQCI6B1-YDRRS8XCC.3GWQTKQ M>?Q#JLR-&;^XV'TD(/\ .HK:PFO'$LTA5#U=SDG_ !K>&6J+O4EH<]3-'+2E M'7S+FJ:MJ?BK4LR%Y!G]W&/NH*[3PSX:2PA6655,YY9O3VK#T^]L-)79 FX] MV/4U>D\9,VVWMX\R-P%'4UTU%-QY*:LCDI."ESU'=G?I<6]N@+.H ]ZR]3\6 MVMLNR)\OV Y)^@K"LM \1:NX:=?LD#=6<_-_WS76:+X/T[2&,I!N9VZR3#./ MH#G%>?-4:;O)W9ZWT%-OM8O]!T M2\TG5$W74B%8)D'RR C]#7H_2L_5=%LM9CC2\BWB-PZD'!!%9K%*4DIKW35X M7EBW!^\1^';0V6@VD)Z^6&/U//\ 6K\EM#-(CR1JSIG:2.F>#3T01HJ*,*HP M*=7))\S;9U1C9)%<6-J(1"($\L-O"XXSZU$VD:>TDLALX2\J[9&V\L/0U=HI M6'9&:=$LX;&>WL(DM#*,;HACFL71/!\EC??:;^>WGVHR*L46P$'KNY.37644 MN5"<$VF5+C3+&ZMEMY[6*2%3D(RY IL>CZ=%$T<=E"J.NUE"\$>E7:*+#LBE M;Z1IUI#)#;V<,<4G#JJX#?6EL]*L-/9C9VD4!;[Q1<9JY119!9!1113&%4Y] M06#4+>T*$F;.&STP,U_O4MV9$I\IZ"TB(5#, 6.!GN:=7F\T^K7[V,$UZGG6^HK&) A MY.UB#U]*?-XBUB6]N)()7"02^6J"%BK#C.3TSS2YR?:KL>BT5Q,NJZOJ;WDU MIO2GS#]HCNZ*\ MZN/$>HQ7*W$=\\J^Z,%ND@"E86D0KG^+' M /UI]TZ"YD38\B9* M^E-2N5&:EL6JY7Q^M]_PCIDL))$>-]S[.I7!KJJYK7_$Z63FPL%$^H..%'(3 MW-=%!2]HG%7L17J6I-^O1W=_G_ SUKT&+0]*BQY=E M$/J,_P ZYGP[X;6S=M0O2INI#N9ZZ9=3C:41H"1ZUT8E\TW[-NQS85_NK'2[.2YN!%'&@ST S3KN^@LK22ZG?;$@RS5X_XPU^7 MQ+K*6=D6>W5ML:C^(^M1AL/*M+7;J:8G$QHPNM^B*7BCQ5/KUTRH!%:*?DC M'/N:Q;>25%/EAB#Z"O2M$^%T(C275IF9B,^7&<8]B>$C M0G^53[!+5E?6&]$;.IZLUS"09,(.YK%?3M86R^WBTG%IU$G'3UQUKKO#_@V: M]NDN]7@\NWCYC@+ [CZFO0O*3RO*VC9C;M[8KGJ8R-%\L%"E67-4=CP^ MVG,ZX:3GL:U+2_GA81O\Z^M6_%?@^73+Q[W3HFDM)22\:#)0^P]*Y^VN0#L: M7:P_A?Y3^1KKC*%6/-$X90G1GRR.K:X79E3S4#7/')Q6&UPR+N\Y!_P(5 +T ML_)DD4=3&A8#\125(IU>ATD,GV<4CS0J1F=!G_:% M+V2'[5G3KK;]*@GU1I@<-6#]HA0?-,@!]6%:.C:--XAF*6\ACLT/[V8=6]EJ M90A!?=0R&"4212@9V/UQ7K>EZ5: M:/9K:VD>U!U)ZD^IK&\7^')-:MHY[0JMY 1J$+V\XZ[A\I^AZ5(DR1CJ.)2<=&=*NKH!AAS43WV\D[CBN>>]#CB2,_1A4)O@#M,R9]-PJ5113K M'4PW04YX/UJQ]N3'*BN1$SL.),#ZU*L[\+YJ_B:3HH:JG2372;24XK'GN)IF M(R0M,4G;F290OJ3BHFO(%/EP;KB8\*D0W<_ATIQA8)2N5KMU1<%R&] "3^E0 MV=^;:?:[M@]BI'\Z[_PEX8>P,FH:@J-=S\@8_P!6/2M7Q%X=MM?L&AD&R8E2B0*.)E_[Z%=')%JZ.7GDG9Z&__:F_/RX-.34".IKG\EAD M/GW!J)[@1?>G0?5A2]DA^U9U OR6^_4HOP/XA7)1WL)Y-S'_ -]"I/MEL?\ MEYC_ .^Q2=$:K'5/JQC' !JG=:RS+QQ7/O>1QKN-PA7V8&H/MD<[".+S)G;H MJ*2::HI:B=9O0DU'6)<%5D('>JMKX8UW61YT5G*8CT=R,']:Z#2/!-]JFH13 MWL'V>S0@E6;)?';%>J1HL4:QJ,*H ]A65?&1H^[3LV;T,%*M>56Z1XLOPXU MXL#L13ZFM>S^&VK38^UW\4:>B [OY8KU2BN268UGV.N.6T$]G]YPT'PXTFU, M?VJ[FF+' #X )].*Z:P\/Z5I@'V2RB0COC)_6K-W9_:I;9]V/)E$GUX/^-6J MYYUZD_BD=4*%*'PQ"BBBL34***C$\1?8)4+>@89HN.Q)1141N(%)!FC!'4%A M2;2W!)O8EHJ,7$#'"S1D^@85)GC-":8--;A147VJW_Y[Q?\ ?8I5GBE%,D*R+V>5->L(E$K-YW MD6>Y19&#R(DK ,WKU]JZ"BCE0N2/8X+Q%H=])J%PMI92.DL*QQO',R@G&/G M[5T&A^'H]-@@>3)N%A,38/'/)K=HI**O<2II.YS9\%V!41F:X\E7#I%YK;5( M.>F:ENO"EEF0HK0U7Q3%IUFB1%9;MT!QV3BO2PKC4CR4]^IP5:UW[2>RV M-K6O$-O8J6N9=O&4B7J:\]U+Q7J-\2J2FWBSPL9P?S'-5;2RU+Q%J.R)7GF< M_,W85ZOX9\ 66C*)[L+YY]K?BN[U?2+ M/30'!5?WOJY[?7BNN^'/A5(+5=6O(OWS_P"J5AT7U_G6Y+X)LY?%*:P=H11G MR@.-PX'Z5TZ(L2!$4*HZ =JXZ^+C[/V=)6ON=M#!R57VE5W:V_S'4445YQZ0 M4444 %5KG3[.\Q]IM89L="Z!OYU9HIIM;":3T9C2>%-$ED#M80@CLJ@#\J;_ M ,(CH?F;_L$>?3''Y5MT5?M:G\S(]E#LB@FB:5&,+IUI_P!^5_PJ>&PL[9]\ M%I!$WJD84_I5BBI!=!1L_96;V:0D5K6>C:?8PF*WM(E0G)&T'-7J*N56S_ ##\C6Q;VL%I$(K>%(HQ_"B@#]*EHI2G*7Q.Y481CL@HHHJ" MBI?:99ZC'LN[>.4#IN4$BLH^"]":0.;3\ W'Y5T%%7&I.*LF1*G"6K1S[>"] M#9L_9,?1L4X>#=#$93[&ISW)R?SK>HJO;5/YF+V5/^5'-KX%T-6)$,W/_39J M4>!M#"D>1+SW\TYKHZ*/;U?YF+V%/^5'-)X$T)&W>5.WL\S,/R-:]EH^GZ=_ MQZVD,;?W@@S^=7J*4JLY?$V.-*$?A5@HHHK,T*M_IUIJ4!ANX$E3_:'(^E8P M\#Z$'W"V?Z>8<5T=%7&K.*M%V(E3A)W:.7?P!H3R;O+N%]EG8#^=6;?P9H=O MTLP__70[_P"=;]%4Z]5Z.3)5"DG=11COX5T5V#'3X 1Z(!0WA;164@Z?!SZ( M*V**7M9]V5[*'9&%%X.T.&<2K8H6!R W(_*M.+3;&!]\-G;QO_>2)0?Y5:HI M2J3ENP5.$=D%%%%06%%%% &=JDC)/IX5B-UR <'J,&M&H+F6&-X!*!EY J9_ MO5/0 4444 5=2NELM.GG8X"H<'W[5Y+!J%Y!>QZBSR;3)NSN.#SR*['Q[J:Q MVL=@C?/(=SCT'^16!=7FE/X8BL8FQ<(=^[U/>O&QU3GJ63MRK\3Z++*7LZ*D MXWYW;T1Z9;3KQ&"HNC5K0O:RW_ M %-;5/",^F6,EW#JDSF,9P?E_K6OX5U.XU'09_M!):+Y0_<\5@ZAX8UV.TDD MENUFC0;BH)YK:\+:M!=Z5-:);K \*'(7H?>E1M"O:SBFMNX8B]3#7S0^6-P(.<\_6KNMZ#=>';=+V#4I9,,!@DC^M9F@:;?:E= MW"6-PL+H,L3GD9J]JN@ZMI\*W5Y*MU#&P)3)P?K7+"-Z-^1W[W.^I.V)Y?:* MW\MOZW.BNK^:^\ 2W4F5E,1!(XZ'%5_!\COX7OBSLQ!?DG/\-/N-3BU/P+=O M%$(MD>TH.@J+P;_R*U_]7_\ 0:[%*]:#O?W3S7'EPU1-6]_8P?#6C2:\\ZO? M30^5CISG/XUT0\!8(/\ :UQP?[O_ ->N7\.Z3>ZJ\XL[I8"F-V2>?RKI+?PG MK45PDCZG&RJF!F@"_1 M110 4444 %%%% !1110 4444 %%%% !115+5-5M=(M#1.UV8?+(:+,9<#W./6M[Q%XDT^_\-R+9 MZDL,\P'EKQO//3%<"UHUV\+W7FA594E'W< ?SS6%6?0Y,15O[L333[2SN[&5[AY M8YE:W7)X!'U]ZN3SV4&FB/4#/M<[;LF3VJY2E-\TMSV(QC!)KF^M+5F82$J64D'(Q7IM%8O KEY5 M*UG6:6FNZ-<2RVEH=T@P=Z$\9JY>W/ MB?6(?LDML C'G:A7]:]'HK-8!J/*INQM+-%*?.Z:YNYR)T&;3_!EU: >9<2) MDA?7TI/"EE6:0-> MT5I&M+0YDQNWH3TK6&O^*\C-I'_WZ/\ C7>T5E#!2@N6-1I&]3,HU)#3$;-%%% !1110 4R::.WB:65PB+R6/:GUD>)+>6YT9TB0N0Z M,5'Z=Y)NHUE$I\P9#HQ)8#W MQ2Y4)4X62ZFM;ZGJ*W$(N8K:2&4?>MV)VGWS54>(KT6Z7[6T(T]Y @()WX)P M#Z=:I6D5L=3M#HUO<6Z[\W*%"B;,U<1 MJZ&36;K4-&G,>?_UUDS20WVHR76I2_86VG:\?(9E]O>H&O-7U#4Y;^:4VJR'!5?XC M3K30]3U@SPVZB29&Y6;@'UZUY\E+GLD>'.,N;EC%VULBO?:HJK$BRP:@S'+# M!!'IT J"*Y2WRS;UC=OFV#)8^V:O6.D#2Y5MM4L9%N]_RD#*D>Q]:]#_ .$2 MM4U2U=;5);-EPZO_ $\+16\]GJM]]DC,<:%ECD'S C/ MZ5OZ;X5T^[TG[1.&:XF!;S Y&WTP <<5T<&E6%JLJP6L<:S#$@4?>K&.@:K; MDP6.JB*R8GY'4EUSV![5Z.'M"'*G9G:J*BDFKG-2:K=07NC%EFNGMYI(]L9& MZ0;#SV'>MRWU>;4O%VG!["ZLPL,W$Q&&X'H:O#PQ'%=Z9+#+A;(L2&&2Y((Z M_C6C/IQFUFTO]X MT==N.N['^%=$ZM-[+H_U)C2J*]WU7Z%^BBBN,[ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]S M:IDW-I=(;*[V6V2+ MNJQD'^=/OX=5DF!LKJ"*/'(="3G\Z -*BJ=E'?1VS+=S1234>GYT ;5%4[Z.^D@464T4.+LKQDG^=6H([Q;+9--&UQC[ZJ0,_2@"U16-#;: MZLR&6]MFC!&X"(@D?G5S4(K^1%%C/%$?XC(A.?UH NT50T^'4HWJR7-O->-"N&EC7)..E)Y%Q+8&& M6?$Q&#)'Q^5%CI\%A$4A!RQRS'JQ]Z +5%%% !1110 4444 %%%% !1110!G MZOJT&C68N;C/E[L$@=*P[KQEY$;N+1S$P!BF0;EY/\7I6OK>D_VE &0(98^5 M60G:WL:YVWL9=+!A>:QV2KEXF9CS[5I%1MJ=5&-)QUU9SU_KWM5=+V72V,$!:*.Y.)(Y!O'L,GI39_P"R;K5(LO-#="YVF5>0@SP. M:;)>-<3W]E]I-V@&(F" $-^0]ZZ;'JQ@DK):=2E>C[)A90<5+117*>,%%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110!'-+%&N))$3/ W'&:\ZLK6QDOKZ> MXN5$*-M79(,-[ =:[37M.M+[3W-WYFV,;@8S@BO,+N!WL(S*UI$2WRB+",,= M-P%;4E='H8.":=G:YH-96EO,MAZI(%G:.1LR"1ADN <5LFDG M)]#O@TDY2>P[PV[6NL21PPC[1'D[F7./;VKTFWU"]$,,DL*9D!/EC@@#OFLK M2/#D-E>O=O<'S'7+Y7AO\^E7PS32&.++F3Y5)Z;?XF%>;BJW-).+.6M*%65[ M&[#()8E<#&>U/IL:".-4'$Q3JU5[:GENU] HHHIB"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MIDJNRX1MI]:JM;WB7#CS82I'.Z9@P'T K)UGLHN_H:JBMY25O4MC5$DYAADE3^ M^N,?K3O[0;_GTF_3_&JTUD5<>;(T@(X#],^E$ME"8EEA01GH<=O?\*SYZNII MRTBPNIVCGRY&V,?X'%5M6TNUO=,EACBAW,!SC%.CLVN(?]?(6'!60Y%,;39X MQE%AS_TS!!_4U4:M5*]@481E[KLQFEZ7:1:4;#R44;?F(YSGOS4%C966CW32 MA0N 4SUZ\U(MK>*<"&8=>3(N*LQZ9*6#,8X^Y*#YOSJ54JO9.Y;<5?FEHRO< M.\C%1$,2$%(R?FS_ (5I65J80TDNTRMUQT4>@J2"TBMR65KGJ:GK2G2L^ M:6YA4JW7+'8****W, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKBXCM8&FE.$7KBJ6M3 M216J+&Y02.$9Q_"/6L*_4V[WELERTL7V=6"DYP=U<]6MR721U4,/[2S;-H>( M;$A"WFHCD .Z87GWJTFI6KWOV-9!YVW=CU%T9]9EEM6S-;QJT9_O8 XK%8BIV['2$2[VW.E,L-R\MN#\\?)]JK:=/#= M?:$1PVQMC#W[FL"+6E\J_O%4B1U""/N&)Q_6DTV6[TW4X#/:R0Q7"B.1F[OV M/ZT>W3DG_7D+ZHXPDNO3UW9UT4"0[MN?F.3DYJ2BBNU))61YS;>K"BBBF(** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** *.JV4FH636\<@CW'DD=15&Q\.Q6MY M<2/Y;PRQA/+P>,'-;E%9RI0E+F:U-HUZD89'$JOC;D>GI4]%7RK>QGSRM:Y4.EV+3&4VT9Q'0U+12Y8KH#G)V;>P 8&!1115$A1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! &1110!__9 end GRAPHIC 39 krbp-20210625xs1035.jpg GRAPHIC begin 644 krbp-20210625xs1035.jpg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end GRAPHIC 40 krbp-20210625xs1036.jpg GRAPHIC begin 644 krbp-20210625xs1036.jpg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krbp-20210625xs1037.jpg GRAPHIC begin 644 krbp-20210625xs1037.jpg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krbp-20210625xs1038.jpg GRAPHIC begin 644 krbp-20210625xs1038.jpg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�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end GRAPHIC 43 krbp-20210625xs1039.jpg GRAPHIC begin 644 krbp-20210625xs1039.jpg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end GRAPHIC 44 krbp-20210625xs1040.jpg GRAPHIC begin 644 krbp-20210625xs1040.jpg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
4EU:[F., =3^5 M).? MTKIZ (+V<6UG+*3C:I->9VK&>]DE/\3$_K76>,[[R=/6W4X:0\_2N3L"$&37 MDXVIS55'L>GA(37GSU&PHHI&8 M*I9C@#J:W,1:P_$NC2ZQ!;)"P5HIEM9$<$JZB8K=C+*@^:23D"@#2\IX,'RC(Y& M61KZ5%D<;1'Z"I-7U016[1VX+.>"1T J2QL[&6P0@*^Y02E-Z] />LNXB<(;F(EC;O@'V_R:V9"NI::LJ$9'S#ZB@" MQ;W4-R>!B1>JGJ*LUAW+M]GCO[N M:65@,"N_\936\.C_ +U0TKL%C'?->;6UY%<:B+&/+3G@ =S7C8O#S51RCK<] MC"5%*DD^AH1 L%-1C@FL(;U?L+G<@*\KWQUJ.7 MP=J4EJ7_ +2'VQD$6\+@!/3K[FLY/&FM+)%))#$877S,#.<9(]*C'Q U&>XE M2"!"&7WWC#66 MTZ190D9=6"LF<@@XS5BU\9ZJ&@LEU@SQW6F:E+=0QF6" M3[RCM6Y&Q>)&(P64'%5]1$AL)O+^]M- &%_:JZC>1EX6$$9R>,Y-:,UQ:S)F M!5<^E,T6>S-@H^17'#@CG-,MH?M-W<-#@6X;C ZF@!$T_P"V9#RF,'^!!BJ= MYI0L=D5O<2%Y#A8P<9K3:66#(2!8S_>8FL:ZFG6[CNDWSRH><#@"D!I1P7EC M:%941X2/F ZTW1)A#=2V>3/I39O$"R6_EB%E=QCYAP*BF"6AM+J.16VG M:^*8&GJ$"V]E=.G&]?N^]0Z'&8FG0?=!''X"I=8DW6$;+RK.I)]J6 &UO&8C M]W* =WH<4 :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0!Y9XUU2:35+L$@+:IB-2>YR"?TH^&GAN1[AM:NT(.?W88=3ZUVVJ>$M,U:^ M6[N(SY@QNPLS5+CPY8WZ0WL4?GD%ON M$X'KQ71UQ>NZ7J+^)3=VUA':EN5+;.N>33K33=(0;;6&W.#N(0@X->=1^%?$DOVAGC M"-(Z,1YN1D Y(]*Z?PUX>O=*U"*:3(5H,3?/G+[O\,4 =#%HFF0L6CLHE).2 M0*.*MZM9->6O[HXE0[E-9[:M=PVWE36^Q\;=Y/% #TE:[5&? MYG(Y4=!6@DT5M ?.\M .@'-5+%K%;01>A!I: "BC-% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!( R3@45@^,YY;;P MEJ,L+LDBQ$AEZB@#;$L;'"NI/H#3MR[MNX9],UX;'?6RV%C]AU+5O[8E(V)) MN".<\]^F,UJ'6=5T_P")$3W-RWDF-(YHL_(K'()H ]>W#.,C/IFC(SC(SZ5Y MM%JUY>_$:*X6X9=/53'Y>[Y2O$@=2!]:6N6\<74UOI5G);RE"UY""5/4%QQ42>-XQIL\K6K"ZAF\@09Y8\X M_,"@#KJ*\^N_B)>Q/=R0Z,TEK9S"*63S,:68F6(30@ M/G>IR?3CI0!W9( R3@4 @C(KSJ^\97T^EWEK>6#6,T]HTUM('SD<>P]:71/& MU]:P:=%JFG-'!<1G9.7R21D\C'M0!Z)17"+X]NQY5]+I17299!&EQOYY. <8 MZ3RY)?,Y[]!CVH ]#HKBK7QO=>;=P7VF&&>.(31*K M[MZD@>G%+X8\#QQTH [2BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ K \9W M';NSMP#+(I"YZ=* /,-.UZYMI]*DL]=N+JXN90LT,J%4QSGD@#]:ZSQ/J^NV MWB#2XX=D.GR3[&8=7XK)7PQXBU&TLM.N+.TM(8'!::/&X@>E=;XAT.YOSI M MR"+6;]>E(-J*#U H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1D>M%<=XBO;F'QIH5O%,RPRL=Z#HW- '8T444 %%%% !67XATU]7T*ZL M8V"O,FT$]!6I10!R-_X-6\\.6=HC)'?6@!CF4="#6;<>![_4#J$UW/$+BZ@5 M59?X7&>>GO7H%% ' /X(OX=+LX;6X07$41220GJ2>M6I?AWIK>'/L4<*+> ! MA/WW@YS7:T4 '].LYID-Q;S122/V.T@G^5<[#IT6K_$O[19NS6= MN \XQ\OFK@#],UZ335C1"2J*I/7 ZT <:_@^Y;3=6MO.3-Y=B=3Z#"C'Z50\ M5>';F&V>_1@VRU$(4==V",UZ'2$!A@@$>] 'G-MX4UK6;-)]4N8@R6?DVZKV MR!R>/:MB]\)37EKH\!E4"SW"3WRI''YUUX&!@44 >>#P;KCV\&C2WP'/^-=S10!PNO>"KW5+N2>"Z$1-N ML0P<9(.?RJ#PGX+U+2/$2:G=M;JJP>5LB)/.#SDCWKT&B@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBLV[U[2[&39<7L2-Z%J -*BJ=GJMC MJ"DVMU'+C^ZPJY0!Q7C;7-:TR:T33X0ENT\:RSMZ%@,"LOQ;XFO+7Q%;V,>J M26-N+M6OB"#42]E MI\-[;RP[,$@%#@>IZ4 9]SK&H:C<:=I6E:P6\R,R2W@1N9MO"&M: ;/4;"$7-U\WGP[@,9ST)/TKJ/!VC7>F MVUQBN-\(7MS_X3+0_ M^?U:/^$ST/\ Y_5JS_PC6D?\^4?Y4O\ PC6D?\^4?Y5SVQ'=?B=M\%VE^!5_ MX3/0_P#G]6C_ (3/0_\ G]6K7_"-:1_SY1_E1_PC6D?\^4?Y46Q'=?B%\%VE M^!5_X3/0_P#G]6E_X3+0_P#G\6K/_"-:1_SY1_E7+7>DV"^-+:U6V00E>5QP M>E%L1W7XF56M@::3:EJ[=#?_ .$ST/\ Y_5H_P"$ST/_ )_%JU_PC6D?\^4? MY4?\(UI'_/E'^5%L1W7XFM\%VE^!5_X3/0_^?U:/^$ST/_G]6K7_ C6D?\ M/E'^5'_"-:1_SY1_E1;$=U^(7P7:7X%7_A,]#_Y_%H_X3/0_^?Q:M?\ "-:1 M_P ^4?Y4?\(UI'_/E'^5%L1W7XA?!=I?@)8^)-+U&X%O;7*O(>@K6KA'LK:Q M^(%G';1+&GEY(7\:[NJH3E)-2W3,\71ITW%T[V:OJ%%%%;G(%%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/5I6ATJXD4,2$XV]:X M738-,$]I%>Z,+BXN_F\V9?,&/J1Q7HI 88(!![&O,?%5ZH\7+97NI_8+9(]T M(B4$YY_+I0!V2^$]+M[V.[LXC:R(0<0G:I^H%;HZ5S'@Y[=[.4V^IRWPWO?]=_ZFNYKAO!?_ ",>O?\ 7?\ J:[F@;"B MBB@04444 %%%% !1110 5'-/% NZ5PH]S4E<9XTUY;+;8K 6DD&0_I08UZT: M,'.1U5K?V][N\A]VTX-6:X/P+'J?VB66;BV/KZUW/G1[=V\8Z9H%AZSJTU-J MP^BJ5]JEM8;/.< LP4#ZFJ,FMW#WDT%K9F818RWUH+E5A%V;-NBL%_$8-O&T M,!>5FV%/0U8M=89[L6UW 8)6&5ST- E6@WHS6HJA%JT$^I/9Q?,R#+-VJ_0: M*2EL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **C>>*-MKR*I] M":07,!.!,GYT 2T444 %%%% !7#^)_\ D>_#W^\?YUW%S3.XHJIIDKS:;;R2'+,@)-6Z#J3NKA1110,**** .,O?^2C6F?\ MGE_C79;E]1^=74]32^M[QK>15VY JG_P (GJ__ $')?U_QKCBZE.4K M1O=GJ5%0K0@W42:5MF=D"#T-%<5X1FO4UN_LKFZ>=8L8+&NUK>E4]I'FM8XL M30]A4Y+WV_$****U, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ KS+Q7'+IGBMM0C>P=98PICN%+,.O(P?>O3:\PUJ&:?X@S+9Z;%?,(1 MO6=@ .O3(- '3^"[Y[ZSE9H[5,-_R[J0/U-=16#X9@N(+:07&F06)SPL3 @_ MD!6]0 4444 %%%% '"^"_P#D9-?'_3?^IKNJX7P7_P C+K__ %W_ *FNZH!A M1110 4444 %%%% !1110!!=7*6L1=\[?4=J\[U6.XU?Q1# &\Y%^8!AVKNM< MN8K72)Y)651MXSZUPO@V2]OO$+WC)N3;M9L<"@\W&R4ZD*+ZL[W3M/ALHOW: M;"PY'O7.7\-T]]/9)O"*_G*1_=QT_.NQINQ2V[:,XQF@[)T5**BM#B;A3>:? M'J-S&VYYU !'169AYFZ1\9R>?2K%S]=!)%' M*,2(K#W%$<,<7^K15^@Q07[#HMC*6)8_$.43:"F20.IK8I-J[MV!GUI:#:,> M6X4444%!1110 4444 %%%% !1110 4444 %%%% !1110!R'CBPT]+,:E<6\T M\^Y8HTCE9@2)';O.ZLKJ MJ, 01W&:\YB_L>YU!;:;5KJQ6<@36C]'(_"@#U^ AH(R.A45)3(E5(45#E0 M!3Z "BBB@ KA_%'_ "/7A[_?_K7<5P_BG_D=_#W^_P#UH&CN.U% Z44""BBB M@ KF_&W_ " 6_P!X5TE=Q7]SH?B?4)S8S2K*1@J*T_P#A-IO^@3<_E7!0KPIQ<9/6[_,]C%X2K6FI MP5U9=5V.QHKCO^$VF_Z!-S^5+_PFTO\ T";G\JV^MTNYR_V=B/Y?Q1V%%(WU6[:!K&: 9W..*J.)IR=DR)X&O" M+E):+S1OT445N<@4444 %%%% !1110 4444 1SM(D#M$NYP,A?6O--8GT*^U M7[1K2WFF7JKM)!*AOR->GUA:YXCT?198X[YE,DA "A-QYH PO"^HV\4OV31X MKR\A=\O<2DE5'U)KNATK/TK4[#4X&DLF4JIPP P16A0!R/B[Q7=:)<6MO:6; MRF25%DE/W5#,!5;6?$>M2ZNVGZ)% 6@A\V9Y21G@' XK0\;V<]YI5NEO$7<7 M43$ =@X)KG]6^W>'O$=Q>QV,MU#>6X4&,9VL !@T 2-XVU/58[*STF&%;^4$ MS>83A,$_X5T7A379]9LY4O(UCO+=S'*%/&1Z5PUKI.I>%YK+66M))_-#>=&@ MR4))Q_2NL\#6-U%;W>H7<1A>\E,@C/50: *?@O\ Y&;7_P#KM_C7=5PG@O\ MY&?7_P#KL/ZUW= ,**** "BBB@ HHHH ***BN/,$#F(@.!P30#.2\=7<;:4; M:2)PQ8;3V-6/!MC)IMHT3P2 2'>'8<&N8\4ZB][J=G;2R*2C?-M%>D6"NEE$ M'8,=O4"@\RCRUL5*I_+H6:***#TPHHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** .=\57DT6F7$<;208VXF7OGL*Y*PTK3VN(+ MF?0[N]FR")YB7'UY%=GXLNK2TT*1[V SQ,RH(U."S'I7#Z;X9\42W\-S9W4F MG66X-Y#L6X_'- 'J28V+@8&.GI3J1 0BACD@_W_ M .M=Q7#^*^/&OAX_]-/ZT#1W Z44#I10(**** "HKB..6!UD177'1AD5+3)? M]4WTH$]CDO!("RZ@% $AP!^%=A7(>"O]=J'_70_TKKZ#FP?\%!1110=0444 M4 %%%% #2BL*-W8+A!D@4V":WN(A(@4 M@C.*Y95M!8>=]L=KET;*9ZTB6QLH=,N(YGW2R%7!/!+[=WVT._P"J1M;F M=_0VCK=IE\0,40D,P7@4Z76+)'B6-/,:52RA5SQ6586NHW,5TD$L20M*PY7G M^5.2_$%G%(X"K;OEF[G(J54FU?H4Z%*[2U:OI?R-JTU"SNRZJ KQC+*PP M13[*_M+R65+9@QC.&(K)C,-]XB8VV&B6/$K+P#STJ31(HX-7U*.-=J C _$U MI"I)M+S,9T8*,GK>R=C?HHHKI.(**** "BBB@ HHHH **** "O+/&-A-/XFE M33WM[BZE",89"-R[23Q7J,DB0QM)(P5%&23VKS36K+2+WQ%-J,^KPVQ9 ;>5 M6(8-S^G2@#9\"VSPR7LERT273, \,71,9_6NTK@_AY%#./$^O\ _78?UKNZX7P;_P C1K__ %V']:[J M@;"BBB@04444 %%%% !6'XKO[C3M#EGMB%<<9/:MLD*"2< 5Q7C2\6_%MIMI M('>5QN ]*#FQ<^2C)K?H9GA;3%O+I+W48GD>0Y4D<"O2 !@"LW1;>2VL8 MX)8538,#%:= 82@J5-+KU"BBB@Z0HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** .;\6]Q;PS:WJ8!( WQD CW.VO2->U!HHQ9V=U;QZA)S&LN#P.O%>=S:K=Z[>?V M3>:QIR*[^6Q2%03]#F@#UN([HD.K,[)&T9#.JY('KB MO++ESIEM:6NAZL^H1SQ%98BV[:HR*_P#D=/#W_73^M<^]W97MIX:M+!XWNHY061/O* 5SGTK>\5<>,/#N>N^@ M:.Z'2B@=!10(**** "F2_P"J;Z4^F2_ZIOI0#.3\%?Z[4/\ KH?Z5U]AHHH M III=FDC2+ H9NM3&UA*HIC&$.5]JFHJ5&*V1;G)[L9'"D((C4*":)791@$U9HIN*:LQ*4D[IZD-O:P6J[88U0'KBG)#''(\BJ S_>/K4E% M%D)R;W84444Q!1110 4444 %%%% !1110!3U6Y2STNXN)$WI&A)7UKS2YOKJ M]TK3PMG:"]U&0^1A2?*CX.>OUKU*YMX[JWD@E7=&XVL*Y/3O 5MIMY)(8#]>:[&L3PYX=BT"VE42O//, MY>25SRQ)S_6MN@ HHHH **** .%\&_\ (T:__P!=A_6NZKA?!O\ R-6O_P#7 M4?UKNJ!L****!!1110 4444 -D94C9G^Z!DUY]IKVNJ^/'FAP(XA\ON17;:I M=QVEC*TJ,R[#G"Y[5R'@.TM7FN;XX\UI#Y8_V]U9Z]=RQ6$MP]W:B"V=!G8Y!!^G45CZI9Q6UE9>'[72GDU-T!:X M"_ZMSSU_&O6R8RV"5+#G!ZBN8D\;Z2EVR%'*JVUIMAV@].N* .EMU9+:-6^\ M% -24B,'0,IR",BEH ;)&DJ,DBAE88((R#6=9>'M*T^9Y;:SC1WZG%:=% &9 M:>']+LKU[NWLXTG?JP'\O2N9\6_\CCX?_P"NG]:[FN&\7''C'P^?^FG]:!H[ MD=!12#H*6@04444 %-D!,; =<4ZB@#S[1;^YT37);.XM2%N)#AC7H-<;XE_Y M&?3/K_C794''A$X<^(XQI?BMM2U&P%_:2Q[8QN&4//;\10!T_A75[W6=/-S=Q MP*"?E\IB01^-;]<9X!M)(XKRZ$2VUO/+NCMPP.T9/-=G0 5SVN^+K+0KR.TF M222>12X2,9.!C_&NAKS;Q/:65QXJFN)-:DLKJ*W(10,<8'6CY0\$'J#Z&O+]'U:677=/O=:($7EM M'%*XP&P3S75> /WDNJW$(/V62X8Q''!''2@"/P;_ ,C5K_\ UU']:[JN%\'? M\C7K_P#UU']:[J@;"BBB@04444 %%%!Z&@#D/&.OQVM@]F%;S)?E_"M/PI!! M'H-L8E'3KCFN&U.*YU+Q3@%>EZ:(ET^$0@! @X'TH/-PTI5:\J MCV6B+5%%%!Z04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110!P?C'4X[#5E:VN)8KQ$!<9.S;[BL*UTQ@5348KK[',WF, M(AK42"*.%8E1=BC 7'04 +"%$* M!/N@#'TI] &.E% !1110 5PWB_\ Y&_P_P#]=*[FN&\7\>+O#Y_Z:4#1W ^Z M/I2T@^Z/I2T""BBB@ HHHH XWQ+_ ,C/IGU_QKLJXWQ+_P C/IGU_P :[*@Y M:'\2IZ_H%%%%!U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 5Y;XE9)?&\L-Q'>WD8B!6*VI^'=+UB1)+VT21TZ,0,UJ44 9E[X?TO4+ M*.TN+2-H8_N+M'R_2K=E96^GVJ6UK$L42# 51BK%% '">#O^1KU__KJ/ZUW= M<)X/_P"1MU__ *ZC^M=W0-A1110(**:[^6A8@G Z"JUIJ$=X6"(Z[>I84";2 M=BT3@$FLG4=7MHK"Y<3&,Q#DX[UBZEXKCL=0N(1<[RH^5 !U]*Y[3['5?$-W MPH."MC%?V=)79J^"8+?4I[R\G_>RLV3FN[2-(E"HH51V K* MT#2TTRQ$8@6-S]XCO6O0;X2DZ=))[A1110=(4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5POC M'_D;- _ZZUW5<+XQ_P"1KT _]-:!H[E?NCZ4M(OW1]*6@04444 %%%% '&^) M?^1GTSZ_XUV5']0EU31X;J8 ._7%!QT96KS@UJ M]34HJB^K6D:.SR;0C;3GUJMJ>NPV,?R N^0" ,XH.EU(I7;->BN=%_J-[?2I M;7$4,:*" Z9/-1'6KZ6WBBC,:SF<1%\9!Z\_I09O$170Z>BL-;Z_L+V&&_9) M8YC@.BXP:>-6N'UT6?DE(=I^9AR305[6/4V:***#4**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** *][=I8V4MU("4C7<0*Y*>XUG78 MX;_1[ZWM[61,@"N,\/_ ]C&BVXN[W48IMOS(EP MP /TH W_ IH-QI*7,]Y=K<7-P^YRG0=?\:Z2LO1=#BT2!HHKBXF#'.9I"Y_ M6M2@ HHHH **** .$\'?\C;K_P#UU']:[NN%\(?\C;K_ /UT']:[J@;"BBLF M^\06-C=?9[A]C8S01*2BKLL:K>K9:9<3JZ[D7(R>]<#HLOB#Q"LD:7!AMR,NY* M'#$(2!^E8-I#+:6%E>)94*;CMP3Z5+8+?R->I;0Q,C28+,>E8>WD[)+4 MZOJE-J6M\2(),LO56!!_6L".R73]6T MR"5E) 8DGIG!JQ)Y4GB>,6Q&?+(D*>E4JL^O>UB98>E:T;[-WZ;FW'?6\MT] MO'(&E3[P':K%<]IUK%:^)+I8EQER"BBBM#$*** M* "BBB@ HHHH **** &R2)%&TDC!449)/:LG3_%.CZG<2P6MY&\D8RPSVJIX MZ>5/"-\8LYV?-CTKS[Q)';6>GZ))I>U;AHRK^4=<_*.]<[X\!M=2T?47'[F&8!CZ=:PY8;.WL_#,MB(Q^G7>?]P_X4!8[:BN)_X6/:_] Z[_ .^#_A1_PL6W[:;=_P#? M!_PH"QVU%<3_ ,+%@_Z!MW_WP?\ "C_A8L'_ $#;O_O@_P"% 6.C\0?\@*[_ M -RJ?@S_ )%FVKG-4\=Q7FFSVZ:;=!G7 )0_X5!H'C6/2]'AM)-.NBZ=2$/^ M%!S.$OK"E;2WZG2:EH\]SJCE%/V>6,Y]FXY_G4*:;=C2'DEA+7!<$KWP"*I_ M\+%@_P"@;=_]\'_"C_A8L'_0-N_^^#_A0-X>+;9I6VC+>ZA-<74$B(RC: Q7 MU]#4VJV)M(;,V5LSK#.'*+R<[.WHKB/^%B1_] J[_P"^3_A1_P + M$C_Z!5W_ -\G_"@UL=O17$?\+$C_ .@5=_\ ?)_PH_X6)'_T"KO_ +Y/^% 6 M.WHKB/\ A8D?_0*N_P#OD_X4?\+$C_Z!5W_WR?\ "@+';T5Q'_"Q(_\ H%7? M_?)_PH_X6)'_ - J[_[Y/^% 6.WHKAS\1%_ATJ[/_ 3_ (4?\+#_ .H1=_\ M?- 6.XHKA_\ A8?_ %"+O_OFC_A8?_4(N_\ OF@+'<45P_\ PL/_ *A%W_WS M70Z!K@URV>7[++!L;&)!C- C7HHHH **** "BBB@ HHHH **** "BBB@ K*U M7Q'I>BNB7]TD3/T!ZUJUYS/#:W7C?51J01@MMB,2''&./-6M)_EDN,21@]QS_C7:7M];Z?; MF>YD"1CN:YWQ5X:GU">'5-+D$6I6_P!T_P!X>A_*N%UWQ!K5\\=CJ5E+&(S\ MVQ2=WO6=24HQ;BKLUI0C.:4Y67<[R[\=Z3#$3#)YKXX"UQ7DW7BW5Y;C/E \ M#/05:TW6=!L( CZ/<32=W:,_X5K6WCC2[-2MMH]Q&#R0L9_PKF=&I5M[5Z=D M=?UBC17^SQU[RL_P\S-M(]2\)WGGW&GB>,\>8!V]J[32O%>FZH JRB.7NC\& ML)_B%:R*5?2[IE/8H?\ "N=U34='OB9(-+N[>;LRHM AAD'(I:\8M?%>OZ>IC@CN)(QTWH:M_P#">^),?\>;?]^S M6BKRMK!F>K45Y3 M_P +!UW_ *!S_P#?!H_X6!KQZ:<__?!H]M_=8?5O[\?O/5J*\J_X6!K_ /T# M7_[X-(?'^O\ _0-?_O@T>V_NL/JW]]?>>K45Y5_PG^O_ /0-?_O@T?\ "P-? M_P"@:_\ WP:/;?W6'U;^^OO/5:*\J_X6!K__ $#7_P"^#1_PL#7_ /H&O_WP M:/;?W6'U;^^OO/5:*\I_X3_Q!_T#G_[X-(?'WB$]-.?_ +X-'MO[K#ZLOYX_ M>>KUGG1; W!F,/S'J-QQ^72O-O\ A/O$7_/@W_?!I1X]\1_] YS_ , -2ZBE MO!_<7&@X?#42^9Z?]@MO(2'RQL1@RCT(J2"VBM]WE+MW')]S7EG_ GGB7/_ M "#GQ_N&G?\ ">^(O^@8_P#WP:%47\C^X3HMJWM%]YZ5>Z9:W[(UQ&69/ND, M01^5.M-/MK('R(]I/4DY/YFO,_\ A/?$?_0-?_O@TW_A//$A( TY^?\ 8-'. MKWY'?T'[*7+R^T5O4]26VB6X:<)^\88+5-7(:#J?B*[O(_MMLJ6[#).,$?K7 M7UI2FIJZ5C&O2E2DE)I^CN%%%%:& 4444 %%%% !1110 4444 17-O%=VTEO M,H:*0;64]Q7/:;X&T?3+F2=(WD9E*J)&W!%/85TU% '-:;X(TC3-2^VQ)(SK MGRU=LJF>N!72U6OK^UTVU:YO)EBA7JS54LO$6E7]C+>6][&\$7^L;/W?K0!I MD!A@C(J+[+;_ //%/^^:I:5XATO6FD6PNXYFC^\%ZBM.@"'[);_\\4_[YI?L ML'_/%/RJ6B@"+[-!_P \D_*C[-!_SR3\JEHH B^RP?\ /%/RH^RP#_EBG_?- M2U7O;VVT^V:XNYEBA7JS'@4 /^S0?\\D_*C[-!_SR3\JS++Q1HVH6\T]O?1- M'",R'/W1ZT_3?$FD:O.8;&]CGD R0N>E &A]F@_YY)^5'V:#_GDGY5+10!%] MF@_YY)^5+]GA_P">2?E4E% $?V>'_GDGY4?9X?\ GDGY5)10!']GA_YY+^5' MV>'_ )Y)^525D7WB?1M-NOLUW?Q13?W#G- &G]GA_P">2?E1]GA_YY)^59=] MXHT;35A-U?1Q^<,IGN/6M2"XBNH$F@D62)QE67H10 ?9X?\ GDGY4?9X?^>2 M?E4E% $?D1#_ )9K^5'D1?\ /-?RJ2B@"/R(O^>:_E1Y$7_/-?RJ2@G S0!' MY$7_ #S7\J>JJHPH 'M6'<>,O#]K,\4^IPQNAPP;/!J:[\4:+8/&ESJ$4;2+ MN4$GD>M &O145O<17=ND\#AXG&58=Q4M !1110 4444 %%%% !1110 4444 M%<_KO@_3-?N$N+D2),HVEXVVDKZ&N@HH YW4/!>DW]A;VIC:(6XQ$T;;6'X_ MB:T](T>TT2Q6TLX]L:]SR2?4FK]% !43V\,C;GB1F]2*EHH A^R6_P#SQ3_O MFC[+;_\ /%/^^:FJF^J62:@E@;A/M+C<(\\XH G^S0?\\D_*C[-!_P \D_*L MRX\4Z+:ZBMA-?Q+<$XV$]#Z5L @C(Z4 1?9H/^>2?E1]F@_YXI^52UCR>*M% MBU$6#W\0N"<;,]#Z4 :?V:#_ )Y)^5'V:#_GDGY5F7GBC1K"^6SN;^*.=OX" M>E:ZLKJ&4@J1D$=Z (_LT'_/)/RH^S0?\\D_*I:Q[CQ3HMKJ(L)K^)+C.-A/ M0^E &G]F@_YY)^5'V:$=(D_*L[4?$VCZ5.D%[?1Q2/R 3V]:U(Y$EC62-@R, M,@CN* &_9X?^>2?E1]GA_P">2?E4E5KR_M=/B$MW.D*$A06/4GM0!+]GA_YY M)^5'V>'_ )Y)^59VI>(])TCR_MMY'$9!E03U'K6A;7,-W D]O(LD3C*LO0T M+]GA_P">2?E1]GA_YY)^525E:AXDT?2K@6][?10RD9"-G.* -'[/#_SR3\J/ ML\/_ #R3\JS+WQ/H^GV\,]S?1HDPS&3_ !"M&UNX+VW2XMI5DB<95EZ&@!WV M>'_GDGY4>1$/^6:_E4E9FJ:_I>C%%O[N.%G^Z&ZF@"_Y,7_/-?RH\B+_ )YK M^59U]XDTC3;:&XNKV)(IAF,Y^\/45>M+RWOK9+BVE66%QE67H: '^3%_SS7\ MJ7R8O^>:_E3ZRM0\2Z1I4_DWU]'#)C.UL]* -6BL9_%>B)IPOSJ$7V9CA7!X M)K1LKZVU&U2YM)EEA<95E[T 6**** "BBB@ HHHH **** "BBB@ HHHH XKQ M]AY]&BF_X]FN5\P'H>1C-<;XK"VVNZA!8X6RD1/M C^[T%>L:OH]IK=D;2\0 MM'D,"#@@CN#6=9^#M)L]/N;,1O*ER,2M*VYC^)H Y\16MMX^TD:>$4/;_O1& M>",'K^->@5A:+X3TW0[A[BW$KRL-N^5]Q ]!GI6[0 4444 %%%% !6/XDCTI MM+:76-IMHCOPW<2Z<=:MK_5+\06FD7/V:X2XAW)+ .5Z]>>G%=!;>!=)@MI;=F MN)89%VE)92P'TJSHWA+3=%N3<0>=+,1M#S/O*CT&>E &]1110 4444 %%%% M!7ENK6%]%K&LZU;7=C(L94F*0'( &,=:]2KFM0\#Z1J-^]W()D:3'F)')M5_ MJ.] ')Z'-:ZWJ]_=ZE#&H>PS'&_ 4;NWXUTWP\)/A5!DE%E8)_N\8JSJ?@O2 M=3>%G22$Q+L!A?9E?0XZBMFPL;?3;*.TM8PD,8PJB@"S1110 4444 %%%% ' M >(;*UUKQA9Z(MLGDI^_NF Y/3 _(FL_5-$NQXAU*_L[VRVVR@"&4'*@ ''6 MO08])M8]6EU)4/VF50K-GL!BLO5/!>E:K?M>2^='+)_K/*DVB3ZCO0!9\*ZF M=8\-65\81"98P2BC@<=JV:AM+6&RM8[:WC$<,:[54= *FH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@!",@CUKSAM)ATWXIVLL;,\L\+LQ8_3_ M !KTBL^;1K2;5HM3=3]IB4JISQ@X_P * /-8[>QE\+>(+BY$9O%N,JS'Y@E>E5R2?#S1XKV2[BDNXY)'WO MMF(!- ',I:V$NE>)9;L1M=I<.%9S\P VX_&N]\,-(WAK3C+G=Y"=?H*H7_@ M?2-0U$WDJRJ[8+HCX5\<\CO7111)#$D4:A40!5 [ 4 .;&TYZ8KS/QC96G]G M3W&EBS\L3J]TQ_UN0P/!S7II&1BN9N_ NCWE^]TZS+O8.\:R81CG/(H X_2# M8ZHVN7%\@YM4V"8\A=IQ7<>#6=O#%IO)/! SZ9.*BU/P3I&J3K-(DL;! A$3 M[0RCC!QUK>MK>*TMHX(5"QH-J@4 2$X!/I7C'CS75U&XN/MJ7$<-E,ODQ^6V M&(SSG'M7M%4=2TBSU:U-O=1AHRP;CU% '"::MEJ7BB[DO51XQ8J81+Q@;5Z9 M]ZW/AV3_ ,(N@SE%5)M#_4=Z .+T2[M=?U][K4(40?8,QQMPH/S9Q73?#IG_L2X3_EBMS( M(_3&:O:AX+TC4(K=#')#Y"[$,+[#M]#CM6OING6VE6,=I:)LB3H* +=>2ZZE M_>>.]35/L^V&VW 7 ."O/ Y^M>M5AZSX4TW7+A+BY$B2J-I>)]I8>A]10!P7 MAJ:SU3Q):_:;=(K=+/$<3_=!VC.*Z?X=DC3;Z-2?(2Y81>F,GI6C?^"](O[> MVB,F1]*U=,TRVTBQ2SM$V1)T]30!7KB M%&(Y /!_G78U1O=)M;^[MKF=2TELVZ/GH?\ (H X6?1[+3?$6@Z;(BBV2V9M MK="^>3^IJ[\.RXN-;B7_ (]DNV$('3;@=*Z76_#MCKT<8NPX>,Y22-MK+]#5 MC2=(M-%LEM;1"J#J24J$]\5U]>9_&/ M_CQT+_K_ !_*@".;QSXSTZ+[7?\ A5Q:+R[((;+Q-I$>H6391N&4 M]5/<&M!422Q"2 ,K)@@],5Y%X'>YAT?QE%87$=MLNR(97.%3[U 'L/G1;]OF M+N],T[<,XR,^E?..L3V.G6!N[?Q3?W.L(0Q9 2A.>GW>GXUU^IZSJ=M9^%?$ MQN9/*D"1748/RL6VC)_,T >OD@'!(S33+&&"EU#'MFO,[G4]0U_XA,NFW#_9 M-/M=Y53\K.0I /ZUYY%?K/,K3Q;9R-'&T%U VV:!_O(?\BNC,T:L%,BACVS7D^F M@V7Q@UF+3F54>VWO_=#X[_K7+:U]AA2ZGN_%5[+JRLS*+<$HASP/NF@#Z#W# MCD'\2:LNI(K827/S <<&@#LJ*** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ K@?BIH6JZWI6G?V3"LT]M<^:58XXQ7?44 >5SZE\2;^U-E'I M=M:^8NPS;\[0>,]*FN/AQ=6WPWN]'M+@MJ-P3+-)G'F,%+'Q+Y0O7F"1G.U'(#?7!H Y+X6Z!QVEK#96L=M @2*-0J@>E34 M&?"MKIMQ+YDJ#+<\ X' KI*** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* .4^(FCWFN>$;FRL4#SOC:":Y&PU'XC66E06$.BVX\M/+5R_3WZ5ZS10!YU MX<\!W]II&KW&HW(?6=41@T@Z1YS@#\ZY&S\->+;?2YM%AT&P1FW*;Y@"S9.< M]/ZU[G10!Y[X5\.S:=\-9='UI4B<(X.3QTZU@_!S193D>(/#MKXCLUMKN25(P;:W8 M^,K35KR/^SK36;"^&]/NY;Y4BENY3)Y"?=C!QP*[V MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**Y_Q3XKM?"MK'<7<,CI(X0%!P"?6MJ"X$]HEPH.UUW 4 345Q\_Q#TZ'5I= M,%M15. ?RKH]'U[3M>M?M%A<+*O0@=5/N* -*BL5O%&F#Q#'H@E MS>NI8+@]!C_&MJ@ HHHH ***KWUVMC92W+JS+$I8A>N!0!8HK"\+>)[;Q5IK MWUHCI&LC1X;KD$C^E3ZWK?\ 8_V7_199_/E\O]V/N\9R: -:BD!R :6@ HHH MH ***R=%UO\ M=[M?LLL'V>3R\R#[W'44 :U%%5[VZ6RM)+AD9@@R0O6@"Q1 M7$V_Q-TBXADN$AN#;QMLDEVG"GWXJ]JWCS1])TZWU!W:6TG("2Q\@D]!^M ' M445R/_"P=-B6.2[M[BV@?&)70[<'OTKIH;ZVN+,7<,JO 5W!U.1B@"Q167I& MOV.MM<"RD+^0Y1SC'-:E !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<7J M6M:MJ>OW6CZ.R1&VCWN[#.3S@?I7:5YOXA\-^*K?Q;)JWAB:WC6X0+.)2>2, M^Q]: ,OQS=:W/\,V.MVR17:7BJ AX8#=@U?L?$>O:/XFT73;\PR6FH1 ($&" MG!_PJ?Q#X;\3^(/!*V-S+;MJ)G5W.3MP,^WO4^K^%-6O/$WAJ_A:+R=/3$^2 MHS3I(ZFT Q&FXG[U2^"]&O_[;\0:\]JUG8W((BA88 MW?[6/\]:V[/PIJL?Q3NM>G\AM/EA\M0>6[X[>]=K?P/+IL\-N%61D(7TS0!P M/P>C23PE=QNH9&N7!!'!K$TC&@_'"\T^P79:7,.]X5^ZK?-SBKOAKPSXW\.: M#=6EM-:"5Y"ZU=P1D8H M X2Z\2:G%=RQKJ-FJJV "@R/UJYH>NW][J2PSWMK*AZK&H!_G71-I%@[%FM8 MBQZDJ*?#IMG;R"2&WC1QW"T 87B_Q*^AK:6ULH:\O)/+BW=!U.?T-4+9_%-M M?WUIJ:Q3:O% %5?B1+_P (AIUX\>+Z['R&EAN6@*J& )P?R%4U^'FN1>#+2WC:#^U[ M.=I8&).P9)Z\>Y[5O>'].\9G[2FNM9&-[=D3REP=Y!']T>U %'P=K?B[Q1 ; MXRVT4,4SQLFT'=AL?TJ70?'5XVB:_J&II'NL)_+14&,],?SK5^'/AW4O#>BW M%IJ31F1[AY%\L\8+$_UK%TKP'J*Z'XDL-0,1^WS>9!L)XZ8S^5 %^UO/&)FT MZ_"0SVMT1YT0X\I3W%=M>_\ 'E-_N&O.O#&F?$.R:TM=3NK1K*+Y6"?>V_E7 MHMU$\EG+'&1O*$+GUH \3\):M#;^"M>L#9S7,\URZI&D98$GWJKJ>AWV@?"/ M2[345VS&^C?RS_ "R<5Z'\.?"VI>'+.^AU40.9;@R1E!G /U%2?$OPWJ?B;0 M[>TTLQ"6.=9#YAP, @^GM0!O_P!EVFK^&H;.\A22&2W52&&?X:X+X-W,TFGZ MYILKF2WL[MHH0W.%QG'ZU?O=/\?G3K:UM+FT4!520GTQ@XXKIO"_A>S\,:8\ M%HFV28[YF))W.>IH Q/ :)'K'B)44*HO7P ,#M7=5R?A/0]1TG5-9GO6C,=U M<&2+:><'UKK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** 3 "BBB@ HHHH **** "BBB@#_V0$! end GRAPHIC 45 krbp-20210625xs1041.jpg GRAPHIC begin 644 krbp-20210625xs1041.jpg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�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end GRAPHIC 46 krbp-20210625xs1047.jpg GRAPHIC begin 644 krbp-20210625xs1047.jpg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ɊAO&8EI NY23[CI7907EO=*&AF1Q[&@">BBB@ KB_"U MS;OXAUR5Y5#^ET5Y9<>._&.CO%#J M7AY27.U71@=Y^F:EA^,5JD_V:]T>\CF'WL#I^% 'IU$6]M'"O1%"BI: "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "D)P":6D90ZE3T- &?I4>X37)^_,^3_G\*T:: MB+&H51@#M3J .8\5KON=.3L9?\:Z3RU:+8PR,8K)\2V+7FE,T?\ K(3O7'6K M6CWRZAID,ZGDCD>AH &66P^9"7@[KW6KJ.LD8=3E2,TI ((/0U#;0?9PR Y4 MG(SVH X_2V,-SX@95/E22A$^OS9I;KP7 V M1SE7CST)YS_.L[4]/>^\1L!*T<46'^7N<8Q0!>O9;1+=H[B1$0CA<\_A4=OK ME^B)*MF38QKMY^^0.^*KG./SICWTLT@@T^W,S'@N1A5H Z"RU M*VO[83PO\F<$-P0?0U2U&_>XE_L^P?,[CYI!R(QZ_6N0U;PM/N.]8VL M6(CO&^WZI#'"I_026"XYR>U6);*78N"'R7/TQ MQ0!0T^\BBC328IA'$26EN1PK9YV@^O/Z5T=AJ*>5Y>GV;M G&\C&3_6H+;2] M.O\ PZ(0596^;C@G\JZ@ MDC)'&!G-9BQ64K%8=0GMH\YV-E1_.LZXNK6:]CRLR>7SY8Y!_&G3WMA(,+9N MC#^+/^)H ZK2HK*W@:.TF67G+L&R2:T,UP5M=6,&Z06DDCR=6#D9_(U))J< M7?!"\,J\AC(3C\": +7Q$_Y EM_U]1?^AK6CHW.MZD?^F<'_ *!7%ZSXD;7C M;Z3)$$F29)&E7)3 8'^E==X8;S[G4;DC+G&1C-5YDM7!1CN]*\-0E%[,^DE.$U>Z M^\N--!/(R0MM'8MVJG]J2"W 60R,6(<>M(P!+!DPW<"DAM#))\J[SCY44_U-86 M\VW5?O<5Z/INF0:9;^5",D\LQZDUV87#N>LMC@QF*C3]V.Y8MX5@MTB0$*HP M 3TJ6BBO7/">H4444 %%%% !1145S,+>VEF/(12WY4 17.GVUT[.ZEMX9AB6)''HPS6;< M:(@1C:-Y9/.T\C->;7WB;6)];^TF,^7\B^0F<+D]_>MNZ\3:U=:7+-;^5;M$ MZKL()8#U/%#BGN.,Y1V.IC1;:(K<0NLAY#HO>M:T=I+=6<$'WK@SXHU"VDG1 M;=.;AU\U]Q7 4']>E3P>+=7FNHS]BC2W$B(ZG.X[AU'Y4HQL.4KG=T4BG7JOC"]U&=\K;'RH%/0?YS M6O>Z1:7S^9+&N_\ O8KF[=1%,"J4(N8APP'WEH G;P[ M;XPH7\5J&7PVAC_=MM?.0R\$?0UJ6^IVUUM$3$EJMT"*F@ZCEG\M]KK\I[USVHZ<+Y4=',5S$AI(&R4? M..N*4@'J ?K0%REX>\2O<[++54\B^ QGHK^XKIZY;5=,M]1LWCE)C(&1(G#+ M]*\\CU;5-/U$:>NK7 MB^-[*#D?4B@#VRBO-=)M96U>%9;J62,JY!WGLN16Y M:V@O=%EN;JYN)2&=%VG!4 XXH Z::^M+=MLUQ&C>C-BJ%SXCL(2%B=KACT$( MW_GBO,K]Q4\+W-L(IXK M2\C[,25;^E/L])N;[]]9P063.N/,E/X7>%X=0AO8[-UFB?>OS\ _2M7P]X;&B&662[EN9Y3EBYX'T%;33PH<-(@ M/H30(DHIB2QR?<=6^AI] !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 (P#*5/0C!KF;"*31=?DM5Q]DN"70=@?2NGJCJEC] MLM?DXF0[D/N* +U%4-*O_MD!60;9X_E=3ZU8N;I+:/G2M?45N[R(27DGV:USDH#R16 M3?VKW^H:8H&Q5?#_.@#1M;)=2U%TO-Q\H[A%V [5TT4,<$82) JCH! M4=O;K&3*RCS7'SD5/0!3U2W%SITT9_N[A^'-PE=[_ #=/ M;-=7--#"A,SJJ]\UP=O%#:ZW>6QOG2.1O-CQT.>3C\Z -4VVI7P*ZE>@H>L< M V@CWY-8$MJ;/5IX;+;&-T87 RW).>:Z2WDME.%GWMZDUDSA(?%$!3YV<%\# MGIS0!IVNG2Z=JHM[1V(GC\UMYX5N!D?G4OB*PL$TI?M01F$J,6:E&@:6! MC['%_P!\B@#BM"NM)MM16TN)8%AMXOE#$')/7GIVIU_2H!S6S M%#'!&(XD"(.P%IV,.5MD571,\*23G'Y5T] !1110 4444 %%%% M!1110 4444 %%%% !1110 44R:00PO(QP%4DUXUHGC+5V\<1W5S=;](O)FAB MCXPI X_G0![117(7WCZTM/$3Z'':S3WBE?E1<\'OUKG].\?:AJFJ:W87-G-# M!;J=LBKS'P#S0!Z?D8S2!@PX(/TKPW7/%M^/"NBVEA/=R)>28>Y ^9AQP.>O M-=/X*\4:;INE:DD\]Y_H6&F-U]X''3J?6@#TRD*AA@C(-><:MXS;4_#D]Q]F MO-/MPRF.X*XW#/;FM+4/&T7A[2;*66VGN(F@5VF [8'O0!V@"H HP/05S_B2 MZNXDCM;*%BTIRQ5:Y?6?$3:AXF\*7&GW#BSNV8LN?O?*W7\JN^-M5OK#Q/H, M%K.8XYYML@ ^\,BHG!RCRIV-*15^5/<\U3U;XB7L'BW3;&QLGFL;I M-^X+RP/<4H4802LMBJE>I4;;>YZ,L4:L65 &/4T[<,XR*XG4/B3IUC>/%Y$L MD4.!<2J!B,GMUKF]1UR[F\8:K]FNW^S?8#)& > >>:T,3UL$'H:*\G\/:U*U MEX6-W?S"6=FR.H?&WKS[UN7?Q0T^":Z\JTN)K6V;8]PJ_*&].M '>45QNH_$ M.PLQ D,4EQ<21"=XD'*)ZGGV-1W'Q+TJ.*P>".6?[8#L6,9.X'!'6@#MJ*Y" MQ^(>E7.C7=_49%P9<],6XZKZ_K73T 0M:P.H5HE('08Z4J MVT*/O6)0WJ!4M% $?DQ;"FQ=I.2,=:1K:%V1FB4LGW21TJ6B@"#[';;BWDID MG)..M*;2W+,QA3+#!..M344 0M:6[)L:%"N+_GFOY5)10 4444 % M%%% !1110 4444 %%%% 'FOC6YEL=>AL]-A(GG3S781%QCGL/I7,G71;SA-0 MMI;>?/RRB,KN_#K7HOB2(6FO:;J6<;B86/H,''ZFK%YI]G?H4NK>.4'N5&?P M/6@#D-*UN#8Y,R[B/ED7L?I6Y:^((UB1;LAGZ>8@X/X=JQ[SP2+7?+IJB5&Z MPN2N/H1S6,U@+3 >6ZLV/#>ZU96I"SN(RN^U M"GARZY/XHZB@#%U6S\0K"$F MOY\=0 _F#]*REOM1*&+ROM03@J@PV?I7?2:):22;BTP&/NB5L?SI\5@EL,PQ MHC+T;;R?J: N<3:7UQ=RJMSI%VA0_*'B8@?I6FUI?27!DL+1DEZAB=@'OS78 MJ7V#>V336D5!EF ^M 7.*MM8\2KJ?V*XU !C_>0Y'TY_6NIMM,LK^1X[N.5; MU5W,Q/WO<'%QB>.)HW] #C]>*L/XGU"XCL9-)TJ>ZG3*R,5 MPN.>] "7#R:5J&VPEM8_+8[\W"JS?AFN]L;E;NRBG4@AEZCUKS>[\,ZCXH8G M5=&CMY"P(FBE92/K@#->CZ?9I86$%K&,+&@7KF@"S1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-J*C3KU-17B,_)- MCT]?TJ_#;JS_ &AR'9ONGT%0ZY)!%HMT]P0(@ASFL?PEK#RV$5C?_NKR-30!IDXZU3GO@I,<(WOZ]A6+)=ZQJDA^RVIB@'>4[,_XT\>'+JY4+>7[B/J8 MX?D_#(/- #+G4=-LY ]U*;N[/W4C!8 ^V*ATRQO=3\0)J]S;K;6\4;)'$>K9 MQR?RK=L]'L+'_46Z!O[Q&3^=7Z *\UE;7";)859?3%0P:/I]M,98;5$D(QN' M7%7J* *FGV$6G6YAA&%+%OS.:MT44 %%%% !1110!4@T^*"_GO%_UDP ;\*M MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% &3XEM[Z[\/WEOII474B M;4+=!7G$WPDDMM!T^2QDQJUO(LKDGY2<@FO7:* .$T/PMJ=MX_N]>O1&8I[5 M(^.NX* ?UJH/">N6GB+6WMQ"]AJ2'YC]Y3@#U]J]&HH \IB^'^L)H/ANS)B\ MW3[D2S?3*]/R-3-\/=1N9/$@EDC1;\JT!'8@#K^5=QX@\26/ARVCEO"Q:5ML M<:#+.?0"I=(UJ+5K#[6(9;=0<%9EVD4 <'<>'O%NJ^$VT:^BM5:/8(Y$_BP< M^M4-?^'^O7]Y 5\FXMQ9+!LD/$;!5&1S[&O1-8\1VVD7-A#(K/\ ;)-B%>E: M_FQB3R]XW]=N>: /-;#P-JUN_A@N8L::S&;'N&Z?F*W/%?AJ^UCQ!HU[;%/* MM)=\F[KC(_PKK9)XHCAY%4XS@GM5/3M;T[55E:RN4E$3%7*GH10!PP\$:G_9 M7B2W/E>9J$H:$^W'7\J9=>#MV/DO/8Q"&96Z8Z$CGWKTE94=-ZN"O MJ#6):^*;6[\27.BQJQE@C$A<="#G_"@#SR^^'&J)KEU<):07EO=,';><%#W[ MCUK7E\#:C_;E[=0B-+>6R\A%]&Y_QK0N?B?86NKMI;:??FZ!.%$)Y .,CVKL MX+N*=5(8!B,[#U% 'G%AX$U6"/PVDC1XL"WGX]#MZ?E7%ZPEQHUIJFBVEY#< M07%R"(PA\S)(.*]_66-SA7!/L:S%T?1&OOM*V=J;DG._8-V: /--1^'.HSWE MGJUM#'<,UJL4MO(<8QGW'K6K#X$O8M3T"X@@A@ALV9IHQV).>.:]':XA59"9 M%Q&,OSTJKI>LV&LPO+87"3(C%6*G."#B@#SV[^'6H7Z:ZKRI&;J836Y'J,'G M\J??^$_$?B+PD=*U-;>&:WV^0R='P._/TKTZB@#S_P ">$[K1KV2XOM/A@D" M!5DC.2W3W->@444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 9/B2P&H:)/%T9<2*?=3G^E4["8W&GP2M]YD&1Z'%="RAE*GH1@UGP:1' M;1LD3$*7+8/;- %:D=$D&'16'H15\6"_WS2_8%_O&@1R&M^'7NI%O=+E%K?1 MC@X^5QZ$5RQ,UO1\W%O_ 2K_>7_ /7VKU?[ O\ ?-4K_P /07\D M,CD!XS][')!ZB@9PC6EIJ,27$>5+#*R)P1427&IZ1N,6JQM&.?+D4DG\1760 M>"Q;+<)%=E4=RR#;]S/;K62WPR$DI>?5)Y03D@$KG]: ,Q?$FI7UD\ESI@EM MU^\(SD_SJE9:AHW,J6S0F3KF,FN_T[PLNGH(X9=B#L!G/UJ33O#$-CNV+!_/-7[+P5I-JN94>Z?^_.V\_K0!SK>)&OI/(M(Y9F MS_ A&/Q-:R>'KZ]"^=.8HV&3Z_2NHM[.VM5Q!!'&,8^50*GH P[3PAHEHHVV M,;/G)=N23ZFME(HXU"HBJ!T %/HH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBN9U#Q'-I_BJ+3I47[/)"9 _N,?XT =-17GL M'CZYETB\G\E!XB&$DCZ@5>U#5+33(Q)=2;%/3C-8.O\ BI+72(+_ $Z5 M)(WF5&;T&1F@":V\,W"+Y=UJL\T?H<#^0K5L]'LK+F.%2Y'+-R33--UW3]4= MHK6Y221!\R@UEVGB*<:SJEC>(JBU3S$8?Q#C_&@#I@ !@# HKE-'\813Z6+[ M46$*2N?*P.J^M+X@\2O:0Z?-I[I)%<2A2W7CF@#JJ*P-,U[SY+XWEW<[017(,@!.T\9QZ5BV_C> M"^_M..V&V6USMW]&QGF@#KZ*PH/$EI#I-O=ZA/&C2CHO>K+^(=+CLH[QKI/( MD.%?/&: -2BJ&GZS8:J7%G<)*4.& -7Z "BBB@ HHHH **X[XB:U>:'I5I]4)?B/>WT>G/IUIL,EWY$RR?5<_P Z /3J*\]OOB5) M97<\?]E22103+"[JW\1!..GL:E3XC*^E7,[69CN;>38\+-R> >..>M '>T5P MJ_$(W.G6,]EI\DLUTS((BV"&&/;WK1L?&MM=>%[G6)('C^S$K)$>H;.,4 =3 M2!@1D$&O,M4^(=W/H][;PV;VU_Y(EC);/R-GGIUXJX\&K0?#=+U-0G@NXXO/ M9F8L6SS_ %H ]"HKB/"^N?8M"MY]6OY;B>XC\WE20!_D4J>/'.FW6JO8,MA& MQ2-]W+D>V* .U) ZD"@$'H0:\FUWQQ/K.EPBU$]G-%<@.5. RD>OXUTW@"^G MNH-1-U-)%PZAAZ&@HC)L*@KZ4 >*6T M&I-:Z$TLOVE1>,8RJM\@PN!R,U6LY->E\62)/.8;M;PE#(&Y3<<#@8QC%>Y" M"(!0(U 7IQTK)U;5[>QNX8$A$UY(0%4=0/6@#S_PXWG>)=0AUS[7_:C.RPYS ML*[>V/QKFDM]0TS1M4M]-@G2Y2]/GY!YCW'^F:][$:,5D9!OQU[BG>6F2=HR MW7WH \+B.O?$Q>RVUR[VAE7S(X@VY!@9QN%;7P_AA_X6#?SV<5P+-[9-CS M\G+5ZA>21Z?833+$-J#)4=Z32YH[RQANDB"&1,Y2N,GU'4Y_$T=U"MQ;2+=%&A .-N.I[5[SY:%]^T;NF:9)#'M=A&I;&>G M4T >.VEAJKZ1XCU*"2Y^V1R2+"I/ 4DYQ^E8\5Y*=6LX]&ENC=?9"9$D/_+3 M/->OV-]!K,5WI\B-;3@E653@X]146B^"=.T?46U#?-<76,+),^XJ/:F!YKX+ MCU2_U QW$Y5S;NMQ$V_IQ2K&BL650">II .HK#U:76;2X%Q9HD]N!\T7>C3O$]G>,(9LVUQ MT*2\?SH W**0$$ @Y![USGCC4[G2/#[7=JY619%''4C/(H Z2BO)KKQQ>W>J MF-/M%K M@9&5U();*\C\ZV&\?O:6<:0VDET88%DGD+8P"2/2@#T#(SC(S2UY M5>>,[W3O%$M^L$T]F;-)7B#\("H.<8KK-=\:VNCZ/97IB9WO.(D]\9_I0!U- M%<#-\2([72X-1GLG2"1FC;)Y#C&.WWO0 M!W=%<&?B,LVH06]I823));BX9LXV+SGM[5%:_%"">6G2 M@#T&BN$;XAA=&AOOLN3++LP&SY?^]Z?C3+GQG'INIW,\[/(A@C9(E;*ECG&# M0!WU%>?2_$K[+!Z7<.UO*W9W!L$#T[4 =)1110 4444 %%%% !17'MXTV^*O[+,'^C[MGG9XW>E:/]O2_$:=( M,0\L1;]^: -^BJ']M:;YOE?;8#)NV[0XSFGS:I8V]P+>6[A24]$9P#0!37B*L<$@1=K@ENG^- '4T5R]WXNBBO]*2 M(QFUO 2TA8?)C'^-;G]JV/V<7'VJ(PDXWAQC/UH N451.M::$9S?6^U3@GS! MUJ'6M5;3]$FU"U03[%W \$4 :E%>,!#H^F7D,7F/>N%"9Z=,UNP:O8S2 MK;BZA-QCE XSGTH O45QC>,;E=0UBW%LA%BZJI+ ;L[?\:Z*?6+:VL4FGGBC M=X]RJS@9XH T:*YGP[XJBU/1FO[YHK<>:R#+ X)']*MZMXIT[2;".\>598Y M'"J4;/4__7H VZ*P$\1"?6;2U@5'@GCW^8'&1T[?C6F-6L#=?9A>0F;ILWC- M %RBJ,VL:?;R-'-=PHZ\$,X!%7$=9$#HP92,@CO0 ZBBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "N#^(FE7UU]DN].A:2=3Y9V]@?_ -5= MY1@'K0!Y4_A6^3Q%901PM]ED0/*W8-S_ (5%-X;O(M2N[>\ANFCFGWQR1(#Q MGCD\BO5;B>.UA::4X5>IHCFBF1'5E^89&>M '"-I=QIOC2UNOL#7%M)"$\S; MDJ>.3^53>,([R+Q'IE_!9R7$<.=P05VL=Q!*7V2(VPX;!Z4\LF 25YZL6UG+'ITR6Y8K,A0%Q]*Y^'0]27P[/;_8I"?M8=8F'5?EKUL,A. 5/L M*CFN(8(9)&9<("2!UH XCP_IUW/XK.HC3S86\<7EE<8W&HO'6E:B=5MKK2X6 MI/)&L9=F7:!G)-4_[5M1I MYO6R(@2.F3D'% 'G\OA_5+JUUJ.*)T9YE=1_? ()'Z5!]AU2;5[2ZL](-LT4 M&SYE !88ZUZ9:7L5VA=%91_M+C^=2BX@,WE"1/,QG;GF@#R_3-,U*3Q!I=S- M92HR2,)V*A5Z-Z?A5M-(O+2[\16_V XN=SPRJO&#GBO2 R$9!7'KFC>F<;ER M?>@#S"+2-0L5TV]FL7NH8XF1H<9VDGTJ)_#>I+H$:26S?OKT2B'^XF5_PKU1 MF1>&*CV)JO:7L5[YGE#(C;:3[T C HH M**** "BBB@#,UK0[77888KK.V&02+CU%5KWPKIM_>7-S/'N:XB\IP.!C&/ZU MN44 5>&?%^KR:IIYO;Z9H;@,9/.^[P,_+0!W4G@K394F5B_P"^F69N M?XE! _G5>X^'VD7$DTC>8'ED\PD,>N /7VJ35O&UG8V4;3Z[>S:G?-%=2"(WT 09Z*2W%=EXG M\<1^&I+2V%LUQ/+&'(# 8'2@">'P#I,4$T9\QVE01EW8DA1T Y]ZW)]*@N-& M;2WSY!B$1]< 5Q3_ !-\V;;9:9)*%@$\F6"E5Y)Z_2JNK>.+E%O;W3 \A6S$ MRQN?E7A?\: .\L]%LK/38K%8E>*--@+#)Q62G@;3$M[FU+2M:SDDPESA2>XY MK'7Q[=Q65E$=.,VH20>?,BR !4YYS^!I;WXC^48?LFGO<>9!YY&X#: 3U^M M &K_ ,('I9LUMF+E5?>#WSC%+;>#H;+5(KBWN)$@61I7C!/S,?\ ]58M[\4K M.)K5;6T>8R())!G!49Q^/-:-EXY6_P#$::9%:,D;(&$DC!M %V]FU^] MO'M[.);: ''G-U-26WA2WWB:_EDNINOSDX'X5T%% $<4$4"!(HU11V48J2BB M@ HHK,UK6(M*M=WWIWXCC'5C0!%KVM#3(!'"/,NY?ECC'7/K4.A:(UL3?7Q\ MV^EY)/\ #["HM#T>9K@ZKJ1W7<@X4]$'I71T %%%% &=KO\ R!;K_"/Q%:-% '*O8:WHKYL)OM=MG_52= M0/K6M>:?'KVEQQ7L9CR5*[YM/TI)DD="9D7*'!Y- #;_PCIVH7 M(GE!#B#R./[O'^%],#:?(]O$ MZ1RS[AP2,]*V]?\ %)TNZL[*TM&NKRZY1 P4 =FZGI=M8W"$I;?ZI@>5-8=Q\0/L6NVVG75EM65E1W60-L8]CBH? M^%D[=4:!].D^RI/Y+3AA@'&>E &Q/X&TRZMHK>X+R0Q X0\#)[_6LFX\!&Z\ M1)+)/(+%+;RAM8@GD<'\JN+XY+?;[O[$PTRT+*9]X^9AVQUK.MOB?'/IUW#TY_&@#I+;PCIEI>_:88RI\C[/MSQMY_Q-5K3P-IEBTIMRZB0 M, .NW/7%)?>+CIGAN#4KRS=)YR%C@W#)8D #/XUDZO\ $5]$2VBN]-87DJ&0 MQ"0':O'?\: -(> M)2QDM SA)7WR<_>/Y\5._@?2)$9&C8H8EB R> HX.:\^ MUKQ->7>HWMS:W$L4+P1NB'C;EP#79:+XQ:ZU>'1VMBI6)299' W'V!ZT 61X M TGR9%B;5V[=HQZ4UXD9"N,9&,B@#Q241Q/HEN; M26*^2Z(GD8_?^][_ $K4U&TF34-5@NK*>:^GFS;2KT SQ79VOA72X=9$SRR3 MW$?[Q4D(.WWKI6"?>8+]30!YK::)/<^,;5-2BDD6.T!+9.-V%JG/I4\]MKX- MJ[[9PR CJ 1TKU?:N=V!GUHVKS\HYZ\4 >:O8P:G>>&T6RD6V",)5(Q@_+UK M*_L^Z31M1M!!-Y2WP$:_[/'2O7MBC'RCCIQ43S01SI"VT._(&.M 'F1\/1_\ M)'JE=5X2MI;GP4EK>*X+!U(?KC)Q74[%SG:,T !1@ M >U 'E7AW3KY]=-G/;N;;3$8Q!APQP<511;VXURTN3;S13I>?,JH NX\YKU MV::&V*E\*7.!QU-0S7]G!YMGLPD07HK8_P#U5ZEM0C.T8//2C", 0%([4 >/VD=Y:^&+ M6V>S=8GN'+ML!*#+8X-,CTJZF\*7*FVFD\BZ#*K#G;D9P*]CV)C&T8^E 11G M"CGVH \UCADG\3Z5+9VTD,7V4CD8"M\M92V4[)!9I8W U9;G<\_;&>N?I7K- MS/;V<7FS;54'&<5, APP4<]\4 >77.C/>:]XA:Z@DD,=J#$W."^&Z5W7A02C MPU9"8,) I!#=>M;&Q* !@# H 6BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@#%\2"5[%(H5)9W&<>@.:R$M9TB6=6F,KW( MVKDX5 ?2NP(!Z@&C:O\ =''M0!PSPS0V\1MR\(N)3]H8\X/./Z5:%K<"1U:: M9TM[;*D$CGVES>2 /Y5VI56ZJ#]11M4=%'Y4 <'%+<>1-#>+<%%C M/D(N?FX[FM34X5AT*QMB6C#,K,P_AR.:Z?RT/\"_E0R(PPR@CW% '):E+<,+ M9-/EEEV$&63MM/%17<#QS7D]JDHF$2!&.20,G:U-;SW"8F@7:CXSQ6]10!Y\_P M_:X\5S74DA33VMUB C;:6ZY!Q]:WV\%Z2PF7RR$E@\AE!_AX_P *Z*B@#EI/ M FFO#;H'F5X4\L2!CED]#^9K,O? *W7B&!U8Q:=';>5A&()X'^%=Y10!R\_@ M+1I9;>6.$1O"NT$#.1G-3?\ "':>VL0ZE)N:6'_5CH%KHJ* "BBB@ HHJKJ& MH0:;:/<3L %' [DT 1:MJL&DV;3S'GHB]V/I6/HVDSWMU_:VJ#=*>88ST05' MI5A-K5[_ &OJ*D1?\L(&Z >M=6 ,#@4 %%%% !1110!G:[_ ,@6Z_W*9X<_ MY -I_N"GZ[_R!;K_ '*9X<_Y -I_N"@#4HHHH *ANK:*[MG@F4,CC!!J:B@# MD]*GET#5#I-TQ^R/_P >TC?R_E765FZWI4>K6+1'Y95^:-QU!JEXU%O<9V!P_![@YJ]10!S4G@G3)(YT._$ MSJ[<]U&!5K5_#-EJ[V\LC21SV_\ JY8V(('X5MT4 #<=F3WQ4!=*N99)'# R($.TX& <_TJ:'P=IT>K0ZBV]YH M!B/)^[7144 %%%% !1110 4444 %%%% !1110!QVH2W']I7;6KE)VE6%6Q_# M@$U'<2W,BW%O)=2"-;M41QP2 PS78^1%NW>6N1SS.9#%$2"1SU-=* M;2W8 &%"!TXIZ0QQ_<0+VX% ''W&JSS2K*ETR2F8J(5'15(ZU&M]J=LMM2F3WQ3O(BX_=KQTXZ4 2N MX]3ZT 4G3'3M1]F@RI\I?E^[QTH Y&>YU)X+J9;HA@5BB '?C)_0TZ?4;S3KF6 MW-P75BJF1A]S)YKK?(BQCRUQG/3O2-;0OG=$ISUR* .15VO+L6IN&N(#.@!; MZ'-=DHVJ .PQ4:VT*$%8E!'3 J6@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HZ45!>RF&SED49(7@4 0Q:M9S"X*3#%N2)/;%0G7;+R MXW5RPDR5 &217(0Z?=,US 4=1?*??DX_2M2REM[._@,R[4CM@ "O<@4 = M/;7<-W#YL+AE_E3+;4;:[GEAAD#/$<-[5APR366F7=RL3*]U)^ZCQTS@5EI% MJ%B+R%X5BFEA"JT9)RQ!YH [JJ_VV+[;]D!S(%W'V%<,QJL MC-S@\9(J&;S[=[F:Q\QHW9(S)(3T!Y/ZT =_D>M&17'P6=P\EK;/=RF+8TC. MI/'/ _6J\,URB3(TDK1F7#S@G[O% '<9I"0!DGBN-CCNY2+:.686LDPV/WQG MFK=G'='1]22)I6^;$6X\XXS_ %H VEU>TDN?(1BS9QD#(S]:NY'K7+V]]%;> M'(TMX_\ 2DC 8%?F4]R:SG%PTD@MIISOC W'IN.#Q^M '=49'K7#S?;].>X2 M*29X251F;DKR,D?A3M1$ZRVUI:3M]DD4DRL3DGB@#MLBJ5UJMK:2>6[DOW51 MDBL70[2Z?4)YI[B1TB&Q,\ GKFG:9-';7MZEZG^DO,=I89RN>,4 =''(LB*Z M]&&12E@H)) ZFN*MGOIKRXN993&T1.(U)Y&<#CI3'M[N*$'S9W9[C!E]0:?FN!D2[0V5C"[1VS0!C(2<[R!G^M;/A^UN);VYNKF>1@C M[8E)X(P.?YT =+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1145Q<16L#S3.%11DDT -O+R"PMGN+APL:C))KF;*UF\37WV^]5ELHS^YB M/\7N:;%#-XJU$7,P9-,B/R)_ST/K76QHL2!$4*JC H 55"J%48 Z 4M%% ! M1110 4444 9VN_\ (%NO]RF>'/\ D VG^X*?KO\ R!;K_O/8VZ0[6N)GV/6F_P!N MM=6MWNB\L1$(1GYLY'^- '145S$>MWEG=2K-$K64;+&),\@DXJU>:OY^BWD\ M(*A1MB;^\: -VBN037GM;-+&\C=)@B'=GDY.*T8]=8>41 3:[Q#YIZENG]* M-ZBN;CULQ',,32FXB@9Y_*@#H:*YV+Q4@J?/6-5**>"YJZ M^MW,,]O!-:JDDQXR>,?XT ;E% Z44 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 F!Z"C:/0?E2T4 &!Z4A ZD"EJ"]F6WLII6. B$F@ CN[::0 MQI*C-Z9%3;1Z"O/K.\DMIHYY?*8QHS1F(YZM_%^=:)U>]6XD>.^6:*",23!4 M&!G/ /X4 =;)+'$5#D#<=J^YI^T8Z"N/DU&XNC;W+CMLZ@DLMD"&FCVOP@X3'/]* .OP/04;1 MZ"N/@UG49;1[GSD ( "XZ$G%3G4KNSNH%NKL,C("=JC.[T- '3I)&V=K+UQQ MZT[ SG KCTEN+R:S9;GR6=&E"JH^8@D?TK2T/4KG4I1N8;(5VR\=7[T ;V!Z M"C ]!2T4 )M'H*4 #I110 4444 %%%% !1110!SOC#79_#^E1W4"!V:4)@^A MJYJ7B"RT>SAFO9"IE^ZBJ68GV JKXP\/R^(]'%I#,(I%<.K'U%9%YX0U34K> MUFNKY/MUHQ,3!05P0!R* -1/&^BN$*W!VLC/DJ1C!P1]:MV/B73]1NH[>VD+ MN\?F# Z#)'/Y5RTWPU232(K5;H^<9FDEDQC.XDD#\36MX5\'CP]<7DKS>:9O ME3_97T_G0!<;QCHXU1M.%QNG!*X X+>F?6HH_&^CR[_+D=C&"T@"GY #CFL> M#X?_ &/Q!)?P2J\;2F8+(.58G-49/ =YI5OJ=W;3":>]C/GQ[>ISQC\ * .E MLO'>B7XD,4[C9%YWSH5RN"@#=_X3316FMH8[ M@R/<+N0*I/%5K[QE8R6>H"PG_?6JG<[(=JD5DW'P^EF>P$FU>=MX(!*H2HR<#)'%8;_#J6.246M[MCNXU2Y#*"< @\?D*E;X>*(]0 MCCF&VY\L(6&2H4D_UH W]7UG[%?::JS(L5P_.1DL,9XJDGBGP_XAG73#*S-( M?E#(0&(YQGI4VJ^&6U%])82[?L.,_P"UA<5CZ?X :R;3&\]2UG,\I('+9&,4 M =Q##';PK%$H5%& !4E%% !1110 4444 %%%% &=KO\ R!;K_&0/ZUJ6OB^ M*.2\DOYXUBA5"$53N!)/'O5*7X?K+HU_:MY)N+B<2K*5&5&0>OX52U3P2]O# M?7;S,Q9HWC"+DAE)/(H MZY\0[5-+^T:6S,\4ZI,KQD$ @GI72Z+XDL-AKSK0_".J:R+ZXO%\GS;A)%+)MW!5QTKM-)\+2Z=<:Q()@ MOVX';M&-N1B@!EUX_P!(BM[XQ.[3VL;/Y>PY;%<0/B7JLYM8P1%YX,K.86.U MY7#VA@''0Y!S^E &SIWCC2[R")I&>&1X?. MVR*1QSZ_2M^QO8M0M([J DQR#*DC'%>9Z_X7U.YL=$TH1[[R%\27$0POE]P2 M/;->FV5LEG906R !8D"#'L,4 3T444 %%%% !1110 4444 %4Y].CN+OSW)) M\LQX]CC_ JY10!@Q^&8D"*9W*Q@B,$_=!__ %U.FAK!<12V\K)M4*X_O 5K MT4 9^H:6+UXI4D:*:/HX]*BCT."-K99- M[,5W=?B@##/AR.2!TGG>1B-H8G[J^GZ5M3N6O715\I$,C>F2<_I3 ZE+2!%0"-?D78O'0>E, M33[2-6"0( W7CK7.2^(+U]GD*!]HRT/RY^4<5,NIZO-/Y4:Q!XHMTN?7GC^5 M(#H94A:/RI I1N-I[U''86D<9CCA0(3D@=ZYJ+5Y[E(C,R-*F6<8QLQ3+35; MW2K>,WDHF%SGRO\ >R<#\J .J>RMI&W/"I/!R?;I2/%;0,T[JBL1AF/<5F76 MH7MO96D9"+=W'4MT7&,UB2W][JUU;6,CJ")OF('#@9H Z?R-.A4'9&JNU$9YP%))&:DAU2\AM3]GD4QVRJ"'' MS.<=ORH Z*YT])(-L(6.15VH^/NC_.:73K"+3K18(^>[-W8]S7/7&MZFTTKV MPC\E75%##EB0#_6DG\0WUK+):.%>8N KJO YYXH ZVBJ6E2W-]#O;Q M;6*Z&]B0N5(!(Z\X]JWYXS-;R1@X+*1FN M_AQ)''IZ27:D6TSR.0F"P;=QU M_P!J@#HX/&>BSW;VZ7'*@D,5(5LU8UK M\/)XY$MYKX/8VP?[*@7#*6&.3GGH*D@^'\L5EI,!N4)LKIIW.S[X))QU]Z - MFT\7$4,=P0TF0NY"!D=NE5[WQOITEOJ%M97&+^")V5&!'(K.N/A_--;Q MQI=JC+<--N"<\@#U]JSH?AE?+J+W4NHJY,K M:I,J-(IW'U.XCBB;QSHEM#%)/.8_,Z*RD$#UQBJEQX*-SX-L]&>YQ/:DO'*! MQNR3T_&LG5/A[?ZQ);WE[>QR7BKY279F$-RD2/;K"JA>A&/?VJQ M:^";N'Q+;:D;Q8XX4VE8EVF3KUYYH [BBBB@ HHHH ***ANFD6UE:(9D"G:/ M>@!#>6RS"$W$0D/\!<9J>O#"]E+X6$UN&VEUQD]J;IEF;#3H;9F#&-<$ MCO7F>J^/]1L];MTMI$DA+*DL;#!!*YXJ2+Q;XA^V)<-)$;-[PVPCV_-V .?Q MH ].EN(85W22*JYQDGO4@96^Z0?H:\7?4K^+3]3^U78N7340%A?J@^;!JUH6 MJ:W#_;LJWWF2VTJMY+OT5R/@K7;WQ&+K4).+(L%A&.7=;K:R>62X^]]*U;;6;?5[&:3372 M:5 1L88P?<5QUU\/]0G%_&+J(1M<"YMODZ-@##<\CK6_X3\-W.C2WM[?3(]Y M>/ND$:X4?0?C0!A6_CS4H/[1DO["&.WL#M?R^I/8#FM!?%&M1:'/JUYIL<, M0/$N>3GUYI#X'-S%K<-U,-E^X9"O5"!3(_#OB.XT.YTC4+R"6 H$B8)@\'OS M0!+X5\97&NZF;*>WC!,(E$D1R!D9P>>O-=G7'>'/!K^'M:6Z@=%MWMUCEC4= M7 S_.NQH **** $P,YQS2T44 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.XTNSNYO-EB#/C!()&: MS=7U)K76;.-%D=5!=U09R,$53TK6I7U!PZNRW$C; W&P*?\ Z] '0?V=:;W8 M0C+KL;W'I3?[*LO)DB\@;)/O#/6LUO$$CNB06V]FR?O 9_PJ.'Q*VZ)KBV M,<!F@#7ETRSE2)7A&(AA,'&!3OL%MB3]WCS!ACD\UBW'B66T^::T MPC1&1<.,XX[?C2R:](5DBGMFC;:I&UQW.* -6+2;&'.R #((//4'K5-]"CFO M;=WP+:V.Z*/K\W/^)JC#K5U!=W"R1EX$*QQ ')9CFI)/$<\/FK)9D-&X0D," M!D9Y].M &W=V=O>(%N$W!3D.)0R#"GTK(\0WTR:5;F(L'ED7 M/E')*Y&<8]JSK+7GL(BK&283O^X1CRH'!S^- '4M86SM(S1 F7[Y]:C_ +)L MO.6;R!O7&.3CCVK,'B-_.B26U,6Z/S&+G'KP/?BHX?%0D9G^RR>1@E7'<^E M&T-.M1C$(X??^.,4R72;*;/F0 DMN)R0)9K>9H7L\R8&U5<'K5VWU6X MN+AH5M@#%CSB7&%H U(D2*,1Q_=7MG-/KF-(U*X2X'FQ%H[FWX5T M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !117'>/-;U/1;:VDL)(HXRW[YF&6 ]AG)H [&CH.:\HO?B!J%O+?J) M@ JQ&WW1D%LM@\?2K\FM^(-1U2XLX)XHK>.SCE=BISDH"<<^] '17/A_PWX@ MN))%BBDN(GRSQY!5JU&T'39"C2VD3BO(-(U74O#WA6WDM;N);J[= MY?FB)W $]3GVKHX?&FJZK)I%O'/#8>?$))9I4)#' X'(H [R30=+EF\Y[*(R M?WMM2C2+ * +9,!_,''\7K^E>>:9XRUV\\3K -C6RR^6\10@XQ]X$FIO&_C/ M4=)UD6^FSHODJK2Q/&?F!/8YQVH [M]$TV25Y&M(R[D%CCJ15+5M$LI[*Z$3 M1VDDRA9)E SBN#N_&7B)GN+RVDA2VMEB=HV0DMN7) YJE/J.K'5-=-U?+)#Y M:.MLZ'G)'3F@#U/0M*M=%T>"RM.8D48;^][UI5XY?>-];MX0MK+#:Q6T$6(W MC.9,CMS[5?N?'&NRZ]%;6RI&D:H6C=#^]R 20<^] 'JE%>6W'B_Q#!JLDP>$ MV,=\+8Q%#N(+ =<^]>H1MOC5O4 T .HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH IG3HCJ#WA)\QX_+^@SFJ,WANVE$6)9$:,L0RL03GK6U10 M!E6^@VUL,(S_ '"G)]3FB30;65<-NP(]@YZ5G/XB2VU>]CN)F$4:X0!"1GCN M!4EGXA\NQB\Y'FEV!I67^'- $O\ PBUHW^LEED.W;EB3QZ=:MR:+;R3M*Q;+ M$9'TJ,Z];_:'C5&(1 [-TP",U5;Q/ \8#12P^8N8V/?G% $\OARWD+D2R*6? M>""?E-,;PQ;F.5//EVRL&DR2=WZ^U16^OE;J6&=&$,$:EI3W)%)>:^9()(XH M9(9-H*LW<9 H U?[,@ M5&=ML"$&?452E\-6DC(P9E=&+ _4YJ2ZN)HVMK19 M<2;=TC>PY_6L6SU^[6QOC,X,_F%8 ?3F@#9F\/V]S,KSR/(%& I/2FIX=MUM M)+<2OL((D2)3%)(,JC2CINH 6#PS: MP71N/,D>0MN)8D]L5.VB0F]EN4ED0RC#J"<'WJ&'Q%#+;C27N(Q!&#(LV#@G;G9GUJKIOCC7)+NWD>>*=)I)(V@4' M*;<8)_.@#TU='L$NA3GZ59O/%7B&'P_:W,@2(>;MED#@LR<@'1].$ M.S5E>0S,#@XR=OZ?K0!V>N>!+37+V.263RX$" MCRT0#@>];QT6P9H6:V0O$H56QS@5YJ?&?B+4%@2W*6S_ &5YF+*?FV@']S@"613NQZ@D?TH LMI%@^[=:QG<_F'Y1RWK5T #H*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RAHR""\3?EK MAMVXCI58^' LC^7<%(I ZXZXK>HH Y?6M$G,#S6[9D">6BJO4>_Y5./#9F6 M-[F?JTGAF%[KSQ(0PA\L#' /'/Z5O44 <[_PB MZ>3Y9G/+Y)QV]*=_PCDGEK$+L^4DGF*H7WKH** ,,Z(T-I;I$^YH <9[DD\_ MK6EI]H+*T6+.6ZL?4]S5JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "J<^E6%S\(:=H% ML8UBCFF+LQF9!NY[9KC8_$\UV-*O 7GG4/OW+@Y"L<<4W3O&FL3WT'F74;K/ M!)*8@O,9 ! /'O0!Z2=*L&M/LILX3;Y)\O8-N?I4;:'I;P1P/80-%&4PQ'I[5DW'C+6]4T_5+59Y$5(5FBF"C=@D^ MGTH ];&BZ8+A9_L,'FJ,!M@R!39-#TN:%89+"W:-#E5,8P#7GT'BV_TZXLK6 M:]#P/IOFB5E^])A>.GN:EC\4Z]=7UK';R)Y?V,W$@*\L06X''M0!Z#_9=AN# M?9(=^#O%NMZUK*+<1@VT@;0-!<1K M)&W56'%344 4%T:PCC18K6-/+!"87[N:PM-\#6EGK3ZG-)YTA!4+C /6NLH MH H#1M. 0?9(L("%&WIGK3(= TJWW^380('78V%ZCTK2HH S'\/:1)%'$^GP M,D7W 4^[]*GBTNQ@D62.VC5E78"!T'I5RB@"E;:1I]G GRAPHIC 47 krbp-20210625xs1048.jpg GRAPHIC begin 644 krbp-20210625xs1048.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BJ\TWE3PJ>DAVCZU8H **0$$9!S43SJDZ0X MRS<_04 3444R.195+(B]@^U MVF8B/,7YHV]Z38[$>K*?L1F3[\1#+^>*LB42VAD0Y#(2#^%5K6X6_L&!'SX* MLI[&H-*D(TF2$GYX T9_ 5/-J5;0LZ4YDL@Q.?F8?K4-I(;G6+J3^&$>4/T/ M]:CTNY2'17G;[J,Y/YT:0RP:2UW*<>82[$_E4J7-R_>-QMI%H^\O^-B4'Q3?G@A M*&F-,ZZ&ZM=0B9497!&&4]1^%9S3R:+&_N5R%QJ%Q++YT9$4OJG% M:%IXGD>,V>IPB5",;QU(K"I)P5Y:>9K"*D[1U\C9N)QIFJ1W<9S:77WR.@/K M^E-2X%MJ]_&6'ES1&1.>O6L":[*QO90R"X@DYC]5-:=IX:N[E$>YF:+C Y( M'I7'[>%C"I_>22L-O2[YF"IVB4\"O2A+FV.*4;;G=Q7T=Q+LA!=1U?M^=6J MX./Q+>Q($18U ]!3_P#A*M0]$K2S,SN:*X;_ (2K4/1*OZ7XJ>6X6&\15#' M<'^=%@.JHKF-PUN>:SSXF<>YIRZM*ME]D0X4GYCZUF7DVV MY<>YJ'S)/+$A4A&Z-7RS]I"K-P/JHX>$Z<.UEM*G"DG#=[GB9BZG MMG&:LEL>>CJG^\/YUM^(_P#CZB_ZY+6(.J?[P_G6WXC_ ./J+_KDM>B><9^F MP6MQ>A+N4QQ[3R#BMS^RM _Y_&_[Z%QJ.VE:*X+"!)D\L[E?TJ %0^P*1QG@<5(B69A MD>>9VGQB..$Y_/%95Y)0>NIO0@Y36FAT/A*Q2>66]D4?*=J+Z>]=C7+^"9T? M3YHP?F1^E=166#BHT8V+QC;K2N%87BC3DNM-:=5'FP\@^M;M9VN3I;Z-QB1;95C+?/+W8BEMX##7,*,NF?45Z'K7_(%N/]P_RK MSU?]8GU%- :>ODF^B).28Q2^'CC4)?\ KBU-U[_C]B_ZYC^M.\/?\A"7_KBU M'0#)W'#$\GYD?=(,@*> *Y8?=;_>/\Z]$T.5'TB#:P.%P M:&!2_P"$2L/[\OYBM/3M,M],A:*W!PQRHI +1110 5#=_\>. K=3VKL?"^EQZKX8>&=,,?NDCD&NR;3K-CEK>, MGZ5+%#% NV) B^@KCI810FYMWN>G7S)U:,::C9KJ>,:C8W6E7[0LK!D.58=Z M[+3=>.I^')X)P1/&N.>XKLI;.WG;=+"CGU(IJZ?:+G;;H,\' JJ.&]C-N+T? M0C$X]8FDHSC[RZGFB@Y7@_>'\ZV_$8/VJ+@_ZM:Z\:;9 Y%LF?I3Y;.WG(,L M*MCID5UW/..-\+Y_M;@?P&MG6-#GU0^83&CI]TKW^M;,5I;6YW11(A]152ZU M0(WE6R&:4\8'05+8XIO8\\N8&BD:&X4I(AY[T:]!]:CORB2BPT>!%G(VM*HX05G/WEKI^9O3]V2L[_D< MQ!=S>&=6^659AC]\J=!7>:?KECJ, DBF4$CE2>17)7^CK"\&CVGSW%P=US*> M2!_D54N- B_MZXL[1W5+>W\QFSWP?\*Y8>THZ15UV.^I&CB$G)VEW\O-?D>@ M7&HVEM$9)9T51[UP&O\ B'^V;A+>(F.S5\,_K6;/ILJ:##JLLC.OG%'7/8$_ MX5MVNFQZ;J7V2Y0/I]^H,;'^%L?_ %J4IU*RY6K(<*-'#OFOS-7_ W^?4@O MK*[LK:WC9HYK3GRY5'(]C4%C$L^I6D3YPTJ@X.#6[##+X?N!:7B_:--<_NW/ M.P^_Z5T":58/+'=01JK A@R=Z[*=E'E/.KWY^:^_4R->T^2UTF0K=2/&/^6; M ?SKEH0?M5OP?]:O\Q7ITD23(4D4,IZ@U NG6:L&6W0$<@XK1:*R,6V]60:U M_P @6X_W#_*O/5SO3@]17J+HLB%'4%3U!JN--L@=7UE+87;PR(0-Q* MGU%0I+/$"(I)$![ UZ;+!%.,2QJP]Q4']F67_/M'^5.X'G?VJ\_Y^)?SH^U7 MF/\ CXE_.O1/[,LO^?:/\J/[,LO^?:/\J+@5?#\DDNE1M*Q9O4UJTV.-(D"( MH51V%.I %%%% !1110 4444 %%%% $XH S+VZEN939V?WOXW[**DC@M]'LI)>I W.QZL:MV]M';IM0?4]S5>\ MM7NYXHV_U"GC?W23_6*ORMW!!Q_2K?A]2NE[6&/WC_ /H1IFC* MUKU6ZHS"BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH :Z+(I5P"I[&G8&,=J** &HBQKM10!UP*! I&@ GRAPHIC 48 krbp-20210625xex10d12001.jpg GRAPHIC begin 644 krbp-20210625xex10d12001.jpg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end GRAPHIC 49 krbp-20210625xex5d1001.jpg GRAPHIC begin 644 krbp-20210625xex5d1001.jpg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krbp-20210625xs1_htm.xml IDEA: XBRL DOCUMENT 0001792581 krbp:SeriesBPreferredStockWarrantMember 2021-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember 2020-12-31 0001792581 krbp:SeriesBPreferredStockWarrantMember 2020-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember 2019-12-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001792581 krbp:CommonStockWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001792581 srt:MinimumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001792581 srt:MaximumMember krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001792581 krbp:SeriesBPreferredStockWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001792581 krbp:CommonStockWarrantMember 2021-03-31 0001792581 srt:ScenarioPreviouslyReportedMember krbp:CommonStockWarrantMember 2020-12-31 0001792581 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001792581 us-gaap:SeriesBPreferredStockMember 2020-01-31 2020-01-31 0001792581 us-gaap:SeriesBPreferredStockMember 2020-01-24 2020-01-24 0001792581 us-gaap:SeriesBPreferredStockMember 2019-11-13 2019-11-13 0001792581 us-gaap:SeriesBPreferredStockMember 2019-09-13 2019-09-13 0001792581 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001792581 2020-06-17 2020-06-17 0001792581 2019-12-17 2019-12-17 0001792581 2019-12-16 2019-12-16 0001792581 us-gaap:RetainedEarningsMember 2021-03-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001792581 us-gaap:RetainedEarningsMember 2020-12-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001792581 us-gaap:RetainedEarningsMember 2020-03-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001792581 us-gaap:RetainedEarningsMember 2019-12-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001792581 us-gaap:RetainedEarningsMember 2018-12-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001792581 us-gaap:NotesPayableOtherPayablesMember 2021-03-31 0001792581 us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0001792581 us-gaap:NotesPayableOtherPayablesMember 2020-11-30 0001792581 us-gaap:CommonStockMember 2021-03-31 0001792581 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2020-12-31 0001792581 us-gaap:CommonStockMember 2020-12-31 0001792581 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001792581 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001792581 us-gaap:CommonStockMember 2020-03-31 0001792581 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001792581 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001792581 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2019-12-31 0001792581 us-gaap:CommonStockMember 2019-12-31 0001792581 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001792581 us-gaap:CommonStockMember 2018-12-31 0001792581 us-gaap:IPOMember 2020-10-15 0001792581 us-gaap:EmployeeStockOptionMember krbp:ShareBasedPaymentArrangementFourNonemployeesMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2020-08-20 2020-08-20 0001792581 srt:ScenarioPreviouslyReportedMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2019-12-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2018-12-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:ShareBasedPaymentArrangementFourNonemployeesMember krbp:StockIncentivePlan2017Member 2020-08-20 2020-08-20 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-03-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-03-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2019-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2017-01-31 0001792581 srt:MinimumMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 srt:MaximumMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 srt:MinimumMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 srt:MaximumMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 srt:MinimumMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2019-01-01 2019-12-31 0001792581 srt:MaximumMember us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2019-01-01 2019-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001792581 krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2021-03-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2020-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2020-08-20 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2019-01-01 2019-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember krbp:MonthlyVestingConditionsMember 2021-01-01 2021-03-31 0001792581 srt:MinimumMember krbp:StockIncentivePlan2017Member krbp:MonthlyVestingConditionsMember 2021-01-01 2021-03-31 0001792581 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember krbp:MonthlyVestingConditionsMember 2021-01-01 2021-03-31 0001792581 srt:MaximumMember krbp:StockIncentivePlan2017Member krbp:MonthlyVestingConditionsMember 2021-01-01 2021-03-31 0001792581 krbp:StockIncentivePlan2017Member krbp:AnnualVestingConditionsMember 2021-01-01 2021-03-31 0001792581 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember krbp:MonthlyVestingConditionsMember 2020-01-01 2020-12-31 0001792581 srt:MinimumMember krbp:StockIncentivePlan2017Member krbp:MonthlyVestingConditionsMember 2020-01-01 2020-12-31 0001792581 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember krbp:MonthlyVestingConditionsMember 2020-01-01 2020-12-31 0001792581 srt:MaximumMember krbp:StockIncentivePlan2017Member krbp:MonthlyVestingConditionsMember 2020-01-01 2020-12-31 0001792581 krbp:StockIncentivePlan2017Member krbp:AnnualVestingConditionsMember 2020-01-01 2020-12-31 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2021-01-01 2021-03-31 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2021-01-01 2021-03-31 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2020-01-01 2020-12-31 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2020-01-01 2020-12-31 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2020-01-01 2020-03-31 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2020-01-01 2020-03-31 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2019-01-01 2019-12-31 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2019-01-01 2019-12-31 0001792581 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-03-31 0001792581 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-03-31 0001792581 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-03-31 0001792581 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-03-31 0001792581 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-03-31 0001792581 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-03-31 0001792581 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-03-31 0001792581 srt:MinimumMember 2021-01-01 2021-03-31 0001792581 srt:MaximumMember 2021-01-01 2021-03-31 0001792581 krbp:OfficeFurnitureFixturesAndEquipmentMember 2021-01-01 2021-03-31 0001792581 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0001792581 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001792581 srt:MinimumMember us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001792581 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0001792581 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001792581 srt:MaximumMember us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001792581 srt:MinimumMember 2020-01-01 2020-12-31 0001792581 srt:MaximumMember 2020-01-01 2020-12-31 0001792581 krbp:OfficeFurnitureFixturesAndEquipmentMember 2020-01-01 2020-12-31 0001792581 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-03-31 0001792581 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001792581 us-gaap:EquipmentMember 2021-03-31 0001792581 us-gaap:ConstructionInProgressMember 2021-03-31 0001792581 krbp:OfficeFurnitureFixturesAndEquipmentMember 2021-03-31 0001792581 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001792581 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001792581 us-gaap:EquipmentMember 2020-12-31 0001792581 us-gaap:ConstructionInProgressMember 2020-12-31 0001792581 krbp:OfficeFurnitureFixturesAndEquipmentMember 2020-12-31 0001792581 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-12-31 0001792581 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001792581 us-gaap:EquipmentMember 2019-12-31 0001792581 krbp:OfficeFurnitureFixturesAndEquipmentMember 2019-12-31 0001792581 2020-06-10 2020-06-10 0001792581 us-gaap:SeriesBPreferredStockMember 2020-06-08 2020-06-08 0001792581 2020-10-15 2020-10-15 0001792581 us-gaap:SeriesBPreferredStockMember 2018-12-31 0001792581 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001792581 srt:MaximumMember us-gaap:SeriesBPreferredStockMember 2020-01-29 0001792581 us-gaap:SeriesBPreferredStockMember 2019-09-13 0001792581 us-gaap:PreferredStockMember 2020-12-31 0001792581 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001792581 us-gaap:PreferredStockMember 2019-12-31 0001792581 2019-12-16 0001792581 2019-12-15 0001792581 us-gaap:SeriesBPreferredStockMember 2019-12-15 2019-12-15 0001792581 srt:MinimumMember us-gaap:SeriesBPreferredStockMember 2019-11-15 2019-11-15 0001792581 us-gaap:DomesticCountryMember 2020-12-31 0001792581 us-gaap:DomesticCountryMember 2019-12-31 0001792581 us-gaap:SubsequentEventMember 2021-03-22 0001792581 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001792581 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001792581 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001792581 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001792581 krbp:SBLoanPaycheckProtectionProgramMember 2020-12-31 0001792581 2018-08-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2021-03-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-12-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 us-gaap:ConvertibleNotesPayableMember 2018-12-31 0001792581 us-gaap:NotesPayableOtherPayablesMember 2020-11-01 2020-11-30 0001792581 us-gaap:SeriesBPreferredStockMember 2019-11-16 0001792581 us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001792581 krbp:SBLoanPaycheckProtectionProgramMember 2020-05-01 0001792581 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001792581 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001792581 krbp:SBLoanPaycheckProtectionProgramMember 2021-02-16 2021-02-16 0001792581 us-gaap:ConvertibleNotesPayableMember us-gaap:SeriesAPreferredStockMember 2019-08-15 0001792581 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001792581 us-gaap:SeriesBPreferredStockMember us-gaap:IPOMember 2020-10-15 2020-10-15 0001792581 us-gaap:SeriesAPreferredStockMember us-gaap:IPOMember 2020-10-15 2020-10-15 0001792581 us-gaap:IPOMember 2021-03-31 0001792581 us-gaap:IPOMember 2020-12-31 0001792581 2020-09-18 0001792581 2020-06-17 0001792581 2019-09-24 0001792581 2018-06-18 0001792581 2020-06-19 0001792581 2019-09-25 0001792581 2020-06-10 0001792581 us-gaap:SeriesBPreferredStockMember 2020-03-31 0001792581 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001792581 us-gaap:SeriesBPreferredStockMember 2021-03-31 0001792581 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001792581 krbp:CommonStockWarrantMember 2020-12-31 0001792581 krbp:CommonStockWarrantMember us-gaap:IPOMember 2020-10-15 0001792581 us-gaap:SeriesBPreferredStockMember 2019-11-13 0001792581 2020-03-31 0001792581 2018-12-31 0001792581 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0001792581 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001792581 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001792581 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001792581 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-03-31 0001792581 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001792581 krbp:SeriesBPreferredStockWarrantMember 2020-01-01 2020-03-31 0001792581 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-12-31 0001792581 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001792581 krbp:SeriesBPreferredStockWarrantMember 2019-01-01 2019-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 us-gaap:ResearchAndDevelopmentExpenseMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 krbp:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0001792581 2020-06-08 2020-06-08 0001792581 us-gaap:EmployeeStockOptionMember krbp:ShareBasedPaymentArrangementFourNonemployeesMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-12-31 0001792581 us-gaap:ResearchAndDevelopmentExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-03-31 0001792581 us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2020-01-01 2020-03-31 0001792581 krbp:StockIncentivePlan2017Member 2020-01-01 2020-03-31 0001792581 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember krbp:StockIncentivePlan2017Member 2019-01-01 2019-12-31 0001792581 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember krbp:StockIncentivePlan2017Member 2019-01-01 2019-12-31 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2019-01-01 2019-12-31 0001792581 us-gaap:SeriesBPreferredStockMember 2020-06-10 2020-06-10 0001792581 us-gaap:SeriesBPreferredStockMember 2019-12-06 0001792581 krbp:CommonStockWarrantMember us-gaap:IPOMember 2020-10-15 2020-10-15 0001792581 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001792581 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001792581 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001792581 krbp:CommonStockWarrantMember 2021-01-01 2021-03-31 0001792581 krbp:CommonStockWarrantMember 2020-01-01 2020-12-31 0001792581 krbp:UniversityOfTexasMdAndersonCancerCenterMember us-gaap:SubsequentEventMember 2021-04-08 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2019-09-04 2019-09-04 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2018-07-20 2018-07-20 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2018-04-18 2018-04-18 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2020-06-19 2020-06-19 0001792581 krbp:ChiefStrategyAndInnovationOfficerMember 2020-06-19 2020-06-19 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2020-06-19 2020-06-19 0001792581 krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember 2020-06-19 2020-06-19 0001792581 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-06-08 2020-06-08 0001792581 krbp:EmployeeMember 2020-06-08 2020-06-08 0001792581 krbp:ChiefMedicalOfficerMember 2020-06-08 2020-06-08 0001792581 krbp:ChiefMedicalOfficerMember 2020-06-08 2020-06-08 0001792581 krbp:SBLoanPaycheckProtectionProgramMember 2020-01-01 2020-12-31 0001792581 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001792581 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001792581 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001792581 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-03-31 0001792581 us-gaap:SeriesBPreferredStockMember 2019-12-06 2019-12-06 0001792581 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001792581 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-12-31 0001792581 2019-08-31 0001792581 krbp:WarrantExercisableBeginningSixMonthsAfterListingDateMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001792581 krbp:WarrantExercisableBeginningNineMonthsAfterListingDateMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001792581 krbp:WarrantExercisableBeginningSixMonthsAfterListingDateMember us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001792581 krbp:WarrantExercisableBeginningNineMonthsAfterListingDateMember us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001792581 us-gaap:ConvertibleNotesPayableMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001792581 us-gaap:ConvertibleNotesPayableMember us-gaap:SeriesAPreferredStockMember 2019-08-15 2019-08-15 0001792581 us-gaap:IPOMember 2020-10-15 2020-10-15 0001792581 2020-11-19 2020-11-19 0001792581 us-gaap:SubsequentEventMember 2021-03-22 2021-03-22 0001792581 2021-03-22 2021-03-22 0001792581 2020-06-08 0001792581 krbp:LeonOfficeH.k.Member us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2021-01-28 2021-01-28 0001792581 krbp:LeonOfficeH.k.Member us-gaap:CollaborativeArrangementMember 2021-01-28 2021-01-28 0001792581 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember krbp:StockIncentivePlan2017Member 2020-08-20 2020-08-20 0001792581 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember krbp:StockIncentivePlan2017Member 2020-08-20 2020-08-20 0001792581 us-gaap:RestrictedStockUnitsRSUMember krbp:StockIncentivePlan2017Member 2020-08-20 2020-08-20 0001792581 us-gaap:EmployeeStockOptionMember krbp:StockIncentivePlan2017Member 2020-08-20 2020-08-20 0001792581 2023-05-01 2023-05-01 0001792581 2022-05-01 2022-05-01 0001792581 2021-08-01 2021-08-01 0001792581 2021-05-01 2021-05-01 0001792581 2020-01-01 2020-01-01 0001792581 krbp:SBLoanPaycheckProtectionProgramMember 2020-05-01 2020-05-01 0001792581 krbp:SBLoanPaycheckProtectionProgramMember us-gaap:SubsequentEventMember 2021-02-16 2021-02-16 0001792581 us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-12-31 0001792581 us-gaap:ConvertibleNotesPayableMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001792581 us-gaap:ConvertibleNotesPayableMember 2019-12-31 0001792581 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleNotesPayableMember us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-12-31 0001792581 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleNotesPayableMember us-gaap:FairValueMeasurementsNonrecurringMember 2019-01-01 2019-12-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001792581 2020-01-01 2020-03-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001792581 2019-01-01 2019-12-31 0001792581 us-gaap:IPOMember 2021-01-01 2021-03-31 0001792581 us-gaap:IPOMember 2020-01-01 2020-12-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001792581 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001792581 2020-01-01 2020-12-31 0001792581 2021-03-31 0001792581 2020-12-31 0001792581 2019-12-31 0001792581 2021-01-01 2021-03-31 shares iso4217:USD shares iso4217:USD utr:sqft pure krbp:item krbp:employee krbp:individual krbp:installment krbp:agreement krbp:Vote 0 0 us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember 7332999 7332999 us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember 0001792581 21822301 0 9869659 0 2863812 2863812 7332999 P1Y P10M 0 0 0 us-gaap:ValuationTechniqueOptionPricingModelMember 0 0 P1Y P10M P10Y P10Y P90D 0 0 0 false S-1 KIROMIC BIOPHARMA, INC. Non-accelerated Filer true true false 10150500 1929100 22200 588800 89100 10739300 2040400 2066000 587900 24400 24400 12829700 2652700 665200 452400 334200 221300 200 105600 362400 1467600 673700 1467600 673700 0.0001 0.0001 24000000 24000000 0 21822301 9134700 0.0001 0.0001 16500000 14130435 0 9869659 1306900 0.0001 0.0001 19500000 21869565 0 0 0.001 0.001 300000000 300000000 7332999 1200 52988700 13965000 -41627800 -22427600 11362100 1979000 12829700 2652700 5052900 1201700 14144000 2503700 19196900 3705400 -19196900 -3705400 3300 22500 3300 22500 -19200200 -3727900 -4.42 -1.39 4505867 2862809 20886782 8727400 2863093 10237600 -18699700 265300 935519 407300 407300 9782609 1056300 1056300 -210600 210600 3443700 3443700 -87050 -40000 40000 1719 11400 11400 522900 522900 -3727900 -3727900 21822301 9134700 9869659 1306900 2864812 13965000 -22427600 1979000 6521738 331700 331700 -692700 692700 2668300 2668300 1399921 4900 4900 1250000 1200 11974200 11975400 19700 19700 377000 377000 -21822301 -9134700 624594 9134700 -16391397 -2331300 469136 2331300 725536 9432000 9432000 3813700 3813700 -19200200 -19200200 7333999 1200 52988700 -41627800 11362100 -19200200 -3727900 200000 87500 13245700 522900 200 20500 22200 -24300 5900 499700 -46200 6600 -7700 293400 112900 -151300 -19000 2000 -6126600 -2913900 1457600 302700 -1457600 -302700 250000 11400 15000000 2667300 4900 115600 10000 540500 178100 3000000 4500000 15805600 4761400 8221400 1544800 1929100 384300 10150500 1929100 220500 74700 3100 134800 407300 40000 <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;">ORGANIZATION</td></tr></table>Nature of BusinessKiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.The Company is a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.Going Concern — The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flows from operations of $6,126,600 for the year ended December 31, 2020, and an accumulated deficit of $41,627,800 as of December 31, 2020. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Although the Company completed its initial public offering on October 15, 2020 and received net proceeds of $12,332,700, the Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in fiscal year 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the U.S. government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase I completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000. -6126600 -41627800 12332700 2235000 851000 1384000 <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</td></tr></table>Basis of PresentationThe accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets.Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded.Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets.Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.Estimated useful lives of property and equipment are as follows for the major classes of assets:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Asset Description</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Estimated Lives</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Laboratory Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 8</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Leasehold Improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">1 - 7</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Office Furniture, Fixtures, and Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">5</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 5</td></tr></table>Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively.Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019.Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH.Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Convertible promissory notes </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Beginning balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Amounts allocated to the embedded derivative liability at inception (at fair value)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> (21,000)</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Conversions from accounts payable into convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 134,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Proceeds from issuances of convertible promissory notes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 250,000</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Conversions into Series A‑1 Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (363,800)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Ending balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="7" style="background-color:#cceeff;vertical-align:bottom;width:100%;margin:0pt;padding:0pt;">Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Convertible promissory note embedded derivative liability</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Beginning balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Realized and unrealized gains and losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Fair value of embedded derivative liability at inception</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 21,000</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Amounts derecognized upon conversion of the related convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (23,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Ending balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options. The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">valuations of the common stock performed by third-party specialists;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">lack of marketability of the common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">current business conditions and projections;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">hiring of key personnel and the experience of management;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the Company’s stage of development;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the market performance of comparable publicly traded companies; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the US and global capital market conditions.</td></tr></table><div style="margin-top:10pt;"/>In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant. Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period. Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019. Basis of PresentationThe accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits. 10 3.494 Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense. Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents. Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency. Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets. 1 Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded. 22200 0 Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets. 2667300 0 0 Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.Estimated useful lives of property and equipment are as follows for the major classes of assets:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Asset Description</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Estimated Lives</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Laboratory Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 8</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Leasehold Improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">1 - 7</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Office Furniture, Fixtures, and Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">5</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 5</td></tr></table> P8Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Asset Description</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Estimated Lives</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Laboratory Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 8</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Leasehold Improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">1 - 7</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Office Furniture, Fixtures, and Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">5</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 5</td></tr></table> P3Y P8Y P1Y P7Y P5Y P3Y P5Y Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively. P5Y 10200 20000 Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception. 0 Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss. Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019. 0 0 Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH 142400 298000 Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations. Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Convertible promissory notes </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Beginning balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Amounts allocated to the embedded derivative liability at inception (at fair value)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> (21,000)</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Conversions from accounts payable into convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 134,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Proceeds from issuances of convertible promissory notes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 250,000</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Conversions into Series A‑1 Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (363,800)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Ending balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="7" style="background-color:#cceeff;vertical-align:bottom;width:100%;margin:0pt;padding:0pt;">Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Convertible promissory note embedded derivative liability</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Beginning balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Realized and unrealized gains and losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Fair value of embedded derivative liability at inception</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 21,000</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Amounts derecognized upon conversion of the related convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (23,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Ending balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table> 0 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Convertible promissory notes </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Beginning balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Amounts allocated to the embedded derivative liability at inception (at fair value)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> (21,000)</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Conversions from accounts payable into convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 134,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Proceeds from issuances of convertible promissory notes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 250,000</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Conversions into Series A‑1 Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (363,800)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Ending balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="7" style="background-color:#cceeff;vertical-align:bottom;width:100%;margin:0pt;padding:0pt;">Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Convertible promissory note embedded derivative liability</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Beginning balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Realized and unrealized gains and losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Fair value of embedded derivative liability at inception</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 21,000</td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Amounts derecognized upon conversion of the related convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (23,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;">Ending balance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table> -21000 134800 250000 363800 2000 21000 -23000 Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options. The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date. P4Y P48M P10Y P6M P12M P10Y Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">valuations of the common stock performed by third-party specialists;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">lack of marketability of the common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">current business conditions and projections;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">hiring of key personnel and the experience of management;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the Company’s stage of development;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the market performance of comparable publicly traded companies; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the US and global capital market conditions.</td></tr></table><div style="margin-top:10pt;"/>In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant. Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period. Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share. 0 0 12.00 15.00 Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019. <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;">NET LOSS PER COMMON SHARE</td></tr></table>Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted loss per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;">Years Ended</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Net loss</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (19,200,200)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,727,900)</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Less: Accretion and settlement of Series B Preferred Stock dividend</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (40,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Less: Series B Preferred Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (692,700)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (210,600)</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Less: IPO Common Stock discount amortization</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (19,700)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Net loss attributable to common shareholders, basic and diluted</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (19,912,600)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,978,500)</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Weighted average common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 4,505,867</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2,862,809</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Net loss per common share, basic and diluted</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (4.42)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (1.39)</td></tr></table>For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Stock options to purchase</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 1,647</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">75,405</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Restricted Stock Units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 95,815</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series A‑1 Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 624,594</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series B Preferred Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 282,478</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Warrants underlying Series B Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 839,784</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,462</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,822,261</td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;">Years Ended</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Net loss</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (19,200,200)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,727,900)</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Less: Accretion and settlement of Series B Preferred Stock dividend</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (40,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Less: Series B Preferred Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (692,700)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (210,600)</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Less: IPO Common Stock discount amortization</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (19,700)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Net loss attributable to common shareholders, basic and diluted</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (19,912,600)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,978,500)</td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Weighted average common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 4,505,867</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2,862,809</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;">Net loss per common share, basic and diluted</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> (4.42)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (1.39)</td></tr></table> -19200200 -3727900 40000 692700 210600 19700 -19912600 -3978500 4505867 2862809 -4.42 -1.39 For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Stock options to purchase</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 1,647</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">75,405</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Restricted Stock Units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 95,815</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series A‑1 Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 624,594</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series B Preferred Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 282,478</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Warrants underlying Series B Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 839,784</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,462</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,822,261</td></tr></table> 1647 75405 95815 624594 282478 839784 97462 1822261 <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;">PROPERTY AND EQUIPMENT, NET</td></tr></table>Property and equipment, net consisted of the following at December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 780,500</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 488,800</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 1,229,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 302,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Office furniture, fixtures, and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 16,600</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 16,600</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 151,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 141,500</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Construction in progress</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 449,200</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 2,627,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 949,600</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Less: Accumulated depreciation</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (561,700)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (361,700)</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,066,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 587,900</td></tr></table>Depreciation expense was $200,000 and $87,500 for the years ended December 31, 2020 and 2019, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the consolidated statements of operations. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 780,500</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 488,800</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 1,229,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 302,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Office furniture, fixtures, and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 16,600</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 16,600</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 151,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 141,500</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Construction in progress</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 449,200</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 2,627,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"> 949,600</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Less: Accumulated depreciation</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (561,700)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (361,700)</td></tr><tr><td style="vertical-align:bottom;width:72.03%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,066,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 587,900</td></tr></table> 780500 488800 1229700 302700 16600 16600 151700 141500 449200 2627700 949600 561700 361700 2066000 587900 200000 87500 <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</td></tr></table>Accrued expenses and other current liabilities consisted of the following at December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued consulting and outside services</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 143,200</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 221,300</td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued compensation</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 334,200</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 221,300</td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued consulting and outside services</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 143,200</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 221,300</td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued compensation</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 334,200</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 221,300</td></tr></table> 143200 221300 191000 334200 221300 <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;">CURRENT LOAN PAYABLE</td></tr></table>On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. The SBA Loan was forgiven on February 16, 2021. See Note 14.The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 during year ended December 31, 2020 in the consolidated balance sheet. During year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020.The Company accrued $200 of interest expense during the year ended December 31, 2020. The Company accrues interest over the term of the loan and does not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency. If any amount of the loan is ultimately forgiven, income from the extinguishment of debt would be recognized as a gain on loan extinguishment in the consolidated statement of operations. 115600 P2Y 0.01 P7M 105600 115600 10000 105600 200 <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;">NOTE PAYABLE</td></tr></table>In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of December 31, 2020, the remaining payable balance on the financed amount was approximately $362,400. 540500 0.0459 P9M 362400 8.CONVERTIBLE PROMISSORY NOTESStarting in June 2016, the Company sold convertible promissory notes to certain investors to help finance its operations. The convertible promissory notes were in amounts ranging from $12,500 to $500,000, earning annual interest between 6% and 17% and all maturing either on June 1, 2019, January 2, 2020, or June 30, 2020 (the “Maturity Date”).The convertible promissory notes were convertible into shares issued in the Company’s Next Financing Close by dividing the total amount of convertible promissory notes, plus accrued interest (the “Balance”) by the applicable conversion price, as defined in the convertible promissory notes. If the convertible promissory notes have not been converted, the Balance shall be payable in full if the Company consummates a change of control transaction. If there has not been a Next Financing Close or a change in control by the Maturity Date, then at the noteholders’ option, the Company shall either repay the Balance then outstanding or convert into the Company’s common stock at a set conversion price then in effect, as defined in the convertible promissory notes.The estimated fair value of the conversion discount related embedded derivative was determined using a probability-weighted expected return model. The probability of a Next Financing Close occurring prior to the Maturity Date was determined to be 55% during the year ended December 31, 2019. The net present value of the conversion discount related embedded derivative was measured using a discount rate of 25% as of December 31, 2019. Below is a table that outlines the initial value of issuances and the bifurcated embedded derivative liability during the years ended December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Convertible promissory notes- issuances</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 250,000</td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Conversion of accounts payable into convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 134,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Total issuances and conversions into convertible promissory notes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 384,800</td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Embedded derivative liability</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Initial fair value upon issuance of convertible promissory notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 21,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Realized and unrealized gains and losses</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,000</td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Converted embedded derivative liability into Series A‑1 Preferred Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (23,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Embedded derivative liability balance at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr></table>On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. See Note 10 for further details. No additional convertible promissory notes were issued for year ended December 31, 2020 following the conversion on August 15, 2019. 12500 500000 0.06 0.17 0.55 0.25 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Convertible promissory notes- issuances</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 250,000</td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Conversion of accounts payable into convertible promissory notes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 134,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Total issuances and conversions into convertible promissory notes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 384,800</td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Embedded derivative liability</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Initial fair value upon issuance of convertible promissory notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 21,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Realized and unrealized gains and losses</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,000</td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Converted embedded derivative liability into Series A‑1 Preferred Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (23,000)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;">Embedded derivative liability balance at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr></table> 250000 134800 384800 21000 2000 -23000 0 0 9.COMMITMENTS AND CONTINGENCIESFacility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.The total lease payments per month will be $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477 and $23,039 beginning May 1, 2021 and May 1, 2022, respectively. The Company records rent expense on a straight-line basis over the term of the leases.As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amount</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"> 265,200</td></tr><tr><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"> 269,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"> 274,200</td></tr><tr><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 230,400</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,039,500</td></tr></table>Annual rent expense for the facility lease agreements was $262,900 and $129,100 for the years ended December 31, 2020 and 2019, respectively, and is included as an allocation between research and development and general and administrative expense in the consolidated statements of operations.License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of December 31, 2020 and 2019, the Company has not incurred any milestone or royalty liabilities related to these license agreements.Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. The Company regularly assesses all contingencies and believes, as of December 31, 2020, the Company was not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows. 4100 P90D 21353 22477 23039 As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amount</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"> 265,200</td></tr><tr><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"> 269,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"> 274,200</td></tr><tr><td style="vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 230,400</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.62%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,039,500</td></tr></table> 265200 269700 274200 230400 1039500 262900 129100 10.STOCKHOLDERS’ EQUITYOn December 16, 2019, the Company amended and restated its certificate of incorporation to, among other things, (i) complete a 1-for-10 reverse split of the Company’s outstanding shares of common stock; (ii) increase the Company’s authorized Preferred Stock to 60,000,000 shares and (iii) change the par value of the Preferred Stock from $0.01 to $0.0001 per share.On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares of common stock.Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits during the years ended December 31, 2020 and 2019.As of December 31, 2020 and 2019, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares and of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock. Additionally, 16,500,000 shares and 14,130,435 shares were designated as Series B Preferred Stock as of December 31, 2020 and 2019, respectively.Common Stock — As of December 31, 2020 and 2019, the Company has a single class of common stock. On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share. In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the year ended December 31, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common stock IPO proceeds, net of issuance costs</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> 12,332,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common stock IPO discount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> (377,000)</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common stock IPO discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Balance at December 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,975,400</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr></table>On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There were 0 and 839,952 warrants outstanding as of December 31, 2020 and 2019, respectively.On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSIO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted the Plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.There were 270,933 shares and 258,813 shares available for issuance as of December 31, 2020 and 2019, respectively.Series A-1 Preferred Stock — In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation the holders of the shares of Series A-1 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.50, the original issue price.On matters submitted to a vote of the stockholders of the Company, Series A-1 Preferred Stock and common stock vote together as one class, with the vote of the Series A-1 Preferred Stock on an as-converted basis. Each holder of Series A-1 Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series A-1 Preferred Stock held by such holder are then convertible.With respect rights on liquidation, winding up and dissolution, shares of the Series A-1 Preferred Stock rank senior to all shares of common stock.Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.Series B Preferred Stock — On September 13, 2019, the Company amended and restated its certificate of incorporation to authorize the issuance of up to 14,130,435 shares of Series B Preferred Stock. On September 13, 2019, the Company sold 7,608,696 shares of Series B Preferred Stock for $3,500,000. On November 13, 2019, the Company issued an additional 2,173,913 shares of Series B Preferred Stock for $1,000,000. In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). See below for further details.Until the filing of the amended and restated certificate of incorporation on December 16, 2019, shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. The amended and restated certificate of incorporation eliminated the clause requiring the dividend accrual. In addition, on December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, the Company issued 87,050 shares of Series B Preferred Stock to the investors. The Company treated this transaction as accretion and settlement of a Series B Preferred Stock dividends in the amount of $40,000. Accordingly, additional paid-in capital was reduced by $40,000.The Series B Preferred Stock conversion price is initially equal to the Series B Preferred Stock original issuance price of $0.46 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock. The holders of the Series B Preferred Stock held a special redemption right. In the event the Company had not filed an initial registration statement with the United States Securities and Exchange Commission and submitted an application to be listed on the Nasdaq Stock market on or prior to November 15, 2019, subject to Delaware law governing distributions to stockholders and the Company’s ability to redeem its shares, all or part of the shares of Series B Preferred Stock held by any holder of record as of such date of shares of Series B Preferred Stock with an aggregate purchase price of at least $1,000,000 would have been be redeemable at the option of such holders of record commencing any time on or after November 16, 2019 at a price equal to the purchase price paid for such shares plus all unpaid dividends accrued on such shares. Also, in the event that the Company was not ultimately approved for listing on a Nasdaq Stock Market tier lower than the Nasdaq Global Select Market, the special redemption right would remain in effect and may have been exercisable on any date thereafter. If the Company was unable to execute a redemption upon request of a holder, interest would accrue on the shares at rate of 14.6%, or warrants underlying the shares would be exercisable and the fair market value of the shares of common stock received in connection therewith would be treated as payment in exchange for the shares of Series B Preferred Stock submitted for redemption by such holder.On November 12, 2019 and November 13, 2019, the Series B Preferred Stock investors signed waivers, which provided consent to the Company to eliminate the special redemption right. When the Company amended and restated its certificate of incorporation on December 16, 2019, the special redemption right provision was eliminated.The elimination of the special redemption right allows for permanent equity classification for the Series B Preferred Stock. Since the Warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series B Preferred Stock and the Warrants. The fair value of the Warrants is offset by a contra account, which is classified as a discount to the Series B Preferred Stock. The discount is amortized using the effective interest method at an effective interest rate of 28% per annum.On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.In connection with the IPO, all shares of the Company's Series B Preferred Stock were converted into 469,136 shares of common stock, and the value of the Series B Preferred Stock converted into additional-paid-in-capital.Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock, the Series B Preferred Stock discount amortized, and value of Series B Preferred Stock that was converted into additional-paid-in-capital during the years ended December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 1,306,900</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,500,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock proceeds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 3,000,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,443,700)</td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock discount</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,668,300)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 210,600</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 692,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 40,000</td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock conversion to common stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,331,300)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Balance at December 31,</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,306,900</td></tr></table>In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.Conversion of Convertible Promissory Notes — On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $405,300. Per the convertible promissory notes, the notes containing a $250,000 principal balance with a 17% coupon rate had a conversion price of $0.43. Additionally, the Company settled an accounts payable with a vendor by issuing a convertible promissory note in the amount of $134,800 with a 6% coupon rate, with a conversion rate of $0.43. Accordingly, 935,519 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. Under the original terms of the warrant agreements, the warrants become have exercisable in accordance with the schedule set forth below following completion by the Company of an IPO and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">An additional 30% of the warrants beginning nine months after the Listing Date; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The remainder of the warrants beginning twelve months after the Listing Date.</td></tr></table><div style="margin-top:10pt;"/>As of December 31, 2019, the Company sold 9,782,609 shares of Series B Preferred Stock, which contained 839,952 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. During the year ended December 31, 2020, the Company sold an additional 6,521,738 shares of Series B Preferred Stock, which contained 559,969 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants were equity classified and the fair value of $5,208,700 is reflected as additional paid-in capital. On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There are no warrants underlying Series B Preferred Stock outstanding as of December 31, 2020.The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the years ended December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">1.54% - 1.88</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">1.54% - 1.84</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">71.95% - 72.71</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">71.95% - 72.20</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 10.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 10.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">%</td></tr></table>Representative's Warrants — In connection with the IPO, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at December 31, 2020.These warrants were equity classified and the fair value of $377,000 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the year ended December 31, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> 0.18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> 94.08</td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;">% </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> 2.74</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;">%</td></tr></table> 10 60000000 0.01 0.0001 3.494 300000000 300000000 60000000 60000000 24000000 24000000 16500000 14130435 12332700 1275000 1392300 1250000 12.00 624594 469136 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common stock IPO proceeds, net of issuance costs</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> 12,332,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common stock IPO discount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"> (377,000)</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Common stock IPO discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;">Balance at December 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,975,400</td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"></td></tr></table> 12332700 377000 19700 11975400 335982 1200 1063939 3700 0 839952 3106 430 402000 320000 0 9432000 1 0 10000000 20000000 30000000 858615 850000 858615 1708615 270933 258813 0.50 624594 14130435 7608696 3500000 2173913 1000000 0.0859 0.003494 0.06 87050 40000 -40000 0.46 1000000 0.146 0.28 4782608 2200000 16500000 1739130 800000 469136 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 1,306,900</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,500,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock proceeds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 3,000,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,443,700)</td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock discount</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,668,300)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 210,600</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 692,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 40,000</td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Series B Preferred Stock conversion to common stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,331,300)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;">Balance at December 31,</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,306,900</td></tr></table> 1306900 4500000 3000000 -3443700 2668300 210600 692700 40000 2331300 1306900 0.46 405300 250000 0.17 0.0043 134800 0.06 0.0043 935519 624594 0.0859 0.003494 P10Y 0.30 0.30 9782609 839952 6521738 559969 5208700 335982 1200 1063939 3700 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">1.54% - 1.88</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">1.54% - 1.84</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">71.95% - 72.71</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">71.95% - 72.20</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 10.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 10.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;">Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">%</td></tr></table> 0.0154 0.0188 0.0154 0.0184 0.7195 0.7271 0.7195 0.7220 P10Y P10Y 0 0 62500 15.00 1.25 P5Y 377000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> 0.18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> 94.08</td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;">% </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> 2.74</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.92%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;">%</td></tr></table> 0.0018 0.9408 P2Y8M26D 0 11.STOCK-BASED COMPENSATION2017 Stock Incentive Plan — Stock OptionsThe Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">0.15% - 2.92</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">1.60% - 2.92</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">72.29% - 82.52</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">72.29% - 78.16</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">4.93 – 6.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">4.93 – 6.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;">%</td></tr></table>The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.The following table summarizes the activity for all stock options outstanding at December 31 under the Plan:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;">Weighted</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;">Exercise</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Options outstanding at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 598,083</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 11.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 520,517</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 8.64</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 86,536</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 17.95</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 209,505</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 17.29</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> (1,719)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 6.64</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (194,901)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15.06</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (130,220)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.56</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Balance at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 489,718</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10.03</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 598,083</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.04</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Options exercisable at December 31:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 441,430</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 9.50</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 368,527</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 7.72</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Weighted average grant date fair value for options granted during the year:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 17.43</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 10.82</td></tr></table>The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2020 and 2019 under the Plan:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:41.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:30.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Exercisable</td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Aggregate</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;">As of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Intrinsic</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Life</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercisable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;">2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 489,718</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 6.37</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> 10.03</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 554,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 441,430</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> 9.50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 598,083</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 8.07</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> 11.04</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 19,163,700</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 368,527</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> 7.72</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> 13,031,000</td></tr></table>Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the consolidated statements of operations for the years ended December 31, 2020 and 2019 as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;">Research and development</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 1,008,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> 332,000</td></tr><tr><td style="vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 332,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 190,900</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,340,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 522,900</td></tr></table>On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $65,900 of stock compensation expense allocable to general and administrative for the year December 31, 2020. Included in that amount were $34,800 of incremental compensation costs resulting from the modifications for the year ended December 31, 2020. As of December 31, 2020, total unrecognized stock compensation expense is $473,900, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.79 years.2017 Stock Incentive Plan — Restricted Stock UnitsIn January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.The following table summarizes the activity for all RSUs outstanding at December 31 under the Plan:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;">Weighted Average</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Nonvested RSUs at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 1,655,579</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 12.84</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Vested</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> (709,334)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 12.87</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Nonvested RSUs at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 946,245</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 12.81</td></tr></table>During the year ended December 31, 2020, 1,655,579 RSUs were granted and 709,334 RSUs were cancelled. During the year ended December 31, 2020, no RSUs vested. No RSUs were granted or vested in the year ended December 31, 2019.On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $748,400 and $1,725,300 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020. Included in those amounts were incremental compensation costs of $166,900 and $402,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020. The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">0.15% - 2.92</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">1.60% - 2.92</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">72.29% - 82.52</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">72.29% - 78.16</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">4.93 – 6.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;">4.93 – 6.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;">%</td></tr></table> 0.0015 0.0292 0.0160 0.0292 0.7229 0.8252 0.7229 0.7816 P4Y11M4D P6Y25D P4Y11M4D P6Y25D 0 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;">Weighted</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;">Exercise</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Options outstanding at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 598,083</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 11.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 520,517</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 8.64</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 86,536</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 17.95</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 209,505</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 17.29</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> (1,719)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 6.64</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (194,901)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15.06</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (130,220)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.56</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Balance at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 489,718</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10.03</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 598,083</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.04</td></tr><tr><td style="vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Options exercisable at December 31:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 441,430</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 9.50</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> 368,527</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 7.72</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.94%;margin:0pt;padding:0pt;">Weighted average grant date fair value for options granted during the year:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"> 17.43</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"> 10.82</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:41.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:30.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Exercisable</td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Aggregate</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;">As of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Intrinsic</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Life</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercisable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;">2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 489,718</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 6.37</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> 10.03</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 554,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 441,430</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> 9.50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:25.54%;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 598,083</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 8.07</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> 11.04</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 19,163,700</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 368,527</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> 7.72</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> 13,031,000</td></tr></table> 598083 11.04 520517 8.64 86536 17.95 209505 17.29 1719 6.64 194901 15.06 130220 11.56 489718 10.03 598083 11.04 441430 9.50 368527 7.72 17.43 10.82 489718 P6Y4M13D 10.03 554900 441430 9.50 598083 P8Y25D 11.04 19163700 368527 7.72 13031000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;">Research and development</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 1,008,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> 332,000</td></tr><tr><td style="vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 332,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 190,900</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.8%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,340,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 522,900</td></tr></table> 1008000 332000 332000 190900 1340000 522900 15792 4 21112 12.81 3959 65900 34800 473900 P1Y9M14D 1708615 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;">Weighted Average</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Nonvested RSUs at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 1,655,579</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 12.84</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Vested</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> (709,334)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 12.87</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.83%;margin:0pt;padding:0pt;">Nonvested RSUs at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 946,245</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 12.81</td></tr></table> 1655579 12.84 709334 12.87 946245 12.81 1655579 709334 0 0 709334 5 12.87 946245 12.81 0 3 2 748400 1725300 166900 402700 12.INCOME TAXESFor the years ended December 31, 2020 and 2019, the Company recognized no provision or benefit from income taxes.The following is a reconciliation of the effective income tax rate to the statutory federal income tax rate for the years ended December 31, 2020 and 2019.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Federal income tax at statutory rates</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 21.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;">% </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 21.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Federal income tax rate reduction</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Change in valuation allowance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21.00)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21.00)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Effective income tax rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">%</td></tr></table>Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. The Company recorded a valuation allowance to fully offset the net deferred tax asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets as of December 31, 2020 and 2019 due to the significant uncertainty about the realization of the deferred tax asset until the Company can operate profitably.The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows as of December 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Deferred tax assets (liabilities):</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Net operating loss carryforward</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 3,842,900</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 2,605,400</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Stock compensation expense</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 3,379,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 597,400</td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Intangible assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 23,600</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 27,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Total gross deferred tax assets</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,245,500</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,230,600</td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Valuation allowance</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (7,061,600)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (3,198,100)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Property and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (183,900)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (32,500)</td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Net deferred tax assets (liabilities)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>As of December 31, 2020 and 2019, the Company has a US net operating loss ("NOL") carryforward of $18,299,500 and $12,406,800, respectively. The NOL carryforwards may be subject to annual limitations due to "change in ownership" provisions of Internal Revenue Code Section 382 ("Section 382") that can be triggered due to future ownership changes. Additionally, the NOL loss carryforwards are subject to examination and adjustments by the Internal Revenue Service until the statute of limitations closes on the year in which the NOL is utilized.As of December 31, 2020 and 2019, there were no material uncertain tax positions taken by the Company. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months.As of December 31, 2020, the Company is not currently under audit by any income tax authority.On March 27, 2020, in response to the COVID-19 pandemic, the president of the United States signed the CARES Act. The Company does not expect there to be any significant benefit to its income tax provision as a result of the CARES Act, and the Company continues to monitor for any potential tax legislation related to the COVID-19 pandemic. 0 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Federal income tax at statutory rates</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 21.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;">% </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 21.00</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Federal income tax rate reduction</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Change in valuation allowance</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21.00)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21.00)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;">Effective income tax rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">%</td></tr></table> 0.2100 0.2100 -0.2100 -0.2100 0 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Deferred tax assets (liabilities):</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Net operating loss carryforward</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 3,842,900</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 2,605,400</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Stock compensation expense</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 3,379,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 597,400</td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Intangible assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 23,600</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 27,800</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Total gross deferred tax assets</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,245,500</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,230,600</td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Valuation allowance</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (7,061,600)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (3,198,100)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Property and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (183,900)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (32,500)</td></tr><tr><td style="vertical-align:bottom;width:71.19%;margin:0pt;padding:0pt;">Net deferred tax assets (liabilities)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table> 3842900 2605400 3379000 597400 23600 27800 7245500 3230600 7061600 3198100 183900 32500 0 0 18299500 12406800 13.RELATED PARTY TRANSACTIONSDuring the year ended December 31, 2020, the Company maintained two separate consulting agreements with the Company’s CSIO and the Company’s CFO and COO. Those consulting agreements were terminated after the completion of the IPO in October 2020.Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO was entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company’s Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company’s business development strategies. The consulting fees paid to the CSIO totaled $579,700 and $207,800 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CSIO 320,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month plus discretionary bonuses approved by management. The consulting fees paid to the CFO and COO totaled $140,000 and $67,500 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CFO and COO 402,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.On June 8, 2020, the Company issued the Chief Medical Officer and another employee 3,106 and 430 shares of common stock, respectively. The shares were issued in exchange for services rendered and no cash considerations. See Note 10. 2 400 19 579700 207800 320000 0 2500 10000 140000 67500 402000 0 3106 430 0 14.SUBSEQUENT EVENTSStrategic Alliance Agreement with Leon Office (H.K.)On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. The cost of the agreement is $360,000 annually, payable in four quarterly installments.Loan Payable ForgivenessDuring the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021 the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,600 and $300, respectively.Lease Facility ExpansionOn March 22, 2020, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.The future minimum commitments under the amended lease agreement will be as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:70.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amount</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"> 380,600</td></tr><tr><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"> 546,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"> 551,100</td></tr><tr><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 461,200</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,939,600</td></tr></table>Legal Complaint Filed Against the Company A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them. 360000 4 105600 300 15385 P90D 3 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:70.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amount</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"> 380,600</td></tr><tr><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"> 546,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"> 551,100</td></tr><tr><td style="vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 461,200</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.87%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,939,600</td></tr></table> 380600 546700 551100 461200 1939600 7335300 10150500 513500 588800 7848800 10739300 2279500 2066000 24400 24400 10152700 12829700 1203200 665200 268900 334200 200 105600 227800 362400 1699900 1467600 1699900 1467600 0.001 0.001 300000000 300000000 7332999 7332999 1200 1200 53933900 52988700 -45482300 -41627800 8452800 11362100 10152700 12829700 1885600 1028100 2071000 824600 3956600 1852700 -3956600 -1852700 105800 3700 102100 -3854500 -1852700 -0.53 -0.78 7332999 2863812 7332999 1200 52988700 -41627800 11362100 24700 24700 24700 24700 945200 945200 -3854500 -3854500 7332999 1200 53933900 -45482300 8452800 21822301 9134700 9869659 1306900 2863812 13965000 -22427600 1979000 6521738 331700 331700 -368400 368400 2668300 2668300 456000 456000 -1852700 -1852700 21822301 9134700 16391397 2007000 2863812 16720900 -24280300 3582300 -3854500 -1852700 95600 33800 945200 456000 105800 -75400 99700 273600 -35200 -65400 17500 -2635900 -1480300 44700 406300 -44700 -406300 134600 3000000 -134600 3000000 -2815200 1113400 10150500 1929100 7335300 3042500 264400 230700 3700 2668300 <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;">ORGANIZATION</td></tr></table>Nature of BusinessKiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.The Company is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.Going Concern — These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $2,635,900 for the three months ended March 31, 2021, and an accumulated deficit of $45,482,300 as of March 31, 2021. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. The Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in the third quarter of 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase 1 completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000. -2635900 -45482300 2235000 851000 1384000 <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</td></tr></table>Basis of PresentationThe accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.All intercompany balances were eliminated upon consolidation.Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets.Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.Estimated useful lives of property and equipment are as follows for the major classes of assets:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Asset Description</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Estimated Lives</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Laboratory Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 8</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Leasehold Improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">1 - 7</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Office Furniture, Fixtures, and Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">5</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 5</td></tr></table>Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020.Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020.Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH. Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020.Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options. The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10-year period from grant date.Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">valuations of the common stock performed by third-party specialists;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">lack of marketability of the common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">current business conditions and projections;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">hiring of key personnel and the experience of management;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the Company’s stage of development;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the market performance of comparable publicly traded companies; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the US and global capital market conditions.</td></tr></table><div style="margin-top:10pt;"/>In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grantSegment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows. Basis of PresentationThe accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.All intercompany balances were eliminated upon consolidation. Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense. Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents. Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities. Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets. 1 Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.Estimated useful lives of property and equipment are as follows for the major classes of assets:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Asset Description</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Estimated Lives</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Laboratory Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 8</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Leasehold Improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">1 - 7</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Office Furniture, Fixtures, and Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">5</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 5</td></tr></table> P8Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Asset Description</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Estimated Lives</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Laboratory Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 8</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Leasehold Improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">1 - 7</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Office Furniture, Fixtures, and Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">5</td></tr><tr><td style="vertical-align:bottom;width:83.79%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.14%;margin:0pt;padding:0pt;">3 - 5</td></tr></table> P3Y P8Y P1Y P7Y P5Y P3Y P5Y Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020. P5Y Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception. 0 Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss. Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020. 0 0 Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH. Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020. 0 0 Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options. The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10-year period from grant date. P4Y P48M P6M P12M Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">valuations of the common stock performed by third-party specialists;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">lack of marketability of the common stock;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">current business conditions and projections;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">hiring of key personnel and the experience of management;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the Company’s stage of development;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the market performance of comparable publicly traded companies; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the US and global capital market conditions.</td></tr></table><div style="margin-top:10pt;"/>In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant 0 Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows. 3.NET LOSS PER COMMON SHAREBasic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, restricted stock units, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;">Three Months Ended</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Net loss</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,854,500)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (1,852,700)</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Less: Series B Preferred Stock discount amortization</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (368,400)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Less: IPO Common Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (24,700)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Net loss attributable to common shareholders, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,879,200)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,221,100)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Weighted average common shares outstanding, basic and diluted</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 7,332,999</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2,863,812</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Net loss per common share, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.53)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.78)</td></tr></table>For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Stock options to purchase</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 677</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">404,391</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Restricted Stock Units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 32,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series A‑1 Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 624,594</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series B Preferred Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 469,136</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Warrants underlying Series B Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,399,807</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 32,677</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,897,928</td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;">Three Months Ended</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Net loss</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,854,500)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (1,852,700)</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Less: Series B Preferred Stock discount amortization</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (368,400)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Less: IPO Common Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (24,700)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Net loss attributable to common shareholders, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,879,200)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,221,100)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Weighted average common shares outstanding, basic and diluted</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 7,332,999</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2,863,812</td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;">Net loss per common share, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.53)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.78)</td></tr></table> -3854500 -1852700 368400 24700 -3879200 -2221100 7332999 2863812 -0.53 -0.78 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Stock options to purchase</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 677</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">404,391</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Restricted Stock Units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> 32,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series A‑1 Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 624,594</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Series B Preferred Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> 469,136</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Warrants underlying Series B Preferred Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,399,807</td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 32,677</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,897,928</td></tr></table> 677 404391 32000 624594 469136 1399807 32677 2897928 4.PROPERTY AND EQUIPMENTProperty and equipment consisted of the following at March 31, 2021 and December 31, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 1,138,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 780,500</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 1,274,600</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 1,229,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Office furniture, fixtures, and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 16,600</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 16,600</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 151,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 151,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Construction in progress</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 355,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 449,200</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 2,936,800</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 2,627,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Less: Accumulated depreciation</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (657,300)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (561,700)</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,279,500</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,066,000</td></tr></table>Depreciation expense was $95,600 and $33,800 for the three months ended March 31, 2021 and, 2020, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the condensed consolidated statements of operations. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 1,138,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 780,500</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 1,274,600</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 1,229,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Office furniture, fixtures, and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 16,600</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 16,600</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Software</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 151,700</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 151,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Construction in progress</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 355,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 449,200</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> 2,936,800</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 2,627,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Less: Accumulated depreciation</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (657,300)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (561,700)</td></tr><tr><td style="vertical-align:bottom;width:72.06%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,279,500</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,066,000</td></tr></table> 1138900 780500 1274600 1229700 16600 16600 151700 151700 355000 449200 2936800 2627700 657300 561700 2279500 2066000 95600 33800 5.ACCRUED EXPENSES AND OTHER CURRENT LIABILITIESAccrued expenses and other current liabilities consisted of the following at March 31, 2021 and December 31, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:8.65pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;">December 31,</td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued consulting and outside services</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 173,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 143,200</td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued compensation</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 95,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 268,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 334,200</td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:8.65pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;">December 31,</td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued consulting and outside services</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 173,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 143,200</td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Accrued compensation</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 95,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 268,900</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 334,200</td></tr></table> 173900 143200 95000 191000 268900 334200 6.LOAN PAYABLEOn May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to apply for forgiveness of the SBA Loan in accordance with the terms of the CARES Act.The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 as of December 31, 2020 in the condensed consolidated balance sheet. During the year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020. The Company accrued interest over the term of the loan and did not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency.During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021, the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,800. The forgiveness was classified as a gain on loan extinguishment in the condensed consolidated statement of operations. 115600 P2Y 0.01 P7M 105600 115600 10000 105600 105800 7.NOTE PAYABLEIn November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of March 31, 2021 and December 31, 2020, the remaining payable balance on the financed amount was $227,800 and $362,400, respectively. 540500 0.0459 227800 362400 8.COMMITMENTS AND CONTINGENCIESFacility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024. On March 22, 2021, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90-days notice of cancellation.If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.The total lease payments per month were $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477, 45,554, and $46,116 beginning May 1, 2021, August 1, 2021, and May 1, 2023, respectively. The Company records rent expense as incurred over the term of the leases.As of March 31, 2021, the future minimum commitments under the amended lease agreement will be as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amount</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 316,600</td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 546,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 551,100</td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 461,200</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,875,600</td></tr></table>Rent expense for the facility lease agreements was $69,000 and $60,000 during the three months ended March 31, 2021 and 2020, respectively. Rent expense is included as an allocation between research and development and general and administrative expense in the condensed consolidated statements of operations.License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of March 31, 2021 and December 31, 2020, the Company has not incurred any milestone or royalty liabilities related to these license agreements.Strategic Alliance Agreement with Leon Office (H.K.) — On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. They will also use commercially reasonable efforts to research the Asian market, with a primary, but not exclusive, focus on determining the most suitable structures for the development of medical partnerships or joint ventures with scientific partners in the Asian market with a mission to test products to be created by the joint venture resulting from such partnership and to develop validation programs for any products produced by such joint venture, including programs for clinical trials and human testing and, ultimately, for product certification. The cost of the agreement is $360,000 annually, payable in four quarterly installments.Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows. 4100 15385 21353 22477 45554 46116 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amount</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 316,600</td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 546,700</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 551,100</td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 461,200</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,875,600</td></tr></table> 316600 546700 551100 461200 1875600 69000 60000 360000 4 9.STOCKHOLDERS’ EQUITY On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share. In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the three months ended March 31, 2021:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Common Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"> 11,975,400</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Common stock IPO discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,700</td></tr><tr><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Balance at March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,000,100</td></tr></table>On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants underlying shares of Series B Preferred Stock became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700.On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted a stock option plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.There were 322,063 shares and 271,949 shares available for issuance as of March 31, 2021 and 2020, respectively.Series B Preferred Stock — On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.Accordingly, in connection with the IPO, all shares of the Company’s Series B Preferred Stock were converted into 469,136 shares of common stock on October 15, 2020.Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized during the three months ended March 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 1,306,900</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock proceeds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 3,000,000</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock discount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (2,668,300)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368,400</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Balance at March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,007,000</td></tr></table>In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. The warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">An additional 30% of the warrants beginning nine months after the Listing Date; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The remainder of the warrants beginning twelve months after the Listing Date.</td></tr></table><div style="margin-top:10pt;"/>As of March 31, 2020, the Company sold 16,391,397 shares of Series B Preferred Stock, which contained 1,399,921 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants are equity classified and the fair value of $5,533,000 is reflected as additional paid-in capital.On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. As of March 31, 2021, there were no warrants underlying Series B Preferred Stock.The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the three months ended March 31, 2021 and 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:77.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;">1.54% - 1.88</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;">71.95% - 72.71</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;"> 10</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">%</td></tr></table>Representative's Warrants — In connection with the IPO on October 15, 2020, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at March 31, 2021.These warrants were equity classified. As of March 31, 2021 and December 31, 2020, the warrant fair values of $332,600 and $357,300, respectively, is reflected as additional paid-in capital. On the issuance date, the Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions on October 15:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"> 0.18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"> 94.08</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"> 2.74</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">%</td></tr></table> 3.494 300000000 300000000 60000000 60000000 24000000 24000000 16500000 16500000 300000000 300000000 60000000 60000000 24000000 24000000 16500000 16500000 12332700 1275000 1392300 1250000 12.00 624594 469136 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Common Stock</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"> 11,975,400</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Common stock IPO discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,700</td></tr><tr><td style="vertical-align:bottom;width:84.2%;margin:0pt;padding:0pt;">Balance at March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,000,100</td></tr></table> 11975400 24700 12000100 335982 1200 1063939 3700 3106 430 402000 320000 0 9432000 1 0 10000000 20000000 30000000 858615 850000 858615 1708615 322063 271949 4782608 2200000 16500000 1739130 800000 469136 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Balance at January 1,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 1,306,900</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock proceeds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 3,000,000</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock discount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (2,668,300)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Series B Preferred Stock discount amortization</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368,400</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Balance at March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,007,000</td></tr></table> 1306900 3000000 2668300 368400 2007000 0.46 0.0859 0.003494 P10Y 0.30 0.30 16391397 1399921 5533000 335982 1200 1063939 3700 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:77.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;">1.54% - 1.88</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;">71.95% - 72.71</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;"> 10</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:78.35%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">%</td></tr></table> 0.0154 0.0154 0.0188 0.0188 0.7195 0.7195 0.7271 0.7271 P10Y P10Y 0 0 62500 15.00 1.25 P5Y 332600 357300 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"> 0.18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"> 94.08</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"> 2.74</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;">Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">%</td></tr></table> 0.0018 0.0018 0.9408 0.9408 P2Y8M26D P2Y8M26D 0 0 10.STOCK-BASED COMPENSATION2017 Stock Incentive Plan — Stock OptionsThere were no options granted during the three months ended March 31, 2021. The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the three months ended March 31:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;">1.59% - 2.92</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;">72.29% - 78.16</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;">4.93 – 6.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">%</td></tr></table>The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.The following table summarizes the activity for all stock options outstanding at March 31 under the Plan:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Weighted</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Exercise</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Options outstanding at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 489,718</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 10.03</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 598,083</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 11.11</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 17,631</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 12.02</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (57,149)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17.88</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (30,768)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.88</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Balance at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 432,569</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8.99</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 584,946</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.09</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Options exercisable at December 31:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 408,306</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 8.75</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 361,720</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 7.67</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Weighted average grant date fair value for options granted during the year:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 35.62</td></tr></table>The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021 and 2020 under the Plan:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:30.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Exercisable</td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Aggregate</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;">As of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Intrinsic</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:25.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Life</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercisable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 432,569</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 6.72</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"> 8.99</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 839,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 408,306</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"> 8.75</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> 269,514</td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 584,946</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 8.02</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"> 11.09</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 18,712,900</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 361,720</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"> 7.67</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> 12,808,800</td></tr></table>Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;">Research and development</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 19,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 425,000</td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 102,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 121,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 456,000</td></tr></table>On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $20,900 of stock compensation expense allocable to general and administrative for the three months ended March 31, 2021. Included in that amount were $9,600 of incremental compensation costs resulting from the modifications for the three months ended March 31, 2021.As of March 31, 2021, total unrecognized stock compensation expense is $252,700, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.25 years.2017 Stock Incentive Plan — Restricted Stock UnitsIn January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.The following table summarizes the activity for all RSUs outstanding at March 31 under the Plan:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;">Weighted Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Weighted Average</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;">Grant Date</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;">Fair Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Nonvested RSUs at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 946,245</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> 12.81</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 6,019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> 9.00</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Vested</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Nonvested RSUs at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952,264</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $267,700 and $556,600 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021. Included in those amounts were incremental compensation costs of $20,400 and $44,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;">1.59% - 2.92</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;">72.29% - 78.16</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Expected life (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;">4.93 – 6.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:81.07%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"> 0</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">%</td></tr></table> 0.0159 0.0292 0.7229 0.7816 P4Y11M4D P6Y25D 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Weighted</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Exercise</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Options outstanding at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 489,718</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 10.03</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 598,083</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 11.11</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 17,631</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 12.02</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (57,149)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17.88</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (30,768)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.88</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Balance at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 432,569</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8.99</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 584,946</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11.09</td></tr><tr><td style="vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Options exercisable at December 31:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 408,306</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 8.75</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 361,720</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 7.67</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.07%;margin:0pt;padding:0pt;">Weighted average grant date fair value for options granted during the year:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 35.62</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:30.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Exercisable</td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Aggregate</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;">As of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;">Intrinsic</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:25.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Life</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercisable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;">2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 432,569</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 6.72</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"> 8.99</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 839,700</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 408,306</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"> 8.75</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> 269,514</td></tr><tr><td style="vertical-align:bottom;width:25.56%;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 584,946</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 8.02</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"> 11.09</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 18,712,900</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 361,720</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"> 7.67</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> 12,808,800</td></tr></table> 489718 10.03 598083 11.11 17631 12.02 57149 17.88 30768 11.88 432569 8.99 584946 11.09 408306 8.75 361720 7.67 35.62 432569 P6Y8M19D 8.99 839700 408306 8.75 269514 584946 P8Y7D 11.09 18712900 361720 7.67 12808800 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;">Research and development</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 19,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 425,000</td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 102,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31,000</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 121,000</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 456,000</td></tr></table> 19000 425000 102000 31000 121000 456000 15792 4 21112 12.81 3959 20900 9600 252700 P1Y3M 1708615 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;">Weighted Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Weighted Average</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;">Grant Date</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;">Fair Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Per Share</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Nonvested RSUs at beginning of year</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 946,245</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> 12.81</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> 6,019</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> 9.00</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Vested</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.77%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Cancelled and forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.58%;margin:0pt;padding:0pt;">Nonvested RSUs at December 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952,264</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table> 946245 12.81 6019 9.00 952264 12.79 709334 5 12.87 946245 12.81 0 3 2 267700 556600 20400 44700 11.INCOME TAXESThe Company’s effective tax rate from continuing operations was 0% for the three months ended March 31, 2021 and 2020. The Company recorded no income tax provision for the three months ended March 31, 2021 and 2020.The provision for income taxes during the interim reporting periods is calculated by applying an estimate of the annual effective tax rate for the full fiscal year to "ordinary" income or loss for the reporting period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities.The income tax rates vary from the US federal statutory rate of 21% primarily due to the full valuation allowance on the Company’s deferred tax assets. The Company has recorded the full valuation allowance based on an evaluation of both positive and negative evidence, including latest forecasts and cumulative losses in recent years. The Company has concluded that it was more likely than not that none of its deferred tax assets would be realized. 0 0 0 0 0.21 0 12.RELATED PARTY TRANSACTIONSDuring the three months ended March 31, 2020, the Company maintained two separate consulting agreements with the Company's Chief Strategy and Innovation Officer (the "CSIO"), and the Chief Financial Officer and Chief Operating Officer (the "CFO and COO"). Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company's Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company's business development strategies. The consulting fees paid to the CSIO totaled $0 and $319,300 in the three months ended March 31, 2021 and 2020, respectively.Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $0 and $30,000 in the three months ended March 31, 2021 and 2020, respectively. After the Company completed the IPO on October 15, 2020, the CFO and COO and the CSIO became full time employees. 2 400 19 0 319300 2500 10000 0 30000 13.SUBSEQUENT EVENTSResearch Grant Agreement with University of Texas MD Anderson Cancer CenterOn April 8, 2021, the Company entered into a letter of intent (the “Letter of Intent”) with the University of Texas MD Anderson Cancer Center (“MD Anderson”) pursuant to which MD Anderson shall receive a research grant from the Company titled, “Validation of biomarker isomeso for pancreatic cancer,” which is aimed at discovering new cancer-specific antigen targets (the “Grant”). The total costs to the Company to be paid in connection with the Grant shall be $300,000. Pursuant to the Letter of Intent, the Grant shall commence on April 1, 2021 and end on March 31, 2022. 300000 XML 51 R1.htm IDEA: XBRL DOCUMENT v3.21.2

Document and Entity Information
3 Months Ended

Mar. 31, 2021

Document and Entity Information

Document Type S-1

Entity Registrant Name KIROMIC BIOPHARMA, INC.

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Central Index Key 0001792581

Amendment Flag false

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

XML 52 R2.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Balance Sheets - USD ($)

Mar. 31, 2021

Dec. 31, 2020

Mar. 31, 2020

Dec. 31, 2019

Dec. 06, 2019

Dec. 31, 2018

Current Assets:

Cash and cash equivalents $ 7,335,300 $ 10,150,500 $ 1,929,100

Inventories 22,200

Prepaid expenses and other current assets 513,500 588,800 89,100

Total current assets 7,848,800 10,739,300 2,040,400

Property and equipment, net 2,279,500 2,066,000 587,900

Other assets 24,400 24,400 24,400

Total Assets 10,152,700 12,829,700 2,652,700

Current Liabilities:

Accounts payable 1,203,200 665,200 452,400

Accrued expenses and other current liabilities 268,900 334,200 221,300

Interest payable 200

Loan payable 105,600

Note payable 227,800 362,400

Total current liabilities 1,699,900 1,467,600 673,700

Total Liabilities 1,699,900 1,467,600 673,700

Commitments and contingencies

Stockholders' Equity:

Common stock, $0.001 par value: 300,000,000 shares authorized as of December 31, 2020 and 2019; 7,332,999 and 2,863,812 shares issued and outstanding as of December 31, 2020 and 2019, respectively 1,200 1,200

Additional paid-in capital 53,933,900 52,988,700 13,965,000

Accumulated deficit (45,482,300) (41,627,800) (22,427,600)

Total Stockholders' Equity 8,452,800 11,362,100 $ 3,582,300 1,979,000 $ 265,300

Total Liabilities and Stockholders' Equity $ 10,152,700 12,829,700 2,652,700

Series A-1 Preferred Stock

Stockholders' Equity:

Preferred Stock 9,134,700

Series B Preferred Stock

Stockholders' Equity:

Preferred Stock $ 2,007,000 1,306,900 $ 4,500,000

Additional paid-in capital $ (40,000)

Preferred Stock

Stockholders' Equity:

Preferred Stock

X

- Definition
The amount of accrued expenses and other current liabilities as at the end of the reporting period.
+ References
No definition available.
+ Details

Name: krbp_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LoansPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R3.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Balance Sheets (Parenthetical) - $ / shares

Dec. 31, 2020

Dec. 31, 2019

Preferred stock, authorized 60,000,000 60,000,000

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, authorized 300,000,000 300,000,000

Common stock, issued 7,332,999 2,863,812

Common stock, outstanding 7,332,999 2,863,812

Series A-1 Preferred Stock

Preferred stock, par value ( in dollars per share) $ 0.0001 $ 0.0001

Preferred stock, authorized 24,000,000 24,000,000

Preferred stock, issued 0 21,822,301

Preferred stock, outstanding 0 21,822,301

Series B Preferred Stock

Preferred stock, par value ( in dollars per share) $ 0.0001 $ 0.0001

Preferred stock, authorized 16,500,000 14,130,435

Preferred stock, issued 0 9,869,659

Preferred stock, outstanding 0 9,869,659

Preferred Stock

Preferred stock, par value ( in dollars per share) $ 0.0001 $ 0.0001

Preferred stock, authorized 19,500,000 21,869,565

Preferred stock, issued 0 0

Preferred stock, outstanding 0 0

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R4.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Operations - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Operating expenses:

Research and development $ 5,052,900 $ 1,201,700

General and administrative 14,144,000 2,503,700

Total operating expenses 19,196,900 3,705,400

Loss from operations (19,196,900) (3,705,400)

Other expense

Interest expense (3,300) (22,500)

Total other expense (3,300) (22,500)

Net loss $ (19,200,200) $ (3,727,900)

Net loss per share, basic and diluted $ (4.42) $ (1.39)

Weighted average common shares outstanding, basic and diluted 4,505,867 2,862,809

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 55 R5.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)

Preferred Stock

Series A-1 Preferred Stock

Preferred Stock

Series B Preferred Stock

Common Stock

Previously Reported

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Series B Preferred Stock

Total

Balance at beginning of period at Dec. 31, 2018 $ 8,727,400 $ 10,237,600 $ (18,699,700) $ 265,300

Balance at beginning of period (in shares) at Dec. 31, 2018 20,886,782 2,863,093

Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock $ 407,300 407,300

Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock (in shares) 935,519

Issuance of Series B Preferred Stock $ 1,056,300 1,056,300

Issuance of Series B Preferred Stock 9,782,609

Common stock issuance net of issuance costs and discount amortization (in shares) 9,782,609

Series B Preferred Stock discount amortization $ 210,600 (210,600) $ (210,600) (210,600)

Warrants underlying Series B Preferred Stock issuance 3,443,700 3,443,700

Accretion and settlement of Series B Preferred Stock dividend $ 40,000 (40,000) $ (40,000) (40,000)

Accretion and settlement of Series B Preferred Stock Dividend (in shares) 87,050

Exercised stock options 11,400 11,400

Exercised stock options (in shares) 1,719

Stock compensation expense 522,900 522,900

Net loss (3,727,900) (3,727,900)

Balance at end of period at Dec. 31, 2019 $ 9,134,700 $ 1,306,900 13,965,000 (22,427,600) 1,979,000

Balance at end of period (in shares) at Dec. 31, 2019 21,822,301 9,869,659 2,864,812 2,863,812

Issuance of Series B Preferred Stock $ 331,700 331,700

Issuance of Series B Preferred Stock 6,521,738

Common stock issuance net of issuance costs and discount amortization (in shares) 16,391,397

Series B Preferred Stock discount amortization $ 368,400 (368,400) $ (368,400)

Warrants underlying Series B Preferred Stock issuance 2,668,300 2,668,300

Warrants underlying common stock issuance $ 5,533,000

Stock compensation expense 456,000 456,000

Net loss (1,852,700) (1,852,700)

Balance at end of period at Mar. 31, 2020 $ 9,134,700 $ 2,007,000 16,720,900 (24,280,300) 3,582,300

Balance at end of period (in shares) at Mar. 31, 2020 21,822,301 16,391,397 2,863,812

Balance at beginning of period at Dec. 31, 2019 $ 9,134,700 $ 1,306,900 13,965,000 (22,427,600) 1,979,000

Balance at beginning of period (in shares) at Dec. 31, 2019 21,822,301 9,869,659 2,864,812 2,863,812

Issuance of Series B Preferred Stock $ 331,700 331,700

Issuance of Series B Preferred Stock 6,521,738

Common stock issuance net of issuance costs and discount amortization $ 1,200 11,974,200 11,975,400

Common stock issuance net of issuance costs and discount amortization (in shares) 1,250,000 6,521,738

Series B Preferred Stock discount amortization $ 692,700 (692,700) $ (692,700) (692,700)

Warrants underlying Series B Preferred Stock issuance 2,668,300 2,668,300

Warrants underlying common stock discount amortization (19,700) (19,700)

Warrants underlying common stock issuance 377,000 5,208,700 377,000

Exercise of warrants 4,900 4,900

Exercise of warrants (in shares) 1,399,921

Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion $ (9,134,700) 9,134,700

Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares) (21,822,301) 624,594

Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion $ (2,331,300) 2,331,300 $ 2,331,300

Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares) (16,391,397) 469,136

Common stock issuance to employees and non-employees 9,432,000 9,432,000

Common stock issuance to employees and non-employees 725,536

Stock compensation expense 3,813,700 3,813,700

Net loss (19,200,200) (19,200,200)

Balance at end of period at Dec. 31, 2020 $ 1,200 52,988,700 (41,627,800) 11,362,100

Balance at end of period (in shares) at Dec. 31, 2020 7,333,999 7,332,999

Warrants underlying common stock discount amortization (24,700) (24,700)

Stock compensation expense 945,200 945,200

Net loss (3,854,500) (3,854,500)

Balance at end of period at Mar. 31, 2021 $ 1,200 $ 53,933,900 $ (45,482,300) $ 8,452,800

Balance at end of period (in shares) at Mar. 31, 2021 7,332,999

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants on preferred stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedPreferredStock

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares issued in settlement of dividend during the period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividendsShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amortization of discount on preferred shares issued.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAmortizationOfDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new preferred stock issued during the period.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodPreferredStockNewIssuesShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new preferred stock issued during the period.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodPreferredStockNewIssuesValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares issued to employee and nonemployees.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodSharesEmployeesAndNonEmployees

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares issued to employee and nonemployees.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodValueEmployeesAndNonEmployees

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of warrant exercised during period.
+ References
No definition available.
+ Details

Name: krbp_WarrantsExercisedDuringPeriodShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of warrant exercised during period.
+ References
No definition available.
+ Details

Name: krbp_WarrantsExercisedDuringPeriodValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 56 R6.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Cash flows from operating activities:

Net loss $ (3,854,500) $ (1,852,700) $ (19,200,200) $ (3,727,900)

Adjustments to reconcile net loss to net cash used for operating activities:

Depreciation 95,600 33,800 200,000 87,500

Stock compensation expense 945,200 456,000 13,245,700 522,900

Non-cash interest 200 20,500

Inventory obsolescence impairment 22,200

Changes in operating assets and liabilities:

Unbilled receivables from granting agency 24,300

Inventories (5,900)

Prepaid expenses and other current assets 75,400 (99,700) (499,700) 46,200

Other assets (6,600)

Accounts payable 273,600 (35,200) (7,700) 293,400

Accrued expenses and other current liabilities (65,400) 17,500 112,900 (151,300)

Deferred rent (19,000)

Convertible promissory notes derivative liability 2,000

Net cash used for operating activities (2,635,900) (1,480,300) (6,126,600) (2,913,900)

Cash flows from investing activities:

Purchases of property and equipment (44,700) (406,300) (1,457,600) (302,700)

Net cash used for investing activities (44,700) (406,300) (1,457,600) (302,700)

Cash flows from financing activities:

Proceeds from sale of convertible promissory notes 250,000

Exercise of stock options 11,400

Proceeds from issuance of common stock 15,000,000

Issuance costs (2,667,300)

Proceeds from warrant exercise 4,900

Proceeds from loan payable 115,600

Repayments of loan payable (10,000)

Borrowings from note payable 540,500

Repayment of notes payable (134,600) (178,100)

Proceeds from Series B Preferred Stock issuance 3,000,000 3,000,000 4,500,000

Net cash (used in) provided by financing activities (134,600) 3,000,000 15,805,600 4,761,400

Net change in cash and cash equivalents (2,815,200) 1,113,400 8,221,400 1,544,800

Cash and cash equivalents:

Beginning of year 10,150,500 1,929,100 1,929,100 384,300

End of period 7,335,300 3,042,500 10,150,500 1,929,100

Supplemental disclosures of non-cash investing and financing activities:

Accruals for property and equipment 264,400 $ 230,700 220,500 74,700

Cash paid for interest on note payable $ 3,700 $ 3,100

Conversion of accounts payable into convertible promissory notes 134,800

Conversion of convertible promissory notes and accrued interest into Series A1 Preferred Stock 407,300

Accretion and settlement of Series B Preferred Stock dividend $ 40,000

X

- Definition
The amount of increase (decrease) in convertible promissory notes derivative liability.
+ References
No definition available.
+ Details

Name: krbp_IncreaseDecreaseInConvertiblePromissoryNotesDerivativeLiability

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of increase (decrease) in deferred rent.
+ References
No definition available.
+ Details

Name: krbp_IncreaseDecreaseInDeferredRent

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received from loan payable.
+ References
No definition available.
+ Details

Name: krbp_ProceedsFromLoanPayable

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in accrued expenses, and obligations classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInUnbilledReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The fair value of notes issued in noncash investing and financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense or loss included in net income that result in no cash flow, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from bank borrowing during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromBankDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to settle a bank borrowing during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfBankDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R7.htm IDEA: XBRL DOCUMENT v3.21.2

ORGANIZATION
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

ORGANIZATION

ORGANIZATION
1.
ORGANIZATION
Nature of Business
Kiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.
The Company is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.
The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.
Going Concern — These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $2,635,900 for the three months ended March 31, 2021, and an accumulated deficit of $45,482,300 as of March 31, 2021. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. The Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in the third quarter of 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase 1 completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

1. ORGANIZATION
Nature of Business
Kiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.
The Company is a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.
The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.
Going Concern — The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flows from operations of $6,126,600 for the year ended December 31, 2020, and an accumulated deficit of $41,627,800 as of December 31, 2020. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Although the Company completed its initial public offering on October 15, 2020 and received net proceeds of $12,332,700, the Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in fiscal year 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the U.S. government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase I completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R8.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.
All intercompany balances were eliminated upon consolidation.
Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.
Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.
Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.
Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets.
Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020.
Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.
Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.
Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020.
Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.
Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH.
Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020.
Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10-year period from grant date.
Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant
Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.
On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.
Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.
Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.
Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.
The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.
Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets.
Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded.
Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.
During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets.
Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively.
Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.
Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.
Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019.
Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.
Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH.
Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.
Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.
Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.
The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.
Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:


December 31,

December 31,

2020

2019
Convertible promissory notes




Beginning balance

$
—

$
—
Amounts allocated to the embedded derivative liability at inception (at fair value)

—

(21,000)
Conversions from accounts payable into convertible promissory notes

—

134,800
Proceeds from issuances of convertible promissory notes

—

250,000
Conversions into Series A‑1 Stock

—

(363,800)
Ending balance

$
—

$
—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability




Beginning balance

$
—

$
—
Realized and unrealized gains and losses

—

2,000
Fair value of embedded derivative liability at inception

—

21,000
Amounts derecognized upon conversion of the related convertible promissory notes

—

(23,000)
Ending balance

$
—

$
—

Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.
Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant.
Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.
The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:
Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period.
Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.
Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.
Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.
Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.
Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R9.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

NET LOSS PER COMMON SHARE

NET LOSS PER COMMON SHARE
3.NET LOSS PER COMMON SHARE
Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, restricted stock units, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share:

Three Months Ended

March 31,


2021

2020
Net loss

$
(3,854,500)

$
(1,852,700)
Less: Series B Preferred Stock discount amortization

—

(368,400)
Less: IPO Common Stock discount amortization

(24,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(3,879,200)

$
(2,221,100)
Weighted average common shares outstanding, basic and diluted

7,332,999

2,863,812
Net loss per common share, basic and diluted

$
(0.53)

$
(0.78)

For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


March 31,

March 31,

2021

2020
Stock options to purchase

677

404,391
Restricted Stock Units

32,000

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

469,136
Warrants underlying Series B Preferred Stock

—

1,399,807
Total

32,677

2,897,928

3.
NET LOSS PER COMMON SHARE
Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted loss per share:

Years Ended

December 31,


2020

2019
Net loss

$
(19,200,200)

$
(3,727,900)
Less: Accretion and settlement of Series B Preferred Stock dividend

—

(40,000)
Less: Series B Preferred Stock discount amortization

(692,700)

(210,600)
Less: IPO Common Stock discount amortization

(19,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(19,912,600)

$
(3,978,500)
Weighted average common shares outstanding, basic and diluted

4,505,867

2,862,809
Net loss per common share, basic and diluted

$
(4.42)

$
(1.39)

For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


December 31,

December 31,

2020

2019
Stock options to purchase

1,647

75,405
Restricted Stock Units

95,815

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

282,478
Warrants underlying Series B Preferred Stock

—

839,784
Total

97,462

1,822,261

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R10.htm IDEA: XBRL DOCUMENT v3.21.2

PROPERTY AND EQUIPMENT, NET
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT, NET
4.PROPERTY AND EQUIPMENT
Property and equipment consisted of the following at March 31, 2021 and December 31, 2020:

March 31,

December 31,

2021

2020
Equipment

$
1,138,900

$
780,500
Leasehold improvements

1,274,600

1,229,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

151,700
Construction in progress

355,000

449,200

2,936,800

2,627,700
Less: Accumulated depreciation

(657,300)

(561,700)
Total

$
2,279,500

$
2,066,000

Depreciation expense was $95,600 and $33,800 for the three months ended March 31, 2021 and, 2020, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the condensed consolidated statements of operations.

4.
PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following at December 31:

2020

2019
Equipment

$
780,500

$
488,800
Leasehold improvements

1,229,700

302,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

141,500
Construction in progress

449,200

—

2,627,700

949,600
Less: Accumulated depreciation

(561,700)

(361,700)
Total

$
2,066,000

$
587,900

Depreciation expense was $200,000 and $87,500 for the years ended December 31, 2020 and 2019, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R11.htm IDEA: XBRL DOCUMENT v3.21.2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
5.ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following at March 31, 2021 and December 31, 2020:

March 31,

December 31,

2021

2020
Accrued consulting and outside services

$
173,900

$
143,200
Accrued compensation

95,000

191,000
Total

$
268,900

$
334,200

5.
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following at December 31:

2020

2019
Accrued consulting and outside services

$
143,200

$
221,300
Accrued compensation

191,000

—
Total

$
334,200

$
221,300

X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R12.htm IDEA: XBRL DOCUMENT v3.21.2

CURRENT LOAN PAYABLE
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

LOAN PAYABLE

CURRENT LOAN PAYABLE
6.LOAN PAYABLE
On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to apply for forgiveness of the SBA Loan in accordance with the terms of the CARES Act.
The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.
As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 as of December 31, 2020 in the condensed consolidated balance sheet. During the year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020. The Company accrued interest over the term of the loan and did not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency.

During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021, the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,800. The forgiveness was classified as a gain on loan extinguishment in the condensed consolidated statement of operations.

6.
CURRENT LOAN PAYABLE
On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. The SBA Loan was forgiven on February 16, 2021. See Note 14.
The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.
As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 during year ended December 31, 2020 in the consolidated balance sheet. During year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020.
The Company accrued $200 of interest expense during the year ended December 31, 2020. The Company accrues interest over the term of the loan and does not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency. If any amount of the loan is ultimately forgiven, income from the extinguishment of debt would be recognized as a gain on loan extinguishment in the consolidated statement of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R13.htm IDEA: XBRL DOCUMENT v3.21.2

NOTE PAYABLE
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

NOTE PAYABLE

NOTE PAYABLE
7.NOTE PAYABLE
In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of March 31, 2021 and December 31, 2020, the remaining payable balance on the financed amount was $227,800 and $362,400, respectively.

7.
NOTE PAYABLE
In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of December 31, 2020, the remaining payable balance on the financed amount was approximately $362,400.

X

- References
No definition available.
+ Details

Name: us-gaap_ShortTermBorrowingsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for short-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R14.htm IDEA: XBRL DOCUMENT v3.21.2

CONVERTIBLE PROMISSORY NOTES
12 Months Ended

Dec. 31, 2020

CONVERTIBLE PROMISSORY NOTES

CONVERTIBLE PROMISSORY NOTES
8.CONVERTIBLE PROMISSORY NOTES
Starting in June 2016, the Company sold convertible promissory notes to certain investors to help finance its operations. The convertible promissory notes were in amounts ranging from $12,500 to $500,000, earning annual interest between 6% and 17% and all maturing either on June 1, 2019, January 2, 2020, or June 30, 2020 (the “Maturity Date”).
The convertible promissory notes were convertible into shares issued in the Company’s Next Financing Close by dividing the total amount of convertible promissory notes, plus accrued interest (the “Balance”) by the applicable conversion price, as defined in the convertible promissory notes. If the convertible promissory notes have not been converted, the Balance shall be payable in full if the Company consummates a change of control transaction. If there has not been a Next Financing Close or a change in control by the Maturity Date, then at the noteholders’ option, the Company shall either repay the Balance then outstanding or convert into the Company’s common stock at a set conversion price then in effect, as defined in the convertible promissory notes.
The estimated fair value of the conversion discount related embedded derivative was determined using a probability-weighted expected return model. The probability of a Next Financing Close occurring prior to the Maturity Date was determined to be 55% during the year ended December 31, 2019. The net present value of the conversion discount related embedded derivative was measured using a discount rate of 25% as of December 31, 2019. Below is a table that outlines the initial value of issuances and the bifurcated embedded derivative liability during the years ended December 31:

2020

2019
Convertible promissory notes- issuances

$
—

$
250,000
Conversion of accounts payable into convertible promissory notes

—

134,800
Total issuances and conversions into convertible promissory notes

—

384,800

Embedded derivative liability




Initial fair value upon issuance of convertible promissory notes

—

21,000
Realized and unrealized gains and losses

—

2,000
Converted embedded derivative liability into Series A‑1 Preferred Stock

—

(23,000)
Embedded derivative liability balance at December 31

$
—

$
—

On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. See Note 10 for further details. No additional convertible promissory notes were issued for year ended December 31, 2020 following the conversion on August 15, 2019.

X

- Definition
The entire disclosure of debt.
+ References
No definition available.
+ Details

Name: krbp_ConvertibleDebtTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 65 R15.htm IDEA: XBRL DOCUMENT v3.21.2

COMMITMENTS AND CONTINGENCIES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES
8.COMMITMENTS AND CONTINGENCIES
Facility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.
On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024.
On March 22, 2021, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90-days notice of cancellation.

If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.

The total lease payments per month were $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477, 45,554, and $46,116 beginning May 1, 2021, August 1, 2021, and May 1, 2023, respectively. The Company records rent expense as incurred over the term of the leases.
As of March 31, 2021, the future minimum commitments under the amended lease agreement will be as follows:


Amount
2021

$
316,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,875,600

Rent expense for the facility lease agreements was $69,000 and $60,000 during the three months ended March 31, 2021 and 2020, respectively. Rent expense is included as an allocation between research and development and general and administrative expense in the condensed consolidated statements of operations.
License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of March 31, 2021 and December 31, 2020, the Company has not incurred any milestone or royalty liabilities related to these license agreements.
Strategic Alliance Agreement with Leon Office (H.K.) — On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. They will also use commercially reasonable efforts to research the Asian market, with a primary, but not exclusive, focus on determining the most suitable structures for the development of medical partnerships or joint ventures with scientific partners in the Asian market with a mission to test products to be created by the joint venture resulting from such partnership and to develop validation programs for any products produced by such joint venture, including programs for clinical trials and human testing and, ultimately, for product certification. The cost of the agreement is $360,000 annually, payable in four quarterly installments.

Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.

The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows.

9.COMMITMENTS AND CONTINGENCIES
Facility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.
On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.
The total lease payments per month will be $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477 and $23,039 beginning May 1, 2021 and May 1, 2022, respectively. The Company records rent expense on a straight-line basis over the term of the leases.
As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:


Amount
2021

$
265,200
2022

269,700
2023

274,200
2024

230,400
Total

$
1,039,500

Annual rent expense for the facility lease agreements was $262,900 and $129,100 for the years ended December 31, 2020 and 2019, respectively, and is included as an allocation between research and development and general and administrative expense in the consolidated statements of operations.
License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of December 31, 2020 and 2019, the Company has not incurred any milestone or royalty liabilities related to these license agreements.
Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. The Company regularly assesses all contingencies and believes, as of December 31, 2020, the Company was not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 R16.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY
9.STOCKHOLDERS’ EQUITY
On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.
Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.
As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.
Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.
On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.
Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.
As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.
Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.
On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share.
In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.
Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the three months ended March 31, 2021:


2021
Common Stock


Balance at January 1,

$
11,975,400
Common stock IPO discount amortization

24,700
Balance at March 31,

$
12,000,100

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants underlying shares of Series B Preferred Stock became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700.
On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.
Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.
The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted a stock option plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.
There were 322,063 shares and 271,949 shares available for issuance as of March 31, 2021 and 2020, respectively.
Series B Preferred Stock — On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.
On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.
With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.
Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.
Accordingly, in connection with the IPO, all shares of the Company’s Series B Preferred Stock were converted into 469,136 shares of common stock on October 15, 2020.

Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized during the three months ended March 31:


2020
Series B Preferred Stock


Balance at January 1,

$
1,306,900
Series B Preferred Stock proceeds

3,000,000
Series B Preferred Stock discount

(2,668,300)
Series B Preferred Stock discount amortization

368,400
Balance at March 31,

$
2,007,000

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.
Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. The warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.
● 30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");
● An additional 30% of the warrants beginning nine months after the Listing Date; and
● The remainder of the warrants beginning twelve months after the Listing Date.
As of March 31, 2020, the Company sold 16,391,397 shares of Series B Preferred Stock, which contained 1,399,921 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants are equity classified and the fair value of $5,533,000 is reflected as additional paid-in capital.
On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.
On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. As of March 31, 2021, there were no warrants underlying Series B Preferred Stock.
The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the three months ended March 31, 2021 and 2020:

March 31,


2020

Risk-free interest rate

1.54% - 1.88
%
Expected volatility

71.95% - 72.71
%
Expected life (years)

10

Expected dividend yield

0
%

Representative's Warrants — In connection with the IPO on October 15, 2020, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at March 31, 2021.

These warrants were equity classified. As of March 31, 2021 and December 31, 2020, the warrant fair values of $332,600 and $357,300, respectively, is reflected as additional paid-in capital. On the issuance date, the Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions on October 15:

2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%

10.STOCKHOLDERS’ EQUITY
On December 16, 2019, the Company amended and restated its certificate of incorporation to, among other things, (i) complete a 1-for-10 reverse split of the Company’s outstanding shares of common stock; (ii) increase the Company’s authorized Preferred Stock to 60,000,000 shares and (iii) change the par value of the Preferred Stock from $0.01 to $0.0001 per share.
On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares of common stock.
Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits during the years ended December 31, 2020 and 2019.
As of December 31, 2020 and 2019, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares and of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock. Additionally, 16,500,000 shares and 14,130,435 shares were designated as Series B Preferred Stock as of December 31, 2020 and 2019, respectively.
Common Stock — As of December 31, 2020 and 2019, the Company has a single class of common stock.
On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share. In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.

Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the year ended December 31, 2020:


2020

Common Stock



Balance at January 1,

$
—

Common stock IPO proceeds, net of issuance costs

12,332,700

Common stock IPO discount

(377,000)

Common stock IPO discount amortization

19,700

Balance at December 31,

$
11,975,400

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There were 0 and 839,952 warrants outstanding as of December 31, 2020 and 2019, respectively.
On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSIO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.
Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.
The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted the Plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.
There were 270,933 shares and 258,813 shares available for issuance as of December 31, 2020 and 2019, respectively.
Series A-1 Preferred Stock — In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation the holders of the shares of Series A-1 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.50, the original issue price.
On matters submitted to a vote of the stockholders of the Company, Series A-1 Preferred Stock and common stock vote together as one class, with the vote of the Series A-1 Preferred Stock on an as-converted basis. Each holder of Series A-1 Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series A-1 Preferred Stock held by such holder are then convertible.
With respect rights on liquidation, winding up and dissolution, shares of the Series A-1 Preferred Stock rank senior to all shares of common stock.
Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.
In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.
Series B Preferred Stock — On September 13, 2019, the Company amended and restated its certificate of incorporation to authorize the issuance of up to 14,130,435 shares of Series B Preferred Stock. On September 13, 2019, the Company sold 7,608,696 shares of Series B Preferred Stock for $3,500,000. On November 13, 2019, the Company issued an additional 2,173,913 shares of Series B Preferred Stock for $1,000,000. In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). See below for further details.
Until the filing of the amended and restated certificate of incorporation on December 16, 2019, shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. The amended and restated certificate of incorporation eliminated the clause requiring the dividend accrual. In addition, on December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, the Company issued 87,050 shares of Series B Preferred Stock to the investors. The Company treated this transaction as accretion and settlement of a Series B Preferred Stock dividends in the amount of $40,000. Accordingly, additional paid-in capital was reduced by $40,000.
The Series B Preferred Stock conversion price is initially equal to the Series B Preferred Stock original issuance price of $0.46 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock. The holders of the Series B Preferred Stock held a special redemption right. In the event the Company had not filed an initial registration statement with the United States Securities and Exchange Commission and submitted an application to be listed on the Nasdaq Stock market on or prior to November 15, 2019, subject to Delaware law governing distributions to stockholders and the Company’s ability to redeem its shares, all or part of the shares of Series B Preferred Stock held by any holder of record as of such date of shares of Series B Preferred Stock with an aggregate purchase price of at least $1,000,000 would have been be redeemable at the option of such holders of record commencing any time on or after November 16, 2019 at a price equal to the purchase price paid for such shares plus all unpaid dividends accrued on such shares. Also, in the event that the Company was not ultimately approved for listing on a Nasdaq Stock Market tier lower than the Nasdaq Global Select Market, the special redemption right would remain in effect and may have been exercisable on any date thereafter. If the Company was unable to execute a redemption upon request of a holder, interest would accrue on the shares at rate of 14.6%, or warrants underlying the shares would be exercisable and the fair market value of the shares of common stock received in connection therewith would be treated as payment in exchange for the shares of Series B Preferred Stock submitted for redemption by such holder.
On November 12, 2019 and November 13, 2019, the Series B Preferred Stock investors signed waivers, which provided consent to the Company to eliminate the special redemption right. When the Company amended and restated its certificate of incorporation on December 16, 2019, the special redemption right provision was eliminated.
The elimination of the special redemption right allows for permanent equity classification for the Series B Preferred Stock. Since the Warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series B Preferred Stock and the Warrants. The fair value of the Warrants is offset by a contra account, which is classified as a discount to the Series B Preferred Stock. The discount is amortized using the effective interest method at an effective interest rate of 28% per annum.
On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.
In connection with the IPO, all shares of the Company's Series B Preferred Stock were converted into 469,136 shares of common stock, and the value of the Series B Preferred Stock converted into additional-paid-in-capital.
Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock, the Series B Preferred Stock discount amortized, and value of Series B Preferred Stock that was converted into additional-paid-in-capital during the years ended December 31:


2020

2019
Series B Preferred Stock




Balance at January 1,

$
1,306,900

$
4,500,000
Series B Preferred Stock proceeds

3,000,000

(3,443,700)
Series B Preferred Stock discount

(2,668,300)

210,600
Series B Preferred Stock discount amortization

692,700

40,000
Series B Preferred Stock conversion to common stock

(2,331,300)

—
Balance at December 31,

$
—

$
1,306,900

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.
On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.
With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.
Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.
Conversion of Convertible Promissory Notes — On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $405,300. Per the convertible promissory notes, the notes containing a $250,000 principal balance with a 17% coupon rate had a conversion price of $0.43. Additionally, the Company settled an accounts payable with a vendor by issuing a convertible promissory note in the amount of $134,800 with a 6% coupon rate, with a conversion rate of $0.43. Accordingly, 935,519 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.
In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.
Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. Under the original terms of the warrant agreements, the warrants become have exercisable in accordance with the schedule set forth below following completion by the Company of an IPO and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.
● 30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");
● An additional 30% of the warrants beginning nine months after the Listing Date; and
● The remainder of the warrants beginning twelve months after the Listing Date.
As of December 31, 2019, the Company sold 9,782,609 shares of Series B Preferred Stock, which contained 839,952 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. During the year ended December 31, 2020, the Company sold an additional 6,521,738 shares of Series B Preferred Stock, which contained 559,969 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants were equity classified and the fair value of $5,208,700 is reflected as additional paid-in capital. On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.
On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There are no warrants underlying Series B Preferred Stock outstanding as of December 31, 2020.
The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the years ended December 31:

2020

2019

Risk-free interest rate

1.54% - 1.88
%
1.54% - 1.84
%
Expected volatility

71.95% - 72.71
%
71.95% - 72.20
%
Expected life (years)

10.00

10.00

Expected dividend yield

0
%
0
%

Representative's Warrants — In connection with the IPO, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at December 31, 2020.
These warrants were equity classified and the fair value of $377,000 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the year ended December 31, 2020:


2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R17.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION
10.STOCK-BASED COMPENSATION
2017 Stock Incentive Plan — Stock Options
There were no options granted during the three months ended March 31, 2021. The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the three months ended March 31:


2020

Risk-free interest rate

1.59% - 2.92
%
Expected volatility

72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

Expected dividend yield

0
%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.

The following table summarizes the activity for all stock options outstanding at March 31 under the Plan:

2021

2020




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

489,718

$
10.03

598,083

$
11.11
Granted

—

—

17,631

12.02
Exercised

—

—

—

—
Cancelled and forfeited

(57,149)

17.88

(30,768)

11.88
Balance at December 31

432,569

$
8.99

584,946

$
11.09
Options exercisable at December 31:

408,306

$
8.75

361,720

$
7.67
Weighted average grant date fair value for options granted during the year:



$
—



$
35.62

The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021 and 2020 under the Plan:

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
March 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2021

432,569

6.72

$
8.99

$
839,700

408,306

$
8.75

$
269,514
2020

584,946

8.02

$
11.09

$
18,712,900

361,720

$
7.67

$
12,808,800

Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 as follows:


2021

2020
Research and development

$
19,000

$
425,000
General and administrative

102,000

31,000
Total

$
121,000

$
456,000

On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $20,900 of stock compensation expense allocable to general and administrative for the three months ended March 31, 2021. Included in that amount were $9,600 of incremental compensation costs resulting from the modifications for the three months ended March 31, 2021.
As of March 31, 2021, total unrecognized stock compensation expense is $252,700, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.25 years.
2017 Stock Incentive Plan — Restricted Stock Units
In January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.
The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.
The following table summarizes the activity for all RSUs outstanding at March 31 under the Plan:

2021

2020




Weighted Average



Weighted Average

Grant Date

Grant Date

Fair Value

Fair Value

Shares

Per Share

Shares

Per Share
Nonvested RSUs at beginning of year

946,245

$
12.81

—

$
—
Granted

6,019

9.00

—

—
Vested

—

—

—

—
Cancelled and forfeited

—

—

—

—
Nonvested RSUs at December 31

952,264

$
12.79

—

$
—

On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $267,700 and $556,600 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021. Included in those amounts were incremental compensation costs of $20,400 and $44,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021.

11.STOCK-BASED COMPENSATION
2017 Stock Incentive Plan — Stock Options
The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:


2020

2019

Risk-free interest rate

0.15% - 2.92
%
1.60% - 2.92
%
Expected volatility

72.29% - 82.52
%
72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

4.93 – 6.07

Expected dividend yield

0
%
0
%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.
The following table summarizes the activity for all stock options outstanding at December 31 under the Plan:

2020

2019




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

598,083

$
11.04

520,517

$
8.64
Granted

86,536

17.95

209,505

17.29
Exercised

—

—

(1,719)

6.64
Cancelled and forfeited

(194,901)

15.06

(130,220)

11.56
Balance at December 31

489,718

$
10.03

598,083

$
11.04
Options exercisable at December 31:

441,430

$
9.50

368,527

$
7.72
Weighted average grant date fair value for options granted during the year:



$
17.43



$
10.82

The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2020 and 2019 under the Plan:

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
December 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2020

489,718

6.37

$
10.03

$
554,900

441,430

$
9.50

$
—
2019

598,083

8.07

$
11.04

$
19,163,700

368,527

$
7.72

$
13,031,000

Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the consolidated statements of operations for the years ended December 31, 2020 and 2019 as follows:


2020

2019
Research and development

$
1,008,000

$
332,000
General and administrative

332,000

190,900
Total

$
1,340,000

$
522,900

On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $65,900 of stock compensation expense allocable to general and administrative for the year December 31, 2020. Included in that amount were $34,800 of incremental compensation costs resulting from the modifications for the year ended December 31, 2020.
As of December 31, 2020, total unrecognized stock compensation expense is $473,900, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.79 years.
2017 Stock Incentive Plan — Restricted Stock Units
In January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.
The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.
The following table summarizes the activity for all RSUs outstanding at December 31 under the Plan:

2020




Weighted Average

Grant Date

Fair Value

Shares

Per Share
Nonvested RSUs at beginning of year

—

$
—
Granted

1,655,579

12.84
Vested

—

—
Cancelled and forfeited

(709,334)

12.87
Nonvested RSUs at December 31

946,245

$
12.81

During the year ended December 31, 2020, 1,655,579 RSUs were granted and 709,334 RSUs were cancelled. During the year ended December 31, 2020, no RSUs vested. No RSUs were granted or vested in the year ended December 31, 2019.
On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $748,400 and $1,725,300 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020. Included in those amounts were incremental compensation costs of $166,900 and $402,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 68 R18.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

INCOME TAXES

INCOME TAXES
11.INCOME TAXES
The Company’s effective tax rate from continuing operations was 0% for the three months ended March 31, 2021 and 2020. The Company recorded no income tax provision for the three months ended March 31, 2021 and 2020.
The provision for income taxes during the interim reporting periods is calculated by applying an estimate of the annual effective tax rate for the full fiscal year to "ordinary" income or loss for the reporting period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities.
The income tax rates vary from the US federal statutory rate of 21% primarily due to the full valuation allowance on the Company’s deferred tax assets. The Company has recorded the full valuation allowance based on an evaluation of both positive and negative evidence, including latest forecasts and cumulative losses in recent years. The Company has concluded that it was more likely than not that none of its deferred tax assets would be realized.

12.INCOME TAXES
For the years ended December 31, 2020 and 2019, the Company recognized no provision or benefit from income taxes.
The following is a reconciliation of the effective income tax rate to the statutory federal income tax rate for the years ended December 31, 2020 and 2019.


2020

2019

Federal income tax at statutory rates

21.00
%
21.00
%
Federal income tax rate reduction

—
%
—
%
Change in valuation allowance

(21.00)

(21.00)

Effective income tax rate

—
%
—
%

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. The Company recorded a valuation allowance to fully offset the net deferred tax asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets as of December 31, 2020 and 2019 due to the significant uncertainty about the realization of the deferred tax asset until the Company can operate profitably.
The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows as of December 31:


2020

2019
Deferred tax assets (liabilities):




Net operating loss carryforward

$
3,842,900

$
2,605,400
Stock compensation expense

3,379,000

597,400
Intangible assets

23,600

27,800
Total gross deferred tax assets

7,245,500

3,230,600
Valuation allowance

(7,061,600)

(3,198,100)
Property and equipment

(183,900)

(32,500)
Net deferred tax assets (liabilities)

—

—

As of December 31, 2020 and 2019, the Company has a US net operating loss ("NOL") carryforward of $18,299,500 and $12,406,800, respectively. The NOL carryforwards may be subject to annual limitations due to "change in ownership" provisions of Internal Revenue Code Section 382 ("Section 382") that can be triggered due to future ownership changes. Additionally, the NOL loss carryforwards are subject to examination and adjustments by the Internal Revenue Service until the statute of limitations closes on the year in which the NOL is utilized.
As of December 31, 2020 and 2019, there were no material uncertain tax positions taken by the Company. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months.
As of December 31, 2020, the Company is not currently under audit by any income tax authority.
On March 27, 2020, in response to the COVID-19 pandemic, the president of the United States signed the CARES Act. The Company does not expect there to be any significant benefit to its income tax provision as a result of the CARES Act, and the Company continues to monitor for any potential tax legislation related to the COVID-19 pandemic.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 69 R19.htm IDEA: XBRL DOCUMENT v3.21.2

RELATED PARTY TRANSACTIONS
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS
12.RELATED PARTY TRANSACTIONS
During the three months ended March 31, 2020, the Company maintained two separate consulting agreements with the Company's Chief Strategy and Innovation Officer (the "CSIO"), and the Chief Financial Officer and Chief Operating Officer (the "CFO and COO").
Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company's Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company's business development strategies. The consulting fees paid to the CSIO totaled $0 and $319,300 in the three months ended March 31, 2021 and 2020, respectively.
Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $0 and $30,000 in the three months ended March 31, 2021 and 2020, respectively.
After the Company completed the IPO on October 15, 2020, the CFO and COO and the CSIO became full time employees.

13.RELATED PARTY TRANSACTIONS
During the year ended December 31, 2020, the Company maintained two separate consulting agreements with the Company’s CSIO and the Company’s CFO and COO. Those consulting agreements were terminated after the completion of the IPO in October 2020.
Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO was entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company’s Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company’s business development strategies. The consulting fees paid to the CSIO totaled $579,700 and $207,800 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CSIO 320,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.
Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month plus discretionary bonuses approved by management. The consulting fees paid to the CFO and COO totaled $140,000 and $67,500 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CFO and COO 402,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.
On June 8, 2020, the Company issued the Chief Medical Officer and another employee 3,106 and 430 shares of common stock, respectively. The shares were issued in exchange for services rendered and no cash considerations. See Note 10.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 R20.htm IDEA: XBRL DOCUMENT v3.21.2

SUBSEQUENT EVENTS
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS
13.SUBSEQUENT EVENTS
Research Grant Agreement with University of Texas MD Anderson Cancer Center
On April 8, 2021, the Company entered into a letter of intent (the “Letter of Intent”) with the University of Texas MD Anderson Cancer Center (“MD Anderson”) pursuant to which MD Anderson shall receive a research grant from the Company titled, “Validation of biomarker isomeso for pancreatic cancer,” which is aimed at discovering new cancer-specific antigen targets (the “Grant”). The total costs to the Company to be paid in connection with the Grant shall be $300,000. Pursuant to the Letter of Intent, the Grant shall commence on April 1, 2021 and end on March 31, 2022.

14.SUBSEQUENT EVENTS
Strategic Alliance Agreement with Leon Office (H.K.)
On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. The cost of the agreement is $360,000 annually, payable in four quarterly installments.
Loan Payable Forgiveness
During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021 the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,600 and $300, respectively.
Lease Facility Expansion
On March 22, 2020, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.
If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.
The future minimum commitments under the amended lease agreement will be as follows:


Amount
2021

$
380,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,939,600

Legal Complaint Filed Against the Company
A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 71 R21.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.
All intercompany balances were eliminated upon consolidation.

Basis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.
On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.

Use of Estimates
Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Cash and Cash Equivalents
Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Concentrations of Credit Risk and Other Uncertainties
Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.

Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.
The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.

Deposit
Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets.

Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets.

Inventories
Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded.

Deferred Initial Public Offering Costs
Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.
During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets.

Property and Equipment
Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Internal Use Software Development Costs
Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020.

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively.

Impairment of Long-Lived Assets
Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.

Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.

Comprehensive Loss
Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Income Taxes
Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020.

Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019.

Research and Development Expense
Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Proceeds from Grants
Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH.
Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH

Convertible Promissory Notes Derivative Liability
Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.
Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.

Fair Value Measurements
Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020.

Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.
The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.
Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:


December 31,

December 31,

2020

2019
Convertible promissory notes




Beginning balance

$
—

$
—
Amounts allocated to the embedded derivative liability at inception (at fair value)

—

(21,000)
Conversions from accounts payable into convertible promissory notes

—

134,800
Proceeds from issuances of convertible promissory notes

—

250,000
Conversions into Series A‑1 Stock

—

(363,800)
Ending balance

$
—

$
—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability




Beginning balance

$
—

$
—
Realized and unrealized gains and losses

—

2,000
Fair value of embedded derivative liability at inception

—

21,000
Amounts derecognized upon conversion of the related convertible promissory notes

—

(23,000)
Ending balance

$
—

$
—

Nonvested Stock Options and Restricted Stock Units
Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10-year period from grant date.

Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.

Stock-Based Compensation
Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant

Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant.
Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.
The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:
Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period.
Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.
Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.
Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.
Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.

Segment Data
Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019.

X

- Definition
Disclosure of accounting policy for convertible promissory notes derivative liability.
+ References
No definition available.
+ Details

Name: krbp_ConvertiblePromissoryNotesDerivativeLiabilityPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for deposit.
+ References
No definition available.
+ Details

Name: krbp_DepositPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for nonvested stock options and restricted stock units.
+ References
No definition available.
+ Details

Name: krbp_NonvestedStockOptionsAndRestrictedStockUnitsPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for proceeds from grants.
+ References
No definition available.
+ Details

Name: krbp_ProceedsFromGrantsPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for deferral and amortization of significant deferred charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredChargesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 40
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 50
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_InternalUseSoftwarePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 72 R22.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of estimated useful lives of property and equipment

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Schedule of Level 3 liabilities measured at fair value on a recurring and nonrecurring basis


December 31,

December 31,

2020

2019
Convertible promissory notes




Beginning balance

$
—

$
—
Amounts allocated to the embedded derivative liability at inception (at fair value)

—

(21,000)
Conversions from accounts payable into convertible promissory notes

—

134,800
Proceeds from issuances of convertible promissory notes

—

250,000
Conversions into Series A‑1 Stock

—

(363,800)
Ending balance

$
—

$
—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability




Beginning balance

$
—

$
—
Realized and unrealized gains and losses

—

2,000
Fair value of embedded derivative liability at inception

—

21,000
Amounts derecognized upon conversion of the related convertible promissory notes

—

(23,000)
Ending balance

$
—

$
—

X

- Definition
Tabular disclosure of estimated useful lives of property and equipment.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R23.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

NET LOSS PER COMMON SHARE

Schedule of earnings per share, basic and diluted

Three Months Ended

March 31,


2021

2020
Net loss

$
(3,854,500)

$
(1,852,700)
Less: Series B Preferred Stock discount amortization

—

(368,400)
Less: IPO Common Stock discount amortization

(24,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(3,879,200)

$
(2,221,100)
Weighted average common shares outstanding, basic and diluted

7,332,999

2,863,812
Net loss per common share, basic and diluted

$
(0.53)

$
(0.78)

Years Ended

December 31,


2020

2019
Net loss

$
(19,200,200)

$
(3,727,900)
Less: Accretion and settlement of Series B Preferred Stock dividend

—

(40,000)
Less: Series B Preferred Stock discount amortization

(692,700)

(210,600)
Less: IPO Common Stock discount amortization

(19,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(19,912,600)

$
(3,978,500)
Weighted average common shares outstanding, basic and diluted

4,505,867

2,862,809
Net loss per common share, basic and diluted

$
(4.42)

$
(1.39)

Schedule of antidilutive securities excluded from computation of earnings per share


March 31,

March 31,

2021

2020
Stock options to purchase

677

404,391
Restricted Stock Units

32,000

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

469,136
Warrants underlying Series B Preferred Stock

—

1,399,807
Total

32,677

2,897,928

For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


December 31,

December 31,

2020

2019
Stock options to purchase

1,647

75,405
Restricted Stock Units

95,815

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

282,478
Warrants underlying Series B Preferred Stock

—

839,784
Total

97,462

1,822,261

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R24.htm IDEA: XBRL DOCUMENT v3.21.2

PROPERTY AND EQUIPMENT, NET (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

PROPERTY AND EQUIPMENT

Schedule of property and equipment

March 31,

December 31,

2021

2020
Equipment

$
1,138,900

$
780,500
Leasehold improvements

1,274,600

1,229,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

151,700
Construction in progress

355,000

449,200

2,936,800

2,627,700
Less: Accumulated depreciation

(657,300)

(561,700)
Total

$
2,279,500

$
2,066,000

2020

2019
Equipment

$
780,500

$
488,800
Leasehold improvements

1,229,700

302,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

141,500
Construction in progress

449,200

—

2,627,700

949,600
Less: Accumulated depreciation

(561,700)

(361,700)
Total

$
2,066,000

$
587,900

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 75 R25.htm IDEA: XBRL DOCUMENT v3.21.2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Schedule of accrued expenses and other current liabilities

March 31,

December 31,

2021

2020
Accrued consulting and outside services

$
173,900

$
143,200
Accrued compensation

95,000

191,000
Total

$
268,900

$
334,200

2020

2019
Accrued consulting and outside services

$
143,200

$
221,300
Accrued compensation

191,000

—
Total

$
334,200

$
221,300

X

- Definition
Tabular disclosure of information pertaining to accrued expenses and other liabilities.
+ References
No definition available.
+ Details

Name: krbp_AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 76 R26.htm IDEA: XBRL DOCUMENT v3.21.2

CONVERTIBLE PROMISSORY NOTES (Tables)
12 Months Ended

Dec. 31, 2020

CONVERTIBLE PROMISSORY NOTES

Schedule of initial value of issuances and the bifurcated embedded derivative liability

2020

2019
Convertible promissory notes- issuances

$
—

$
250,000
Conversion of accounts payable into convertible promissory notes

—

134,800
Total issuances and conversions into convertible promissory notes

—

384,800

Embedded derivative liability




Initial fair value upon issuance of convertible promissory notes

—

21,000
Realized and unrealized gains and losses

—

2,000
Converted embedded derivative liability into Series A‑1 Preferred Stock

—

(23,000)
Embedded derivative liability balance at December 31

$
—

$
—

X

- Definition
Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.
+ References
No definition available.
+ Details

Name: us-gaap_ConvertibleDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R27.htm IDEA: XBRL DOCUMENT v3.21.2

COMMITMENTS AND CONTINGENCIES (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

COMMITMENTS AND CONTINGENCIES

Schedule of future minimum rental payments for operating leases


Amount
2021

$
316,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,875,600

As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:


Amount
2021

$
265,200
2022

269,700
2023

274,200
2024

230,400
Total

$
1,039,500

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 78 R28.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Schedule of initial value of issuances allocated to IPO common stock, IPO common stock discount amortized and value of IPO common stock converted into additional paid-in-capital


2021
Common Stock


Balance at January 1,

$
11,975,400
Common stock IPO discount amortization

24,700
Balance at March 31,

$
12,000,100


2020

Common Stock



Balance at January 1,

$
—

Common stock IPO proceeds, net of issuance costs

12,332,700

Common stock IPO discount

(377,000)

Common stock IPO discount amortization

19,700

Balance at December 31,

$
11,975,400

Schedule of initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized


2020
Series B Preferred Stock


Balance at January 1,

$
1,306,900
Series B Preferred Stock proceeds

3,000,000
Series B Preferred Stock discount

(2,668,300)
Series B Preferred Stock discount amortization

368,400
Balance at March 31,

$
2,007,000


2020

2019
Series B Preferred Stock




Balance at January 1,

$
1,306,900

$
4,500,000
Series B Preferred Stock proceeds

3,000,000

(3,443,700)
Series B Preferred Stock discount

(2,668,300)

210,600
Series B Preferred Stock discount amortization

692,700

40,000
Series B Preferred Stock conversion to common stock

(2,331,300)

—
Balance at December 31,

$
—

$
1,306,900

Common Stock Warrants - Representative

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Schedule of assumptions used to estimate fair value of warrants

2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%


2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%

Series B Preferred Stock

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Schedule of assumptions used to estimate fair value of warrants

March 31,


2020

Risk-free interest rate

1.54% - 1.88
%
Expected volatility

71.95% - 72.71
%
Expected life (years)

10

Expected dividend yield

0
%

2020

2019

Risk-free interest rate

1.54% - 1.88
%
1.54% - 1.84
%
Expected volatility

71.95% - 72.71
%
71.95% - 72.20
%
Expected life (years)

10.00

10.00

Expected dividend yield

0
%
0
%

X

- Definition
Tabular disclosure of initial value of issuances allocated to IPO common stock, IPO common stock discount amortized and value of IPO common stock converted into additional paid-in-capital.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfInitialValueOfIssuancesAllocatedToPreferredStockTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term, (b) expected volatility, (c) expected dividends, and (d) risk-free rate(s).
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfWarrantsFairValueValuationAssumptionsTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_CommonStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R29.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

STOCK-BASED COMPENSATION

Schedule of assumptions used to estimate fair value of stock options


2020

Risk-free interest rate

1.59% - 2.92
%
Expected volatility

72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

Expected dividend yield

0
%

The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:


2020

2019

Risk-free interest rate

0.15% - 2.92
%
1.60% - 2.92
%
Expected volatility

72.29% - 82.52
%
72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

4.93 – 6.07

Expected dividend yield

0
%
0
%

Schedule of stock option activity

2021

2020




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

489,718

$
10.03

598,083

$
11.11
Granted

—

—

17,631

12.02
Exercised

—

—

—

—
Cancelled and forfeited

(57,149)

17.88

(30,768)

11.88
Balance at December 31

432,569

$
8.99

584,946

$
11.09
Options exercisable at December 31:

408,306

$
8.75

361,720

$
7.67
Weighted average grant date fair value for options granted during the year:



$
—



$
35.62

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
March 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2021

432,569

6.72

$
8.99

$
839,700

408,306

$
8.75

$
269,514
2020

584,946

8.02

$
11.09

$
18,712,900

361,720

$
7.67

$
12,808,800

2020

2019




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

598,083

$
11.04

520,517

$
8.64
Granted

86,536

17.95

209,505

17.29
Exercised

—

—

(1,719)

6.64
Cancelled and forfeited

(194,901)

15.06

(130,220)

11.56
Balance at December 31

489,718

$
10.03

598,083

$
11.04
Options exercisable at December 31:

441,430

$
9.50

368,527

$
7.72
Weighted average grant date fair value for options granted during the year:



$
17.43



$
10.82

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
December 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2020

489,718

6.37

$
10.03

$
554,900

441,430

$
9.50

$
—
2019

598,083

8.07

$
11.04

$
19,163,700

368,527

$
7.72

$
13,031,000

Schedule of stock-based compensation


2021

2020
Research and development

$
19,000

$
425,000
General and administrative

102,000

31,000
Total

$
121,000

$
456,000


2020

2019
Research and development

$
1,008,000

$
332,000
General and administrative

332,000

190,900
Total

$
1,340,000

$
522,900

Schedule of restricted stock unit activity

2021

2020




Weighted Average



Weighted Average

Grant Date

Grant Date

Fair Value

Fair Value

Shares

Per Share

Shares

Per Share
Nonvested RSUs at beginning of year

946,245

$
12.81

—

$
—
Granted

6,019

9.00

—

—
Vested

—

—

—

—
Cancelled and forfeited

—

—

—

—
Nonvested RSUs at December 31

952,264

$
12.79

—

$
—

2020




Weighted Average

Grant Date

Fair Value

Shares

Per Share
Nonvested RSUs at beginning of year

—

$
—
Granted

1,655,579

12.84
Vested

—

—
Cancelled and forfeited

(709,334)

12.87
Nonvested RSUs at December 31

946,245

$
12.81

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 80 R30.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES (Tables)
12 Months Ended

Dec. 31, 2020

INCOME TAXES

Schedule of reconciliation of the effective income tax rate to the statutory federal income tax rate


2020

2019

Federal income tax at statutory rates

21.00
%
21.00
%
Federal income tax rate reduction

—
%
—
%
Change in valuation allowance

(21.00)

(21.00)

Effective income tax rate

—
%
—
%

Schedule of tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets


2020

2019
Deferred tax assets (liabilities):




Net operating loss carryforward

$
3,842,900

$
2,605,400
Stock compensation expense

3,379,000

597,400
Intangible assets

23,600

27,800
Total gross deferred tax assets

7,245,500

3,230,600
Valuation allowance

(7,061,600)

(3,198,100)
Property and equipment

(183,900)

(32,500)
Net deferred tax assets (liabilities)

—

—

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 81 R31.htm IDEA: XBRL DOCUMENT v3.21.2

SUBSEQUENT EVENTS (Tables)
12 Months Ended

Dec. 31, 2020

SUBSEQUENT EVENTS

Schedule of future minimum rental payments for renewed operating lease upon commencement


Amount
2021

$
380,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,939,600

X

- Definition
Tabular disclosure of estimated future minimum payments required in the aggregate and for each of the five fiscal years upon commencement for renewed operating leases.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfEstimatedFutureMinimumRentalPaymentsForRenewedOperatingLeasesTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 82 R32.htm IDEA: XBRL DOCUMENT v3.21.2

ORGANIZATION (Details) - USD ($)
3 Months Ended 12 Months Ended

Oct. 15, 2020

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

ORGANIZATION

Cash flow from operations $ (2,635,900) $ (1,480,300) $ (6,126,600) $ (2,913,900)

Accumulated deficit (45,482,300) (41,627,800) $ (22,427,600)

Common stock IPO proceeds, net of issuance costs $ 12,332,700

NIH Grant receivable $ 2,235,000

Phase I approved amount of grant $ 851,000

Phase II approved amount of grant $ 1,384,000 $ 1,384,000

X

- Definition
Phase one approved amount of grant.
+ References
No definition available.
+ Details

Name: krbp_PhaseOneApprovedAmountOfGrant

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Phase two approved amount of grant.
+ References
No definition available.
+ Details

Name: krbp_PhaseTwoApprovedAmountOfGrant

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_GrantsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 83 R33.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
12 Months Ended

Jun. 17, 2020

Dec. 17, 2019

Dec. 16, 2019

Dec. 31, 2020

USD ($)

item

Mar. 31, 2021

item

Dec. 31, 2019

USD ($)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Stock split (Reverse stock split) ratio 3.494 10 10

Reserve for inventory obsolescence $ 22,200 $ 0

Decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO 2,667,300

Deferred offering costs $ 0 $ 0

Lease facility | item 1 1

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalDeferredIpoOfferingCosts

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
It represents the number of lease facility on the company.
+ References
No definition available.
+ Details

Name: krbp_NumberOfLeaseFacility

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735
+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

XML 84 R34.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Property and Equipment

Impairment of long-lived assets held-for-use $ 0 $ 0

Unrecognized tax benefits, interest or penalties $ 0 $ 0 0 $ 0

Grants recognized $ 142,400 298,000

Minimum

Property and Equipment

Property plant and equipment useful life 1 year 1 year

Maximum

Property and Equipment

Property plant and equipment useful life 8 years 8 years

Equipment | Minimum

Property and Equipment

Property plant and equipment useful life 3 years 3 years

Equipment | Maximum

Property and Equipment

Property plant and equipment useful life 8 years 8 years

Leasehold improvements | Minimum

Property and Equipment

Property plant and equipment useful life 1 year 1 year

Leasehold improvements | Maximum

Property and Equipment

Property plant and equipment useful life 7 years 7 years

Office furniture, fixtures, and equipment

Property and Equipment

Property plant and equipment useful life 5 years 5 years

Software

Property and Equipment

Property plant and equipment useful life 5 years 5 years

Capitalized software development costs $ 10,200 $ 20,000

Software | Minimum

Property and Equipment

Property plant and equipment useful life 3 years 3 years

Software | Maximum

Property and Equipment

Property plant and equipment useful life 5 years 5 years

X

- Definition
The amount of grants received recognized as reductions to research and development expense.
+ References
No definition available.
+ Details

Name: krbp_IncomeFromGrants

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Additions made to capitalized computer software costs during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_CapitalizedComputerSoftwareAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=krbp_OfficeFurnitureFixturesAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 85 R35.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Fair Value Measurements

Changes in fair value hierarchy levels $ 0 $ 0 $ 0 $ 0

Conversions into Series A1 Stock (407,300)

Non-recurring | Convertible promissory notes | Level 3

Fair Value Measurements

Amounts allocated to the embedded derivative liability at inception (at fair value) (21,000)

Conversions from accounts payable into convertible promissory notes 134,800

Proceeds from issuances of convertible promissory notes 250,000

Conversions into Series A1 Stock (363,800)

Recurring | Convertible promissory notes | Level 3

Convertible promissory note embedded derivative liability

Realized and unrealized gains and losses 2,000

Fair value of embedded derivative liability at inception 21,000

Amounts derecognized upon conversion of the related convertible promissory notes $ (23,000)

X

- Definition
Amounts allocated to the embedded derivative liability at inception (at fair value).
+ References
No definition available.
+ Details

Name: krbp_AmountsAllocatedToEmbeddedDerivativeLiabilityAtInceptionAtFairValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amounts derecognized upon conversion of the related convertible promissory notes.
+ References
No definition available.
+ Details

Name: krbp_AmountsDerecognizedUponConversionOfRelatedConvertiblePromissoryNotes

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of conversion of accounts payable in to convertible debt instrument.
+ References
No definition available.
+ Details

Name: krbp_ConversionsOfAccountsPayableIntoConvertibleDebt

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Realized and unrealized gain (losses) on fair value of the embedded derivative or group of embedded derivatives.
+ References
No definition available.
+ Details

Name: krbp_EmbeddedDerivativeGainLossOnEmbeddedDerivativeLiabilityRealizedAndUnrealizedGainsLosses

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Changes in the fair value hierarchy levels during the period.
+ References
No definition available.
+ Details

Name: krbp_FairValueChanges

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of fair value of embedded derivative liability at inception.
+ References
No definition available.
+ Details

Name: krbp_FairValueOfEmbeddedDerivativeLiabilityAtInception

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 86 R36.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) - $ / shares
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Oct. 15, 2020

Nonvested Stock Options

Expected dividend yield 0.00% 0.00%

RSU

Nonvested Stock Options

Expiration period 10 years 10 years

Monthly Vesting Conditions | Minimum | RSU

Nonvested Stock Options

Vesting period 6 months 6 months

Monthly Vesting Conditions | Maximum | RSU

Nonvested Stock Options

Vesting period 12 months 12 months

Stock Incentive Plan 2017

Nonvested Stock Options

Expiration period 10 years 10 years

Stock Incentive Plan 2017 | Annual Vesting Conditions

Nonvested Stock Options

Vesting period 4 years 4 years

Stock Incentive Plan 2017 | Monthly Vesting Conditions | Minimum

Nonvested Stock Options

Vesting period 10 months 10 months

Stock Incentive Plan 2017 | Monthly Vesting Conditions | Maximum

Nonvested Stock Options

Vesting period 48 months 48 months

IPO

Nonvested Stock Options

Share price $ 12.00

Common Stock Warrants - Representative

Nonvested Stock Options

Warrant exercise price $ 15.00

Common Stock Warrants - Representative | IPO

Nonvested Stock Options

Warrant exercise price $ 15.00

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=krbp_MonthlyVestingConditionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=krbp_AnnualVestingConditionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_CommonStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 87 R37.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

NET LOSS PER COMMON SHARE

Net loss $ (3,854,500) $ (1,852,700) $ (19,200,200) $ (3,727,900)

Less: Accretion and settlement of Series B Preferred Stock dividend (40,000)

Series B Preferred Stock discount amortization (692,700) (210,600)

Less: IPO Common Stock discount amortization (24,700) (19,700)

Net loss attributable to common shareholders, basic and diluted $ (3,879,200) $ (2,221,100) $ (19,912,600) $ (3,978,500)

Weighted average common shares outstanding, basic and diluted 7,332,999 2,863,812 4,505,867 2,862,809

Net loss per common share, basic and diluted $ (0.53) $ (0.78) $ (4.42) $ (1.39)

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amortization of discount on preferred shares issued.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAmortizationOfDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 88 R38.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) - shares
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 32,677 2,897,928 97,462 1,822,261

Series A-1 Preferred Stock

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 624,594 624,594

Series B Preferred Stock

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 469,136 282,478

Stock Options

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 677 404,391 1,647 75,405

RSU

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 32,000 95,815

Series B Preferred Stock Warrant

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 1,399,807 839,784

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=krbp_SeriesBPreferredStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 89 R39.htm IDEA: XBRL DOCUMENT v3.21.2

PROPERTY AND EQUIPMENT, NET (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross $ 2,936,800 $ 2,627,700 $ 949,600

Less: Accumulated depreciation (657,300) (561,700) (361,700)

Total 2,279,500 2,066,000 587,900

Depreciation 95,600 $ 33,800 200,000 87,500

Equipment

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 1,138,900 780,500 488,800

Leasehold improvements

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 1,274,600 1,229,700 302,700

Office furniture, fixtures, and equipment

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 16,600 16,600 16,600

Software

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 151,700 151,700 $ 141,500

Construction in progress

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross $ 355,000 $ 449,200

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=krbp_OfficeFurnitureFixturesAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 90 R40.htm IDEA: XBRL DOCUMENT v3.21.2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)

Mar. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued consulting and outside services $ 173,900 $ 143,200 $ 221,300

Accrued compensation 95,000 191,000

Total $ 268,900 $ 334,200 $ 221,300

X

- Definition
The amount of accrued expenses and other current liabilities as at the end of the reporting period.
+ References
No definition available.
+ Details

Name: krbp_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 91 R41.htm IDEA: XBRL DOCUMENT v3.21.2

CURRENT LOAN PAYABLE (Details) - USD ($)
3 Months Ended 12 Months Ended

May 01, 2020

Mar. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Current loan payable

Loan payable $ 105,600

Loan initial proceeds 115,600

Interest expense $ 3,700 3,300 $ 22,500

SBA Loan

Current loan payable

Principal amount $ 115,600

Loan payable 105,600

Loan initial proceeds 115,600

Loan repayments 10,000

Loan term 2 years

Loan fixed interest rate 1.00%

Loan first payment due 7 months

Interest expense $ 200

X

- Definition
Period of first payment due from the date of initial cash receipt.
+ References
No definition available.
+ Details

Name: krbp_DebtInstrumentFirstPaymentDue

Namespace Prefix: krbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received from loan payable.
+ References
No definition available.
+ Details

Name: krbp_ProceedsFromLoanPayable

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LoansPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=krbp_SBLoanPaycheckProtectionProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 92 R42.htm IDEA: XBRL DOCUMENT v3.21.2

NOTE PAYABLE (Details) - USD ($)
1 Months Ended

Nov. 30, 2020

Mar. 31, 2021

Dec. 31, 2020

Note payable

Note payable $ 227,800 $ 362,400

Director and Officer Insurance Policy Financing

Note payable

Note payable $ 540,500 $ 227,800 $ 362,400

Interest rate 4.59%

Note term 9 months

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtPercentageBearingFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 93 R43.htm IDEA: XBRL DOCUMENT v3.21.2

CONVERTIBLE PROMISSORY NOTES (Details) - Convertible promissory notes - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2020

Jun. 30, 2016

CONVERTIBLE PROMISSORY NOTES

Convertible promissory notes $ 0

Probability of next financing close (as a percent) 55.00%

Embedded derivative discount rate ( as a percent) 25.00%

Minimum

CONVERTIBLE PROMISSORY NOTES

Convertible promissory notes $ 12,500

Annual interest (as a percent) 6.00%

Maximum

CONVERTIBLE PROMISSORY NOTES

Convertible promissory notes $ 500,000

Annual interest (as a percent) 17.00%

X

- Definition
Percentage of discount on embedded derivative.
+ References
No definition available.
+ Details

Name: krbp_EmbeddedDerivativeDiscountRate

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of probability of next financing close.
+ References
No definition available.
+ Details

Name: krbp_ProbabilityPercentageOfNextFinancingClose

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 94 R44.htm IDEA: XBRL DOCUMENT v3.21.2

CONVERTIBLE PROMISSORY NOTES - Initial Issuance and Bifurcated Embedded Derivative Liability (Details) - Convertible promissory notes
12 Months Ended

Dec. 31, 2019

USD ($)

CONVERTIBLE PROMISSORY NOTES

Convertible promissory notes- issuances $ 250,000

Conversion of accounts payable into convertible promissory notes 134,800

Total issuances and conversions into convertible promissory notes 384,800

Embedded derivative liability

Initial balance 21,000

Realized and unrealized gains and losses 2,000

Converted embedded derivative liability into Series A1 Preferred Stock (23,000)

Ending balance $ 0

X

- Definition
The amount of accounts payable converted into convertible debt.
+ References
No definition available.
+ Details

Name: krbp_ConversionOfAccountsPayableIntoConvertibleDebt

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of preferred stock from converted embedded derivative liability.
+ References
No definition available.
+ Details

Name: krbp_ConvertedEmbeddedDerivativeLiabilityIntoPreferredStock

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Realized and unrealized gain (losses) on fair value of the embedded derivative or group of embedded derivatives.
+ References
No definition available.
+ Details

Name: krbp_EmbeddedDerivativeGainLossOnEmbeddedDerivativeLiabilityRealizedAndUnrealizedGainsLosses

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(13))
-URI http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959
+ Details

Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 95 R45.htm IDEA: XBRL DOCUMENT v3.21.2

COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended 12 Months Ended

May 01, 2023

USD ($)

May 01, 2022

USD ($)

Aug. 01, 2021

USD ($)

May 01, 2021

USD ($)

Mar. 22, 2021

Nov. 19, 2020

Jan. 01, 2020

USD ($)

Mar. 31, 2021

USD ($)

Mar. 31, 2020

USD ($)

Dec. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

ft²

COMMITMENTS AND CONTINGENCIES

Area leased | ft² 4,100

Period of time after notice of cancellation that the lease effectively terminates 90 days 90 days

Total lease payments per month $ 46,116 $ 23,039 $ 45,554 $ 22,477 $ 21,353

Rent expense $ 69,000 $ 60,000 $ 262,900 $ 129,100

Future minimum commitments

2021 546,700 265,200

2022 551,100 269,700

2023 461,200 274,200

2024 230,400

Total $ 1,875,600 $ 1,039,500

X

- Definition
Represents the area of property leased.
+ References
No definition available.
+ Details

Name: krbp_AreaOfPropertyLeased

Namespace Prefix: krbp_

Data Type: num:areaItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of total lease payments per month under the operating leases.
+ References
No definition available.
+ Details

Name: krbp_LesseeOperatingLeasePaymentsPerMonth

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The period of time after notice of cancellation that the lease effectively terminates.
+ References
No definition available.
+ Details

Name: krbp_OperatingLeaseTerminationPeriodAfterNoticeOfCancellation

Namespace Prefix: krbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 96 R46.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) (Details)
3 Months Ended 12 Months Ended

Jun. 19, 2020

USD ($)

shares

Jun. 17, 2020

shares

Jun. 10, 2020

USD ($)

shares

Jun. 08, 2020

USD ($)

Vote

shares

Dec. 17, 2019

Dec. 16, 2019

$ / shares

shares

Mar. 31, 2021

$ / shares

shares

Dec. 31, 2020

USD ($)

$ / shares

shares

Sep. 18, 2020

shares

Mar. 31, 2020

shares

Dec. 31, 2019

$ / shares

shares

Dec. 15, 2019

$ / shares

Sep. 25, 2019

shares

Sep. 24, 2019

shares

Sep. 13, 2019

shares

Jun. 18, 2018

shares

Stockholder's equity (Deficit)

Reverse split 3.494 10 10

Preferred stock, authorized 60,000,000 60,000,000 60,000,000 60,000,000

Preferred stock, par value ( in dollars per share) | $ / shares $ 0.0001 $ 0.01

Proceeds from issuance of common stock | $ $ 15,000,000

Common stock, authorized 1,708,615 858,615 300,000,000 300,000,000 858,615 300,000,000 30,000,000 20,000,000 858,615

Warrants to purchase shares 1,063,939 335,982

Proceeds from Issuance of Warrants | $ $ 3,700 $ 1,200 $ 4,900

Warrants outstanding 0 839,952

Stock compensation expenses | $ $ 9,432,000

Number of Votes | Vote 1

Dividend paid | $ / shares $ 0 $ 0

Shares available for issuance 850,000 322,063 270,933 271,949 258,813 10,000,000

Employees

Stockholder's equity (Deficit)

Shares issued for services 430

Cash consideration | $ $ 0

CMO

Stockholder's equity (Deficit)

Shares issued for services 3,106

Cash consideration | $ $ 0

CFO and COO

Stockholder's equity (Deficit)

Shares issued for services 402,000

Cash consideration | $ $ 0

CSIO

Stockholder's equity (Deficit)

Shares issued for services 320,000

Cash consideration | $ $ 0

Series A-1 Preferred Stock

Stockholder's equity (Deficit)

Preferred stock, authorized 24,000,000 24,000,000 24,000,000

Preferred stock, par value ( in dollars per share) | $ / shares $ 0.0001 $ 0.0001

Series B Preferred Stock

Stockholder's equity (Deficit)

Preferred stock, authorized 16,500,000 16,500,000 14,130,435 14,130,435

Preferred stock, par value ( in dollars per share) | $ / shares $ 0.0001 $ 0.0001

Warrants to purchase shares 559,969 1,399,921 839,952

Proceeds from Issuance of Warrants | $ $ 3,700 $ 1,200

Warrants outstanding 0

X

- Definition
Number of votes per share.
+ References
No definition available.
+ Details

Name: krbp_NumberOfVotesPerShare

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of cash consideration in exchange for shares issued for services rendered by related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionCashConsiderationInExchangeForServiceShares

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate dividends paid during the period for each share of common stock outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_CommonStockDividendsPerShareCashPaid

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=krbp_ChiefMedicalOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=krbp_ChiefFinancialOfficerAndChiefOperatingOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=krbp_ChiefStrategyAndInnovationOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 97 R47.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Oct. 15, 2020

Jun. 10, 2020

Jun. 08, 2020

Jan. 31, 2020

Jan. 24, 2020

Dec. 06, 2019

Nov. 13, 2019

Sep. 13, 2019

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Common stock

Offering expenses $ 2,667,300

Beginning Balance $ 1,200

Common stock IPO proceeds, net of issuance costs $ 12,332,700

Common stock IPO discount (377,000)

Common stock IPO discount amortization 24,700 19,700

Ending Balance 1,200 $ 1,200

Series B Preferred Stock

Common stock

Shares issued 1,063,939 335,982 1,739,130 4,782,608 87,050 2,173,913 7,608,696 16,391,397 6,521,738 9,782,609

Common stock IPO discount $ (3,700) $ (5,533,000) $ (5,208,700)

IPO

Common stock

Underwriting discounts and commissions 1,275,000

Offering expenses $ 1,392,300

Shares issued 1,250,000

Share price $ 12.00

Beginning Balance 11,975,400

Common stock IPO proceeds, net of issuance costs $ 12,332,700 12,332,700

Common stock IPO discount (377,000)

Common stock IPO discount amortization 24,700 19,700

Ending Balance $ 12,000,100 $ 11,975,400

IPO | Series A-1 Preferred Stock

Common stock

Stock issued on conversion 624,594

IPO | Series B Preferred Stock

Common stock

Stock issued on conversion 469,136

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash flow from payments of underwriting discounts and commissions.
+ References
No definition available.
+ Details

Name: krbp_PaymentsOfUnderwritingDiscountsAndCommissions

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 98 R48.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Jun. 10, 2020

Jun. 08, 2020

Jan. 31, 2020

Jan. 24, 2020

Dec. 15, 2019

Dec. 06, 2019

Nov. 15, 2019

Nov. 13, 2019

Sep. 13, 2019

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Mar. 31, 2021

Jan. 29, 2020

Dec. 16, 2019

Nov. 16, 2019

Stockholder's equity (Deficit)

Issuance of stock $ 11,975,400

Preferred stock, authorized 60,000,000 60,000,000 60,000,000 60,000,000

Accretion of dividend $ 40,000

Additional paid-in capital $ 52,988,700 $ 13,965,000 $ 53,933,900

Series A-1 Preferred Stock

Stockholder's equity (Deficit)

Original issue price $ 0.50

Preferred stock, authorized 24,000,000 24,000,000 24,000,000

Common shares issued for preferred stock converted 624,594

Series B Preferred Stock

Stockholder's equity (Deficit)

Shares issued 1,063,939 335,982 1,739,130 4,782,608 87,050 2,173,913 7,608,696 16,391,397 6,521,738 9,782,609

Issuance of stock $ 800,000 $ 2,200,000 $ 1,000,000 $ 3,500,000

Original issue price $ 0.46 $ 0.46 $ 0.46

Preferred stock, authorized 14,130,435 16,500,000 14,130,435 16,500,000

Warrants to purchase 0.0859 0.0859 0.0859

Warrant exercise price $ 0.003494 $ 0.003494 $ 0.003494

Annual dividend rate 6.00%

Accretion of dividend $ 40,000 $ 40,000

Additional paid-in capital $ (40,000)

Effective interest rate (as a percent) 28.00% 14.60%

Common shares issued for preferred stock converted 469,136

Series B Preferred Stock | Minimum

Stockholder's equity (Deficit)

Aggregate purchase price $ 1,000,000

Series B Preferred Stock | Maximum

Stockholder's equity (Deficit)

Preferred stock, authorized 16,500,000

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_PaymentsForProceedsFromPreviousAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 99 R49.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Dec. 06, 2019

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Stockholder's equity (Deficit)

Accretion and settlement of Series B Preferred Stock dividend $ 40,000

Series B Preferred Stock discount amortization $ 692,700 210,600

Series B Preferred Stock

Stockholder's equity (Deficit)

Balance at beginning of period $ 1,306,900 1,306,900 4,500,000

Series B Preferred Stock proceeds 3,000,000 3,000,000 (3,443,700)

Accretion and settlement of Series B Preferred Stock dividend $ 40,000 40,000

Series B Preferred Stock discount (2,668,300) (2,668,300)

Series B Preferred Stock discount amortization 368,400 692,700 210,600

Series B Preferred Stock conversion to common stock $ (2,331,300)

Balance at end of period $ 2,007,000 $ 1,306,900

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amortization of discount on preferred shares issued.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAmortizationOfDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.4-07)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770
+ Details

Name: us-gaap_PreferredStockDiscountOnShares

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 100 R50.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details) - Series A-1 Preferred Stock - USD ($)
12 Months Ended

Aug. 15, 2019

Dec. 31, 2020

Stockholder's equity (Deficit)

Common shares issued for preferred stock converted 624,594

Convertible promissory notes

Stockholder's equity (Deficit)

Outstanding principal and interest $ 405,300

Number of shares converted 935,519

Principal amount $ 250,000

Coupon rate 17.00% 6.00%

Conversion of accounts payable into convertible promissory notes $ 134,800

Conversion rate 0.43% 0.43%

X

- Definition
The amount of accounts payable converted into convertible debt.
+ References
No definition available.
+ Details

Name: krbp_ConversionOfAccountsPayableIntoConvertibleDebt

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of coupon rate.
+ References
No definition available.
+ Details

Name: krbp_PercentageOfCouponRate

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 101 R51.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Warrants Underlying Series B Preferred Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Jun. 10, 2020

Jun. 08, 2020

Jan. 31, 2020

Jan. 24, 2020

Dec. 06, 2019

Nov. 13, 2019

Sep. 13, 2019

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Stockholder's equity (Deficit)

Warrants to purchase shares 1,063,939 335,982

Fair value of warrants reflected as additional paid-in capital $ 377,000

Proceeds from issuance of warrants $ 3,700 $ 1,200 $ 4,900

Warrants outstanding 0 839,952

Series B Preferred Stock

Stockholder's equity (Deficit)

Warrants to purchase 0.0859 0.0859 0.0859

Warrant purchase price (in dollars per share) $ 0.003494 $ 0.003494 $ 0.003494

Warrant expiration term 10 years 10 years

Shares issued 1,063,939 335,982 1,739,130 4,782,608 87,050 2,173,913 7,608,696 16,391,397 6,521,738 9,782,609

Warrants to purchase shares 1,399,921 559,969 839,952

Fair value of warrants reflected as additional paid-in capital $ 3,700 $ 5,533,000 $ 5,208,700

Proceeds from issuance of warrants $ 3,700 $ 1,200

Warrants outstanding 0

Series B Preferred Stock | Warrants exercise beginning six months after the listing date

Stockholder's equity (Deficit)

Warrant exercise percentage 30.00% 30.00%

Series B Preferred Stock | Warrants exercise beginning nine months after the listing date

Stockholder's equity (Deficit)

Warrant exercise percentage 30.00% 30.00%

X

- Definition
Percentage of warrant exercise.
+ References
No definition available.
+ Details

Name: krbp_PercentageOfWarrantExercise

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=krbp_WarrantExercisableBeginningSixMonthsAfterListingDateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=krbp_WarrantExercisableBeginningNineMonthsAfterListingDateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 102 R52.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details) - Series B Preferred Stock Warrant

Mar. 31, 2021

Dec. 31, 2020

Mar. 31, 2020

Dec. 31, 2019

Weighted average valuation assumptions

Warrants and Rights Outstanding, Valuation Technique [Extensible List] us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember

Measurement Input, Risk Free Interest Rate | Minimum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.0154 0.0154 0.0154 0.0154

Measurement Input, Risk Free Interest Rate | Maximum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.0188 0.0188 0.0188 0.0184

Measurement Input, Price Volatility | Minimum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.7195 0.7195 0.7195 0.7195

Measurement Input, Price Volatility | Maximum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.7271 0.7271 0.7271 0.7220

Measurement Input, Expected Term

Weighted average valuation assumptions

Warrants and Rights Outstanding, Term 10 years 10 years 10 years 10 years

Measurement Input, Expected Dividend Rate

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0 0 0 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_SeriesBPreferredStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 103 R53.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details) - Common Stock Warrants - Representative

Oct. 15, 2020

$ / shares

shares

Mar. 31, 2021

USD ($)

Dec. 31, 2020

USD ($)

$ / shares

Weighted average valuation assumptions

Warrants fair value | $ $ 332,600 $ 357,300

Warrants and Rights Outstanding, Valuation Technique [Extensible List] us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember

Warrants

Warrant exercise price | $ / shares $ 15.00

IPO

Weighted average valuation assumptions

Warrants and Rights Outstanding, Term 5 years

Warrants

Number of warrants granted | shares 62,500

Warrant exercise price | $ / shares $ 15.00

Exercise price as a percentage of the initial offering price 125.00%

Measurement Input, Risk Free Interest Rate

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.0018 0.0018

Measurement Input, Price Volatility

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.9408 0.9408

Measurement Input, Expected Term

Weighted average valuation assumptions

Warrants and Rights Outstanding, Term 2 years 8 months 26 days 2 years 8 months 26 days

Measurement Input, Expected Dividend Rate

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0 0

Previously Reported

Weighted average valuation assumptions

Warrants fair value | $ $ 377,000

X

- Definition
The warrant exercise price as a percentage of the initial offering price.
+ References
No definition available.
+ Details

Name: krbp_WarrantExercisePricePercentOfInitialOfferingPrice

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants granted.
+ References
No definition available.
+ Details

Name: krbp_WarrantsAndRightsSharesGranted

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_CommonStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 104 R54.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Weighted average assumptions

Expected dividend yield 0.00% 0.00%

Stock Incentive Plan 2017 | Stock Options

Weighted average assumptions

Risk-free interest rate, minimum 1.59% 0.15% 1.60%

Risk-free interest rate, maximum 2.92% 2.92% 2.92%

Expected volatility, minimum 72.29% 72.29% 72.29%

Expected volatility, maximum 78.16% 82.52% 78.16%

Expected dividend yield 0.00% 0.00% 0.00%

Stock Incentive Plan 2017 | Stock Options | Minimum

Weighted average assumptions

Expected life (years) 4 years 11 months 4 days 4 years 11 months 4 days 4 years 11 months 4 days

Stock Incentive Plan 2017 | Stock Options | Maximum

Weighted average assumptions

Expected life (years) 6 years 25 days 6 years 25 days 6 years 25 days

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 105 R55.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) - Stock Incentive Plan 2017 - Stock Options - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Stock option activity

Options outstanding at beginning of year 489,718 598,083 598,083 520,517

Granted 17,631 86,536 209,505

Exercised (1,719)

Cancelled and forfeited (57,149) (30,768) (194,901) (130,220)

Balance at September 30 432,569 584,946 489,718 598,083

Options exercisable at September 30: 408,306 361,720 441,430 368,527

Weighted average exercise price

Options outstanding at beginning of year $ 10.03 $ 11.11 $ 11.11 $ 8.64

Granted 12.02 17.95 17.29

Exercised 6.64

Cancelled and forfeited 17.88 11.88 15.06 11.56

Balance at September 30 8.99 11.09 10.03 11.11

Options exercisable at December 31: $ 8.75 7.67 9.50 7.72

Weighted average grant date fair value for options granted during the year: $ 35.62 $ 17.43 $ 10.82

Additional stock option information

Options outstanding, number 432,569 584,946 489,718 598,083

Options outstanding, weighted average remaining contractual life 6 years 8 months 19 days 8 years 7 days 6 years 4 months 13 days 8 years 25 days

Options outstanding, weighted average exercise price $ 8.99 $ 11.09 $ 10.03 $ 11.11

Options outstanding, aggregate intrinsic value $ 839,700 $ 18,712,900 $ 554,900 $ 19,163,700

Options exercisable, number 408,306 361,720 441,430 368,527

Options exercisable, weighted average exercise price $ 8.75 $ 7.67 $ 9.50 $ 7.72

Options exercisable, aggregate intrinsic value $ 269,514 $ 12,808,800 $ 13,031,000

Previously Reported

Weighted average exercise price

Options outstanding at beginning of year $ 11.04 $ 11.04

Balance at September 30 $ 11.04

Additional stock option information

Options outstanding, weighted average exercise price $ 11.04

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 106 R56.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Stock Option Modifications (Details)
3 Months Ended 12 Months Ended

Aug. 20, 2020

USD ($)

employee

$ / shares

shares

Jun. 08, 2020

USD ($)

Mar. 31, 2021

USD ($)

shares

Mar. 31, 2020

USD ($)

$ / shares

shares

Dec. 31, 2020

USD ($)

$ / shares

shares

Dec. 31, 2019

USD ($)

$ / shares

shares

Stock compensation expense

Stock compensation expense $ 9,432,000

Stock Incentive Plan 2017

Stock compensation expense

Stock compensation expense $ 121,000 $ 456,000

Stock Incentive Plan 2017 | Research and development

Stock compensation expense

Stock compensation expense 19,000 425,000

Stock Incentive Plan 2017 | General and administrative

Stock compensation expense

Stock compensation expense $ 102,000 $ 31,000

Stock Incentive Plan 2017 | Stock Options

Stock compensation expense

Stock compensation expense $ 1,340,000 $ 522,900

Cancelled and forfeited | shares 57,149 30,768 194,901 130,220

Number of persons to whom shares were cancelled | employee 4

Granted | shares 17,631 86,536 209,505

Weighted average grant date fair value for options granted during the year: | $ / shares $ 35.62 $ 17.43 $ 10.82

Total unrecognized stock compensation expense $ 252,700 $ 473,900

Unvested Shares to be recognized over the remaining weighted-average vesting period 1 year 3 months 1 year 9 months 14 days

Stock Incentive Plan 2017 | Stock Options | Research and development

Stock compensation expense

Stock compensation expense $ 1,008,000 $ 332,000

Stock Incentive Plan 2017 | Stock Options | General and administrative

Stock compensation expense

Stock compensation expense $ 20,900 332,000 $ 190,900

Stock Incentive Plan 2017 | Stock Options | Four Nonemployees

Stock compensation expense

Cancelled and forfeited | shares 15,792

Granted | shares 21,112

Weighted average grant date fair value for options granted during the year: | $ / shares $ 12.81

Options vested | shares 3,959

Stock Incentive Plan 2017 | Stock Options | Four Nonemployees | General and administrative

Stock compensation expense

Stock compensation expense 65,900

Incremental compensation costs $ 9,600 $ 34,800

X

- Definition
Represents the number of persons to whom shares originally granted were cancelled.
+ References
No definition available.
+ Details

Name: krbp_NumberOfPersonsToWhomSharesWereCancelled

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
An excess of the fair value of the modified award over the fair value of the award immediately before the modification.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=krbp_ShareBasedPaymentArrangementFourNonemployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 107 R57.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)
3 Months Ended 12 Months Ended

Aug. 20, 2020

shares

Aug. 20, 2020

$ / shares

Aug. 20, 2020

individual

Aug. 20, 2020

item

Jun. 08, 2020

USD ($)

Mar. 31, 2021

USD ($)

$ / shares

shares

Mar. 31, 2020

USD ($)

Dec. 31, 2020

USD ($)

$ / shares

shares

Dec. 31, 2019

shares

Jan. 31, 2017

shares

Restricted stock units

Stock compensation expense $ 9,432,000

Stock Incentive Plan 2017

Restricted stock units

Stock compensation expense $ 121,000 $ 456,000

Stock Incentive Plan 2017 | Research and development

Restricted stock units

Stock compensation expense 19,000 425,000

Stock Incentive Plan 2017 | General and administrative

Restricted stock units

Stock compensation expense $ 102,000 $ 31,000

Stock Incentive Plan 2017 | RSU

Restricted stock units

Authorized shares | shares 1,708,615

Number of persons to whom shares were cancelled | individual 5

Restricted stock unit activity

Nonvested RSUs at beginning of year | shares 946,245

Granted | shares 946,245 6,019 1,655,579 0

Vested | shares 0 0 0

Cancelled and forfeited | shares (709,334) (709,334)

Nonvested RSUs at March 31 | shares 12.81 952,264 946,245

Weighted average grant day fair value per share

Nonvested RSUs at beginning of year | $ / shares $ 12.81

Granted | $ / shares 9.00 $ 12.84

Cancelled and forfeited | $ / shares $ 12.87 12.87

Nonvested RSUs at March 31 | $ / shares $ 12.81 $ 12.79 $ 12.81

Stock Incentive Plan 2017 | RSU | Research and development

Restricted stock units

Stock compensation expense $ 267,700 $ 748,400

Incremental compensation costs 20,400 166,900

Stock Incentive Plan 2017 | RSU | General and administrative

Restricted stock units

Stock compensation expense 556,600 1,725,300

Incremental compensation costs $ 44,700 $ 402,700

Stock Incentive Plan 2017 | RSU | Non-Employees

Restricted stock units

Number of persons to whom shares were cancelled 2 2

Stock Incentive Plan 2017 | RSU | Employees

Restricted stock units

Number of persons to whom shares were cancelled 3 3

X

- Definition
Represents the number of persons to whom shares originally granted were cancelled.
+ References
No definition available.
+ Details

Name: krbp_NumberOfPersonsToWhomSharesWereCancelled

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
An excess of the fair value of the modified award over the fair value of the award immediately before the modification.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 108 R58.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES - Tax Rate Reconciliation (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

INCOME TAXES

Income tax provision $ 0 $ 0 $ 0 $ 0

Reconciliation of the statutory federal income tax rate to the effective tax rate

Federal income tax at statutory rates 21.00% 21.00% 21.00%

Change in valuation allowance (21.00%) (21.00%)

Effective income tax rate 0.00% 0.00% 0.00% 0.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 109 R59.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Deferred tax assets (liabilities):

Net operating loss carryforward $ 3,842,900 $ 2,605,400

Stock compensation expense 3,379,000 597,400

Intangible assets 23,600 27,800

Total gross deferred tax assets 7,245,500 3,230,600

Valuation allowance (7,061,600) (3,198,100)

Property and equipment (183,900) (32,500)

Net deferred tax assets (liabilities) $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 110 R60.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES - Net Operating Loss Carryforward (Details) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

U.S.

Operating loss carryforwards

Net operating loss carryforwards $ 18,299,500 $ 12,406,800

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 111 R61.htm IDEA: XBRL DOCUMENT v3.21.2

RELATED PARTY TRANSACTIONS (Details)
3 Months Ended 12 Months Ended

Jun. 19, 2020

USD ($)

shares

Jun. 08, 2020

USD ($)

shares

Sep. 04, 2019

USD ($)

Jul. 20, 2018

USD ($)

item

Apr. 18, 2018

USD ($)

Mar. 31, 2021

USD ($)

Mar. 31, 2020

USD ($)

agreement

Dec. 31, 2020

USD ($)

agreement

Dec. 31, 2019

USD ($)

Related party transactions

Number of separate consulting agreements | agreement 2 2

CSIO

Related party transactions

Consulting fee per hour $ 400

Threshold number of hours per month for which consulting fees are entitled | item 19

Consulting fee paid $ 0 $ 319,300 $ 579,700 $ 207,800

Shares issued for services rendered | shares 320,000

Cash consideration $ 0

CFO and COO

Related party transactions

Consulting fee per hour $ 10,000 $ 2,500

Consulting fee paid $ 0 $ 30,000 $ 140,000 $ 67,500

Shares issued for services rendered | shares 402,000

Cash consideration $ 0

CMO

Related party transactions

Shares issued for services rendered | shares 3,106

Cash consideration $ 0

Employee

Related party transactions

Shares issued for services rendered | shares 430

Cash consideration $ 0

X

- Definition
Represents the number of separate consulting agreements.
+ References
No definition available.
+ Details

Name: krbp_NumberOfSeparateConsultingAgreements

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash consideration in exchange for shares issued for services rendered by related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionCashConsiderationInExchangeForServiceShares

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the consulting fees per hour paid to the related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionConsultingFeesPerHour

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the threshold number of hours per month the related party is entitled to receive consulting fees.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionThresholdNumberOfHoursPerMonthForWhichConsultingFeesAreEntitled

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_ChiefStrategyAndInnovationOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_ChiefFinancialOfficerAndChiefOperatingOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_ChiefMedicalOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_EmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 112 R62.htm IDEA: XBRL DOCUMENT v3.21.2

SUBSEQUENT EVENTS (Details)

Mar. 22, 2021

USD ($)

ft²

item

Feb. 16, 2021

USD ($)

Jan. 28, 2021

USD ($)

installment

Nov. 19, 2020

Mar. 31, 2021

USD ($)

Dec. 31, 2020

USD ($)

Lease expansion

Additional office space leased | ft² 15,385

Period of time after notice of cancellation that the lease effectively terminates 90 days 90 days

Future minimum commitments

2021 $ 546,700 $ 265,200

2022 551,100 269,700

2023 461,200 274,200

2024 230,400

Total $ 1,875,600 $ 1,039,500

Leon Office (H.K.) | Strategic Alliance Agreement

Subsequent events

Annual cost $ 360,000

Number of quarterly installments | installment 4

SBA Loan

Loan payable

Loan principal forgiven $ 105,800

Subsequent Event

Lease expansion

Additional office space leased | ft² 15,385

Period of time after notice of cancellation that the lease effectively terminates 90 days

Number of months rent due as a termination payment if lease cancellation option exercised | item 3

Future minimum commitments

2021 $ 380,600

2022 546,700

2023 551,100

2024 461,200

Total $ 1,939,600

Subsequent Event | Leon Office (H.K.) | Strategic Alliance Agreement

Subsequent events

Annual cost $ 360,000

Number of quarterly installments | installment 4

Subsequent Event | SBA Loan

Loan payable

Loan principal forgiven 105,600

Accrued interest forgiven $ 300

X

- Definition
Decrease for amounts of indebtedness for accrued interest forgiven by the holder of the debt instrument.
+ References
No definition available.
+ Details

Name: krbp_DebtInstrumentAccruedInterestDecreaseForgiveness

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of quarterly installments for payment of annual agreement costs.
+ References
No definition available.
+ Details

Name: krbp_NumberOfQuarterlyInstallments

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The square footage of additional space leased per the amended lease agreement.
+ References
No definition available.
+ Details

Name: krbp_OperatingLeaseAdditionalSquareFootage

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of months rent due as a termination payment if the operating lease cancellation option is exercised.
+ References
No definition available.
+ Details

Name: krbp_OperatingLeaseLeaseCancellationTerminationPaymentNumberOfMonthsRent

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The period of time after notice of cancellation that the lease effectively terminates.
+ References
No definition available.
+ Details

Name: krbp_OperatingLeaseTerminationPeriodAfterNoticeOfCancellation

Namespace Prefix: krbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The annual cost of a strategic alliance agreement entered into by the entity.
+ References
No definition available.
+ Details

Name: krbp_StrategicAllianceAgreementAnnualCost

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentDecreaseForgiveness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LesseeOperatingLeaseDescriptionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_CounterpartyNameAxis=krbp_LeonOfficeH.k.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=krbp_SBLoanPaycheckProtectionProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 113 R63.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Balance Sheets - USD ($)

Mar. 31, 2021

Dec. 31, 2020

Mar. 31, 2020

Dec. 31, 2019

Dec. 06, 2019

Dec. 31, 2018

Current Assets:

Cash and cash equivalents $ 7,335,300 $ 10,150,500 $ 1,929,100

Inventories 22,200

Prepaid expenses and other current assets 513,500 588,800 89,100

Total current assets 7,848,800 10,739,300 2,040,400

Property and equipment, net 2,279,500 2,066,000 587,900

Other assets 24,400 24,400 24,400

Total Assets 10,152,700 12,829,700 2,652,700

Current Liabilities:

Accounts payable 1,203,200 665,200 452,400

Accrued expenses and other current liabilities 268,900 334,200 221,300

Interest payable 200

Loan payable 105,600

Note payable 227,800 362,400

Total current liabilities 1,699,900 1,467,600 673,700

Total Liabilities 1,699,900 1,467,600 673,700

Commitments and contingencies

Stockholders' Equity:

Common stock, $0.001 par value: 300,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 7,332,999 shares issued and outstanding as of March 31, 2021 and December 31, 2020 1,200 1,200

Additional paid-in capital 53,933,900 52,988,700 13,965,000

Accumulated deficit (45,482,300) (41,627,800) (22,427,600)

Total Stockholders' Equity 8,452,800 11,362,100 $ 3,582,300 1,979,000 $ 265,300

Total Liabilities and Stockholders' Equity $ 10,152,700 12,829,700 2,652,700

Series A-1 Preferred Stock

Stockholders' Equity:

Preferred Stock 9,134,700

Series B Preferred Stock

Stockholders' Equity:

Preferred Stock $ 2,007,000 1,306,900 $ 4,500,000

Additional paid-in capital $ (40,000)

Preferred Stock

Stockholders' Equity:

Preferred Stock

X

- Definition
The amount of accrued expenses and other current liabilities as at the end of the reporting period.
+ References
No definition available.
+ Details

Name: krbp_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LoansPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 114 R64.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Mar. 31, 2021

Dec. 31, 2020

Sep. 18, 2020

Jun. 19, 2020

Jun. 17, 2020

Dec. 31, 2019

Sep. 25, 2019

Sep. 24, 2019

Jun. 18, 2018

Condensed Consolidated Balance Sheets

Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001

Common stock, authorized 300,000,000 300,000,000 858,615 1,708,615 858,615 300,000,000 30,000,000 20,000,000 858,615

Common stock, issued 7,332,999 7,332,999 2,863,812

Common stock, outstanding 7,332,999 7,332,999 2,863,812

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 115 R65.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Statements of Operations
3 Months Ended

Mar. 31, 2021

USD ($)

$ / shares

shares

Operating expenses:

Research and development $ 1,885,600

General and administrative 2,071,000

Total operating expenses 3,956,600

Loss from operations (3,956,600)

Other expense

Gain on loan extinguishment 105,800

Interest expense (3,700)

Total other expense 102,100

Net loss $ (3,854,500)

Net loss per share, basic and diluted | $ / shares $ (0.53)

Weighted average common shares outstanding, basic and diluted | shares 7,332,999

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 116 R66.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Statements of Stockholders' Equity - USD ($)

Preferred Stock

Series A-1 Preferred Stock

Preferred Stock

Series B Preferred Stock

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Series B Preferred Stock

Total

Balance at beginning of period at Dec. 31, 2018 $ 8,727,400 $ 10,237,600 $ (18,699,700) $ 265,300

Balance at beginning of period (in shares) at Dec. 31, 2018 20,886,782 2,863,093

Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock $ 407,300 407,300

Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock (in shares) 935,519

Issuance of Series B Preferred Stock $ 1,056,300 1,056,300

Issuance of Series B Preferred Stock 9,782,609

Common stock issuance net of issuance costs and discount amortization (in shares) 9,782,609

Series B Preferred Stock discount amortization $ 210,600 (210,600) $ (210,600) (210,600)

Warrants underlying Series B Preferred Stock issuance 3,443,700 3,443,700

Accretion and settlement of Series B Preferred Stock dividend $ 40,000 (40,000) $ (40,000) (40,000)

Accretion and settlement of Series B Preferred Stock Dividend (in shares) 87,050

Exercised stock options 11,400 11,400

Exercised stock options (in shares) 1,719

Stock compensation expense 522,900 522,900

Net loss (3,727,900) (3,727,900)

Balance at end of period at Dec. 31, 2019 $ 9,134,700 $ 1,306,900 13,965,000 (22,427,600) 1,979,000

Balance at end of period (in shares) at Dec. 31, 2019 21,822,301 9,869,659 2,863,812

Issuance of Series B Preferred Stock $ 331,700 331,700

Issuance of Series B Preferred Stock 6,521,738

Common stock issuance net of issuance costs and discount amortization (in shares) 16,391,397

Series B Preferred Stock discount amortization $ 368,400 (368,400) $ (368,400)

Warrants underlying Series B Preferred Stock issuance 2,668,300 2,668,300

Warrants underlying common stock issuance $ 5,533,000

Stock compensation expense 456,000 456,000

Net loss (1,852,700) (1,852,700)

Balance at end of period at Mar. 31, 2020 $ 9,134,700 $ 2,007,000 16,720,900 (24,280,300) 3,582,300

Balance at end of period (in shares) at Mar. 31, 2020 21,822,301 16,391,397 2,863,812

Balance at beginning of period at Dec. 31, 2019 $ 9,134,700 $ 1,306,900 13,965,000 (22,427,600) 1,979,000

Balance at beginning of period (in shares) at Dec. 31, 2019 21,822,301 9,869,659 2,863,812

Issuance of Series B Preferred Stock $ 331,700 331,700

Issuance of Series B Preferred Stock 6,521,738

Common stock issuance net of issuance costs and discount amortization $ 1,200 11,974,200 11,975,400

Common stock issuance net of issuance costs and discount amortization (in shares) 1,250,000 6,521,738

Series B Preferred Stock discount amortization $ 692,700 (692,700) $ (692,700) (692,700)

Warrants underlying Series B Preferred Stock issuance 2,668,300 2,668,300

Warrants underlying common stock discount amortization (19,700) (19,700)

Warrants underlying common stock issuance 377,000 5,208,700 377,000

Exercise of warrants 4,900 4,900

Exercise of warrants (in shares) 1,399,921

Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion $ (9,134,700) 9,134,700

Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares) (21,822,301) 624,594

Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion $ (2,331,300) 2,331,300 $ 2,331,300

Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares) (16,391,397) 469,136

Common stock issuance to employees and non-employees 9,432,000 9,432,000

Common stock issuance to employees and non-employees 725,536

Stock compensation expense 3,813,700 3,813,700

Net loss (19,200,200) (19,200,200)

Balance at end of period at Dec. 31, 2020 $ 1,200 52,988,700 (41,627,800) 11,362,100

Balance at end of period (in shares) at Dec. 31, 2020 7,332,999

Common stock discount amortization 24,700 24,700

Warrants underlying common stock discount amortization (24,700) (24,700)

Stock compensation expense 945,200 945,200

Net loss (3,854,500) (3,854,500)

Balance at end of period at Mar. 31, 2021 $ 1,200 $ 53,933,900 $ (45,482,300) $ 8,452,800

Balance at end of period (in shares) at Mar. 31, 2021 7,332,999

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from amortization of common stock discount.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants on preferred stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedPreferredStock

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares issued in settlement of dividend during the period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividendsShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amortization of discount on preferred shares issued.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAmortizationOfDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new preferred stock issued during the period.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodPreferredStockNewIssuesShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new preferred stock issued during the period.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodPreferredStockNewIssuesValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares issued to employee and nonemployees.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodSharesEmployeesAndNonEmployees

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares issued to employee and nonemployees.
+ References
No definition available.
+ Details

Name: krbp_StockIssuedDuringPeriodValueEmployeesAndNonEmployees

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of warrant exercised during period.
+ References
No definition available.
+ Details

Name: krbp_WarrantsExercisedDuringPeriodShares

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of warrant exercised during period.
+ References
No definition available.
+ Details

Name: krbp_WarrantsExercisedDuringPeriodValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 117 R67.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Statements of Cash Flows
3 Months Ended

Mar. 31, 2020

USD ($)

Cash flows from operating activities:

Net loss $ (1,852,700)

Adjustments to reconcile net loss to net cash used for operating activities:

Depreciation 33,800

Stock compensation expense 456,000

Changes in operating assets and liabilities:

Prepaid expenses and other current assets (99,700)

Accounts payable (35,200)

Accrued expenses and other current liabilities 17,500

Net cash used for operating activities (1,480,300)

Cash flows from investing activities:

Purchases of property and equipment (406,300)

Net cash used for investing activities (406,300)

Cash flows from financing activities:

Proceeds from Series B Preferred Stock issuance 3,000,000

Net cash (used in) provided by financing activities 3,000,000

Net change in cash and cash equivalents 1,113,400

Cash and cash equivalents:

Beginning of year 1,929,100

End of period 3,042,500

Supplemental disclosures of non-cash investing and financing activities:

Accruals for property and equipment 230,700

Warrants underlying Series B Preferred Stock issuance $ 2,668,300

X

- Definition
The non cash part of warrants underlying preferred stock issuance.
+ References
No definition available.
+ Details

Name: krbp_WarrantsUnderlyingPreferredStockIssuance

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in accrued expenses, and obligations classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 118 R68.htm IDEA: XBRL DOCUMENT v3.21.2

ORGANIZATION
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

ORGANIZATION

ORGANIZATION
1.
ORGANIZATION
Nature of Business
Kiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.
The Company is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.
The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.
Going Concern — These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $2,635,900 for the three months ended March 31, 2021, and an accumulated deficit of $45,482,300 as of March 31, 2021. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. The Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in the third quarter of 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase 1 completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

1. ORGANIZATION
Nature of Business
Kiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.
The Company is a target discovery and gene-editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.
The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business has not generated any revenues.
Going Concern — The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flows from operations of $6,126,600 for the year ended December 31, 2020, and an accumulated deficit of $41,627,800 as of December 31, 2020. To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Although the Company completed its initial public offering on October 15, 2020 and received net proceeds of $12,332,700, the Company does not have sufficient cash on hand or available liquidity to meet its obligations through the twelve months following the date the consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in fiscal year 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
NIH Grant — In August 2018, the National Institute of Health ("the NIH"), the primary agency of the U.S. government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase I completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 119 R69.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.
All intercompany balances were eliminated upon consolidation.
Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.
Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.
Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.
Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets.
Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020.
Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.
Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.
Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020.
Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.
Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH.
Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020.
Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10-year period from grant date.
Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant
Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.
On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.
Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.
Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.
Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.
The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.
Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets.
Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded.
Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.
During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets.
Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively.
Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.
Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.
Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019.
Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.
Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH.
Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.
Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.
Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.
The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.
Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:


December 31,

December 31,

2020

2019
Convertible promissory notes




Beginning balance

$
—

$
—
Amounts allocated to the embedded derivative liability at inception (at fair value)

—

(21,000)
Conversions from accounts payable into convertible promissory notes

—

134,800
Proceeds from issuances of convertible promissory notes

—

250,000
Conversions into Series A‑1 Stock

—

(363,800)
Ending balance

$
—

$
—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability




Beginning balance

$
—

$
—
Realized and unrealized gains and losses

—

2,000
Fair value of embedded derivative liability at inception

—

21,000
Amounts derecognized upon conversion of the related convertible promissory notes

—

(23,000)
Ending balance

$
—

$
—

Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.
Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant.
Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.
The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:
Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period.
Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.
Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.
Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.
Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.
Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 120 R70.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

NET LOSS PER COMMON SHARE

NET LOSS PER COMMON SHARE
3.NET LOSS PER COMMON SHARE
Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, restricted stock units, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share:

Three Months Ended

March 31,


2021

2020
Net loss

$
(3,854,500)

$
(1,852,700)
Less: Series B Preferred Stock discount amortization

—

(368,400)
Less: IPO Common Stock discount amortization

(24,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(3,879,200)

$
(2,221,100)
Weighted average common shares outstanding, basic and diluted

7,332,999

2,863,812
Net loss per common share, basic and diluted

$
(0.53)

$
(0.78)

For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


March 31,

March 31,

2021

2020
Stock options to purchase

677

404,391
Restricted Stock Units

32,000

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

469,136
Warrants underlying Series B Preferred Stock

—

1,399,807
Total

32,677

2,897,928

3.
NET LOSS PER COMMON SHARE
Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted loss per share:

Years Ended

December 31,


2020

2019
Net loss

$
(19,200,200)

$
(3,727,900)
Less: Accretion and settlement of Series B Preferred Stock dividend

—

(40,000)
Less: Series B Preferred Stock discount amortization

(692,700)

(210,600)
Less: IPO Common Stock discount amortization

(19,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(19,912,600)

$
(3,978,500)
Weighted average common shares outstanding, basic and diluted

4,505,867

2,862,809
Net loss per common share, basic and diluted

$
(4.42)

$
(1.39)

For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


December 31,

December 31,

2020

2019
Stock options to purchase

1,647

75,405
Restricted Stock Units

95,815

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

282,478
Warrants underlying Series B Preferred Stock

—

839,784
Total

97,462

1,822,261

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 121 R71.htm IDEA: XBRL DOCUMENT v3.21.2

PROPERTY AND EQUIPMENT
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT
4.PROPERTY AND EQUIPMENT
Property and equipment consisted of the following at March 31, 2021 and December 31, 2020:

March 31,

December 31,

2021

2020
Equipment

$
1,138,900

$
780,500
Leasehold improvements

1,274,600

1,229,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

151,700
Construction in progress

355,000

449,200

2,936,800

2,627,700
Less: Accumulated depreciation

(657,300)

(561,700)
Total

$
2,279,500

$
2,066,000

Depreciation expense was $95,600 and $33,800 for the three months ended March 31, 2021 and, 2020, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the condensed consolidated statements of operations.

4.
PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following at December 31:

2020

2019
Equipment

$
780,500

$
488,800
Leasehold improvements

1,229,700

302,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

141,500
Construction in progress

449,200

—

2,627,700

949,600
Less: Accumulated depreciation

(561,700)

(361,700)
Total

$
2,066,000

$
587,900

Depreciation expense was $200,000 and $87,500 for the years ended December 31, 2020 and 2019, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 122 R72.htm IDEA: XBRL DOCUMENT v3.21.2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
5.ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following at March 31, 2021 and December 31, 2020:

March 31,

December 31,

2021

2020
Accrued consulting and outside services

$
173,900

$
143,200
Accrued compensation

95,000

191,000
Total

$
268,900

$
334,200

5.
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following at December 31:

2020

2019
Accrued consulting and outside services

$
143,200

$
221,300
Accrued compensation

191,000

—
Total

$
334,200

$
221,300

X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 123 R73.htm IDEA: XBRL DOCUMENT v3.21.2

LOAN PAYABLE
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

LOAN PAYABLE

LOAN PAYABLE
6.LOAN PAYABLE
On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to apply for forgiveness of the SBA Loan in accordance with the terms of the CARES Act.
The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.
As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 as of December 31, 2020 in the condensed consolidated balance sheet. During the year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020. The Company accrued interest over the term of the loan and did not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency.

During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021, the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,800. The forgiveness was classified as a gain on loan extinguishment in the condensed consolidated statement of operations.

6.
CURRENT LOAN PAYABLE
On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. The SBA Loan was forgiven on February 16, 2021. See Note 14.
The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.
As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 during year ended December 31, 2020 in the consolidated balance sheet. During year ended December 31, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of December 31, 2020.
The Company accrued $200 of interest expense during the year ended December 31, 2020. The Company accrues interest over the term of the loan and does not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency. If any amount of the loan is ultimately forgiven, income from the extinguishment of debt would be recognized as a gain on loan extinguishment in the consolidated statement of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 124 R74.htm IDEA: XBRL DOCUMENT v3.21.2

NOTE PAYABLE
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

NOTE PAYABLE

NOTE PAYABLE
7.NOTE PAYABLE
In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of March 31, 2021 and December 31, 2020, the remaining payable balance on the financed amount was $227,800 and $362,400, respectively.

7.
NOTE PAYABLE
In November 2020, the Company entered into a financing arrangement for its Director and Officer Insurance policy. The total amount financed was approximately $540,500 with an annual interest rate of 4.59%, to be paid over a period of nine months. As of December 31, 2020, the remaining payable balance on the financed amount was approximately $362,400.

X

- References
No definition available.
+ Details

Name: us-gaap_ShortTermBorrowingsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for short-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 125 R75.htm IDEA: XBRL DOCUMENT v3.21.2

COMMITMENTS AND CONTINGENCIES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES
8.COMMITMENTS AND CONTINGENCIES
Facility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.
On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024.
On March 22, 2021, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90-days notice of cancellation.

If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.

The total lease payments per month were $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477, 45,554, and $46,116 beginning May 1, 2021, August 1, 2021, and May 1, 2023, respectively. The Company records rent expense as incurred over the term of the leases.
As of March 31, 2021, the future minimum commitments under the amended lease agreement will be as follows:


Amount
2021

$
316,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,875,600

Rent expense for the facility lease agreements was $69,000 and $60,000 during the three months ended March 31, 2021 and 2020, respectively. Rent expense is included as an allocation between research and development and general and administrative expense in the condensed consolidated statements of operations.
License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of March 31, 2021 and December 31, 2020, the Company has not incurred any milestone or royalty liabilities related to these license agreements.
Strategic Alliance Agreement with Leon Office (H.K.) — On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. They will also use commercially reasonable efforts to research the Asian market, with a primary, but not exclusive, focus on determining the most suitable structures for the development of medical partnerships or joint ventures with scientific partners in the Asian market with a mission to test products to be created by the joint venture resulting from such partnership and to develop validation programs for any products produced by such joint venture, including programs for clinical trials and human testing and, ultimately, for product certification. The cost of the agreement is $360,000 annually, payable in four quarterly installments.

Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.

The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows.

9.COMMITMENTS AND CONTINGENCIES
Facility Lease Agreements — The Company leases its premises in Houston, Texas under a noncancelable operating lease expiring in May 2021. The lease renewal, which occurred in 2019, resulted in an expansion to the lease of approximately 4,100 square feet.
On November 19, 2020, the Company’s board of directors approved the lease renewal of its premises in Houston, Texas. Once the current lease expires in May 2021, the renewed lease agreement will commence under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.
The total lease payments per month will be $21,353 beginning January 1, 2020. The total lease payments per month will be $22,477 and $23,039 beginning May 1, 2021 and May 1, 2022, respectively. The Company records rent expense on a straight-line basis over the term of the leases.
As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:


Amount
2021

$
265,200
2022

269,700
2023

274,200
2024

230,400
Total

$
1,039,500

Annual rent expense for the facility lease agreements was $262,900 and $129,100 for the years ended December 31, 2020 and 2019, respectively, and is included as an allocation between research and development and general and administrative expense in the consolidated statements of operations.
License Agreements — The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of December 31, 2020 and 2019, the Company has not incurred any milestone or royalty liabilities related to these license agreements.
Legal Proceedings — In the normal course of business, the Company may have various claims in process and other contingencies. The Company regularly assesses all contingencies and believes, as of December 31, 2020, the Company was not involved in any matters that would have a material effect on the Company’s financial position, results of operations and cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 126 R76.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY
9.STOCKHOLDERS’ EQUITY
On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.
Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.
As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.
Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.
On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares common stock.
Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of this stock split.
As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock and 16,500,000 shares were designated as Series B Preferred Stock.
Common Stock — As of March 31, 2021 and December 31, 2020, the Company has a single class of common stock.
On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share.
In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.
Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the three months ended March 31, 2021:


2021
Common Stock


Balance at January 1,

$
11,975,400
Common stock IPO discount amortization

24,700
Balance at March 31,

$
12,000,100

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants underlying shares of Series B Preferred Stock became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700.
On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.
Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.
The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted a stock option plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.
There were 322,063 shares and 271,949 shares available for issuance as of March 31, 2021 and 2020, respectively.
Series B Preferred Stock — On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.
On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.
With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.
Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.
Accordingly, in connection with the IPO, all shares of the Company’s Series B Preferred Stock were converted into 469,136 shares of common stock on October 15, 2020.

Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized during the three months ended March 31:


2020
Series B Preferred Stock


Balance at January 1,

$
1,306,900
Series B Preferred Stock proceeds

3,000,000
Series B Preferred Stock discount

(2,668,300)
Series B Preferred Stock discount amortization

368,400
Balance at March 31,

$
2,007,000

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.
Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. The warrants become exercisable in accordance with the schedule set forth below following completion by the Company of an initial public offering and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.
● 30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");
● An additional 30% of the warrants beginning nine months after the Listing Date; and
● The remainder of the warrants beginning twelve months after the Listing Date.
As of March 31, 2020, the Company sold 16,391,397 shares of Series B Preferred Stock, which contained 1,399,921 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants are equity classified and the fair value of $5,533,000 is reflected as additional paid-in capital.
On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.
On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. As of March 31, 2021, there were no warrants underlying Series B Preferred Stock.
The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the three months ended March 31, 2021 and 2020:

March 31,


2020

Risk-free interest rate

1.54% - 1.88
%
Expected volatility

71.95% - 72.71
%
Expected life (years)

10

Expected dividend yield

0
%

Representative's Warrants — In connection with the IPO on October 15, 2020, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at March 31, 2021.

These warrants were equity classified. As of March 31, 2021 and December 31, 2020, the warrant fair values of $332,600 and $357,300, respectively, is reflected as additional paid-in capital. On the issuance date, the Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions on October 15:

2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%

10.STOCKHOLDERS’ EQUITY
On December 16, 2019, the Company amended and restated its certificate of incorporation to, among other things, (i) complete a 1-for-10 reverse split of the Company’s outstanding shares of common stock; (ii) increase the Company’s authorized Preferred Stock to 60,000,000 shares and (iii) change the par value of the Preferred Stock from $0.01 to $0.0001 per share.
On June 17, 2020, the Company filed an amendment to its amended and restated certificate of incorporation to complete a 1-for-3.494 reverse split of the Company’s outstanding shares of common stock.
Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits during the years ended December 31, 2020 and 2019.
As of December 31, 2020 and 2019, the Company was authorized to issue 300,000,000 shares of common stock and 60,000,000 shares and of Preferred Stock, of which 24,000,000 shares were designated as Series A-1 Preferred Stock. Additionally, 16,500,000 shares and 14,130,435 shares were designated as Series B Preferred Stock as of December 31, 2020 and 2019, respectively.
Common Stock — As of December 31, 2020 and 2019, the Company has a single class of common stock.
On October 15, 2020, the Company received net proceeds of $12,332,700 from its IPO, after deducting underwriting discounts and commissions of $1,275,000 and other offering expenses of $1,392,300 incurred. The Company issued and sold 1,250,000 shares of common stock in the IPO at a price of $12.00 per share. In connection with the IPO, all shares of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock were converted into 624,594 and 469,136 shares of common stock, respectively.

Below is a table that outlines the initial value of issuances allocated to the IPO common stock, the IPO common stock discount amortized, and value of IPO common stock that was converted into additional-paid-in-capital during the year ended December 31, 2020:


2020

Common Stock



Balance at January 1,

$
—

Common stock IPO proceeds, net of issuance costs

12,332,700

Common stock IPO discount

(377,000)

Common stock IPO discount amortization

19,700

Balance at December 31,

$
11,975,400

On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder. On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There were 0 and 839,952 warrants outstanding as of December 31, 2020 and 2019, respectively.
On June 8, 2020, the Company issued 3,106 and 430 shares of common stock to the Company’s Chief Medical Officer and another employee, respectively. In addition, on June 19, 2020, the Company issued 402,000 and 320,000 shares of common stock to the Company’s Chief Financial Officer and Chief Operating Officer ("the CFO and COO") and Chief Strategy and Innovation Officer ("the CSIO"), respectively. The shares were issued in exchange for services rendered and no cash considerations. These issuances resulted in $9,432,000 in stock compensation expenses.
Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class.
The Company has never paid dividends and has no plans to pay dividends on common stock. As of December 31, 2017, the Company adopted the Plan. On September 25, 2019, the board of directors approved an additional 10,000,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 20,000,000 to 30,000,000. After the reverse stock splits, the total number of authorized shares was updated to 858,615. On June 19, 2020, the board of directors approved an additional 850,000 shares to be reserved and authorized under the Plan. This approval increased the total number of authorized shares from 858,615 to 1,708,615.
There were 270,933 shares and 258,813 shares available for issuance as of December 31, 2020 and 2019, respectively.
Series A-1 Preferred Stock — In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation the holders of the shares of Series A-1 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.50, the original issue price.
On matters submitted to a vote of the stockholders of the Company, Series A-1 Preferred Stock and common stock vote together as one class, with the vote of the Series A-1 Preferred Stock on an as-converted basis. Each holder of Series A-1 Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series A-1 Preferred Stock held by such holder are then convertible.
With respect rights on liquidation, winding up and dissolution, shares of the Series A-1 Preferred Stock rank senior to all shares of common stock.
Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.
In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.
Series B Preferred Stock — On September 13, 2019, the Company amended and restated its certificate of incorporation to authorize the issuance of up to 14,130,435 shares of Series B Preferred Stock. On September 13, 2019, the Company sold 7,608,696 shares of Series B Preferred Stock for $3,500,000. On November 13, 2019, the Company issued an additional 2,173,913 shares of Series B Preferred Stock for $1,000,000. In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock ("Warrants"). See below for further details.
Until the filing of the amended and restated certificate of incorporation on December 16, 2019, shares of Series B Preferred Stock had accrued unpaid dividends at an annual rate of 6% per share. The amended and restated certificate of incorporation eliminated the clause requiring the dividend accrual. In addition, on December 6, 2019, the Series B Preferred Stock investors voted in favor of forfeiting all accrued and unpaid dividends, along with all future dividends. In exchange, the Company issued 87,050 shares of Series B Preferred Stock to the investors. The Company treated this transaction as accretion and settlement of a Series B Preferred Stock dividends in the amount of $40,000. Accordingly, additional paid-in capital was reduced by $40,000.
The Series B Preferred Stock conversion price is initially equal to the Series B Preferred Stock original issuance price of $0.46 per share divided by the rate at which shares of Series B Preferred Stock may be converted into shares of common stock. The holders of the Series B Preferred Stock held a special redemption right. In the event the Company had not filed an initial registration statement with the United States Securities and Exchange Commission and submitted an application to be listed on the Nasdaq Stock market on or prior to November 15, 2019, subject to Delaware law governing distributions to stockholders and the Company’s ability to redeem its shares, all or part of the shares of Series B Preferred Stock held by any holder of record as of such date of shares of Series B Preferred Stock with an aggregate purchase price of at least $1,000,000 would have been be redeemable at the option of such holders of record commencing any time on or after November 16, 2019 at a price equal to the purchase price paid for such shares plus all unpaid dividends accrued on such shares. Also, in the event that the Company was not ultimately approved for listing on a Nasdaq Stock Market tier lower than the Nasdaq Global Select Market, the special redemption right would remain in effect and may have been exercisable on any date thereafter. If the Company was unable to execute a redemption upon request of a holder, interest would accrue on the shares at rate of 14.6%, or warrants underlying the shares would be exercisable and the fair market value of the shares of common stock received in connection therewith would be treated as payment in exchange for the shares of Series B Preferred Stock submitted for redemption by such holder.
On November 12, 2019 and November 13, 2019, the Series B Preferred Stock investors signed waivers, which provided consent to the Company to eliminate the special redemption right. When the Company amended and restated its certificate of incorporation on December 16, 2019, the special redemption right provision was eliminated.
The elimination of the special redemption right allows for permanent equity classification for the Series B Preferred Stock. Since the Warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series B Preferred Stock and the Warrants. The fair value of the Warrants is offset by a contra account, which is classified as a discount to the Series B Preferred Stock. The discount is amortized using the effective interest method at an effective interest rate of 28% per annum.
On January 24, 2020, the Company issued 4,782,608 shares of Series B Preferred Stock for $2,200,000. On January 29, 2020, the Company filed a certificate of correction to its amended and restated its certificate of incorporation to authorize the issuance of up to 16,500,000 shares of Series B Preferred Stock. On January 31, 2020, the Company issued an additional 1,739,130 shares of Series B Preferred Stock for $800,000.
In connection with the IPO, all shares of the Company's Series B Preferred Stock were converted into 469,136 shares of common stock, and the value of the Series B Preferred Stock converted into additional-paid-in-capital.
Below is a table that outlines the initial value of issuances allocated to Series B Preferred Stock, the Series B Preferred Stock discount amortized, and value of Series B Preferred Stock that was converted into additional-paid-in-capital during the years ended December 31:


2020

2019
Series B Preferred Stock




Balance at January 1,

$
1,306,900

$
4,500,000
Series B Preferred Stock proceeds

3,000,000

(3,443,700)
Series B Preferred Stock discount

(2,668,300)

210,600
Series B Preferred Stock discount amortization

692,700

40,000
Series B Preferred Stock conversion to common stock

(2,331,300)

—
Balance at December 31,

$
—

$
1,306,900

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or the occurrence of a liquidation, the holders of the shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $0.46, the original issue price.
On matters submitted to a vote of the stockholders of the Company, Series B Preferred Stock, Series A-1 Preferred Stock, and common stock vote together as one class, with the vote of the Series B Preferred Stock on an as-converted basis. Each holder of Series B Preferred Stock shall have a number of votes equal to the shares of common stock into which the shares of Series B Preferred Stock held by such holder are then convertible.
With respect rights on liquidation, winding up and dissolution, shares of Series B Preferred Stock rank senior to all shares of common stock, but not senior to Series A-1 Preferred Stock.
Each share of Series B Preferred Stock is convertible at any time at the option of the holder at the then current conversion rate. In addition, upon the closing of the sale of shares of common stock to the public in an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, all shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate.
Conversion of Convertible Promissory Notes — On August 15, 2019, each holder of convertible promissory notes issued during 2019 agreed to voluntarily convert the amounts of principal and interest then outstanding into shares of Series A-1 Preferred Stock. At the time of conversion, outstanding principal and accrued interest of the convertible promissory notes totaled $405,300. Per the convertible promissory notes, the notes containing a $250,000 principal balance with a 17% coupon rate had a conversion price of $0.43. Additionally, the Company settled an accounts payable with a vendor by issuing a convertible promissory note in the amount of $134,800 with a 6% coupon rate, with a conversion rate of $0.43. Accordingly, 935,519 shares were issued to convert the outstanding principal and accrued interest into Series A-1 Preferred Stock.
In connection with the IPO, all shares of the Company's Series A-1 Preferred Stock were converted into 624,594 shares of common stock.
Warrants Underlying Series B Preferred Stock — In connection with the sale of the Series B Preferred Stock, each investor was issued warrants to purchase 0.0859 shares of common stock for each share of Series B Preferred Stock purchased at a price of $0.003494 per share of common stock. Under the original terms of the warrant agreements, the warrants become have exercisable in accordance with the schedule set forth below following completion by the Company of an IPO and thereafter may be exercised at any time prior to expiration ten years from the date of issuance.
● 30% of the warrants beginning six months after the date on which the securities of the Company are first listed on a United States national securities exchange (such date, the "Listing Date");
● An additional 30% of the warrants beginning nine months after the Listing Date; and
● The remainder of the warrants beginning twelve months after the Listing Date.
As of December 31, 2019, the Company sold 9,782,609 shares of Series B Preferred Stock, which contained 839,952 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. During the year ended December 31, 2020, the Company sold an additional 6,521,738 shares of Series B Preferred Stock, which contained 559,969 underlying warrants to purchase common stock based on the exercise price and vesting schedule outlined above. These warrants were equity classified and the fair value of $5,208,700 is reflected as additional paid-in capital. On June 8, 2020, the Company agreed to amend the warrant vesting schedule such that the warrants became immediately exercisable for each warrant holder.
On June 8, 2020, warrant holders exercised their option to purchase 335,982 shares of common stock for proceeds of $1,200. Then, on June 10, 2020, warrant holders exercised their option to purchase an additional 1,063,939 shares of common stock for proceeds of $3,700. There are no warrants underlying Series B Preferred Stock outstanding as of December 31, 2020.
The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the years ended December 31:

2020

2019

Risk-free interest rate

1.54% - 1.88
%
1.54% - 1.84
%
Expected volatility

71.95% - 72.71
%
71.95% - 72.20
%
Expected life (years)

10.00

10.00

Expected dividend yield

0
%
0
%

Representative's Warrants — In connection with the IPO, the Company granted the underwriters warrants (the "Underwriters' Warrants") to purchase an aggregate of 62,500 shares of common stock at an exercise price of $15.00 per share, which is 125% of the initial public offering price. The Underwriters' Warrants have a five-year term and are not exercisable prior to April 13, 2021. All of the Underwriters' Warrants were outstanding at December 31, 2020.
These warrants were equity classified and the fair value of $377,000 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions for the year ended December 31, 2020:


2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 127 R77.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION
10.STOCK-BASED COMPENSATION
2017 Stock Incentive Plan — Stock Options
There were no options granted during the three months ended March 31, 2021. The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the three months ended March 31:


2020

Risk-free interest rate

1.59% - 2.92
%
Expected volatility

72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

Expected dividend yield

0
%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.

The following table summarizes the activity for all stock options outstanding at March 31 under the Plan:

2021

2020




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

489,718

$
10.03

598,083

$
11.11
Granted

—

—

17,631

12.02
Exercised

—

—

—

—
Cancelled and forfeited

(57,149)

17.88

(30,768)

11.88
Balance at December 31

432,569

$
8.99

584,946

$
11.09
Options exercisable at December 31:

408,306

$
8.75

361,720

$
7.67
Weighted average grant date fair value for options granted during the year:



$
—



$
35.62

The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021 and 2020 under the Plan:

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
March 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2021

432,569

6.72

$
8.99

$
839,700

408,306

$
8.75

$
269,514
2020

584,946

8.02

$
11.09

$
18,712,900

361,720

$
7.67

$
12,808,800

Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 as follows:


2021

2020
Research and development

$
19,000

$
425,000
General and administrative

102,000

31,000
Total

$
121,000

$
456,000

On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $20,900 of stock compensation expense allocable to general and administrative for the three months ended March 31, 2021. Included in that amount were $9,600 of incremental compensation costs resulting from the modifications for the three months ended March 31, 2021.
As of March 31, 2021, total unrecognized stock compensation expense is $252,700, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.25 years.
2017 Stock Incentive Plan — Restricted Stock Units
In January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.
The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.
The following table summarizes the activity for all RSUs outstanding at March 31 under the Plan:

2021

2020




Weighted Average



Weighted Average

Grant Date

Grant Date

Fair Value

Fair Value

Shares

Per Share

Shares

Per Share
Nonvested RSUs at beginning of year

946,245

$
12.81

—

$
—
Granted

6,019

9.00

—

—
Vested

—

—

—

—
Cancelled and forfeited

—

—

—

—
Nonvested RSUs at December 31

952,264

$
12.79

—

$
—

On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $267,700 and $556,600 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021. Included in those amounts were incremental compensation costs of $20,400 and $44,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the three months ended March 31, 2021.

11.STOCK-BASED COMPENSATION
2017 Stock Incentive Plan — Stock Options
The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:


2020

2019

Risk-free interest rate

0.15% - 2.92
%
1.60% - 2.92
%
Expected volatility

72.29% - 82.52
%
72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

4.93 – 6.07

Expected dividend yield

0
%
0
%

The fair value of the common shares underlying the stock options has historically been determined by the board of directors, with input from management. Because there was no public market for the Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the stock option by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.
The following table summarizes the activity for all stock options outstanding at December 31 under the Plan:

2020

2019




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

598,083

$
11.04

520,517

$
8.64
Granted

86,536

17.95

209,505

17.29
Exercised

—

—

(1,719)

6.64
Cancelled and forfeited

(194,901)

15.06

(130,220)

11.56
Balance at December 31

489,718

$
10.03

598,083

$
11.04
Options exercisable at December 31:

441,430

$
9.50

368,527

$
7.72
Weighted average grant date fair value for options granted during the year:



$
17.43



$
10.82

The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2020 and 2019 under the Plan:

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
December 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2020

489,718

6.37

$
10.03

$
554,900

441,430

$
9.50

$
—
2019

598,083

8.07

$
11.04

$
19,163,700

368,527

$
7.72

$
13,031,000

Total stock compensation expense recognized from stock-based compensation awards classified as stock options were recognized in the consolidated statements of operations for the years ended December 31, 2020 and 2019 as follows:


2020

2019
Research and development

$
1,008,000

$
332,000
General and administrative

332,000

190,900
Total

$
1,340,000

$
522,900

On August 20, 2020, the board of directors canceled and terminated 15,792 stock options, granted during the quarter ended June 30, 2020 to four non-employees. Thereafter, on August 20, 2020, the board of directors granted 21,112 stock options to the same individuals with a grant date fair value of $12.81 per share. There were 3,959 stock option grants that were considered vested on the grant date. The effects of the stock option modifications resulted in $65,900 of stock compensation expense allocable to general and administrative for the year December 31, 2020. Included in that amount were $34,800 of incremental compensation costs resulting from the modifications for the year ended December 31, 2020.
As of December 31, 2020, total unrecognized stock compensation expense is $473,900, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 1.79 years.
2017 Stock Incentive Plan — Restricted Stock Units
In January 2017, the Company’s board of directors approved the adoption of the Plan. The Plan permits the Company to grant up to 1,708,615 shares of the Company’s common stock awards, including incentive stock options; non-statutory stock options; and conditional share awards to employees, directors, and consultants of the Company. All granted shares that are canceled, forfeited, or expired are returned to the Plan and are available for grant in conjunction with the issuance of new common stock awards. Restricted stock units (“RSUs”) vest over a specified amount of time or when certain performance metrics are achieved by the Company.
The fair value of the common shares underlying the RSUs has historically been determined by the board of directors, with input from management. As there was no public market for Company’s common shares prior to October 15, 2020, the board of directors determined the fair value of the common shares at the time of grant of the RSUs by considering a number of objective and subjective factors, including important developments in the Company’s operations, third-party valuations performed, sales of Series A-1 Preferred Stock, sales of Series B Preferred Stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common shares, among other factors.
The following table summarizes the activity for all RSUs outstanding at December 31 under the Plan:

2020




Weighted Average

Grant Date

Fair Value

Shares

Per Share
Nonvested RSUs at beginning of year

—

$
—
Granted

1,655,579

12.84
Vested

—

—
Cancelled and forfeited

(709,334)

12.87
Nonvested RSUs at December 31

946,245

$
12.81

During the year ended December 31, 2020, 1,655,579 RSUs were granted and 709,334 RSUs were cancelled. During the year ended December 31, 2020, no RSUs vested. No RSUs were granted or vested in the year ended December 31, 2019.
On August 20, 2020, the board of directors canceled and terminated 709,334 RSUs, granted during the quarter ended June 30, 2020. The cancelled RSUs were originally granted to five individuals with a grant date fair value of $12.87 per share. Thereafter, on August 20, 2020, the board of directors granted 946,245 RSUs to the same individuals with a grant date fair value of $12.81 per share. None of the RSU grants were considered vested on the grant date. The RSU grants were modified for three employees and two non-employees. The effects of the RSU modifications resulted in $748,400 and $1,725,300 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020. Included in those amounts were incremental compensation costs of $166,900 and $402,700 of stock compensation expense allocable to research and development and general and administrative, respectively, during the year ended December 31, 2020.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 128 R78.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

INCOME TAXES

INCOME TAXES
11.INCOME TAXES
The Company’s effective tax rate from continuing operations was 0% for the three months ended March 31, 2021 and 2020. The Company recorded no income tax provision for the three months ended March 31, 2021 and 2020.
The provision for income taxes during the interim reporting periods is calculated by applying an estimate of the annual effective tax rate for the full fiscal year to "ordinary" income or loss for the reporting period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities.
The income tax rates vary from the US federal statutory rate of 21% primarily due to the full valuation allowance on the Company’s deferred tax assets. The Company has recorded the full valuation allowance based on an evaluation of both positive and negative evidence, including latest forecasts and cumulative losses in recent years. The Company has concluded that it was more likely than not that none of its deferred tax assets would be realized.

12.INCOME TAXES
For the years ended December 31, 2020 and 2019, the Company recognized no provision or benefit from income taxes.
The following is a reconciliation of the effective income tax rate to the statutory federal income tax rate for the years ended December 31, 2020 and 2019.


2020

2019

Federal income tax at statutory rates

21.00
%
21.00
%
Federal income tax rate reduction

—
%
—
%
Change in valuation allowance

(21.00)

(21.00)

Effective income tax rate

—
%
—
%

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. The Company recorded a valuation allowance to fully offset the net deferred tax asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets as of December 31, 2020 and 2019 due to the significant uncertainty about the realization of the deferred tax asset until the Company can operate profitably.
The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows as of December 31:


2020

2019
Deferred tax assets (liabilities):




Net operating loss carryforward

$
3,842,900

$
2,605,400
Stock compensation expense

3,379,000

597,400
Intangible assets

23,600

27,800
Total gross deferred tax assets

7,245,500

3,230,600
Valuation allowance

(7,061,600)

(3,198,100)
Property and equipment

(183,900)

(32,500)
Net deferred tax assets (liabilities)

—

—

As of December 31, 2020 and 2019, the Company has a US net operating loss ("NOL") carryforward of $18,299,500 and $12,406,800, respectively. The NOL carryforwards may be subject to annual limitations due to "change in ownership" provisions of Internal Revenue Code Section 382 ("Section 382") that can be triggered due to future ownership changes. Additionally, the NOL loss carryforwards are subject to examination and adjustments by the Internal Revenue Service until the statute of limitations closes on the year in which the NOL is utilized.
As of December 31, 2020 and 2019, there were no material uncertain tax positions taken by the Company. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months.
As of December 31, 2020, the Company is not currently under audit by any income tax authority.
On March 27, 2020, in response to the COVID-19 pandemic, the president of the United States signed the CARES Act. The Company does not expect there to be any significant benefit to its income tax provision as a result of the CARES Act, and the Company continues to monitor for any potential tax legislation related to the COVID-19 pandemic.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 129 R79.htm IDEA: XBRL DOCUMENT v3.21.2

RELATED PARTY TRANSACTIONS
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS
12.RELATED PARTY TRANSACTIONS
During the three months ended March 31, 2020, the Company maintained two separate consulting agreements with the Company's Chief Strategy and Innovation Officer (the "CSIO"), and the Chief Financial Officer and Chief Operating Officer (the "CFO and COO").
Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO is entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company's Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company's business development strategies. The consulting fees paid to the CSIO totaled $0 and $319,300 in the three months ended March 31, 2021 and 2020, respectively.
Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month. The consulting fees paid to the CFO and COO totaled $0 and $30,000 in the three months ended March 31, 2021 and 2020, respectively.
After the Company completed the IPO on October 15, 2020, the CFO and COO and the CSIO became full time employees.

13.RELATED PARTY TRANSACTIONS
During the year ended December 31, 2020, the Company maintained two separate consulting agreements with the Company’s CSIO and the Company’s CFO and COO. Those consulting agreements were terminated after the completion of the IPO in October 2020.
Beginning in the year ended December 31, 2014, the Company entered into its first consulting agreement with the CSIO. Pursuant to the amended agreement dated July 20, 2018, the CSIO was entitled to a consulting fee of $400 per hour, provided that he is limited to nineteen (19) hours per month unless he obtains approval from the Company’s Chief Executive Officer. The consulting agreement indicates that the CSIO will provide a leadership role for the Company’s business development strategies. The consulting fees paid to the CSIO totaled $579,700 and $207,800 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CSIO 320,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.
Beginning in the year ended December 31, 2018, the Company entered into its first consulting agreement with the CFO and COO. Initially, his title was "Consultant", and the Company changed his title to CFO and COO on October 25, 2019. The CFO and COO was elected as a director of the Company on January 17, 2020. Pursuant to the agreement on April 18, 2018 and amended on September 4, 2019, the CFO and COO is entitled to a consulting fee of $2,500 per month amended to $10,000 per month plus discretionary bonuses approved by management. The consulting fees paid to the CFO and COO totaled $140,000 and $67,500 in the years ended December 31, 2020 and 2019, respectively. In addition, the Company issued the CFO and COO 402,000 shares of common stock on June 19, 2020 in exchange for services rendered and no cash considerations. See Note 10.
On June 8, 2020, the Company issued the Chief Medical Officer and another employee 3,106 and 430 shares of common stock, respectively. The shares were issued in exchange for services rendered and no cash considerations. See Note 10.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 130 R80.htm IDEA: XBRL DOCUMENT v3.21.2

SUBSEQUENT EVENTS
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS
13.SUBSEQUENT EVENTS
Research Grant Agreement with University of Texas MD Anderson Cancer Center
On April 8, 2021, the Company entered into a letter of intent (the “Letter of Intent”) with the University of Texas MD Anderson Cancer Center (“MD Anderson”) pursuant to which MD Anderson shall receive a research grant from the Company titled, “Validation of biomarker isomeso for pancreatic cancer,” which is aimed at discovering new cancer-specific antigen targets (the “Grant”). The total costs to the Company to be paid in connection with the Grant shall be $300,000. Pursuant to the Letter of Intent, the Grant shall commence on April 1, 2021 and end on March 31, 2022.

14.SUBSEQUENT EVENTS
Strategic Alliance Agreement with Leon Office (H.K.)
On January 28, 2021, the Company executed a strategic alliance agreement with Leon Office (H.K.) (“Leon”) a company established under existing laws of Hong Kong. It is intended that Leon acts as an independent business development advisor on behalf of the Company. Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. The cost of the agreement is $360,000 annually, payable in four quarterly installments.
Loan Payable Forgiveness
During the year ended December 31, 2020, the Company applied for forgiveness of the SBA Loan in accordance with the terms of the CARES Act. On February 16, 2021 the SBA granted forgiveness of the SBA Loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled $105,600 and $300, respectively.
Lease Facility Expansion
On March 22, 2020, the Company’s board of directors approved a lease expansion within its premises in Houston, Texas. The amended lease agreement will commence on August 1, 2021 under an operating lease agreement that is noncancelable from commencement until May 1, 2024. The amended lease agreement adds approximately 15,385 square feet. The Company has the option to cancel the lease thereafter until the agreement expires on May 1, 2026. The termination date is effective after 90 days notice of cancellation.
If the Company exercises the cancellation option, the Company must also pay the lessor a termination payment equal to three months of base rent.
The future minimum commitments under the amended lease agreement will be as follows:


Amount
2021

$
380,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,939,600

Legal Complaint Filed Against the Company
A complaint was filed on March 22, 2021 in the Court of Chancery of the State of Delaware against the Company by a former consultant and director. The complaint alleges, among other things, that the plaintiff is entitled to additional stock options and he is seeking declaratory judgment and specific performance. The Company believes that all of the claims in the complaint are without merit and the Company intends to defend vigorously against them.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 131 R81.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.
All intercompany balances were eliminated upon consolidation.

Basis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2020 are not necessarily indicative of results to be expected for any future year.
On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.

Use of Estimates
Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and IPO common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Use of Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Cash and Cash Equivalents
Cash and Cash Equivalents — As of March 31, 2021 and December 31, 2020, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Cash and Cash Equivalents — As of December 31, 2020 and 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Concentrations of Credit Risk and Other Uncertainties
Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.

Concentrations of Credit Risk and Other Uncertainties — Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.
The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.
The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.

Deposit
Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets.

Deposit — In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s consolidated balance sheets.

Inventories
Inventories — Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of December 31, 2020, the Company recorded a reserve for inventory obsolescence of $22,200 as the inventory was near its expiration date with no significant marketing activities taking place. As of December 31, 2019 no such adjustments have been recorded.

Deferred Initial Public Offering Costs
Deferred Initial Public Offering Costs — During the year ended December 31, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering ("IPO"), which were deferred in other current assets in accordance with ASC 505-10-25, Equity, in the consolidated balance sheet. Upon completion of the IPO, these costs have been offset against proceeds received. Offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital.
During the year ended December 31, 2020, the Company classified deferred offering costs of $2,667,300 as a reduction to additional paid-in capital upon completion of the Company's IPO on October 15, 2020. As of December 31, 2020 and 2019, there were no deferred offering costs recorded on the Company's consolidated balance sheets.

Property and Equipment
Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Property and Equipment — Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.
Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Internal Use Software Development Costs
Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company did not capitalize any software development costs for the three months ended March 31, 2021 and 2020.

Internal Use Software Development Costs — The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the years ended December 31, 2020 and 2019, respectively.

Impairment of Long-Lived Assets
Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.

Impairment of Long-Lived Assets — The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.

Comprehensive Loss
Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Comprehensive Loss — Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Income Taxes
Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three months ended March 31, 2021 and 2020.

Income Taxes — The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying consolidated financial statements.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.
The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. No such interest or penalties were recognized during the years ended December 31, 2020 and 2019.

Research and Development Expense
Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Research and Development Expense — The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.
The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Proceeds from Grants
Proceeds from Grants — During the three months ended March 31, 2021 and 2020, the Company did not recognize any reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH.
Proceeds from Grants — During the years ended December 31, 2020 and 2019, the Company recognized $142,400 and $298,000, respectively, as reductions to research and development expense within the consolidated statements of operations pursuant to its grant from the NIH

Convertible Promissory Notes Derivative Liability
Convertible Promissory Notes Derivative Liability — During the year ended December 31, 2019, the Company recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in interest expense in the consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability was valued using a probability weighted expected return model. See Note 8.
Upon repurchase of convertible promissory notes, ASC 470, Debt, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the consolidated statements of operations.

Fair Value Measurements
Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the three months ended March 31, 2021 and 2020.

Fair Value Measurements — The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, and accrued expenses and other current liabilities approximate their fair value due to their short-term nature.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:
Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 — Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.
Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
There were no changes in the fair value hierarchy levels during the years ended December 31, 2020 and 2019.
The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.
Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:


December 31,

December 31,

2020

2019
Convertible promissory notes




Beginning balance

$
—

$
—
Amounts allocated to the embedded derivative liability at inception (at fair value)

—

(21,000)
Conversions from accounts payable into convertible promissory notes

—

134,800
Proceeds from issuances of convertible promissory notes

—

250,000
Conversions into Series A‑1 Stock

—

(363,800)
Ending balance

$
—

$
—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability




Beginning balance

$
—

$
—
Realized and unrealized gains and losses

—

2,000
Fair value of embedded derivative liability at inception

—

21,000
Amounts derecognized upon conversion of the related convertible promissory notes

—

(23,000)
Ending balance

$
—

$
—

Nonvested Stock Options and Restricted Stock Units
Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to board members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10-year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10-year period from grant date.

Nonvested Stock Options and Restricted Stock Units — Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options.
The vesting conditions for stock options include annual, and monthly options. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.
The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.

Stock-Based Compensation
Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. The Company did not grant any stock options during the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non-initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. From February 2018 to October 2020, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant

Stock-Based Compensation — The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation — Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.
Until the Company’s common stock became publicly traded, the board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.
The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:
Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock under the lock-up agreements and market standoff components of the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience after restricted periods expire. The Company has previously used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period.
Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.
Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.
Common Stock Valuations. During the years ended December 31, 2020 and 2019, the Company’s board of directors, with input from management and third-party valuations, determined the fair value of the common stock underlying all stock-based compensation grants. The Company believes that the board of directors had the relevant experience and expertise to determine the fair value of the Company’s common stock before the Company’s common stock became publicly traded. On the date of the grants in the years ended December 31, 2020 and 2019, the fair value of the Company’s common stock, was determined in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. The board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:
● valuations of the common stock performed by third-party specialists;
● the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
● lack of marketability of the common stock;
● current business conditions and projections;
● hiring of key personnel and the experience of management;
● the Company’s stage of development;
● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
● the market performance of comparable publicly traded companies; and
● the US and global capital market conditions.
In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.
For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability — weighted expected return model (“PWERM”).
The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.
PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.
Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.
For valuations after the completion of an initial public offering, the fair value of each share granted by the board of directors will be equal to the closing price of the common stock on the date of grant.
Warrants Underlying Shares IPO common stock — The Company records warrants to purchase shares of common stock underlying shares of IPO common stock in accordance with ASC 470, Debt with conversion and other options. The fair value of the warrants was estimated on the IPO date using the Black-Scholes option- valuation model. The calculation of warrants requires that we make assumptions and judgments about the variables used in the Black-Scholes option-valuation model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, risk-free interest rate, and exercise price.
The Company estimated the fair value of warrants underlying shares of IPO common stock using the Black-Scholes option-valuation model and the assumptions used to value such warrants are determined as follows:
Expected Term. The expected term represents the period that warrants are expected to be outstanding. The expected term was calculated by taking the average of the vesting period and contract period.
Risk-Free Interest Rate. The Company based the risk-free interest rate used in the Black-Scholes option-valuation model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the warrants.
Volatility. The Company determined the price volatility based on the historical volatilities of industry peers as the Company had one day of trading history as of the initial public offering date. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of the Company’s common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.
Dividend Yield. The expected dividend assumption is based on current expectations about anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, it used an expected dividend yield of zero.
Common Stock Valuations. The fair value of common stock when the warrants were issued is equal to the IPO common stock issuance price of $12.00 per share.
Exercise Price. The representative warrants’ exercise price to purchase common stock is $15.00 per share.

Segment Data
Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Segment Data — The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

Recently Issued Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
In June 2016, FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April 8, 2020, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.
On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the years ended December 31, 2020 and 2019.

X

- Definition
Disclosure of accounting policy for convertible promissory notes derivative liability.
+ References
No definition available.
+ Details

Name: krbp_ConvertiblePromissoryNotesDerivativeLiabilityPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for deposit.
+ References
No definition available.
+ Details

Name: krbp_DepositPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for nonvested stock options and restricted stock units.
+ References
No definition available.
+ Details

Name: krbp_NonvestedStockOptionsAndRestrictedStockUnitsPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for proceeds from grants.
+ References
No definition available.
+ Details

Name: krbp_ProceedsFromGrantsPolicyTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for deferral and amortization of significant deferred charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredChargesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 40
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 50
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_InternalUseSoftwarePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 132 R82.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of estimated useful lives of property and equipment

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Asset Description

Estimated Lives
Laboratory Equipment

3 - 8
Leasehold Improvements

1 - 7
Office Furniture, Fixtures, and Equipment

5
Software

3 - 5

Schedule of Level 3 liabilities measured at fair value on a recurring and nonrecurring basis


December 31,

December 31,

2020

2019
Convertible promissory notes




Beginning balance

$
—

$
—
Amounts allocated to the embedded derivative liability at inception (at fair value)

—

(21,000)
Conversions from accounts payable into convertible promissory notes

—

134,800
Proceeds from issuances of convertible promissory notes

—

250,000
Conversions into Series A‑1 Stock

—

(363,800)
Ending balance

$
—

$
—

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:
Convertible promissory note embedded derivative liability




Beginning balance

$
—

$
—
Realized and unrealized gains and losses

—

2,000
Fair value of embedded derivative liability at inception

—

21,000
Amounts derecognized upon conversion of the related convertible promissory notes

—

(23,000)
Ending balance

$
—

$
—

X

- Definition
Tabular disclosure of estimated useful lives of property and equipment.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 133 R83.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

NET LOSS PER COMMON SHARE

Schedule of earnings per share, basic and diluted

Three Months Ended

March 31,


2021

2020
Net loss

$
(3,854,500)

$
(1,852,700)
Less: Series B Preferred Stock discount amortization

—

(368,400)
Less: IPO Common Stock discount amortization

(24,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(3,879,200)

$
(2,221,100)
Weighted average common shares outstanding, basic and diluted

7,332,999

2,863,812
Net loss per common share, basic and diluted

$
(0.53)

$
(0.78)

Years Ended

December 31,


2020

2019
Net loss

$
(19,200,200)

$
(3,727,900)
Less: Accretion and settlement of Series B Preferred Stock dividend

—

(40,000)
Less: Series B Preferred Stock discount amortization

(692,700)

(210,600)
Less: IPO Common Stock discount amortization

(19,700)

—
Net loss attributable to common shareholders, basic and diluted

$
(19,912,600)

$
(3,978,500)
Weighted average common shares outstanding, basic and diluted

4,505,867

2,862,809
Net loss per common share, basic and diluted

$
(4.42)

$
(1.39)

Schedule of antidilutive securities excluded from computation of earnings per share


March 31,

March 31,

2021

2020
Stock options to purchase

677

404,391
Restricted Stock Units

32,000

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

469,136
Warrants underlying Series B Preferred Stock

—

1,399,807
Total

32,677

2,897,928

For the years ended December 31, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):


December 31,

December 31,

2020

2019
Stock options to purchase

1,647

75,405
Restricted Stock Units

95,815

—
Series A‑1 Preferred Stock

—

624,594
Series B Preferred Stock

—

282,478
Warrants underlying Series B Preferred Stock

—

839,784
Total

97,462

1,822,261

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 134 R84.htm IDEA: XBRL DOCUMENT v3.21.2

PROPERTY AND EQUIPMENT (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

PROPERTY AND EQUIPMENT

Schedule of property and equipment

March 31,

December 31,

2021

2020
Equipment

$
1,138,900

$
780,500
Leasehold improvements

1,274,600

1,229,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

151,700
Construction in progress

355,000

449,200

2,936,800

2,627,700
Less: Accumulated depreciation

(657,300)

(561,700)
Total

$
2,279,500

$
2,066,000

2020

2019
Equipment

$
780,500

$
488,800
Leasehold improvements

1,229,700

302,700
Office furniture, fixtures, and equipment

16,600

16,600
Software

151,700

141,500
Construction in progress

449,200

—

2,627,700

949,600
Less: Accumulated depreciation

(561,700)

(361,700)
Total

$
2,066,000

$
587,900

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 135 R85.htm IDEA: XBRL DOCUMENT v3.21.2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Schedule of accrued expenses and other current liabilities

March 31,

December 31,

2021

2020
Accrued consulting and outside services

$
173,900

$
143,200
Accrued compensation

95,000

191,000
Total

$
268,900

$
334,200

2020

2019
Accrued consulting and outside services

$
143,200

$
221,300
Accrued compensation

191,000

—
Total

$
334,200

$
221,300

X

- Definition
Tabular disclosure of information pertaining to accrued expenses and other liabilities.
+ References
No definition available.
+ Details

Name: krbp_AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 136 R86.htm IDEA: XBRL DOCUMENT v3.21.2

COMMITMENTS AND CONTINGENCIES (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

COMMITMENTS AND CONTINGENCIES

Schedule of future minimum rental payments for operating leases


Amount
2021

$
316,600
2022

546,700
2023

551,100
2024

461,200
Total

$
1,875,600

As of December 31, 2020, future minimum commitments under the facility lease agreement are as follows:


Amount
2021

$
265,200
2022

269,700
2023

274,200
2024

230,400
Total

$
1,039,500

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 137 R87.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Stockholders' Equity

Schedule of initial value of issuances allocated to IPO common stock, IPO common stock discount amortized and value of IPO common stock converted into additional paid-in-capital


2021
Common Stock


Balance at January 1,

$
11,975,400
Common stock IPO discount amortization

24,700
Balance at March 31,

$
12,000,100


2020

Common Stock



Balance at January 1,

$
—

Common stock IPO proceeds, net of issuance costs

12,332,700

Common stock IPO discount

(377,000)

Common stock IPO discount amortization

19,700

Balance at December 31,

$
11,975,400

Schedule of initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized


2020
Series B Preferred Stock


Balance at January 1,

$
1,306,900
Series B Preferred Stock proceeds

3,000,000
Series B Preferred Stock discount

(2,668,300)
Series B Preferred Stock discount amortization

368,400
Balance at March 31,

$
2,007,000


2020

2019
Series B Preferred Stock




Balance at January 1,

$
1,306,900

$
4,500,000
Series B Preferred Stock proceeds

3,000,000

(3,443,700)
Series B Preferred Stock discount

(2,668,300)

210,600
Series B Preferred Stock discount amortization

692,700

40,000
Series B Preferred Stock conversion to common stock

(2,331,300)

—
Balance at December 31,

$
—

$
1,306,900

Common Stock Warrants - Representative

Stockholders' Equity

Schedule of assumptions used to estimate fair value of warrants

2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%


2020

Risk-free interest rate

0.18
%
Expected volatility

94.08
%
Expected life (years)

2.74

Expected dividend yield

0
%

Series B Preferred Stock

Stockholders' Equity

Schedule of assumptions used to estimate fair value of warrants

March 31,


2020

Risk-free interest rate

1.54% - 1.88
%
Expected volatility

71.95% - 72.71
%
Expected life (years)

10

Expected dividend yield

0
%

2020

2019

Risk-free interest rate

1.54% - 1.88
%
1.54% - 1.84
%
Expected volatility

71.95% - 72.71
%
71.95% - 72.20
%
Expected life (years)

10.00

10.00

Expected dividend yield

0
%
0
%

X

- Definition
Tabular disclosure of initial value of issuances allocated to IPO common stock, IPO common stock discount amortized and value of IPO common stock converted into additional paid-in-capital.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized.
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfInitialValueOfIssuancesAllocatedToPreferredStockTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term, (b) expected volatility, (c) expected dividends, and (d) risk-free rate(s).
+ References
No definition available.
+ Details

Name: krbp_ScheduleOfWarrantsFairValueValuationAssumptionsTableTextBlock

Namespace Prefix: krbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_CommonStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 138 R88.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION (Tables)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

STOCK-BASED COMPENSATION

Schedule of assumptions used to estimate fair value of stock options


2020

Risk-free interest rate

1.59% - 2.92
%
Expected volatility

72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

Expected dividend yield

0
%

The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted-average assumptions for the years ended December 31:


2020

2019

Risk-free interest rate

0.15% - 2.92
%
1.60% - 2.92
%
Expected volatility

72.29% - 82.52
%
72.29% - 78.16
%
Expected life (years)

4.93 – 6.07

4.93 – 6.07

Expected dividend yield

0
%
0
%

Schedule of stock option activity

2021

2020




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

489,718

$
10.03

598,083

$
11.11
Granted

—

—

17,631

12.02
Exercised

—

—

—

—
Cancelled and forfeited

(57,149)

17.88

(30,768)

11.88
Balance at December 31

432,569

$
8.99

584,946

$
11.09
Options exercisable at December 31:

408,306

$
8.75

361,720

$
7.67
Weighted average grant date fair value for options granted during the year:



$
—



$
35.62

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
March 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2021

432,569

6.72

$
8.99

$
839,700

408,306

$
8.75

$
269,514
2020

584,946

8.02

$
11.09

$
18,712,900

361,720

$
7.67

$
12,808,800

2020

2019




Weighted



Weighted

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price
Options outstanding at beginning of year

598,083

$
11.04

520,517

$
8.64
Granted

86,536

17.95

209,505

17.29
Exercised

—

—

(1,719)

6.64
Cancelled and forfeited

(194,901)

15.06

(130,220)

11.56
Balance at December 31

489,718

$
10.03

598,083

$
11.04
Options exercisable at December 31:

441,430

$
9.50

368,527

$
7.72
Weighted average grant date fair value for options granted during the year:



$
17.43



$
10.82

Options Outstanding

Options Exercisable

Weighted

Average

Weighted

Weighted

Remaining

Average

Aggregate

Average

Aggregate
As of

Options

Contractual

Exercise

Intrinsic

Options

Exercise

Intrinsic
December 31,

Outstanding

Life

Price

Value

Exercisable

Price

Value
2020

489,718

6.37

$
10.03

$
554,900

441,430

$
9.50

$
—
2019

598,083

8.07

$
11.04

$
19,163,700

368,527

$
7.72

$
13,031,000

Schedule of stock-based compensation


2021

2020
Research and development

$
19,000

$
425,000
General and administrative

102,000

31,000
Total

$
121,000

$
456,000


2020

2019
Research and development

$
1,008,000

$
332,000
General and administrative

332,000

190,900
Total

$
1,340,000

$
522,900

Schedule of restricted stock unit activity

2021

2020




Weighted Average



Weighted Average

Grant Date

Grant Date

Fair Value

Fair Value

Shares

Per Share

Shares

Per Share
Nonvested RSUs at beginning of year

946,245

$
12.81

—

$
—
Granted

6,019

9.00

—

—
Vested

—

—

—

—
Cancelled and forfeited

—

—

—

—
Nonvested RSUs at December 31

952,264

$
12.79

—

$
—

2020




Weighted Average

Grant Date

Fair Value

Shares

Per Share
Nonvested RSUs at beginning of year

—

$
—
Granted

1,655,579

12.84
Vested

—

—
Cancelled and forfeited

(709,334)

12.87
Nonvested RSUs at December 31

946,245

$
12.81

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 139 R89.htm IDEA: XBRL DOCUMENT v3.21.2

ORGANIZATION (Details) - USD ($)
3 Months Ended 12 Months Ended

Oct. 15, 2020

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

ORGANIZATION

Cash flow from operations $ (2,635,900) $ (1,480,300) $ (6,126,600) $ (2,913,900)

Accumulated deficit (45,482,300) (41,627,800) $ (22,427,600)

Common stock IPO proceeds, net of issuance costs $ 12,332,700

NIH Grant receivable $ 2,235,000

Phase I approved amount of grant $ 851,000

Phase II approved amount of grant $ 1,384,000 $ 1,384,000

X

- Definition
Phase one approved amount of grant.
+ References
No definition available.
+ Details

Name: krbp_PhaseOneApprovedAmountOfGrant

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Phase two approved amount of grant.
+ References
No definition available.
+ Details

Name: krbp_PhaseTwoApprovedAmountOfGrant

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_GrantsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 140 R90.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
12 Months Ended

Dec. 31, 2020

USD ($)

item

Mar. 31, 2021

item

Dec. 31, 2019

USD ($)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Reserve for inventory obsolescence $ 22,200 $ 0

Decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO 2,667,300

Deferred offering costs $ 0 $ 0

Lease facility | item 1 1

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalDeferredIpoOfferingCosts

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
It represents the number of lease facility on the company.
+ References
No definition available.
+ Details

Name: krbp_NumberOfLeaseFacility

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735
+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 141 R91.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Property and Equipment

Impairment of long-lived assets held-for-use $ 0 $ 0

Unrecognized tax benefits, interest or penalties $ 0 $ 0 0 $ 0

Grants recognized $ 142,400 298,000

Minimum

Property and Equipment

Property plant and equipment useful life 1 year 1 year

Maximum

Property and Equipment

Property plant and equipment useful life 8 years 8 years

Equipment | Minimum

Property and Equipment

Property plant and equipment useful life 3 years 3 years

Equipment | Maximum

Property and Equipment

Property plant and equipment useful life 8 years 8 years

Leasehold improvements | Minimum

Property and Equipment

Property plant and equipment useful life 1 year 1 year

Leasehold improvements | Maximum

Property and Equipment

Property plant and equipment useful life 7 years 7 years

Office furniture, fixtures, and equipment

Property and Equipment

Property plant and equipment useful life 5 years 5 years

Software

Property and Equipment

Property plant and equipment useful life 5 years 5 years

Capitalized software development costs $ 10,200 $ 20,000

Software | Minimum

Property and Equipment

Property plant and equipment useful life 3 years 3 years

Software | Maximum

Property and Equipment

Property plant and equipment useful life 5 years 5 years

X

- Definition
The amount of grants received recognized as reductions to research and development expense.
+ References
No definition available.
+ Details

Name: krbp_IncomeFromGrants

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Additions made to capitalized computer software costs during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_CapitalizedComputerSoftwareAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=krbp_OfficeFurnitureFixturesAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 142 R92.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Fair Value Measurements

Changes in fair value hierarchy levels $ 0 $ 0 $ 0 $ 0

Conversions into Series A1 Stock (407,300)

Non-recurring | Convertible promissory notes | Level 3

Fair Value Measurements

Amounts allocated to the embedded derivative liability at inception (at fair value) (21,000)

Conversions from accounts payable into convertible promissory notes 134,800

Proceeds from issuances of convertible promissory notes 250,000

Conversions into Series A1 Stock (363,800)

Recurring | Convertible promissory notes | Level 3

Convertible promissory note embedded derivative liability

Realized and unrealized gains and losses 2,000

Fair value of embedded derivative liability at inception 21,000

Amounts derecognized upon conversion of the related convertible promissory notes $ (23,000)

X

- Definition
Amounts allocated to the embedded derivative liability at inception (at fair value).
+ References
No definition available.
+ Details

Name: krbp_AmountsAllocatedToEmbeddedDerivativeLiabilityAtInceptionAtFairValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amounts derecognized upon conversion of the related convertible promissory notes.
+ References
No definition available.
+ Details

Name: krbp_AmountsDerecognizedUponConversionOfRelatedConvertiblePromissoryNotes

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of conversion of accounts payable in to convertible debt instrument.
+ References
No definition available.
+ Details

Name: krbp_ConversionsOfAccountsPayableIntoConvertibleDebt

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Realized and unrealized gain (losses) on fair value of the embedded derivative or group of embedded derivatives.
+ References
No definition available.
+ Details

Name: krbp_EmbeddedDerivativeGainLossOnEmbeddedDerivativeLiabilityRealizedAndUnrealizedGainsLosses

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Changes in the fair value hierarchy levels during the period.
+ References
No definition available.
+ Details

Name: krbp_FairValueChanges

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of fair value of embedded derivative liability at inception.
+ References
No definition available.
+ Details

Name: krbp_FairValueOfEmbeddedDerivativeLiabilityAtInception

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 143 R93.htm IDEA: XBRL DOCUMENT v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Nonvested Stock Options

Expected dividend yield 0.00% 0.00%

RSU

Nonvested Stock Options

Expiration period 10 years 10 years

Monthly Vesting Conditions | Minimum | RSU

Nonvested Stock Options

Vesting period 6 months 6 months

Monthly Vesting Conditions | Maximum | RSU

Nonvested Stock Options

Vesting period 12 months 12 months

Stock Incentive Plan 2017

Nonvested Stock Options

Expiration period 10 years 10 years

Stock Incentive Plan 2017 | Annual Vesting Conditions

Nonvested Stock Options

Vesting period 4 years 4 years

Stock Incentive Plan 2017 | Monthly Vesting Conditions | Minimum

Nonvested Stock Options

Vesting period 10 months 10 months

Stock Incentive Plan 2017 | Monthly Vesting Conditions | Maximum

Nonvested Stock Options

Vesting period 48 months 48 months

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=krbp_MonthlyVestingConditionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=krbp_AnnualVestingConditionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 144 R94.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) - USD ($)
3 Months Ended 12 Months Ended

Dec. 06, 2019

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Net loss per common share

Net loss $ (3,854,500) $ (1,852,700) $ (19,200,200) $ (3,727,900)

Less: Accretion and settlement of Series B Preferred Stock dividend (40,000)

Series B Preferred Stock discount amortization (692,700) (210,600)

Less: IPO Common Stock discount amortization (24,700) (19,700)

Net loss attributable to common shareholders, basic and diluted $ (3,879,200) $ (2,221,100) $ (19,912,600) $ (3,978,500)

Weighted average common shares outstanding, basic and diluted 7,332,999 2,863,812 4,505,867 2,862,809

Net loss per common share, basic and diluted $ (0.53) $ (0.78) $ (4.42) $ (1.39)

Series B Preferred Stock

Net loss per common share

Less: Accretion and settlement of Series B Preferred Stock dividend $ (40,000) $ (40,000)

Series B Preferred Stock discount amortization $ (368,400) $ (692,700) $ (210,600)

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amortization of discount on preferred shares issued.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAmortizationOfDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 145 R95.htm IDEA: XBRL DOCUMENT v3.21.2

NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) - shares
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 32,677 2,897,928 97,462 1,822,261

Series A-1 Preferred Stock

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 624,594 624,594

Series B Preferred Stock

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 469,136 282,478

Stock Options

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 677 404,391 1,647 75,405

RSU

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 32,000 95,815

Series B Preferred Stock Warrant

Dilutive Securities Excluded From the Computations of Earnings Per Share

Potentially dilutive securities 1,399,807 839,784

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=krbp_SeriesBPreferredStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 146 R96.htm IDEA: XBRL DOCUMENT v3.21.2

PROPERTY AND EQUIPMENT (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross $ 2,936,800 $ 2,627,700 $ 949,600

Less: Accumulated depreciation (657,300) (561,700) (361,700)

Total 2,279,500 2,066,000 587,900

Depreciation 95,600 $ 33,800 200,000 87,500

Equipment

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 1,138,900 780,500 488,800

Leasehold improvements

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 1,274,600 1,229,700 302,700

Office furniture, fixtures, and equipment

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 16,600 16,600 16,600

Software

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross 151,700 151,700 $ 141,500

Construction in progress

PROPERTY AND EQUIPMENT

Property, Plant and Equipment, Gross $ 355,000 $ 449,200

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=krbp_OfficeFurnitureFixturesAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 147 R97.htm IDEA: XBRL DOCUMENT v3.21.2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)

Mar. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued consulting and outside services $ 173,900 $ 143,200 $ 221,300

Accrued compensation 95,000 191,000

Total $ 268,900 $ 334,200 $ 221,300

X

- Definition
The amount of accrued expenses and other current liabilities as at the end of the reporting period.
+ References
No definition available.
+ Details

Name: krbp_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 148 R98.htm IDEA: XBRL DOCUMENT v3.21.2

LOAN PAYABLE (Details) - USD ($)
12 Months Ended

Feb. 16, 2021

May 01, 2020

Dec. 31, 2020

Current loan payable

Loan payable $ 105,600

Loan initial proceeds 115,600

SBA Loan

Current loan payable

Principal amount $ 115,600

Loan payable 105,600

Loan initial proceeds 115,600

Loan repayments $ 10,000

Loan term 2 years

Loan fixed interest rate 1.00%

Loan first payment due 7 months

Loan principal forgiven $ 105,800

X

- Definition
Period of first payment due from the date of initial cash receipt.
+ References
No definition available.
+ Details

Name: krbp_DebtInstrumentFirstPaymentDue

Namespace Prefix: krbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received from loan payable.
+ References
No definition available.
+ Details

Name: krbp_ProceedsFromLoanPayable

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentDecreaseForgiveness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LoansPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=krbp_SBLoanPaycheckProtectionProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 149 R99.htm IDEA: XBRL DOCUMENT v3.21.2

NOTE PAYABLE (Details) - USD ($)
1 Months Ended

Nov. 30, 2020

Mar. 31, 2021

Dec. 31, 2020

Note payable

Note payable $ 227,800 $ 362,400

Director and Officer Insurance Policy Financing

Note payable

Note payable $ 540,500 $ 227,800 $ 362,400

Interest rate 4.59%

Note term 9 months

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtPercentageBearingFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 150 R100.htm IDEA: XBRL DOCUMENT v3.21.2

COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended 12 Months Ended

May 01, 2023

USD ($)

May 01, 2022

USD ($)

Aug. 01, 2021

USD ($)

May 01, 2021

USD ($)

Mar. 22, 2021

ft²

Jan. 28, 2021

USD ($)

installment

Nov. 19, 2020

Jan. 01, 2020

USD ($)

Mar. 31, 2021

USD ($)

Mar. 31, 2020

USD ($)

Dec. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

ft²

Leases

Area of office space leased | ft² 4,100

Additional office space leased | ft² 15,385

Period of time after notice of cancellation that the lease effectively terminates 90 days 90 days

Total lease payments per month $ 46,116 $ 23,039 $ 45,554 $ 22,477 $ 21,353

Rent expense $ 69,000 $ 60,000 $ 262,900 $ 129,100

Future minimum commitments

2021 316,600

2022 546,700 265,200

2023 551,100 269,700

2024 461,200 274,200

2024 230,400

Total $ 1,875,600 $ 1,039,500

Strategic Alliance Agreement | Leon Office (H.K.)

Strategic Alliance Agreement

Annual cost $ 360,000

Number of quarterly installments | installment 4

X

- Definition
Represents the area of property leased.
+ References
No definition available.
+ Details

Name: krbp_AreaOfPropertyLeased

Namespace Prefix: krbp_

Data Type: num:areaItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of total lease payments per month under the operating leases.
+ References
No definition available.
+ Details

Name: krbp_LesseeOperatingLeasePaymentsPerMonth

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of quarterly installments for payment of annual agreement costs.
+ References
No definition available.
+ Details

Name: krbp_NumberOfQuarterlyInstallments

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The square footage of additional space leased per the amended lease agreement.
+ References
No definition available.
+ Details

Name: krbp_OperatingLeaseAdditionalSquareFootage

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The period of time after notice of cancellation that the lease effectively terminates.
+ References
No definition available.
+ Details

Name: krbp_OperatingLeaseTerminationPeriodAfterNoticeOfCancellation

Namespace Prefix: krbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The annual cost of a strategic alliance agreement entered into by the entity.
+ References
No definition available.
+ Details

Name: krbp_StrategicAllianceAgreementAnnualCost

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherCommitmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=krbp_LeonOfficeH.k.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 151 R101.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Information (Details)
3 Months Ended 12 Months Ended

Jun. 19, 2020

USD ($)

shares

Jun. 17, 2020

shares

Jun. 10, 2020

USD ($)

shares

Jun. 08, 2020

USD ($)

Vote

shares

Dec. 17, 2019

Dec. 16, 2019

$ / shares

shares

Mar. 31, 2021

$ / shares

shares

Dec. 31, 2020

USD ($)

$ / shares

shares

Sep. 18, 2020

shares

Mar. 31, 2020

shares

Dec. 31, 2019

$ / shares

shares

Dec. 15, 2019

$ / shares

Sep. 25, 2019

shares

Sep. 24, 2019

shares

Sep. 13, 2019

shares

Jun. 18, 2018

shares

Stockholder's equity (Deficit)

Reverse split 3.494 10 10

Preferred stock, authorized 60,000,000 60,000,000 60,000,000 60,000,000

Preferred stock, par value ( in dollars per share) | $ / shares $ 0.0001 $ 0.01

Proceeds from issuance of common stock | $ $ 15,000,000

Common stock, authorized 1,708,615 858,615 300,000,000 300,000,000 858,615 300,000,000 30,000,000 20,000,000 858,615

Warrants to purchase shares 1,063,939 335,982

Proceeds from Issuance of Warrants | $ $ 3,700 $ 1,200 $ 4,900

Warrants outstanding 0 839,952

Stock compensation expenses | $ $ 9,432,000

Number of Votes | Vote 1

Dividend paid | $ / shares $ 0 $ 0

Shares available for issuance 850,000 322,063 270,933 271,949 258,813 10,000,000

Employees

Stockholder's equity (Deficit)

Shares issued for services 430

Cash consideration | $ $ 0

CMO

Stockholder's equity (Deficit)

Shares issued for services 3,106

Cash consideration | $ $ 0

CFO and COO

Stockholder's equity (Deficit)

Shares issued for services 402,000

Cash consideration | $ $ 0

CSIO

Stockholder's equity (Deficit)

Shares issued for services 320,000

Cash consideration | $ $ 0

Series A-1 Preferred Stock

Stockholder's equity (Deficit)

Preferred stock, authorized 24,000,000 24,000,000 24,000,000

Preferred stock, par value ( in dollars per share) | $ / shares $ 0.0001 $ 0.0001

Series B Preferred Stock

Stockholder's equity (Deficit)

Preferred stock, authorized 16,500,000 16,500,000 14,130,435 14,130,435

Preferred stock, par value ( in dollars per share) | $ / shares $ 0.0001 $ 0.0001

Warrants to purchase shares 559,969 1,399,921 839,952

Proceeds from Issuance of Warrants | $ $ 3,700 $ 1,200

Warrants outstanding 0

X

- Definition
Number of votes per share.
+ References
No definition available.
+ Details

Name: krbp_NumberOfVotesPerShare

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of cash consideration in exchange for shares issued for services rendered by related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionCashConsiderationInExchangeForServiceShares

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate dividends paid during the period for each share of common stock outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_CommonStockDividendsPerShareCashPaid

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=krbp_ChiefMedicalOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=krbp_ChiefFinancialOfficerAndChiefOperatingOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=krbp_ChiefStrategyAndInnovationOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 152 R102.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Common Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Oct. 15, 2020

Jun. 10, 2020

Jun. 08, 2020

Jan. 31, 2020

Jan. 24, 2020

Dec. 06, 2019

Nov. 13, 2019

Sep. 13, 2019

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Common stock

Common stock IPO proceeds, net of issuance costs $ 12,332,700

Offering expenses $ 2,667,300

Beginning Balance $ 1,200

Common stock IPO discount amortization 24,700 19,700

Ending Balance 1,200 $ 1,200

Series B Preferred Stock

Common stock

Shares issued 1,063,939 335,982 1,739,130 4,782,608 87,050 2,173,913 7,608,696 16,391,397 6,521,738 9,782,609

IPO

Common stock

Common stock IPO proceeds, net of issuance costs 12,332,700 $ 12,332,700

Underwriting discounts and commissions 1,275,000

Offering expenses $ 1,392,300

Shares issued 1,250,000

Share price $ 12.00

Beginning Balance 11,975,400

Common stock IPO discount amortization 24,700 19,700

Ending Balance $ 12,000,100 $ 11,975,400

IPO | Series A-1 Preferred Stock

Common stock

Stock issued on conversion 624,594

IPO | Series B Preferred Stock

Common stock

Stock issued on conversion 469,136

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.
+ References
No definition available.
+ Details

Name: krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash flow from payments of underwriting discounts and commissions.
+ References
No definition available.
+ Details

Name: krbp_PaymentsOfUnderwritingDiscountsAndCommissions

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 153 R103.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Preferred Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Jun. 10, 2020

Jun. 08, 2020

Jan. 31, 2020

Jan. 24, 2020

Dec. 15, 2019

Dec. 06, 2019

Nov. 15, 2019

Nov. 13, 2019

Sep. 13, 2019

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Mar. 31, 2021

Jan. 29, 2020

Dec. 16, 2019

Nov. 16, 2019

Stockholder's equity (Deficit)

Issuance of stock $ 11,975,400

Preferred stock, authorized 60,000,000 60,000,000 60,000,000 60,000,000

Accretion of dividend $ 40,000

Additional paid-in capital $ 52,988,700 $ 13,965,000 $ 53,933,900

Series A-1 Preferred Stock

Stockholder's equity (Deficit)

Original issue price $ 0.50

Preferred stock, authorized 24,000,000 24,000,000 24,000,000

Common shares issued for preferred stock converted 624,594

Series B Preferred Stock

Stockholder's equity (Deficit)

Shares issued 1,063,939 335,982 1,739,130 4,782,608 87,050 2,173,913 7,608,696 16,391,397 6,521,738 9,782,609

Issuance of stock $ 800,000 $ 2,200,000 $ 1,000,000 $ 3,500,000

Original issue price $ 0.46 $ 0.46 $ 0.46

Preferred stock, authorized 14,130,435 16,500,000 14,130,435 16,500,000

Warrants to purchase 0.0859 0.0859 0.0859

Warrant exercise price $ 0.003494 $ 0.003494 $ 0.003494

Annual dividend rate 6.00%

Accretion of dividend $ 40,000 $ 40,000

Additional paid-in capital $ (40,000)

Effective interest rate (as a percent) 28.00% 14.60%

Common shares issued for preferred stock converted 469,136

Series B Preferred Stock | Minimum

Stockholder's equity (Deficit)

Aggregate purchase price $ 1,000,000

Series B Preferred Stock | Maximum

Stockholder's equity (Deficit)

Preferred stock, authorized 16,500,000

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_PaymentsForProceedsFromPreviousAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 154 R104.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Dec. 06, 2019

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Stockholder's equity (Deficit)

Accretion and settlement of Series B Preferred Stock dividend $ 40,000

Series B Preferred Stock discount amortization $ 692,700 210,600

Series B Preferred Stock

Stockholder's equity (Deficit)

Balance at beginning of period $ 1,306,900 1,306,900 4,500,000

Series B Preferred Stock proceeds 3,000,000 3,000,000 (3,443,700)

Accretion and settlement of Series B Preferred Stock dividend $ 40,000 40,000

Series B Preferred Stock discount (2,668,300) (2,668,300)

Series B Preferred Stock discount amortization 368,400 692,700 210,600

Series B Preferred Stock conversion to common stock $ (2,331,300)

Balance at end of period $ 2,007,000 $ 1,306,900

X

- Definition
Value of accretion and settlement of dividend during the reporting period.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAccretionAndSettlementOfDividends

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amortization of discount on preferred shares issued.
+ References
No definition available.
+ Details

Name: krbp_PreferredStockAmortizationOfDiscount

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.
+ References
No definition available.
+ Details

Name: krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.4-07)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770
+ Details

Name: us-gaap_PreferredStockDiscountOnShares

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 155 R105.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Conversion of Convertible Promissory Notes (Details) - Series A-1 Preferred Stock - USD ($)
12 Months Ended

Aug. 15, 2019

Dec. 31, 2020

Stockholder's equity (Deficit)

Common shares issued for preferred stock converted 624,594

Convertible promissory notes

Stockholder's equity (Deficit)

Outstanding principal and interest $ 405,300

Number of shares converted 935,519

Principal amount $ 250,000

Coupon rate 17.00% 6.00%

Conversion of accounts payable into convertible promissory notes $ 134,800

Conversion rate 0.43% 0.43%

X

- Definition
The amount of accounts payable converted into convertible debt.
+ References
No definition available.
+ Details

Name: krbp_ConversionOfAccountsPayableIntoConvertibleDebt

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of coupon rate.
+ References
No definition available.
+ Details

Name: krbp_PercentageOfCouponRate

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 156 R106.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Warrants Underlying Series B Preferred Stock (Details) - USD ($)
3 Months Ended 12 Months Ended

Jun. 10, 2020

Jun. 08, 2020

Jan. 31, 2020

Jan. 24, 2020

Dec. 06, 2019

Nov. 13, 2019

Sep. 13, 2019

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Stockholder's equity (Deficit)

Warrants to purchase shares 1,063,939 335,982

Fair value of warrants reflected as additional paid-in capital $ 377,000

Proceeds from issuance of warrants $ 3,700 $ 1,200 $ 4,900

Warrants outstanding 0 839,952

Series B Preferred Stock

Stockholder's equity (Deficit)

Warrants to purchase 0.0859 0.0859 0.0859

Warrant purchase price (in dollars per share) $ 0.003494 $ 0.003494 $ 0.003494

Warrant expiration term 10 years 10 years

Shares issued 1,063,939 335,982 1,739,130 4,782,608 87,050 2,173,913 7,608,696 16,391,397 6,521,738 9,782,609

Warrants to purchase shares 1,399,921 559,969 839,952

Fair value of warrants reflected as additional paid-in capital $ 3,700 $ 5,533,000 $ 5,208,700

Proceeds from issuance of warrants $ 3,700 $ 1,200

Warrants outstanding 0

Series B Preferred Stock | Warrants exercise beginning six months after the listing date

Stockholder's equity (Deficit)

Warrant exercise percentage 30.00% 30.00%

Series B Preferred Stock | Warrants exercise beginning nine months after the listing date

Stockholder's equity (Deficit)

Warrant exercise percentage 30.00% 30.00%

X

- Definition
Percentage of warrant exercise.
+ References
No definition available.
+ Details

Name: krbp_PercentageOfWarrantExercise

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=krbp_WarrantExercisableBeginningSixMonthsAfterListingDateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=krbp_WarrantExercisableBeginningNineMonthsAfterListingDateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 157 R107.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Estimate the fair value of the warrants (Details) - Series B Preferred Stock Warrant

Mar. 31, 2021

Dec. 31, 2020

Mar. 31, 2020

Dec. 31, 2019

Weighted average valuation assumptions

Warrants and Rights Outstanding, Valuation Technique [Extensible List] us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember

Measurement Input, Risk Free Interest Rate | Minimum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.0154 0.0154 0.0154 0.0154

Measurement Input, Risk Free Interest Rate | Maximum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.0188 0.0188 0.0188 0.0184

Measurement Input, Price Volatility | Minimum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.7195 0.7195 0.7195 0.7195

Measurement Input, Price Volatility | Maximum

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.7271 0.7271 0.7271 0.7220

Measurement Input, Expected Term

Weighted average valuation assumptions

Warrants and Rights Outstanding, Term 10 years 10 years 10 years 10 years

Measurement Input, Expected Dividend Rate

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0 0 0 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_SeriesBPreferredStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 158 R108.htm IDEA: XBRL DOCUMENT v3.21.2

STOCKHOLDERS' EQUITY - Representative's Warrants (Details) - Common Stock Warrants - Representative

Oct. 15, 2020

$ / shares

shares

Mar. 31, 2021

USD ($)

Dec. 31, 2020

USD ($)

$ / shares

Weighted average valuation assumptions

Warrants fair value | $ $ 332,600 $ 357,300

Warrants and Rights Outstanding, Valuation Technique [Extensible List] us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember

Warrants

Warrant exercise price $ 15.00

IPO

Weighted average valuation assumptions

Warrants and Rights Outstanding, Term 5 years

Warrants

Number of warrants granted | shares 62,500

Warrant exercise price $ 15.00

Exercise price as a percentage of the initial offering price 125.00%

Measurement Input, Risk Free Interest Rate

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.0018 0.0018

Measurement Input, Price Volatility

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0.9408 0.9408

Measurement Input, Expected Term

Weighted average valuation assumptions

Warrants and Rights Outstanding, Term 2 years 8 months 26 days 2 years 8 months 26 days

Measurement Input, Expected Dividend Rate

Weighted average valuation assumptions

Warrants and Rights Outstanding, Measurement Input 0 0

X

- Definition
The warrant exercise price as a percentage of the initial offering price.
+ References
No definition available.
+ Details

Name: krbp_WarrantExercisePricePercentOfInitialOfferingPrice

Namespace Prefix: krbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants granted.
+ References
No definition available.
+ Details

Name: krbp_WarrantsAndRightsSharesGranted

Namespace Prefix: krbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=krbp_CommonStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 159 R109.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Weighted average assumptions

Expected dividend yield 0.00% 0.00%

Stock Incentive Plan 2017 | Stock Options

Weighted average assumptions

Risk-free interest rate, minimum 1.59% 0.15% 1.60%

Risk-free interest rate, maximum 2.92% 2.92% 2.92%

Expected volatility, minimum 72.29% 72.29% 72.29%

Expected volatility, maximum 78.16% 82.52% 78.16%

Expected dividend yield 0.00% 0.00% 0.00%

Stock Incentive Plan 2017 | Stock Options | Minimum

Weighted average assumptions

Expected life (years) 4 years 11 months 4 days 4 years 11 months 4 days 4 years 11 months 4 days

Stock Incentive Plan 2017 | Stock Options | Maximum

Weighted average assumptions

Expected life (years) 6 years 25 days 6 years 25 days 6 years 25 days

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 160 R110.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) - Stock Incentive Plan 2017 - Stock Options - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Stock option activity

Options outstanding at beginning of year 489,718 598,083 598,083 520,517

Granted 17,631 86,536 209,505

Exercised (1,719)

Cancelled and forfeited (57,149) (30,768) (194,901) (130,220)

Balance at September 30 432,569 584,946 489,718 598,083

Options exercisable at September 30: 408,306 361,720 441,430 368,527

Weighted average exercise price

Options outstanding at beginning of year $ 10.03 $ 11.11 $ 11.11 $ 8.64

Granted 12.02 17.95 17.29

Exercised 6.64

Cancelled and forfeited 17.88 11.88 15.06 11.56

Balance at September 30 8.99 11.09 10.03 11.11

Options exercisable at December 31: $ 8.75 7.67 9.50 7.72

Weighted average grant date fair value for options granted during the year: $ 35.62 $ 17.43 $ 10.82

Additional stock option information

Options outstanding, number 432,569 584,946 489,718 598,083

Options outstanding, weighted average remaining contractual life 6 years 8 months 19 days 8 years 7 days 6 years 4 months 13 days 8 years 25 days

Options outstanding, weighted average exercise price $ 8.99 $ 11.09 $ 10.03 $ 11.11

Options outstanding, aggregate intrinsic value $ 839,700 $ 18,712,900 $ 554,900 $ 19,163,700

Options exercisable, number 408,306 361,720 441,430 368,527

Options exercisable, weighted average exercise price $ 8.75 $ 7.67 $ 9.50 $ 7.72

Options exercisable, aggregate intrinsic value $ 269,514 $ 12,808,800 $ 13,031,000

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 161 R111.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Stock Option Modifications (Details)
3 Months Ended 12 Months Ended

Aug. 20, 2020

USD ($)

employee

$ / shares

shares

Jun. 08, 2020

USD ($)

Mar. 31, 2021

USD ($)

shares

Mar. 31, 2020

USD ($)

$ / shares

shares

Dec. 31, 2020

USD ($)

$ / shares

shares

Dec. 31, 2019

USD ($)

$ / shares

shares

Stock compensation expense

Stock compensation expense $ 9,432,000

Stock Incentive Plan 2017

Stock compensation expense

Stock compensation expense $ 121,000 $ 456,000

Stock Incentive Plan 2017 | Research and development

Stock compensation expense

Stock compensation expense 19,000 425,000

Stock Incentive Plan 2017 | General and administrative

Stock compensation expense

Stock compensation expense $ 102,000 $ 31,000

Stock Incentive Plan 2017 | Stock Options

Stock compensation expense

Stock compensation expense $ 1,340,000 $ 522,900

Cancelled and forfeited | shares 57,149 30,768 194,901 130,220

Number of persons to whom shares were cancelled | employee 4

Granted | shares 17,631 86,536 209,505

Weighted average grant date fair value for options granted during the year: | $ / shares $ 35.62 $ 17.43 $ 10.82

Total unrecognized stock compensation expense $ 252,700 $ 473,900

Weighted-average period over which cost not yet recognized is expected to be recognized 1 year 3 months 1 year 9 months 14 days

Stock Incentive Plan 2017 | Stock Options | Research and development

Stock compensation expense

Stock compensation expense $ 1,008,000 $ 332,000

Stock Incentive Plan 2017 | Stock Options | General and administrative

Stock compensation expense

Stock compensation expense $ 20,900 332,000 $ 190,900

Stock Incentive Plan 2017 | Stock Options | Four Nonemployees

Stock compensation expense

Cancelled and forfeited | shares 15,792

Granted | shares 21,112

Weighted average grant date fair value for options granted during the year: | $ / shares $ 12.81

Options vested | shares 3,959

Stock Incentive Plan 2017 | Stock Options | Four Nonemployees | General and administrative

Stock compensation expense

Stock compensation expense 65,900

Incremental compensation costs $ 9,600 $ 34,800

X

- Definition
Represents the number of persons to whom shares originally granted were cancelled.
+ References
No definition available.
+ Details

Name: krbp_NumberOfPersonsToWhomSharesWereCancelled

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
An excess of the fair value of the modified award over the fair value of the award immediately before the modification.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=krbp_ShareBasedPaymentArrangementFourNonemployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 162 R112.htm IDEA: XBRL DOCUMENT v3.21.2

STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)
3 Months Ended 12 Months Ended

Aug. 20, 2020

shares

Aug. 20, 2020

$ / shares

Aug. 20, 2020

individual

Aug. 20, 2020

item

Jun. 08, 2020

USD ($)

Mar. 31, 2021

USD ($)

$ / shares

shares

Mar. 31, 2020

USD ($)

Dec. 31, 2020

USD ($)

$ / shares

shares

Dec. 31, 2019

shares

Jan. 31, 2017

shares

Restricted stock units

Stock compensation expense $ 9,432,000

Stock Incentive Plan 2017

Restricted stock units

Stock compensation expense $ 121,000 $ 456,000

Stock Incentive Plan 2017 | Research and development

Restricted stock units

Stock compensation expense 19,000 425,000

Stock Incentive Plan 2017 | General and administrative

Restricted stock units

Stock compensation expense $ 102,000 $ 31,000

Stock Incentive Plan 2017 | RSU

Restricted stock units

Authorized shares | shares 1,708,615

Number of persons to whom shares were cancelled | individual 5

Restricted stock unit activity

Nonvested RSUs at beginning of year | shares 946,245

Granted | shares 946,245 6,019 1,655,579 0

Vested | shares 0 0 0

Cancelled and forfeited | shares (709,334) (709,334)

Nonvested RSUs at March 31 | shares 12.81 952,264 946,245

Weighted average grant day fair value per share

Nonvested RSUs at beginning of year | $ / shares $ 12.81

Granted | $ / shares 9.00 $ 12.84

Cancelled and forfeited | $ / shares $ 12.87 12.87

Nonvested RSUs at March 31 | $ / shares $ 12.81 $ 12.79 $ 12.81

Stock Incentive Plan 2017 | RSU | Research and development

Restricted stock units

Stock compensation expense $ 267,700 $ 748,400

Incremental compensation costs 20,400 166,900

Stock Incentive Plan 2017 | RSU | General and administrative

Restricted stock units

Stock compensation expense 556,600 1,725,300

Incremental compensation costs $ 44,700 $ 402,700

Stock Incentive Plan 2017 | RSU | Non-Employees

Restricted stock units

Number of persons to whom shares were cancelled 2 2

Stock Incentive Plan 2017 | RSU | Employees

Restricted stock units

Number of persons to whom shares were cancelled 3 3

X

- Definition
Represents the number of persons to whom shares originally granted were cancelled.
+ References
No definition available.
+ Details

Name: krbp_NumberOfPersonsToWhomSharesWereCancelled

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
An excess of the fair value of the modified award over the fair value of the award immediately before the modification.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=krbp_StockIncentivePlan2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 163 R113.htm IDEA: XBRL DOCUMENT v3.21.2

INCOME TAXES (Details) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

INCOME TAXES

Effective tax rate from continuing operations 0.00% 0.00% 0.00% 0.00%

Income tax provision $ 0 $ 0 $ 0 $ 0

Federal statutory rate 21.00% 21.00% 21.00%

Realized deferred tax assets $ 0

X

- Definition
Represents the amount of deferred tax assets expected to be realized.
+ References
No definition available.
+ Details

Name: krbp_RealizedDeferredTaxAssets

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 164 R114.htm IDEA: XBRL DOCUMENT v3.21.2

RELATED PARTY TRANSACTIONS (Details)
3 Months Ended 12 Months Ended

Jun. 19, 2020

USD ($)

shares

Jun. 08, 2020

USD ($)

shares

Sep. 04, 2019

USD ($)

Jul. 20, 2018

USD ($)

item

Apr. 18, 2018

USD ($)

Mar. 31, 2021

USD ($)

Mar. 31, 2020

USD ($)

agreement

Dec. 31, 2020

USD ($)

agreement

Dec. 31, 2019

USD ($)

Related party transactions

Number of separate consulting agreements | agreement 2 2

CSIO

Related party transactions

Consulting fee per hour $ 400

Threshold number of hours per month for which consulting fees are entitled | item 19

Consulting fee paid $ 0 $ 319,300 $ 579,700 $ 207,800

Shares issued for services rendered | shares 320,000

Cash consideration $ 0

CFO and COO

Related party transactions

Consulting fee per hour $ 10,000 $ 2,500

Consulting fee paid $ 0 $ 30,000 $ 140,000 $ 67,500

Shares issued for services rendered | shares 402,000

Cash consideration $ 0

Consulting fee per month $ 10,000 $ 2,500

CMO

Related party transactions

Shares issued for services rendered | shares 3,106

Cash consideration $ 0

Employee

Related party transactions

Shares issued for services rendered | shares 430

Cash consideration $ 0

X

- Definition
Represents the number of separate consulting agreements.
+ References
No definition available.
+ Details

Name: krbp_NumberOfSeparateConsultingAgreements

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash consideration in exchange for shares issued for services rendered by related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionCashConsiderationInExchangeForServiceShares

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the consulting fees per hour paid to the related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionConsultingFeesPerHour

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the consulting fees per month paid to the related party.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionConsultingFeesPerMonth

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the threshold number of hours per month the related party is entitled to receive consulting fees.
+ References
No definition available.
+ Details

Name: krbp_RelatedPartyTransactionThresholdNumberOfHoursPerMonthForWhichConsultingFeesAreEntitled

Namespace Prefix: krbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_ChiefStrategyAndInnovationOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_ChiefFinancialOfficerAndChiefOperatingOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_ChiefMedicalOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krbp_EmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 165 R115.htm IDEA: XBRL DOCUMENT v3.21.2

SUBSEQUENT EVENTS (Details)

Apr. 08, 2021

USD ($)

Subsequent Event | MD Anderson

Subsequent events

Research grant received $ 300,000

X

- Definition
The amount of research grant received from a third party.
+ References
No definition available.
+ Details

Name: krbp_ResearchGrantReceived

Namespace Prefix: krbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=krbp_UniversityOfTexasMdAndersonCancerCenterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 166 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 167 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 168 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 169 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 305 386 1 false 57 0 false 11 false false R1.htm 100090 - Document - Document and Entity Information Sheet http://www.kiromic.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100100 - Statement - Consolidated Balance Sheets Sheet http://www.kiromic.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100200 - Statement - Consolidated Statements of Operations Sheet http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100300 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) Sheet http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit Consolidated Statements of Changes in Stockholders' Equity (Deficit) Statements 5 false false R6.htm 100400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 110101 - Disclosure - ORGANIZATION Sheet http://www.kiromic.com/role/DisclosureOrganization ORGANIZATION Notes 7 false false R8.htm 110201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 110301 - Disclosure - NET LOSS PER COMMON SHARE Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShare NET LOSS PER COMMON SHARE Notes 9 false false R10.htm 110401 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 10 false false R11.htm 110501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 11 false false R12.htm 110601 - Disclosure - CURRENT LOAN PAYABLE Sheet http://www.kiromic.com/role/DisclosureCurrentLoanPayable CURRENT LOAN PAYABLE Notes 12 false false R13.htm 110701 - Disclosure - NOTE PAYABLE Sheet http://www.kiromic.com/role/DisclosureNotePayable NOTE PAYABLE Notes 13 false false R14.htm 110801 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotes CONVERTIBLE PROMISSORY NOTES Notes 14 false false R15.htm 110901 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.kiromic.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 111001 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.kiromic.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 16 false false R17.htm 111101 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensation STOCK-BASED COMPENSATION Notes 17 false false R18.htm 111201 - Disclosure - INCOME TAXES Sheet http://www.kiromic.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 18 false false R19.htm 111301 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.kiromic.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 19 false false R20.htm 111401 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.kiromic.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 120202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 130203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 130303 - Disclosure - NET LOSS PER COMMON SHARE (Tables) Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTables NET LOSS PER COMMON SHARE (Tables) Tables http://www.kiromic.com/role/DisclosureNetLossPerCommonShare 23 false false R24.htm 130403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNet 24 false false R25.htm 130503 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 25 false false R26.htm 130803 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) Notes http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesTables CONVERTIBLE PROMISSORY NOTES (Tables) Tables http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotes 26 false false R27.htm 130903 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.kiromic.com/role/DisclosureCommitmentsAndContingencies 27 false false R28.htm 131003 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables STOCKHOLDERS' EQUITY (DEFICIT) (Tables) Tables http://www.kiromic.com/role/DisclosureStockholdersEquity 28 false false R29.htm 131103 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.kiromic.com/role/DisclosureStockBasedCompensation 29 false false R30.htm 131203 - Disclosure - INCOME TAXES (Tables) Sheet http://www.kiromic.com/role/DisclosureIncomeTaxesTables INCOME TAXES (Tables) Tables http://www.kiromic.com/role/DisclosureIncomeTaxes 30 false false R31.htm 131403 - Disclosure - SUBSEQUENT EVENTS (Tables) Sheet http://www.kiromic.com/role/DisclosureSubsequentEventsTables SUBSEQUENT EVENTS (Tables) Tables http://www.kiromic.com/role/DisclosureSubsequentEvents 31 false false R32.htm 140101 - Disclosure - ORGANIZATION (Details) Sheet http://www.kiromic.com/role/DisclosureOrganizationDetails ORGANIZATION (Details) Details http://www.kiromic.com/role/DisclosureOrganization 32 false false R33.htm 140201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 140202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 34 false false R35.htm 140203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) Details 35 false false R36.htm 140204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) Details 36 false false R37.htm 140301 - Disclosure - NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) Details 37 false false R38.htm 140302 - Disclosure - NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) Details 38 false false R39.htm 140401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) Sheet http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails PROPERTY AND EQUIPMENT, NET (Details) Details http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetTables 39 false false R40.htm 140501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 40 false false R41.htm 140601 - Disclosure - CURRENT LOAN PAYABLE (Details) Sheet http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails CURRENT LOAN PAYABLE (Details) Details http://www.kiromic.com/role/DisclosureCurrentLoanPayable 41 false false R42.htm 140701 - Disclosure - NOTE PAYABLE (Details) Sheet http://www.kiromic.com/role/DisclosureNotePayableDetails NOTE PAYABLE (Details) Details http://www.kiromic.com/role/DisclosureNotePayable 42 false false R43.htm 140801 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details) Notes http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails CONVERTIBLE PROMISSORY NOTES (Details) Details http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesTables 43 false false R44.htm 140802 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Initial Issuance and Bifurcated Embedded Derivative Liability (Details) Notes http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails CONVERTIBLE PROMISSORY NOTES - Initial Issuance and Bifurcated Embedded Derivative Liability (Details) Details 44 false false R45.htm 140901 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTables 45 false false R46.htm 141001 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails STOCKHOLDERS' EQUITY (DEFICIT) (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 46 false false R47.htm 141002 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 47 false false R48.htm 141003 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 48 false false R49.htm 141004 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails STOCKHOLDERS' EQUITY (DEFICIT) - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 49 false false R50.htm 141005 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details) Notes http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 50 false false R51.htm 141006 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Warrants Underlying Series B Preferred Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails STOCKHOLDERS' EQUITY (DEFICIT) - Warrants Underlying Series B Preferred Stock (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 51 false false R52.htm 141007 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 52 false false R53.htm 141008 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details) Details http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables 53 false false R54.htm 141101 - Disclosure - STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details) Details 54 false false R55.htm 141102 - Disclosure - STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) Details 55 false false R56.htm 141103 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Modifications (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails STOCK-BASED COMPENSATION - Stock Option Modifications (Details) Details 56 false false R57.htm 141104 - Disclosure - STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details) Details 57 false false R58.htm 141201 - Disclosure - INCOME TAXES - Tax Rate Reconciliation (Details) Sheet http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails INCOME TAXES - Tax Rate Reconciliation (Details) Details 58 false false R59.htm 141202 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details) Sheet http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails INCOME TAXES - Deferred Tax Assets and Liabilities (Details) Details 59 false false R60.htm 141203 - Disclosure - INCOME TAXES - Net Operating Loss Carryforward (Details) Sheet http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails INCOME TAXES - Net Operating Loss Carryforward (Details) Details 60 false false R61.htm 141301 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.kiromic.com/role/DisclosureRelatedPartyTransactions 61 false false R62.htm 141401 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.kiromic.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.kiromic.com/role/DisclosureSubsequentEventsTables 62 false false R63.htm 200100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Uncategorized 63 false false R64.htm 200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Cover 64 false false R65.htm 200200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 65 false false R66.htm 200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 66 false false R67.htm 200400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 67 false false R68.htm 210101 - Disclosure - ORGANIZATION Sheet http://www.kiromic.com/role/DisclosureOrganizations ORGANIZATION Notes 68 false false R69.htm 210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciess SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 69 false false R70.htm 210301 - Disclosure - NET LOSS PER COMMON SHARE Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShares NET LOSS PER COMMON SHARE Notes 70 false false R71.htm 210401 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.kiromic.com/role/DisclosurePropertyAndEquipment PROPERTY AND EQUIPMENT Notes 71 false false R72.htm 210501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiess ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 72 false false R73.htm 210601 - Disclosure - LOAN PAYABLE Sheet http://www.kiromic.com/role/DisclosureLoanPayable LOAN PAYABLE Notes 73 false false R74.htm 210701 - Disclosure - NOTE PAYABLE Sheet http://www.kiromic.com/role/DisclosureNotePayables NOTE PAYABLE Notes 74 false false R75.htm 210801 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciess COMMITMENTS AND CONTINGENCIES Notes 75 false false R76.htm 210901 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.kiromic.com/role/DisclosureStockholdersEquitys STOCKHOLDERS' EQUITY Notes 76 false false R77.htm 211001 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensations STOCK-BASED COMPENSATION Notes 77 false false R78.htm 211101 - Disclosure - INCOME TAXES Sheet http://www.kiromic.com/role/DisclosureIncomeTaxess INCOME TAXES Notes 78 false false R79.htm 211201 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.kiromic.com/role/DisclosureRelatedPartyTransactionss RELATED PARTY TRANSACTIONS Notes 79 false false R80.htm 211301 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.kiromic.com/role/DisclosureSubsequentEventss SUBSEQUENT EVENTS Notes 80 false false R81.htm 220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 81 false false R82.htm 230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPolicies 82 false false R83.htm 230303 - Disclosure - NET LOSS PER COMMON SHARE (Tables) Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTabless NET LOSS PER COMMON SHARE (Tables) Tables http://www.kiromic.com/role/DisclosureNetLossPerCommonShare 83 false false R84.htm 230403 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.kiromic.com/role/DisclosurePropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNet 84 false false R85.htm 230503 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabless ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 85 false false R86.htm 230803 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTabless COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.kiromic.com/role/DisclosureCommitmentsAndContingencies 86 false false R87.htm 230903 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.kiromic.com/role/DisclosureStockholdersEquity 87 false false R88.htm 231003 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationTabless STOCK-BASED COMPENSATION (Tables) Tables http://www.kiromic.com/role/DisclosureStockBasedCompensation 88 false false R89.htm 240101 - Disclosure - ORGANIZATION (Details) Sheet http://www.kiromic.com/role/DisclosureOrganizationDetailss ORGANIZATION (Details) Details http://www.kiromic.com/role/DisclosureOrganization 89 false false R90.htm 240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 90 false false R91.htm 240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 91 false false R92.htm 240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details) Details 92 false false R93.htm 240204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) Sheet http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details) Details 93 false false R94.htm 240301 - Disclosure - NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details) Details 94 false false R95.htm 240302 - Disclosure - NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) Sheet http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details) Details 95 false false R96.htm 240401 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetTables 96 false false R97.htm 240501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 97 false false R98.htm 240601 - Disclosure - LOAN PAYABLE (Details) Sheet http://www.kiromic.com/role/DisclosureLoanPayableDetails LOAN PAYABLE (Details) Details http://www.kiromic.com/role/DisclosureLoanPayable 98 false false R99.htm 240701 - Disclosure - NOTE PAYABLE (Details) Sheet http://www.kiromic.com/role/DisclosureNotePayableDetailss NOTE PAYABLE (Details) Details http://www.kiromic.com/role/DisclosureNotePayable 99 false false R100.htm 240801 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss COMMITMENTS AND CONTINGENCIES (Details) Details http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTables 100 false false R101.htm 240901 - Disclosure - STOCKHOLDERS' EQUITY - Information (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails STOCKHOLDERS' EQUITY - Information (Details) Details 101 false false R102.htm 240902 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails STOCKHOLDERS' EQUITY - Common Stock (Details) Details 102 false false R103.htm 240903 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails STOCKHOLDERS' EQUITY - Preferred Stock (Details) Details 103 false false R104.htm 240904 - Disclosure - STOCKHOLDERS' EQUITY - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails STOCKHOLDERS' EQUITY - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details) Details 104 false false R105.htm 240905 - Disclosure - STOCKHOLDERS' EQUITY - Conversion of Convertible Promissory Notes (Details) Notes http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails STOCKHOLDERS' EQUITY - Conversion of Convertible Promissory Notes (Details) Details 105 false false R106.htm 240906 - Disclosure - STOCKHOLDERS' EQUITY - Warrants Underlying Series B Preferred Stock (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails STOCKHOLDERS' EQUITY - Warrants Underlying Series B Preferred Stock (Details) Details 106 false false R107.htm 240907 - Disclosure - STOCKHOLDERS' EQUITY - Estimate the fair value of the warrants (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails STOCKHOLDERS' EQUITY - Estimate the fair value of the warrants (Details) Details 107 false false R108.htm 240908 - Disclosure - STOCKHOLDERS' EQUITY - Representative's Warrants (Details) Sheet http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails STOCKHOLDERS' EQUITY - Representative's Warrants (Details) Details 108 false false R109.htm 241001 - Disclosure - STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details) Details 109 false false R110.htm 241002 - Disclosure - STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details) Details 110 false false R111.htm 241003 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Modifications (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss STOCK-BASED COMPENSATION - Stock Option Modifications (Details) Details 111 false false R112.htm 241004 - Disclosure - STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details) Sheet http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details) Details 112 false false R113.htm 241101 - Disclosure - INCOME TAXES (Details) Sheet http://www.kiromic.com/role/DisclosureIncomeTaxesDetails INCOME TAXES (Details) Details http://www.kiromic.com/role/DisclosureIncomeTaxesTables 113 false false R114.htm 241201 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss RELATED PARTY TRANSACTIONS (Details) Details http://www.kiromic.com/role/DisclosureRelatedPartyTransactions 114 false false R115.htm 241301 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss SUBSEQUENT EVENTS (Details) Details http://www.kiromic.com/role/DisclosureSubsequentEventsTables 115 false false All Reports Book All Reports krbp-20210625xs1.htm krbp-20210625.xsd krbp-20210625_cal.xml krbp-20210625_def.xml krbp-20210625_lab.xml krbp-20210625_pre.xml krbp-20210625xex10d11.htm krbp-20210625xex10d12.htm krbp-20210625xex1d1.htm krbp-20210625xex23d2.htm krbp-20210625xex4d1.htm krbp-20210625xex5d1.htm krbp-20210625xs1006.jpg krbp-20210625xs1008.jpg krbp-20210625xs1009.jpg krbp-20210625xs1010.jpg krbp-20210625xs1011.jpg krbp-20210625xs1012.jpg krbp-20210625xs1013.jpg krbp-20210625xs1014.jpg krbp-20210625xs1015.jpg krbp-20210625xs1016.jpg krbp-20210625xs1017.jpg krbp-20210625xs1018.jpg krbp-20210625xs1019.jpg krbp-20210625xs1020.jpg krbp-20210625xs1021.jpg krbp-20210625xs1022.jpg krbp-20210625xs1023.jpg krbp-20210625xs1026.jpg krbp-20210625xs1027.jpg krbp-20210625xs1028.jpg krbp-20210625xs1029.jpg krbp-20210625xs1030.jpg krbp-20210625xs1031.jpg krbp-20210625xs1032.jpg krbp-20210625xs1033.jpg krbp-20210625xs1034.jpg krbp-20210625xs1035.jpg krbp-20210625xs1036.jpg krbp-20210625xs1037.jpg krbp-20210625xs1038.jpg krbp-20210625xs1039.jpg krbp-20210625xs1040.jpg krbp-20210625xs1041.jpg krbp-20210625xs1047.jpg krbp-20210625xs1048.jpg http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 172 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "krbp-20210625xs1.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 305, "dts": { "calculationLink": { "local": [ "krbp-20210625_cal.xml" ] }, "definitionLink": { "local": [ "krbp-20210625_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "krbp-20210625xs1.htm" ] }, "labelLink": { "local": [ "krbp-20210625_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "krbp-20210625_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "krbp-20210625.xsd" ], "remote": [ "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 478, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 31, "http://www.kiromic.com/20210625": 8, "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 41 }, "keyCustom": 70, "keyStandard": 316, "memberCustom": 16, "memberStandard": 32, "nsprefix": "krbp", "nsuri": "http://www.kiromic.com/20210625", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100090 - Document - Document and Entity Information", "role": "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110401 - Disclosure - PROPERTY AND EQUIPMENT, NET", "role": "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": null }, "R100": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_iBYcaZbdvUi2pf_HMGMr5A", "decimals": "INF", "first": true, "lang": null, "name": "krbp:AreaOfPropertyLeased", "reportCount": 1, "unitRef": "Unit_Standard_sqft_kksOQ8SVH0yCMrqm2dJ-aw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240801 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_17_2020_To_6_17_2020_yNatE72BRE278PteXfi4Zg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240901 - Disclosure - STOCKHOLDERS' EQUITY - Information (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "shortName": "STOCKHOLDERS' EQUITY - Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R102": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_10_15_2020_To_10_15_2020_PzkmqjiQ9kSh6sxqmceEPQ", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240902 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R103": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240903 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R104": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_iBYcaZbdvUi2pf_HMGMr5A", "decimals": "-2", "first": true, "lang": null, "name": "krbp:PreferredStockAccretionAndSettlementOfDividends", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240904 - Disclosure - STOCKHOLDERS' EQUITY - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R105": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ygtdXDAnHUOUDqPwltn2fQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240905 - Disclosure - STOCKHOLDERS' EQUITY - Conversion of Convertible Promissory Notes (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "shortName": "STOCKHOLDERS' EQUITY - Conversion of Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R106": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_6_10_2020_BDuzIqRPEkywmXBRR074yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240906 - Disclosure - STOCKHOLDERS' EQUITY - Warrants Underlying Series B Preferred Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Warrants Underlying Series B Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R107": { "firstAnchor": { "ancestors": [ "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "p", "td", "tr", "table", "krbp:ScheduleOfWarrantsFairValueValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_krbp_SeriesBPreferredStockWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_MNAcRCzcOUSwV2Sdun3npw", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240907 - Disclosure - STOCKHOLDERS' EQUITY - Estimate the fair value of the warrants (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "shortName": "STOCKHOLDERS' EQUITY - Estimate the fair value of the warrants (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R108": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_us-gaap_ClassOfWarrantOrRightAxis_krbp_CommonStockWarrantMember_k_8bt8CcPEiffKBbwP5EHQ", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240908 - Disclosure - STOCKHOLDERS' EQUITY - Representative's Warrants (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "shortName": "STOCKHOLDERS' EQUITY - Representative's Warrants (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R109": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241001 - Disclosure - STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "shortName": "STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "role": "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": null }, "R110": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_krbp_StockIncentivePlan2017Member_4AMuk2H_r0yzxJ9pL8BrXg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241002 - Disclosure - STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "shortName": "STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R111": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_8_2020_To_6_8_2020_x-F92KQK20W5M5r3tm1hYg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241003 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Modifications (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "shortName": "STOCK-BASED COMPENSATION - Stock Option Modifications (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R112": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_8_2020_To_6_8_2020_x-F92KQK20W5M5r3tm1hYg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004 - Disclosure - STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "shortName": "STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R113": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241101 - Disclosure - INCOME TAXES (Details)", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "lang": null, "name": "krbp:RealizedDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_Ux6-dyHXVkOFllfAJysaOA", "decimals": "INF", "first": true, "lang": null, "name": "krbp:NumberOfSeparateConsultingAgreements", "reportCount": 1, "unitRef": "Unit_Standard_agreement_ScO6Podzs0ucFQF0uqKudA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241201 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_9_4_2019_To_9_4_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_krbp_ChiefFinancialOfficerAndChiefOperatingOfficerMember_5psdbVoOeUqMvIOi54s4ZA", "decimals": "-2", "lang": null, "name": "krbp:RelatedPartyTransactionConsultingFeesPerMonth", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_4_8_2021_srt_CounterpartyNameAxis_krbp_UniversityOfTexasMdAndersonCancerCenterMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8y27iwb8q0uSyUbTRDUJxQ", "decimals": "0", "first": true, "lang": null, "name": "krbp:ResearchGrantReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241301 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_4_8_2021_srt_CounterpartyNameAxis_krbp_UniversityOfTexasMdAndersonCancerCenterMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8y27iwb8q0uSyUbTRDUJxQ", "decimals": "0", "first": true, "lang": null, "name": "krbp:ResearchGrantReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110601 - Disclosure - CURRENT LOAN PAYABLE", "role": "http://www.kiromic.com/role/DisclosureCurrentLoanPayable", "shortName": "CURRENT LOAN PAYABLE", "subGroupType": "", "uniqueAnchor": null }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110701 - Disclosure - NOTE PAYABLE", "role": "http://www.kiromic.com/role/DisclosureNotePayable", "shortName": "NOTE PAYABLE", "subGroupType": "", "uniqueAnchor": null }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110801 - Disclosure - CONVERTIBLE PROMISSORY NOTES", "role": "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotes", "shortName": "CONVERTIBLE PROMISSORY NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110901 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.kiromic.com/role/DisclosureCommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111001 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111101 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": null }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111201 - Disclosure - INCOME TAXES", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111301 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.kiromic.com/role/DisclosureRelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100100 - Statement - Consolidated Balance Sheets", "role": "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": null }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111401 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.kiromic.com/role/DisclosureSubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "120202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130303 - Disclosure - NET LOSS PER COMMON SHARE (Tables)", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTables", "shortName": "NET LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "role": "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130503 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "krbp:ConvertibleDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130803 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables)", "role": "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesTables", "shortName": "CONVERTIBLE PROMISSORY NOTES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "krbp:ConvertibleDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130903 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131003 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131103 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_v0T0GQymtUaT3tk-Qw3jkg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100105 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ygtdXDAnHUOUDqPwltn2fQ", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131203 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ScheduleOfEstimatedFutureMinimumRentalPaymentsForRenewedOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131403 - Disclosure - SUBSEQUENT EVENTS (Tables)", "role": "http://www.kiromic.com/role/DisclosureSubsequentEventsTables", "shortName": "SUBSEQUENT EVENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ScheduleOfEstimatedFutureMinimumRentalPaymentsForRenewedOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140101 - Disclosure - ORGANIZATION (Details)", "role": "http://www.kiromic.com/role/DisclosureOrganizationDetails", "shortName": "ORGANIZATION (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_17_2020_To_6_17_2020_yNatE72BRE278PteXfi4Zg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "krbp:FairValueChanges", "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "krbp:FairValueChanges", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140301 - Disclosure - NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details)", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "shortName": "NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140302 - Disclosure - NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details)", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "shortName": "NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)", "role": "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "PROPERTY AND EQUIPMENT, NET (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100200 - Statement - Consolidated Statements of Operations", "role": "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "krbp:AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_v0T0GQymtUaT3tk-Qw3jkg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140601 - Disclosure - CURRENT LOAN PAYABLE (Details)", "role": "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "shortName": "CURRENT LOAN PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_krbp_SBLoanPaycheckProtectionProgramMember_lwA3o4oDcEa1hdmotdbCPg", "decimals": "-2", "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140701 - Disclosure - NOTE PAYABLE (Details)", "role": "http://www.kiromic.com/role/DisclosureNotePayableDetails", "shortName": "NOTE PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "p", "krbp:ConvertibleDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_T-e2PLBq20-tzEH8bxzGpQ", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140801 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details)", "role": "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "shortName": "CONVERTIBLE PROMISSORY NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "krbp:ConvertibleDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_T-e2PLBq20-tzEH8bxzGpQ", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "krbp:ConvertibleDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2019_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_yYPtuwsIJk638AS5LtgMRg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140802 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Initial Issuance and Bifurcated Embedded Derivative Liability (Details)", "role": "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "shortName": "CONVERTIBLE PROMISSORY NOTES - Initial Issuance and Bifurcated Embedded Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "krbp:ConvertibleDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2019_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_yYPtuwsIJk638AS5LtgMRg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_iBYcaZbdvUi2pf_HMGMr5A", "decimals": "INF", "first": true, "lang": null, "name": "krbp:AreaOfPropertyLeased", "reportCount": 1, "unitRef": "Unit_Standard_sqft_kksOQ8SVH0yCMrqm2dJ-aw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140901 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_17_2020_To_6_17_2020_yNatE72BRE278PteXfi4Zg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141001 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141002 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "krbp:ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2kLEt_1kcUSzr9Gn-OPq3w", "decimals": "-2", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141003 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_iBYcaZbdvUi2pf_HMGMr5A", "decimals": "-2", "first": true, "lang": null, "name": "krbp:PreferredStockAccretionAndSettlementOfDividends", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141004 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-a3qKRYGXk-XeN51zDdZIg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100300 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "role": "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ygtdXDAnHUOUDqPwltn2fQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141005 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_6_10_2020_BDuzIqRPEkywmXBRR074yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141006 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Warrants Underlying Series B Preferred Stock (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Warrants Underlying Series B Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "p", "td", "tr", "table", "krbp:ScheduleOfWarrantsFairValueValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_krbp_SeriesBPreferredStockWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_MNAcRCzcOUSwV2Sdun3npw", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141007 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_us-gaap_ClassOfWarrantOrRightAxis_krbp_CommonStockWarrantMember_k_8bt8CcPEiffKBbwP5EHQ", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141008 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_ClassOfWarrantOrRightAxis_krbp_CommonStockWarrantMember_c7SX5RPGtU-cp95BphzC5g", "decimals": "0", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141101 - Disclosure - STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "STOCK-BASED COMPENSATION - Weighted-average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_krbp_StockIncentivePlan2017Member_4AMuk2H_r0yzxJ9pL8BrXg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141102 - Disclosure - STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "shortName": "STOCK-BASED COMPENSATION - Summarizes Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_8_2020_To_6_8_2020_x-F92KQK20W5M5r3tm1hYg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141103 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Modifications (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "shortName": "STOCK-BASED COMPENSATION - Stock Option Modifications (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_6_8_2020_To_6_8_2020_x-F92KQK20W5M5r3tm1hYg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141104 - Disclosure - STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141201 - Disclosure - INCOME TAXES - Tax Rate Reconciliation (Details)", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails", "shortName": "INCOME TAXES - Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_B38ke-CTIUmaT_r3nEQE6A", "decimals": "4", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_v0T0GQymtUaT3tk-Qw3jkg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141202 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "INCOME TAXES - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_v0T0GQymtUaT3tk-Qw3jkg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100400 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_0xFopbH_oUWx_q4LU2UOkg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141203 - Disclosure - INCOME TAXES - Net Operating Loss Carryforward (Details)", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails", "shortName": "INCOME TAXES - Net Operating Loss Carryforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_0xFopbH_oUWx_q4LU2UOkg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_Ux6-dyHXVkOFllfAJysaOA", "decimals": "INF", "first": true, "lang": null, "name": "krbp:NumberOfSeparateConsultingAgreements", "reportCount": 1, "unitRef": "Unit_Standard_agreement_ScO6Podzs0ucFQF0uqKudA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_3_22_2021_To_3_22_2021_WXaH7Jxvp0GezYbzvvVSOw", "decimals": "INF", "first": true, "lang": null, "name": "krbp:OperatingLeaseAdditionalSquareFootage", "reportCount": 1, "unitRef": "Unit_Standard_sqft_kksOQ8SVH0yCMrqm2dJ-aw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141401 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_3_22_2021_To_3_22_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s6BLr8BN7UyYpmZ0Bk9vTA", "decimals": "INF", "lang": null, "name": "krbp:OperatingLeaseAdditionalSquareFootage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_kksOQ8SVH0yCMrqm2dJ-aw", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_rUMSkjvTPkSO_MjvgkJEXA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_rUMSkjvTPkSO_MjvgkJEXA", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200200 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-a3qKRYGXk-XeN51zDdZIg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VtZocfr1wEyqkZVr4CINfw", "decimals": "-2", "lang": null, "name": "krbp:AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_Ux6-dyHXVkOFllfAJysaOA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200400 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_Ux6-dyHXVkOFllfAJysaOA", "decimals": "-2", "lang": null, "name": "krbp:WarrantsUnderlyingPreferredStockIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210101 - Disclosure - ORGANIZATION", "role": "http://www.kiromic.com/role/DisclosureOrganizations", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciess", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110101 - Disclosure - ORGANIZATION", "role": "http://www.kiromic.com/role/DisclosureOrganization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210301 - Disclosure - NET LOSS PER COMMON SHARE", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShares", "shortName": "NET LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": null }, "R71": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210401 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://www.kiromic.com/role/DisclosurePropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": null }, "R72": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "role": "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiess", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210601 - Disclosure - LOAN PAYABLE", "role": "http://www.kiromic.com/role/DisclosureLoanPayable", "shortName": "LOAN PAYABLE", "subGroupType": "", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210701 - Disclosure - NOTE PAYABLE", "role": "http://www.kiromic.com/role/DisclosureNotePayables", "shortName": "NOTE PAYABLE", "subGroupType": "", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210801 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciess", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210901 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquitys", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211001 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensations", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211101 - Disclosure - INCOME TAXES", "role": "http://www.kiromic.com/role/DisclosureIncomeTaxess", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": null }, "R79": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211201 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionss", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": null }, "R80": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211301 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.kiromic.com/role/DisclosureSubsequentEventss", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": null }, "R81": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R83": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230303 - Disclosure - NET LOSS PER COMMON SHARE (Tables)", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTabless", "shortName": "NET LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230403 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230503 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabless", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R86": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230803 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTabless", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R87": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "krbp:ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230903 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R88": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231003 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.kiromic.com/role/DisclosureStockBasedCompensationTabless", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R89": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240101 - Disclosure - ORGANIZATION (Details)", "role": "http://www.kiromic.com/role/DisclosureOrganizationDetailss", "shortName": "ORGANIZATION (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110301 - Disclosure - NET LOSS PER COMMON SHARE", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShare", "shortName": "NET LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": null }, "R90": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_v0T0GQymtUaT3tk-Qw3jkg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R91": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R92": { "firstAnchor": { "ancestors": [ "krbp:FairValueChanges", "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "-2", "first": true, "lang": null, "name": "krbp:FairValueChanges", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R93": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_YEWG1tC00U6K0M_h1vZTfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details)", "role": "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R94": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240301 - Disclosure - NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details)", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "shortName": "NET LOSS PER COMMON SHARE - Computation of basic and diluted earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R95": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_nbuZC15isEKI4IV1HKp9Yw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Unit_Standard_shares_s7sZfcgaUEuCwTsb8WwPTA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240302 - Disclosure - NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details)", "role": "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "shortName": "NET LOSS PER COMMON SHARE - Dilutive Securities Excluded From the Computations of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R96": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240401 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R97": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "krbp:AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240501 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R98": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_12_31_2020_v0T0GQymtUaT3tk-Qw3jkg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240601 - Disclosure - LOAN PAYABLE (Details)", "role": "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "shortName": "LOAN PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R99": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "krbp-20210625xs1.htm", "contextRef": "As_Of_3_31_2021_DscT00Cky0W9QL2Ajo5UXg", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_v-wRaziL2UGk5ok1N_ykdw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240701 - Disclosure - NOTE PAYABLE (Details)", "role": "http://www.kiromic.com/role/DisclosureNotePayableDetailss", "shortName": "NOTE PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null } }, "segmentCount": 57, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "krbp_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued expenses and other current liabilities as at the end of the reporting period.", "label": "Accrued Expenses and Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "krbp_AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to accrued expenses and other liabilities.", "label": "Accrued Liabilities And Other Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabless" ], "xbrltype": "textBlockItemType" }, "krbp_AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from amortization of common stock discount.", "label": "Adjustments to Additional Paid in Capital, Amortization of Common Stock Discount", "terseLabel": "Common stock discount amortization" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "krbp_AdjustmentsToAdditionalPaidInCapitalDeferredIpoOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO.", "label": "Adjustments to Additional Paid in Capital, Deferred IPO Offering Costs", "terseLabel": "Decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDeferredIpoOfferingCosts", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from the amortization of discount on warrants underlying common stock.", "label": "Adjustments to Additional Paid in Capital, Warrant Discount Amortization", "negatedLabel": "Warrants underlying common stock discount amortization", "negatedTerseLabel": "Less: IPO Common Stock discount amortization", "terseLabel": "Common stock IPO discount amortization" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants on preferred stock.", "label": "Adjustments to Additional Paid in Capital, Warrants Issued, Preferred Stock", "verboseLabel": "Warrants underlying Series B Preferred Stock issuance" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedPreferredStock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_AmountsAllocatedToEmbeddedDerivativeLiabilityAtInceptionAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts allocated to the embedded derivative liability at inception (at fair value).", "label": "Amounts Allocated To The Embedded Derivative Liability At Inception (At Fair Value)", "terseLabel": "Amounts allocated to the embedded derivative liability at inception (at fair value)" } } }, "localname": "AmountsAllocatedToEmbeddedDerivativeLiabilityAtInceptionAtFairValue", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_AmountsDerecognizedUponConversionOfRelatedConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts derecognized upon conversion of the related convertible promissory notes.", "label": "Amounts Derecognized Upon Conversion Of The Related Convertible Promissory Notes", "terseLabel": "Amounts derecognized upon conversion of the related convertible promissory notes" } } }, "localname": "AmountsDerecognizedUponConversionOfRelatedConvertiblePromissoryNotes", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_AnnualVestingConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to annual vesting conditions.", "label": "Annual Vesting Conditions [Member]", "terseLabel": "Annual Vesting Conditions" } } }, "localname": "AnnualVestingConditionsMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "krbp_AreaOfPropertyLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the area of property leased.", "label": "Area Of Property Leased", "terseLabel": "Area of office space leased", "verboseLabel": "Area leased" } } }, "localname": "AreaOfPropertyLeased", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "areaItemType" }, "krbp_ChiefFinancialOfficerAndChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to chief financing officer and chief operating officer.", "label": "Chief Financial Officer And Chief Operating Officer [Member]", "terseLabel": "CFO and COO" } } }, "localname": "ChiefFinancialOfficerAndChiefOperatingOfficerMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "domainItemType" }, "krbp_ChiefMedicalOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to chief medical officer.", "label": "Chief Medical Officer [Member]", "terseLabel": "CMO" } } }, "localname": "ChiefMedicalOfficerMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "domainItemType" }, "krbp_ChiefStrategyAndInnovationOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to chief strategy and innovation office.", "label": "Chief Strategy And Innovation Officer [Member]", "terseLabel": "CSIO" } } }, "localname": "ChiefStrategyAndInnovationOfficerMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "domainItemType" }, "krbp_CommonStockWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Common Stock warrants.", "label": "Common Stock Warrant [Member]", "terseLabel": "Common Stock Warrants - Representative" } } }, "localname": "CommonStockWarrantMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "domainItemType" }, "krbp_ConversionOfAccountsPayableIntoConvertibleDebt": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accounts payable converted into convertible debt.", "label": "Conversion of Accounts Payable into Convertible Debt", "terseLabel": "Conversion of accounts payable into convertible promissory notes" } } }, "localname": "ConversionOfAccountsPayableIntoConvertibleDebt", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "krbp_ConversionsOfAccountsPayableIntoConvertibleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of conversion of accounts payable in to convertible debt instrument.", "label": "Conversions Of Accounts Payable Into Convertible Debt", "terseLabel": "Conversions from accounts payable into convertible promissory notes" } } }, "localname": "ConversionsOfAccountsPayableIntoConvertibleDebt", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_ConvertedEmbeddedDerivativeLiabilityIntoPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock from converted embedded derivative liability.", "label": "Converted Embedded Derivative Liability into Preferred Stock", "terseLabel": "Converted embedded derivative liability into Series A1 Preferred Stock" } } }, "localname": "ConvertedEmbeddedDerivativeLiabilityIntoPreferredStock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "krbp_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of debt.", "label": "Convertible Debt [Text Block]", "terseLabel": "CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "krbp_ConvertiblePromissoryNotesDerivativeLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for convertible promissory notes derivative liability.", "label": "Convertible Promissory Notes Derivative Liability [Policy Text Block]", "terseLabel": "Convertible Promissory Notes Derivative Liability" } } }, "localname": "ConvertiblePromissoryNotesDerivativeLiabilityPolicyTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "krbp_DebtInstrumentAccruedInterestDecreaseForgiveness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness for accrued interest forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Accrued Interest, Decrease Forgiveness", "terseLabel": "Accrued interest forgiven" } } }, "localname": "DebtInstrumentAccruedInterestDecreaseForgiveness", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "krbp_DebtInstrumentFirstPaymentDue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of first payment due from the date of initial cash receipt.", "label": "Debt Instrument First Payment Due", "terseLabel": "Loan first payment due" } } }, "localname": "DebtInstrumentFirstPaymentDue", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails" ], "xbrltype": "durationItemType" }, "krbp_DepositPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deposit.", "label": "Deposit [Policy Text Block]", "terseLabel": "Deposit" } } }, "localname": "DepositPolicyTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "krbp_EmbeddedDerivativeDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of discount on embedded derivative.", "label": "Embedded Derivative Discount Rate", "terseLabel": "Embedded derivative discount rate ( as a percent)" } } }, "localname": "EmbeddedDerivativeDiscountRate", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "krbp_EmbeddedDerivativeGainLossOnEmbeddedDerivativeLiabilityRealizedAndUnrealizedGainsLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Realized and unrealized gain (losses) on fair value of the embedded derivative or group of embedded derivatives.", "label": "Embedded Derivative Gain Loss On Embedded Derivative Liability Realized And Unrealized Gains Losses", "terseLabel": "Realized and unrealized gains and losses" } } }, "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeLiabilityRealizedAndUnrealizedGainsLosses", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to an employee.", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "domainItemType" }, "krbp_FairValueChanges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Changes in the fair value hierarchy levels during the period.", "label": "Fair Value Changes", "terseLabel": "Changes in fair value hierarchy levels" } } }, "localname": "FairValueChanges", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_FairValueOfEmbeddedDerivativeLiabilityAtInception": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fair value of embedded derivative liability at inception.", "label": "Fair Value Of Embedded Derivative Liability At Inception", "terseLabel": "Fair value of embedded derivative liability at inception" } } }, "localname": "FairValueOfEmbeddedDerivativeLiabilityAtInception", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_IncomeFromGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of grants received recognized as reductions to research and development expense.", "label": "Income From Grants", "terseLabel": "Grants recognized" } } }, "localname": "IncomeFromGrants", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_IncreaseDecreaseInConvertiblePromissoryNotesDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in convertible promissory notes derivative liability.", "label": "Increase (Decrease) In Convertible Promissory Notes Derivative Liability", "terseLabel": "Convertible promissory notes derivative liability" } } }, "localname": "IncreaseDecreaseInConvertiblePromissoryNotesDerivativeLiability", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "krbp_IncreaseDecreaseInDeferredRent": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in deferred rent.", "label": "Increase (Decrease) In Deferred Rent", "terseLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInDeferredRent", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "krbp_LeonOfficeH.k.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Leon Office (H.K.).", "label": "Leon Office H.k. [Member]", "terseLabel": "Leon Office (H.K.)" } } }, "localname": "LeonOfficeH.k.Member", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "krbp_LesseeOperatingLeasePaymentsPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of total lease payments per month under the operating leases.", "label": "Lessee, Operating Lease Payments Per Month", "terseLabel": "Total lease payments per month" } } }, "localname": "LesseeOperatingLeasePaymentsPerMonth", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_MonthlyVestingConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to monthly vesting conditions.", "label": "Monthly Vesting Conditions [Member]", "terseLabel": "Monthly Vesting Conditions" } } }, "localname": "MonthlyVestingConditionsMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "krbp_NonvestedStockOptionsAndRestrictedStockUnitsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for nonvested stock options and restricted stock units.", "label": "Nonvested Stock Options and Restricted Stock Units [Policy Text Block]", "terseLabel": "Nonvested Stock Options and Restricted Stock Units" } } }, "localname": "NonvestedStockOptionsAndRestrictedStockUnitsPolicyTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "krbp_NumberOfLeaseFacility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the number of lease facility on the company.", "label": "Number of Lease Facility", "terseLabel": "Lease facility" } } }, "localname": "NumberOfLeaseFacility", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" ], "xbrltype": "integerItemType" }, "krbp_NumberOfPersonsToWhomSharesWereCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of persons to whom shares originally granted were cancelled.", "label": "Number Of Persons To Whom Shares Were Cancelled", "terseLabel": "Number of persons to whom shares were cancelled" } } }, "localname": "NumberOfPersonsToWhomSharesWereCancelled", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "integerItemType" }, "krbp_NumberOfQuarterlyInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of quarterly installments for payment of annual agreement costs.", "label": "Number of Quarterly Installments", "verboseLabel": "Number of quarterly installments" } } }, "localname": "NumberOfQuarterlyInstallments", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "krbp_NumberOfSeparateConsultingAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of separate consulting agreements.", "label": "Number Of Separate Consulting Agreements", "terseLabel": "Number of separate consulting agreements" } } }, "localname": "NumberOfSeparateConsultingAgreements", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "integerItemType" }, "krbp_NumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes per share.", "label": "Number of Votes Per Share", "terseLabel": "Number of Votes" } } }, "localname": "NumberOfVotesPerShare", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "integerItemType" }, "krbp_OfficeFurnitureFixturesAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to office furniture, fixtures, and equipment.", "label": "Office Furniture Fixtures And Equipment [Member]", "terseLabel": "Office furniture, fixtures, and equipment" } } }, "localname": "OfficeFurnitureFixturesAndEquipmentMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "krbp_OperatingLeaseAdditionalSquareFootage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The square footage of additional space leased per the amended lease agreement.", "label": "Operating Lease, Additional Square Footage", "terseLabel": "Additional office space leased" } } }, "localname": "OperatingLeaseAdditionalSquareFootage", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "krbp_OperatingLeaseLeaseCancellationTerminationPaymentNumberOfMonthsRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of months rent due as a termination payment if the operating lease cancellation option is exercised.", "label": "Operating Lease, Lease Cancellation, Termination Payment, Number of Months Rent", "terseLabel": "Number of months rent due as a termination payment if lease cancellation option exercised" } } }, "localname": "OperatingLeaseLeaseCancellationTerminationPaymentNumberOfMonthsRent", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "krbp_OperatingLeaseTerminationPeriodAfterNoticeOfCancellation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after notice of cancellation that the lease effectively terminates.", "label": "Operating Lease, Termination Period After Notice of Cancellation", "terseLabel": "Period of time after notice of cancellation that the lease effectively terminates" } } }, "localname": "OperatingLeaseTerminationPeriodAfterNoticeOfCancellation", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "krbp_PaymentsOfUnderwritingDiscountsAndCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash flow from payments of underwriting discounts and commissions.", "label": "Payments Of Underwriting Discounts And Commissions", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfUnderwritingDiscountsAndCommissions", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "krbp_PercentageOfCouponRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of coupon rate.", "label": "Percentage of Coupon Rate", "terseLabel": "Coupon rate" } } }, "localname": "PercentageOfCouponRate", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "krbp_PercentageOfWarrantExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant exercise.", "label": "Percentage of Warrant Exercise", "terseLabel": "Warrant exercise percentage" } } }, "localname": "PercentageOfWarrantExercise", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "percentItemType" }, "krbp_PhaseOneApprovedAmountOfGrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Phase one approved amount of grant.", "label": "Phase One Approved Amount of Grant", "terseLabel": "Phase I approved amount of grant" } } }, "localname": "PhaseOneApprovedAmountOfGrant", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganizationDetails", "http://www.kiromic.com/role/DisclosureOrganizationDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_PhaseTwoApprovedAmountOfGrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Phase two approved amount of grant.", "label": "Phase Two Approved Amount of Grant", "terseLabel": "Phase II approved amount of grant" } } }, "localname": "PhaseTwoApprovedAmountOfGrant", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganizationDetails", "http://www.kiromic.com/role/DisclosureOrganizationDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_PreferredStockAccretionAndSettlementOfDividends": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of accretion and settlement of dividend during the reporting period.", "label": "Preferred Stock, Accretion and Settlement of Dividends", "negatedLabel": "Accretion and settlement of Series B Preferred Stock dividend", "negatedTerseLabel": "Less: Accretion and settlement of Series B Preferred Stock dividend", "terseLabel": "Accretion of dividend", "verboseLabel": "Accretion and settlement of Series B Preferred Stock dividend" } } }, "localname": "PreferredStockAccretionAndSettlementOfDividends", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_PreferredStockAccretionAndSettlementOfDividendsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued in settlement of dividend during the period.", "label": "Preferred Stock, Accretion and Settlement of Dividends, Shares", "negatedLabel": "Accretion and settlement of Series B Preferred Stock Dividend (in shares)" } } }, "localname": "PreferredStockAccretionAndSettlementOfDividendsShares", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "krbp_PreferredStockAmortizationOfDiscount": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of discount on preferred shares issued.", "label": "Preferred Stock, Amortization of Discount", "negatedLabel": "Series B Preferred Stock discount amortization", "terseLabel": "Series B Preferred Stock discount amortization" } } }, "localname": "PreferredStockAmortizationOfDiscount", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_ProbabilityPercentageOfNextFinancingClose": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of probability of next financing close.", "label": "Probability Percentage Of Next Financing Close", "terseLabel": "Probability of next financing close (as a percent)" } } }, "localname": "ProbabilityPercentageOfNextFinancingClose", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "krbp_ProceedsFromGrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for proceeds from grants.", "label": "Proceeds from Grants [Policy Text Block]", "terseLabel": "Proceeds from Grants" } } }, "localname": "ProceedsFromGrantsPolicyTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "krbp_ProceedsFromLoanPayable": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from loan payable.", "label": "Proceeds From Loan Payable", "terseLabel": "Proceeds from loan payable", "verboseLabel": "Loan initial proceeds" } } }, "localname": "ProceedsFromLoanPayable", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "krbp_RealizedDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred tax assets expected to be realized.", "label": "Realized Deferred Tax Assets", "terseLabel": "Realized deferred tax assets" } } }, "localname": "RealizedDeferredTaxAssets", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "krbp_RelatedPartyTransactionCashConsiderationInExchangeForServiceShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash consideration in exchange for shares issued for services rendered by related party.", "label": "Related Party Transaction, Cash Consideration In Exchange For Service Shares", "terseLabel": "Cash consideration" } } }, "localname": "RelatedPartyTransactionCashConsiderationInExchangeForServiceShares", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "monetaryItemType" }, "krbp_RelatedPartyTransactionConsultingFeesPerHour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the consulting fees per hour paid to the related party.", "label": "Related Party Transaction, Consulting Fees Per Hour", "terseLabel": "Consulting fee per hour" } } }, "localname": "RelatedPartyTransactionConsultingFeesPerHour", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_RelatedPartyTransactionConsultingFeesPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the consulting fees per month paid to the related party.", "label": "Related Party Transaction, Consulting Fees Per Month", "terseLabel": "Consulting fee per month" } } }, "localname": "RelatedPartyTransactionConsultingFeesPerMonth", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_RelatedPartyTransactionThresholdNumberOfHoursPerMonthForWhichConsultingFeesAreEntitled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold number of hours per month the related party is entitled to receive consulting fees.", "label": "Related Party Transaction, Threshold Number Of Hours Per Month For Which Consulting Fees Are Entitled", "terseLabel": "Threshold number of hours per month for which consulting fees are entitled" } } }, "localname": "RelatedPartyTransactionThresholdNumberOfHoursPerMonthForWhichConsultingFeesAreEntitled", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "integerItemType" }, "krbp_ResearchGrantReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research grant received from a third party.", "label": "Research Grant Received", "verboseLabel": "Research grant received" } } }, "localname": "ResearchGrantReceived", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "monetaryItemType" }, "krbp_SBLoanPaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the details pertaining to SBA Loan under the Paycheck Protection Program which was established under the Coronavirus Aid, Relief, and Economic Security Act (the \"CARES Act\") administered by the U.S. Small Business Administration (the \"SBA\").", "label": "S B Loan Paycheck Protection Program [Member]", "terseLabel": "SBA Loan" } } }, "localname": "SBLoanPaycheckProtectionProgramMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "krbp_ScheduleOfEstimatedFutureMinimumRentalPaymentsForRenewedOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of estimated future minimum payments required in the aggregate and for each of the five fiscal years upon commencement for renewed operating leases.", "label": "Schedule of Estimated Future Minimum Rental Payments for Renewed Operating Leases [Table Text Block]", "terseLabel": "Schedule of future minimum rental payments for renewed operating lease upon commencement" } } }, "localname": "ScheduleOfEstimatedFutureMinimumRentalPaymentsForRenewedOperatingLeasesTableTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsTables" ], "xbrltype": "textBlockItemType" }, "krbp_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of estimated useful lives of property and equipment.", "label": "Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]", "terseLabel": "Schedule of estimated useful lives of property and equipment" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless" ], "xbrltype": "textBlockItemType" }, "krbp_ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of initial value of issuances allocated to IPO common stock, IPO common stock discount amortized and value of IPO common stock converted into additional paid-in-capital.", "label": "Schedule of Initial Value of Issuances Allocated To IPO Common Stock [Table Text Block]", "terseLabel": "Schedule of initial value of issuances allocated to IPO common stock, IPO common stock discount amortized and value of IPO common stock converted into additional paid-in-capital" } } }, "localname": "ScheduleOfInitialValueOfIssuancesAllocatedToIpoCommonStockTableTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "krbp_ScheduleOfInitialValueOfIssuancesAllocatedToPreferredStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized.", "label": "Schedule of Initial Value of Issuances Allocated to Preferred Stock [Table Text Block]", "terseLabel": "Schedule of initial value of issuances allocated to Series B Preferred Stock and the Series B Preferred Stock discount amortized" } } }, "localname": "ScheduleOfInitialValueOfIssuancesAllocatedToPreferredStockTableTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "krbp_ScheduleOfWarrantsFairValueValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term, (b) expected volatility, (c) expected dividends, and (d) risk-free rate(s).", "label": "Schedule of Warrants, Fair Value Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to estimate fair value of warrants" } } }, "localname": "ScheduleOfWarrantsFairValueValuationAssumptionsTableTextBlock", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "krbp_SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock.", "label": "Series A1 Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split and Conversions, Shares", "verboseLabel": "Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares)" } } }, "localname": "SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "krbp_SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common shares and fractional share adjustments from stock splits and conversion of Series A-1 Preferred Stock.", "label": "Series A1 Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split and Conversions, Value", "verboseLabel": "Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion" } } }, "localname": "SeriesA1PreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.", "label": "Series B Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split and Conversions, Shares", "verboseLabel": "Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares)" } } }, "localname": "SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsShares", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "krbp_SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common shares and fractional share adjustments from stock splits and conversion of Series B Preferred Stock.", "label": "Series B Preferred Stock, Common Stock and Fractional Shares Adjustment From Stock Split And Conversions, Value", "negatedLabel": "Series B Preferred Stock conversion to common stock", "verboseLabel": "Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion" } } }, "localname": "SeriesBPreferredStockCommonStockAndFractionalSharesAdjustmentFromStockSplitAndConversionsValue", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_SeriesBPreferredStockWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Series B Preferred Stock warrants.", "label": "Series B Preferred Stock Warrant [Member]", "terseLabel": "Series B Preferred Stock Warrant" } } }, "localname": "SeriesBPreferredStockWarrantMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "krbp_ShareBasedPaymentArrangementFourNonemployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to four non-employees.", "label": "Share Based Payment Arrangement Four Nonemployees [Member]", "terseLabel": "Four Nonemployees" } } }, "localname": "ShareBasedPaymentArrangementFourNonemployeesMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "domainItemType" }, "krbp_StockIncentivePlan2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2017 Stock Incentive Plan.", "label": "Stock Incentive Plan2017 [Member]", "terseLabel": "Stock Incentive Plan 2017" } } }, "localname": "StockIncentivePlan2017Member", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "krbp_StockIssuedDuringPeriodPreferredStockNewIssuesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new preferred stock issued during the period.", "label": "Stock Issued During Period, Preferred Stock, New Issues, Shares", "terseLabel": "Issuance of Series B Preferred Stock" } } }, "localname": "StockIssuedDuringPeriodPreferredStockNewIssuesShares", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "krbp_StockIssuedDuringPeriodPreferredStockNewIssuesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new preferred stock issued during the period.", "label": "Stock Issued During Period, Preferred Stock, New Issues, Value", "terseLabel": "Issuance of Series B Preferred Stock" } } }, "localname": "StockIssuedDuringPeriodPreferredStockNewIssuesValue", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_StockIssuedDuringPeriodSharesEmployeesAndNonEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued to employee and nonemployees.", "label": "Stock Issued During Period, Shares, Employees and Non-employees", "terseLabel": "Common stock issuance to employees and non-employees" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeesAndNonEmployees", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "krbp_StockIssuedDuringPeriodValueEmployeesAndNonEmployees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued to employee and nonemployees.", "label": "Stock Issued During Period, Value, Employees and Non-Employees", "terseLabel": "Common stock issuance to employees and non-employees" } } }, "localname": "StockIssuedDuringPeriodValueEmployeesAndNonEmployees", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_StrategicAllianceAgreementAnnualCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The annual cost of a strategic alliance agreement entered into by the entity.", "label": "Strategic Alliance Agreement, Annual Cost", "terseLabel": "Annual cost" } } }, "localname": "StrategicAllianceAgreementAnnualCost", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "krbp_UniversityOfTexasMdAndersonCancerCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to University of Texas MD Anderson Cancer Center (\"MD Anderson\").", "label": "University Of Texas Md Anderson Cancer Center [Member]", "terseLabel": "MD Anderson" } } }, "localname": "UniversityOfTexasMdAndersonCancerCenterMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "domainItemType" }, "krbp_WarrantExercisableBeginningNineMonthsAfterListingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to exercise of warrants beginning nine months after the listing date.", "label": "Warrant Exercisable Beginning Nine Months After Listing Date [Member]", "terseLabel": "Warrants exercise beginning nine months after the listing date" } } }, "localname": "WarrantExercisableBeginningNineMonthsAfterListingDateMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "krbp_WarrantExercisableBeginningSixMonthsAfterListingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to exercise of warrants beginning six months after the listing date.", "label": "Warrant Exercisable Beginning Six Months After Listing Date [Member]", "terseLabel": "Warrants exercise beginning six months after the listing date" } } }, "localname": "WarrantExercisableBeginningSixMonthsAfterListingDateMember", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "krbp_WarrantExercisePricePercentOfInitialOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrant exercise price as a percentage of the initial offering price.", "label": "Warrant Exercise Price, Percent of Initial Offering Price", "terseLabel": "Exercise price as a percentage of the initial offering price" } } }, "localname": "WarrantExercisePricePercentOfInitialOfferingPrice", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "percentItemType" }, "krbp_WarrantsAndRightsSharesGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants granted.", "label": "Warrants and Rights, Shares Granted", "terseLabel": "Number of warrants granted" } } }, "localname": "WarrantsAndRightsSharesGranted", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "sharesItemType" }, "krbp_WarrantsExercisedDuringPeriodShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrant exercised during period.", "label": "Warrants Exercised During period, Shares", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "WarrantsExercisedDuringPeriodShares", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "krbp_WarrantsExercisedDuringPeriodValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of warrant exercised during period.", "label": "Warrants Exercised During period, Value", "terseLabel": "Exercise of warrants" } } }, "localname": "WarrantsExercisedDuringPeriodValue", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "krbp_WarrantsUnderlyingPreferredStockIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The non cash part of warrants underlying preferred stock issuance.", "label": "Warrants Underlying Preferred Stock Issuance", "terseLabel": "Warrants underlying Series B Preferred Stock issuance" } } }, "localname": "WarrantsUnderlyingPreferredStockIssuance", "nsuri": "http://www.kiromic.com/20210625", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r48", "r82" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r213", "r215", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r380", "r381" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r213", "r215", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r380", "r381" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r203", "r213", "r215", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r380", "r381" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r203", "r213", "r215", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r380", "r381" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r98", "r99", "r100", "r101", "r102", "r116", "r153", "r154", "r254", "r281", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r98", "r99", "r100", "r101", "r102", "r116", "r153", "r154", "r254", "r281", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r88", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r98", "r99", "r101", "r102", "r116", "r153", "r154", "r254", "r281", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "label": "Scenario Previously Reported [Member]", "terseLabel": "Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r178", "r214", "r336" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r149", "r330" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiess" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r35" ], "calculation": { "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": 1.0, "parentTag": "krbp_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued consulting and outside services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r30", "r168" ], "calculation": { "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r254" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r88", "r89", "r91", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r217", "r220", "r257", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r181", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "negatedLabel": "Common stock IPO discount", "terseLabel": "Warrants underlying common stock issuance", "verboseLabel": "Fair value of warrants reflected as additional paid-in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r220", "r246", "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock compensation expense", "verboseLabel": "Stock compensation expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Dilutive Securities Excluded From the Computations of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r134", "r142", "r146", "r151", "r291", "r293", "r308", "r361", "r371" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r47", "r79", "r151", "r291", "r293", "r308" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r221", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accruals for property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized software development costs" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r27", "r69" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r70", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r63", "r69", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r63", "r309" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r77", "r79", "r105", "r106", "r107", "r110", "r112", "r121", "r122", "r123", "r151", "r308" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Stockholder's equity (Deficit)", "verboseLabel": "Common stock" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r201", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price", "verboseLabel": "Warrant purchase price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrants to purchase" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Strategic Alliance Agreement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r177", "r365", "r377" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r174", "r175", "r176", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingencies", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividend paid" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Common stock, $0.001 par value: 300,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 7,332,999 shares issued and outstanding as of March 31, 2021 and December 31, 2020", "verboseLabel": "Common stock, $0.001 par value: 300,000,000 shares authorized as of December 31, 2020 and 2019; 7,332,999 and 2,863,812 shares issued and outstanding as of December 31, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets (liabilities):" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r126", "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and Other Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r72", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Number of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r72", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Stock issued on conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of initial value of issuances and the bifurcated embedded derivative liability" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r16", "r363", "r373", "r392" ], "calculation": { "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total issuances and conversions into convertible promissory notes" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r14", "r362", "r370", "r392" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible promissory notes" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r17", "r18", "r191", "r194" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Common shares issued for preferred stock converted" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r72", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "negatedLabel": "Conversions into Series A1 Stock", "negatedTerseLabel": "Conversions into Series A1 Stock", "terseLabel": "Conversion of convertible promissory notes and accrued interest into Series A1 Preferred Stock", "verboseLabel": "Conversion of convertible promissory notes and accrued interest into Series A1 Preferred Stock" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r72", "r74" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Debt Conversion, Converted Instrument, Rate", "terseLabel": "Conversion rate" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOAN PAYABLE" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r362", "r363", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r182", "r363", "r370" ], "calculation": { "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Convertible promissory notes- issuances", "verboseLabel": "Outstanding principal and interest" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "Loan principal forgiven" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r319", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Convertible promissory notes", "verboseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r37", "r319" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Loan fixed interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r37", "r183", "r319" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Annual interest (as a percent)", "verboseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Current loan payable" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r38", "r83", "r191", "r195", "r196", "r197", "r318", "r319", "r321", "r368" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Loan term", "verboseLabel": "Note term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r31", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Initial Public Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r46", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r270" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r272" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r277", "r278" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r277", "r278" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r271" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r277", "r278" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r67", "r166" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensation", "http://www.kiromic.com/role/DisclosureStockBasedCompensations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "U.S." } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share, basic and diluted", "verboseLabel": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Net loss per common share" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r113", "r114", "r115", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShare", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShares" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r264" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate from continuing operations", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDetails", "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "verboseLabel": "Reconciliation of the statutory federal income tax rate to the effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r264", "r284" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate", "verboseLabel": "Federal income tax at statutory rates" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDetails", "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r264", "r284" ], "calculation": { "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Initial balance" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Embedded derivative liability" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": 2.0, "parentTag": "krbp_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.kiromic.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period over which cost not yet recognized is expected to be recognized", "verboseLabel": "Unvested Shares to be recognized over the remaining weighted-average vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r88", "r89", "r91", "r93", "r99", "r102", "r120", "r152", "r190", "r198", "r251", "r252", "r253", "r280", "r281", "r310", "r311", "r312", "r313", "r314", "r315", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r297", "r298", "r299", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Weighted average valuation assumptions", "verboseLabel": "Stockholders' Equity" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r298", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r297", "r298", "r301", "r302", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r298", "r340" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of Level 3 liabilities measured at fair value on a recurring and nonrecurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Convertible promissory note embedded derivative liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r297", "r298", "r301", "r302", "r304", "r307" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value Measurements Nonrecurring [Member]", "terseLabel": "Non-recurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r305", "r307" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r67", "r184", "r185" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on loan extinguishment", "terseLabel": "Gain on loan extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r216", "r218", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantsReceivable": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.", "label": "Grants Receivable", "terseLabel": "NIH Grant receivable" } } }, "localname": "GrantsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganizationDetails", "http://www.kiromic.com/role/DisclosureOrganizationDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r67", "r165", "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairment of long-lived assets held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r76", "r164", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r265", "r268", "r274", "r282", "r285", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxes", "http://www.kiromic.com/role/DisclosureIncomeTaxess" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r80", "r101", "r102", "r133", "r263", "r283", "r286", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesDetails", "http://www.kiromic.com/role/DisclosureIncomeTaxesTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r51", "r76", "r261", "r262", "r268", "r269", "r273", "r279", "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInUnbilledReceivables": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.", "label": "Increase (Decrease) in Unbilled Receivables", "negatedLabel": "Unbilled receivables from granting agency" } } }, "localname": "IncreaseDecreaseInUnbilledReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r132", "r317", "r320", "r367" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 }, "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r62", "r64", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest on note payable" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r7", "r8", "r35" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalUseSoftwarePolicy": { "auth_ref": [ "r76", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.", "label": "Internal Use Software, Policy [Policy Text Block]", "terseLabel": "Internal Use Software Development Costs" } } }, "localname": "InternalUseSoftwarePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r44" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r45", "r76", "r119", "r155", "r157", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r44", "r86", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "verboseLabel": "Reserve for inventory obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r156" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory obsolescence impairment" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "verboseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Lease expansion" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34", "r79", "r143", "r151", "r292", "r293", "r294", "r308" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r79", "r151", "r308", "r364", "r375" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r79", "r151", "r292", "r293", "r294", "r308" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "LOAN PAYABLE", "verboseLabel": "CURRENT LOAN PAYABLE" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayable", "http://www.kiromic.com/role/DisclosureLoanPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r38", "r180" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input Expected Dividend Rate [Member]", "terseLabel": "Measurement Input, Expected Dividend Rate" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Measurement Input, Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input, Risk Free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r65", "r68" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used for operating activities", "verboseLabel": "Cash flow from operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganizationDetails", "http://www.kiromic.com/role/DisclosureOrganizationDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r49", "r50", "r53", "r68", "r79", "r92", "r94", "r95", "r96", "r97", "r101", "r102", "r108", "r134", "r141", "r144", "r145", "r147", "r151", "r308", "r366", "r378" ], "calculation": { "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r94", "r95", "r96", "r97", "r103", "r104", "r109", "r112", "r134", "r141", "r144", "r145", "r147" ], "calculation": { "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common shareholders, basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Conversion of accounts payable into convertible promissory notes" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable Other Payables [Member]", "terseLabel": "Director and Officer Insurance Policy Financing" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r134", "r141", "r144", "r145", "r147" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Leases" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Future minimum commitments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2022", "verboseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2024", "verboseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2023", "verboseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganization", "http://www.kiromic.com/role/DisclosureOrganizations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Commitments [Abstract]", "terseLabel": "Strategic Alliance Agreement" } } }, "localname": "OtherCommitmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Non-cash interest" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Nonoperating Income (Expense).", "negatedTotalLabel": "Total other expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromPreviousAcquisition": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.", "label": "Payments for (Proceeds from) Previous Acquisition", "terseLabel": "Aggregate purchase price" } } }, "localname": "PaymentsForProceedsFromPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r61" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Issuance costs", "terseLabel": "Offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r221", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDiscountOnShares": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.", "label": "Preferred Stock, Discount on Shares", "negatedLabel": "Series B Preferred Stock discount" } } }, "localname": "PreferredStockDiscountOnShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Annual dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value ( in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r25", "r26" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromBankDebt": { "auth_ref": [ "r59" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from bank borrowing during the year.", "label": "Proceeds from Bank Debt", "terseLabel": "Borrowings from note payable" } } }, "localname": "ProceedsFromBankDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuances of convertible promissory notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Common stock IPO proceeds, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganizationDetails", "http://www.kiromic.com/role/DisclosureOrganizationDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r58" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Series B Preferred Stock proceeds" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r58" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from Series B Preferred Stock issuance" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r58" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from warrant exercise", "verboseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r59" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from sale of convertible promissory notes" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r58", "r250" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r30", "r169" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r173", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT", "verboseLabel": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipment", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r29", "r167" ], "calculation": { "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "PROPERTY AND EQUIPMENT", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r169", "r376" ], "calculation": { "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r28", "r76", "r169", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetTables", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r167" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property plant and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r211", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Consulting fee paid" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r211", "r327", "r331", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r325", "r326", "r328", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactions", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionss" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfBankDebt": { "auth_ref": [ "r60" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to settle a bank borrowing during the year.", "label": "Repayments of Bank Debt", "negatedLabel": "Repayments of loan payable" } } }, "localname": "RepaymentsOfBankDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Loan repayments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCurrentLoanPayableDetails", "http://www.kiromic.com/role/DisclosureLoanPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r60" ], "calculation": { "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r260", "r397" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r76", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "RSU" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r198", "r254", "r374", "r386", "r391" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureOrganizationDetails", "http://www.kiromic.com/role/DisclosureOrganizationDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r88", "r89", "r91", "r93", "r99", "r102", "r152", "r251", "r252", "r253", "r280", "r281", "r382", "r384" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTables", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "verboseLabel": "Schedule of tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTables", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r105", "r106", "r110", "r112", "r117" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the effective income tax rate to the statutory federal income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r220", "r245", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r220", "r245", "r256" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationTables", "http://www.kiromic.com/role/DisclosureStockBasedCompensationTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of future minimum rental payments for operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r30", "r169" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r81", "r329", "r331" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r221", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationTables", "http://www.kiromic.com/role/DisclosureStockBasedCompensationTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r227", "r237", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationTables", "http://www.kiromic.com/role/DisclosureStockBasedCompensationTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to estimate fair value of stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationTables", "http://www.kiromic.com/role/DisclosureStockBasedCompensationTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r40", "r77", "r121", "r122", "r187", "r188", "r189", "r191", "r192", "r193", "r195", "r196", "r197", "r198" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r76", "r135", "r136", "r137", "r138", "r139", "r140", "r148" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Data" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A-1 Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r66" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested RSUs at March 31", "periodStartLabel": "Nonvested RSUs at beginning of year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted stock unit activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested RSUs at March 31", "periodStartLabel": "Nonvested RSUs at beginning of year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant day fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted average assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Nonvested Stock Options", "verboseLabel": "Restricted stock units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Authorized shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional stock option information" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable at September 30:", "verboseLabel": "Options exercisable, number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable at December 31:", "verboseLabel": "Options exercisable, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Cancelled and forfeited", "terseLabel": "Cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value for options granted during the year:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r229", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at September 30", "periodStartLabel": "Options outstanding at beginning of year", "terseLabel": "Options outstanding, number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock option activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at September 30", "periodStartLabel": "Options outstanding at beginning of year", "terseLabel": "Options outstanding, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental compensation costs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r219", "r225" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r76", "r221", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r218", "r244" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share Based Payment Arrangement Employee [Member]", "terseLabel": "Employees" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r216", "r244" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share Based Payment Arrangement Nonemployee [Member]", "terseLabel": "Non-Employees" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSchedule2017StockIncentivePlanRestrictedStockUnitsDetailss", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Original issue price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r242", "r255" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationStockOptionModificationsDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Share price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r13", "r362", "r372" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Note payable" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE PAYABLE" } } }, "localname": "ShortTermBorrowingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "CONVERTIBLE PROMISSORY NOTES", "verboseLabel": "Note payable" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-term Debt, Other Disclosures [Abstract]", "terseLabel": "Loan payable" } } }, "localname": "ShortTermDebtOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.", "label": "Short-term Debt, Percentage Bearing Fixed Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "ShortTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-term Debt [Text Block]", "verboseLabel": "NOTE PAYABLE" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNotePayable", "http://www.kiromic.com/role/DisclosureNotePayables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureConvertiblePromissoryNotesInitialIssuanceAndBifurcatedEmbeddedDerivativeLiabilityDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetails", "http://www.kiromic.com/role/DisclosureNotePayableDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software And Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r77", "r79", "r105", "r106", "r107", "r110", "r112", "r121", "r122", "r123", "r151", "r190", "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareDilutiveSecuritiesExcludedFromComputationsOfEarningsPerShareDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitConversionOfConvertiblePromissoryNotesDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInitialValueOfIssuancesAllocatedToSeriesBPreferredStockAndSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityTables", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r43", "r88", "r89", "r91", "r93", "r99", "r102", "r120", "r152", "r190", "r198", "r251", "r252", "r253", "r280", "r281", "r310", "r311", "r312", "r313", "r314", "r315", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r88", "r89", "r91", "r120", "r348" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r190", "r191", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Shares issued for services rendered", "verboseLabel": "Shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.kiromic.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r190", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock issuance net of issuance costs and discount amortization (in shares)", "verboseLabel": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r190", "r198", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "terseLabel": "Exercised stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetails", "http://www.kiromic.com/role/DisclosureStockBasedCompensationSummarizesStockOptionsOutstandingDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common stock issuance net of issuance costs and discount amortization", "verboseLabel": "Issuance of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityPreferredStockDetails", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercised stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r22", "r23", "r79", "r150", "r151", "r308" ], "calculation": { "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kiromic.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r78", "r198", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquity", "http://www.kiromic.com/role/DisclosureStockholdersEquitys" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split (Reverse stock split) ratio", "verboseLabel": "Reverse split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityInformationDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent events" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r316", "r335" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r316", "r335" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r316", "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r316", "r335" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r334", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSubsequentEvents", "http://www.kiromic.com/role/DisclosureSubsequentEventss" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitCommonStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.kiromic.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized tax benefits, interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r127", "r128", "r129", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetails", "http://www.kiromic.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonvestedStockOptionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]", "terseLabel": "Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants fair value" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitWarrantsUnderlyingSeriesBPreferredStockDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityWarrantsUnderlyingSeriesBPreferredStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Valuation Technique [Extensible List]" } } }, "localname": "WarrantsAndRightsOutstandingValuationTechniqueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityDeficitRepresentativeSWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityEstimateFairValueOfWarrantsDetails", "http://www.kiromic.com/role/DisclosureStockholdersEquityRepresentativeSWarrantsDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetails", "http://www.kiromic.com/role/DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedEarningsPerShareDetailss", "http://www.kiromic.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kiromic.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-07)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r398": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r399": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 173 0001104659-21-085768-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-085768-xbrl.zip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�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
_%T[BY-$06!^K%R0TSD0B7R?[C*_?[Q\3W?"<^W#OR48\4+1>(DK2[L;9LA\?F+LE#G]0 MKK$NE%9'[*-86_G*<&[MA7E"C,%%%'H^A .) M.H!LZX#4:_25+9-IFEICCR'UA!\UB'2X".0E&[QN(<34R2ZCFD)0)[F+EO1M MAI&65#:(2Q^B,'T.#AV J;4'9F324[> IN;FV+%)4_I1P6DK9+"/3B,;(R./ M#)^L*6UO!2(2@AB7AK7N<1NDB-6HDKP"J31 O *IE[/W],C3K("<]65O_]2U MTB2AIW4,,Q(KY"XPIH$KR30C\$'LD*.JVWO[%!B2\Y;\_(@Y\5(!VW?+"FQ'"R#W?G/$Z MA3"M5!%CB$'E!H4G+5=#6FZ&7-M^IPV!&6_@9EQ2PO5Z5[MQ8,0>+S1^C-!; M1)K!$FZ2/4P4,\1V_I]L3^B6U_!Z9]KJ]2Q>*]XW&-0(\M?0?XUS0).:UF:# M138IY'NH0K"930MC6#8WR*[6(!/#X&.[41Z/C7+U9>?'O+$P29/1#=&? P": M-.4)^ID@CAWZC.IH$?=*F>R#'@J;2@9! 7I]9@+Y!>C]5L3T3"\*8>VE_^)[ M-/3NG%19.6("OG, R2E,;R1TU&6*'50GT=TBV$H5WB1I.0AS>4DN, &)9Q9^ M3O8A"FMYN;4./@ULXW2R8FHSB\2^2]E4Q'_79&)%^SG@8I.J)WA6UQ@[#C7* M/ @_$B)(+P@G#C&7 R+SCZ>MF0'-"T^V1XX2;+>_.8 >J7K^,Y_>DZOOM#8 M]1/*]2W^F&1_352[9'UI(7?H02:J/ ;?AQ!B(!BF3^]W9X K5 G)2$-UG=P&Y(T?$B\* B=. M8!%+$@#C7J_RFL'A&PJ5@*,MA>KJRQ?'#Z JVT/$(LQM%/*CI^0EMQI"\ 99O2<&4\)=I@2V1^2[X MBVON.!@;I4[0A"\VS -/%! G36/_<9_FAG&%83BD%(9Y!)[\60//#_9L;8:A MK.HR3'TNCO]"[^%-.?[.W-47-]A[U!//?VYW>W%U8[VY;55# M3) CU3A&K:^R:H(#8IP;25$3]59E@4@I$LS.]\P>3U#,< 17&>QI?MB>)4W,TY^M=T%T8%2O@82":R--U6:VB-W MZU95JT\3*QHC=N1VF7L?&F:4*XG.EJ^DC*=M8S;WD *,-&:N?W[+VM XSJ[2 M9)N0#648=7HA=;V.:I-^SO;0IZ[- M.+XQE"KGF_PV*S7:5Q_;*D)[Y77=V[Z"A\:DETWF!#GX@W:2,$F]36>+DN)=OW$^4T'[=>-CU80&P5$0?KW( M>*2?95A<$"'/+!'1D"EOHQ3*=CM!<""%29-"'(L9A0QYTWC/WX5:A;=Q],2^ M0GV=1LTNR#%)1^%*&F!#>\0(HB5V[Z0^B3A9A20G;WG[:3J=_1#>W>7D+;ZO M$T>PQW" RDWI,O2N_MC[.]@!^26.$N4#3VV=D+NOGM*5]W@:>R!V84W!>T]) M&?D%+V26\F2G@L6"<":67O#!I_B$RP[7W6_W_)WO2RB%Z_H\,F$_!Y1?7 H] M%I/$J?]W<4E492M5.&2./'*D,&W(ROK#$&W$Z&- V4L7)%U4O-XMK/PEKAO0)A&QB!&U5T!!^ %4">R/0),%B0C(6E38AI MU&9C+=D'O+X-P%VT3Q/?@WV&^,5W;>XRY(D!=Y2#S;7O//H!W_EH]FR=?LB= M6UOUNE0792?$+JXO^]#4E[-8L" 2CW$=7>/>W/CJE]Y>EC.PY]J7]#%=\:T1 M"$R:[IC4MT3NO@WJR0Y;TPRQBS9):^+>Q744/IVQ27%+@!,I627VKU)4=6^X M 5';<%:C577?X+35;,:JD>S^HT%I/:N_JF)K-G]#\UD-S^;L?57;V0Q5@QGK MQP,609;^5+H:R,I7I?Z>7T=.>.L1'$4.B]^O$_(TO<6A*U!?+K)]C[9D(BVOILG M_OW-6^)X6R9?P@" T7X\<,(?O[W_EMQOG2 @Y_O$ M#^&H=YFURTI+"D),H6_>3IW)/,GWO"?GXE,U?2";"N65&1U M:Z3@K*FF.E"ZGD'>;YO$QN+Z:]OIN&-IFFTED0 0:><<8$V-Q2??.VYS\FM# M\UEYY:FB:KQO[H>OOG( XM=]RRA?^=J)R;[+>@+H*2]0T0PXY*L6J3_=5VR"& M&*6H ]99&4'8> :2ME[C,ZP87VS$!54LL_L#C;=ZIPJB(7+W4BO7<+K#6B%V ML09ACATP^*-6IULX<8JA!VE)(6"^9?[N'C1 M2W1AP9'*TD/#C),T>S+C<'V=]:'5 ZKWZRA9'(XVML1^)Z G?>Y7(QS>$ MYQN@3+*0EGA[*FZ0\@,2<%;6Q ]]N"9)7"=Y9N&O2_U=.O&!PKC6.-ZDY/2+ M=W48!PN'!^-JG '3T:?'4%#Y_CF*>;P%!M KCUS;!2F,=5&XOG3Q:7O$ 8>6 MV";2VSAY*;_->DY;55_&K2&M3=46^QAN4K'Z1E--0\RCME'>WL.U.D39BIU1 MMI[H=J)K8YZ;NO7%Z?+-Y8$J(H!:S7';5153YW3>N%9 MV#1*;L5I\IH%Y7'VR-U54^W**S7-71"[KZ[D0S8>$Y(1)9Q#_B_; MY4'&5OW29^M5YIH\W6Z]V?@NTYTMJ_:Q$\++B%'@NP>VW@O9/_WP"_7MT]K,ZOK\CMW?K#ZOY^ M??=7FSA,]IP[L?[^'/6MY6US'1%I4 MY@11^F918E<[B;F 6@=-C 7A)4^2,26<:_5 "0$03F"1HT=T8>L?)Q[T18T0/)<8Y5EX0P5 "#6QGR\8ML@S#O1.49\MO MG(0X<*$)&)R\Q6LG=V94 U1 L47] 8?LMW'T*&I&'$KAUYL;^B4MUHX70934 M'KAWZ8P4[_H9H3B(U^Z)_5"^NR(##NCSR"?:0-9ZSA?^&3)^9),S)"YPG/A M?D)+2+I+5EEO"# K]VX(9V?AI-Z.*13#8#P,O-H^4L^#(GFQ_^) L>Q+/W'A MBD'-^E"O!V:TTU.W@+CFYMAQ35-Z,V#F9:1)%!*:,29>P7EB(!M9]9P\*>F3 MG(&%Q>ND*I??M/SF(DXC@T%JC,7LA1/'!X:D'6Y*GG1!"FE=%%8O4:OM9[,H M58C=/W=.KJ1EM2KWJ'HV79L\(^Q?>SA#0W*#TK#NZWV:I$[H05RU*V]4AF4> MM\'(2A@ZX6^=+%V.D_F9*%O?1M)WJ+E&V8\"4I@:8(XB$NO6'7MDUE.;ON/^ MX9EF]X8A4G,RAOEI%12S!7;B.D.4_Y,CA,?83QRZ36R;DAW8)F=8Y%5PB\B8 M.?W%5_M6.1DQ)^.D[0+^E 60C\/@]XX?_^H$>[9Z/_WC#4V7CU!;R5571AY M$"DBFS-6M99R7VJ(@TX#2IE<<@59E>.#\4B%X?^I.GE1Y0. 3/4-7S5*]:"$ MU$\,F.U5L"5U M6U<%9S&Q'SVC;2W:L6BEQB$CK)2].KY\UV:O .JQ+Q?QK'62[* ^6S">B@U;;B,K6:_4 #!<,Q$=>'*'2PDY>GXH'N_BU]Z7 M&_8Y;Z*4F76]N8!-S"!0.ND 6IA!=:B)"N#M2P@[. _6:TC NBO*,Z3^EH$X M,(/M$@ "]DM7XL=0WDDYU',W(G2S@2K#+S0X\&)#(#5-)L9[:\8K&(O)0%3% MRGAG!6<(YTYN"FO* EB8/*S9ZM;T(#.(X/ 6(J55TV3E+^ 9^ ]1F#[7&5.S M'V9D[J)Z@<(ZG; C;B<=S&P'I%'J!-F8+FI6,@'(%IA)9?RC E=XXZGQ=!+3 M""8+1V5DK&.+IRS6B]9M/Y8!5ZDO?[=!_3 M#W[H;_?;'(@N][3EB+ [%>1^V],LLD=W)('8U_MJ8@X%!$N2\2RG;L:5_=%/ M7#:__94Z;!YW4O'BT*=<&DOWR:>V66:A;68A-]IN_=1R.6]-&S2_R]R9R.M MEH87F[M1F#^NF'K,N".L\&LX#Y]I\$+%\L!2,NS$5F*^_(.M0&MZ5=^A1\=5 M^/ Y@KE-536G#YW7@9&GIND!DR61^2-EC2ZC@^4"T)+X(8/*B,=@N&'2H(F8 M7_^('"G-:GLR+V $2\:5FH%+F=*K I[,E4@!,_WS-Y&L%,F]%J@\\0XO9"SH/(:@/-4F>EP$WC/ C;- M&:D.-=&AR#!SO1J\& 2\T>&:;?JQO%_.#,WX/]F#N]1O& #J?WGAXO 21+- M!VQJ>B#W;@UU%<_7'#='[,4Z4O>N=2H_7L/O(CT>"*=O_.V:)$ZE<O7,H1S7S=WG,N(UM1CF M"^N*+P!+(O,D#Q$17"T]BF//,D"9'-5-\V>?;CY0SW>=('NWH_;%F];& M2#U;3\GR2KBJ)?:D[G;!#5QT],--%&_%306XG<;&(BR)H/((L"=;P3^[2A=/ M?9%[-!-PRB0C73QO8^=%G[%5_; VC2Y9<=9"TF7H\=\7"U8]W.E,!CTB]3-, M%:NZT9@%BO54:0)\*VL 9PC'*]6)OY4W5RRBW\2F$[A8,"V0D;$EXF_EOAD6 MU)S:1._7?)!;!4YV M4&,";$PR:;+BG;D\&1K: ,,)["- +F?$<:]DA0;RIC#$_:H7OIDY$_@E=L*4 M\E=/]DG#^]]U[9"B7*MJ\J[_22.$NTOMLO8=>QE%(DA:?^B[HF#C(]_U+>]N>_)0_RRFX;GGJ6]46N9R_\CV.FIS< M[ %)F<;4A1H /DTNG""@WODA:Y=D#5M :0#5><#74+/5 %U?DO@A<;!F M@\$SHTRBF'#2"R*DX,!:R$&$()!NEXM2]+"4(F_;@H4=THCLF';/[+IS]S@HT[T$?!!8H/(\TTJ7T*<6M4)=T(@ M&EHER9YZEPS4PB=1@Y0O_Q+Q^_=1?$_C%]^EJNBC,Q'D_M[/*)5=D4X4$&-! M3T4&K4>(H$L$PZQ(\(((GHO\KQL&&CE?2WLD$]N&T^7//&;J)QEI$E.HBSI] M&7ITEC"8.<$S=F'[*TX/#PRQ$\>%T] +)WF^B,+$]W@62!2NPJLO+#X+GVBI MHA"P[IC5"%6D\&G8;$4JQG"2V+,T#&IHI@RSRSC#*TPE:[BX3#/FPN7:X0A6 M=+%0C>Q MXF3.Q"8-1.!M+P,.''JE<FIHESKBIL,;_/-S%_AR5\6KG.=ZJ8 54.D M*-6N7!%7UK;"'BHV"]UWS)7;\B] ES^QP .\B2.VL;7C=/FS&9RRA8AJ$@TM MGA'P0U8.89=P&96M! HM(9*[=?SC5S [=D6*.WT,4#DOT.B'.#+J)/[ $WS. M94$*/HO2H;-5%7"S='PPA1URRFQ1?:JG%5^_<'9^Z@1BR7='82> ;_F)VD*P M PAOE[7;3)O.?%"@FVD4D*!'9![XT%$7,V"1,4FQ]>8C; M^AM2)\.G23US8;4S@6B4\^9$D M4!ZC+F3J2@ I-O0W1K%BZ=0;^TJFGS(&][!_% MMW'D4NHE[YD_,$N\^-$^6;I_[/W$K]D\ZT4 N^]W-D8% ;1[8\:![DH,WM^# M'?\W.3>^%?J6Y R)Q-$2*$QGD>734TR?&!Z4MRTMKV@NZ6.Z"I,TYIOHJY!9 MBR8I(.+59D/=U']ICPNZTD .$KU,(N-$)P*(H:*?'KVS#1@W4K);D)QA%CL4 M/*U'$=/:I=3;SPT"$05YXR3$@0PZ8'120V/J(X'4?PQH-;R2]U _[J*PW&1M MW(7M2@DYF@PPS^F)0B\3GQ]HS:!&"X-D2%5D7Z[#V M>K5V)_0XH:-TTP9HM0=J%- 2W."FI^ 1_UC7*G]2:@<\IT$K\M^IV'-E3Z= M9R[9\^GK*'QB&+B%M=H#8]90A%W1%+G_-BDH>VU=.\2^VBANWW$*1,^ *@&R M"P*$K9=E/]:TL3*[LO',1JFZ/GM]RQF-5$-%S'.R?*AF(]5JI?81]3SU2>LE MVQ69@!?Y>K=CCFNE'W)?U59=(].U[(38@_5E'R/?]4*UA6(UY=6@\F6.4+:? M-&C32'7KI]AHA\4K;-S!/OR1SLTMD;JEAGKEA9W:9NAOYC1+W7L]5I#E5W X M87YD,O5EFBG4$X3Y$9F-RS'CJ'A1?C.[)^,E2!:X6![\U0!-U[Y(H:>7"8Y/ MP%L[(HX,NLD_Z,2[9+,H0X+*.?CTOCVM&:0@R:C')W$J>3O[U[&GLU_]#=Z* MXM6N[AF0.;$?U6P4-;5#ZL&MJH&W*ALA],QV67MO8F;$3&$Z0V_C/G',-E1 MU]_XU*O=!VIKBWD8MJE8#$550ZS#L57>P4-2(FUI%V@B18=L_"A6AMFUBZLO M+$;U$Z@\<4Z?_! >";[WOWR(PO0Y66Z8XM=^PJ]T,W!1OU(]B!I2[S1DIF(5 MVI\4]I6J /N9@D\;^0+1>4." IIQ8( M<8DW_>K8HDGSBVD2;U(P)XP[$>P)YT\R 0A(8//I;/L62\I!UF%@38/I-WY( M#8*Z!KF9HKJNH71@O8W6C'%=6S7;P!["DY$S0?;1C=H,[> Y/>C[K@<9;Q::61C>DR-Y5<7E'MJT/PC5V9]$'.P"4V1(L MY ?B%@2XV-F!G4IW*/WN9Z^#I#7:&CJAK<)+'CY0)]G'5-S@ MW.W;DH0;FB/%)%U%Y2A!U19Q=- J%("G']V4>K#SUPD":CO.S/_5 MRCYD?G\% 985"V S]OE,J6]O+Z6P$R]7VT,'10X M[3U#-&A08@14J%3P10H/4UADH3 )SO/O7YU@ST]P'JC['/I_[.G5EY2&"13V M@0R"'L>-&B218XH)@^F>J;?10XP[1M0:[2R^D( 4(I!/I1 \H\?B5E^3\8[A MJX?]:TC,V.E4!M%ULN/^,W4JI1JC.=')[(;387K81.E%*K+!1' RO(Q26/'U9[?E+WGYLG-9FATZOJN<_+O M%@U,NCJP(B4O\BGG9FE=.K4MS-^H*44798!^@5]2[TA?O1Y(O;:#NL=77Q3- ML6=J:DH_O+Y3<2OE29"V<^%D+#UK$*@HXI7QL'=C9/J/.]IU/O%B:):(NMZL M0C_UG6"]V="815!U3]7V)C(#B.IN%,6%/0T*,P&R'@KU'?X/S_0D_5P\U43D M9U>R_&UQ?X^+P?XIY!"MK5Z]F$0QZGKXO2\>.D/K)/Q)3EC&R\36[+.U8"A M8_EI\'.F@'<1;73ULR;_'>L[4I[,_299+LMSOH M!?/3!YH^1UX41$^'EJ7A-)R1HK\%\Y^\DCXN6\3+V2FU[UTM!P0X@Y\](DM) M)#'A]66Y728JX;(N"$C+CU HD>3ED:TDL?4%]1R^QF\4PFYF8N>%QH#F3LGR ME6!W;1(NFZVV>]7EZ@G9?TTHKO$A1H/R!MY?"Y[KF =J"NSVAK(%^P_^I!OOHAI@5YP?NK!ODC$\P*Y(7L MKQ7D#7T9-J\MJ!_WXQ06?"G(O[:07F' Z8+Z-@'^@?93!?:-W+]RM,@_:N) M[L?]./5HCR*V?VPWX&,7 \+M5=7SE*,RG .:CVKL$_0>A1MVM!Y7:Q'%3_\5JD2*#5A)) MY^-_C8+/UP.G5=..A*2"R=Z(L//!1'RC0*<.QK[D7<5>A.!IR%3GSNL M(V1AI^2>.1ZO$T-^_'Y$$]VG3IS.RT@981))SUX+ M$M;ZWGRF9'Z)+%F%MWP4_Q)'B:HL_CB<7OFTW&!>DQ-S#9M7/#4W:8MAA?KIG7RRWS$CFK^?TRE&SP;PF4;.& MS2M&S29M,:"F)%\)G68Q\R=AY9 ^.0Q^QD3-,8Q] 4N:((!K2*%'-H+#U 4) M7H&!YC/-2&^$CKI?5L?GE4\Q2M.:G&!.F+SBZ46M*X;)19)NU/VRT7'3O)GS M;0TJO:-\M&_V\RBV>J'Q8_0*K#7_32!IKRR_ZKP4-YTK!33@9&LSU6&XOB"O M?*;J_W%&.OK1E.(5SW4#C(%A,JP<'A6U#3(-CLK[S+<^A+UO=5(NHEI6ZM7/ M$W:_Y#]FA*//8&$:^ ?VSQ;P7T4:P:A?YG4G%XQJNJ\FY6!J*R[(Y]D&'4FG M$\@Q @^C$LP]^##_.3H%(.;8SSD(&<$*K_>POLU8N3VL8DA7(5X[C/3Z*$:1 MI),$KQE,^AEBS(5-TO%,WXW]<4*&: VK2QUSH'3/VE7G-&E843#'WN M&[8 AA.,2O[6/+$=R5=1I'M=4C<[R'CW&K*]IC;AG/??AVPU\C]>.BDMBLR, M]&V[2_'*I]">GV6\6X>M(KSB*;6O)3!,K:>W%4_F5]Z$@ I2@:QY3K-3?ZF3 M7##^M";QP);E^]ZPM,K*O!2/;Q)OSU^(@V?CX$S\9%J>SQ2R]#P??G""\J7D M9*SWX31YOO+I0#1H:O&/KU],8 ]*6DTH/JR>P3?,?] )+1$KD8EQ\R MR-YR46=86[8U8>F.;AT?,K(NHI ;2'B>^. MN2G4Q&\.<\.8IA[IUD>5&7:<'U5G=&A>R#GG#9KQ[%Z+R\[34\S+P<"C<)GU M7NJL-Y^H7CH&J5K0^(L1.@SG@,.C&MMD**[FAAV)QU4: Q17CJCQ0#%.P]<> MH6+$8O>9>ON KC=7VUT0'2B]I_&+[U+%-!=P6=A/Z\T==:.GT/\[,RT_:[B( MDC1Y $U5GVLD7M@1>$P35\!W#$:8<7=4?4U ;@&E)22)IW;")$LYO'!V?NH$ M(,F"++?1GK7^Q 4YV:VVL4S.0;.4_R8*:6;M#U2K9)L>#>Q.W,/W/W???_G'_[$ MG1]^TZC%>V8T29.DUOW[4T$* /- A#0DX1E$/ B=P_"\1G3S%<>_L(]W3%5 MJ$CG*T%5ZO0C;;TGOD55_@ZBTF77WS5PQ3-/9#B9@=UY3"IH3GBH$A'ZKY#5] F M!7&24R>?@+[%98)"Z\L(#OZZ6:KH,\_17%598SR+#O,;T4=RCS"F!0=+03PV MK:?SY3L65C$_>%Z&WB5]H4&T PFSK8K&A;Y>3^1^W4%]V;LUNB'V\2[2]X_8 M!0_"F!")2[X+9GG5/JD)8+_/*[G8<_9?:$AC)V!*+[TM6S=!*FGJOU ==]?M MB]SA.YE =GFMCHB=OIO\O6MJ"2[4D6D%"JL:/ \ M0SR*LMXP#9(H3!ZBWYZC+5<]^8W&M"C_4K=-V:$O4FSJ98+BQ$*W(_9SBLYZ M&#B=@#NMXM$K,&73 M4;IY5DA!>@H#FTS1K>.#.)0<55T,:;E"P/S1/T 2(>0\4W)',7>>C/O"B6/( MJ^MX=>26*?XA\OR-+X+S5>C&O(,3R)0@0F]-3QJ5]1PP=J(/8.1^6@>^V#%X M*O5'6^.#,$26!FY!%/(0$,)VZB%B\\JFJBSZ7=A60+X=>A.%8N[@9F/+@1H+ MW43I7VE:;IKP_8ULYAFR)6. -W)4GO03=-Y0'_@G:JZ\63 M"_&UXGGC1YD$V&LE^!H1OMD0TT&]$N*%@+SNI"3B*X/\<;Y"7DCH+"_E(Q[I M)!'[)_G\[+O//&@G869V:8[P$SXGN/"%TH@\4NF/MJINS\SZ'_,1GIV%')M1 M? 8X8"HK+'T^_F) OX@OMP,=[RJ.X#+??H(UPJT@SZ*$13N)<%KA.AAAK"(WT)P(DE. MN.@L '3"\A"X$+\&\3^!2B33R7IUA%E\N#M&,?;Y*D;L>NU9=$\<-_5?F#2O M>GX0P\?>9RSX_V-6J'Z*B2<$P?SKG@N.;###:6 4M!>;"E>A9QGQ#7V>#7]7Y\-Z+U[E,G3E^K_1[IDQ_RC2D6A<#3/J]QQJP^M#3Y5SQA M_]7.E_4?8IKILLK[JYPM%2; /UD>OPOWVE9&AC_,+^**RFN$_R&F@?(J[Z\2RA4FP _E0O#7"^6&/\RO<[T'T6JH]U&\H;Y-,*^3X*O% M<^7GF ;23]A_E:BNM@)^8"]D'PO;?Q)?)N3/,EC:T#+_@8K[R;P>Q2:G_QH1 MO]A]:GWJ&L7)=TB:H)=E7 M.5GU,A#^F4I2ZVN=I";]LNB.(,7K6P_.EZQ6_SD-Z<97UJU23SP939&N'B>YDU&^ZVMLB4CZYHR77=Q].(G_FE9G D+>&TV%*Y5 MTD+=.P9#%U&8^N'>#Y_6.QIS $RR/T&ME=#U U_ 8G:,IK"A.>K(O=ZP&2NU MM,R01HPJIC7LZYF%'$3"(^!'J@QY<2L70J"1CY%UBBLAL5V5+&SL0H6D)'72 M/4.N ]E0C[_$Y9?H%X-ETX@WI(7I\[]@@\0CNZ7OA4+WN8:5QIT^5E?*LX3" M7N9KA\%.9&<'@?VT&Q_^G)1DHI!"EN-.!4A:*OF'P*"YC4H4K ,VNS.%'8M( MLP ;2U7[V*Q%KF&BBV?8!UB%EW1#XYAZK-$R26B:P+)=&#$(HL^P^A[P(;IQ M>04S0@^S=IT=.K"8^4S11]/Q9PTA%9Q5Y7+QMD(R4HA&"MEF,(5,:>G2?B^% MK9R<.C;0K%N!#%["S!7JFHS1;ZD_.X!J5&*R!3LF(!G9(L4*&P8H<0MF)"JX MC6,-J-R,SAI'VP[VT!+.E**0GPYM3B:-EMU4W;[(,;*3"61XU.J(&!F[R=\[ M3"BXP"Y<7:AE^_++-'8H-.>K3*'Y&S8A/+)9(?5I\O9G>RAPHG4&>N'3=90D M%TX<'S;B9HXJ:.I& 3DB]#"'C L=NB-&ASY:#/:-$A7@U::,'P&&I,+1#E!, M:9(;FN:A$;- !9P)0:(L(+]D/\N.YJN)*J$7G92G=1GLC0\4CH2J[FACT$# M-\*4 3YSPC.3ZAH%/OBY^$,FVJ*:#@ BC_IVKJ9Q-S@3\,@C;#6T'].<*6CAE$8RAERL"E9 M9G]' BMC6D72V:G5V29*Q"PBU#92UGAVGB\KV>SCT')6WEP1V*S? FD[>ZDC MJ2D>GWT"6L0[W49!Y);:A^ZOXB"]Y^'XO ^\ISA:K?7KFA-I6[7OIK#!KY@. ME26%K\LMV]L8=FC2PRU3,641"-RXV<%5FW:S:5*9#P!T,8L"#'1(S ,8.FEB M!"0DC@N2\V0_ 5<>P!=\$6#&).;)*7/MJ4I[B[&"9(4;JKT%>M)K/A#1I'9C M?%#M,@$:)3<:%S "".)]@UK"T<@->%^]=34GD.K#W\>G,= %?BW]T+NT)IJ MRP[=T@6Q0^M*WG>(-YUQDD^S&:U71YA$KVLYJS!Z);';4 M"N*6$L]PZ#KA$H@)E:2^>Q'MPS0^?* -3PNKVB+WSD85*XNW-$ 3E)NG3@]/,1.F#@NOWQV?JC\I6&'L2\MY)X^R$25 M6J)]""'&AV'Z],ZES;C"I:Z,.N'DB(#UM-9.!:FBC\&A 6MT- MM::>CL?]'C]R/WKW_9]_^!/W(OC-WZZVNR Z4%J[E5G? JG?-*@##E/S9\N> MXD4N+VO-53*6(W.+'?[ %SUIM[RMB(>D#)/H!]H^533/F["\?NVJ4?4G_MK'H1&NAT MPAXP=-+!0!@!A:9#SA,V49*,*]3&RM@2I^ [<30QB2D$$[+>D)P-*?F0DI&% MT&-*_5N_O4%84X!SJ=Y[2I-;&O^%V;/.+AW[8X:Y/J8HX*Y+9^RPUTL70_ G MC?<-X$?9']F?-CD[GMY,?Y8GO G!L*)C:,(ZQ8R, )'*"!)@*<%;)S4)!>5 M 5*,C_$A\8%U2IZCP,NG E 'U/H0A>GS^RC^[=EWGZM*+V-Z%:9^&E"O@^&& M>(GA&8"P4004Y=" MY=2C&0/'=&#?X,J)HQ"-E.$VEXY/(5P^> N1< E/IADF),FEQ#/5V#;W@\: MWC";?N8V/8YQ'&93JK"I];W(K#97\IXAN'P8^IN?/LM=NFW^=*"*="XS;#:- MC4Y=DO/;!^VLV0BPF,L@RI'+4I#/3(QJS@JJC=3)K'<<>K,5F<4$N?UC0O_8 M,]R\>F'_:+VSCTKB!).U7Y.V;&:C%]# IFZ M],T:SJCH7HLL;'1"I2M)W_5:-N8 ];4?GZC5IT1IFP\KY%K*(%* M,7:MYHEAT=::KS;>FU6UG9>/JN_-UC:1\ M[%_'CL=^]3=^!YC&?#/RQMG6Q7,-S9"Z6YMBX&FJ-@B=K%74_FO?DB@!JJ;C M-:TA>$=WS$K/3*(BZ^!8V]J8K6M?Q(.ULPGR$:S=$>FP[B[_@-.:C%.9M*?2U'G#@?$VC<+W9^"[]R[>_?ZN^.:!HA]196U4KCFKK&F$_:&V4 MN7^5'M4U F!'!#_RYB_?_L>W;R<^YQQ%7UDK(&OS;L'H"HK/9F_-"$O7]689 MQ_!(,XSMAOU(55ND4*.EHKQFK&V(<-[7D[?_Y!8P/A%4/WAA4WU)G5=(EO^] M3I]I3-)G!UZ0DCO9WK24A$R6H7<3A4[Y&_DPK'&+I#L5Y([0TRRRBW0D@=AY M^FK2UZUD?H0Q)%6.U;-EN]LT4YO&!.)8WWRMR"/)W @QK9V0(XJ>TM7'L)MZ M(,8+3<'-^X!=+!A9[?L4[K,\^2X\5N/#XRWEY@*:@Y3KEHNW# M[(GI=,*^1]9)A_ZIUY0%CT".N(P>9%X[)"DF&R>?;(K;DY!J3>$!$3],(ZA& M!C<->/KUU%?))K%/T[R[((*1A6>AIS/ LAP<(Y0#^,^]$S,E@\,J3%(VV%KK M *@Z8$8P+65/;O[7ML:.67K"#P&K\H;('SD/!D4E$WY19.<<.%8!FHGQ6^(7 MC&1;U__',4MY[[V@3V0&4U>>G53E^E%@<4GT',7I XVWE_0QY=LPEW[B!E&R M9U9>/L+4ZJH>I]/MBQ3L>IF@LG+2Z8AY&=5)_MXA"7 Y8V-^2X#/(MOLDUB1 M3SDS6VNL20QQ'3DA0#W<5;#Y#N5C"M@6\YGQDKHQ9=*]9[1\M@JD#:_*M_=# M[NC:JE=?HVSIA-C!]67O.Z:! RE9+$C.9$$D-I9>^'1L1^Z_HX%;9N, MM,&%1U6'I>O&>^JM^)(VT7#>OC20.O(@DQ0KEJX$L"]B>NO3W^D%3;YV<;:0 M-)= ;.N''A.%>L!$_$W( GLO7)C"0_*-&+A$+^)B^!?TYF&QT&3B18\%,QYA M9\:3Y$Q+-+4'IG9,LU0-''MQTS73B]+R=1)0^9(F;NSOP#%;EDKZO9%";T\S MR)&49E?$\517#?HG$@(?ME(JW^<1,97$S/JB:3IC #2+SLG3!A=@\%55?:E MY_D@N!/+_RJA/J;32/9]45=ILFRI2DEUM4IWNT;))ESO'CHS= M)OWKRP"V<=:?+ ODI4UV8;["_& 88)ZCF$"*,B3BY2!< T5<\H3_+CYNMX$= MKX7<6.@(WEI&(#F!8N5AS>/&!)K&N3PXKH^*LV&=^&>#.;@T%6Z"FU\T$S_N M9#*BWA 7;VJQ/?]DVDJF9-\/3IYDN $4-:+YOC#V-!7MY-_$NVP,"DRJ)17' M5@81E*T<31:.RFA4JQ0HL#C6Q.=?BO_PD<(74L24.ZM7B/9CX", EVLU78X5 M:)* $F4%;4),B@/[GH.!SE'>CQ7OC(;H\*!L1J2_8/E;1#.&!3P)VV9?7]# M%64'E'W[B+L) S'%G'Z!3A:+5==#X\E. 0?%\V4W=1#D !?(XB/P\=WE@7Z# M7.R"Q]]2[XS\P ?UQL)@1^ISO5/,-I .!S^1?U J.RRLC8GANSQK%@;769P_ M$?4@XX"M)CL%#F?SE.X4V1[M$3"0S13<>)K7*(,D#1>*^-%%83N.S&/4=,R1 MSZSQ _*'7!SW()*FQ8AVG?Q7L5(1)B@2BX6HP%!62)2PCB/; M0 S<2H%/$?<:.Y M9-^S! _9\G&^X\U)49!$:'7-6(4A 86)T9IF8$+2=H6"E600.F 0AW!)0;H MGT2'^P6,"(O$MS%5OLG1)R 9^9_[>O6?FOLF.P4^ZN*3/%-S2 MV9-V7'N?S,ZLN*#J\<9X5SUV595506YI1I^J)W5(ANT)OMJ7X$&9*\KB*/V7 M1$-OY9U"[UUYNX&IAH%@ ;%W@Q$F.EF"#[Y ELQ!<:^/JO$O&@%P.I4B ,H0 M KJX-!GNMGL^?8$A#949C8D+5R/-0P>-"46/SEKTM W9Y:=$-O9H<MPA(/62X'BO;\E:W"3V\![+8N]14AN&,HCN+W6V 9@;!ARL 8&G0M MZ!T^G)DH8PGBXDY5=+FC+*YMR -7'-JP5:'*QXM*4LX!SJUYI*:"G5[L8 5: M 7ED*9(4@JD7,'1IE$UGD+1CQ"(X?L_H3ZXQ+5^WCP_D)6*WR1HC/L:5P@5A ML1$/WPZ7%UM*(&1P-#)& XZ+>H<.CF;*F [TX1)FK1RX'!22P.T7J&61=P1Y MN":D@8L/VG3P#<]A[4E, MN$I)_P31WS!DV!M53EO[];0*'<;&A3[I]?@F1BT4#_B!3/BODHLZ&,_7<;3P MM8([A_(U51!DH:;KY;7E,VO8_8.Z+MK,^+ >*KG8WR)0D!E1IRVSW/DZP'WG M,2G-!]I/RM1ECUU!\P)C&XHGJ;Q4"6^4&ZD&?MSF?0RZH>K>;QJ$/_"L5>MN M*'HMR6U?KR&7LET!<)93W<^!4^T = M+Q,T!=F8ID@U2;FL_O4'X$4B)0($2%!(0HJ]]K3+!D!DYH=$ LC+?_W?]Z73 M>4-^@#WW'S]<_GCQ0P>YMC?'[LL_?E@''ZS QOB'__O__;__SW_]KP\?_G4[ M>>C,/7N]1&[8L7UDA6C>^8[#U\[,6ZTLM_.(?!\[3N?6Q_,7U.G<_/CEQ^OK MRX\_?KKX]/ECY\.'9*1;*R ]/;<3#7GUX^7V+[UD5,_]>^?+3U>??[JZN+KL M?/W[U2ZP=_? _R/'U[#5/_WI\F-JO:&E]P&X06JZ-?DAZT4%RW=Z??2?M M^/&G]!MI<_I7S&F_/_S[P?C)M"YO;FY^BOY*F@;X[T$TO0?/ML)(:J4SZC!; MT']]2)M]H+_Z<'GUX>/EC^_!_ ?"O4[GOWS/01.TZ$03^'NX6:%__!#@Y\Y=)SIZ]$:4J3R!A%"T5C MWR.J,-S0[9PL_A5='&1^TC0QQ]%"%0&,OT;S_OL*N0$*R*1&9&?S>VN?[G$/ MV'K&#@ZKP%-B9"V4IQ/Q+'=L;:QG1QZ>14/H66U>B*H2D>NK1Q*>2TYU(28S M&--I!H'G;^BTY$''&TH3;T/ -BN;=B^U6SGBDUR1G?7ICB0#@[' MSJ](+GD67I\8!9H1;++!X1FC58FM'1$()9IX=""SOR!!6. =B2JTJGY.B M.5!DQ33+%>X7 7/JWL+^+Y:S1H_(HKVB7;)95O$_"9A70VHP!='#$]F%1JOH M?-XLK_B?A'.:HKOQ.HPTY&A!]F=LDX5PAYTUF7K?\EU"$NT1M:W*,74?AL.W M:*;X#4V1O?:C,T;_W7;6,%HWR4%@\2'14="D>+5%4%7%OU?.Q*;F!TL*\1X21"BWZ M%>&75Z)HNT0[6"^H2S3PLN;U6]7O .)*?(6(_T1!]G9PM YI'!2-.%/+'/'/ M0>+1;JIQ?%L# \4!9\*SXT2-HK1X+4^P1(7M0)P!4> M6;O'5SU?+]C>*$VYG(#RCU#DW0#)-T&)1P)T/X0&/1!TR;).$"ZHZ-M:G@4 M7X25O@7#N0U6<=,+Z^9)U0T2@)N 6N=\:*=X=>=W*"?W^F=VV+9?TS:@;EM0 M)JBTV9!54-9P58+Y@X&QC!6&K+8I7K7Q@%6 -EM5RD6&!&*_*0OB!!N]J39\ M$\)]47)3KR1$$/;>69E2V>$!\X 3LZSH"!6%SBQ>VIR-4$)05 M6R%D3U^P("C.*0C2@Q,N".GDH3)8L%V1@LV'"@*XKZ\J7L#1@2K" P&>"RM3 M)S0FD)-A)L>^.J?NHD&!T-M(@!?@R*ZF8C]@QW: #>(R/'KKV&%;[8S7.GJ@ M5DLCM(X2FM6BF*S&@[%,BL(Z6A@6++Z(!D8=.Q +&)?X,5)'"L4"QI.JL5#: M@[$ ^. H"3P"'%6C/*P&BG=.C8MPUD#2=.TV7<]]('],B*$?+)F-6.6\#+O0 M>XB($3C?_A:']".7%Q<7-Q>=#YUTI.R/1(]WXF$[U2KR1502.LD9)S>9Z,SC M^7GAT>$",EXT5H#L'U^\MY_F"-,"D!?T!RK9BP\7ETDEP_]-?O7OGD=VY^XS MT1 $9>EXCO6,G'_\L/>WGYJ?3GR MXN;+U\P4L\#H^OGI6KZ=CDU^/,!*7A1)BY]64530!_L5.UL(+ BH#KB4?,D3 MG+'G$R.2P.B'SCH@\_"B+8_&'1V!VS$T)^@%T\F[X=!:%G&]J%D[N"\\\T0* M5_JD<(\=Y/>(WG\A9V^F$'*MVB2#\HDG(OBH3P33I>4XM^L N[$;2[$(>;[WT/7ZF):[GLU5#8.D_9U<7-]0U8D8@3D(CF MLT;1O$>V**8?'B,?>W.V7 Z:MDHH8K-/)/)%GT1ZA$;?<@;$*GW_;\1>)GOM MVB0+D:DG@KC6(8@NL>WFU+Z[=ZR7 @'D_MX.QI=/.6'X5P;#_^NG_5-9S;.: M4"UPH9,:^3]R/-N.1W[.#ME)QNQ(IS^0!EJ*LX45/$?CK8,/+Y:UBL&&G#!( M?[./NN37_]X2,5K<8Y=,&UO.V(NU%N,X)]=5?O4H)&J6Q%ARIQ\U K.HJ@B& MKCD)LA2>%17*JN=809HSH?N.]RWGTO9P)TL(N0X2' M#>'*3D@,AV(4))$IOU7Z+/P0LXY)4D1/B/P 12TUK>'H+;N;?\M^1,MGY+-6 M,;L'."P(RK)@+4L2:10:;J714-C#-#2($\F\2VP7&B1@8+;\905_>(/9+L%O MMU!R2$,#\F.I1;=M"$[H]4PY/ET*WPSJ"RU)N,D_^.4;P146G^^' A.@RY M M.J8T"=(0DO9>VSQS/A+F?-0K= '9L00N0IHAUX$$N8*7UC,AUX/DF+V0LO1J@_B(&;J M\1ONE3UE*@)V%Z @D#04I2DT9'/(:+BAY]KB%T2L3N T8M^7+A4 $"52U6%#]YO_ MJ^>',^0O;SW?][[3/'^L1__#EN9)7Y1(9E1.NZ1_R"_ATX)YLA>DD1G^T]I; MAG*90Q:VXB,A3^:U+3[-,NE[QM%&6T>0B0I-\1B MS'O%\OR/"EJ"@X2D# M]#(2(U'Y_I&X+29)T<5W/]IJ9)W^]C"\X';LU8XC(ID%UX?%[;9\)V[ZT'!\5:3;$4B@LIBYF0IH'!4$:55TLP;E=*+2T M*_HN@(-%<_<0XO0W!AD-^3S&$<=?48CMG751GMSCLWARC\Y?<]_XVP_G9!_: MB*J:[ / PF\BV4=^/<-($=%0L@]($F1+@B,^(?) 25)9L@](LA,20\'A78Q$ M0^YL&DSV 0 +@K(L6,N21!J%AD:2?;0?#>)$&N($IC391YOE+ROXMM_C*4OV M 4#H]4PY/EV@DGWD04H.LB,_(F,>/4&D!5J%UB^K;S+^#=(VAD"/AB) M"AG#HK9/.30T<*T*1FN#45!N3QS6LF@Y LJ-"5X7@[$@:$8HI,;'O!;?ERW=#OWDN=[9FLM685B%KLO MVXAI_N29[<$MZ!*AY'(*21%ER!72A$B$<)-FU;Q#;\CQHB1:"0>8GIZ5I/CA*>AD'CRKT&G+/>, ZT=W" M.!"(4:CJ3E&S[^^6V'AO?? .:JIR6H(3?14#H80<0Z*)HY0Y0\_U\F2GV79+ M+$2ASGGV71/V7;8'#=4I-.1Q(BW%[0<$V]*D>+B V9 M"W QB%0;K,W(44AQ8R^,QW].Z+U:[@L*!NYA?.1>!'K9,\-'F6>&Y+,=[':R M'_Y+)_YTYZ_)Q]L345@AU8]0WU;&% +0#%*B$0TJ+#M4:!563%K/6ZX\-TJT M)1!86-0'KBC9$N&(49A$4%)5&DH"28;"XC@4J3"AAKP)9=PD],6H M-.2UAY$+B0L#;A\C(2%/L2&7P?NID+BX*&YL)" D2#7$LWR/6=Q )$TAP10(5I)60TX"#::9, 84 MXK0:T *NC$5V3!W;=EE6JB3"]NT7,9B]!BRZRI+]=,VC2Q)%_-^I=7)LR$)C<__(L$)T:9( M^:Z(4>Y15P,_U+E:!>-F2\)(6RUV(=(4:6<@4J=(C^/#[]8^(7D<32M*)-'S MW#>R AUHT7\?8M )#@H0=:K! M(PS0.BS3?AQA5"MGD)J_!QNB[U&3H*C"5-5A ")+4I\II5S[6Z(2@,1+I#Y" MXG'RC+JYN/ERK0G3JL]9&4KI7L"JH)I*(A3P]'PERHFY,/3&2^!'.X*3REQVD_N-22GB#J M!KA98]L^BH3BSJ%)W#)(=J/#&54I[;N!3S#1Y(\]OU, MI8%RW/I,Z+S^K/&"1H6HZZ&'PQ4 2608$$J-M_X[\FT<%!PKB_!2W@L,..HI MD(J$IO(&=T#FTL/6#P+=P B\CMQDI-_@B"#.^K]R<$B:[M[S.<_;S7X2(#(K/85KX%(*TKJN/PW< M)#;'#LXK>\/?!(-4;8 [&N:;-RX;P_SMT55S4U_,L__RXN;+37LU\U&9E&*T MKD-3FT!:II<;^R08F.I"V['PSF$W8*7,.6?TERO'VR!"OSL?>N[VGQ(N?-QQ MP""S$2]/>=)3E.CSO)(#20QX!2CA#P0&)FJE+8:B"JS1?C8_WK-WQ!V:G'5. M<_$@-XA@,$%_K'& 0T14_1NV4MH1I'B/9=G1Y;:J*" MVRUU(=)2H==UJ2H6NH9L]U;P>N]XWX5KYWZ22FI/1N^DP[+)Z@NZ M:-J@Z4S&OD?]=^:WFR=BQ S<;=FXKAWBMRBFLX0T^8'@:@&.0/=V>!4D&W*0 MJ6GJ 9"_(GE*F8)F82!W5J(''=?&#LJ1/_/4Z)LF/G4ZB#P:]PQ)5W6'R'QM M7!3?4M0$')".)N]#J)7RQ1#=E]91R]\!\8Y$!XW/L*G$(4-T3%IUTR;\%*M* MFFEYAHX\>PQ)F31PWPB7/7_SJX]#=.=]9RF=PX9GU$AS1WN2&E6@L7U$M.L= MBO^;X6#RIE%B?XL/D&?CQ[C>_,F"K!;7#,E9(K\I\J6N< P9>1/K.EI #6E'G4P26,!_J&NR M@=2UHQPQP=C:<"I,E_8[1?B(L,!8:YLF<5B3V6.+F(SQ,291R%L^9_XF RN) M84\4=74Y5#58E7E##N")+/Y 0?4]^B(/#\ MS= +47"'?'(V#?$;2G&^[RNH8LB3PTY][M1-(P=DKQ-_,*_MQ@0.9!JO-6MR M3=6>YI&%! ]\](HE4.%+QQD('!@5^=+)DFS(4S YE:0!)_8?:^Q3K4[64K@9 M.Y9+XS&IA_EJ>6A8R0\ #CF*D' (L9H\,>;>7)S!M=53GI&?R/;QU5!PU>2) M*KT%
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�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�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�N$3^!#K M@,-.XI BTP%^=P[N8>XB<"!%'_ M"G#AXZ$P)WF>6_4U1!'"G-+==BQXZPJ\W=/1V],5[+ZC"67DW M;IF9][4)G"99.*_+U MTK(Y?X9EE@T2B3[;9&B$BO -:'(H>$=7M"N!A\I*$:IAH??>TG>'=@X$IL97086FLD:RR%(XFK5[?SE"[9S/.!698^ MLW9!*@(=?*7W#=SH^P%./^\5@;8HMXMV=VNK5]10O0>-N)F&(19Y1(YJ9+*C MO3<3Y^8'^+M.VJ;9/R,??\BH#WJYA[D@-T1&_CVEU2'?4WC"")H&DZJ:!@AT MT/4,E]P'WJE9:N&2#K0\)I%7;4*_'$MH3-M-,^BX#<5P$H.C5$" \6F6,RA4 M[HB TC-UGY$=J=$,2$[2GJ&OH"??JFW'>^+0^P%T5"M%#Y<^_23@7+)BJ#_J MOJ_D3#Z]7^_\PN/N.^A6@N]1/2P\'2NDEGB+0=+3! M+HKZHT^)2#.=*^,(L&&:Q3;INV@U+-('ZM:/JVS+=>U#[M>I5D\@2:1 M@9N]9G,Q:(29*E@R#G.64)))H4L86R),JON]T\.;"]\_9$H+PW,[>6%/@W$$ M"O!@?A3I' \[19<:]$SF#LRJHJJ[KQ'$O +Z?MDXM7!\$9U[:*YR\7BS&_>( M[8VW25@V7!AG.;.-'5K8B)734^#2C8<<\J >K(QDJ*AC$:R!F=]Z;_=4F&[_ MWA2=6:G.XYUYHIM)['GYU+V9ZJP=2U?3&0[0VQ1E("!ZQX6VC?3->C-[61E\ M(;D#_GHAO5,:%0;_X!]M;>V'SPOT='<4S2DS8-!,O-8/^OUT[+?6LP;1L0AE MKV$8S=&M!0'V*WU$:&)#6;F'=LE=VEY\'..=O\;VUO5N(DX5I'VI;/N:NET- M+.PGS,60.^O.L3J_B4[4(C>8RT:10W*,/:]X3VS7E?+H^_0]V[#_B]KP374* M7@/,C$#MF(//R!"(I$Y>@IY<3VT_<.%QR<%LA(C08F6(22OXW_B3M';Q/?@ MEYR\%#S,-'A9)AZ;Z%*5_E5U\C_Z&NS_Q_\LX(>4>61/*&9MP!2E(>YIG-## MN8&N!NX+;%$)DJ>5J'F1R22!='U*F$-=-%.6 VX_Q@"N#5I4F'T*B)[$'%P5 M-;QOA[EG?2Q^M[-%^C38&K/]T=#3B7-%-$4F#PXQ*>V!N\-3+^#93], M;":(_2F%.\[^H,?R>;ARZ6,GUGJ?".:^0=N]O]Q4']?R4)_L9!19<;UKA[=< MNX0M>N9$Q?ZS*89&9V=22I%DF:%!/U[=T*_6W$/T0=6<"VM@;_[@2*K8$X. MU-OPP0^/L\19)WY$VU\'S#XMX]U@_IT]6CJ69;86U\!&C'.8L1I M196R3[)F>+6%BO6(*2.FE8@SF>['FI6NJT(J;>D0R(8LLZ@/P./)"DX*Q, E M!L-?:6#4ERQHFK1BV7+P:W"8MOP8W'A2SYN4GPN$4' 7/M5BJFFY^**@<\[! ME2;O5XRL)'/#_$!,VQ+%DFLFCEZL;3"+LR58HUJ9:9?=U#.?^31CUF$'[?(D M9-9SI- ]>?!E^EBM:82-:OL;&G7Q5QD1,[SZ(Z0=$^^/C"93%YE6G!I?J,N] M2^E^$X*Z= N:D\=Q=L/RH_:)ZLMP2ZCCWI>.'Q0OY9 IMH]MY\]I*83T,!.* M]' )OR9G9-IELZFHF\5^WH_/9(O*6;8!RPX)+E:M>=%^8^]%F00W\8IV: MW9O+"X4=6U"\MD%+_&=1WI-(Z4;#91ZAW@Y+YC\5"!_['-:CM2Y"*N,\#+<8 M7*[(=CCV& J.E(I1EV/&^ MI;O,1;BW-7&W+CQK62FC#"Q?K6@I+D5A!\!-JEFD\RNW5Y<6W*=N*,,G(4SU M%_:] AQ> 8SF7M&)U3A"+42Q8M3PZ>GJ.%^.UEW*$ ,$NE#6]7H+\-)=-*^T M-[)7-!14H**;'#.-\"T*>2BMUSO^(=]H4XPE!^9:<)@K\7(WS$IL0A==,YZE M;#\1&4O@P%91DF;3$ZV^ KY;;SB[DWV$7$]*/YC[S-,\1VRESJ#3)'9NOA,= MSXM:7390L"A;[ELSQQB25@FPPCZ@/Z8,546)^RDI6.O#]#'AGP&UZ$)J MET#S)Y7S!9;'0W9^]!C,Z4I]CZV>@8OVP[D-G*R) MBPH#P_D%WVY]X($%DB-RI.C3\@X#TU!*$N R%[W%8GSX7FYRP+PU+=CQP^D@ M" *23,>+\SM& ^U/:\SY*!__XN9EFKTS>R',1;K_)I$@VY0,+!->'DV^HC%; M7M 8,](*DOFA^UE72\@LPJNVBNI8G_G]U;$A:_REUO-J7A]P ?/2"LX RO/\ M%?:.P0(70T-J[^F^W-D:/8];K=\#ZLSTW7IWA\+.2TL'?I3;.W%__EC9IBG" MNT0!5;J+ZL>9&&EG4XI7=09W::?!\T^Z;]\(7P''\T*YRRNKO2@&^@JD2C!Q MQE),#=O\U1F?6_D8G)$MK7&H2)@PM([5&\(_K_8G]*G\LB^FAWDAF85>I^Z' M5.W*1%[NX#B?Z=I7&MC49>CIR:K241SK,8$*[+W)2B+4%3!L3W]K4)O#L@M4 M#VO@^907'-##Q;5.\BAQHHYJ@9@J5$*H=V2$@O3GUDH\>9OLKEN64,^%VX)) M"WYM_U@O\LJ@=V7TP@9MT&2\8$$=*ILZ;:M&W\N'OL!Z$P,.7Z90.36 M7VZ3YY"G(J$NE1XES) MCHE-AHN"XNB3F2324&F >:FN-+FJS$JLFC7B9#Y)5U/S=ZRK![4: ]NR?'W 6@T:([ 2B%J/M: M[0!H.:@<^%R,1;;V-93WTU8 Z]1;NEHF4/Z\&%./5:W/OI7GK\8^I2+RZ-ZU M^D?.%?VKG#-7T; _,YZIHFEK=?@YP,=%WA/ O*,ZSU'BL2\QQV)'U]0ZL3A@ M@+D&]^';374,T7NK9,G'RC=%*/?/SYE!7T%E_J6ZA\ECCIZR)4>: MNE6_6FI;9#=%R##Q8-S^>W7 J"GU1K+/ZW*UR9?0'@G"46) 6SI3:NW%0%B9 MCLA3R3=!4DJ'9_GS2@PUG3$YKVSQ4'-@Z\$U M$'MNN>C3R.VR]1]4VD'<$]"DG21%)8((GUOZ\MLKZLL,5$[\[;#-T-7-V9L3<6=9'K& M?P-$O\Z7&:N(X;DR!9D5C5*;)1F4B\H%?:Y[I,VN?IK@.Z,VFTW0V@\4"EYD MW'7.5,\% .!^B+WS\L,?]W#"?U38*3BS7Y)T"6TE\0[*NR_?0@VJ@YR?1L0J MK.6\21]]G5$[0V_:CR\7L?7J8+?] M +WF[![51S(!ZKS+A7!=/)'[&7I\:?SQ>RJ$MZH._EGV-DXLVCR+=#MF<$EZB]?E-T3AK8;Q>VW M#MV9KQ:&R3,5^U)O/MT?@WQNB5W>%>_4P\R,^80^H4M[LHSG$2RX'!MT#Z#% MUPP5'(I1E?(9)9B+^8O.#+33OO] M1J.V8Y:5G+-M2F4DT/O'"7_UWO0XZCOX]U/!XH?';Q.H[UWHYYX<2X^=UF9" MR933@G%AT$6%\\HPDI,I^G!CM
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®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�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�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
$H"Y$IG(B/QY2^";H>@3YYK'JKK1 LUL"2C*0L0 MS$SKNNAR,U"8$=M=)"[?!]KX;Z8"&G5CA6PA[#74]0Q%$04/*LGLR,V7S@-, MH7ZSVU=5[;3Y#F"3POJZK_>JB?$ _$-,96;6)G16Q^NSH"$:K%,]T*0)C\@/ M4Y,)WE$SM1LJE8?!3J V,3_ZDE+(B["FI%I#:S]K+;TS(5B#8I'G*(E1E&_$ M_Z[00+(2E19>V34+"= &,*Y-D*NM-%US?=$*I^@P5@CEL7$];(\8:H0GJ6M;5$+6%A0FI MQX#B__TLQ= EZU:T?N]RU4*WG$_VT?[,J>!:5#HJ\7YJV2(_KYS+<0@K&T6Y M.DI '>JYU!N'.X!0]1W@HX72 DW:-FX(X\$9YKJ6VH"G,M2*X'[L^=JMC]4= MX,VWW7)RX5[K6'-GO6[5WPZIP/\[F*:_Q(S)EI6Z%*Y:B#66F MWX-4@DK6R\T3L!3%-GT?B42**_0";/W:!+@!!M(V5ZL1]WH"?]%S]+DWX--U M@5-I^G4^=)?7 O5!_\V#J=N+K%OT-(([P !]TQ[HQ*IH79"&XU?(^#^&_$T* M9E*NQ2VM[^FIM!:LJZ%E%_/ D>YPI1MJ5UEE&)&,H'Q3351<_$(+%72>WD$Z M"N(/ @6_RRA5G>2'6_GY) ^Y:PH!GCM NI;7')M7L])2VN5#R,V1+KC*XS<0 M[K^$N,R6+1)C3V_$B+KGE6M]N'AO(P5J:4UE#6C&V3D>,U6Q#8/DE[X<=QP; M90O:(3,2BWR%3N/!,O!UH_JTWWJW/(5?#Y]\T'3=_MA?#-"Z;]CI]] N_;#XWP,#[.[8[;QV\_ MDY'0B,&1#7GS$0VK'\#H.L>8=SB^;2)$5K^=/N"\OH"LZ.9EG=O34N5A(Y3S M12? $19)7SWKOW4I75&7>F]]*JY,2X%1F[2D-Y7Z[ Z0QG&=__VY[IL8DSL MG]IAUL\/*&VG'68VUMT:NXR?K@4UK?4VT0A"^&3N )6%VKE=P##KW> ?LQ[ M"5\J[@"IM!<*]_CTTZV+'Z07!A056C@SD+K**) M5X-@,E\VT]@X^4=MDK]HFW-?:\:5T77/0>E._Q.O_O>>RE[6+N]OWTP=EAI] M5^VW:. _B<[Z*K@BO#-^Q-K>] MQA9PMSV>044K04&]VC1'4."&LQ5>O MWD=@L>(?^@+ MJK_%[^1'OT.PK,._%NA_#]+./O?8I7I/ D0H(F>ZD_AF)SQ.KX5G+6B;+2Y0 MJHQ5RZ\%2C=AJ8UX_YWNO!=JCLD;)NA;-*Y#P7W'L_:&?ZD]9Z/VG= MJ&5^B=H5]JT:P&':'T""_S1H6>W'0&,&N_BU053-$R;=Q;'VA:?FR# ]!3%< M%@SDZPPPH2/B&U'UAM)4/JB3&HFATQI&/$@5U9=QCV6%-J_3#0WMB$937 MY'F*LQ_U$B#6 FD+6KS_P?#S#T@$K[7>HPOS6"-X"DM[G-?I,F H1+ M,V.C]=9!\(M0$"(2R3H/:3N=M%30,-LA1SS3LM+]T9=/G@]K20^]KHPL*D>1 MP,SY[_:=/\JQGR4=9>^>T1RRDAIILP\\DPZOVKOZ-EJN>*'%WO>G6MFO7?I? M[PDAZ6&X+%-!2UL:1,0G_-BN)496XYTH5J*.J#I$>MV-!\/]#HOYL5_$R(PP[I(#C6IB[+UY[+W:O;GT M?IAN_&6[=_AG(NA/)/TV.'@+SR/:L?$L!W7-MB.96JIG?7/*#QC#2,N#2(8U M,E6:4QI%W:PA>=4YV=.:8L\K0[PE"HZO],K5A:TGZ/'FD^7ADGX8AX+2I_5T MS)BZ\]M6M#]<) Q5?C/I[S:4YA-M3N9!5:L7L'-9Y?)?^=1F:2"@I/2_%>_4]/0AKP#OW+-?566_N69-T5F[3L^Y^SI6?H&R^4**V2( MGPX3;RS:P)$0HB@9QPB=.](81430CLWKCW$*HU8X10?CN-_FV=.9%94>^G.: ME9Q8"[[0$8GZZ>,-PK"^D6SK/10>?E: ^SX 4C=:G9:;<_*9]@G S6V,\YJ. M\,FM&V1%B% '4[/YDE"LER&=O'V)!%3QUZ\/C2U4#_M-W@WW3-H;],^">:B@ M(P)%1ZQS7,'&,2_?W0&Z*4C69O/NF[.SQGT(;M^/B_M@?@,U*^Z=Q2#H;M[' MM5S0T.P1P"532^L7]OZ&_P]I;QT6Y[/DBP\9++@'A^#N[JY!@VO0,,#@+L$) M[A+<'880!M?@P75PMP#!77/S/7MW?[OG=^[>>_;\T<\S_?;37>_TVUWUJ>JN M*BWSD[(BC.! VG_O<;6^?U;T@KWZ\25D)B"OI^*@D[=YEAR05L1E>3PA,,[H MV.Y(FU;A;@/K#J6467P<%)E$Z+J3=\][P!A["4 1WR2#!?P4%K]_8M(Y3PW5 M+,8)Q_WFB(+HJD-YKA)SGF:\B*)701H%*/D-0#[Y(^PE_X(PF_)/U*T3STA_ M9+YX&.5Y3L?7U0 2F=JW,I2^'S/KQ*/?AO;L+9G2R7Q[6861)$:QFM2KP)%Y4#K9VGZPHG;Y,$IOCO0YULX+K.XH[$K\CRGE[^,$KAZC_LU"/@\D[+ M8#^FJY[X1U$HX8GIV OL0>U MQACD-.5AO76-(8?"A?TCUUC/!IHG9M#?69HB:&:=D\8)3\Z,D0&+2*:VU8[_HQJS&+4Q%9DMR' M=)\'KNR?/C7XS\7R2.QMW12^RNP7ZY]%22 >4VS]HX*Q"L?DU;P]KYSJ4VH]G?/\P^ M-(6S;\RS7H/Y[=J5X&+;-M2!;C466M!S^%:V$JIA%)SXH^^5)N0IW\ONPF4! MJ:G-XN\-?*Q#*E;M+NR(OR@L@UX3/XL_7(%RR3H;O\*H$N6.RBPHQ%K^2LG= MVW"N,O8Y5&1!@V!+40F"1*:B>4[J,[P$FK9]_YHZM9>!HL>?6=\/UY\]'*$J MH4ECR%C>G OD>,6.?<27EKA*8\/ZY0-PQ/+] M*Q/\Y2XJ+>^C6OWQ8TZ;;LGBP.2B-(G_K@2Z2_SF$>R\YS!(?K%[P/4J_]6V M1I[:N7]:JCT^*Y&@A%@#6NOSQ=T:6$3@46@P0?30$=?&)R5SM;&J%,&;FI I M8*+C??W9R=<7.K#FN;KC.ZR.?4(Q/B*10M4>UHNC0Q'2:J&>?IP^N M;307B\XO.++EJ]L:?Y)>_AN=UCZ7\K$?8J8\CQ3HZY(;(S6\L]X7?!(3TX%$ ME7<]AQ08^FH.1<>Z B:^;A.7E4W$:1V;]_8.#BQDNZ0>):DHF'9+[STW+*3[*+.>-I_?=9(8]\K;[ MN/%CX6\NEXOG "1Y!^HI/GL>S"OZBYUV=N:ENK4:KHKEH)JPT3-?QOML7XTA M&4_YB=+H.!3NKK]UO97U,'!J(>#TKPX16\_[PPEL_VZ!HAB$9SA6R%5QY0RY MQ B%Z!?U".G#*Q(\CQ+NM]0\, "%!F6^S7QI:&=ZO5VF%!Z ?C"/DT$3S6;H MX7]D$@78G^\A-E]C'8>QM0RHO9M=/XO1\PZ:TU<0V>X :T@0ZN;BS=0:\53V M?128(*IXTYN6:R#7OXB%KRT:=,AL'07H#>EI=>-B#C,?7@[WU9J^\QG0BR*\ M0![DK9$%?#CX1*K, ,'Q?K<&^NF+T5.2WJN#:_QZ$4-B8&VN7A9@QA_&Q.]MJ'*#?'YEP%DDZ+L> M@Q7:B@BH'YM;O&@ &( M[*73+8TG@55'"D&P 2W9"]D[))STUEGD&;3]'3S)0LB2AQ@99P7W* 1[ZS\V M"XZ!=*PZ0N1KC4PR>ED2X2\N;YU<,P$S_\+]#.#$$ZAL7;:FM_*[W4VSAI/% M(8+II)]TF7*IL1I"Y;)13TL2BSF4-^/ZSC%@RQB,=X9/*FYQ#].)WU0N37HY M56=(6F5;C9ZR 3+-:Y^3-YBY5AJ.UQ73'$=@MB-M:AP9C&:N!YLU?X'C&L?O MOD:L6;+Y1#7U"$SHA6G8$6/LW\2'"6<)DA$Q= #(COF[\P M,+)Q+J1&E/EA-A/UJ0QB._]"1RR61=57WF)=)?;V;/>FP+6X'06Y41MS(K^\ M@0+3%F9"\S(_/4?#QC$T"Y>^Z=YB2F'$NH@N5(5(W>'QZ>WT+XC;459DS=2N MWCAAG*RYS2?RV6,_S8>2O1Y:34-'(718:M&$G1O FQ\NWEG/ MXX7\'"'&<\F_50X,027;>=A?"X3;BE5^P8)U72+ETBSG.=B6K+5M&2+_JMU) M)6)SPG<>% \S)<>=_1Q*HKK4Z9WL:;(RMVK:FS[OPY<*)@Z^V56^_&GS*LK. M9R^]=DD^@*I=5^]>_FS_-V!>4[GF<.DT8F\&>A"*U<=E2#KW[-I[V[34F>6, M$YL 7K\SK^3_W !^8Y*N,8--IRA'1!Q(46SW$ %65NWX,$\PK"1PJLTC:MIG MD-FP/PS.1T]4^TB"C/6_PZ;O9Z^1H6VOV7;A"S$DJE*# MMMGO"2"?0NXG$=V[XG^M%*F!>3@$>X:TMB!'Y!S?IM\!+88_$JF$"$*H"&;= MGQ'7%9IFB'!C5CBV\2U,OPE]JBHPX';DW,"Q 59"SSMBFEXCS&HNU3_/4&U0 M##2ZHUL/OFO$71DOC^$J$_V4.NHGU=3T9__Z""I5#E>C8''X:N<(JWW6.@NK M7Y??XW%.:NM,@:LM\@H?,=)7*3"G%A D+%T\LKXU:*F+P_VV'IXL8MWB&'X( M/%1"!*0$Z8JHV'D6@%R42$9>;+*G&\#MP*%)21_NNI]HCP7;0R?-:2S#JN<$# ,&?FG?M,R*R&Y%QW()-S8V!F+Q M70OD8UR\;"PMJ#@5T;YQPD_>-'8Q]AA0W(UYJ\L<9 1)KEJ[;VV,]^3\(O/9 M+K>CDA7I?;+BF@UL^INK0.$/MV_@^?IT)1W>PI[/(K]XQ.0I6 MG_[B@:UI1KT/K<&R )5_$F,AH"OKST"]8,J/S?DZ B0+://LSN>OAB<&@"HM MN835)JM6BHN!*PIC?]1J;!'!2J.[>M6Y_J)#(7L1T6])'-[[U_BI6^O($Y## MIC?*)4-4QH(RR )+CS[J2(I;$Q'SF3IM'TM_WC#[.9ASA>LHV594I;D=QVZ>P?&[!%/3&OX M8&RHBIAA>8T5.Z6)7A)GL@3)"_E=A*.C T^-08^RB@[A:*[JZS6D,OR 'A,N M1UQ;XMBJA1^VL+@W.$YJY%\@GI*3O+&N6YA/M*VIY=_"WEX4AEY3S\+FPZZ6 MVTR)O8+W;)2DN0MBX^7N90$>LW^ODN8@9-(U.;NQ\7/WX?7GM4T83%6/^-+$ MF[:TXYYXOT6VF'A'NA?(\X]"7?^_EN&V^6/[:R^W1>#]]/,*!K-.LXKGB_RS M\$_Q$NM#XM7-G5,WG/#F.&R\S?SH6J MW5EU>SOI0E2;V_C5Q^+T7+@ER#_+>N>DGM17'R[%%NONT7QFP4"0!7G6VA*K MK'0MT8H-]#DAFE*$ 7QB\?='MI6+SPS64A%_MD2+JW+K&!6YDCF/N5K$Y Y_ZHN&_M#:&Z^0W0/H.46=*UVY4[B)V93=>SU3A\O MI M8(L:NG,/D#R0(.O+I70[M_013^MWNM:)<@E673M0HOB- '^DO."S%56W] M2?1GH;\!."L'Z4T4-@KS'EL,P,DJS+[,(QLG::K!KE&G#KO0]'Y76^Y5U?D+ M0WOQEM@WE,^V_KI:63IG#:&7\6NO@Y./AO8"A87CL43>W.CT3,N_02%L#0FK MF1JJ%9^]5FYSQ 813"G JQ&?$)*G&JT?$<='L_.,^,[@V25A(.'!'>#IXF^L MRJO[JSZJ=&:/?A 1?+)K^#\K!/7NJX+7*DR&"@O,XJX&6NJ('I%EC1DETK8[ MW'(<"OA!6Q-HZT=O;N9U- M%1/E]YLUD TZ!MTQ8)J^8%\D"64QV'.(=9 M+\I28: @.]J=^=&[6;I9=BN=7,D8RNZ*=I7-'PUMRXQ;B>H2BY2WD-PHP*Z? MY&;DM? (B3HI,JZKS,TWS_GG#4'FJUYI [ 77\%O-)'\V5?4/ UN=:'7N'Z;HB=WMD*8QFJ'J0(IZU 5L3AK;.R M>,CQQ_<\\X>Q4,2+ <"S#;"T#08&V\-V%5*)@@/+6LK&J@P,^_17I4-7WHO M9'QHBWU>SVRWOA,7GA!YB I[XK>?9FIX2'*.>=Z2&*P!@.2W?-_,I)UGV3:M MOMO)]&N]D'='$__H0BOQ>,&!\$%RX\A. 07U;OB6K650M&6KD6X&[)#Z:A5" M0,&"Y5^7"9C,TOL:0@Z>M5&K*";N#XH1:)$JWO[S[:P#X)?7%.#G"U;8 (._ M 2;5[,%%4?(V'U$@KE"(Q#8>W"2DRO("WC"4116 U&$$,:= E@:$%O>)N""M MQJGQSC!T_^_H_O4?ZL-%/;8./H[68NG$BR*Z9D[_X6T,%O,0=@+[,1I)8G$) M#%<)8K=_P3_(52@WR-5[*]I8B5\#3SK!!R;6L+GJJ]N:Q&@9NESOM+"#K%V;!,G*[>Z7?CT_ M1Q9NRGE6@7T$Z9PRQPZP\]P2;ZJV80;@YW.,D#\2"T++C4EC23BN4$)#%'JHR\9SU3SS1X=K&+"9?7\R&M M48#+QWCDPTSWIXEB*-UK58_FQX:B"B^7WP"-*?OCQ4+];:=I+ %1YMK"0(%G M^=XWG@9[.3YQP<+N<$&GJC/MO)YV6\LY&JMH7!B (V-W/+C1GYD(XWE;J(\' MQN]<\U(P.GX#!EIM_QOCQ+<&%2NW^XV&.&[6V7WL >'M9(.&^&H;"XV6IK9P MC^##E:0D]B["?)3!_M<(E\O&RU!KGK51(91F/VFSM.6W5EIK>FZOZMS%$48J MVH8?4BIH$G^Y= R(I41OQ+-_4+[')V!G*7]A=^T'V"MND2@4H]R3) C%[=/C MF1Q9$X0SVWED;FDTT^??5J_?R9#1!F^R%S_*<(;JBIN^=)AV3M&W<*BA'WWW M)#[F8C]' 2A/8*&BMI'812C]<'%R?J*KDM\:RC,5,DU-PWCO)!;"8WJGR,N^ MMK+29E1.;A1RAUDCEXO2:"SIV+[W*+QFLC.U"A208,EQ3ZANDJ#MS;JK!_ST I W)P,,][=Y(/P M 0: KR^T,]0*.?MPEH"0@TS0.6N@7+(K86I4AO K9JK];H];G+Z!S9O*,*M? M3JYR!1MI+4T7YIUI G+;NW&A>3V![,K;K"R&(RR:GY';/A?LUJ@4,XA&$N:CKQ]G!?S: M],,?E5_.J_DKB5.5,C>RCO\T_FK04GE3&/W+=V-.=\9PTL:7NZL#[>TS4NSN M0S;34:N!ERNX!OH(Z,]JA)UDA(C&-7]_)NZM6 YY$N]UO\2X;3)7;4^(X?]]N MD'NA_AK'^FN'K)_O=JB\1D3TA@%"%;P[1ZM2-*=68]$5@OBKX0=R)LCIG8A>*+XT5/PWYOCWM,ZD]OMW M3UUK9',G,LI< M>UKN8A[;DVA:R7?OU?79T-NK\2<1$'[LB\S_%3R9+N&7[>3VL\Y:ACA>ZYYRA)!<[P.=CVV_<"$+B7W!4A%]\Q)\?'<^JC]\/I#4:BJ2 7.>9Y"\KTJA2 MM%>BPG':=X<+>U4F'6HRET#&,3\HV3S)=7?UFT+#=YC3.M@@F* M(3&T;PBV_KH-K_"W7 _V!#=5$"/59%R7*02ORRG7OUF/IQ=YCZ*+T_DQL73? M71$=_0NR)S3PM2@"*S6#%9,/=H@$(7U?%6-STM)J25,3K8GJ(IFM0KM&&=?@ MOM+;C\;#)!U:\;WI?(6'2VL[_G&[&5'\VO009K[M;D=G'DS:(?>0%*1[=21Y MB@@6:[VG%JYI1DOR?,]G1O-Y^YU, 6EK>>,%LL\=%@9WJE[$"UE!CR56&V[P MV$'W(+SY$_P%-CVV^ ;$(2?FL!O8B.X=UKQ.OPW51ZX#'J M\V7V7B#O51<.76V9FC,8FTNJGPC3A9&U72FV2*S$$RB-Y9*/489$,5TX)4)/ MD B?<%^RO6;"^;PR%Y(?T!=Q\.+X=K'77U$<%HAJBJ=G9*NI5W_OPC"TNJ*U M?I8$^O MJQBM^@UY\57U[5GAA$@ZC@+\-](ZX#*^*CMP@ 9CO TF:^4\&^@U M!@ K;ODS46T9IDIU9'7P>"7UET2P!!9!CM=2?YAZD:B_.5]%C8>*;7'YOG(= MLQW9"'%N6-NWVZ9A?S>)N/.):J:$,S3+56%9*JZE@JUAA(0Y$:$OBS!FYZJ: M4(2"1ME!4R9*;P=MFF$GYC? X%/3)F-#=-K'EA[2#[>DYH&\N/W$[R)12Z:Y ME)RJF?2?I$L-UUFSTQGH[/VZ3%(G#.]PA+6@LI:)U!)QU4(;^U2UQG=BJ%45 M>^PAE!*8[JAYY_FH27>UBK'T9BZU.S&-:[\!2DUT=7;X*?PNG'HE ]/^1U^B MN]^^'[9+TN3P^R:4G7UIL%0:Y%Q^T CK]#)E)^DF)24&-(O(EV0U-;YAWF-* M$Y?48(^"AJ^^I!0YU@:4N!QM/#;R][\<(ETX>;O87J>'[&3:"5?!)&!'4+FB M\J,Q@.-O0(]TZ?T NX@#D"[SA78Z,2JK>(B2W$?'LA-+_Z28G>\MS;>@61Q. M;=-N=52]1"/A<#&0XS9B(*_#DW[9\J%.(\.+97VS9%/^T)AC7.K@X$8MT\NT MS!=D<#$.TW9NCKC!+Z17__^(Y#M^5I5KH'D"5"2L^F0Z$O@-Z];#*L^RI;44 M?NS7*!\=?-61N$3,.#J^01^9B-@&?I[3.0D<#788P?S4EWB7^GF;+X:?GU?5 M\FL(141+#=\E#=H#"X:3% >G\[P+%TS'ZXVZ:=P/DIS_;!?N@"W#VB9Y^^&Z M1**4>\=F[#'KE;O&B[T>3G"H5@[^RH]+TCRE8ZJSFPQL6G"X&A&+"O<+=BSU M*.:-[!!EG"H7 Y I -M8[_ (K3+65EM.^4.PA&#IQ#:1./2$Y1BL:4IIV?CT M2IQIK76*YQ&V*@(7Q[=/X_RN:9)G1'. ^0,J&HXB313@^^8;";M)<3"0E#)XH@DW MO9( Y=MV'Z[Q ,??<;&R)1IKG_&7<* MDWZ%/,0#54=$K*2:><=6EP&L(S':P)/VB[9V3)C MZ2[715:GG678J>=^HL4Y13_.3?VN@Z^U7F] 7H*20L9[;%+(^W1A/$;6D5[C+Z;,*M7/IH,\2YX?ERH)9>YO2U-PT-;41NGMDA O,35F_3"U M-("XG$K)WP&2X]Z[30L7B)S>,8HW%M]8R=2P0&-GEB>8,QX$N)6SG/",+)N) M*!/TYN;K\KU@SHY2\N*PNGV%0V@!GAB&D)64=@$1NPZ3I=31--.U/][_)V'(/1 M)A]3;+I=I4*Y^E"1BCHE8YJ'ZP."E.O=O'215VQ#6'.:L,O;S\&N/QR5OKT0 M3Z_FQ'82K;1A]>&H&32!2@WT9)MBRAYULT_\2A//V3A)^(]^-X(E\CP; M2T[IT>B&2',7429H+M[4+G/K\LD#)QY<(E+,"=NL" %ED0-E^N#JT5)I .&O M<,," -_DAH*GWR+UUYIFJ#(RMJ8 0'L<:;Y&9HUX>DEJ8+U6>\4I 50 -KR MMFZN5ZQ)PVLQ'NY_Z=HTIJ2,"4G4HI"M2RQ@Q?!+C+@7T5XHU+- #D$1_0EW M]4_MF!0+&K2'3(-M/T?6"Y4R5&I**JE17)% [BC +^D*&D3XN'SR% ?X;6K> M/1_KHLJ#A_DE-I$I_ TN 2<%U0U?]XJB6??HV8 MTIE 1II7K\F<31PI(AJ\Y)/HM)*'URJG=EJNRED;3K$D_19#BU3+QSJ\T'RB M -,II)M:<:ZQY6V/[= MPI-(^1HF_@1M6\*?DQB6."J+B\?(@3J91TM1=R)KK=9WSCU/Q;\!80#WV; 4 MK-> W+G]Z"UQ[!\E_O7FU8EL!ISDGGFV:3.:LPUD'U63O%'V3WMP23Y!X=8) M@!6DT_,HOP%+Q]6MJ(WW#A0.NH%\SZ!$KVA3?RNP"!2Y&G'/R/&Z'^!)YY7: MF*'.7V"6Z7$UX,F&Z3=/4JTO;)ONBI#LU+C2I@;7#/&N*M#6 MP'C>::[)NOA.'V+ E0'S!+A=98O1+(AXP7NFPNF[@ 2B\X-.5Q@OV$(SU[&I M$#F0L/L[4@? _9\&BYJ6/M.3<+)T"6!#;G*::'D 1KY$>!;>O M:YC&@IGQYQUH8KMFWDDH<#_]>9:/SO0_S@A23 _(!/!C>)/Z3B7&[$==>-?R M_K"<*XP]06YN<8^)>8HHWJ<(J@&)R/I3A.U'LSC,( ?&?XEQS\>4&AIPX512 M -+,9ZS:^C14LM$EU*8AOR.]/M+IVGP[QU:(S8A3G-#&*?L])JA[#.!#8 .A M[GVAG>5%70#GTL.C*=20\\4;W5;0G)/=V7WY1J"PR]PUU2OK(ZY2N1YK# IJ((;J+N_AL5PFR,\HKGE>84NC. M3BN'Z)M9!T6MK!S9X 1VC4&EB<:YAARQ\:TKP1S^O-64'T\,P*G7 ,ML322Y MG\.?PEN,<76;YZL=^GID)=KY>D))W:J%RT^O'I6%LQ0=]$,($O4C5X11 %?F MAQUZF!5EEKI)RN[5([[V\UPCA,W6"46"ZD7!".X/+VV>18N+K%#[/5DBI[8! M?P9@]1A^;UFDNZ.8=B9O+ '@,>K*_JK\<\2U1U=#\)I,3,P1A11 V ;8 M4=C^LMR?V3_6,!J-N,Z0X#D8XSKI RL-JUU=.QQ8VA5_Q%;$GNP- 6S1)6X_)".UD*X_5GG(]XZ\&59UZLCA!Z+O;9U?^& M-XG?"5%176)"TD#W#9].+)HF\OR$L!:8@M<)]HFHHWZ65]GF&"G9F8M'$X<# M0/]D9ZH[[8Z7IY:C?Y+V6COJ(XD$X58@/^%!P#+J:X6QO7%$8>U+/+1/EC%Y M3LQ4RJ^MYFLC M+A#82J"A%E 8\#EC'@O/J9;=65*!G^"#W:KL MU)(Q -LX);JM!2;*7A6M@VD&J,KUD9P$('H';\Y5['9'G ZIJ51&A4@_-6B. MR,$L@L^&C8.2&5#1OCVH(SG4=7]F2L3,?Y6S*[-J(9UW(^L$ZR2;WO,_[CW;O&=F.Z5SC!9G0"]]5-QS0!9&Y(+\T MA#F>I1FFS*9KS&*,U+:1&C'E>C_; )75[NK,W)TFC?35P-0R5A$"%$*/KEJ% M=R-VG#'RQ:O)#'3L*7YW1W'^%:QB^*N\@TL-K&H3FJ.C] M:FBB91WTU \ 'W;ALEXMUASK#.B?TD2/>R7G1$^(^E>AZMTU,'?&TT7;6$<= M&B>%S)+&Q,.JC?Q8VH..(=!5_:3K#X\BXT^G)JY/!S-/]'P/8GF(&7[F[="\ M":ZOCZ,*]/?JB#I9Y\3@-X8PQ"*P*X^<)34P0E(CP?L:4JM_EU4&2H\&PX-= MI%[3,#\!LK75[G3G74!"<]!YFQE;EM@N,F1U=.O#KM=6:1>H'6)7\F]E%>?" MI3_L!0JN8]T-G[>;\H[E/%58PCZ9E__RV&LCB8],^#FEMZ0($EWM:^PQRB>] MNKVM?GZ_R7/;="JB:Q,!ZU1=\1S@-O1X>95)9@V[AF"'\@5\9(XKBPM0 ASZ MB=8LWWV6:YJM"7K-M \Z9-;\*D*1+QY^A0P]H,'APO%$6?_+GO_XYN9Z(OTW M@")7_5)\=8*B!J0#[EH(:'(0J7O)V,7D?E[Y"_"F_D\!+YXF=H(L0(._U66< M"AWSRZ@<@,QW+H]J(?N>\^/SE(D_:%.Y'^8P6J>X*SHR#"%THZ>J7OSY,+\, M?IES=2F/64#N)9P@^L.2H6#C6[@.C\8J2 M0TT5G[,,+6A0$4/WQS*#D>9IWK81@F"%8L-T%^/;V!)1!F![?1IL#[\Y"%OZ M2@"0F3+HX/IE:[\6F+G!SF/L(6#5U'@)WVQ*)=&+S,&%N:T*!NJ#S- NCO5T M/4?%;KR?&8"=%Q\^B'L2 M?*VYN]]E*2W>W[U*D0D:3.74;!:CXVKS<&2;Z)W.79-I83[0*QX+\!13^?K] MHG#[#^5R-@=[\%2N*?,.M0@&=[^STX%/1QN>F;-H>98SVK8SZ:S=YK%LYIT: M6MP\B0=9[RY"IX'UFE@AA\!3"/IV)M\RL>+)W2 M:Y5M6 TO<08R-U2A#?1=\79(H"D4Q6!%5&*J(S)PRLFAL(FE/#"\HFL*.^\D M7";CRM_*GI+K1HQ5((,C8[Q2A\?5_RZB0M(79EB+5V=@V!U5UQ.%]\%,5D46 M(+\C'2Q2_/WH(LY&CTINI:XP3SU?*^4?Q8B(A'A%L>+8V13'M!EQHL:;90*6 M"UN4Q4F632:$^H'W'%S523ZXOP&'-=$=MDLP0X4?*PYZ3-MK@3P_J_?G-'@M MOS)\S_%$/-8P.;I) W&N&/7&/OJJ(S8BNLI:E$5"&YOT.R?SR2M]HI2[0[1;NKMPN89X&+)"WO)KH2;]4&LO]BY@"J5:]5]RX M,&^+W%IH@L0A![<$"8\.VB?FF=U&Q<1X 5HUC??26V NR]C0#>_00$P-"1(\ MG?=>T2KP",TZM#=H/K--Q'.Q-3W?6;H5G =+;8!24:/-\]!'&YK44GAZ&I2H M_;XTOB7_CNWTBQ/NW?,?^>A1S%2]?1YO)NNK"Y0@6^BF]1W!#Q1\J[T0YWZ MWO_+%;/$.3]#OJSJE44HY4!BN-RUX('&Q+97X0SJ+ZK383:\..ZH+,V.:<1Z M%GX/JPPY@_ETLACOP@[Z:<4Q+->F>V12TM9 MDB;<;'7$E#4Z7)L0=:@<:COS"86;IT#A?K^35*E K_ OP@3,=&>B;_4PSF-UG^-^ M@*S_=HU8=R7494AA8JBE)'[@QE6VA3++"UP=IL"\SK/ ZL?OZO)UD-#Z$QS- MQJ-.E9>KRD?V';,O.PD*8P"-D $"3URY2+PVXQM$YJ#,G]^'$.OGI;]JR^H! MM,#=F :30 #*'_W\#^P?;?+%K36B^? ,E4+[3-&;*VXP4[U 4R=TW.=<^V 3 M083Y^*^K%7E* /FW*9SCSRWV]>O66 G!Y0O)TM3Q&MYNZ=VY?, G-<'$L1X M.KY'K49FJ"9]P.K@35#2_"/_29.1M&:%,U2N'TK/2NQ&;O M&Z*5?>O@OU4F95VHV0(F"\L;Z\M8HL)/.$:Y$$'1D ,P77]'1*-SS"1B++YB M@[\H_TE;A/WCRE4Q^*.:<49KC".1R1^UN4/6]>O=C'SFU7))]S9EW4$V+.9A M-Y2SWK^ ,&P%(&H#E(L:;#AGRQ%MSMA7"-I Y/VD(C7-[)ZS+XGK#YLP -3+ MJK\LS;B$'"?Z_09XYD)#C&:(U5A,9+L$EG.OX IDK>.Q0#0)[(4T[D05VW,L M)=D2ZB8HVNL=D/34U*U&_ #L?_GSOI@HO MLXQCZ[H$EH0A"LPA <)*CS6V7%0J!]:^)(IK7U/ASLY4\I9MW9GC82A*]4\Q M-_]^O&ZWR!XKS2M;-@W>>? .R'"KT7UZ3AASH'VR7 MMT>[-!Y3*_@ ARC43&USP:::&83=6"NS0^UJN)*;0%;G"7CE$GBW", I<7O!PN>Y=!3 MO%C-,X,O:%16=$3M;5_FW.G:%Q5%,&":]!VC=E_8EKV*J?+O2V%VWVS2#'Q0^PE MAP$H9/KJ-77"']C*+?3581N>XL! EYPT:5^R9898O=.BGAG3I\\4QV35JQ!& M:QWW^@T=]]WL?K^+X=UGC9GLI/<@*2^ JP2N\D;$SF>5& 4 ]'']>&YD A4U M^)$6F5C."PD\ ]'4@5_?V2 M9W),Y)"8$ELJ#AEO:N,@S=K9J"R0,HZ=!PQ>)!RS M7+]KW-K$@:UAD\Z(857M[[ZDP/'DHEK-F#>$.T&2O7,=G6>>&!UX2(YB/=XG M[O HQ%*["QP9K"^S$N2S$'",D1KN>/I9/-D)W/5!7:IU"A739&75G_C4D 3R M$3&11FXRD):ZG$8"A?>@#E!!"$^;80"G3-H]8#LD,:K(;ENF31_-8X/$[SF? M>]M!5!0$Z^3@SS7HMUS>23>W/).'.$M@)O0X/\+\RG?8_E:9Z*'P?"A@;,!$\WP$&?\ M0AC(J+/=B %ZR L_YK6QB#IB21S0D"^5-X#,\W,4NRS7CPG[WT5N!(2)/QKJ M_ ;D.[Z(_@; JL7JR,L/'JH?>&\7*GX#D"T_:4HY[' 4(:+XAS,9YB$9&(E4 M6UIQ4;Z/M\C,^L\=BQYU_ZI\_+?*$=;EXQ=_G;+TM8BBL[!JCYOSUR18G1O^ MH',O X92D-]VFO\"F=#[K@9WQP?$@.WU9UOQ_^^G6!VF>,OG.5MO_Y]ESAM? MZ!?01W[)PNG.(/&RK.$H1K6T.C-HAG5('K__#; ]7+]"^PT8['J82ZRQ(WZX M_R1;)'L4Y_I>1(NJ]N/M&S4$39?=5E,>AR4O'U29((W(BVP!L;*GS,5*(9GZ ML=*>6\I(A?MO3->.1*XTX_J#::KL^1JR^#)A?W,*,YRP7GH>Y1R,+@GE;JK< MCX=!C_C6ML8:1B)P1(RK)7/.YUP'Q0T T__3R^;%9JG4LYK3W&#-M1 >N%[9 M#7UPV&.O (Z),K5XL\7@;N;7%S0S/(/6O^*-:-5U(C\ M;XV)B874+$X^^PW6_5O+RSG"ZNY6^DG2.X$9/7'<<5=P^!.]3;FKZ<= 7WR' M.R,^!7RP"":-RQO];D(_=@=;8W:#67=TKCUV*'Q;/"V-3=WDQT2=JQK5AQD) M_J7B(Z=?3@6XCF(I@-:T(+:"XN7E+X7ZA915& NGZNMW.H9ML\V)L'>&$1&B M0S3[UQ4EY[:&*[V.K&W>$'Z!]SE%#=8@,;$?[FH=OK29:4S13[GO.3Y= SV7'3JK 8+(O>L5(OMQNU&0" M>X$,"U[X8'9Z3\LD.BEZZT9'M+D%Q[LFUV MF?LJQNV6%RU7(%B0@*\Q@,OD _!N\"H?V=X/=^==K$@T$^02^CC3 .8""TLW MZ&WRJSDRFA'^=/TC<>HP8XI6CMSMSWZA)\^G'C)IGVOR9K_/<@$.825Y$4T( MYF-H4KQ:/W0V7#'B"+P/EU4]R)UK%<$I_*5*Q(4OOR4\>]O)9N,WU]2XIAU< MP#H[IZQ&J ;&NQ5*@3]H7V:W7!)&CM]3- M@B&TJ7H]R&M"B7\T4*'' 1SE,A'8D 5E<,TL?N'(8**R)UE6S_BFU@_*C5>J M#' .(F0L2]G?[BNI SA.7]BS&G2CNQE8,T5"7>GV'$^=C=<-&( 3;"((WN[/ MF35<5(NI3+K4!6,^6(1XT']L-E%QT\=.#-<.1R[3Q$'21 !8&-Z9*C=Z$PM@ M&.WL1@Y.9[ENBI*?_%Q1 ;=*QV\);"\U]@(G0ZY*\M$41>B+%1D2EC=#3DGT M8HB;0$6+BR:*[FB62ML(T;C]-KAQT S"<:]\M*,QE)Z'&^&6S546?PP%I$/A MF8*IZOQ,1HM0YOY;M1(;30>2NL0_B"Q8F($J4S^-L]/(<<)/Q]7+0MD&0LV1 MD]RX1S+.?7Q@\#A/XT!$)@>2KD(+A_<)D2!RNO-5#?8J51#W)NRIH\FD/[O) M& 5OT]VI-&)Y_RB@<*%_="-%V\DRO)0Q@TYSEPH9D'21((% M9?@V9DC0*\$., M9,9@8WPRCQO.M?D,;JCFPZM )$EE!4+R4(H2 "M>!K"BY+]UOT.CP%: '3E, M;J(*_@#6XH_U5QKWX@U?U"G2]?"78O*N&NM+>^&]:VO,CJIV$\9%2C)#X#]] MLHN"D!>7[KZQF"J(*D&QY=85/+-JF66+-F[_],YV)&3 B=E1<3;7&-OAI'E) MS.)0U%:1AYG1FNL;61_ >0W"6RVWL!SZBHIOPTNF& /UT[<%236-I'&PB)[8A MZ!!=RQ$-5%V 9DHIB+I W $J,UQ49.[.>E?&>F+S:O4_') -5PP:.UP=$K=V MS=!.#UL.#-RS$%;KC]()?F"PX5".T0G%7/U+VHFY5!*B AD#D&"[YP9W5=FI M;9LK?HV)$ZX+)?T%^UA$Z%L_-&QYT-DH=(UR?G>6G9QCBH8V6$+]:=G']50C MP/$HG1OB$ O--?UBMJ X)+ L07;U9]*X5 $$1T[5/R9EE0$JY4^[<3X,T?- MN@=@-1Y@KZV2H T/3)UYJ[GVO66-EN@M%(% V="F8!#I/!?:5[6(T14)"[> M0[?Y7M;?<78M-+M _A<6+=M/S"G@]R;)0X;>-)>T4F@Q92&Y#?BG$;Q'SF3M M]?>L0/3I5/'.'P<29 VP,) [62N'%19Z5.Q55PIHZ3^J&4(EN*M$-(NJZ;;:AMO:Y,!"R>7/O!SE%Q[*@@G8L,)9SE M)D;S3Z9F6NXC'2ILQZQF+79.U&L78?3>%+W]KM.'0KL'SOQ?+"Y)"#51_#H8 M@(W^2&IYKGAH)!X!&\:V['?ROPQ664:2$AN?N_:/C&X_G_(R.%:S[B:9OIW[ M%J9F(DA7L1+KTJO1:=69C*OZ:E@KD7B[# ]N_C>@A[?L_F+D:S*]_9E8"O]G MM]-?M]]2^:6I$3\,5E0'8!QFP@I$9YL"B]7[/-BF^?,,]FNO53X=J;:Q6+ZU M7/FBB?*HC@3&#(/>U9 O,-KH[0"7LC!#K]J\U[2BT3: $P5#$)_#[3Y'G#&0 MB[F"!IQ4&9M2L*VHO,;YJ](L>"Z.9F\T367H=JFK!'FH &')F'?'7MT6JM>G ML9O/;_B^/8UC)7+M_P;4/,P9BDKW\;6:+NVVI>U9MVSA?+ZUE*4?Q3$H-?K MY$BK:=8M;";Z&*2G OT-P&!N*5\36 @^+(X+"\S'%*J;YR5TSRJO$?GQ%J7$ M,UCQ:!!60X%_],IFBEI19&CQ"_QO@);D +HG,T)KHPY#B$\84;[A5;$4TE@E#:)S#S)XG!?(Q M^::S#+LR?P/4+6@X 'VX;_=K26Q78]*CW;[JKZBP%C?^FL?0RXG/Y?#5_>A< M 4J3D:5)I-M#A<+-S@UM!^G>.@]4KJ\"K ,%K><<>2:0EU4SO"-1QK<%B YM M0W.Y6^/F/(:^C5LQE5C8@)Z-0C6.#F1[U9?&V'1P\REC.> MQ<_"(#P4OHAM8 4 !;#U.<;1[Q'9KVM-D3^=Z=UBJ/7I'*,5 O; MU&8(J@$&L.2^^5;W!+GTL59N#A2+B6',&O?Y-\3N!8Z<9A@ &@2BG6U>@?!I M]=J=/M>AX2C GKLA9M-1IE8MS1"-A+%&!%$5SN$MAZEQ[QX3[5=A:N:T9& Y M)'*)<'[,/Y#R<2U5%?68[^)Z*Z:?9HA+%=%9@CS >0OUV?QD(9[30I-+"G^_ MN>88R:@M:4]%;//KIF+TZ[S1>9T/#;'*WAH 00&-?HMX')M(:JRIJF )83G# M PG2AKPH=V%6DML9(D>T8K#-Y<6,V_H;6W7:J3283/RH-89ZHXNO/W/=Y_=3 M)ZQ6+5K1EO+[PVA1[;7F-W8N.-1PQMW'A-_S,53]'1YN)9535@C'\?78IN4P M;5?.^OO'^E/"#YU9@LYGX-%0YA4*;%)8%+]>($Y%^<@E[O_M$OAOP;K^\_% MK3"Q&?X!!1"'^@6BG4F/AG";7O?=VDQ=!^>E+^Z^^%R(S9*[.;7)TVE' MVO7UT#?O5:NP?_I_2H&S&:CFT*+HB6<2:WLC*J0M?+8?Y_EVT MRZ5.W!(!J% M';2I;/$&7O::-;I$2P2MC3P?0/J/>%M(_ULY1'DE>,Z01.(_4%D??Y;#+)A+ ML,S2)PH BL34>G^GL4LIB-SR\%YE5,H,VZP])DC3TGVH'T M!Y&T0B(O3!Y1 M.ZG=55T1E=5]=&]IUI,);',#3,+W\,)C!6*OX_'8]*(%QCO_U4[R^5W,Y"MX M[<=*I.GD8=5/LONU>,>]L-C>6?57]D86-D4CTB%02U_-$_+"3.L8 :E#PK^N M"L-%OM[%>\'S5IP8:G]4ORAVAL9T,\4DRV@63WV.#6'\*0M Q6%?E:605,*6 M'-+(=/_'P75TN;=L>%\[LN2N*-Q$J64F9N,X#QY%'53EGE-$IDMD3K/3*,RC M28P< X$\<,.]Q7[L!1T=^&)7W/OS?V M9,GJ[.A"J6*/9,'9+GY,+=U2%W;:RHHDDCWU0 M0(2+T':R!.E-T:9O"Z_V,EY,W%32XV> >P6)PKSL02S$ 6>65+8N7![6RN!G M9CG1:&4SOW?_$"=Z^'[KF-$Z&)?ZOOZY;_G'$\,K2%:I9UY36FI7*3$(G4R\F90:%XS^EKAD>\>G*W&LF1SSUOIS>XTLYXNKY%]): M#7.P$,9Y7>'!Z:HW=NCS_'IM LA(821:\;<3VIK0\?88J(^$3MM!C/',5NU M?RQF$&]/^'I8((AO;8J]2&,[I-]48"FP^94;%BBHZ#:!I?)RQ;/_RKO M*Z/J7)9$-TYP#R0;=PT>W!)DX[IQ=W>'8($0?$. X 1W=TEP=S9L++B[DT" M(>>>>??.K'7/K'=GS9L?[T?]^59W5W57?5W55=U51B/L7#?1>+NWVS\G*]D0 MTZ23ZZ(+"R3=\7[$+,S.+J]OVH%,+I2$^4;?+K^:;NB:_!E5T[#2&OUU.Y"_ M7%<,:AH'LJBI*UCF66ERQTZX5:O@'K59[F6C]FY[!'"T=4)NF*NJ87;N)%'@ MX][ 1HC]NLB!S]0H6YK+Q>?NWTK[SGH:4)C>SGVLBNJP4CI4A-'$I'?XW+HH5J8AN%G\GR)K_336YB; M7$-#^9^I=AR$_1D07DI,U[]-VCLIS%@JQ8QZIY8EF_>5I#56L;&E"9/[^H)+ M&NG0D[ ML_A4W#0T/XCD<ZZ [ZA21( M#$$J8'R*;;TMS"(" 4=;-DZ*T]]6JK8N\L?)>LH4.0--*.K51KG5?_#'(P-. MOV:0,Q4EU":_^EZ;:O/# W6H1"]4Y7EB(W4FZ*$^H_S[^'WSCI39N;VTH'B? M4KF%@O>K1?F28\VQ < ]3(6,>ZJVIE,U^0LDD?80 N24NYW#?4?-R27Y@>O !8Y MCX#W!99W(G/!R?O8/F1,J7B=8%]*JE.S #O09IOW6Z.2XJ,QVR_5U7*X[&^R M.&ZR')@SZV=IPWE%U&B:6'9"RP<=A48%+(*Z!R*#-6=+"#=HW13DN5JL<5A,PM1':LNZ@S2A'4M;_MYE M[QI+P )D$,NVW,G7$'Q7MDXW13!PI(N+?E'$U#XGP4,!M3GY ;6+1;5SK8F MJI(K#<+[OI>EMU#O9AVNVT]+_ D""]9N*"]A(BEE"EPZJ=??OZ_3H\!] I.D M=_L[Q7*-,@=K))ZC0-62Z!CI6B*(^?GYAJ5B-H%1(1 9+81@,9'$P=Y*?6U= M%C4&$RI58JQTSP+>?&=?5WL&.W+6*NDWHZ_*NPLV;J/E#JIAS*66M@@Q3=PH MJD[$^+N8K@VBU@VG=[+?N&.>L0A$Y.<;+"[*TUSD)4E%U5;['?%=%EZEZ>S# MGL^\W-[RK)Z;U/LDPM"4"J*2!%.>ED?48C5[T7.,1$;W>ETA<+-HO*[*#RXE M'8N/V!P//P&K%G!3O_R&EMBFV*W2&"1FE@ 7QH\<&EF C:!;/96"PXM>)))2 MJ(E;)%-9N?RQPD X'$.,EW.^U'']91$B^#@0M%4L^&%YH%BKJ>!GI!=)7;K^ ML;MQT*[X[0N=#8KVIE"CA#'&E[*>.V>EMY[A.G=JO.G<=GQ&'!'.O>)UF=$) M0@3K:3IY;E1OZ>&@6?)3R1I\+' B!(GJ0'6BC78\(34;&*:O MTUF;](U*6)\D.LY/!Y@NYIHF3\*>?VN&BE$N3:"P MW5/HF3P(6>^6P[SU'4 M9 P!X5XG<#8LIF ;?6#3HU-R1U2'^J-J,HNR'!+#FU2'E2D!2A;+O/" %_Y. M8!69AG(FV6UQYSH'?N+MN@HA.6?[!GHQ()"HGR W,KJ2QZ0P,/DU"^E81<36 MD9^T,Y<>=TDQ 2A>;)P'YTQ^U+'-[N[.$]+']+51$4:]SU-I2VI/.-P8?IPT M27<>A+$(1SKJYC%*K9LK"W#A=-:1J+,XC+*9R.#QQIN0DB0 %]"+BK[G/@AQ M,U]^-^7R0W1GMI:GG,Y6[IY-RSYUOV\Q[(-0K,_A;C:V$.R0)P-\C7[$N;08 M*<0I]0CH<1W?4YG?O2W=;[A-'$',53PT&6< 6&YDV) 5+FY ?5@"_C5^VQZ MI ]\!T<1,0KT:B%*VF53QBP)?I-)Y)X1ESC9>&* S+HZN.VD%L]P,ZC6B*66 M_"$[L:F%USV#C)#BE$R\]VIP%QT&.[+7J(\^ =S.38, %'=O%'YHP_)6<^2U MYRHXJ>'VPR^JW53[M@=;W)FPK3^>?5XVGB$F#3K3I[,1E(0NL4OQEW#-V1)I MX@JW<9:A]@QY8D!B9O:@427[&F'B1V)DNHBW,[NF%HV&%A=:@!X' ]O0<@SVW< MAG5:.TJVD=&9I@!_D\\XT'FY=8$!8=@A;[9\H^;B8>8CFT2;C3* #"7I(_VP[4JXTD[8XD\LS4D8H7*>.KHV:#4Y=L3-9>FMD:17] M645:-T0.*Z5!@_HF2IU$=[L%_;)?1A]DGGO@G41"G:,M0%MO1R9Z;[M]%UOGZ!=%:; MB%% -DD/=;CW7XD;L%Z.^ 5C*XE'Y'Q%;I!)I6W[]"107O; B]3]W6PL[5_8 M%M==V'6R!$3"PM9JG1[5^QXMD>,TM8ML,TABB)J_WSB+D)[>S://5W"2K2:J MBW9D9HV5*JQ&6EUP+BE1%PFJ8Z5<5GR- *S5D:,,;B_I[2,E+C)%J%LZMNM$ M=O!6R\?[-ZP%6]IDAE 3PB;%B%\O$S5\K0_[ON54+;D5A95+7$3>F>20YST% M<.(C"R&<>FHB8!E&.4V[W(BUIF8"GVU/*/L*0:>@^/JF-14DU$GW$M(YQER: M$\A_%XO6S9/16Z,OAS?^ZG,O'W5,(G+*ZH!;HGM#VR>6P ](XM\A!_K"3]:( MZ'O6@CH )5=;]L**<7U0*H/.TH(?RHCXAC J8F"7"Y?D"K;XQ1?\Y) MZ 18]6OBS__0"78>I1D7BF4)'QH1VQ&9F9X4(RQCF>T:$S0S&0H!I-;^11)+ MU=> +!L=*3Y5_R($45"[W*Z%6 0<2QY'JL7/9\!-LWH,UM!*Q1E5$>H,B]?7 M7O!="(VUAIH%].H_ A17DA\!!K$_2K_M+9X_(9JZ5FX_5"U7H:MLGBP/K9AD0WWPU.'2G*?P((/2\%WQG>.\CNE[Q""AT''@$1(O(7-,O*#5/ M\F;83'YB+U9UD6X761Y[J35/)488H^!J>*89,-VX]0B Y?X[>9.#+Y>[7!/ M=KNYT^54EF9!"*)J$6Y@\"F[U3J:M+SFZS_Q2/^R>@1$M#YD?'OUT Z$Z"/O MT+<*:)=3-%$,$YL(X,LT\ YW?/2Q_\6<]FO0;/.TN"UF M#4$8>XE/D$I%AE7,2!7;]KZSWLDOC97+HY_D9_] %UGG.-N.E!WK9QQC5;2C M7XS4TT02\^(?9 R&'(MZ> I\^4L<.:\ )F)06I%F^ MK"U#)6DYT[OY&X: J]V_T[>DMDO+SYHR09=B^=)!BP"X$Y%P"+YK]'[#/^H: M\,=2;0;T_.;L[Z#V^4E2 6CZ3^9TDX0[WO$1;:'0Y78LYLR_C_KM M3--']_=Z;<8:72<Q%D(,9-1K+ODJ/)]F*O<'V>3_ MV"'^V$VJ:R[[#5HB"H5I.XV.>QG>SVJ)DH?LOW$\_T^2VEE_HW*1KO(%V;L6 MR%F9IA2HPTOM+]<#9XD:\_;"NJXK59 M*)-68SGBN$P+N5U*=;K4XCWE':_-XUC\0H?=BQQ.N+^_H//>E'GC<6PKJGWV M%NR*SDQXIW%Q6I0>=&Q3D+'FS?:TW'57,/PE,O"K-7&)]^ !X.:-N>?9BSK% M!8=8EDG*9;TH[$J=A2FZ:MAE72M1!PH_4W><#3D.'S\:).VMJ.R0TLS>-'@,"Q/<;V/&:'"IN(?3MC47XU9WI^*WUV M.AI#KPH=S5?FJ=77\*!P=J H*2/,@+J^OC%LM;1.]7X6OB*#J;=M='; KSMY MX$#9QL=RH2RW,9 )T4BLWP903A]QV03>&$TVU0TT4X-:)"B<*825<^9_L1P/ MD!UH.K5K%#BPP9-IE:$HK 2J_@CHNM$1OFO-$:C%(_8@@)L@#5#4K;6#H=4@ MSX^[[H$S'Z:$')O$(9 $O<9?U*X-.6-GTE1E#R9)Q^P!?45Z/UXIM[5+Q;_% ME6I5=QT8!7B<[?.Z J5=7P(M0V1YT"5:0[MPT]U/] P25WTCL5_?E*!S-U$+ M(>\R?6]\GW_GIHEOIRZ-V-/?3R%X88D@F M7X7/(Z KVK>T??'0_%4ZN9)LN>L:>C($0_55,G"4JG\NZGX!L/\D W8=*$<< MJU%7Q7C'SR@Y\TI,2;7(F"%0(5K>+W<=U1W#9!.1Z98\UD+\+FZVPTX'&,G$ M"Y$WFL2_T]RN"&2$*_?M"Y%QI=)![8T#QZ8+QO6N*D3Z.XXP6\LZ22+8^Q01 M<&S&*G5C-VSCI9(49VXE05F MPM>XP<@RH\X^AD$&4_"U/QVV^9][BGI]%?]5PN"'Z1T&VL8>H)*_@.4#// . M4NU>O6A?,AKP*!16T*YMB[@FYR4:VHP=:F9>0>&883E>E6EK HQ(\]$W5X1( MU,:/3?;DV@HFU'EL!_)8_9/<2TSEQVFV14SE4#FJX@$,+G!QV?XW[\#;"62D M1T"HO<,QZXA-M23N&*&3@F&R^+1EJ$G2[&OQ,5126S&!J@$CZZY SO73Z^1G MR((RT+!E5(3*S/P_&\3%":0K$Y.]?_%GBX$^U[]P$D9WB,K^5IY63[JS]77FP5[]UK:&N!6RUE9-G]S#Z*] MP$$(Y H2(VV\+H]1]R]AJ>YX^8'[VP).Y%6-8-NLPD8,ZBWLN?U:.:\]F#'I M?M.\)XCK/&BVY1/1M*V)QB?'QLAAZ@8L3("MB@);-KR6ZU3Q]_V&!DG$RIMS M9.$B^"M"^7V/SG4E=H?DXXA,YL\6&*807>O.SCTQO$EY_+>*B)%9Y:\^!T+: MG&&I '>"&7>_(R/G/<6_C JCO>A+36U(8\TES>\?6OXPVZSUZ_6Z-?RB0IE] M@R*<^ 7N3]C3.IM9BP"KIK!3"'P+17TTMV(W=.+QJ$R>._554BR!>LN@7]/!!7/XTR594TA@*X[B7K94JB M0:#+P!A)0^-G*6$NC32I,WS01XMXF;G@C1&1C-()JVPLC%V?WHK/[_JYBYFO M%';@6XXH]"J2'1I#\$/A^EQ'#?X>.L7X+Y.!_V6QYA-"[90C*G?K-Q\)_#)3 M"">@+FU6H7D4##NI@ N-++WIBE=1;-O05JHOB%GE-KLM7PL6H$YZ \MRNDGJ ML_>[S@FA;N28>O-YG]M++N/5S<3,<-=^UR\+XUR65[*?$0TVP<'9\BZ M:'(VYH\IJ'9&E)*WW&_I$O_,DH)!Z_Q%(-_)D4+ '7A"^(*G358'I,K;_0BH M??!G4A %S[AC2HQ:6I."MZHZ98:.3E(O<1JZ: 5Q"9\.(!J^PZVDG/,5YFA% M'S)R:?#%@.XCRU21/8T:*B*:-S:+& 44[^NPBAS3#WS>HP^D_]W*[>+@-% MB@_('#]G= 57<+2':>P]O%*R6-ZG(/MHYNC)F3M6C9GH[VQ]CU'@G-WNN\> MV!E%:4(&J,L!3D2WXY$\SY.'(4:(&5_BSB(HSL#?KFTC?1/-TK.3^"6 6,Z- ME_>VDT&-REBF)'LGRGJCYO;<'/(1+TPT1 S%GYAT5Z[6@_+\J^\G=L8[OC?# MI@E@?+TS0"*)VR(>[ZW:"O&#^_#"OL_77&>$)1(Y)EETICAL>HAD/@*Z$)%%JRQHJ7\RIP"]1P5$PN6"C\ M!=+K_C;KO-$F'",N0]I8O!N_;!OD(GFS;.I,3+Y4]SFKLC<8:$D)NCX=?[^_ M>P1HMYRZOY^MD845'!&&JW)R7R/6:'AW .Z)\G<][06=]I%%1#&S.($GP@N6]EL2.AU9AW4+ M^I;R%?5V*FQV/AS7T\(JRBK9Y"%4#T<2Z7!7%:FX&)/]0E9-QHE\.X14/1&] MB00<^V+9*/^L^J0J1U>"G,P2XZTR$B;342552BH"UB#:!JG_@42MF^^\HW%* M?N0P(Z,R1U2LSG_8@+.Q$%1.8XJ=N0\PBB@SHF*S3BQCIPK;3K_'7ZP@Q(F,&PZ-;M[WMZT9R!^S0HB=;A,M M>N/J */5Z^NI2]F,P!>'EHW.U3,WN,SM%$CK'#Z1A;?8Y5,F9S7NUB?S,VZG M7"NMNZ5N"LD0EOKUYI,UBG=M[HCH5K!\XAH>\SD>M!*[KF-^&4DB'97>F8*7S:6Q4G7 M:Z6"G$7'&,M/M<$]:Z#+TALR8/RP4AWO+HPK;Y@FA50,4<-:R)NV[;:.2\>X M3)F]\VXG,RO1<,I/A;?4F\ 6+8<3V>YJ4QG)2TC0@S+)4D.;KAG?V_0'"O!= MHF>/#_=M4G'^.%IT%:AYD92??$WS6.A-X:*>$*=""/F*\*=;L']_).62R%". M>A_H,AOUF#MR[HK!+![D2 78 -K1G'646?FQEOB'7=%E6ELD %#NVGA=F*NF MW4L55$'4C?[C."_O/Q+FBP$],G)6YO>)5)'\I(AEN,Y7-ZY*/ U>0,'7(%-- M*XS6S6BM6,[?3I[XEHGCO*FZN4VI5#E/VD\YK^I(FEM76E$E2+G.F M$Y?K[0A/\I4:T/6RN#XMMNX[UT]+*T@XY<7AN_K:LEV=_.N47!8'OSO-[Z]% M?2,.B[*Q^=.Z6O+.!RF5VJG9$2\19QN^Y>P_5["SBRKE?(N3OB:H:2S%@!"H MA+F/9T,TG:@=S4Z%Q4 "?$7U;6:?]RB'YZ[BWE.:COQ)&K2JA/' M6RU)5KAMW:@:1DHJ,:*R)6ZDLC_AFO$HEOL=SCGZR0OM5?2%(A@J6)LA*1("42181K6MT*7M4-[:W*8XO/("NJ= MA)%8 K?%Y+__#RLQM1CS.37,5)V*X&-OL_RZUE*LO=*36%(49 MX,,2G9U="?K6R1F3) A,2JJNVH[#%LQ\ U^@BZ6&F(/,;4MQ/>2? M-T1FLAA/QQ]:8ZZPCF%U1^SWVVFCWH1Y M'?L[?"A4651>8&W,GIBT/*9F%I_K;'3F];DIU&6MF&VD.>PU9>U15B_XV$SFSTAM>V_I:D7<$(4:O7I81 '&E[M%Z\(\E=)ME_.0WO?P>8 MZ;6R5-]WWF>A)K!^&#?6@2JC"%N7V( /_$5* 3&H+J:+2ZY:MQ\B*]>@;A<8 M3$89Z 1C());F"TW[I+$Z= 72!\J3U(FR;1I_&MM03UGA-4-*Q=+3$52RB4=98BRTIV;"B-M$"1;!XV$U1 MV2]18W,GRQB6 1!%(]]X/L#8FHR^):$[-?I^0C-I%BS>^*4;5RWCW>E> NC% M%R]-C)Y'P/.I^HT).ZJJIMH8',KT^ UH0FH$.>9<3Q-E&C5FPDT1 AHV"6A3 M@LUTGEW#$N%'+7CMS)4+@;98Z\8H_;) /'!/+#CPO$62X_14K+]/!\:DEYD5ZH\B[Q'2;-@ M%8I/VN]+H(JU9;KF8!8216QA*P1JM5EWAC:))(_B9L PADH.4@*;G&O#:7W#GXX@]F2JZB7MPD;VSK1R0R:TU0H2DP@$S:&.TYM6^V8 MF<=L2G<\X#GK1V0,H1YS:<=FSW,_6"F4F>'Q"L:YZF3\7[Z8<&Q1\M&16@6Z M]P(L]UX_U\09@:EXV]7@Y$)]?GNM+Y:5,/K.>*L^A6Z0_&?#S\<04V9QABVB M_]M(E.EQPB/@@$=7^52RX(M#55L9_!$_63_/C(H8<,0 J_$YO'>^-= !\ BH M\55;Z:H>S"]/&&X=BAO$%8X5#A#8W 3N% M>])_=G_J1=97>%YS3_CFJ3'?A:AL6QGIFU=O%&0YYQ,89$7QB"(82FC^W_VL MU5>MI+)GV7>8*W&$-0_K@;R*DCX#%R@6KK4&%=LU*V:T* MMBM,T6[G4408MO/UM_7-1!+B;&SY@2N"9K+Z+2[# ^RBLG&A9?VA9XC^\!?3 MEQ4)&BW-6BQ4,6M?,-X?HY1B&"FCF$LZJ7DE*T^[!9\P9.J_+Y[S.>YC3/CQ M0?\YA[?Q6Q=!-C0R]N9L;+&<)N8LPGW(J_2XS1PVXP67G_N2-H\ Z_VLT]AN M-X_(CRL >U&&[4"!".:@9/W9G&FP=56??!%J(450.O3ZQ7&^2+A#6P<=&H&$ M^J;O!(JCI/,+I8\$# M,=)ZPLY8_/U9+,R%9Z9&Z269Z.KDIY #9_AA7$L6K6*UZ08&A(G=2J&LWAZS60-BV?W;#O:%VXM3@8*WS,%?SZ0*"Q4(R_:U M!K[\FI$0NRX4^5;>GC&S//$1=XYZP<5UY8\W9IMM@K[>PJ/9S2T7VALF&XA& M@^0/>M.HID'GNB3PO]O<6UA-+0]B]%T:O\^C MOZLO_.?*VS63 G&I ,5F]X!:8X;ED#Z,^?--6QL;LT#53G1TD<:UZS9_>^'$ ME+WC&WT6@9@$3H06=B5B81LK!^[%V-?##2MG1^1W.=6' M5QETY^OK-&A"\7 F?#2/@-N20YW>D&Q&@=#O5?@=HXY2D87^BG92E!H@&BL5 MC6A$#C"50^'H5) %BU^ I#"'<*J!+/6%?BK4+)"^N@II?'BNL M0D6,<#3TBUBY(PE"-A/C(\ B)/8[/2E?L54VJD)^L]&RO&]@AZ#U@RHA>K5' M3,CO,GK4]L\ Q'%!BP0SM0UJB<'L2CG02V5$J@7"Y%&<[(2[#E=9^R^6;"82 M_<54^3F!5+9:0.,O$L*SL;7=Z3]!67KJ=8F-4?CC:(PK%B'\YPDB M3;\1&LP^$_G%L**BR/Y6G$QG]8KX0/6)O)SJQK#54:!L9909VE_%-O\>XWP3 MTY3_I#2<801P;T"^_1%J/DW&E.@/1U9@AQC'*"[_)IP'Z_F'(^M_G@%&VR[:SS,Q*09T/N5S>S_,YXW;R$5X "[_Q<63T5,C MSOGNE+RM>3%+=N])I\@IGI;WAK!4.M$'I+E4K0:[JNXND\8O]QV9TY*9-K K M>E0:_]QNB6! ^!C9^9IC9.P5?&X+%U4EBN.&VHJ7A&_1+/%Q$E^( Z5F.LSP M=^+OK/=]N5YL[Z;.6CJHB:\0+[1=?Q#M>U%'UQ,-$N@&,ZVEC @9$VUB=)& MWRX-4F5 #HGU\'^7[/F72^?\KT&>W>I&.2L!7%:^?^-0VM'S/KS;UKJM?N=4I.G?JJ=FVIVD\_GS8 ;$4Y!3D [@4 MP#W_@*=E0 9 1D1$0GR)C(2$A(*"C(J.CX&.AH9.@HN'A4].2DE!3DI&1D7' MP4A%PT9+1L;TFIF-BYN/CX^244A,D$>4@Y>/YV\G<"@H*.AHZ,08&,0\U&34 M//_'Z>D[@(,,MP(O#@]' [S @8/'@7OJ RB?Q_D2[A\)^%>">P&/\!(1"1D% M%>VY02,V\ (.'OX% OS+EP@(S[7^S_4 LY+7&IN*40\=3,D&A=\GN"D?&1: MZ=H?!!K3IW2\YJZ?4% )B8A)2.D9&)F86?CX!5X+"@G+O)&5DW^KH*BII:VC MJZ=O8&%I96UC:V?OYN[QT=/+VROOZ!P:'A$&>%P\>!Y KF^9"H)0_R?H'61&U0VPY^-9(9:WG&NFM,0XFM#&,T,<6J^I(QYO@$V UPYRQ69T+YUVHW M%B]RL67*7K9X,(N!NT<&D1+%F."7[W^>R5T.'?!*C\3V:\\FS<)#N@*C[W0" MP^N]8N[,Y3IG.9*D= 5#"]]"DJS7[6*21ZE'$I2 M/ $[ RJOJP,:O&M/%GS_%_\M*&@^=D2D",3B<:+OG ZN/CN M(UTQB^J;3)U/8JZC=QK^RM5P]*^)/UJZQ."NK"W:G2!8,[/_#--=>HT(O\ZO.^ )_NI5R\$/ MROQUNJ$M<+Y4#R"1-8GMP2\-?LP[M MJ8K/A01^M0]@O[&C[NI(&8.=O,C#"CPM:76!8F"RWF42U7ON MO\K*\ID?!G.]Y:&B+6-C36U*W^WMQKC?9%U5=;8V$G%50'L"YFM0'J?F:SJX MNIA23+.,5M:\E5\,?:A(WR*YRL,J,W@C.]I6=LF(WV6^03X:,I/3>#X9TZ'Z M/ "V&&F;3H&F^0-I T+,WY)"@K?SVA.M6\CN5<(3!]#C\;B-<*2,#^:56FXY M+>. /U\=;4KC7.T"DF#Q.5[ ^&C[C.A"J*VGSWI(%_,38#[^5 P/$BO=80)-#^V@4%6ZXW:R%RKQE\5!/:(;0-6=NNZJN&<]]V?V U MU6Q*9_?M$5BBBQQCQQOQEI,2OC/:@BCC^_$5:@T,JQ5,).@0O )H*DX(&R; M#4"=4\T$ZX,BK["67;L)K&+ODU@/8TRL%X9&RS]EZ'?RG;XM#8R@;< NM_CK3W-[>6], M?TP;&@ORC@SH: NAY;C<3B'FQ$#++R5P#@PLEWR7^ZT_U+<2!V1+"._[]7'6 M^QQ?3/*?.T?=RU;*E-]447>G(? R)8!PX@G3#[;Z L@B>A[I_%U]H_A?:WM] MB9\2W*KI!'QUX^YMB$(J:5J3\9B3FL*0""(V)Z/3;[MJ*')]K:]P%7DIP0'7 MD-::>(CH(]ET,3&N:'2O& \HHS5"8\;/=W.T!I\.;P!6UD2XC=%!9HD*W+X9 M"OET@*72$*[7&\J1/WF:,N[56=75&KA%'O#GTDXV/?GL;=-&%C>0*'RQH8N& M%>DG7S/H5KE$KF&LS"BNF]+25Y'R SY!$;B-*HDB9AV*'LQC@RNV0>7I@SM0 M]EN%9COMJF'QX=FK?EWNH3 CBTWZON)!N5MEOWJXQCS?1;#_NE:958YNV9?N MS9\P@ PV607XRC5"R25D&A6.CVEEDYI*5 VFB-3]$XTRU G'[^H'6'?6*8JK MRS?)$<]ZM5I:FG&]&2<861:!7<8FUIE+#)X3V1L)7P3/NM71*[4>:04J,A=) M_,; V%J# YYENS;+I5"7+!*S;=V\/9^1@R7^QOO:AZRQUK-M09J.ZXTL ]8; M0@EVQZ5#E_-KN'91C\K<&'"J^25;0WM[35,O2J*,PR]U 'Y', \+Q%$1^XUD M/T4R22^11(%<4HQUE]QP@/3HI!<#]^0((NO5'*"I6"GEW#G?IHSH:-/SR)"U M:I^\CI;-MTK@JD*,*.KVFPE^Z=UTQ4L['+V+ET%\WN4=#)%[MF9[L=XJDZL@\ZWQJ, M9?1/N_N8^;"./-N;VYKLT./[.PI#)DWM@5MX/MW0X2I[Q>/NTV^.+72!7RGO MM9V]2@<-UH(M2@P,&+,RF._&M4HL3'M+GS=CIF_9TD_#4?X^V$!MN45KD& U MD=Q-;&]F4?3S:O0@+V7:A*\N#M21TCGH4LSA)O:0R.EK[/3P&=70%HG@ MH=XC8_.WB.\4V.D_:(C"$C\%.;&?[02)1W?/LE\5G-&WD2F;11\K/I1L(#].DS93?[RF3',-8/\$ M6>]=>^DO1FOX:;1A0(@/[H""]B;-;//A(SO_PA@2A4,0C,(?I-1G(C#30$[( M+C.F_^X[<:'FZ /K@)/%IRUY6$=;<\W4?.43@,[&V6@H,BYW!BJJCQPD MTW#%,E'MYE]7EZ20J;GG]!?I]4PW8$M1R?!$'B#<)UX=I@RSO['9%,@N/)A? M:AS_-?ZKC[LFO9XL<@))!02QS<,4D;GQ+;5M"Z_Y2._=W3! +T\&-WBC@QZ( MQ.[(>3^*87VU-#5$=R=, 3?A,M\I'@VW5_1[^I<9#3L$NSFHCO3+ MB=F+.6\J=]4''"\USG[4<%RW%U)#%*1,\^''A^O?#\2XJ&(U]I=#]$]PO+* MNRO^(']9'6#Z25AI;;A>K4U97$%TL 'I%^/Y-?]!JAH2$>AT5[D.QC3_/OV- M5YWF M9D+<"8$Q:E'!^T.I+E+;PTW9*?;1?DP8[9"0S7NW%.-&?+@WBW0^2OJIYQ8X M^#\#(RV*O>A/>@T[Y?4(;ZU3/"WC7#K'*OV*2$2#4P[W3:51"NT,^-\;^R0H M)F)>P.W>/@$]RQA.ADJS[>!1M4]S2)OL6?/SZJOV&;JXABJ,F/?; MGS"%[W2+U"7)_">#')S\')&BD*58V7\:4>=@C) MWC7.)'\4[@^G]_+057%N?+!P]GCV=7%YY*F NLMJ^=YNY,I[D3+Z,8/^W[4% M:6?D\1/^]28ILL"'I=>][+QOISV,V:V3]?B)..XB5AG))5@&9\4Q]%=[2^F$ ML_LX+;"CZ-0G7OK$X!FU87LC]LL^N%\DPOC M] "UQ^@9NAJFG#T!PI?13/ 3?@JG"2HPPF*"Q5D.QW1\%#+UAUGX&?!>!^4F MWVE::'JYO\M'\F:G["B:-L7GYAZ4H0;6Q6Y?5=E7OA^@DWRG]"1^ E";O]YS MSUP:4[Z9*6I+LX#H\;W!-"0^_*/K*0NXK/&>8M3$\E48DE1;AAI:6##M1@], M!V#;S9-FD<8]YKN5*2/=%J>>=E?Y:./#3=J)XS= :OB5TI**'Z?-(17NNV75 MQO'*F>W"Z@?E?)L/$_P8[8V(A5UU MG(S*',>1&<^?*J>XLY2L+9(*W4!4=KIY\.VH9EM=O!P6&S<9(FVWJ?V% 1-\ M8B"P*!&GV3< 56TH<%B,QS*%58B+G$[#3,.JW6??U^7FT/AR3;"6% 2)^@Z* M8RY<=J/:DGK'C+,KDC1L27F76E,N3&14GP ,QGV=G'#:#_YM":3)I-U MNU R+4DF?\]JS*.LJ]71DJY?.$M[ML8HA"JX_T?'.NPT4 G"[U5CW=G2KN26 MZ64EI/<$&%Q\98*??&;07$4889,'4BOX90JBEX4$V^?+!_LG(/*1S([T,<7. MXMR0__,+%//-]'9A)OCLTXS0R@[:XH?XV8;X0?=ZB36W _OTW U#8][^YAS: M3YZ@S##:4:>@!=-GWA2'/PV;C*CV,+S[0ZA4L3^6%8AZ13G2;L^4]R+Z?YAB MI_67JF;G$P?IE-HYX+'L@:EQ6BY9MM679K:D:0^_K^V\L=)KFX\GA.-9K3?3 MJ*P3_?+<%-JIB\OV2A0R7,FBD\OWSZ7X7E8-#H.;4_85L<#,\8KC^;9%PY.* M//XL4831[Z93]B719!E4BTG$4X$&#9NV0]&3$.3K=6?.L"CNCFC>L)?7H'E'C:N:E2^S5+-.NKX M>J)7BGRL=N#@( Y=\2'7JZ0[/3*U-BQ(882 (0@(M:A(&LH>9"%[91!MCY78 MRJZ\F9!P$K)HP.2B8750C-G5GPG.MF3['X/"+ !3BJ+C*?US?'9NDB_QU?]% MI.]R%0$#9AY_IN&+O)=_.X_]+PMV(4'/L'.?\3]W731\4<@("6)2?@*H;;M7 M^?/USP.'##BOE4W_\5YFAZ_+?- B"=D4?%G)<5YS(R#\]U6S+_"_5UY[#-B^ M4&3!\4!Y7Z U? 1.%)"3!803W9^[S*,05H,O*QIG_Y_5_J'PL];IX#&B\A=! M + '? 77'<\PD@P.>4LH-B&+(7\%5RJ+9XK:\^B_)%&%FS.'7-+VRGS)8WNF*W\M6F3: MF)%+718?^/=$>M:-O6YD>HA'_X.:RH$FT."2%]+B3+(W($2D&>P#8WKL'FGA M)77+1AJ:N&\KHC9VNQ1ZIW,24DT?HH\MIYK&-,II=J*G#^ MM3T!"':6)[/; MD^-G>5^W<]GBA.)V]NQ$,UK"T%Z>4P M);(]$6OY:] 70($LXUH&!17"K\AXV M MZR'Y[\LAA_,-!3#MR0B^Q?G-4?[.;U[YHE_0N'8O'UC+8[Z#Z0S)QNA,+QFPMMU^ U/O+P/"1(\#"3W^K0T?G+"[N;, M]783W?M<;XO_555+^7UUY_G+&^.0WAD6-[0D\_)/D7,ANMR2+N=^!X.,#2=M MZ.:5<1',X(\P.S^XZ#12(O^T%TYKO&NH<'E!W,OJ_XL6@7)L"HF@!'3[&>PH MZXEFUXA5/TPMA/RUWU6"I4[4N7QY#13H](*$+5$4^V,:YG2[A*8QJQ>CRMG1 M1KC^5E.X#'68Z2]7%>\2SF"^G638\:^<7\=XHZNTVP7;9%@JLH#KTF ?Z$AX M0>F-EF_F9T(%+0I=_AFOU]KS_*];?']&-L"]4WD"O)*%OD[Y<4\5Q,5\^=7" M1*N?\ZXN>(8B&U0PU: U[2@:UIKCE]O)F\X'5R&+KP;WWR!$O_4SPIB'&5VK M1'F\5D%4E*^:_]RF!CD$+<%0OR.7ABU(D*C<$Z UGPYZT.8L$@#'?6^*PW\8 MPU:@#*Y:=L8[Y+H)\+W9C6/_368X^"H7[-J*)+Y+L"R[L4HC)K[V77H S5MT MZ(?H\1- 4XX5L21_U=IIP1Q5=*Y<&[B:,>$6GVT+GYP!)6S\8)T.04 FIX[# MTNB7$GMLM#?%!U6X5?1DN'C[>&GN8+N.J0@LF!&%N'M9RK\U=%7>C0^,00BD M5> ,^E MM7*PQK3 CQ:E)!WYK0PIZ.,GEYL0@Z/3.QE_$[$W?8^65OI$GG 1?CI=*7F+ MMM]69*UC"3TY&;:R4B0IM-Q;&E:Q-!=(0>$91R;&+9S?=:A<_H 7(:*RY7KK MV2R;2T(:8TH@/+?=[%:)F?/J^:V>)<(B3[^,9+@W$B:HZ*>#2;F;2I:1<\M/>2TP' MUCLZY"E0$]9T,>-\&_$]EWPEC+X4>LO? 2X"D2]S&.OF57&K&_90!=.@CV'# MI0LQ%),_R^J":(#I/U ()(AUS9@^.VN!QW\HL?4>$91S.AGOOHYGFT&:WUG_'*VR2S)<9L[>Q6VUL:?9$1>^6H/U"?*[E)ZXSK9+Y#AUME9^0J_ MCC+314U%[%SKXLA-[;2O.<50QAL=;_DX7B0=W57EM8LD!8R]1R[>D]E*X^,N MN.K%8=]56VSMJ'.Y<*36?6Q[)M444KOA8;E+S?J\=O#QSS@=W+">K <^%<#'\U6"@G"*N:,4>[X5%L">V\$*$B7U; M1N3EN(IWP2R#KUU'NU7C>T)1G]U]DY0:L=E<5 [2&X)6@>X.I#*A/,Q,F3GH M@KNAL@J@PQK96R;V0=84E]D\_X?SNW,CHO":HID S$5C:5+O[ W'TWH501N$4:4UY6JCYY=RYE!9\.#ZO!7FCT.A95 M:XM/7ZA70M_+P$-ZP?1SBP7)Y FHLC,P7/-*@%87@@1*70CBP(."PA_WN"[?'^:^C^.3N9%@F2_B2::X=)"2* 9^)2_8&KLD26QNM@1VT M2_[SN:+;[/C@4J]R#U!&6XH&X?@KKB6UNECW"X:V45_?A$@*YMGT:_4^EQ\1]4K"8] MW9OM0/>9 Z$!L\!K9<"-@J K!WIU*U24+%GUPPS2?(DFT!%'0,^=]GZ18,)+ MQRY7IULWA0GY^R#Y8?6A) E8)5,@RP;7J.&0UNE5NW:<TV\+IG4IY[BYU[B;60H>4)H'04T%GG6J$,/IS_UC<\$ O^[1P6G69;N@)5 M?/Q=T^C#&>+4-9W/8H'(P.)BHNG(EE"])C>FR/*):*;*QSE8(([!B&MUQU5, MB!]JQ=Q3G^#AMC1ND/V28^R@5HYIG-T?Y[S'/%9C6A(EWK:??-\6CEN.V38/ MH9^XN" (&]7@WQG/X$'S=+&7PM% C:-[AGJ&Y'?XA,]:3T MY(D2LBA M' 8[/O"Y>+#S6KMP,B-Z9WE32&:>I^-=>-?]SA9+RN:O]UL7NH6]G8."O*3E&#C.0N;BUB0\Z: M>&,&PWP"!A:6LHC2:WN:NMWS)[S[ 7>P;BC-])6LH[_;U1L$-@QJ%J02%MH- M#,H[7']&T /8+G;LM5M+DN]D,= M\*_BA.B&)!N"'=%R_-OK(TF*R!RT&=S'8YCV_6C9RXZL)P!#0!5AW_7G?GJH M1$8IEZWW,?B_8L/OV&29!NGVE6=]]<&'G/] M7[)#%).$4 <77C1Q-GSV(*=1%MZK[Z=Q<%5EJ.IUP>@YCM9V.2@I;.L(QW<_ M3U142]/P9L2'&UOR0EV"3(@0=+6#F!;>!PU]/+JH,/ ,#4\?2E^*^]DD1R=M M*?+!UY]U[)YY:QWWX)%MH0%ZR+FXE?J# DD-4T0WST]T5E2FS'9& LGNS>2++OQNLJU3@G*S35\,$>/VN4V,J\Q4%&K& M6/1GKK/OG$6A&9BAC> MJ=(+^D,:\R?%;_7/$T":UD%4W#E7/(S5-0_O3"G1X_;(4'9XFQM%!=-)0DRS M3]Y/?@(&Q[[LCWM,\LA2[!NKP0TS%@-N2)M7\>Z"?-DU5[9.+WOB5HZ')""M MW?AVNDN>4:0GBA#&Q''DF(E/CNW?@#]!%'/[29/XTR?QLNZ7B)\7/FZ2C W7 M^F1=Y&'Z?OZ!/[2M@"W,926&S'?['U0RBU#" M<6[NIL1(49E3T5O'XF05'*WM*23V3=9(DZLS7BJ><$'CQ:$K@FE[TF@[V,!Q MJ^Z'U@ENH]P0:%.&5GN;S"LAQE$F'RR?WTX.FQVR"C,^(8F\:T',^P8KP@T9 MS+@\GU_9K:X'3QYJVI\17U1$D"66UD!*HY>84+C?E!E63\?.*7MMR;8^ 1_F M/;++A_^0JNN6$^S8W AO5KN7>@+DNZ5;QIB@SZ>O[X/7'\X?0&65WYPN:-8M M'%R5.FBNS6-&9DY;,]@1/9-AV6]09FU;M"J!/>%!H%]CO\O)E1:8.J3;TN1#V_?0<_JVO,MM0ASJYB\$4;Y5Z8 MHHJPM53YF@-ZKZ<]=$S]V5J(8+!VW&M3:IEVST531JR_Z1T1+H//?=^")6_9 M0TM6RG#N8M)OX%P.-&(V?ZGDJ<'FX7BM72]ZA06EQ"#*#97],)RBH$V6GIV3:%?)+*+^1?JLNK4_^9^*( - M++]_-F+^01LBB3G. >*5"X>^TC&,&AO32WR[QZH2A ZQ?E89[R [T4QPO$K@ M=PGJ3^_WX-P4P-&&%5YREE_P?<%C[3"=" N\CMM45&S+N)4IQ ';\0\9 M$D2BC A6Z==C9M-:J#L>6/'SH%<8$JK)"B)$&]I,"A?T$ZSEOX6J/?MR^*;O M^>WH,CS?6JN?]52BX5W48,QU<7CE:J(G\7U,2HIE9/RCBR,Z8_QNQDB9#L(] M;&-N/\>&3F=C&_DQ0>)94GV:\M,LNOD$$:JLAMJ8 MI9"8M000G"DP3L WL?17C??'0D%*452)[DQ]VB-@7QS2."?_%#"O*;_MLP;R M4RKFJ830;\O$U?QXU%Y>]/.8^8)OHJ=$EMO?8!DH/#R3S*]-,VDRCK" 8@-S M[LFP;^T\^WSEA[IO!A.(^8#?7V[8=)S+KZ1,"/8E7<2W+H@^6/-8Q2_;FB7- M<'U>X #W\.>=QR!?5IR'P! FJI&3&O/WQ.:_T)L+S:QV%F*CB0CJ];C^87Y1 M'M6!H,/;QT(W,['-%LPD40L:MEV$A3D*5LCQ90W&ZOZ\)K)-]L<(L8J,&]_3 M53_ZO-7%M0Y//*-=7\>C1V7 -1"Q0_KZ$6'VHO5S0WJT]+'H5I7V0Z[$-GO- M$Y +K7H"4/R89T5YH<;2,.>D2J>TP52D=UFW\[F]JA$9 *<(ZN\.3#2NJA*<1?\*;%3%6JVZ:9+N= MCEP%1LOT2\,0X$:]O79+Q.R=*>\YGH#03(T$/4CU>'HY!=)GD:UBP'L@V 6* MYDPFY59JEY%.:D><3.10HZ)JT'AZ+9XKE[H>42" MQ<4W$DPT0@G;&K27IK8W(W;U>.^)YJOX[\HOC!VKV)P,=[4%1535YX,$Z0 MC #*V48%735]ZK9@J'3OSC""Y?F)H3CQS?NVP! /#'B=-!NEV3J14*05(=?@R)TR M-(?N=*WYU?[M.0>X[L16:D!^AC\0BM2C-(ES$\<_3G%OL++A-%EV+)2'VL6B MP!<8F8,WXW!<;&A$5GW\*FF^U<+;=TLBEF?O-NVB5D^>6AVU"0ZP(=C3N!>> MY@"WI"70_[F=+LZBVSX9"7]O>)!G8K&5I. M)_LQ5'N;B'"'2X:MS[RMZK"/G-+&[X6F=V ?*ZH-30]T36V"C_D MYZ?1:4Y5P.LW/Q)/-]*[N)5*_KIM^I$[\8WAE*36A2.DW&BQS97&ABWT03 / M;4Y5%Q7+4;R>++UC7>KCBA8V M20&8%^P!$)A<":1/6&K $PA.*M:J&[7$K\G1 ?AGMO#)IYZ?,SS56Q)^;:1= M[K3C& 6&8C\!MFLM6E:B)Q0=,&/,BW,/GE74E=SS^Q#.O7(YJ^>LN'\!U[B M;O'_+E$Y#(^P1T!59Y$*2C/:Q1A/]\ JZ_W&8M1$/GP*N4*HF1"^+F MG!JLP>EVB[4BBE@?%FO,3[0Y^$9%\N\.;5=ND_2@IYS8?U+!]W$?/O^2K%;DT1XJW7$_ X4*")G,-983F M0BEX\Q?,UO5")^N1;.ZHV:D9ETGPI:I!/GW5BE1L>G(9N)Q_KYLV$^.5U&WW MV+-!MR,L'3^K0:@^%P:PXZ]S47QQOI:S[]/1K0\R;T@+WON89" =IW#/[1"E M%2K.:$[*?610ZV6JESUSS1*YJB#&:K+\/1DOLZ)+#%]76[093Z+>63/9.YZ" MTOXQ@C94R).%:L$PI6)S017ZL^K@*L M*UD?/IZH0?V)M8B7#DM8;Z4?2^3#H',6=19?A=A4ATK+"#IE"8YZ1&O5115& MZ*9OM+]PQ;-^3H&UIYA[D4>1JS6%M-"A%0'[UGPP0W<,W>T=IQ>]JZ^ M@[1D!['Y6B[X&R'U?-:@Q#)B<3]?[O(%G_1K-3.($*]1P<33-C.MTONL/M%&ZY8[)UVO0/'XXGJH='#=>\Z_OYHFS%_D:G>1&":?2NZ:<.!/&." MJ";3GTOOUHO!&VT2/Z5JY3%P]@^)$VW?.$:M!I*6&:="BA+:1X*W33,1+[$* MT;6+(IUD6_F5Y9POF\^;Y[[6$[IE>%H<#X!)5*4QV+F1">1E\1O^>8F"DQP M01P8$+\2O#]0;*9H9R,%[7U:(XS7[!C3W:7X_LBOD7SP>NIY9LVQ"W+R-,HM MA70];KF?)[J9L+Q4W1\@2@3H= FV/R:3WV$K%.,!O'EO?:.I?"0]ZU>8B] M&I78-"0,Q!+5]A_S 5%=)D*+RRZ9A2Z$*[#B2<=;ECTM\!^WA!X](/OKY'Q? M/M)?IDYQ;W[&"3:J2OC![@.E3]XY(T9YQ.9] )7.B"/:3:?Z2U\I# E9F<"5 M!8Q-^\I +OR=>DUJ#<>%7?C8!S8-9(JM]Y8HJE+@+ M Z@C;5D_<=$X._S?C^!&[_A)06\N8FXN#@T5./E1B%Q[*8DI2B74]6%>RYIA M2NM>KL=\Y%/ECPUP2PKH;G(:6KH:7#+HT3N76$C+D;]RWWZLZQA0&^AC./'8 M5UOTDX%P&#J,NC@^ <8TSGLLSP*2P0".$O;8?=T;& 9HGC9'E73E&#/J1/R^ M;6Q>-X%@G;![:.]*V(HSWH18>1?+0>?[WX(WRM4931 #"CI)@U"C-[7S$KE& MCH0(V.4E;K](K$J,! D%HDAAMW: R;[BQ85>5%<&^41O=U"Z/"9YPU,A",A@ M0ML&/%0[)&_!@!'7]N"2$'JW;?'I.&SO2ET!T7[]ZYA V@]A([4,U M?X-BD].\&U=$IN5]6(MV4+G_'JJ1,JU@#Q51JJL6!#&-%NZ?4^;,/PMV. +U M#LYB[LE%V 5_O>R;_1NK%">&WM[65F13C\B >%B>E\Y9$2<#T+?OJ.*L<:0]H#OGMU>.^/C&LJL>5(HKO"%./B]&RKXIY: M*5+Y9<;R"D:;U[ KR#2I%TU$:DD%JJ-)0L&)97//"_%/+U ML>-_*;+1)C''Q]R>@B\K0B>V)$M05P(#3(5\__2MU$R"'$HP8O&%QE755ED[ MBRHH7J=1V938PF>?OE'K+QKYAH!J17>T/]\6#'EVZU'UUQ?M(/(![WE(4"A4 MWUFWH3J[L'^*59>E#J,&8K&1KXL+@JC3)Y8\EMD[5,1(X"K;:U!L=0NOEZQ: MKW&"#;74D,A?]U*BO?.>Z=F]JY1U6VK^P4YXR&GFPE]A$7P='HAG4JP0SY(* M/E"*]L?*O%P/-:&!T/(:LJSU\:A,=B#],L)CE:>5I4E-PB1150/]AO":!&XY MAY,Z1]$D'TSK+*C#LQP(6IP8R-6X"6G\]MN2-9QM6.ZD54L?N*4EF\["EC=U MT6:U>,$@>Z?1#;,@8']6^C64BOYT OBUA>,L_;A\R)Q3]7B.9S#_B#]5)7G6,&J6H/>C"LSB-%)'$S^_AH]&AE,0'ZR%F@@(HVM, MOS57$]: 8*8"#?^_=]3:QTYY#<$E+6D6L1[6?'"Y4&/9BW%<[ZTGP#"N?-*M MW^66,639H/%U\[4&8@!7*9*GJRW,.FSP!*JQOP'(:R3NSA66+!SG8&]W<=;&CRCAG-YR$)E_2 M1@+VL:P5BDR*[J_W;^H3)D*4HY6BM"Q\0AH"^(>7O"9-ZV?%(5"%H\_WT]\D M2HNM;3VY?^"^R5>MZ72_6HKK>(?>M!G14CJ43#^7XOLSQS1:CA^N81@GX;HM MD,7/%!_J"E?G7.;\V&B6]U*<3V51]Q:MFT-#0X9$>N*F^!-1F271*-W_;(..29"%H+G;X>9Z#75,- M9UFVBRGS.O?(5]>TY*94-7Q1W:+I#/:I.H3VXNNVDKE_H6^V:O"]0=MEZ>*N M8%N4G(*$3SN."3ZX0/^PQKOHC7Y(^#*E-.]0C5HMK"3;#=W:*AV)RFFM!9AW M"\N>;A3.T+%1EK61K=[7%/AYDL_FZU2!>#MG1&M$93%E7<_?.N95\Z;+6'J] M3YA+,]">"T;YQR%[<(]E)V2+7<200B8%Y-4AUO$$L-HLBX$*$7"2(-\\)E'L MVGZ>TR4,MU&Z>G7I()T>2K["U5]61$Y&_DG1IRV3M_]F^Z=4[O5+UXI : UZ M2_S5PIVFJA$ -'B38'-R5)/_3B(].&\[^Y M4(].!PO/E %EG-2^,?HT<5>\U? ^6A=JB%@1[BA\ZLSI&RIG'HXM_*6!ELW3 M++P$J#_J6%;QX;Z4[,'LZL9I1'@575WM+VZP:]\C#_JD%[1HG IO"9$S*YD- MNKY"U E*!= O")S*]Z>)JT8^7[E!JK5F;@A&RF$B*&OI\1?:B<0%T4S 7RK\ M&WWRG .D65@C<7V]:3Q>ZK_M5Y;:EZ0P*[9CE8A:&M#\O&G^\Q+^"9@S^4)F MAXL@BUJ81S"X=_6[2WA6OPTNZ6:GG=;(2U@QBSQ#]T_VYZ7JHBW/Z0#YS)L[ M[=DJ/XM\J=(?]$.2ULD(#C8GF*#T9]\=?*@!$^L?R$M>+N+PE.H^_KU[6:.G MBKE<$VDUK[]8ZM615W1:* 3]5GK*D&E^?9OCN&3R@R.TMC,ULFKD?H?+I5WH8M#I4O5[%]7<0I_XNWS+^EEZ&[6 L_=) MN:6C"GDWXB<:,'PB/"EOQ](EZ6'*)845M/>;)A49.'DF2O(VLX.0/H.[#UQP-MG%&+DFC?T^)*B6$8BW/-.IPHU M['7L+[;V6% 'M%1E)@"4-V\Y&GW9=:!+2B6K+)Q4Y[D&PS"B(,N&&6=GOA+P MKD:;#'I02KC.@.HV#Y[CMTIA&N+:W\6&:-HPB#;[=*[R+U\-.]EP16YA0'!F-VP.-8W]A)J( M"#-(/9:7QE'9G)9EO*/%W"[YX!(88SO>\K.*Z!]!IM=^CN#,B/L&B:OY4O@? MU-PSZ#8'X*7[_K%(US\6S:7A7YK:RJ+\'M X8R_^,D5CSJ(S4S/U#[)HV/(U M,=SX:Y4;YU(#6)KNKS59GKY,RUX=.[/7Z"\= MTJM$N"\;XWJ[NV^0Y/5:V09B$ZU#J_*G8,G+_(-K( NP/YL,)VJI69ZG6?8/ M/BVK)J;OB)63U.Q74C]:\)OJ$2(B8_M"&(V$QO M R'=&=V^5[IQ>*1V/G+DVE*+^V!Q1%7#1(GI9_P$2$8\@ IP=81*B<;=4JG^ M?+_J%V]SOM'-83U_0<[<2Q$"]KYQ@6Y(;.,^:\0;[7..[;/1VO)3GPVIK<3* MUG.:[^+9H'V6,^=P2HSC!I'ER*M'00O3KHYPD(;ZEFQ2RZ3D M^N"V9"KIV![X=.8DV2Z\KF>S+0SRR+;@0\^BW4SRP\6U0&-'>\+*X1*U2=E:P?M/^;%@,:. MOF7_R'2V,!;K8#1,*HC>7MX7. !^?K!\ @2+TB%HS PSQT0?L[U0Y"3.ACLE M%'G/\ERBV48&NFPZV1:0]#?N^E76G;,.KY/DN['7N%RRVF@8^08,,Y)G6F5 M$I%ADFC',,!R@V+@4=HWVU'_UK.T.*U.WU((?T0/KC.[UO.9MX_7'@]>.C(!^[5,FGD35E:>LW[G)TM9QK MUXVV_*20;P_ID?JS'M2AXCZUA MU"Z?PJ2"#A=KTR%)IEF]XD)$B/'TL1:'*'VO6GZ=!$$WUVC-KNUCJ1BX(P,G MY$RYY?*B>):V30$\>E3+978]2/( XEF7RK1CIG+#01]"&I.OHDMF;J9=Z,"K M+C[.8>>@8W6C7-4]&%V^U34UD;4I6U0NK5FB(UR8'\WT#?ZQ55M5A01%J!M' M-TB6LTC]K6\AAM5268S4]CI,:^[+WAOX'R25[(&]'V\[8]BDWG>H@DD6/E49 MM@YM[,0W?JD=NI'O:R:JFRP\F([T4%(AIDBNN0[SN.SU.NY;FK2"LDJ7>UAN MC>UFQ,(2 EJK>R:NT Z]=L)EK9)DT"D&@MBFG[T>#>Z>E'TE*9(\=&4\(T<# MZ#%AZ."V -QE5?HP$AFII<#4=[U^TGR+E.#YG/%&!:'O1? 6Z!41(G$2?#^+ M]759D&]C-?=TFD(\NPILP+Q*:]'F>'S_N-^8!AO\XW[CV>WE^_)L:>/QM3YO MM1WWVB> (+TL\*?I#DC&Y%O7K(-?)MJ6C8#;#M83H*T^HQX1<\E ^RDFY :\ M!]-\:6FTNM@;V,,(C0T,11Q0^S1 HZW\B*JC\! M,C)/P#KM$Q!5]*SS5/LI+_@4G@"_A-/J@VA@,W 3'R;_@($;N$Y[S_SO,L_- MJ[>PZ'$Y_3++44]R0.&>):,W$.ZF5R89+5O)R+T1B=TJ:Q%EC6O0][T5Z[+\$(X.=;1X"-!8R+8GR/'.RP+/?SXX//#M"#6HOK/]9;#3] MMW@+\CRADZE/0-\2]>-PQ;V/-DKW-CO174G#\PS+_>UE' $"(07^]5AR\BOT[)*<.UKCJ?=4&4^K60UNLITM^$!F5O2S M5D'>/H $&:D]^V^E9,/LDO*O2_N$RAZ>5&_(Q10N:B0R^KOH8>@GA&&V-*&4 MEQ."@[^TG:HG$T25R+ 5=28(T ^\!JM,880U-H[V.933$_W[;%$_,0O%&^T% M9LJSBOV=\\=70!0,I,%-$=KZ;Y\ 8Q9 &ZN8QUC<,M)X *+*YM@F[ZI@MM;@ M4 EHQ_,MA5Q6?UHUKX],1QV3$\A57'AC5IG3_C*NJK4Q^NBSMP:3%7PG^]P! MTP:"U!3J]]?KB[H:DF,F$&D#'HF@6QW_G;+Z"W.D*8A2RTJRCES88SG9T%0B MB9X%>)<4H4,3=.U,]:? ^I%Z_T3F77LPFR1C-CSY)>3 M?E_&"%S=T\NOQH:1R]:H..I"KF#-3RFBZY*SF]W*7_IB?FC.M^D=4;?]891E M\9]M($MYJ7%G9Z6:40)]?=B2%[_BU6R4P95LYXLG0+6]X7%RGKT/ POE0S1/ M]XE[A0G#J=@8J::] !&6&_:?;T5GW8KCR2>_;PN,BD32=!V"XLET)D*V\$H- M.BM_608/]REG%=QJV%6IJ[LD-\3+R+[=:K8[9E]3S+ PQ)GUB7;< M=]7R:)P@&5NH'X+A[E;@#2 U?J1X54\DH/@^PZF0:"(L 9?IH*2A0WYCN*%* M]^C6$E')KNL>=$_09^^3VN:QGO'>,OJ-A@%**8F]3WSSYB$G[HWI M$2&,33>I7**=^$^$^I\%N,W+:#3]K;37(T*THA6HY44@<''CCPZE*/3H']%/ M !KFQD+180"F<"K7P:U!Y>OX_**$^MD:3SG;)\"[TE/&CWI+B+Y%^;6VQ\MP MZL_NSA8GQ@_>JS6]4?1G'$[58V[.6'1V4^]W7S3SYY+L=Y%UA2AG6R:K*@WP'7O<_$&YIG#HLZ+@ID%WE"B+W.9-SR0 M[.$^(#I_=TT4Q*5/G%B^#-]L\%NNN7!MJ<_@@#!^VZ]L\ 2K6 GTU4Y:QL+1 M#=E6E\(@M^VE@G6Z[;@;T:,@I(K?D%V<^65?AH;W^P$OS2PWG2H__6(C_:99<)N3(&D=HUK: WYJUQ6TGG)0Y MR0*&X^RN;8/Q#=DU5^#\/[M+/@_$+7@WV FZ]@% M#"AEE #8<6M_2;NHK22O% .?-E1\&_HMH:^&\/N/8S]RKHA6:=Z$NX,@D3M! M!N6 8VMI6JM7A@LIAB35B O0KM#I$'^"\9 GX*-M9L*03F"4.'W50\'^(R:[ M[U>5C^5:5')B*L^V/45FBT^TT4X'K=&I:J2?V.853&PPFD.B8;.O!@_GV_FU M/,7E@0G\0BF,,Y3-0^GSE3(+1N_L5A7@_O=\@GSO/Q&._QTJ9E/Q8%KA','? MGEOZ3XS%X/[_;U R@M/!%YOW%0\T/?U67F05^*9 OMX\ M6+?D$&/,UOZ(38V+3KF)_N58E=^8X,!$-)? %E#2&"9R,.&35OD[$B,U(T/" M8:X4--JQ[2STYA;56/D=V#T/O2ZV6D1[;S-9\ZP:9# J9_-R^UVIWT65H0+9 MOA!O#*A9R=;#7SBP?A7GUY \#'/CT<-I2>- VXP:^G!2[C(+GEAH*+]@5R:0 M$O:#$,G\] U(F[:S9O5EZ$R,%=>K?3PIAE^PL)[W&J]3)D'@NH]3G^4<>JEU M!F)@77SO7:PW\G/$M:OBY**H)#.-BDNXLC8Q'86V$]=B(0.6O3AV__# MVEN&Q1&%78*-!/< P2%XL.!NP25H<'=H-(W3.$&"N[M#H"&XNP5W" Z-NT/C MFV]G9W9WGIV9G=WY<>KWO6]5O>>.?>+\G(4R[:[S;Z,3-%QQW:GI8HMXU"I"TG'C.?N!NGKG-/*(F. MTPP5515M7$+EVF(GZO=@'B6^(>I_Z[4K9C8ITW+!)P>%Z6'41Z!6V;Y3WAF\ MY2#TMD:A' G!^?T+T= ^,2NFOF03KV^G ZY)ZGOF:HJ*9$H; 32)G%^\&9.< MVV)DMPWXPKF%LAE/VAL1QBB/XWS^Z1.%N\=0Z )Z\W/;SP2I&S>D,>>76N(I/A!)8#/DE(37 M3Y7+J/G)ZH$7DV&E?3/';P!\R$>KYM"IY=_QVXA(Q,9)&;>V0*FU-MNSVR&> M^"G/FQQ2J\OU"H*.1(>&WP.%G#Z_EDY\O7C&@*U*I^O13)(@6G"_&B],BJ66 M8V@\Y3SC[)4:5M&_3MC9F*H4- VI,I#(['SBVYW)GQ7VIHCWNWNE#EJ[5=\B MKYPBSXP!F >*DXVAEAH<4Q"2:*4+&G2#W*%X;?K"9_S[67-&A/J8?-^ /BJE M!B*%7S>L.25T-3O3JN5_#/F1OR[FC* [T_Y$98@W@U-U&Q:+ED;N%T,_4=*2Q7%=T8]TH]HCW4;J8WXR3=IRDZVAI^4D4Q@@G0)GL M"&/6#^M_Y%_05M'72OZ);/(N@!^9&V['/L-AS(\P[.O,OI+,^D%FXQ4*DY]3 M.VC2]A$M3U'(9BV;%:IEGM #H"_]?[:UA9GTJ+RWRZ 'C:30 .'$+=J%&CL_ MNE KZ2Z^X+@AC#[6*/ B9#$;5KHEG=-4WEA1:ON!Q/+)=S\@CO3X3Z6<#\TE M35^M5ZM5"_FSW8)08D+?;'X>MF;;K'WU(-NI69I_8TN9O:O(YZ_Q136_FYI< MY@O%4:N^*<*"/W8TS3PK6=*GEBGU.E&VN9RHP+3=V65\;1 &_+AMO]EFG(5O M">FRLQD(=X-=A@Z-6@H/XPZ6E1JS'0$QB"CL@M!V\\&(5NTAU@]J&2@K EA*80_K\V]O\97+\!2!O=^+6G[9#6ETI 0P2SL)*-B?GD M6,M?[NM*M6#RMS8 7F&O,])0 MO %>P/6+A1Y(OXPJN-"/O_O<4/**_=34F=B#%%8NJ&TCOEONFUTNC."RYAW? M.+BB3!7KMA.*>X,(N[M&DK@U3. MEK6->G56[V_IN9@WU_>R]D3=IF76P5PRO8;Q@G[Z[UKO5U87BST]>GA)2(IJ MK8Y.9827!(9F9V(I]"K723(D\NJ-.9^T_&;U27_Q:GMGDK#N:#]*-_1_E*C% M ASJ43?GAM[CR1>.(F3]S$4307KG/I^HYZKS@7.X_OZH==V%/D28-$D!4.B0)0:0$"]"W1LE#D,->EC \= M[[^6OJ,B_?-_>L\T^V?2,AE-KUJR5CD1RE[2RXI(VYR,77D MW?P]2)*,4]C[7"A-C3PVL=&4H-%ZQX,4="'%P+\O,9_ U.#-5VZXPV7ZCE)8 M4,]G[N.0%-XC9$W1T/JZC"M_!%F*U$O]_@S#_"7K!@O\JB=#UL0EN MMM@;BW$ X&7OAT*B$M*NZN:=K')*=I;!+B^]3UZ1?%$=0G_)6E)>TK"9P>QM MB@GIS5>[#QRB F?ZPH/L[<$$FU1J]^_S'%02SVQ: ]E\!5GO;*GJJ] M/>UE/@*I1\Q %4E[",[N#8 "R:?RM_&M$JN-OZ]K<3$**?3J^@OVS!1U6BK< MR#4LY-DGS*%<]''81G>PZR,_9.-Y2O56HU&)_KZ$5\.0I/=U6E#1/_Y7!42<^(E2RHEWBN=]-:? M(HY#L+E3BQ;_NE_V8\1=)"FSK^ $LZ+. B.U:EGD%!J@3IKX?U'(U7\'_+'X M$^^_ 7+FQR>]>^#K?[,R 3PA'A< M5,A,64D-$:?[JAF 9R@T"\W_%"S2*"N)*M2QYB2 M@*M*O;$N=HN G4)2Y M<"R&&J8*)H6.JDQHH4SH?3GSJE::=1T5H9]WJ,R3,S,:7:\MI[.C*4@68!@; M3:ND)!8L#:E6I.#5>OG^!L#C^8@4E\+$>=TDVEL;T<:;6&L?NY6'K-+JKSUT MP-Q>I=T-]JJYN'$83E2%D'5NT>W?TDAN_W;-1+P842%>>1JT8JCBE4=8T!C,,6X1J!M_"5/6A?G,@XHFAM\7T! R#!U[9?MGSW M>KR)CM%X@,2Q(5*7F*Q'$H##^8 2!6E34WTH]'J4EDLJG?CYN/CB_J=]NWRI M;^UP#-SRT2J!:&BBY!1+O2\].O]F= 0;\4B0SN,B ZUU=PY=RO78&R"_HIEBTGNUAS+2NK?7];^RV!!G_]&JW;RU?;HGS MWA5$#%^*/!WF$,]]-G>HE43@S/W.B*#!+H+"W; )IF@13:8KJ7%P\1+<;("E MGG'0!B!W,1L&^7QMCU29D]Y+W]U8<6#&V7$P#U 1TP/D@]X77ONJS6U M3)]4L6[AK9>GR >*ZN4- ?:K>?ZLVZ9Z:(/U#HUM4O3;&M-HFHA4^ZZ@ 2+= MOY$3%8V4RCQ?-A0;FKN"^[R WX>YU7*(HLPIHYU@8H-ZH1V5*I9N9H0<1,D, M4>1YN'&E(@<(K?]Y_/A_HMK;R\G4FG5^K@*?HVK?_> =0*>09T?]V;RM;:[$ M$+EOD20ZB@&3$\/QGIBZWOZ5ZT")F"2Y8SRD>W. &L__ZQ1RB57$U:$HW\$G M3QS=M4S[S64'#]U /=_>K > =A],XI#%0CP0H!2EI9E_> S9 MT4."51QK7%J4986?2 WO_[WNMTV1=^*_0:JB-33.\B8$,1E_PR.:;_=:W'" M.?803'[.7?+S:DYY,,4]([)GH/6V4$5N<$(H+T:F;B_Q)U;QL'X#O+?Q&WET M&V6!X 8\:J7)RM2EM+_-ZUAH"_EO.A ^I/>S(M0,$;@,@5(JLCDS!HB;L2/TU[_RQ7;:Z.!M^!\J>:"=87 M[OC,!_]R[1/V!J#0NR7]+ETO.8U\E8=J)WJL6U>?.YPBV=6LEN5K^V)B)^B? M2'/$WHK$'$[0_3'$4DL]RNF]'D=P,9"T0,/FN;O/E'@MAT/#X1;">[330S#G M0"7"*5 EJ3W7P"HF8Z-;@#/2;O+<3>'+=)L:QKISL=8^$8K>O.@9[REP7^46 M[I+*0KB2;:P1_'%<[>RDTEUS G8$U3=^=Y30*P=",(F8F;9N;IZ!)AQ3. K0 M=,C_TI']!4PEY'P#5*2CD1Q'M218XQ>.,A#^(U&D2E:(#_J[?BIB1YUVR)'+ M?T082E433+'X.%PLZT?JU)^?*E%ZN3$..6.;QAX;QH:*,@#]/L[')%VH6/LA M^:2G E_=I++'_UOJ##^TY6F2%.;>IZG$NZ\1R+:Z^=&T)P\K-)$G'(I->/!* M4J\?K7!JKLL?_678Y80Y*W'@]>,"B^ZS2-X(W[_59NP0&%=+BI,UA5?&1KY^ M6J(/(94$E? ZGB-_=;EZ\2(_7@I#XW0Q* VMS]^BQ%HUM$WXV.)LU9HL^^WV M^9>B&('!$6_0V9!BAKX5:?R%G^FQ.'Z[TK; C9(?N;"X6> LJ-65I:/YQ;;^ M$^)R46MQTL'4:MFU)I;S>KOKH5Z=9VY?$UB@?>XY.=J@?U@07K,%T>6&9P08 M.M@WJ*V5H5'!DSPG^AUE26="_%G0KQ[ND,1AS"ENC::AS*CT_G7C4[RNT(!;F_G%OCUOW8K7874S . M$Y1/8;+;KP-HS95C+#D3S*3Q=79R -OSR/ M#I7J_?0DVYQ2.%;R?F58-3F[#9N&>I$LRZV>FMZC($XAUOKP6L\ZU->4\?W- M^Q;UP3(-J/K%+F_7B]>N.3Z_RD6QIS+)(D63H&C M-\ ZPU55;.^C]&"BU?2X"_Y634.A 09V_R*64]7YS5-PS)V\9L$&$T7>=9:V M]68+3:)XY&@K\(+= [O5EQ&A\+^065S6-[H^[.G)F6/4^T@JLM0=@B0A4)L/JS'W+E( %A_=ZL4G?+4(XN]+RL"49,K8Z M/_WV1XMTIZV<9>+$WJ9(UC*F//80M>S,W?+N\_K1-"Y1AMVR5_L&J!'6AMB1 M^!5"CS/UE42'GS<^D09Y'7??YF%5*9ZB=XL2APRTKO3C(X;R/&0]FFC3/Q8/ M-N1O>(:>2]3'H(3;:$$IL\.$KR,Z*EG\Z"\=(&.D#+.NU]^'A\ MB QRS,U'1G HL?"BV'9U,)_@7OUC8UC9 ML"6([W%7%RWT.1H 'I%+8-MQL[S]EN'FL[(%\>XWQGSV_A!VFSG87)\>8$Z3 MTBV"0M\9V=0>M$M0D$S$_JL&&@L]#KKD6X MF>*U4S7_*] 4Q_H<[<@6:U"NN->'SD% M4KP4G<^/_#_J4^!/[4UO+3MNY>#DXPP*;B_F-(SI&AO9JDX$W4ERQW-DT S. MP!WJ;V"O8<4=L!G)RO3);'3;(%3CUP>E_'?]G7"3852TWM8?X09)TZT719TT M63PBUJX8JS.1=^!O0$(5CA0Y@M7;5:9EZL%\37&U*;3YN9D_/6H+)Y,SKD+D M)$NF#2$:@=>BHE:B)?4UXO@-\HPX'<*3TJ1H)-GF)=LNV28W$\-[UI]V[1 )'K;:VK'8L:81&^GHD9E' MF#)KW]^R[GMRPK3Y?<2GACQ?I>V3P*>)W'1=-:F[Z,#-3ZB8(.\('U-2HJYF M, ,F0%%PWHUHX^(1L=,TE-&Y69'.8/:_33_:4*AJ#:VH0E2,YCMI'.G)7GWT MXRG<:NN?PQP_4:L=HOFN8R[R*;'XK-J7FV-\=SF_9PB\62[@7$Z_P3OLKT\1 M[&6V:J"^>UQ]Z\+4I^#@H6U7$?62@-R;_\K)#.F@,,IE5.O-[R;(6BZ.B6^< MUD@HS"XH[+A\5Y\2%>_(MDT6DU0^5RB1&9FP=WRD)+< X9XS_JPB/GV;23MC MPKE*S;?VKUWJY_\HLQ1 M""Y;G;EJC3$;P@W^VD^GAY&^Z35T:^W%X:UTQYC M)]4-%S8>JUQ_\3>]U6AJW%G M=CM1LKK9'[(1HR5>0*PT 0D 4T06.ECA D^LT(=3,7]2\L M4?62+:3\<[8;1HG4G&8XU7,[UMH+<\L;()A)26+7M.8R9#+N%^)%T5-Z)EF. MH$O&(4L[C^46*_R9"!9F76T*VVI=4WD>EG5O%YKY3 .'%^1(J4*8QJ%5P1D' MO(V0<9,D'2U1$*(V!1=H9,O2D-XN1G!;TL)I^W=]F,V]YKB)P$X"%L?@67_J M.+@W<_-Z,KJ;$ 6VYG^MAUNR7?AMNZPY_T.A.1DMBT(6O.6#Z0NRJ -R-N[/ M%E_Q84.-@JI7#X9Y^BO(U\;;JYQI90?H$TN_%)SA6LD3-XW29*6*E@1P.[2_ M*Y6M5ODU]0D6%LW9'6: W4-&J[^?38R.5[(JQ/.YS;05"?G^;[C)$!ACP,[YV[ MEE:-G2A[4\RZTO97E8W5F*K5RYR7?V:P'Q8NW"K;GTVC,^]0G"L1 BX;&=SX M/":[:;=@[\1ZBT[D"*'5#M+$B.I,)JPV)2PM6ET:QQM)R%>/XN?I?Z;.D7L6 M\RA>Q:.O:;89H=PBEQ'C$*>(E$8HQH?[L 2]_IJC=T[SKF:<@P42'\F"&RK2 M78&O^HYT%%NP5]';"H?+F5@6G%_@Z2Q"+[^?\$VD?\,W#12KL%80P$R?"R3E MHFNWU0\2/U;_XH192Q#*(\W KZ8^_5]T)8I=_ROW4482N#@D>!"*B:3L2!_6 MI?+:X6WZ"YR3:EVI,VSI"Z_D1-5'@S&%C(K=YX_LF=K7R*DG@6C&46OS-U2T MY1E(LJUX@1O9UTDV,S!12+76-/M20ONDS5-YF$,#TV4!AR:"[T4I\5ZOIH*^ MVOH*O":OB&:7>$)G-HRGG90ZME0)H5Q_**($[_,P0BZK?][(+[,:BP/OKVKU M :#3A?(>MKK+]_T<=*^Y/"F13J.#0Q2FS]@=#D!M\&!ZV>HA.*0[Q2; A>:GNZ:_E,_TF!_=/BI[_J%N2ST MW#<-5[Z36-Q2=+!TGMRI$$D.7V8;6?B,XE9F'>4T#T<\D(8<'RL);A)6K9)# MWOEQMM3FW%ZF?E5P/+NMTJY7>N)'<=IEOC M;$J2JDFR:'X6CVB :R=XSPV-6;?$+6S"6]&V2LX3> 7X+#.>]LZ$&_A,Y;$A\ MN.-2C80_5U+6V96@>6M3Z\J9-U,A^'HSGNAEBH:'97G2G_7O0W4$^ M' #"%>21$;Y59WGH4SR5M,MQO__F 5YR*KB=W\U/GUC.4QZPT0XM74.QGJ03)P!:OKM_S;]A#7OWHF6M*Z M$?W(ZE0D\@2R[V+''3\NJI\K["[*E[1Y>&MMA=OJHIGSIR+/%CJXP,\ D&P*0E8X<%VBCK?,^(!$:";; M8+[L:49)];'UFO<"Y::NU 0!U'D1?@O6 <&)(%KU,:Q7KH$K0F=U>U*#1N:G:2W'!F MJO!)0B>=N7,MEFWQ)F2J'5B>BW/01!(=FO\#L09>5X4,8:78XPV X2-?)'<% M \\J^/)"5YVNLGS&1.2/ESO(MR(,O.)IMDMVD0EV_'%/C'M%Z6HO&W.>=+-9 MSZC)B>6';GF.*>1/\#7UT?.]3=_-7-!%&V!_C9K_]7_<$3_=& WG1D_/,T- M@?N1$6'?..P>%6H<19(\\1NQCH:220!)8CL&KEH'%HM5]?H^002?W3Z66[;/ M_CS*VZH9^V<.T3]B%!H@%.68SAWE7'V7@_NLN\USRCOK6S(CD/Z=5ER.&VY7 ME.#B+)"N2*74]C[>5AR!@Y-LOYFYM4,&%1K4YYH83L@]VE*E/_!H%74WZ4;0 MNWS$4Z ,X=!EH4&*G"T MTBRV[IU"ERJ-39UM(<7M,PMXI#NRAOW81M+J"+H7];'%AX1F=O1[Q%F7E$V4 M(=J)@WK[84ZF@J?MWPZO&DF@9*\'3WL!@J1$Z]XWB([+?DZV,YTUM0'<5SL6 M-\@=M/2?&X>\WV/7C:5C,)%K.36LRB(:<\;(X\.EG:",)"";$>BT%FNXD;$ MW%HM].RU+H]\I8&%@<-.1TOLW@!+??O:L2[633,!]'AT ^%X;!8_376TE/I9 M>=8B\;7DC%UVK#N,-;QHXWKY=^)/U6@6K6Q;7Y>OZ&7RSB"> MEN.FE=*\JOO>'$85/-V14\>%1=7&X3S',AL$%>UYJNGZBFB)W: !>$+:1[U'([3@R>EV'0#9F_PDXG^]&]8&GDS08*ZV9];2Z2!T,5:/&:Y_B5?(:5 MFQ5MH7>4XJL
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~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ł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

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2021
Document and Entity Information
Document Type	S-1
Entity Registrant Name	KIROMIC BIOPHARMA, INC.
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001792581
Amendment Flag	false

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 06, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 7,335,300	$ 10,150,500		$ 1,929,100
Inventories				22,200
Prepaid expenses and other current assets	513,500	588,800		89,100
Total current assets	7,848,800	10,739,300		2,040,400
Property and equipment, net	2,279,500	2,066,000		587,900
Other assets	24,400	24,400		24,400
Total Assets	10,152,700	12,829,700		2,652,700
Current Liabilities:
Accounts payable	1,203,200	665,200		452,400
Accrued expenses and other current liabilities	268,900	334,200		221,300
Interest payable		200
Loan payable		105,600
Note payable	227,800	362,400
Total current liabilities	1,699,900	1,467,600		673,700
Total Liabilities	1,699,900	1,467,600		673,700
Commitments and contingencies
Stockholders' Equity:
Common stock, $0.001 par value: 300,000,000 shares authorized as of December 31, 2020 and 2019; 7,332,999 and 2,863,812 shares issued and outstanding as of December 31, 2020 and 2019, respectively	1,200	1,200
Additional paid-in capital	53,933,900	52,988,700		13,965,000
Accumulated deficit	(45,482,300)	(41,627,800)		(22,427,600)
Total Stockholders' Equity	8,452,800	11,362,100	$ 3,582,300	1,979,000		$ 265,300
Total Liabilities and Stockholders' Equity	$ 10,152,700	12,829,700		2,652,700
Series A-1 Preferred Stock
Stockholders' Equity:
Preferred Stock				9,134,700
Series B Preferred Stock
Stockholders' Equity:
Preferred Stock			$ 2,007,000	1,306,900		$ 4,500,000
Additional paid-in capital					$ (40,000)
Preferred Stock
Stockholders' Equity:
Preferred Stock

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, authorized	60,000,000	60,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	7,332,999	2,863,812
Common stock, outstanding	7,332,999	2,863,812
Series A-1 Preferred Stock
Preferred stock, par value ( in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	24,000,000	24,000,000
Preferred stock, issued	0	21,822,301
Preferred stock, outstanding	0	21,822,301
Series B Preferred Stock
Preferred stock, par value ( in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	16,500,000	14,130,435
Preferred stock, issued	0	9,869,659
Preferred stock, outstanding	0	9,869,659
Preferred Stock
Preferred stock, par value ( in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	19,500,000	21,869,565
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 5,052,900	$ 1,201,700
General and administrative	14,144,000	2,503,700
Total operating expenses	19,196,900	3,705,400
Loss from operations	(19,196,900)	(3,705,400)
Other expense
Interest expense	(3,300)	(22,500)
Total other expense	(3,300)	(22,500)
Net loss	$ (19,200,200)	$ (3,727,900)
Net loss per share, basic and diluted	$ (4.42)	$ (1.39)
Weighted average common shares outstanding, basic and diluted	4,505,867	2,862,809

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Preferred Stock Series A-1 Preferred Stock	Preferred Stock Series B Preferred Stock	Common Stock Previously Reported	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Series B Preferred Stock	Total
Balance at beginning of period at Dec. 31, 2018	$ 8,727,400				$ 10,237,600	$ (18,699,700)		$ 265,300
Balance at beginning of period (in shares) at Dec. 31, 2018	20,886,782			2,863,093
Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock	$ 407,300							407,300
Conversion of convertible promissory notes and accrued interest into Series A-1 Preferred Stock (in shares)	935,519
Issuance of Series B Preferred Stock		$ 1,056,300						1,056,300
Issuance of Series B Preferred Stock		9,782,609
Common stock issuance net of issuance costs and discount amortization (in shares)							9,782,609
Series B Preferred Stock discount amortization		$ 210,600			(210,600)		$ (210,600)	(210,600)
Warrants underlying Series B Preferred Stock issuance					3,443,700			3,443,700
Accretion and settlement of Series B Preferred Stock dividend		$ 40,000			(40,000)		$ (40,000)	(40,000)
Accretion and settlement of Series B Preferred Stock Dividend (in shares)		87,050
Exercised stock options					11,400			11,400
Exercised stock options (in shares)				1,719
Stock compensation expense					522,900			522,900
Net loss						(3,727,900)		(3,727,900)
Balance at end of period at Dec. 31, 2019	$ 9,134,700	$ 1,306,900			13,965,000	(22,427,600)		1,979,000
Balance at end of period (in shares) at Dec. 31, 2019	21,822,301	9,869,659	2,864,812	2,863,812
Issuance of Series B Preferred Stock		$ 331,700						331,700
Issuance of Series B Preferred Stock		6,521,738
Common stock issuance net of issuance costs and discount amortization (in shares)							16,391,397
Series B Preferred Stock discount amortization		$ 368,400			(368,400)		$ (368,400)
Warrants underlying Series B Preferred Stock issuance					2,668,300			2,668,300
Warrants underlying common stock issuance							$ 5,533,000
Stock compensation expense					456,000			456,000
Net loss						(1,852,700)		(1,852,700)
Balance at end of period at Mar. 31, 2020	$ 9,134,700	$ 2,007,000			16,720,900	(24,280,300)		3,582,300
Balance at end of period (in shares) at Mar. 31, 2020	21,822,301	16,391,397		2,863,812
Balance at beginning of period at Dec. 31, 2019	$ 9,134,700	$ 1,306,900			13,965,000	(22,427,600)		1,979,000
Balance at beginning of period (in shares) at Dec. 31, 2019	21,822,301	9,869,659	2,864,812	2,863,812
Issuance of Series B Preferred Stock		$ 331,700						331,700
Issuance of Series B Preferred Stock		6,521,738
Common stock issuance net of issuance costs and discount amortization				$ 1,200	11,974,200			11,975,400
Common stock issuance net of issuance costs and discount amortization (in shares)				1,250,000			6,521,738
Series B Preferred Stock discount amortization		$ 692,700			(692,700)		$ (692,700)	(692,700)
Warrants underlying Series B Preferred Stock issuance					2,668,300			2,668,300
Warrants underlying common stock discount amortization					(19,700)			(19,700)
Warrants underlying common stock issuance					377,000		5,208,700	377,000
Exercise of warrants					4,900			4,900
Exercise of warrants (in shares)				1,399,921
Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion	$ (9,134,700)				9,134,700
Series A-1 Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares)	(21,822,301)			624,594
Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion		$ (2,331,300)			2,331,300		$ 2,331,300
Series B Preferred Stock conversion to common stock and fractional shares adjustments from stock split and conversion (in shares)		(16,391,397)		469,136
Common stock issuance to employees and non-employees					9,432,000			9,432,000
Common stock issuance to employees and non-employees				725,536
Stock compensation expense					3,813,700			3,813,700
Net loss						(19,200,200)		(19,200,200)
Balance at end of period at Dec. 31, 2020				$ 1,200	52,988,700	(41,627,800)		11,362,100
Balance at end of period (in shares) at Dec. 31, 2020			7,333,999	7,332,999
Warrants underlying common stock discount amortization					(24,700)			(24,700)
Stock compensation expense					945,200			945,200
Net loss						(3,854,500)		(3,854,500)
Balance at end of period at Mar. 31, 2021				$ 1,200	$ 53,933,900	$ (45,482,300)		$ 8,452,800
Balance at end of period (in shares) at Mar. 31, 2021				7,332,999

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (3,854,500)	$ (1,852,700)	$ (19,200,200)	$ (3,727,900)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	95,600	33,800	200,000	87,500
Stock compensation expense	945,200	456,000	13,245,700	522,900
Non-cash interest			200	20,500
Inventory obsolescence impairment			22,200
Changes in operating assets and liabilities:
Unbilled receivables from granting agency				24,300
Inventories				(5,900)
Prepaid expenses and other current assets	75,400	(99,700)	(499,700)	46,200
Other assets				(6,600)
Accounts payable	273,600	(35,200)	(7,700)	293,400
Accrued expenses and other current liabilities	(65,400)	17,500	112,900	(151,300)
Deferred rent				(19,000)
Convertible promissory notes derivative liability				2,000
Net cash used for operating activities	(2,635,900)	(1,480,300)	(6,126,600)	(2,913,900)
Cash flows from investing activities:
Purchases of property and equipment	(44,700)	(406,300)	(1,457,600)	(302,700)
Net cash used for investing activities	(44,700)	(406,300)	(1,457,600)	(302,700)
Cash flows from financing activities:
Proceeds from sale of convertible promissory notes				250,000
Exercise of stock options				11,400
Proceeds from issuance of common stock			15,000,000
Issuance costs			(2,667,300)
Proceeds from warrant exercise			4,900
Proceeds from loan payable			115,600
Repayments of loan payable			(10,000)
Borrowings from note payable			540,500
Repayment of notes payable	(134,600)		(178,100)
Proceeds from Series B Preferred Stock issuance		3,000,000	3,000,000	4,500,000
Net cash (used in) provided by financing activities	(134,600)	3,000,000	15,805,600	4,761,400
Net change in cash and cash equivalents	(2,815,200)	1,113,400	8,221,400	1,544,800
Cash and cash equivalents:
Beginning of year	10,150,500	1,929,100	1,929,100	384,300
End of period	7,335,300	3,042,500	10,150,500	1,929,100
Supplemental disclosures of non-cash investing and financing activities:
Accruals for property and equipment	264,400	$ 230,700	220,500	74,700
Cash paid for interest on note payable	$ 3,700		$ 3,100
Conversion of accounts payable into convertible promissory notes				134,800
Conversion of convertible promissory notes and accrued interest into Series A1 Preferred Stock				407,300
Accretion and settlement of Series B Preferred Stock dividend				$ 40,000

ORGANIZATION (Details) - USD ($)		3 Months Ended		12 Months Ended
ORGANIZATION (Details) - USD ($)	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Aug. 31, 2019	Aug. 31, 2018
ORGANIZATION
Cash flow from operations		$ (2,635,900)	$ (1,480,300)	$ (6,126,600)	$ (2,913,900)
Accumulated deficit		(45,482,300)		(41,627,800)	$ (22,427,600)
Common stock IPO proceeds, net of issuance costs	$ 12,332,700
NIH Grant receivable							$ 2,235,000
Phase I approved amount of grant						$ 851,000
Phase II approved amount of grant		$ 1,384,000		$ 1,384,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)				12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Jun. 17, 2020	Dec. 17, 2019	Dec. 16, 2019	Dec. 31, 2020 USD ($) item	Mar. 31, 2021 item	Dec. 31, 2019 USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Stock split (Reverse stock split) ratio	3.494	10	10
Reserve for inventory obsolescence				$ 22,200		$ 0
Decrease in additional paid in capital (APIC) resulting from deferred offering costs related to the IPO				2,667,300
Deferred offering costs				$ 0		$ 0
Lease facility \| item				1	1

PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	3 Months Ended		12 Months Ended
PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	$ 2,936,800		$ 2,627,700	$ 949,600
Less: Accumulated depreciation	(657,300)		(561,700)	(361,700)
Total	2,279,500		2,066,000	587,900
Depreciation	95,600	$ 33,800	200,000	87,500
Equipment
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	1,138,900		780,500	488,800
Leasehold improvements
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	1,274,600		1,229,700	302,700
Office furniture, fixtures, and equipment
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	16,600		16,600	16,600
Software
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	151,700		151,700	$ 141,500
Construction in progress
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	$ 355,000		$ 449,200

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued consulting and outside services	$ 173,900	$ 143,200	$ 221,300
Accrued compensation	95,000	191,000
Total	$ 268,900	$ 334,200	$ 221,300

CURRENT LOAN PAYABLE (Details) - USD ($)		3 Months Ended	12 Months Ended
CURRENT LOAN PAYABLE (Details) - USD ($)	May 01, 2020	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current loan payable
Loan payable			$ 105,600
Loan initial proceeds			115,600
Interest expense		$ 3,700	3,300	$ 22,500
SBA Loan
Current loan payable
Principal amount	$ 115,600
Loan payable			105,600
Loan initial proceeds			115,600
Loan repayments			10,000
Loan term	2 years
Loan fixed interest rate	1.00%
Loan first payment due	7 months
Interest expense			$ 200

NOTE PAYABLE (Details) - USD ($)	1 Months Ended
NOTE PAYABLE (Details) - USD ($)	Nov. 30, 2020	Mar. 31, 2021	Dec. 31, 2020
Note payable
Note payable		$ 227,800	$ 362,400
Director and Officer Insurance Policy Financing
Note payable
Note payable	$ 540,500	$ 227,800	$ 362,400
Interest rate	4.59%
Note term	9 months

CONVERTIBLE PROMISSORY NOTES (Details) - Convertible promissory notes - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Jun. 30, 2016
CONVERTIBLE PROMISSORY NOTES
Convertible promissory notes		$ 0
Probability of next financing close (as a percent)	55.00%
Embedded derivative discount rate ( as a percent)	25.00%
Minimum
CONVERTIBLE PROMISSORY NOTES
Convertible promissory notes			$ 12,500
Annual interest (as a percent)			6.00%
Maximum
CONVERTIBLE PROMISSORY NOTES
Convertible promissory notes			$ 500,000
Annual interest (as a percent)			17.00%

COMMITMENTS AND CONTINGENCIES (Details)								3 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details)	May 01, 2023 USD ($)	May 01, 2022 USD ($)	Aug. 01, 2021 USD ($)	May 01, 2021 USD ($)	Mar. 22, 2021	Nov. 19, 2020	Jan. 01, 2020 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) ft²
COMMITMENTS AND CONTINGENCIES
Area leased \| ft²											4,100
Period of time after notice of cancellation that the lease effectively terminates					90 days	90 days
Total lease payments per month	$ 46,116	$ 23,039	$ 45,554	$ 22,477			$ 21,353
Rent expense								$ 69,000	$ 60,000	$ 262,900	$ 129,100
Future minimum commitments
2021								546,700		265,200
2022								551,100		269,700
2023								461,200		274,200
2024										230,400
Total								$ 1,875,600		$ 1,039,500

STOCKHOLDERS' EQUITY (DEFICIT) (Details)							3 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (DEFICIT) (Details)	Jun. 19, 2020 USD ($) shares	Jun. 17, 2020 shares	Jun. 10, 2020 USD ($) shares	Jun. 08, 2020 USD ($) Vote shares	Dec. 17, 2019	Dec. 16, 2019 $ / shares shares	Mar. 31, 2021 $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Sep. 18, 2020 shares	Mar. 31, 2020 shares	Dec. 31, 2019 $ / shares shares	Dec. 15, 2019 $ / shares	Sep. 25, 2019 shares	Sep. 24, 2019 shares	Sep. 13, 2019 shares	Jun. 18, 2018 shares
Stockholder's equity (Deficit)
Reverse split		3.494			10	10
Preferred stock, authorized						60,000,000	60,000,000	60,000,000			60,000,000
Preferred stock, par value ( in dollars per share) \| $ / shares						$ 0.0001						$ 0.01
Proceeds from issuance of common stock \| $								$ 15,000,000
Common stock, authorized	1,708,615	858,615					300,000,000	300,000,000	858,615		300,000,000		30,000,000	20,000,000		858,615
Warrants to purchase shares			1,063,939	335,982
Proceeds from Issuance of Warrants \| $			$ 3,700	$ 1,200				$ 4,900
Warrants outstanding								0			839,952
Stock compensation expenses \| $				$ 9,432,000
Number of Votes \| Vote				1
Dividend paid \| $ / shares							$ 0	$ 0
Shares available for issuance	850,000						322,063	270,933		271,949	258,813		10,000,000
Employees
Stockholder's equity (Deficit)
Shares issued for services				430
Cash consideration \| $				$ 0
CMO
Stockholder's equity (Deficit)
Shares issued for services				3,106
Cash consideration \| $				$ 0
CFO and COO
Stockholder's equity (Deficit)
Shares issued for services	402,000
Cash consideration \| $	$ 0
CSIO
Stockholder's equity (Deficit)
Shares issued for services	320,000
Cash consideration \| $	$ 0
Series A-1 Preferred Stock
Stockholder's equity (Deficit)
Preferred stock, authorized							24,000,000	24,000,000			24,000,000
Preferred stock, par value ( in dollars per share) \| $ / shares								$ 0.0001			$ 0.0001
Series B Preferred Stock
Stockholder's equity (Deficit)
Preferred stock, authorized							16,500,000	16,500,000			14,130,435				14,130,435
Preferred stock, par value ( in dollars per share) \| $ / shares								$ 0.0001			$ 0.0001
Warrants to purchase shares								559,969		1,399,921	839,952
Proceeds from Issuance of Warrants \| $			$ 3,700	$ 1,200
Warrants outstanding								0

STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) - USD ($)									3 Months Ended		12 Months Ended
	Oct. 15, 2020	Jun. 10, 2020	Jun. 08, 2020	Jan. 31, 2020	Jan. 24, 2020	Dec. 06, 2019	Nov. 13, 2019	Sep. 13, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Common stock
Offering expenses											$ 2,667,300
Beginning Balance									$ 1,200
Common stock IPO proceeds, net of issuance costs	$ 12,332,700
Common stock IPO discount											(377,000)
Common stock IPO discount amortization									24,700		19,700
Ending Balance									1,200		$ 1,200
Series B Preferred Stock
Common stock
Shares issued		1,063,939	335,982	1,739,130	4,782,608	87,050	2,173,913	7,608,696		16,391,397	6,521,738	9,782,609
Common stock IPO discount		$ (3,700)								$ (5,533,000)	$ (5,208,700)
IPO
Common stock
Underwriting discounts and commissions	1,275,000
Offering expenses	$ 1,392,300
Shares issued	1,250,000
Share price	$ 12.00
Beginning Balance									11,975,400
Common stock IPO proceeds, net of issuance costs	$ 12,332,700										12,332,700
Common stock IPO discount											(377,000)
Common stock IPO discount amortization									24,700		19,700
Ending Balance									$ 12,000,100		$ 11,975,400
IPO \| Series A-1 Preferred Stock
Common stock
Stock issued on conversion	624,594
IPO \| Series B Preferred Stock
Common stock
Stock issued on conversion	469,136

STOCKHOLDERS' EQUITY (DEFICIT) - Conversion of Convertible Promissory Notes (Details) - Series A-1 Preferred Stock - USD ($)		12 Months Ended
	Aug. 15, 2019	Dec. 31, 2020
Stockholder's equity (Deficit)
Common shares issued for preferred stock converted		624,594
Convertible promissory notes
Stockholder's equity (Deficit)
Outstanding principal and interest	$ 405,300
Number of shares converted		935,519
Principal amount	$ 250,000
Coupon rate	17.00%	6.00%
Conversion of accounts payable into convertible promissory notes		$ 134,800
Conversion rate	0.43%	0.43%

STOCKHOLDERS' EQUITY (DEFICIT) - Estimate the fair value of the warrants (Details) - Series B Preferred Stock Warrant	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Weighted average valuation assumptions
Warrants and Rights Outstanding, Valuation Technique [Extensible List]	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember
Measurement Input, Risk Free Interest Rate \| Minimum
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input	0.0154	0.0154	0.0154	0.0154
Measurement Input, Risk Free Interest Rate \| Maximum
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input	0.0188	0.0188	0.0188	0.0184
Measurement Input, Price Volatility \| Minimum
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input	0.7195	0.7195	0.7195	0.7195
Measurement Input, Price Volatility \| Maximum
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input	0.7271	0.7271	0.7271	0.7220
Measurement Input, Expected Term
Weighted average valuation assumptions
Warrants and Rights Outstanding, Term	10 years	10 years	10 years	10 years
Measurement Input, Expected Dividend Rate
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input	0	0	0	0

STOCKHOLDERS' EQUITY (DEFICIT) - Representative's Warrants (Details) - Common Stock Warrants - Representative	Oct. 15, 2020 $ / shares shares	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) $ / shares
Weighted average valuation assumptions
Warrants fair value \| $		$ 332,600	$ 357,300
Warrants and Rights Outstanding, Valuation Technique [Extensible List]		us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember
Warrants
Warrant exercise price \| $ / shares			$ 15.00
IPO
Weighted average valuation assumptions
Warrants and Rights Outstanding, Term	5 years
Warrants
Number of warrants granted \| shares	62,500
Warrant exercise price \| $ / shares	$ 15.00
Exercise price as a percentage of the initial offering price	125.00%
Measurement Input, Risk Free Interest Rate
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input		0.0018	0.0018
Measurement Input, Price Volatility
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input		0.9408	0.9408
Measurement Input, Expected Term
Weighted average valuation assumptions
Warrants and Rights Outstanding, Term		2 years 8 months 26 days	2 years 8 months 26 days
Measurement Input, Expected Dividend Rate
Weighted average valuation assumptions
Warrants and Rights Outstanding, Measurement Input		0	0
Previously Reported
Weighted average valuation assumptions
Warrants fair value \| $			$ 377,000

STOCK-BASED COMPENSATION - Stock Option Modifications (Details)			3 Months Ended		12 Months Ended
	Aug. 20, 2020 USD ($) employee $ / shares shares	Jun. 08, 2020 USD ($)	Mar. 31, 2021 USD ($) shares	Mar. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares
Stock compensation expense
Stock compensation expense		$ 9,432,000
Stock Incentive Plan 2017
Stock compensation expense
Stock compensation expense			$ 121,000	$ 456,000
Stock Incentive Plan 2017 \| Research and development
Stock compensation expense
Stock compensation expense			19,000	425,000
Stock Incentive Plan 2017 \| General and administrative
Stock compensation expense
Stock compensation expense			$ 102,000	$ 31,000
Stock Incentive Plan 2017 \| Stock Options
Stock compensation expense
Stock compensation expense					$ 1,340,000	$ 522,900
Cancelled and forfeited \| shares			57,149	30,768	194,901	130,220
Number of persons to whom shares were cancelled \| employee	4
Granted \| shares				17,631	86,536	209,505
Weighted average grant date fair value for options granted during the year: \| $ / shares				$ 35.62	$ 17.43	$ 10.82
Total unrecognized stock compensation expense			$ 252,700		$ 473,900
Unvested Shares to be recognized over the remaining weighted-average vesting period			1 year 3 months		1 year 9 months 14 days
Stock Incentive Plan 2017 \| Stock Options \| Research and development
Stock compensation expense
Stock compensation expense					$ 1,008,000	$ 332,000
Stock Incentive Plan 2017 \| Stock Options \| General and administrative
Stock compensation expense
Stock compensation expense			$ 20,900		332,000	$ 190,900
Stock Incentive Plan 2017 \| Stock Options \| Four Nonemployees
Stock compensation expense
Cancelled and forfeited \| shares	15,792
Granted \| shares	21,112
Weighted average grant date fair value for options granted during the year: \| $ / shares	$ 12.81
Options vested \| shares	3,959
Stock Incentive Plan 2017 \| Stock Options \| Four Nonemployees \| General and administrative
Stock compensation expense
Stock compensation expense					65,900
Incremental compensation costs	$ 9,600				$ 34,800

STOCK-BASED COMPENSATION - Schedule 2017 Stock Incentive Plan-Restricted Stock Units (Details)						3 Months Ended		12 Months Ended
	Aug. 20, 2020 shares	Aug. 20, 2020 $ / shares	Aug. 20, 2020 individual	Aug. 20, 2020 item	Jun. 08, 2020 USD ($)	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 shares	Jan. 31, 2017 shares
Restricted stock units
Stock compensation expense					$ 9,432,000
Stock Incentive Plan 2017
Restricted stock units
Stock compensation expense						$ 121,000	$ 456,000
Stock Incentive Plan 2017 \| Research and development
Restricted stock units
Stock compensation expense						19,000	425,000
Stock Incentive Plan 2017 \| General and administrative
Restricted stock units
Stock compensation expense						$ 102,000	$ 31,000
Stock Incentive Plan 2017 \| RSU
Restricted stock units
Authorized shares \| shares										1,708,615
Number of persons to whom shares were cancelled \| individual			5
Restricted stock unit activity
Nonvested RSUs at beginning of year \| shares						946,245
Granted \| shares	946,245					6,019		1,655,579	0
Vested \| shares	0							0	0
Cancelled and forfeited \| shares	(709,334)							(709,334)
Nonvested RSUs at March 31 \| shares	12.81					952,264		946,245
Weighted average grant day fair value per share
Nonvested RSUs at beginning of year \| $ / shares						$ 12.81
Granted \| $ / shares						9.00		$ 12.84
Cancelled and forfeited \| $ / shares		$ 12.87						12.87
Nonvested RSUs at March 31 \| $ / shares		$ 12.81				$ 12.79		$ 12.81
Stock Incentive Plan 2017 \| RSU \| Research and development
Restricted stock units
Stock compensation expense						$ 267,700		$ 748,400
Incremental compensation costs						20,400		166,900
Stock Incentive Plan 2017 \| RSU \| General and administrative
Restricted stock units
Stock compensation expense						556,600		1,725,300
Incremental compensation costs						$ 44,700		$ 402,700
Stock Incentive Plan 2017 \| RSU \| Non-Employees
Restricted stock units
Number of persons to whom shares were cancelled			2	2
Stock Incentive Plan 2017 \| RSU \| Employees
Restricted stock units
Number of persons to whom shares were cancelled			3	3

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets (liabilities):
Net operating loss carryforward	$ 3,842,900	$ 2,605,400
Stock compensation expense	3,379,000	597,400
Intangible assets	23,600	27,800
Total gross deferred tax assets	7,245,500	3,230,600
Valuation allowance	(7,061,600)	(3,198,100)
Property and equipment	(183,900)	(32,500)
Net deferred tax assets (liabilities)	$ 0	$ 0

INCOME TAXES - Net Operating Loss Carryforward (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
U.S.
Operating loss carryforwards
Net operating loss carryforwards	$ 18,299,500	$ 12,406,800

RELATED PARTY TRANSACTIONS (Details)						3 Months Ended		12 Months Ended
RELATED PARTY TRANSACTIONS (Details)	Jun. 19, 2020 USD ($) shares	Jun. 08, 2020 USD ($) shares	Sep. 04, 2019 USD ($)	Jul. 20, 2018 USD ($) item	Apr. 18, 2018 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($) agreement	Dec. 31, 2020 USD ($) agreement	Dec. 31, 2019 USD ($)
Related party transactions
Number of separate consulting agreements \| agreement							2	2
CSIO
Related party transactions
Consulting fee per hour				$ 400
Threshold number of hours per month for which consulting fees are entitled \| item				19
Consulting fee paid						$ 0	$ 319,300	$ 579,700	$ 207,800
Shares issued for services rendered \| shares	320,000
Cash consideration	$ 0
CFO and COO
Related party transactions
Consulting fee per hour			$ 10,000		$ 2,500
Consulting fee paid						$ 0	$ 30,000	$ 140,000	$ 67,500
Shares issued for services rendered \| shares	402,000
Cash consideration	$ 0
CMO
Related party transactions
Shares issued for services rendered \| shares		3,106
Cash consideration		$ 0
Employee
Related party transactions
Shares issued for services rendered \| shares		430
Cash consideration		$ 0

SUBSEQUENT EVENTS (Details)	Mar. 22, 2021 USD ($) ft² item	Feb. 16, 2021 USD ($)	Jan. 28, 2021 USD ($) installment	Nov. 19, 2020	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Lease expansion
Additional office space leased \| ft²	15,385
Period of time after notice of cancellation that the lease effectively terminates	90 days			90 days
Future minimum commitments
2021					$ 546,700	$ 265,200
2022					551,100	269,700
2023					461,200	274,200
2024						230,400
Total					$ 1,875,600	$ 1,039,500
Leon Office (H.K.) \| Strategic Alliance Agreement
Subsequent events
Annual cost			$ 360,000
Number of quarterly installments \| installment			4
SBA Loan
Loan payable
Loan principal forgiven		$ 105,800
Subsequent Event
Lease expansion
Additional office space leased \| ft²	15,385
Period of time after notice of cancellation that the lease effectively terminates	90 days
Number of months rent due as a termination payment if lease cancellation option exercised \| item	3
Future minimum commitments
2021	$ 380,600
2022	546,700
2023	551,100
2024	461,200
Total	$ 1,939,600
Subsequent Event \| Leon Office (H.K.) \| Strategic Alliance Agreement
Subsequent events
Annual cost			$ 360,000
Number of quarterly installments \| installment			4
Subsequent Event \| SBA Loan
Loan payable
Loan principal forgiven		105,600
Accrued interest forgiven		$ 300

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020	Sep. 18, 2020	Jun. 19, 2020	Jun. 17, 2020	Dec. 31, 2019	Sep. 25, 2019	Sep. 24, 2019	Jun. 18, 2018
Condensed Consolidated Balance Sheets
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001				$ 0.001
Common stock, authorized	300,000,000	300,000,000	858,615	1,708,615	858,615	300,000,000	30,000,000	20,000,000	858,615
Common stock, issued	7,332,999	7,332,999				2,863,812
Common stock, outstanding	7,332,999	7,332,999				2,863,812

Condensed Consolidated Statements of Operations	3 Months Ended
Condensed Consolidated Statements of Operations	Mar. 31, 2021 USD ($) $ / shares shares
Operating expenses:
Research and development	$ 1,885,600
General and administrative	2,071,000
Total operating expenses	3,956,600
Loss from operations	(3,956,600)
Other expense
Gain on loan extinguishment	105,800
Interest expense	(3,700)
Total other expense	102,100
Net loss	$ (3,854,500)
Net loss per share, basic and diluted \| $ / shares	$ (0.53)
Weighted average common shares outstanding, basic and diluted \| shares	7,332,999

Condensed Consolidated Statements of Cash Flows	3 Months Ended
Condensed Consolidated Statements of Cash Flows	Mar. 31, 2020 USD ($)
Cash flows from operating activities:
Net loss	$ (1,852,700)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	33,800
Stock compensation expense	456,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(99,700)
Accounts payable	(35,200)
Accrued expenses and other current liabilities	17,500
Net cash used for operating activities	(1,480,300)
Cash flows from investing activities:
Purchases of property and equipment	(406,300)
Net cash used for investing activities	(406,300)
Cash flows from financing activities:
Proceeds from Series B Preferred Stock issuance	3,000,000
Net cash (used in) provided by financing activities	3,000,000
Net change in cash and cash equivalents	1,113,400
Cash and cash equivalents:
Beginning of year	1,929,100
End of period	3,042,500
Supplemental disclosures of non-cash investing and financing activities:
Accruals for property and equipment	230,700
Warrants underlying Series B Preferred Stock issuance	$ 2,668,300

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonvested Stock Options (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Nonvested Stock Options
Expected dividend yield	0.00%	0.00%
RSU
Nonvested Stock Options
Expiration period	10 years	10 years
Monthly Vesting Conditions \| Minimum \| RSU
Nonvested Stock Options
Vesting period	6 months	6 months
Monthly Vesting Conditions \| Maximum \| RSU
Nonvested Stock Options
Vesting period	12 months	12 months
Stock Incentive Plan 2017
Nonvested Stock Options
Expiration period	10 years	10 years
Stock Incentive Plan 2017 \| Annual Vesting Conditions
Nonvested Stock Options
Vesting period	4 years	4 years
Stock Incentive Plan 2017 \| Monthly Vesting Conditions \| Minimum
Nonvested Stock Options
Vesting period	10 months	10 months
Stock Incentive Plan 2017 \| Monthly Vesting Conditions \| Maximum
Nonvested Stock Options
Vesting period	48 months	48 months

PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		12 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	$ 2,936,800		$ 2,627,700	$ 949,600
Less: Accumulated depreciation	(657,300)		(561,700)	(361,700)
Total	2,279,500		2,066,000	587,900
Depreciation	95,600	$ 33,800	200,000	87,500
Equipment
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	1,138,900		780,500	488,800
Leasehold improvements
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	1,274,600		1,229,700	302,700
Office furniture, fixtures, and equipment
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	16,600		16,600	16,600
Software
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	151,700		151,700	$ 141,500
Construction in progress
PROPERTY AND EQUIPMENT
Property, Plant and Equipment, Gross	$ 355,000		$ 449,200

Proposed Maximum

Aggregate Offering

Amount of

Price⁽¹⁾

Registration Fee

Common Stock, $0.001 par value per share

$57,500,000